-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 W10lsLW1Jpi5ugPUM2PNyogbwtd8/InziKzU/y/Gtq6Q6dGbvXjzFg0xPAOkDy45
 Ts2pchbzkbmWt2nPuuus8A==

<SEC-DOCUMENT>0001144204-09-062449.txt : 20091130
<SEC-HEADER>0001144204-09-062449.hdr.sgml : 20091130
<ACCEPTANCE-DATETIME>20091130171806
ACCESSION NUMBER:		0001144204-09-062449
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20081231
FILED AS OF DATE:		20091130
DATE AS OF CHANGE:		20091130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOVIE MEDICAL CORP
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		091212879

	BUSINESS ADDRESS:	
		STREET 1:		734 WALT WHITMAN ROAD
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		5164215452

	MAIL ADDRESS:	
		STREET 1:		734 WALT WHITMAN ROAD
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>v167911_10ka.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizer 4.0.6.4-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S.
SECURITIES AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM
10-K/A</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Amendment
No. 3)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Wingdings">x</font> ANNUAL REPORT UNDER
SECTION 13 OR 15(d) OF THE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
EXCHANGE ACT OF 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
fiscal year ended December 31, 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
file number 0-12183</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CORPORATION
</font>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
name of registrant as specified in its charter)</font></div>
    <div>
      <div align="center">
        <div align="center">
          <div align="center">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td valign="top" width="34%" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Delaware
      No.</font></div>
                  </td>
                  <td valign="top" width="32%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="top" width="34%" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11-2644611</font></div>
                  </td>
                </tr>
                <tr>
                  <td valign="top" width="34%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State
      or other jurisdiction</font></div>
                  </td>
                  <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="top" width="34%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(IRS
      Employer Identification No.)</font></div>
                  </td>
                </tr>
                <tr>
                  <td valign="top" width="34%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of
      incorporation or organization)</font></div>
                  </td>
                  <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="top" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
            </table>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">734
Walt Whitman Rd., Melville, New York 11747</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(631)
421-5452</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Issuer's
telephone number)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <div align="center">
          <div style="TEXT-ALIGN: center" align="left">
            <table cellpadding="0" cellspacing="0" width="85%" style="TEXT-ALIGN: center">
                <tr style="TEXT-ALIGN: center;">
                  <td align="left" valign="top" width="50%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Title of each Class</font></font></div>
                  </td>
                  <td align="left" valign="top" width="50%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-STYLE: normal">Name of each Exchange on which
      registered</font></font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="50%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common
      Stock, $.001 Par Value</font></div>
                  </td>
                  <td align="left" valign="top" width="50%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NYSE
      Euronext (AMEX)
Market</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Securities registered under Section
12(g) of the Exchange Act</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the Company is a well-known seasoned issuer, as defined in Rule
405 of the Securities Act.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes:
<font style="DISPLAY: inline;" face="Wingdings">o
</font>&#160;&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the Company is not required to file reports pursuant to Section
13 or Section 15(d) of the Act.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes:&#160;
<font style="DISPLAY: inline;" face="Wingdings">o
</font>&#160;&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant (I) filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes
<font style="DISPLAY: inline;" face="Wingdings">x</font> No <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by checkmark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the best
of registrant&#8217;s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a small reporting
company.&#160;&#160;See definition of &#8220;large accelerated filer&#8221;, &#8220;accelerated
filer&#8221; and &#8220;small reporting company&#8221; in Rule 12b-2 of the Exchange Act (Check
one):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Large
accelerated filer <font style="DISPLAY: inline;" face="Wingdings">&#168;
</font>Accelerated filer <font style="DISPLAY: inline;" face="Wingdings">x
</font>Non-accelerated filer <font style="DISPLAY: inline;" face="Wingdings">&#168; </font>Small reporting company
<font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Act).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes <font style="DISPLAY: inline;" face="Wingdings">&#168;&#160; </font>No <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
aggregate market value of the voting stock held by non-affiliates computed by
reference to the price at which the stock was sold, or the average bid and asked
prices of such stock, as of March 2, 2009 was approximately
$101,800,000</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
number of shares of the registrant's $.001 par value&#160;common stock
outstanding on the NYSE Alternext Exchange as of March 2, 2009 was
16,987,698</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Company
Symbol-BVX and Company SIC (Standard Industrial Code)-3841</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXPLANATORY
NOTE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are
filing this Amendment No. 3 (the &#8220;Amendment&#8221;) on Form 10-K/A to our Annual
Report on Form 10-K for the year ended December 31, 2008, to update our list of
exhibits and the re-filing of certain exhibits that are the subject of
Confidential Treatment Applications.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except as
described above and description of items previously amended in our 10-K/A
Amendment No. 1 and 10K/A Amendment No. 2, no other amendments have been made to
the 10-K . All other informational disclosure items of the 10-K as amended are
unaffected by this Amendment. This Amendment does not reflect events occurring
after March 13, 2009 or modify or update the disclosure contained in the Form
10K as originally filed, in any way other than as required to reflect the
revisions discussed above.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized, in Clearwater, Florida on November
30, 2009.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bovie
      Medical Corporation</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">By: /s/ ANDREW
    MAKRIDES&#160;</font></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Andrew
      Makrides</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">President</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chairman
      of the Board</font></div>
              </td>
            </tr>
        </table>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized, in Clearwater, Florida on November
30, 2009.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bovie
      Medical Corporation</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">By: /s/ GARY D.
    PICKETT&#160;</font></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gary
      D. Pickett</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Financial Officer,</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Treasurer,
      and Secretary</font></div>
              </td>
            </tr>
        </table>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the
capacities and on the dates indicated.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="center">
        <div align="center">
          <div align="center">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td valign="top" width="28%" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name</font></div>
                  </td>
                  <td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title</font></div>
                  </td>
                  <td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Principal
      Executive Officer:</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;ANDREW
      MAKRIDES</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Andrew
      Makrides</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Executive Officer and Chairman of the Board</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      30, 2009</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Principal
      Financial Officer:</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;GARY
      D. PICKETT</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gary
      D. Pickett</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Financial Officer, Treasurer, and Secretary</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      30, 2009</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Directors:</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;J.
      ROBERT SARON</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">J.
      Robert Saron</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">President
      of Aaron Medical Industries, Inc. and Director</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      30, 2009</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;GEORGE
      KROMER</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">George
      Kromer</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      30 , 2009</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;MICHAEL
      NORMAN</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Michael
      Norman</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      30, 2009</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/
      AUGUST LENTRICCHIA</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August
      Lentricchia</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      30, 2009</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;STEVE
      LIVNEH</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Steve
      Livneh</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">President
      of Bovie Canada and</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      30, 2009</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;STEVEN
      MACLAREN</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Steven
      MacLaren</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      30, 2009</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;DR.
      PETER PARDOLL</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dr.
      Peter Pardoll</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      30, 2009</font></div>
                  </td>
                </tr>
                <tr>
                  <td valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/
      Gregory A. Konesky</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gregory
      A. Konesky</font></div>
                  </td>
                  <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director</font></div>
                  </td>
                  <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="15%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      30, 2009</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT
INDEX</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.2</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Original
      Equipment Manufacturer Agreement between Arthrex, Inc. and Bovie Medical
      Corp. dated as of June, 2002. ***</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.11*</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consulting
      and Intellectual Property Assignment Agreement dated January 12, 2006
      among Bovie, Henvil Corp. Ltd and Steve Livneh.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.12</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Distribution
      Agreement between Bovie Medical Corporation and Boston Scientific dated
      October 6, 2006 amended and as re-filed, inclusive of Exhibit
      A..**</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.13</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">First
      Amendment to Distribution Agreement between Boston Scientific Corporation
      and Bovie Medical Corporation August 23, 2007, as re-filed.
    **</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.14</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Termination
      Purchase and License Agreement between Boston Scientific Corporation and
      Bovie Medical Corporation dated April 29, 2008 as amended and re-filed,
      inclusive of Exhibit A.**</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.15*</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Asset
      Purchase Agreement dated as of October 2, 2006 between Bovie Medical
      Corporation and Lican Developments, Ltd as re-filed, inclusive of Exhibit
      A, B, C and D.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.16*</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">First
      Amendment to Manufacturing and Development Agreement dated August 24, 2007
      between Bovie Medical Corporation and Arthrex, Inc. **</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.17*</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">First
      Amendment to OEM Agreement between Arthrex, Inc. and Bovie Medical Corp.
      dated as of July, 2007.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.18*</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amended
      Employment Agreement dated January 15, 2006 between Bovie Medical
      Corporation and Andrew Makrides.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.19*</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amended
      Employment Agreement dated January 15, 2006 between J. Robert Saron and
      Bovie Medical Corporation.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.20*</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amended
      Employment Agreement dated January 15, 2006 between Moshe Citronowicz and
      Bovie Medical Corporation..</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.21*</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
      Agreement dated June 18, 2007 between Bovie Medical Corporation and Gary
      Pickett.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.22*</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
      Agreement dated October 2, 2006 between Steve Livneh and Bovie Medical
      Corporation.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      10.23*</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amendment
      to Consulting and Intellectual Property Assignment Agreement dated June
      22, 2006 among Bovie, Henvil Corp. Ltd and Steve
Livneh.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      31.1</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
      pursuant to Section 302 of Sarbanes-Oxley Act of 2002.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      31.2</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
      pursuant to Section 302 of Sarbanes-Oxley Act of 2002.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      32.1</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
      pursuant to Section 906 of Sarbanes-Oxley Act of 2002.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      32.2</font></div>
            </td>
            <td align="left" valign="top" width="60%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
      pursuant to Section 906 of Sarbanes-Oxley Act of
  2002.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div>&#160;</div>
        <div>
          <hr style="COLOR: black" align="left" noshade size="1" width="100%">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*
Previously filed.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">**Subject
to a confidential treatment application made by the Company.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">***&#160;
Subject to a previous Confidential Treatment application which has been
withdrawn; and agreement is re-filed in its entirety without
redactions.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>v167911_ex10-2.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizer 4.0.6.4-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ORIGINAL
<font style="DISPLAY: inline; FONT-WEIGHT: bold">EQUIPMENT </font>MANUFACTURER
AGREEMENT</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Original Equipment Manufacturer Agreement (the "Agreement") is entered into as
of the 25TH<font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">&#160;</font>day
of June, 2002, by and between BOVIE MEDICAL CORPORATION, a Delaware corporation
with its principal place of business at 7100 30th Avenue North, St. Petersburg,
FL 33710-2902 ("Bovie"), and ARTHREX, INC., a Delaware corporation having its
principal place of business at 2885 South Horseshoe Drive, Naples, FL 34104
("Arthrex").</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS,
Bovie manufactures, packages and sells certain devices and components for resale
and desires to manufacture and supply certain Products (as defined
below);</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS,
Bovie desires to invest time and resources in the development and the
improvement of the Products, and in consideration therefor, Arthrex desires to
purchase its Products inventory from Bovie; and</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS,
Arthrex desires that Bovie manufacture and supply the Products to
Arthrex;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOW,
THEREFORE, in consideration of the terms and provisions of this Agreement, and
for other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, Bovie and Arthrex agree as follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.0 </font>DEFINITIONS.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">1.1&#160; </font>An "Affiliate" of a
Person means any company, corporation, partnership, limited liability company,
association, organization, entity, individual or other that directly or
indirectly controls, is controlled by or is under common control with such
Person.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"Delivery
Date" means a date for which delivery of Product is properly requested in a
Purchase Order (as such term is hereinafter defined).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;1.3&#160;
"FDA" means the United States Food and Drug Administration or any successor
agency or authority, the approval of which is required to market, distribute,
supply and sell health care products in the United States.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;1.4&#160;
"Product or Products" mean any one or more of the devices and components set
forth in Appendix A, and such other devices and components as may be added, in
writing, to Appendix A by Arthrex from time to time.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;1.5&#160;
"Purchase Order" means a written order issued by Arthrex to Bovie with respect
to purchases of Products, substantially in the form attached hereto as Appendix
B, which shall be subject to, and governed exclusively by, the terms of this
Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"Ramp-Up
Period" shall mean the first six months of the Term (as defined below) of this
Agreement.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.0 PURCHASE </font>AND SALE OF <font style="DISPLAY: inline; FONT-WEIGHT: bold">PRODUCTS.
2.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Bovie's Supply
Obligations</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bovie
shall use its best efforts to supply Arthrex with Product inventory. Subject to
the provisions of Section 5 below, all Products sold under this Agreement shall
conform in all material respects to the product specifications ("Product
Specifications") and manufacturing processes ("Manufacturing Processes") as set
forth in Appendix A as such Products, Product Specifications and Manufacturing
Processes may be modified from time to time by Bovie's engineering and design
teams; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">however,</font> that no
changes, modifications or improvements may be made to, or implemented within,
any Products delivered to Arthrex pursuant to this Agreement without Arthrex's
prior written consent, such consent not to be unreasonably
withheld.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject
to Section 2.1(c), Bovie shall agree to any reasonable and lawful modification
to the Product Specifications requested by Arthrex in writing, which are
designed to improve the Products; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">however,</font> that Bovie
shall have a reasonable period of time to implement such Product
Specifications.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding
anything to the contrary in Sections 2.1(a) and (b), in the event that any
change or modification to the Products or the Product Specifications results in
a material change to the costs incurred by Bovie in the development, production,
manufacture, sterilization and/or packaging of the Products, Bovie shall so
notify Arthrex prior to the implementation of the change or modification and,
upon the written consent of Arthrex thereto, the purchase prices, as set forth
in Section 3.1, shall be modified accordingly.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bovie
agrees, and shall cause its officers, directors, employees, advisers, agents and
consultants (collectively, "Representatives") to agree, that if any Product
Specification requested by Arthrex in accordance with Section 2.1(b), includes
changes to the Products or to the Product Specifications ("Inventions"), that
all Inventions shall be the sole property of Arthrex to the maximum extent
permitted by applicable law and to the extent permitted by law shall be "works
made for hire" as that term is defined in the United States Copyright Act (17
USCA, Section 101). Arthrex shall be the sole owner of all patents, copyrights,
trade secret rights and other intellectual property or other rights in
connection with the Inventions. Bovie shall, and shall cause its Representatives
to, assign to Arthrex all right, title and interest Bovie and/or its
Representatives may have or acquire in any and all Inventions. Bovie shall, and
shall cause its Representatives to, assist Arthrex in every proper way to
obtain, and from time to time, enforce, all patents, copyrights or other rights
on said improvements in any and all countries, and to that end Bovie shall, and
shall cause its Representatives to, execute all documents necessary. Arthrex
shall have the sole and exclusive right to:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i) apply
for, obtain and vest in the name of Arthrex alone (unless Arthrex otherwise
directs) letters patent, copyrights or other analogous protection in any country
throughout the world and when so obtained or vested to renew and restore the
same in its sole discretion; and</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)
defend any opposition proceedings in respect of such applications and any
opposition proceedings or petitions or applications for revocation of such
letters patent, copyright or other analogous protection.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)
Bovie's and its Representatives' obligations to assist Arthrex in obtaining and
enforcing patents and copyrights for the Inventions in any and all countries, as
set forth above, shall continue beyond the Term, at Arthrex's cost.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Arthrex's Purchase
Obligations</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject
to Section 2.11, Arthrex shall engage Bovie as the exclusive manufacturer of one
hundred percent (100%) of its Product requirements in the marketplace,
including, without limitation, Products required for engineering, testing and
clinical trials, if any. Except as expressly set forth herein, Arthrex agrees to
purchase all of its Product requirements exclusively from Bovie, and from no
other manufacturer, person or entity, including, without limitation, any entity
belonging, in whole or in part, to Arthrex.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject
to Section 2.2(a) above, Arthrex shall provide Bovie with firm Purchase Orders
for Products in accordance with the lead-times set forth in Section 2.4(a);
<font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> that
Arthrex shall have the right, up to the date of manufacture, and with the
consent of Bovie, which shall not be unreasonably withheld, to issue binding,
written change orders to increase or decrease the quantity of such Purchase
Orders. Arthrex agrees to accept partial shipments of Products should it, for
any commercially reasonable reason, become necessary to ship in advance of order
completion. Bovie shall make all commercially reasonable efforts to comply with
any revisions to Purchase Order requirements consistent with the provisions of
Section 2.3. Within seven days after receipt of a Purchase Order from Arthrex,
Bovie shall acknowledge such receipt and confirm whether the order can be
supplied.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Estimates of
Requirements</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a) (i)
Upon execution and delivery of this Agreement, and upon each successive
three-month anniversary of the execution and delivery of this Agreement, Arthrex
shall deliver to Bovie a rolling three-month written commitment of Arthrex's
requirements of Products for the immediately succeeding three-month period
(each, a "Quarterly Commitment"). Arthrex shall deliver Quarterly Commitments to
Bovie no later than 30 days prior to the applicable three-month anniversary
date. Bovie shall, no later than 15 days after receipt of each Quarterly
Commitment, notify Arthrex of any prospective problems, of which Bovie is aware,
that might prevent Bovie from meeting Arthrex's order quantities or estimated
Delivery Dates.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii) Upon
execution and delivery of this Agreement, and upon each successive annual
12-month anniversary of the execution and delivery of this Agreement, Arthrex
shall deliver to Bovie a written, non-binding good faith estimate of Arthrex's
requirements of Products from Bovie for delivery during the immediately
succeeding 12 months (each, an "Annual Forecast"). Arthrex shall deliver Annual
Forecasts to Bovie no later than 60 days prior to the applicable annual
anniversary date. Bovie shall, no later than 15 days after receipt of each
Annual Forecast, notify Arthrex of any prospective problems, of which Bovie is
aware, that might prevent Bovie from meeting Arthrex's forecasted requirements
or estimated Delivery Dates.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b) Bovie
and Arthrex agree to cooperate with each other and work jointly to establish and
maintain a smooth and efficient timetable for the manufacture and supply of
Products to Arthrex hereunder. Bovie shall use commercially reasonable efforts
to supply Arthrex with all of its Product requirements, including, but not
limited to, the use of commercially reasonable efforts to accommodate "Rush"
orders from Arthrex; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">however,</font> Bovie shall
not be in breach of this Agreement for any failure to supply quantities of
Products which exceed the Quarterly Commitments provided by Arthrex under
Section 2.3(a) by more than 200%.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Orders,
Packaging and Delivery</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unless
otherwise agreed to in writing by the parties, all Products purchased pursuant
to this Agreement shall be effected by Arthrex's issuance of a firm written
Purchase Order, consistent with Section 2.3 above. Each Purchase Order shall
specify the type and quantity of the Product to be delivered, as well as
requested Delivery Dates. All requested Delivery Dates shall provide for at
least 30 days lead time for the manufacture and delivery of the Products ordered
(taking into consideration the production schedule established in the Quarterly
Commitments). After the end of the Ramp-Up Period, subject to Section 2.3(b), a
failure by Bovie to deliver Products within 30 days of a Delivery Date shall be
a material breach of this Agreement and be subject to Section 7.1.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)
Bovie shall be responsible for, in accordance with the terms, provisions and
conditions set forth in this Agreement: (i) the sterilization of the Products at
its facility or facilities or at any contract facility or facilities; (ii) the
packaging of the Products for shipment in accordance with validated procedures;
and (iii) the shipment of such Products. Arthrex, at its own expense, will
provide Bovie with Arthrex's labeling for the Products bearing Arthrex's
corporate name and trade dress. Bovie will print, either directly or through a
third party, labels and other printed material to be included as part of the
finished Products. Products manufactured by or on behalf of Bovie after Bovie's
receipt of any new or altered labeling for the Products, shall bear such new
labeling. Bovie shall also place other required notices and marks, such as ETL
and CE (both as defined below) notices and markings, as Arthrex may hereafter
prescribe from time to time as it deems appropriate, on all copies and
embodiments of the Products and associated documentation and advertising. Bovie
shall not remove any Arthrex approved or designated notice from any Products. As
set forth in Section 3.1, Arthrex will pay the costs of all private labeling by
Bovie.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2) Bovie
shall not hire, contract with or otherwise engage any one or more contract
facilities to perform any of its obligations as set forth in this Agreement with
respect to the sterilization of the Products without the prior written consent
of Arthrex, which consent shall not be unreasonably withheld or delayed; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> that any
contract facility that is engaged in any way with the sterilization of the
Products shall (i) perform the sterilization of the Products in accordance with
specifications that have been provided or approved in writing by Arthrex and
(ii) meet the same governmental and regulatory requirements, and maintain the
same registrations and certifications, as applicable, that Bovie is required to
meet under Section 2.5; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">further,</font> that Bovie
shall be liable for, and shall indemnify and hold Arthrex harmless in connection
with liabilities arising from, any violations of this Section
2.4(b)(2).</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unless
otherwise agreed to, in writing, by the parties, all Products manufactured for
Arthrex shall be delivered to Arthrex at its principal place of business in
Naples, Florida. All shipments of Products to Arthrex shall be billed F.O.B.
Bovie's manufacturing plant in Florida. All deliveries shall be delivered in a
manner as may be, intermittently, agreed to by the parties. Title to and risk of
any loss and/or damage to the Products shall pass to Arthrex upon delivery of
such Product by Bovie, or any agent of Bovie, to the shipping
agent.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bovie
shall assist Arthrex in arranging any desired shipping insurance (in amounts
that Arthrex shall determine) and shall use its best efforts to deliver all
Products by their respective requested Delivery Dates (provided that in no event
shall a Delivery Date be less than 30 days after the date the Purchase Order is
issued, unless otherwise consented to by Bovie), using mutually agreeable
carriers. All costs and expenses relating to transportation and delivery shall
be at Arthrex's expense. Arthrex shall have the right to require and inspect any
special or varied packing that it believes is reasonably necessary to meet the
customs, regulatory or other requirements within a territory.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bovie
shall certify, in writing, upon Arthrex's written request, that each delivery of
Product was produced and tested in compliance with the Product
Specifications.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Arthrex
may return any defective Products to Bovie, pursuant to a product recall or
otherwise, for credit or replacement as Arthrex shall determine.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quality
Control and Regulatory Compliance</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During
the Term, Bovie shall establish and maintain a quality assurance control program
to be maintained by its Quality Control Team. Bovie shall enter into Arthrex's
Contract Manufacturers/Suppliers/Vendors Agreement with respect to quality
assurance, a copy of which is attached hereto as Appendix C. Arthrex shall
maintain its Quality Control Department, which shall provide technical and other
assistance to Bovie in order for Bovie to better understand and meet the Product
Specifications and manufacturing requirements. Bovie's Quality Control Team and
Arthrex's Quality Control Department shall work together in an effort to
establish total quality assurance.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During
the Term, Bovie shall manufacture the Products in a manner that is in compliance
with all federal and state governmental and regulatory requirements in the
United States of which Bovie is legally required to comply, including, but not
limited to, the FDA's Quality System Regulations ("QSR"), including Good
Manufacturing Practices ("GMP"), as well as ISO-9001 registrations (provided and
for such time that such standards remain valid) and EN 46001 certification, and
with the laws and regulations of each jurisdiction located outside of the United
States. Bovie, at its sole expense, shall have ETL Semko's medical devices group
("ETL") test and evaluate each of the Products and maintain the eligibility of
the Products for ETL Certification and for ETL's Certification Mark. Boyle shall
also comply with the essential requirements of the European health, safety and
environmental protections legislations set forth in the European Union Council
Medical Device Directives (the "EU Medical Device Directives") and declare such
compliance by affixing the "CE Marking" to the Products shipped to
Arthrex.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bovie
shall maintain all documents and records necessary for regulatory compliance and
such documents and records shall be maintained for a period of no less than
seven years from creation. Upon request and within a reasonable period of time,
Bovie shall make such documents and records completely available for inspection
by Arthrex, at any reasonable time during normal business hours. All such
documents and records reviewed by Arthrex shall be subject to the
confidentiality provisions of Section 8 herein.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bovie
hereby covenants, after reasonable input from Arthrex, to implement a failure
investigation mode that is reasonably satisfactory to Arthrex and to establish a
formal complaint system as required by the United States Food, Drug &amp;
Cosmetic Act, as amended, including all regulations promulgated pursuant thereto
(the "Act"), including, without limitation, the time requirements set forth in
the Medical Device Reporting regulations. Each party shall maintain a record of
all complaints received with respect to any Product in each jurisdiction in
which the Products are sold, and shall promptly notify the other party of such
complaints, in order to allow the responsible party to comply with any and all
regulatory requirements imposed upon it, by any country. Further, Bovie agrees
to assist Arthrex in analyzing and responding to such complaints and to make all
records readily accessible to Arthrex. Arthrex shall, upon receipt, notify
Bovie, in writing, of all warnings, disclaimers or informed consent statements
relating or affixed to any Products, or required to be acknowledged as a
condition to use of such Products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
the event of a regulatory audit at Arthrex, which involves any Products, Arthrex
shall notify Bovie of such audit within one week thereof. Pursuant to such
notice of audit, Bovie shall supply Arthrex with documents from the Quality
Control Team, related to the Products, within three business days from a request
by Arthrex.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bovie
shall promptly notify Arthrex whenever a request for a plant inspection is
received from the FDA and shall promptly advise Arthrex of any scheduled FDA
inspection and the results thereof A copy of Form 483 observation or other
applicable report, which applies to the Products, shall be supplied to Arthrex
upon request. Bovie shall promptly take steps to remedy any valid deficiencies
found by the FDA inspectors relating to the manufacture, sterilization and
packaging of the Products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Plant
Inspection</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Arthrex
shall have the right to have qualified Arthrex employees, contractors or agents
present at Bovie's manufacturing facility, at mutually agreeable times during
normal business hours to (i) observe Bovie's manufacture of Products; (ii)
inspect Bovie's facility and manufacturing procedures, as such relate to
Products manufactured hereunder, and quality assurance/control procedures for
compliance with (A) QSR, including GMP, as well as ISO-9001 registrations
(provided and for such time that such standards remain valid) and EN 46001
certification, (B) ETL standards for testing and evaluation of each of the
Products and (C) compliance with the EU Medical Device Directives in connection
with the CE Marking; and (iii) inspect Bovie's inventory, work-in-process, raw
materials, QSR records and such other matters as may be pertinent to proper
quality assurance of Products to be delivered under the tea's of this
Agreement.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">License</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
to the provisions of this Agreement, during the Term, Arthrex grants to Bovie a
limited non-exclusive, non-transferable license to any intellectual property
that may be provided from time to time by Arthrex to Bovie in accordance with
Section 2.1, solely to manufacture, sterilize and package the Products. Such
license is personal to Bovie and shall not be sublicensed to, transferred to or
used for the benefit of, any person or entity not authorized in writing by
Arthrex except to a Back-up Supplier as set forth in Section 2.11. No other
licenses of any rights of Arthrex, except those expressly granted by this
Agreement, shall be construed to be extended to Bovie or its affiliates, foreign
divisions, licensees or customers, expressly or by implication, whether
pertaining to the subject matter of this Agreement or otherwise. To the extent
reasonable and practical, Bovie shall place all notices, including, but not
limited to, intellectual property notices such as patent notices or
confidentiality notices, and legends and other notices as Arthrex may hereafter
prescribe from time to time as it deems appropriate, on all copies and
embodiments of the Products and associated documentation and advertising. Bovie
shall not remove any Arthrex approved or designated notice from any
Products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Acceptance
and Rejection</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except
as provided herein, Arthrex shall accept all Products delivered in accordance
with the terms and conditions of this Agreement. Arthrex may reject any portion
of any shipment of Products if such shipment does not conform in any material
respect with (i) the Product Specifications or (ii) subject to Section 2.3(b),
the quantities requested in the Purchase Order. In order to reject a shipment,
Arthrex must give Bovie a reasonably detailed statement of its reasons for
rejection and, where appropriate, Product samples demonstrating the proposed
nonconformance and requesting that Bovie either remedy or provide a reasonable
plan to promptly remedy such nonconformance within a reasonable time which shall
not to exceed 45 days. If no such statement is received by Bovie, then Arthrex
shall be deemed to have accepted the shipment of Product. In the event of proper
rejection by Arthrex, Bovie shall, within five days, notify Arthrex of whether
it accepts Arthrex's notice of nonconformity or it shall be deemed to accept
such notice.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If
Bovie disagrees with any proposed nonconformity by Arthrex, then both parties
agree to cooperate and make every reasonable effort to resolve the disagreement.
If Bovie confirms Arthrex's rejection, Bovie shall, at its sole option, and in a
reasonably prompt manner, either (i) replace (if it has not already done so) the
nonconforming Product with conforming Product or (ii) credit to Arthrex the
purchase price therefor.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any
replacement shipments shall be subject to the provisions and procedures
contained in this Agreement. Whether or not Bovie accepts Arthrex's basis for
rejection, upon receipt of a notice of rejection and at Arthrex's request, Bovie
shall use its reasonable commercial efforts to promptly provide replacement
Product, which shall be purchased by Arthrex pursuant to this
Agreement.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Product
Recalls</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
the event that either Bovie or Arthrex determines that a recall of any one or
more Products is necessary for any reason, Bovie and Arthrex, as applicable,
shall so notify each other in writing. Arthrex shall, immediately upon receipt
of such notice, give notice of the recall to each customer to which it has sold
any Products, along with the instructions, if any, delivered by Bovie or
prepared by Arthrex and/or Bovie relating to the recall.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Arthrex
and Bovie shall assist each other in giving effect to the recall. Bovie shall
bear all costs and expenses of any recall caused by its manufacturing,
packaging, misbranding or other issues caused by acts of Bovie that potentially
affect the safety, use or efficacy of the Products including, without
limitation, obligations to third parties, costs of notifying customers and costs
associated with the shipment of recalled Products from customers to Arthrex or
Bovie, and replacement of such products. Arthrex shall, however, bear all costs
of any recall caused by its misrepresentations or other acts causing a recall to
occur.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.10
Arthrex's Right of First Refusal/Offer of Additional Manufacturing</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
the event that, at any time and from time to time, Bovie desires on its own
behalf, and not in connection with any contract, agreement or arrangement with
any third party, to manufacture, develop or produce any products which are
compatible with or otherwise relate to the technology contained in the Products
("Other Products"), Bovie shall first give written notice to Arthrex of such
desire, allowing Arthrex a reasonable opportunity to offer to be the exclusive
sellor or distributor of such Other Products, upon terms, conditions and
provisions reasonably similar to the terms, conditions and provisions contained
herein; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">however,</font> that subject
to Section 10, Bovie shall have no obligation to make any such offer to Arthrex
in connection with any Other Products which Bovie develops, produces or
manufactures on behalf of third parties.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Arthrex
must, within 30 days after receipt of the written notice, provide Bovie with a
written notice of acceptance ("Notice of Acceptance"), specifying a good faith
estimate of the quantity of Other Products that it shall sell or distribute,
based upon terms and conditions reasonably similar to the terms and provisions
contained herein. If, within 30 days of receipt of the written notice, Arthrex
has not delivered an effective Notice of Acceptance, Bovie shall have the right
to solicit any third party for the exclusive distribution of the Other Products;
without incurring any liability to Arthrex.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.11
Alternate Source of Supply</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If Bovie
is unable to supply Arthrex with its Product requirements in accordance with
Sections 2.1, 2.2 and 2.3 herein, including, but not limited to, an order by
Arthrex for Products which exceeds a Quarterly Commitment by more than 200%,
then Bovie shall promptly notify Arthrex of its inability to supply such
Products. If the supply issue cannot be resolved, Arthrex shall have the right
to engage a Back-Up Supplier to manufacture and supply the Products and to
terminate any Purchase Order, in whole or in part, that Bovie was unable to fill
without liability or charge. Such right shall continue until 30 days after Bovie
notifies Arthrex that it is prepared to supply all of Arthrex's Product
requirements, as provided herein. Bovie shall, in good faith, cooperate fully
with Arthrex and any Back-Up Supplier in supplying Arthrex with Products,
including assisting in the transfer of molds and any information necessary for
the supply of such Products. Any disclosure by Bovie and/or Arthrex to, or with
regard to, a Back-Up Supplier, or use of technical information by a Back-Up
Supplier, shall be subject to the Confidentiality provisions set forth in
Section 8 herein. Nothing in this Section 2.11, or this Agreement, shall
interfere with Arthrex's right to designate a Back-up supplier to manufacture
Products under the terms of this Section 2.11.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.0 P CE
AND PAYMENT; <font style="DISPLAY: inline; FONT-WEIGHT: bold">REBATE.</font></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Purchase
Price</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
prices for Products purchased hereunder shall be set forth in the Pricing List,
attached hereto as Appendix D. The prices set forth in the Pricing List shall
include all charges related to Bovie's preparation, labeling, packaging, crating
and loading of the Products; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">however,</font> that in no
event shall the Prices exceed the lowest price that Bovie receives from third
party purchasers of like products in like volumes.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Taxes
and Duties</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except as
provided in this Agreement, each party shall be responsible for the payment of
all taxes and other governmental charges assessed against it and applicable in
any respect to this Agreement, and the grant or exercise of the rights granted
by this Agreement, and, in the event the other party is required to collect such
charges, shall promptly pay such charges to the other party. If any transaction
undertaken pursuant to this Agreement shall be subject to a foreign, state or
local sales tax, use tax, value added tax, customs duties or other similar taxes
or duties, the transferee of the property in the transaction giving rise to such
tax or duty shall be liable for payment of such tax or duty, and shall reimburse
the transferor for any tax or duty payments the transferor shall be required to
make to any governmental authorities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payment
of the Purchase Price</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
shall bill Arthrex for all purchases made under this Agreement, by invoice sent
to Arthrex at Arthrex's address referenced on the first page of this Agreement.
All invoices submitted by Bovie to Arthrex shall be payable within 30 days after
Arthrex's receipt of said invoices; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> that
Arthrex shall be entitled to a 1% discount from each invoice if such payment is
made within 10 days' of receipt of such invoice.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Rebate</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
shall issue a credit or refund to Arthrex for, or replace at no charge to
Arthrex, all defective or otherwise unmerchantable Products returned by Arthrex,
or returned by the customers to Arthrex and subsequently returned to Bovie by
Arthrex, within 30 days of return to Bovie, and Bovie shall bear responsibility
for all costs associated with such Products, including any regular surface
freight charge.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">4.0 </font>CAPITAL. <font style="DISPLAY: inline; FONT-WEIGHT: bold">EQUIPMENT;
</font>DESIGNS/SPECIFICATIONS.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Capital
Equipment</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
shall provide for such capital equipment as Bovie deems reasonably necessary for
the manufacturing, sterilizing and packaging of the Products at the Bovie plant
or facility or any contract facility used by Bovie. All such capital equipment
provided by Bovie shall remain the sole property of Bovie, and all processes and
specifications that relate to such capital equipment shall constitute Bovie's
proprietary Confidential Information, as defined in Section 8 herein, belonging
exclusively to Bovie. Any and all copyrights, patents, trademarks, proprietary
rights and/or trade secrets, registered or otherwise, arising or occurring,
under federal, state or other law and/or regulation, from or as a result of
Bovie capital equipment or any Confidential Information belonging to Bovie,
shall remain the sole property of Bovie.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 69.15pt"></font>4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Tooling
Equipment</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the
event that any tooling equipment is needed for the manufacturing, sterilizing
and packaging solely of the Products (the "Tooling Equipment"), Arthrex shall,
at its sole discretion, either pay for such Tooling Equipment or reimburse Bovie
for the purchase of such Tooling Equipment at Bovie's purchase price including
any discounts, rebates or other purchase price reductions to which Bovie is
entitled; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> that
Arthrex shall consent in writing to the need for any Tooling Equipment prior to
the purchase or order thereof. Any such Tooling Equipment shall be and remain
the sole property of Arthrex. Bovie shall reimburse Arthrex for any damage to
the Tooling Equipment that exceeds the normal wear and tear of such Tooling
Equipment or was caused by the abuse or misuse of such Tooling Equipment by
Bovie, its Representatives or the representatives of any contract facility
engaged by Bovie.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 69.15pt"></font>4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Designs/Specifications; Manufacturing
Processes</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Arthrex
shall retain sole ownership of the designs and specifications provided by it for
Products, to the extent that such designs and specifications constitute
proprietary Confidential Information, as defined in Section 8 herein. Bovie
shall retain sole ownership of all design and specifications, manufacturing
processes, including, but not limited to, injection or insert molding, and
assembly and packaging procedures, which processes shall constitute proprietary
Confidential Information, as defined in Section 8 herein.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 69.15pt"></font>4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Retention
of Samples</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
shall retain as samples such quantities of Products as Arthrex shall reasonably
request. Retained samples shall be maintained in a suitable manner for a
reasonable period of time past the manufacture date. All such samples shall be
available for inspection and testing by Arthrex at reasonable times and upon
reasonable notice.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.0
WA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
NTIES; LIMITATION OF LIABILITY; <font style="DISPLAY: inline; FONT-WEIGHT: bold">INSU</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CE.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 69.4pt"></font>&#160;
5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Product
Warranties</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
to the provisions set forth in Section 5.3 below, Bovie warrants: (i) that all
Products delivered hereunder shall conform in every material respect to Product
Specifications at the time of shipment; (ii) that all Products shall be
manufactured, sterilized and packaged in accordance with (A) QSR, including GMP,
as required by the Act, (B) the pertinent rules and regulations of the FDA and
(C) the EU Medical Device Directive, and shall have been evaluated and tested by
ETL; (iii) that no Product delivered hereunder shall at time of shipment be
adulterated or misbranded within the meaning of the Act, or within the meaning
of any applicable state or municipal law in which the definitions of
adulteration and misbranding are substantially the same as those contained in
the Act, provided such laws are constituted and effective at the time of such
delivery; and (iv) the Bovie-provided Product Specifications embedded in the
design and manufacture of any of the Products do not constitute or create an
infringement of any United States or non-United States patent, copyright,
trademark or other proprietary right or trade secret, be it registered or
otherwise, arising under federal, state or other law and/or regulation
(collectively, the "Product Warranties"). These Product Warranties shall be null
and void and shall not apply to any Product which is in any way altered,
modified, damaged or replaced by any person other than Bovie, or which is abused
or misused whether intentionally or accidentally.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 69.4pt"></font>&#160;
5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Limitation of
Liability of Bovie</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THE
FOREGOING WARRANTIES, SET FORTH IN SECTION 5.1 ABOVE, ARE EXCLUSIVE AND ARE IN
LIEU OF ALL OTHER WARRANTIES AND REPRESENTATIONS OF ANY D. BOVIE HEREBY
DISCLAIMS ALL OTHER WARRANTIES AND REPRESENTATIONS, WHETHER EXPRESS OR IMPLIED,
INCLUDING, WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS
FOR USE AND/OR PARTICULAR PURPOSES. BOVIE SHALL NOT, UNDER ANY CIRCUMSTANCES, BE
LIABLE FOR SPECIAL, INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY NATURE
WHATSOEVER, INCLUDING, WITHOUT LIMITATION, ANY LOST REVENUES OR PROFITS OF
ARTHREX AND/OR ITS CUSTOMERS, AGENTS AND DISTRIBUTORS, RESULTING FROM OR ARISING
OUT OF OR IN CONNECTION WITH ANY SALE, MANUFACTURE, DISTRIBUTION OR ANY USE OF
ANY PRODUCT, WHETHER OR NOT BOVIE HAS BEEN ADVISED OF THE POSSIBILITY OF
DAMAGES, EXCEPT TO THE EXTENT OF NEGLIGENCE AND WILLFUL MISCONDUCT OF BOVIE OR
ITS REPRESENTATIVES. THE FOREGOING LIMITATION OF LIABILITY APPLIES BROADLY, AND
TO ANY AND ALL PRODUCTS MANUFACTURED AND SUPPLIED HEREUNDER, AND SHALL NOT BE
CONSTRUED TO APPLY ONLY TO DAMAGES OCCURRING AS A RESULT OF BREACH OF ANY
PRODUCT WARRANTIES, BUT SHALL ALSO APPLY TO ANY DAMAGES TO ARTHREX OCCURRING AS
A CONSEQUENCE OF THIS AGREEMENT OR ANY BREACH THEREOF, EXCEPT TO THE EXTENT OF
NEGLIGENCE AND WILLFUL MISCONDUCT OF BOVIE OR ITS REPRESENTATIVES. ALL
LIMITATIONS OF LIABILITY, PURSUANT TO THE TERMS</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">HEREIN,
SHALL SURVIVE ANY TERMINATION OR EXPIRATION OF THIS AGREEMENT.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Limitation
of Liability of Arthrex</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ARTHREX
HEREBY DISCLAIMS ALL EXPRESS OR IMPLIED WARRANTIES AND REPRESENTATIONS,
INCLUDING, WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS
FOR USE AND/OR PARTICULAR PURPOSES. ARTHREX SHALL NOT, UNDER ANY CIRCUMSTANCES,
BE LIABLE FOR SPECIAL, INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY NATURE
WHATSOEVER, INCLUDING, WITHOUT LIMITATION, ANY LOST REVENUES OR PROFITS OF BOVIE
AND/OR ITS CUSTOMERS, AGENTS AND DISTRIBUTORS, RESULTING FROM OR ARISING OUT OF
OR IN CONNECTION WITH ANY SALE, DISTRIBUTION OR ANY USE OF ANY PRODUCT, WHETHER
OR NOT ARTHREX HAS BEEN ADVISED OF THE POSSIBILITY OF DAMAGES, EXCEPT TO THE
EXTENT OF NEGLIGENCE AND WILLFUL MISCONDUCT OF ARTHREX OR ITS REPRESENTATIVES.
THE FOREGOING LIMITATION OF LIABILITY APPLIES BROADLY, AND TO ANY AND ALL
PRODUCTS DISTRIBUTED OR SOLD HEREUNDER, AND SHALL NOT BE CONSTRUED TO APPLY ONLY
TO DAMAGES OCCURRING AS A RESULT OF BREACH OF ANY PRODUCT WARRANTIES, BUT SHALL
ALSO APPLY TO ANY DAMAGES TO BOVIE OCCURRING AS A CONSEQUENCE OF THIS AGREEMENT
OR ANY BREACH THEREOF, EXCEPT TO THE EXTENT OF NEGLIGENCE AND WILLFUL MISCONDUCT
OF ARTHREX OR ITS REPRESENTATIVES. ALL LIMITATIONS OF LIABILITY, PURSUANT TO THE
TERMS HEREIN, SHALL SURVIVE ANY TERMINATION OR EXPIRATION OF THIS
AGREEMENT.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Insurance</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
shall acquire and maintain products liability insurance in a minimum amount of
$5 million in the aggregate and $2 million per occurrence, and Bovie shall name
Arthrex as an additional insured on all such policies and will provide Arthrex
with proof of insurance prior to the Start Date (as defined below) and
thereafter upon Arthrex's reasonable request. Such insurance shall be in
addition to, and not in lieu of, any insurance policy or policies maintained by
Arthrex. Bovie shall not cancel or terminate such products liability insurance
without 30 days prior notice to Bovie. Bovie shall notify Arthrex not less than
30 days' prior to any proposed cancellation, termination, non-renewal or
modification of such products liability insurance. Bovie acknowledges that a
failure to comply with this Section 5.4 shall be a material breach under Section
7 of this Agreement</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.0</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;T
E.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Agreement shall commence upon execution and delivery of this Agreement. The term
of this Agreement shall be five years, commencing on the date of the first
commercial shipment of Products manufactured at, and from, Bovie's facility (the
"Start Date"), and closing upon expiration of the fifth full year following the
Start Date (the "Term"). Following closing of the initial Term, this Agreement
shall be renewed for consecutive three-year periods, subject to the written
consent of both parties. If this Agreement is extended in accordance with the
preceding sentence, the "Term" shall be extended until the end of the applicable
extension period. Written notification to terminate must be given not less than
180 days prior to the intended termination date; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> that if
Arthrex elects to have the Agreement terminate in accordance with this Section
6.0, Arthrex shall purchase all of Bovie's remaining inventory of the Products
up to and to the extent that Bovie's inventory does not exceed the Quarterly
Commitment for the quarter during which this Agreement is so terminated by
Arthrex.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.0 TE
INATION.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Termination
for Material Breach</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Either
party may terminate this Agreement, in writing, in the event of a material
breach by the other of this Agreement; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">however,</font> that the
parry asserting such breach must first serve written notice of the alleged
breach on the offending party, and must allow the offending party 45 days, from
the date of delivery of such notice, within which to cure the alleged breach.
For purposes of this Agreement, the term "material breach" shall include, but
not be limited to:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bovie's
breach of Section 2.1(a) or 2.1(d);</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the
termination, for any reason, of the Manufacturing and Development Agreement
entered into between the parties hereto, dated as of the date
hereof;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bovie's
breach of Section 2.4(a); or</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bovie's
transfer or sale of all or part of its individual assets, or all or part of its
individual business pertaining to the Products manufactured and supplied
pursuant to this Agreement; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">however,</font> that it
shall not be a material breach hereunder if any party that it is not a
competitor of Arthrex, other than any Affiliate of Bovie, becomes a party to
either: (i) a merger by, with or of Bovie, or any part, Affiliate or subsidiary
of Bovie that is involved in the manufacture, development, sterilization,
packaging or supply of the Products; or (ii) an acquisition of Bovie or any
part, Affiliate or subsidiary of Bovie that is involved in the manufacture,
development, sterilization, packaging or supply of the Products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notwithstanding
the preceding, Arthrex may terminate this Agreement immediately, without notice
or cure period, upon a material breach described in either clause (iii) or
clause (iv) above.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Arthrex
shall have the right to both immediately terminate this Agreement and obtain
injunctive relief in the event of the unauthorized use and/or disclosure of the
Confidential Information by Bovie. Arthrex may terminate this Agreement
immediately upon any attempt, unless, if curable, cured within 45 days by Bovie,
to assign, delegate, sublicense or otherwise transfer the license set forth in
Section 2.7 or any of its rights or obligations under this Agreement, except as
expressly provided for in this Agreement.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Bankruptcy;
Insolvency</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Either
Party may terminate this Agreement, effective immediately upon the giving of
written notice, if the other Party shall file a petition for bankruptcy, or
shall be adjudicated a bankrupt or insolvent, or shall take advantage of the
insolvency laws of any state of the United States or of any country, or shall
make an assignment for the benefit of creditors, or shall have a receiver
appointed, whether by private instrument or by court officer, for its property
which is not dismissed within 60 days, or become subject to an involuntary
petition for bankruptcy which in not dismissed within 60 days.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 69.15pt"></font>&#160;
7.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Effect of
Termination</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the
event of termination of this Agreement pursuant to this Section 7, both parties
shall cooperate with each other and make all reasonable, good faith efforts to
accommodate each other, including but not limited to, with the transfer and/or
return of molds, equipment, Confidential Information and any other information,
documentation and/or data. Termination of this Agreement, for whatever reason,
shall not affect any rights or obligations that may have accrued to either party
prior to the effective date of such termination.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 69.15pt"></font>&#160;
7.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Survival</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
obligations of consent to change the Products and the Product Specifications set
forth in Section 2.1, the obligations of Confidentiality, set forth in Section
8, the Warranties and Limitation of Liability provided for in Section 5, the
Indemnification provisions set forth in Section 9 and the provision for
Assignment set forth in Section 11 herein, shall survive the expiration or
termination of this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.0
</font>CONFIDENTIALITY.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">8.1 </font>The parties hereby agree
to keep strictly confidential and to not use, or permit the use of, for any
purpose whatsoever during the Term, and for a period of five years following
expiration or termination of this Agreement, all information received or
observed from the other party pursuant to this Agreement or otherwise
(including, without limitation, information of such party or such party's
customers or the business associates disclosed or observed, infoimation that is
known or reasonably should be known to be trade secrets and/or proprietary in
nature, and licenses, patents, patent application, technology or processes and
business plans of the other party) (the "Confidential Information"), except as
disclosure or use of such Confidential Information is expressly permitted by
this Agreement. Confidential Information does not include information which: (i)
is or becomes available to the general public or to other manufacturers within
the applicable industry, through no act or fault of the recipient; (ii) is
rightfully disclosed to recipient by a third party under no obligation of
confidentiality with respect to such information; or (iii) is rightfully in the
possession of the recipient at the time of disclosure without obligation of
confidentiality or non-use with respect thereto.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;8.2
The recipient of Confidential Information shall protect it from disclosure with
the same degree of care by which it protects its own Confidential Information.
Each party shall use its best efforts to ensure that its Representatives do not
disclose or make any unauthorized use of Confidential Information, and each
parry agrees to promptly notify the other upon discovery of any unauthorized use
or disclosure of the other party's Confidential Information. Each party shall be
liable for the unauthorized use or disclosure of the other party's Confidential
Information by such party's Representatives.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;8.3
Bovie shall not use the proprietary Confidential Information belonging to
Arthrex, including, without limitation, Arthrex's designs, specifications,
drawings, processes, materials, molds, tooling, jigs and fixtures, for any
purpose other than to manufacture Products for Arthrex, without Arthrex's prior
written consent.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;8.4
In the event that Bovie or any of its Representatives is requested or required
(by oral questions, deposition, interrogatories, requests for information or
documents, subpoena, civil investigative demand or other process) to disclose
all or any part of any Confidential Information, Bovie will provide Arthrex with
prompt notice of such request or requirement so that Arthrex may seek an
appropriate protective order or waive compliance with the provisions of this
Agreement, as well as notice of the terms and circumstances surrounding such
request or requirement. In such case, the parties will consult with each other
on the advisability of pursuing any such order or other legal action or
available steps to resist or narrow such request or requirement. If, failing the
entry of a protective order or the receipt of a waiver hereunder, Bovie is, in
the opinion of counsel acceptable to Arthrex, legally compelled to disclose
Confidential Information, Bovie may disclose that portion of the Confidential
Information which counsel advises Bovie that it is legally compelled to
disclose. In any event, Bovie will use its best efforts to obtain and will not
oppose action by Arthrex to obtain an appropriate protective order or other
reliable assurance that confidential treatment will be accorded the disclosure
of such information. Bovie will cause its Representatives and agents to comply
with this paragraph.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.0
</font>INDEMNIFICATION.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">9.1 </font>Arthrex agrees to and
shall indemnify and defend Bovie, and hold Bovie harmless, from and against any
and all claims, alleged claims, losses, harms, damages, liabilities, penalties,
lawsuits, threats of lawsuits, recalls or other governmental action, costs and
expenses, including, without limitation, reasonable attorneys' fees, suffered or
incurred, made against or sustained by Bovie or any of its Affiliates, arising
from or as a result of: (i) any actual or alleged defects in the
Arthrex-provided Product Specifications, if any; (ii) any Arthrex breach of this
Agreement; (iii) any acts, negligent or otherwise, or willful malfeasance on the
part of Arthrex or its Representatives or customers, in connection with
Arthrex's design, sale, marketing or distribution of Product and/or any other
activities or actions in connection with the Product; and/or (iv) any claims or
allegations that the manufacture, use or sale of any Product manufactured by
Bovie resulting solely from such Arthrex-provided Product Specifications, if
any, hereunder constitutes or creates an infringement of any United States or
non-United States patent, copyright, trademark or other proprietary right or
trade secret, be it registered or otherwise, arising under federal, state or
other law and/or regulation.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;9.2
Bovie agrees to and shall indemnify and defend Arthrex, and hold Arthrex
harmless, from and against any and all claims, alleged claims, losses, harms,
damages, liabilities, penalties, lawsuits, threats of lawsuits, recalls or other
governmental action, costs and expenses, including, without limitation,
reasonable attorneys' fees, suffered or incurred, made against or sustained by
Arthrex or any of its Affiliates, arising from or as a result of: (i) injury to
person or property to the extent that such claims arise out of or result from
(A) any product liability claim with respect to the manufacturing,
sterilization, packaging, branding and delivery of the Products, (B) any actual
or alleged defects in the designs of any product if such defect is the result of
Bovie-provided Product Specifications or (C) the failure of Bovie to meet all of
the Arthrex-provided Product Specifications; (ii) any Bovie breach of this
Agreement; (iii) any acts, negligent or otherwise, or willful malfeasance on the
part of Bovie or its Representatives, contract facilities or customers, in
connection with Bovie's manufacturing, sterilizing, packaging, branding and
delivery of the Products and/or any other activities or actions in connection
with the Products; and/or (iv) any claims or allegations that the manufacture of
any of the Products resulting solely from Bovie's manufacture of such Products
or from Bovie-provided Product Specifications hereunder constitutes or creates
an infringement of any United States or non-United States patent, copyright,
trademark or other proprietary right or trade secret, be it registered or
otherwise, arising under federal, state or other law and/or
regulation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;9.3
Nothing in this Section, or in the terms of this Agreement, shall limit Bovie's
liability to an unaffiliated third party for a claim, or alleged claim, against
Bovie for death or bodily injury to such third party caused by gross negligence
or willful misconduct in the manufacture of a Product hereunder.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">9.4 </font>Each party shall give the
other prompt notice of any potential liability, and upon receiving notice of any
such liability, each party shall, when possible, promptly notify the other of
commencement of any action, a general summary of the action and, when
applicable, notice by Bovie to Arthrex of demand for indemnification. In the
later event, Arthrex shall have the right to participate in and to assume the
defense of such action with counsel of its choosing; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">however,</font> that both
parties should cooperate in such defense, if and when such cooperation would
benefit the overall defense. No settlement of such action may be made without
the consent of Arthrex, which consent shall not be unreasonably withheld or
delayed. The terms of this Section shall survive the expiration or termination
of this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.0
</font>NON-COMPETITION.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
the Term, Bovie agrees not to, whether directly or indirectly, or through any
person or entity, whether on its own behalf or on behalf of any third party
other than Arthrex or Arthrex's Affiliates, (i) sell any of the Products to
third parties or Affiliates of Bovie or (ii) sell any console (as defined in
Appendix A) to any orthopedic distributor or company or to specifically market,
promote or advertise any such modified console for any orthopedic use; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">however,</font> that Bovie
may continue to perform under any contract, agreement or arrangement that would
otherwise violate this Section 10 which was in effect prior to the date hereof,
<font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">further,</font> that Bovie
shall not expand, increase or enlarge the scope of, or quantities involved with,
any such existing agreements, contracts or arrangements with third parties.
Notwithstanding the foregoing, Bovie may not sell any Products or consoles if
such Products or consoles contain any intellectual property or Confidential
Information of Arthrex.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">11.0 BINDING
</font>EFFECT/ASSIGNMENT.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">11.1 </font>This Agreement and the
performance of any obligations hereunder shall be binding upon, shall inure to
the benefit of and be enforceable by, the parties hereto and any and all
permitted assignees, successors and legal representatives of the parties
hereto.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.2 This
Agreement, and all rights, remedies, obligations, liabilities or interests in or
arising hereunder, as well as the performance of any obligations hereunder, may
not be assigned, delegated, encumbered or in any other manner transferred,
directly or indirectly, by a party hereto, without prior written consent of the
other party. Any attempted assignment, delegation, encumbrance or other transfer
in violation of this Agreement shall be void and of no effect, and shall be a
material breach hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.3
Bovie agrees that it shall not transfer all or part of its individual assets, or
all or part of its individual business pertaining to the Products manufactured
and supplied pursuant to this Agreement, unless and without establishing and
demonstrating, in writing, to Arthrex that the transferor of such assets and/or
business expressly agrees to assume all rights and obligations set forth in this
Agreement. The terms of this Section shall survive the expiration or termination
of this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">12.0
</font>MISCELLANEOUS.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.1
Further Assurances</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
party hereto agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate
in order to carry out the purposes and intent of this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.2
Force Majeure</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except
where set forth expressly herein, neither party shall be liable for any delay or
for any consequence of any delay in the production or delivery or purchase, as
the case may be, of any of the Products if such delay shall be due to any cause
beyond its reasonable control, including, but not limited to, acts of God or the
public enemy, valid law, acts or requests of any national or provincial
government, or of any national or provincial officer or agent purporting to act
under duly constituted authority, wars, floods, fires, storms, strikes,
lockouts, delivery of nonconforming or defective material, supplies or
equipment, interruptions of transportation, freight embargoes or failures,
exhaustion or unavailability on the open market or delays in delivery of
material, supplies, equipment or services necessary for the performance of any
provision hereof, or happening of any unforeseen acts, misfortune, or casualty
by which performance hereunder is delayed or prevented; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">however,</font> that the
party so affected will use all commercially reasonable efforts to remedy the
situation, except that nothing contained herein shall require such party to make
settlement of any labor dispute on terms unacceptable to it and no such party
shall be liable to the other for any losses, damages, or costs by reason of its
inability to remedy the situation. If any such delay occurs, then (unless the
cause thereof shall frustrate or render impossible or illegal the performance of
this contract or shall otherwise discharge the same), the parties' period for
performing their respective obligations shall be extended by such period (not
limited to the length of the delay) as the other party may reasonably require to
complete the performance of its obligation. In addition to the foregoing, the
parties agree that Bovie shall have no obligation to supply Product to Arthrex
during any period in which Arthrex is in breach of any of its obligations under
this Agreement.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.3
<font style="DISPLAY: inline; FONT-WEIGHT: bold">Relationship</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Agreement shall not be construed to create between the parties hereto or their
respective successors or permitted assignees, the relationship of principal and
agent, joint-venturers, co-partners or any other similar relationship, the
existence of which is hereby expressly denied by each party. Each of the parties
shall be, in all matters connected to this Agreement, independent contractors.
Neither party shall be liable to any third party in any way for engagement,
obligation, contract, representation or transaction or for any negligent act or
omission to act, of the other, except as expressly provided herein.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.4
Notice</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
notices, requests, consents, demands or communications contemplated or required
by this Agreement shall be in writing and, in order to be valid, shall be
delivered by personal delivery or sent by certified or registered mail or
equivalent, return receipt requested, by facsimile or telex, promptly confirmed
by a writing sent by registered or certified mail, or by recognized overnight
courier, addressed to the parties at the addresses set forth on the first page
of this Agreement, or such other addresses as may be designated, in writing, by
the respective parties. Any notice shall be deemed given when received by the
other parry.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.5
Legal Construction/Severability</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If any
part of this Agreement shall be held invalid or unenforceable, the remainder of
the Agreement shall nevertheless remain in full force and effect.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.6
Section Headings/Construction</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
captions and headings appearing in this Agreement are for reference purposes
only and shall not be considered part of this Agreement. Such captions and
headings shall not modify, amend or affect the provision hereof. This Agreement
has been jointly prepared and shall not be strictly construed against either
party hereto.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.7
Entire Agreement; Modifications; Consents; Waivers</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Agreement, together with the Appendices attached hereto, contains the entire
Agreement of and between Bovie and Arthrex, with respect to the subject matter
hereof. This Agreement may not be modified or amended except by an instrument or
instruments in writing, signed by the party against whom enforcement of any such
modification or amendment is sought. Each party hereto may, by an instrument in
writing, waive compliance by the other party with any term or provision of this
Agreement on the part of such other party to be performed or complied with. The
waiver by either party hereto of a breach of any term or provision of this
Agreement shall not be construed as a waiver of any subsequent
breach.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.8
Governing Law</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
provisions of this Agreement shall be governed, in all respects, by the laws of
the State of Florida and adjudicated, respectively, within the exclusive
jurisdiction of the courts in the State of Florida. The United Nations
Convention on the International Sale of Goods shall not apply to transactions
made pursuant to this Agreement.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.9
Counterparts; Telecopies</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Agreement may be executed by telecopy in multiple counterparts and all of such
counterparts taken together shall be deemed to constitute one and the same
instrument. Transmission by telecopier of an executed counterpart this Agreement
shall be deemed to constitute due and sufficient delivery of such counterpart.
Each fully executed counterpart of this Agreement shall be deemed to be a
duplicate original.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.10
Litigation</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
Party hereby unconditionally and irrevocably consents to the jurisdiction and
venue in the Courts of the State of Florida and in the U.S. District Court for
the Middle District of Florida, and irrevocably waives any objection (including
any objection with respect to venue) that any Party may now or hereafter have to
the jurisdiction of said courts, and irrevocably consents to the service of
process of said courts in any matter relating to this Agreement by the mailing
of process by registered or certified mail, postage prepaid, at the addresses
specified in this Agreement. If necessary, Bovie shall appoint a registered
agent in the State of Florida for acceptance of service of process and/or other
notices provided for under this Agreement and shall notify Arthrex of the
identity of such registered agent within 30 days after the Start Date. Any award
made by a court in conjunction with litigation between the Parties regarding
this Agreement shall include an award of all reasonable attorneys' fees and cost
incurred by the Party in whose favor the final decision is
rendered.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ThESS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
OF, the pities he eve executed this Agmmt ;as <font style="DISPLAY: inline; FONT-WEIGHT: bold">of the date </font>fast it ten <font style="DISPLAY: inline; FONT-WEIGHT: bold">above.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <div align="left">
          <div align="right">
            <div style="TEXT-ALIGN: right" align="left">
              <table cellpadding="0" cellspacing="0" width="50%" style="TEXT-ALIGN: right">
                  <tr style="TEXT-ALIGN: right;">
                    <td align="left" colspan="2" valign="top" width="100%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">BOVIE </font>DIC ..
      CORPORATION</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="top" width="95%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
                    </td>
                    <td align="left" valign="top" width="95%" style="BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="top" width="95%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nanrxe:&#160;</font></td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="5%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                    </td>
                    <td valign="top" width="95%">
                      <div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:&#160;</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="2" valign="top" width="100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr>
                    <td align="left" colspan="2" valign="top" width="100%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ARX,
      rNC.</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="top" width="95%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr>
                    <td valign="bottom" width="5%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
                    </td>
                    <td align="left" valign="top" width="95%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><img src="sig.jpg" alt=""></font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td align="left" nowrap valign="top" width="95%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Title:
  </font>VP.</font></div>
                    </td>
                  </tr>
              </table>
            </div>
          </div>
        </div>
      </div>
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Products that are subject to the Original Equipment Manufacturer Agreement (the
"Agreement") are as follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Product Specifications for each of the aforementioned Products are as
follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">To Be
Determined</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Manufacturing Process for each of the aforementioned Products are as
follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">To Be
Determined</font></font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Appendix
D</font></div>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form of
Purchase Order</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Appendix
D</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Arthrex,
Inc.'s ("Arthrex") Form Contract Manufacturers/Suppliers/Vendors
Agreement</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Appendix
D</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Product
Price List</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">To Be
Determined</font></font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div>
      <div align="left">
        <div align="left">
          <div align="left">
            <div align="left">&#160;</div>
          </div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sig.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.`#:`P$1``(1`0,1`?_$`'D```("`@,!`0``````
M```````)!P@&"@(#!0$$`0$`````````````````````$``!!`,``@$$``,#
M"@<````$`@,%!@$'"``)$1(3%!4A,18B-!DC,V,E-54V5Q@*46&!,F07.!$!
M`````````````````````/_:``P#`0`"$0,1`#\`W^/`/`/`/`/`/`/`/`/`
M/`J+V!TXYSK4:;!TJM*V)T/OJW.:DYJU6V0D)FY[0*KLU8\R5JEUX4U5=8T&
MO09<W9IAW"L!Q@BFF&R#R0A"03EH:G=*[R]B&L9&G=#[#V(WQG:+HQ[$^B2+
ME::IHK:^T[+3I,&)XHYGYI#M;M5C];:GF+2J1D;#(1YQ8I<6R&[-'3#,@G`;
M(_@'@'@'@'@'@'@8O=+O3=;U6<O6PK96Z-2JR"N3L=MM\W&URM04<VI"%FR\
MW+DB1L<+AQQ*?K=<0GZE8Q\_.<8\!:4?U?U-V:W5);U]4:CTKG&QC"S:NV.G
MH&W_`*FX0B)(IAQOGSF<`FE[!V$%-!L-/!66R2U3A'!GE/B-R2,-?>#YLOU"
M\Y](U"TU[LG8/2'5\GL&KQ59OIMYWWLFA4R0:B[.%<QEU73.FK!KS4%#:!L`
M>/Q,@0V#D!Y^P^63G*W5A56^^@?EK3)MGZ'];P6QN0.OX.I'L4.9U3O"[4[7
MMY)`KCD9$:_V95)M%ZI9E+E7V!G7<KAWDIDAQS"6BTMO,/@TSA#I?'8W'?.O
M3:H`FKF;CUA`6J8KQ+HK^8FQ9;<C+*(,0&XX.3'(L$>3D1S'TY<%RVI2$*SE
M"0MIX!X!X!X!X!X'E3L["5B$F++99B+KU=KT7(3D_/S9XL5#0D+$B.GRDO+R
MASK`4=&1H+"WGWWEH:9:0I:U83C.?`3,KOWIOO!>PJYZE:;IV1UQ2)U-5E.\
M.DYFS-Z(L4P.0D2P1O.6OZ)!S%EW5(0GP_G]R<5#5Q+H[>6U'C%CO*#G8/4)
MM+8]P3L[:_MR]G4ELJ*?=?J!^IMHZLT3KRL*+K<3$R6,Z=I6I7J!.(.EPB#,
MH,&<;0T0EC"?J;4^Z$C^HK?6X]N:FZ#UEO#8QNY[?R'U=MSE0;<T[36:+<=H
MU_6+T5^CM%XB(^0/@9.U+`E4,%2T<D4244S][\=#V75.`V3P#P#P#P-8W4VX
M]C^T#V"]=XT%LRVTS66CC9/D*Q;H@X^P!)T%J^IVTIC<]8Y[L$C'N4Z8ZNZ[
MOU::?+M<<L@6AZUK\&2WDJ8/&0.&PMHK16J>:M4TW2FE:?'4C75%B68J$A@/
MNODD+3CZY">L,P8X_+VFWV,]3ALO,R+Y,G+R+[Q9C[Q#SCB@ESP#P#P#P#P#
MP*D]@]F:JXRH=?LU["M-XO6QK4!KO1VB=8QHMCW+OC9LOG&(VBZSJQ)\:R>8
MAK.29`XH@2+B`&UE&DL-)^K(5>KG$6P.KKM6M]>RA%?L3M3D&)G3O$5(M<K9
M>8=1/!R\/8ZY<=KLFQL*QT5T'#G13?W).1'55(5>%LQ`"U85)E`U-EED=EH<
M=IMAAAM#+##*$M,LLM)PAMIIM&$H;;;0G&$IQC&,8Q\8\#L\!=?M1ZQ!X_XM
MVK?!8F[6W8]X#:T[IC7^KH\^8VI>-G[+P[78@'7D1%Y0>;8*W%D&3JLH6W]D
M6*=<^O&4IQD)SXHT2KF7DW0&B7S<R4GKK6E>B;#(8`CXE@VV&#YF;>2##Q45
M"1T-%O6B3+4($R(P@0;+;.$_V/G(6A\`\`\`\`\#RYR<A:S"R]DLDO&5^O5^
M,/FIV>FSQ8J&A8:+%=.DY:6DSG6`HZ-C@F%O/OO+0TTTA2E*PG&<^`I:F"*]
ML,O%;<L!QF?6/$E/JU3J,T45D7NJRUJPNM#[LVU'DQS,TSS)"R\4O%4IY;OX
M]W4VB:F1<QV(X0@&V1$/$5^+`@X&+CH2%BA608N(B`1HV+C0AT8;'#`CPFF1
M`Q6&\82AMM"4)QCXQC&/`J'W;U_7>,M!678ZPA+?M"5')KNCM1MR;(=AVSLT
MQGZ(>N0HOT$'D`1V7/SY=\=A]046.\[]"UX;;6%?/4'QCLOC?EN>5T&=#275
MO46ZMF==]7E5AYI=48WINN1%D9^$K(P6$1`<9686-CXY204X$<)%=<;4ZE>'
M5@U#P#P#P$!^X[V5RNFM1]&::YML$]%WO5&D[=L7J#?U:A90ZO\`,5"?@OP*
MW1(2Z!(5#1?7F\)Z?C(JB1R_R_Z=</;L4R,F+';26%Z?4YRQ7>-_7KRYI*$B
M'(J7%U=7;ML9TF8%L<C,[7V,`Q=-D34G8PQ`1YXHJU3)"$%):3A8S36,?.$X
MSD&)^`>`>!Y(<]!2,G,PL?-1)\S75@MV")#D0RI."<E!$R$8W,@,/+*C%R("
ML/L8?0C+S.<+1\I_CX%;;3V/I2H]2T'CL\ZR2&ZMA57^L@8VOUHZ?A:W"$B7
MDZ#(O,K&?D+J+5G'UI/YCGRV4!O+BW4*>0O+27`M1X%5.O.M*5R)KB&M4[!3
MVP=A;&N4/J;06E*;D+%ZWKNRUL'.U#6=3>E'A82(=D41Q!4A*R3X\7"Q(A1Q
M;J&!U_(0MR?R'9HZZ8[([!7`[%[?N\`H8<M@9!-1Y,U_:(6O/2G,6@D_L9&/
M;JU=F@2/VUJ;0S-7$UYXDQS`V1@QP8IX!X$)=%=$Z?Y2TY=M\[VN(=(UK08M
MR2FI<ADDXXM[/^3CX*NPD>T3+V6T3IF4#1\:$R\8:4XEMIM2L^`E+CS3O0?L
MRZ:UA[0.TZ#/Z4T?IELJT>MSDNR14`'<:LFX!6"!D^A=TR(IA\\Y<;Q3EQQ@
M,$^@,6.4L5S#2W`&2R@=GT7?=BZLT)N/9.H=6G;OVE1=;V^U:^U!&22(B0V3
M;H.$,D(*FAR*V"OQ2)Z080PG*6G%YROX0G*LXQX&5ZLM\GL'6.N;]-5"Q:^F
M;O0ZA;Y:A7`',7;:1)V6OQ\T?4+1&9<>S'6*M%&K".8RM7V265H^<_'SX&>>
M`>`>`>`FKIPQ?L?Z3F_7C5GR<<L\_FZZV'[";S%OPI8&P[`0<BUZXX%5'2@C
MQ*@K]$B"VG8!X?U*$K:`8CZT.S;JAP;8$?5:Z=7]>Q3(<4\W7GGH&N0\6L>-
MBJS7/UT4VVTS'"8BX*,#P6P.(TO+"',)RAA*L-+P@%[=\^T'2_$CM1U9%14O
MT#V)N4]56Y_Y(U6^%);)O=P/&83!$V]S+V0M5ZW5(R`B3K',Y8$&'>4\VE_#
M3N$!!/&_KXW7;]_H]C'LRL<#?^O#JUBOZ=T'3)4F9YQXJHQ<HQ/-UC6\><(P
MFU[8?>$"5.VDO)CBI,12H][`^&%(!U'@'@'@*%ZO[.V?MS;LQZ]_7/+PLKT^
MD8=/2'0Q4>FQ:OX%UY+I4TNSVYI2<Q5OZ*L0>5YI=&4YAQYW'[*3PS&,9_("
MDG?O#^H.>^#^:^$*!:YJLRG67>G)L9NC;Y#Y+UYZ.VP/9*79=T;1V$*X<<W<
M-K[@K6I'I(T=2%QY!@GUO)9%8RML-E-*4H2E"$I0A"<)0A.,)2E*<?"4I3CX
MPE*<8^,8Q_+P.7@'@1SM[;6O-#ZOONYMLVF(I.MM9U:7N-SM,Z<+'1D/!0@C
MA9;[Q)KP['WG<(PTPU]>%OOK0TC&5K3C(:S?KVW'`<OZR[D]T_8NS)&"L/LB
MVFQ8N?>=$6O+_P#4^L]=(71>;J1K:KR"BY6V[7O*95J._,!^[&9BOPC6FQ07
M%_;">/6#KVOZ_P!Z]2^Q+V"[1T/K[NSJR8CZZ+KF1W/!,.:#YOK04/\`_7VN
M8^O6J1KTU5R+(,`))%!RL>W-#,-#)+RP4X8*V#=-E]_\2ZDH-OV7>.K>?8VI
MT>&*FY\MC;^OCRFQAOAML4,`2Q.EG29Y;B!Q1VTY=()=0VC&5*QCP*K<$ZQW
M;O>\3'L6[#B)BL["V)'R\'R3SC98N)%8Y#YIE)(IZ$))`'D)YT7HO?5<3'R=
M\D%%8($:0-!MH8'">;=!LV<XQCYSG&,?^.?X8\!%/._N#TA:][=\V3</67,E
M)XTT?N*HZ#TA>-@7VBZPLLUM>LPY;N](\.)F9IB6L-"AIV8C(^+GB,):F"1B
MG0DY$QA>0Z[/[H,](/*UGZCN>-D=Q;/GJQ+24?NBS5&\:+XUUB[@251#S&P]
MP[,K59*M223XQS(<77A2,S"FLL-G#*5EUL/8TOZF+CM_;%#ZZ]LNX0.P.CJ,
M0S/ZRT?5@3:[Q%S19AY")*$E]/:OE4JG+7;6FJ\&IZ<LCY+CQ&75?C?*6'$`
M\/P#P#P#P#P#P*4^PCKA'%'*^P-TQ5?:O&SR'X#6G/\`K'/Y"R-L=#[1F!:5
MIK7(PP3K,@2U8+K+#9-P,K\AN-9)=;_M-^!#6DZSK?U3<(REYWQ-KG+TX6?N
MCJ+8%:@?VESWYU;NF=!<MQ4##@_ZPLUEN^PYH2N5<%QYQQF.9C0E/_:'R[@%
MB\*R7=O>0?7=[KFQ1^-KG?=W&:VZ0V':P1=E]-::-I-8:C0^4=":C.FLTGG"
M)TS!S8YS=DL3UI*LD[89&=$C6&#`\C@\WE[C;1O)555"ZVA).>N4QEDS8F\M
MF26+YO[<5A;;>;5:MM;9E!DV6Y366R7&V$N+;!CAE8%!'%$0VP@+4>`>`>`G
M3HWIW=/6>[;1P-Z][>Y3CZ*>)&]N]P1@(4U7^68@I"""M*Z<<-9+@;CV#:HQ
MS'TL.((`HH3OYL@E1JAA<`R70N@M8<V:XB-8:I@G(J"CW#)"4E90XJ=N%UM$
MP81*66];`MTFM^<NEZMLV8^=)RA[SI19;ZUJ5C&<)P"@NL"X_HOW=^MG1<%#
MSTKCBK77077VV['`V.$8CZ@[LZF8U'J&'LL(XZ]*N(G)84U6?AI*U,DM_1G#
M:G5X"Y/LP]CNMO7#HC.PINM3^W-R7F4Q1N>^=:`,5,;&W/LV0C90^)A8N'BA
M9*7#K(+$2^3+2J17FPQFLI0AXIT8=X,2US[0-6P^IZE/]6CJT]L6"E(+7G3,
MG1*UM#:',W.^XY%$2*33[WT[&4(?4];PQ-6&,`,0;)I<@)23;`DEM.L/N)">
M>V=-;RZ+T\%KG1/4LIR1&V"44?LO>%#C(J6V7'Z\#@)8YL'6DG,I<@:Z?,6%
M,?\`G2CBD.L0Z2?QG$/+0M(:<F@/6SS_`-,]T/\`4'.73W8MNXSX;LKTUTS[
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M1`5M3JS4N/M/NI'6\&MP+1R7'?J(XSU?3JUNC2W"=(BY>.C*<[=-VZEYSKT]
MMF9BW1I:3E+`7)U&'#L4J1-+S+FH'80#'N.9=;9&';1AL&13UJUSJFB%VJRV
M&FZYUI48=HLVPS,I"U2DUN!82TT.^_)EO`PD5%MI<0AO.5H:_M)2G^>,>!B6
MB>A-)].:^$VKH#9E4VOKPV4EH5BTU"0P?'?MH,K(DE'OX4AHH0IE7T.H2ZVC
M+XKS)+7UCOLNK"I+OM9XH-Z;H7)%$V3+[CVY>+0_32W-)TFU;6U_KNR-P\Q.
MC1.S]ETZ,DZ54#C(^O'N*9<,=>!;#<>.0(Q]+J@8SX%+.L.^>>^++/IFM[Y/
MML"UN\^SAUZU1E6+EJ96QZ<73A;#*7JQ(>9%KP(*+P(1A&,/ENAL&$MLJ8")
M6T%T&W&W6T.M+0XTXA+C;C:L+;<;7C"D+0M.<I6A:<_.,X_AG'@<_`/`29OB
M[:IWE[*HU_:=MK<3SCZB=/,],[1GY><;'JL/U1ON.M58UFS=1S"F0V2M0:.@
M)F="4V,6\HZU"8;(&<'=%,"/./IBX^V7J)COO9%!V70.&N;9),7Z[=8;"_-J
MN=T[4%*L\3>>X+CKUU$?,CY$B3$P-$#FFW4`"J+D&FFC'E*0'?O$Q[UB>RLW
ML:5C_P!%P7WI7:U0.P-AX_;%P^B>K:C^LJVB-R7S+1AHE8U=?:KC^EY&5R`,
M#&R;K),E((84,T@'TC$CF#L&!OLE"%,M$BE#.H?')'?0EUA]A]I2FGF7FE84
MA:<Y2I.<9QGX\"#>;^C->]3:O$VUK,2[QU<)L-LJSL;L6B6;7-LCYNEV$^MS
M(Y]9M<?'238ZC8]3@Q"$N#%#.(<;<5A7\`GCP-=[VT>QW;@FN^C-+<.8M@C>
MCJBI?8G951BVCX/FP:QRXU*`UEJ"2D$MP%RZ.7,RZ"IU;3_XFO:Z&<:8\U*-
MBL-`X7C?G+2G*7-FJ-)<_I!,UM6*M&D`W`<F,E)/:,O+BLR,]MNV62);0)<+
MGLN4?<F).6^5?GE%*<3GZ,HQ@,8[.[TY7X$U=);4Z<VQ6Z("V"<[5*:J1`*V
M5L^9$&>?&J6L*+@MJ<N=FE7F?LLLC-_:;6K"GW664K<2"9>.YBY\G5;K+W!]
MR56QU+I?V.;(U[5=+\JRLU7ZQ9*9K6$<EJ[REH67F;#8`*=#7F4K9F)2SS$P
MJ-%KHB"'C$C-BDMX"C[_`%5M*QWG9&[N`:$U[<_:L37]H5V=Z*AIMV<X@X`I
MDX!9[NYSMS;*G)K=2LQ-4:&CHU@]EL67V`68THR2<0Z[$AA`G/VL^NY[6NYN
M2(#2_L*Z1[4]HD'6(GN3I?O/2^P^8N/=#Z>:AR838+=/@)-IDV8ETQA\K%1I
MD6&'+2"WFGA<AO,L"J!C^Z-K;A]BMCQZ4^&=B7$WGO0E3KG/OM%]B<@/"2DV
M''P%3)K%JYYUM^2V$!,;EV>W6C`+),CANAP[Q#S*6\?2[G`6P]D'%-BL.G.(
M^&>=^<]NS_%D!:DA;:H7-&QM,Z9!C8K7?]'YU/6MR*V@V[%VK0EIF).7D+B)
M'1<I+F%Q[!?V"'<*8)!X]1J-6H%5KM'H]=AJC3:C"QM<JU7KL<+$0->@(<1H
M"*AX>+!:9#`CH\)A#3+3:$H0A.,8QX&1>`D/36R=+Z+]O'LL"WC+TG3=\VUK
MKD78VHK?>[1'4X+;>DJ[J]K75F=B3INQ#0,V5K_;D$>&0TD=N1"0:TIS*AB1
MLY"'NE?9[O\`['N;/(GI.@(W;=DL#9D1NWV%3,:<KEGE:!,/)KY4S1[/(BBU
M_>VU(QP4MT4&$<E`F"!TIR@M22T!A46@[IKOKGM%=];OJ)YVVEV3U[NRU24O
MT_W!M&-M<QI@C;`F;6UL/:.\=JO2HP$]<("SI7@\".(2!$CN9$P](2K&8X@*
M+=3^N?K^W=2T_771_(MH]E6R[B'K_.Z^OMM(GJ7IAV0G1K_8HFL<VV:J;*TI
M1M):GU/8K0%3)2'FS2[-?/VBR689#$5'B2`7-W?Z<O8[U94`I?L'V#:(V]OZ
MJ3,_*07(@,K=-2\8:IA-A58N@:,-#$HL,ULN9)JU\KX)(C1T0R]8<LFQ7[1?
MWBB"@[J1Z333-9JU/WU[;8B*T+7TQ5/MO.O(+&H^1M29VRY2G@X\?81CJ)%=
MWNE2@0QU1)4Y'8ES!(>/(4R-B-%0T%^+%ZN_7W6*[I35/#O5)GKRV;KIU<33
MI3E?<>OX:V[D,5+&U]X#>4%,/25EWZ4*6N?!$06:@@.2DRU)5EYAA#`00GAK
M;+K4F4U_W-?1ZQH?[69=YNV<P+8B<$%)"8_8NX?R@'#IB\,H^[E/U.9PG'RK
M/QX'7:/1]ZH]C5:GW+M_MKH3M,&>.LLE5[ET_P!_2BZ#)75Q<4/?IG6$74++
M2*O#*;E@G,/A1[I#822LCN_6EH?#0103IOTA<^[$D0=-^\[<W'I=;Q+P\GJ+
M4_M#ICVNX>9F90R;LIJ:!MUC;$-$R\O)2&72&QL,C,N(PIEEE>7,K#V-2[1X
M"I-W@['LC_NA=E[JJT=75"RNO9SLGG&DP]AM[SA:'I\R=H4!"6H"`8"?;_&B
M13&7&RF<.NFOMJ4/D'Q_]*>I/^<'1?\`P[^Z_P#U+N/_`-__`#&_XS_VS_\`
M*_N?^A\#7C']4_L2[+O^]Y?JN&Y\U1J,CO"<WA<N;2#MC&ZU[5F:A!P]0USM
MW8=PH][)LTQJ.!I%0J@L%4"8ZLI>.ASB)0'))&#B`?I4HCV2!Q5:CI8S@NL#
MBU.-9D8JI5/?,O%5^?&:&'76JTDFT5-$E4X\=*D#'+8C7E);0G\!K"L_0%;Y
M[G'W!VNKS%)N79_KTOE1L,7(0-B@KYZ[=B6./L\#)M.BG1%JBD=CQE:FPSP7
MLLDM?KF1B$9SC+*4JRGP(VUUZX?8=IS6#U"T%[%-*<Q`YCBL1NO='<&5T_3=
M<LY5R$ERK37(#>.[MQ6R&5*55EV.?BA98>":>=_)&"8>^M;@2S2>._:G#CQ+
MMS]Q)UPD<F+S8V4<&\R0T,Y'#R+YP+=:8C6QI2-.,&'%#/6:5(-N#/%Y&0*0
ML5\4*8776WLNV)T$]R#I_P!M^X=CIC8(IWJS:D3RWR/1J[S;7IX`1RNU#%GI
MVM`K'([XV/"F$/1$3#2T9*UT/#,T8\.PX"DP+)T3UC=HZMUI%Z7UK[6[=3-0
M0<,;7(C7$=PKQ7(5L:`D5%+DHX_$_K^7DK(Y,N'/NR1DJ0:?*DD/$&OD$//.
MK"N47_V_T_6*O"4G7G?NW--4^)N4#;2:MHBB/:2K<F+#9CR3Z>U7]9[3K<)4
MJI<98<HN;37QX@\]4@ZQ^4V(R$.*$G1/I/LE1WP3T/KCJ375"OQLM$3I,A_T
M(\\;0GOVT5&)B%G`;1WT1MK=\&1*@XR@I4?:!<KPKX1]"4HPD,EWKZG.INE]
M;;!U;N_VF;1O-<V$_KB0<<*Y@YZ!,I$[K93ZAK'K)L".8BJ1.6K[V,R[PPN?
MN+;PL7`B\K4L,RY3]1]MYUISM%LOL4[.V%6(\B.Q2:U3)JB<]5"E18T@/(R4
M3'U74M4CHLAJ;6RXRZY\-+;8*>^U]#^67V0L+/>O-R8QC\#NGV)U?XBYZ/\`
MF!Z2%?SDJ8D7#@)K/]2T*PX_:5<9>`P$X^`UC)QDQ@M_ZGLAX55]7^O*$5>"
M*!TOV?0FMA6<J[V4*E[NCJT-(7B6@51-ENLDY$T<8ZQVVVRF&IB2D)=Z1)?D
MF&\)6@/Z@U!EM\X`;N#`K4#VG[`]7+'%DQW2:'TL4:^:Z?\`A?BG%8V35-A#
MI*A?Q%_BX9;:95^2Y^0V_P##7V@Q^S^N8RP6:&GHOO[V1TJ,BP`0S*96.CX(
MBLV(@1TAQ^5F2+AK"UVUH^32^E#Z0)4$;"6D?99:5E:EABTCZQ;`;"UZ+']F
MOM,B381N31(V*.Z&UBY-6U4@>HP5ZPM2FA)*`8<A1U8%%_5@QJ%#XQDA+[WR
M]D((W+Z`>+M_5NIUG;.U>X;X/1+U';#IIUX[`VML<VM6&(D)V3BG(=G9AMSB
M`D@$VB1PEU`N#'&B_MNON-LC)8":M(>FCC+0:6&J;)=52(*2[+,'P%E[5ZK/
MIDS:KG)$SEPNLEKZ/VU%4#%LL]@.)D3"AXP?[AQ+KV$I4K^`6%A_7KR;70,Q
M5>H5P@8S+C[RHZ%WGOV*!4\2>;*$.J%`V>.PIQ^3DR25YRG.5$$.N9_MN+SD
M/DMZ\^3)X5L"=H5PFP69&)EV0I?>F_I(1J6@)0.<@I1H8W:#[+<C"S4<.8(_
MA.'1BF&W6U)<0E6`P,_U/^OZ4M$I=Y/GP.1NDY+TB?FK>?L;;QEHF)W63WY.
MMYF5GR-@.2TC*:])_P`K!OO/+=B7?[8JFE?Q\#$;3Z8/6#>6[`S=^0J#<FK9
M;&[]:FK7.[!L3=FO;,>7$LW6PHF+B8F:MS44>^*F2)PZ:D=YQO#GT+4G(8$C
MT%^G)I:'6O7[H=IYM:'&GVX^QMD,N-JPM#K+Z+%AYEU"\?5A2585A7\?GY_C
MX'#_``!O39\XS_A[Z`_L_P`O]4SWQ_+X_CC]_P#"O_7Y\"5O\'+U9N0D)6S.
M#.:):`K-8=IU;B)_6D+88^OUXBQ#VTL*$&G&Y!N)?/LH^3226,-E$OO/J=<7
M^21]T)1%]:?KF"&'#%X%XL9&%9;88:3RWH_.&VFDX0A/RJCJ4KX3C^><YSG^
M><_/@?HQZWO7>G.%)X*XOQG&<9QG'+>CL9QG'\<9QG%&^<9QGP+A?JXS_=P'
9]P_5_P!T'_V9_N[_`#?]P_T/^;_\O`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>4
<FILENAME>v167911_ex10-12.htm
<TEXT>
<html>
  <head>
    <title>Unassociated Document</title>
    <!--Licensed to: VF-->
    <!--Document Created using EDGARizer 4.0.6.1-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><img src="ex10-12logo.jpg" alt=""></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="top" width="39%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporation</font></div>
            </td>
            <td align="right" valign="top" width="39%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DISTRIBUTION
      AGREEMENT</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Article
I.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Distribution Agreement ("Agreement") is made as of October 6, 2006 ("Effective
Date") by and between Boston Scientific Corporation, One Boston Scientific
Place, Natick, MA 01760 ("Buyer"), and Bovie Medical Corporation, 7100 30<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>
Avenue-North, St. Petersburg, FL&#160;&#160;33710 ("Seller") for the purpose of
purchase, sale and delivery of Products (as defined in Section 1.1) in
accordance with this Agreement.&#160;&#160;Buyer and Seller are herein referred
to collectively as &#8220;Parties&#8221; and individually as a &#8220;Party.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">MAILING
ADDRESSES AND FAX NUMBERS FOR NOTICES, ETC. UNDER AGREEMENT</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <div align="left">
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" nowrap valign="top" width="32%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Seller</font>:</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bovie
      Medical Corporation</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7100
      30<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>
      Avenue North</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">St.
      Petersburg, FL 33710</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Attn:&#160;&#160;Moshe
      Citronowicz, COO</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;(727)
      344-3876</font></div>
                  </td>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">with copy to</font>:</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bovie
      Medical Corporation</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7100
      30<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>
      Avenue North</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">St.
      Petersburg, FL 33710</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Attn:
      General Counsel</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;(727)
      344-3876</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" nowrap valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">&#160;</font></td>
                  <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline">&#160;</font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="32%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Buyer</font>:</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Boston
      Scientific Corporation</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One
      Boston Scientific Way</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Marlborough,
      Massachusetts 01752-1242</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Attn:&#160;&#160;President,
      Oncology</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;(508)
      683-5693</font></div>
                    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                  </td>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">with copy to</font>:</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Boston
      Scientific Corporation</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One
      Boston Scientific Place</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Natick,
      Massachusetts&#160;&#160;01760-1537</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Attn:&#160;&#160;General
      Counsel</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;(508)
      650-8956</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>NOW, THEREFORE, for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereto hereby agree as follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">1</font><font style="DISPLAY: inline">.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Purchase and
Sale.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Products</font>.&#160;&#160;For
purposes of this Agreement, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Product</font>&#8221; shall mean the
medical resection device having a sintered tip, manufactured by Seller, as more
particularly described in the Specifications (defined below) attached hereto as
Exhibit A.&#160;&#160;Additional products, together with specifications and
pricing therefor, may be added to this Agreement by mutual agreement of the
Parties in accordance herewith.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exclusivity</font>. Seller
will manufacture, offer and sell on an exclusive, worldwide basis Products to
and for Buyer during the term of this Agreement.&#160;&#160;Seller shall not
offer or sell to any third party or for itself or its Affiliates or have made,
offered or sold on its behalf the Products.&#160;&#160;Buyer shall purchase the
minimum quantity of Products, as described in Sections 1.3(b) and 1.3(f),
below.&#160;&#160;&#160;For purposes of this Agreement, <font style="DISPLAY: inline; FONT-WEIGHT: bold">"Affiliate" </font>means, as to
either Party, any other person or entity that, directly or indirectly, controls,
is under common control with, or is controlled by, that Party. For purposes of
this definition, "control" (including, with its correlative meanings, the terms
"controlled by" and "under common control with"), as used with respect to any
person or entity, shall mean direct or indirect ownership of more than 50% of
the stock or (partnership) shares of such person or entity.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline">Ordering.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Buyer
shall place all orders with Seller for Products under this Agreement on Buyer&#8217;s
form of purchase order. A copy of Buyer&#8217;s current purchase order form is
attached hereto as Exhibit B and is made a part hereof.&#160;&#160;All Buyer
purchase orders shall set forth the Specifications (including relevant revision
level), quantities, and delivery schedule, and shall state such additional terms
and conditions as Buyer may deem appropriate.&#160;&#160;If a Buyer purchase
order conflicts with this Agreement as to Specifications, terms or conditions,
the Specifications, terms and conditions of this Agreement shall
control.&#160;&#160;No other terms or conditions (including those on Buyer&#8217;s
purchase order) and no modification, alteration or amendment of this Agreement
shall be binding on the Seller unless accepted in writing, in advance, by an
authorized officer of Seller.</font></font></font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Buyer
will deliver to Seller an initial binding purchase order for two hundred (200)
units for the first three (3) calendar months of Product (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial Purchase
Order</font>&#8221;).&#160;&#160;Buyer shall deliver such Initial Purchase Order to
Seller with a mutually agreed lead-time prior to the first Product delivery date
set forth on that Initial Purchase Order.&#160;&#160;The first calendar month of
the Initial Purchase Order will be deemed to be the month in which the Initial
Purchase Order is placed.&#160;&#160;From time to time, Buyer may also place
additional purchase orders for Product.&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Contract Year</font>&#8221; means the
one-year period beginning on the Product Launch Date and ending on the 12-month
anniversary thereof, and each successive one-year period thereafter, during the
term of this Agreement.&#160;&#160;Notwithstanding anything herein to the
contrary, Buyer shall purchase a minimum
of&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;** units of Product
during the
first&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;Contract
Years of the term of this Agreement as follows: during the first Contract Year,
a minimum
of&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;units
in order quantities of at least 200 (as the Initial Purchase
Order),&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;respectively;
and during the second Contract Year, a minimum of the difference
between&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;and
the actual number of units purchased
by&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;units.&#160;&#160;The
quantity of Product ordered by Buyer prior to the Product Launch Date (if any),
subject to the minimum per-order quantities set forth above, shall accrue to
the&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;unit
minimum purchase requirement for
the&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;** Contract
Years.&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Product
Launch Date</font>&#8221; means the date the Seller ships to Buyer Product for
commercial resale (subject to all required regulatory approvals), but no later
than ninety (90) days after mutual execution of the design transfer document
required under applicable law; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that Seller
timely ships Product to Buyer in accordance with the Initial Purchase
Order.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Within
five (5) Business Days after receipt of a purchase order from Buyer, Seller
shall acknowledge receipt and confirm whether the order can be supplied within
the delivery dates set forth therein.&#160;&#160;Unless Seller advises Buyer to
the contrary, in writing and within five (5) Business Days of the date Seller
receives Buyer&#8217;s sent purchase order, Seller shall be conclusively presumed to
have accepted the Specifications, quantities, due dates, and other terms of such
purchase order. For purposes of this Agreement a &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Business Day</font>&#8221; means any day,
other than Saturday, Sunday, or a legal holiday in Massachusetts or
Florida.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Due
dates on the purchase orders are the dates that the Products must be received at
Buyer&#8217;s facility indicated on that purchase order. Orders arriving up to three
(3) Business Days early or three (3) Business Days late will be considered on
time.&#160;&#160;As soon as it becomes apparent to Seller that it cannot meet a
due date on a purchase order, Seller shall notify Buyer in writing of the
expected delivery delay.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller
shall invoice Buyer and Buyer shall pay all shipping, insurance and related
charges.&#160;&#160;Seller shall pay premium freight charges in excess of normal
shipping charges to ensure timely deliver of Products ordered pursuant to a
purchase order if Seller is responsible for a delay in shipment unexcused by
Force Majeure (as set forth in Section 7.3).</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
the first two (2) Contract Years, Buyer shall purchase at least the minimum
quantity of Product as set forth in Section 1.3(b), above, at the unit transfer
price set forth in Exhibit E (Transfer Pricing) for that
period.&#160;&#160;Thereafter, during each of the next three (3) Contract Years
during the term of this Agreement, if Buyer orders any Product, Buyer shall
issue a binding purchase order for a minimum
of&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;units
of Product, with a minimum per-shipment quantity of not less
than&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;units,
for delivery during the subsequent 12-month period.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Pricing Period</font>&#8221; means the six
(6) month period beginning on the commencement date of the first Contract Year,
and each successive six (6) month period thereafter during the term of this
Agreement.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As set
forth in Exhibit E, for Products purchased during Contract Years one (1) and two
(2), the price per unit of Product purchased during such twenty-four (24) month
period shall be&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**
for the first&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;** units
purchased, and
(b)&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;for all
Product above the
first&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;purchased
(whether purchased in Contract
Year&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**).</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
initial pricing set forth in Exhibit E is based on the Specifications Revision
&#8220;A-1,&#8221; as set forth in Exhibit A.&#160;&#160;Seller reserves the right to amend
the pricing in Exhibit E for the Product in accordance with changes to the
Specifications requested by Buyer; provided, that (i) Seller will provide Buyer
advance notice of any such price change, (ii) Seller will implement such changes
to the Specifications and amend such pricing, only upon Seller&#8217;s receipt of the
Buyer&#8217;s Oncology division&#8217;s president&#8217;s written approval thereof.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
each of Contract Years three (3) through five (5), for each Pricing Period,
Buyer will initially pay the Product transfer price (set forth in Exhibit E)
that corresponds to the forecasted quantity of Products to be ordered for that
Pricing Period as set forth in the twelve (12)-month rolling forecast delivered
by Buyer in accordance with Section 1.6 of the Agreement on the last day of the
second month immediately preceding the commencement of such Pricing
Period.&#160;&#160;Within thirty (30) days following the end of each of Pricing
Period during Contract Years three (3) through five (5), the Parties will
compare the total amount actually paid for Products by Buyer during that Pricing
Period with the total amount which should have been paid based upon the actual
purchases of Products in such Pricing Period using the applicable Product prices
set forth in Exhibit E, as amended.&#160;&#160;Any difference will be paid to
the appropriate Party within forty-five (45) days following the end of the
applicable Pricing Period.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Buyer
shall timely place and Seller shall timely fulfill binding purchase orders as
required under this Agreement.&#160;&#160;However, if (i) Seller is unable to
fulfill such binding purchase orders, (ii) Product is recalled as permitted
under Section 3.11 (Product Recalls), or (iii) Buyer rejects or returns all or
any part of a shipment of Product as permitted under Section 3.4 (Product
Acceptance) or 3.12 (Product Returns), as applicable, Seller shall suspend
Buyer&#8217;s minimum purchase obligations set forth in this Section 1.3 until fifteen
(15) business days after either (x) Seller is able to fulfill such binding
purchase orders, or (y) Seller satisfies its applicable obligations under
Section 3.4, 3.11, or 3.12.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Shipping; Freight
Terms</font>.&#160;&#160;Subject to the terms set forth in Section 1.3, above,
Seller shall deliver Products that meet the Specifications in accordance with
the quantities, timing and shipping destination specified in Buyer&#8217;s purchase
orders utilizing Buyer&#8217;s appointed carriers and Buyer&#8217;s contracted
rates.&#160;&#160;Seller shall deliver all Products to Buyer free and clear of
all liens and encumbrances or other defects in title.&#160;&#160;All Products
shall be shipped F.O.B. St. Petersburg, FL.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Inventory;
Scheduling.</font></font></font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;Except
as expressly set forth herein, during the term of this Agreement, Buyer shall
purchase its Product requirements exclusively from Seller (including Products
required for engineering, testing, and clinical trials, if any) and from no
other manufacturer, person or entity, including, without limitation, any
division or Affiliate of Buyer.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;Buyer
shall provide Seller with firm purchase orders for Products in accordance with
the procedures and requirements set forth in Section 1.3; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that Buyer
shall have the right, exercisable only one (1) time per any three (3) month
period, up to five (5) Business Days prior to the date of shipment, and with the
prior written consent of Seller, which shall not be unreasonably withheld, to
issue binding, written change orders to delay up
to&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;of
the quantity of Products on such purchase orders by no more than sixty (60)
calendar days from their originally scheduled shipment date. Buyer agrees to
accept partial shipments of Products from Seller should it, for any commercially
reasonable reason, become necessary to ship in advance of Seller&#8217;s ability to
complete each order. Seller shall make all commercially reasonable efforts to
comply with any revisions to a purchase order consistent with the provisions of
this Agreement.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller
shall maintain its production capacity with respect to finished products and raw
materials
at&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;Percent&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**
of all undelivered Product quantities on open purchase orders for the
then-current month. Seller will immediately notify Buyer in the event of any
material obsolescence, supply shortage, or other interruption or potential
interruption, in supply of any Products, or component or sub-assembly thereof,
as soon as Seller becomes aware of such.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Within
the mutually agreed lead-time for the Initial Purchase Order set forth in
Section 1.3(b), above, Seller shall accumulate a finished goods inventory of
Products to be held in reserve equal to the average monthly quantity, based on
the Initial Purchase Order.&#160;&#160;Thereafter, for each subsequent month,
Seller will hold in inventory an amount of finished Products equal to the
average monthly quantity of the then-current Binding Forecast (defined
below).&#160;&#160;All Products held in inventory pursuant to this Section shall
be referred to herein as &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Shelf
Inventory</font>.&#8221;&#160;&#160;Seller may only deplete Shelf Inventory when
Buyer&#8217;s orders exceed the applicable Binding Forecast.&#160;&#160;Seller will at
all times throughout the term of this Agreement maintain the agreed upon Shelf
Inventory level, except that Seller will replace any units taken from Shelf
Inventory in accordance with previous sentence within thirty (30) days of the
date Seller takes such units from Shelf Inventory.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Estimates of
Requirements</font>.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
At the same time Buyer issues its Initial Purchase Order, and by the last day of
each calendar month thereafter, Buyer shall deliver to Seller a written,
twelve-month rolling forecast of Buyer's requirements for
Products.&#160;&#160;The first three (3) months of each such twelve-month
rolling forecast shall be binding upon Buyer (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Binding Forecast</font>&#8221;) and the
remaining nine (9) months of each such forecast will be non-binding and subject
to adjustment. Seller shall, no later than twenty-five (25) days after receipt
of each twelve-month rolling forecast delivered pursuant to this Section, notify
Buyer of any prospective problems of which Seller is aware that might prevent
Seller from meeting Buyer<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#8217;</font>s
forecasted requirements or estimated delivery dates.&#160;&#160;In the event
Seller so notifies Buyer of any issues in meeting quantities, Seller shall state
in writing the quantity of Products it estimates it can deliver and Buyer shall
only be required to purchase such revised quantity.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
addition to the forecasts delivered pursuant to Section 1.6(a), above, Buyer
will create a non-binding twelve-month forecast for Products, the first month of
which will be the month this Agreement is signed and delivered and which will be
attached hereto as Exhibit C.&#160;&#160;For the avoidance of doubt, Exhibit C
is being delivered for planning purposes only and no portion of Exhibit C will
be binding on either Party hereto.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Seller and Buyer agree to cooperate with each other and work jointly to
establish and maintain a smooth and efficient timetable for the manufacture and
supply of Products to Buyer hereunder. Seller shall use commercially reasonable
efforts to supply Buyer with all of its Product requirements, including, but not
limited to, the use of commercially reasonable efforts to accommodate "Rush"
orders from Buyer; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, Seller shall
not be in breach of this Agreement for any failure or delay to supply quantities
of Products which exceed the Binding Forecast for the then-current month by more
than&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;percent&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>1.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Materials Requirements
Process.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller
will deliver to Buyer a list of all components with lead times greater than
twelve&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;weeks
(&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Long Lead Time
Components</font>&#8221;) upon the Parties&#8217; mutual finalizations of and approvals for,
the Product requirements, Specifications, design, and bill of materials, which
list shall be set forth as Exhibit D and attached hereto.&#160;&#160;Seller
shall use its best efforts to reduce and minimize the number of Long Lead Time
Components.&#160;&#160;Seller shall use reasonable efforts to update the list of
Long Lead Time Components every quarter and to present an updated list of Long
Lead Time Components to Buyer.&#160;&#160;Each revised list of Long Lead Time
Components shall be deemed an amendment to Exhibit D.&#160;&#160;In the event
that Seller fails to present an updated list of Long Lead Time Components, (i)
the Parties shall continue to rely on the preceding list (as updated in writing
by the Parties) and (ii) Buyer will accept responsibility for Long Lead Time
Components ordered outside the lead times set forth in the list provided that
Seller can demonstrate to Buyer&#8217;s reasonable satisfaction that such components
were ordered in accordance with the then-current vendor lead times. (Buyer
acknowledges that lead times constantly change and the Seller might not always
be able to present Buyer with a current list of Long Lead Time
Components.)</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Buyer
shall be financially liable for all Long Lead Time Components when ordered in
accordance with this Section 1.7 if Buyer terminates this Agreement without
cause or Seller terminates this Agreement pursuant to Section 7.1(a) or
(d).&#160;&#160;Seller shall otherwise be financially liable for all Long Lead
Time Components. Specifically, Buyer&#8217;s&#160;&#160;component&#160;&#160;liability
for Long Lead Time Components shall be equal to Seller&#8217;s delivered cost
(delivered cost is the cost paid by Seller for the components, net of all
credits and discounts, plus a materials margin equal
to&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;of
all components ordered in support of any Binding Forecast.&#160;&#160;At Buyer&#8217;s
request, Seller shall use commercially reasonable efforts to minimize Buyer&#8217;s
component liability by attempting to return components to the vendor; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>,
that&#160;&#160;Seller shall not be obligated to attempt to return to a vendor
components that are, in the aggregate, worth less
than&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**
Dollars&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Pricing; Payment; Continuous
Improvement.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Pricing;
Escalation</font>.&#160;&#160;Prices for the Products are set forth in Exhibit E
attached hereto, and include packaging (as set forth in the then-applicable
Specifications) and taxes.&#160;&#160;Subject to the provisions of Section
1.3(f), such prices shall be fixed for the
initial&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;Contract
Year period of this Agreement.&#160;&#160;Thereafter, Seller may adjust prices
for each successive Contract Year period of this Agreement, according to the
annual Producer Price Index for Finished Goods (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">PPIFG</font>&#8221;) or its replacement if
so identified by the publisher, published by the United States Department of
Labor, Bureau of Labor Statistics (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">BLS</font>&#8221;<font style="DISPLAY: inline; FONT-WEIGHT: bold">)</font>; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, that such
increases or decreases will be capped
at&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**
Percent&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;** of the
previous Contract Year&#8217;s Product transfer price.&#160;&#160;Such PPIFG shall not
be seasonally adjusted. The frequency for periodic adjustments hereunder shall
be annual, using the first publication of the annual value in the month
following the anniversary month of each successive Contract Year period of this
Agreement.&#160;&#160;The adjustments shall be calculated using the &#8220;simple
percentage method&#8221; as set forth by the BLS.&#160;&#160;Such PPIFG-based price
changes shall be in addition to price changes (if any) permitted under Section
1.3(f).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; TEXT-DECORATION: underline">Payment</font>.&#160;&#160;Payment
will be due forty five (45) days from Buyer&#8217;s receipt of Seller&#8217;s invoice,
except to the extent Buyer in good faith disputes each
invoice.&#160;&#160;Seller shall invoice Buyer at the time of shipment of the
applicable Product and as otherwise provided for hereunder.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Continuous
Improvement; Seller Performance Business Reviews</font>.&#160;&#160;During the
term of this Agreement, Seller shall use commercially reasonable efforts
(including reasonable engineering support) to improve and enhance Product
design, quality, performance and manufacturing
processes&#160;&#160;(collectively, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Improvements</font>&#8221;)
so as to maintain or increase the competitive advantage of the Products as
compared to similar products in the marketplace.&#160;&#160;Improvements may
result from Seller&#8217;s own initiative (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Bovie
Improvements</font>&#8221;) or the request or suggestion of Buyer (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">BSC
Improvements</font>&#8221;) but, if a proposed BSC Improvement or Bovie Improvement
changes the Specifications or requirements of a purchase order the proposed
Improvement must be approved in writing by Buyer prior to implementation as
described in Section 3.1 hereof.&#160;&#160;Buyer shall pay Seller for waste or
remanufacturing of raw materials, work-in-progress, intermediate sub-assemblies
and finished goods inventory, which are rendered unusable by said BSC
Improvements or any other changes approved by Buyer (collectively, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Waste
Reimbursement</font>&#8221;); provided, however, Buyer shall not be responsible for
Waste Reimbursements for Bovie Improvements.&#160;&#160;BSC Improvements
approved in accordance with this Section 2.3 and Section 3.1 hereof shall be
promptly incorporated into the Specifications and Products in accordance
herewith.&#160;&#160;In order to establish an effective system to identify and
achieve productivity and quality objectives, BSC Improvements and Bovie
Improvements, Seller shall submit a productivity report to key administrators
designated by Buyer on a mutually agreeable basis.&#160;&#160;Seller&#8217;s and
Buyer&#8217;s representatives will meet as reasonably requested by Buyer for the
specific purpose of driving mutual productivity and quality
objectives.</font></font></font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Tooling and Capital
Equipment</font>.&#160;&#160;In addition to the price for each Product set forth
on Exhibit
E,&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;shall&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;Seller
the actual cost, net of all third party credits and discounts, plus a fifteen
percent (15%) management fee (&#8220;Management Fee&#8221;), of tooling, machining, molding,
and other capital expenditures necessary or appropriate for the manufacturing of
Product and that are purchased solely for use in connection with manufacturing
Product (collectively, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Manufacturing
Equipment</font>&#8221;).&#160;&#160;Buyer will not be responsible for paying for any
Manufacturing Equipment unless Buyer approves the purchase of such Manufacturing
Equipment in writing in advance of purchase.&#160;&#160;&#160;&#160;Payment for
Manufacturing Equipment will be due in accordance with Section 2.2. Seller will
use Manufacturing Equipment solely in connection with the manufacturing of
Products for Buyer.&#160;&#160;Buyer will at all times have title to and own all
Manufacturing Equipment.&#160;&#160;Seller shall not take any action that would
cause a lien or other encumbrance to be placed on any Manufacturing Equipment.
At all times while the Manufacturing Equipment is in Seller&#8217;s custody and
control, Seller will maintain adequate levels of loss insurance to cover loss or
damage to the Manufacturing Equipment.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Payment of Start-up
Fee</font>.&#160;&#160;Upon the execution of this Agreement, Buyer shall pay
Seller
a&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;start-up
fee of&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**
Dollars&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;(&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Start-up Fee</font>&#8221;), which is in
addition to any other payments from Buyer due hereunder.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Quality
Assurance; Recordkeeping; Notification.&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">The
following obligations of Seller set forth in Sections 3.1 through 3.10 shall be
collectively referred to throughout this Agreement as the "</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; TEXT-DECORATION: underline">QA
Standards</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">".</font></font></font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Changes.</font>&#160;&#160;Seller
shall not make any changes to its documentation, shipping, manufacturing process
(including vendors) or manufacturing location, pertaining to any Product, to any
Product (including materials, packaging, labeling and Directions for Use) or to
the Specifications unless approved by Buyer in writing in advance. All such
changes shall be submitted to Buyer no later than sixty (60) days prior to
Seller&#8217;s proposed date of implementation for such change.&#160;&#160;If a
proposed change is approved by Buyer in writing in its sole discretion, Seller
shall be responsible for properly communicating and implementing such change,
including with respect to any of Seller&#8217;s vendors.&#160;&#160;Seller shall
notify Buyer in writing and must receive approval by Buyer prior to any (a) use
of any nonconforming material in the manufacture of any Product, (b)
implementation of&#160;any&#160;Seller-authorized temporary deviation that could
affect the production, interconnectivity, sterility, or handling of any Product,
or (c) implementation of any Seller-initiated corrective action that could
affect the safety or efficacy of any Product.&#160;&#160;Without limiting any
other of Seller&#8217;s obligations hereunder, Seller will assume full responsibility
and costs for any product development activities necessary to remedy any
non-conformance in Products (with respect to quantity, Specifications,
requirements and delivery dates), including costs to implement such changes on
all units in the field and in inventory.&#160;&#160;&#160;&#160;Notwithstanding
anything in this Agreement to the contrary, Buyer shall pay Seller for Waste
Reimbursements, as set forth in Section 2.3 above.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Seller&#8217;s
Vendors</font>.&#160;&#160;At Buyer&#8217;s request, Buyer will perform a quality
system assessment of the vendors who provide Seller with raw
components/materials, sub-assemblies or contract services for
Products.&#160;&#160;&#160;All such vendors who provide Seller with such
materials and services as of the Effective Date are set forth on Exhibit F
attached hereto, which Exhibit F will be amended from time to time as Seller&#8217;s
vendors change.&#160;&#160;Buyer shall confirm in writing to Seller no later
than thirty (30) days after the Effective Date (and no later than thirty (30)
days after the date of any amendment to Exhibit F) the vendors listed on Exhibit
F with which Buyer&#8217;s Oncology Business (defined below) has a pre-existing
relationship (collectively, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Buyer&#8217;s
Vendors</font>&#8221;).&#160;&#160;Seller agrees to assist Buyer in arranging visits
and inspection of the plants at which Seller&#8217;s vendors manufacture any
component/material, sub-assembly or service for any Product.&#160;&#160;Seller
shall not change the outsourcing of any sub-component of any Product unless
approved in writing in advance by Buyer in accordance with Section 3.1
hereof.&#160;&#160;In addition, Seller shall obtain Buyer&#8217;s prior written
approval, which Buyer shall not unreasonably withhold, with respect to each
supplier, including a new supplier or a change to an existing supplier, of any
material, component, sub-assembly or service relating to any Product as
described in Section 3.1 hereof.&#160;&#160;For avoidance of doubt, Seller shall
not incorporate into any Product any material, component or sub-assembly
purchased from a third-party supplier, or permit any third party to perform
services relating to a Product, unless approved in writing in advance by Buyer
in accordance with Section 3.1 hereof.&#160;&#160;Buyer agrees, on behalf of its
Oncology Business, not to contract directly with any vendors listed on Exhibit
F, as amended, who supply Seller with Product components, for components of the
Product for sale by Buyer&#8217;s Oncology Business during, and for a period of two
(2) years after any termination or expiration of, this Agreement for any reason
except as set forth in the next sentence; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font> that this
restriction in no way applies to or otherwise limits Buyer&#8217;s right to contract
directly with (a) Mott Corporation (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Mott</font>&#8221;), (b) Buyer&#8217;s Vendors,
or (c) any vendor that Buyer introduces to Seller, and further, except as
permitted in subclauses (a), (b) and (c) of this sentence, Buyer&#8217;s Oncology
Business will not accept via intra-company transfer or otherwise such Product
components purchased by Buyer or its Affiliates from Seller&#8217;s vendors listed on
Exhibit F, as amended.&#160;&#160;Notwithstanding the foregoing, such
restriction on Buyer&#8217;s Oncology Business&#8217; contracting with Seller&#8217;s vendors as
set forth in the preceding sentence shall not apply in the event Seller breaches
this Agreement and Buyer terminates therefor pursuant to Sections 7.1(a),
7.1(b)(i), or 7.4, hereof.&#160;&#160;Seller agrees that, at such time as the
Parties mutually execute the design transfer document referenced in Section
1.3(b), Seller will enter into, and during the balance of the term of this
Agreement, will maintain, a written supplier agreement with Mott for the supply
of the sintered tip incorporated into the Product, and a written understanding
with Mott whereby Buyer would be able to visit and inspect Mott upon reasonable
notice; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, that Seller
agrees that it will not at any time during and for a period of five (5) years
after any termination or expiration of this Agreement for any reason enter into
an exclusive supply arrangement or any other agreement or arrangement with Mott
that would limit Mott&#8217;s ability to sell or otherwise provide any components or
products to Buyer or its Affiliates.&#160;&#160;As used herein, &#8220;Buyer&#8217;s
Oncology Business&#8221; means that part of Buyer&#8217;s business primarily responsible for
Buyer&#8217;s oncological business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Product
Conformity</font>.&#160;&#160;Seller will manufacture Products in accordance
with the then-current (a) Specifications, (b) applicable regulations relating to
the current Good Manufacturing Practices (as defined by the Food, Drug and
Cosmetic Act, as amended) and similar protocols (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">cGMP</font>&#8221;), (c) the United States
Food and Drug Administration (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">FDA</font>&#8221;) quality system
regulations (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">QSR</font>&#8221;),
including master device and lot history records, ISO 13485 requirements,
ISO14971 requirements, MDD requirements and CMDCAS requirements, and (d) other
pertinent rules and regulations of FDA and similar regulatory bodies in other
applicable jurisdictions set forth in the Specifications, as
amended.&#160;&#160;In the event that Seller is required or deems it desirable
to obtain ISO Quality System Certification, Seller shall promptly notify Buyer
in writing of Seller&#8217;s selection (or change in registrar) for obtaining ISO
Quality System Certification. Seller shall maintain a current Declaration of
Conformity status with EU Notified Bodies per MDD requirements when Buyer is
distributing in European markets.&#160;&#160;During the term of this Agreement,
Seller will maintain or cause to be maintained the Product manufacturing
facility&#8217;s registration as a certified medical device manufacturing facility and
will maintain such facility registration with all applicable regulatory bodies
or cause such facility to be maintained such that the facility would pass an
audit for compliance with cGMP and QSR.&#160;&#160;Seller shall maintain ongoing
quality assurance and testing policies sufficient to satisfy its obligations
under this Agreement, and Seller's standard quality assurance
policies.&#160;&#160;Any non-conformance in Product, material or process which
Seller wishes to use &#8220;as is&#8221; or rework will require prior written approval from
Buyer.&#160;&#160;&#160;&#160;Seller will assume full responsibility and its
costs for any product development activities necessary to remedy any
non-conformance in Products arising exclusively from defects in Product design,
manufacture or materials, or from deviation from quality standards (<font style="DISPLAY: inline; TEXT-DECORATION: underline">but not in any way from
Product claims</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">which are the sole
responsibility of Buyer</font>), which non-conformance is not approved by Buyer
in accordance with the requirements of the preceding sentence. Seller shall be
responsible for obtaining and maintaining any required regulatory filings and
registrations set forth in the Specifications, as amended, including ISO
registration (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">CE Mark</font>&#8221;)
and 510(k) filings with the FDA (collectively, the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Regulatory Filings</font>&#8221;) for the
Products under Seller&#8217;s notified body or through other applicable Regulatory
Authorities (defined below and set forth in the Specifications, as amended);
<font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, that
Buyer will have the right to review any Regulatory Filings and provide comments
on such filings (which Seller will consider in good faith) before they are
submitted by Seller; and <font style="DISPLAY: inline; TEXT-DECORATION: underline">further</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, that Buyer
will at all times upon notice to Seller have the right to make any Regulatory
Filings with Regulatory Authorities outside of the United States in Buyer&#8217;s name
and Seller will provide Buyer with access to all documents necessary or
appropriate for Buyer to make such Regulatory Filings and with authorization to
use such documents and the information contained therein to make Regulatory
Filings as the distributor of Products. Upon termination or expiration of this
Agreement, Buyer may purchase from Seller physical and legal ownership of all
Regulatory Filings for the Product, including all documents and communications
to and from the pertinent Regulatory Authorities. Products will bear Seller&#8217;s
regulatory registration mark(s), including<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Seller&#8217;s CE
Mark.&#160;&#160;&#160;As used in this Agreement, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Regulatory Authority</font>&#8221; means
any national supra-national, foreign, regional, state or local regulatory
agency, department, bureau, notified body, commission, council or other
governmental entity, including FDA, as set forth in the Specifications, as
amended.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Product
Acceptance</font>.&#160;&#160;Each shipment of Product from Seller to Buyer
shall be inspected by Seller prior to shipment and shall contain such quality
control certificates reasonably requested by Buyer certifying, among other
things, that the Products are in conformity with Specifications.&#160;&#160;All
Products are subject to final inspection and acceptance at Buyer within thirty
(30) Business Days of delivery.&#160;&#160;Buyer shall notify Seller within
thirty (30) Business Days of delivery of any apparent defective material or
workmanship or non-conformity of any Product to the Specifications or applicable
purchase order.&#160;&#160;If Buyer fails to notify Seller within thirty
(30)&#160;&#160;Business Days of delivery of an apparent defect, Buyer will be
deemed to have accepted the Product; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, that the
warranty contained in Section 8 hereof shall survive such
acceptance.&#160;&#160;Without prejudice to any other right or remedy of Buyer,
in case any Product is defective in material or workmanship or otherwise not in
conformity with the Specifications or the requirements of Buyer&#8217;s purchase
order, Buyer will have the right to reject it; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that Buyer
shall notify Seller of any rejection hereunder, and the basis for it, in
writing, within the thirty (30) Business Day timeframe set forth
above.&#160;&#160;Any Product that has been rejected must be replaced by and at
the expense of Seller promptly after notice.&#160;&#160;Buyer will return all
rejected Products to Seller at Seller&#8217;s expense.<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">&#160;</font>Seller
shall investigate the cause for the rejection and provide to Buyer in writing
all proposed corrective actions associated with the cause for
rejection.&#160;&#160;From time to time during the term of this Agreement, Buyer
may also request final inspection testing results from Seller, in addition to
the quality control certificates, as evidence that the supplied Product meets
Specifications.&#160;&#160;Seller will timely and fully respond to all such
requests.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Complaints and Corrective
Action</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As
used in this Section:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Complaint</font>&#8221; means any written,
electronic or oral communication, that alleges deficiencies related to the
identity, quality, durability, reliability, safety, effectiveness or performance
of a Product after it is released for distribution (marketed).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Complaint Investigation</font>&#8221; means
a documented process for determining the root cause (or the most probable cause)
of a Complaint.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Medical Device Report</font>&#8221; or
&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">MDR</font>&#8221; means a report
filed with FDA to communicate an event when Seller or Buyer becomes aware (as
such phrase is defined in 21 CFR 803.3(c)) of information that reasonably
suggests that one of its marketed Products:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 108pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">May
      have caused or contributed to a death, Serious Injury or serious
      deterioration in the state of health of a user or patient;
    or</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 108pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Has
      malfunctioned (see definition of Reportable Malfunction in 21
      CFR&#160;&#160;803.3 (n)) and that the Product or a similar device
      marketed by the manufacturer or importer would be likely to cause or
      contribute to a death or Serious Injury of a user or patient if the
      malfunction were to recur.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Medical Device Vigilance
Report</font>&#8221; or &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">MDV</font>&#8221;
means the official notification provided to regulatory authorities outside of
the United States of adverse events deemed reportable pursuant to the local laws
and/or regulations.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Serious Injury</font>&#8221; means an
injury or illness that:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 108pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Is
      life threatening (i.e. when continued use of the device is likely to have
      resulted in the death of a patient or when a patient was at substantial
      risk of dying at the time of the adverse event);
  or</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 108pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Results
      in permanent impairment or damage to a body structure or body function, or
      necessitates medical or surgical intervention to preclude permanent
      impairment or permanent damage to a body structure or body
      function.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Buyer
will be the initial contact for all Complaints from its
customers.&#160;&#160;Buyer may require Seller to perform Complaint
Investigations related to the manufacturing, Seller&#8217;s design, or packaging of
Products in order to investigate the cause of any such Complaints and to
determine any required corrective actions.&#160; In connection with every
Complaint Investigation, Seller will perform a lot history or device history
review of the affected Product.&#160;&#160;If the Complaint is accompanied by or
followed by return of the subject Product to Buyer, Buyer will return to Seller
the Product that is the subject of the Complaint; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, Buyer may
at its option perform an initial evaluation of the returned Product to determine
the root cause of failure.&#160;&#160;Seller will maintain records of all such
Complaint Investigations as required by cGMP and other applicable rules and
regulations of any Regulatory Authority. No later than fifteen (15) business
days after Seller&#8217;s receipt of a written request from Buyer to perform a
Complaint Investigation including receipt of the allegedly defective Product
(unless such Product is unavailable), Seller will provide Buyer with an initial
report of such Complaint Investigation, and no later than thirty (30) days after
Seller&#8217;s receipt of a written request from Buyer to perform a Complaint
Investigation including receipt of the allegedly defective Product (unless such
Product is unavailable), Seller shall perform and provide to Buyer a written
report of such Complaint Investigation, including a complete investigation that
contains a root cause analysis and corrective action recommendations. In the
event of an MDR or MDV, Buyer may require Seller to expedite the Complaint
Investigation in order to comply with any applicable regulatory filing
requirements of any Regulatory Authority.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller
will be responsible for filing all required Complaint reports (including MDRs
and/or MDVs) with the appropriate Regulatory Authorities.&#160;&#160;In any
event, Buyer retains the right to file all required Complaint reports, including
MDR and MDV reports; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that Buyer
shall immediate notify Seller, in writing, of its intention to file such
reports.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller
will maintain a cross-reference from Seller&#8217;s Complaint response to Buyer&#8217;s
associated Complaint file numbers.&#160; Seller will complete all corrective
actions, including any corrective actions identified in a response to Buyer
pursuant to this Section 3.5 or any corrective actions reasonably requested by
Buyer, within a mutually agreed upon timeframe, and upon request of Buyer,
provide written evidence of such completion.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Inspection;
Access</font>.&#160;&#160;Buyer shall have the right to have employees and other
representatives of Buyer (including external auditors and representatives of
Buyer&#8217;s notified body) present at any plant or production facility relating to
or used in connection with the manufacturing of Product during normal business
hours to conduct an initial and periodic inspections of such facilities and
manufacturing procedures for compliance with ISO, cGMP and QSR, and the
Specifications and to inspect Seller&#8217;s inventory of Products, work-in-process,
raw materials to be used for Products, production records, design history file,
quality manuals, regulatory dossiers and such other matters as may be pertinent
to proper quality assurance of Products to be delivered
hereunder.&#160;&#160;Buyer agrees to give Seller a minimum of two (2) Business
Days&#8217; prior notice<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>of any such inspection
&#8220;for cause&#8221; and ten (10) Business Days&#8217; prior notice for any other
inspection.&#160;&#160;Seller shall immediately use its best efforts to take
such action as is required to correct any deficiencies identified by Buyer or
its representatives relating to the production of any Product.&#160;&#160;Seller
is not currently a party to, and shall not enter into, any third-party
manufacturing agreement relating to any Product that does not grant to Buyer and
its representatives, as third-party beneficiaries, rights to inspect the plant
or plants at which Product components or materials are manufactured on the terms
set forth in this Section.&#160;&#160;Seller further agrees to use its best
efforts to provide such documentation or conduct such analyses as Buyer or its
representatives may reasonably request in connection with any regulatory
submission or audit hereunder.&#160;&#160;In accordance with applicable laws and
regulations governing regulatory inspections, Seller shall permit authorized
representatives of relevant regulatory authorities, including FDA, to inspect
any plant and production facilities relating to or used in connection with the
manufacture of any Product.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Records</font>.&#160;&#160;For
the longer of seven (7) years after delivery to Buyer of each Product, or such
longer period as may be required by cGMP and other applicable rules and
regulations of any Regulatory Authority or by law, Seller shall:&#160;&#160;(a)
maintain traceability records for each Product, including the manufacture date
and lot number of each unit of Product and each component and material
comprising the Product; (b) maintain records subject to 21 CFR 820 Subpart M
(such as the Device Master Record, quality system record and Complaint files);
and (c) provide Buyer a copy of such records without charge upon Buyer&#8217;s
request.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Upon
termination or expiration of this Agreement, such records shall be placed in
escrow on terms mutually agreed to by the Parties.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Required
Notification</font>.&#160;&#160;Each Party hereto shall immediately notify the
other Party by fax, with confirming notice by Overnight Delivery, as soon as a
Party becomes aware of any:&#160;&#160;(a) defect or condition which renders or
may render any Product ineffective or dangerous; (b) Product that is not in
compliance with the Specifications (including manufacturing process, labeling or
packaging) or other QA Standards; (c) breach by either Party of the terms of
this Agreement; (d) regulatory, FDA or ISO inspections or other communications
with regulatory, FDA or ISO authorities related to a Product or that would in
any way impact the Product or either Party&#8217;s performance hereunder; or (e)
infringement by any party of intellectual property rights applicable to the
Product.&#160;&#160;Without limiting the generality of the foregoing, each Party
will notify the other Party immediately if it becomes aware of any death or
bodily injury caused by a Product (or suspected to be caused by a Product) or
any malfunction of a Product.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">EEO
Laws</font>.&#160;&#160;Seller acknowledges that Buyer is an equal employment
opportunity/affirmative action employer subject to Executive Order 11246, the
Vietnam Era Veterans Readjustment Assistance Act, Section 503 of the Vocational
Rehabilitation Act, and their implementing regulations (collectively, "<font style="DISPLAY: inline; FONT-WEIGHT: bold">EEO Laws</font>").&#160;&#160;Seller
may be governed by these laws and implementing regulations which are
incorporated into this Agreement by reference.&#160;&#160;By acceptance of this
Agreement, Seller certifies that it complies and will continue to comply with
all applicable EEO Laws, and it shall not discriminate on the basis of race,
age, color, religion, gender, sexual orientation, disability, veteran status,
national origin or any other characteristic protected by federal, state or local
law.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.10&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Quality
Plan</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller and Buyer
shall establish a quality plan which will define the quality practices, the
resources and the activities relevant to Products that are designed and/or
manufactured for Buyer.&#160;&#160;This plan will define how the quality
requirements will be met and will be approved in writing by both
Parties.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.11&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Product
Recalls</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If,
in the judgment of Seller or Buyer, any Product defect or any government action
requires a recall of, or the issuance of an advisory letter regarding, any
Product, either Party shall undertake such recall or issue such advisory letter
only after notification to and consultation with the other
Party.&#160;&#160;Each Party shall notify the other Party
within&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;Business
Days&#160;of becoming aware (as such&#160;phrase is defined in&#160;21 CFR 803)
of any issue that could lead to a field action related to the
Products.&#160;&#160;The Parties shall endeavor to reach an agreement prior to
making any recall or issuing any advisory letter regarding the manner, text and
timing of any publicity to be given in such matters in time to comply with any
applicable legal or regulatory requirements, but such agreement will not be a
precondition to any action that either Party deems necessary to protect users of
Products or to comply with any applicable governmental orders or
mandates.&#160;&#160;The Parties agree to provide reasonable assistance to one
another in the event of any recall or issuance of any advisory
letter.&#160;&#160;Notwithstanding anything in this Agreement to the contrary,
Buyer shall have the right to manage any Product recall.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
the event of a recall of Product, Seller shall correct any deficiency relating
to its manufacturing, packaging, testing, labeling, storing or handling of
Product, if applicable, or cause the vendor of any material, component, or
sub-assembly incorporated into Product to do likewise with respect to such
material, component, or sub-assembly, and shall, at Seller&#8217;s option, either (i)
at its cost replace each unit of Product recalled (including units held in
inventory by Buyer or its customers) with a corrected Product within a
reasonable period of time, or (ii) refund the Buyer&#8217;s purchase price
thereof.&#160;&#160;Seller shall promptly pay or reimburse Buyer for its costs
and expenses (i.e., shipping, quality control testing, and notification)
incurred by Buyer as a result of any recall or advisory letter;<font style="DISPLAY: inline; TEXT-DECORATION: underline"> provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that if the
recall is related to requirements or Specifications (i.e., materials, design or
process changes, and Product claims) originating with Buyer, then Buyer will pay
the costs and expenses incurred for such recall.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.12&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Product
Returns</font>.&#160;&#160;Seller shall accept returns of Product shipped by
Seller if:&#160;&#160;(a) the request to return such Product is received
within&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;Business
Days of invoice date (or, if later, the date that shipment is received); (b) the
Product is returned in new condition, salable and in its original packaging, and
(c) the reason for the return is directly related to defective product
quality.&#160;&#160;Nothing express or implied in this Section 3.12 shall be
deemed to modify or diminish the right of Buyer to reject Products in accordance
with the provisions of Section 3.4 or limit the warranty for Products set forth
in Section 8.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.13&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Compliance with
Laws</font>.&#160;&#160;Seller will comply with all applicable laws and
regulations of the Regulatory Authorities set forth in the Specification, as
amended, pertaining to the testing, manufacture, labeling or packaging of
Products or pertaining to performance by Seller of its obligations under this
Agreement, including the maintenance of ongoing quality assurance and testing
procedures to comply with applicable regulatory requirements.&#160;&#160;Without
limiting the generality of the foregoing, Seller will (a) report to every
applicable Regulatory Authority within any relevant time periods all events that
are required to be reported (including any death or serious bodily injury caused
by a Product); and (b) deliver, within the permitted time periods, all annual or
other periodic reports required to be delivered to every applicable Regulatory
Authority.&#160;&#160;Seller represents and warrants that it is the legal
manufacturer of the Product.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.14&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Product Specifications;
Packaging and Labeling</font>.&#160;&#160;All Products delivered by Seller
hereunder shall be in full compliance with the Specifications therefor and shall
be ready for end-user sale, including all packaging, labeling,
instructions-for-use and sterilization set forth therein, as
amended.&#160;&#160;All Products shall be labeled (including bar coding/UPN
numbers) in accordance with the work instructions, procedures and label
text/graphics specified in writing from time to time by Buyer and mutually
approved by Buyer and Seller. Buyer shall give Seller at least thirty (30) days
advance written notice of any change to its labeling procedures prior to the
date when such changes are to take affect.&#160;&#160;Notwithstanding anything
in this Agreement to the contrary, Buyer shall pay Seller for Waste
Reimbursements, as set forth in Section 2.3 above. All Products will be marked
to make it clear that they have been manufactured by Seller and are being
distributed by Buyer.&#160;&#160;Buyer may include Product as a component in any
kit or collection of products.&#160;&#160;Buyer maintains the right to
over-label Products as it deems necessary or appropriate in accordance with work
instructions, procedures, and label text/graphics, which are mutually approved
by both Parties hereto.&#160;&#160;Seller is not responsible for any
over-labeling or any consequences thereof.&#160;&#160;&#160;&#160;As used in
this Agreement, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Specifications</font>&#8221; for the
Product means the specifications set forth on Exhibit A, as revised from time to
time pursuant to the next sentence, and as provided by Seller and approved by
Buyer, including the part number, revision level, controlled drawing, and
packaging and sterilization instructions for the Product and all requirements of
any applicable laws and regulations of the Regulatory Authorities, specified
therein.&#160;&#160;The Parties understand that the Specifications may need to
be revised from time to time up to the Product Launch Date.&#160;&#160;Each
version (each, a &#8220;Revision Level&#8221;) of the Specifications will be labeled with a
Revision Level number (&#8220;Revision Level Number&#8221;), starting with &#8220;A-1,&#8221; and
continuing sequentially with &#8220;A-2,&#8221; &#8220;A-3,&#8221; etc., and each revision of the
Specifications will be so labeled and attached to this
Agreement.&#160;&#160;Each subsequent Revision Level will replace and supersede
all former Revision Levels for all purposes hereunder, except with respect to
Article 4 of this Agreement.&#160;&#160;Attached to this Agreement as Exhibit A
as of the Effective Date is Revision Level &#8220;A-1.&#8221;</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Confidential Information;
Intellectual Property.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Confidential
Information</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Confidential Information</font>"
means all information disclosed by or on behalf of either Party hereto (a
&#8220;Disclosing Party&#8221;) to the other Party hereto (a &#8220;Receiving Party&#8221;), or any of
the Receiving Party&#8217;s employees, officers, directors, Affiliates,
subcontractors, agents, successors or assigns (collectively &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Representatives</font>&#8221; and together
with the Disclosing Party, the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Disclosing Group</font>&#8221;), including
information&#160;&#160;(i) relating to the matters that are the subject of this
Agreement, including the terms, existence and nature of this
Agreement,&#160;&#160;(ii) all other information regarding the Disclosing
Party&#8217;s past, present or future research, technology, know-how, ideas, concepts,
designs, products, markets, customer information, computer programs, prototypes,
processes, machines, articles of manufacture, compositions of matter, business
plans and operations, technical information, drawings, specifications (including
Specifications), (iii) BSC Improvements or Bovie Improvements (as applicable),
and (iv) any knowledge or information developed by the Disclosing Party as a
result of work in connection with this Agreement that directly relates to the
Product, except information which is:&#160;&#160;(i) at the time of disclosure,
or thereafter becomes lawfully part of the public domain through no act or
omission by the Receiving Party; (ii) lawfully in the possession of Receiving
Party prior to disclosure by or on behalf of Disclosing Party, as shown by
written records; (iii) lawfully disclosed to the Receiving Party by a third
party which did not acquire the same under an obligation of confidentiality from
or through the Disclosing Group; or (iv) independently developed by the
Receiving Party without use of Confidential Information, as shown by written
records.&#160;&#160;If a Receiving Party believes in good faith that it is
required by law to disclose any Confidential Information, it shall provide
notice to the Disclosing Party, prior to making such disclosure so as to allow
Disclosing Party time to undertake legal or other action, to prevent such
disclosure or otherwise obtain confidential treatment of such
disclosure.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A
Receiving Party shall not, without the prior consent of the Disclosing Party,
disclose any Confidential Information to anyone for any reason at any time or
use any Confidential Information for any purpose except as requested by the
Disclosing Party.&#160;&#160;The Receiving Party shall limit dissemination of
Confidential Information to only those Receiving Party Representatives having a
"need to know."&#160;&#160;A Receiving Party shall not, except as permitted
under this Agreement:&#160;&#160;(i) appropriate or use a Disclosing Party&#8217;s
Confidential Information in Receiving Party&#8217;s own manufacture of Products for
itself or for any third party or for any other purpose; or (ii) by virtue of
either this Agreement or its supply or purchase of Products, as applicable,
obtain any title to, or any interest or license in, any Confidential Information
of a Disclosing Party.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither
Party shall issue a press release or other public announcement concerning this
Agreement (or any term sheet, bids, negotiations or other related information),
the transactions contemplated herein, or the relationship between the Parties
without the prior written approval of an authorized representative of the other
Party, which approval shall not be unreasonably withheld or
delayed.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither
Party shall:&#160;&#160;(i) disclose to the other Party any confidential or
proprietary information belonging to any third party without the consent of such
party; or (ii) represent as being unrestricted any designs, plans, models,
samples, or other writings or products that the Disclosing Party knows or has
reason to know are covered by valid patent, copyright, trade secret, or other
form of intellectual property protection.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Buyer&#8217;s
Property</font>.&#160;&#160;&#160;&#160;&#160;&#160;All tangible property
provided to Seller in connection with this Agreement, including: Product
requirements, drawings, standard operating protocols, quality testing and other
documentation, all samples, Buyer&#8217;s Confidential Information, all reports,
brochures, manuals, sales literature, all equipment and tooling, provided by
Buyer to test, manufacture or assemble the Products, and all Manufacturing
Equipment (collectively, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Buyer&#8217;s Property</font>&#8221;) shall be
and remain the exclusive property of Buyer unless otherwise agreed in
writing.&#160;&#160;Seller shall:&#160;&#160;(a) keep and maintain in its
custody and subject to its control any Buyer&#8217;s Property that it receives or
develops during the term of this Agreement, for the sole benefit of Buyer; (b)
use Buyer&#8217;s Property solely in furtherance of fulfilling its obligations to
Buyer under this Agreement; and (c) return or surrender to Buyer all Buyer&#8217;s
Property within fifteen (15) days after termination or expiration of this
Agreement or otherwise upon written request by Buyer provided; however, such
return of Buyer&#8217;s Property does not interfere with Seller&#8217;s performance
hereunder.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Intellectual
Property</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Buyer
and Seller acknowledge and agree that (i) the performance of engineering
services; and (ii) the development of designs, concepts, inventions, prototypes
and the like, and intellectual property relating thereto, by Seller prior to the
Effective Date, either solely or in cooperation with others including Buyer,
which relate solely to any medical device having a sintered, conductive metal
tip, are within the scope of this Agreement and the results of such services and
development are the exclusive property of Buyer and included within the
definition of BSC Intellectual Property provided in Section
4.3(b).&#160;&#160;Consideration for such services and development has been
accounted for in the price of the Products herein.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except
for Seller&#8217;s intellectual property related solely to electrosurgical generators
(e.g., RF energy generation, monitoring and control), (i) all intellectual
property, both domestic and foreign, including any and all tangible and
intangible trade secret rights, patents rights (including registrations,
applications, renewals, extensions, continuations, divisions, reexaminations and
reissues), processes, know-how, prototypes, Specifications, drawings, designs,
tools, industrial property rights, inventions, Improvements (excluding
manufacturing processes), developments or discoveries, conceived or made by
Buyer or Seller, whether patentable or not, related solely to any medical device
having a sintered, conductive metal tip, (ii) Buyer&#8217;s Confidential Information,
and (iii) Buyer&#8217;s Property (except Manufacturing Equipment) (collectively,
&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">BSC Intellectual
Property</font>&#8221;), shall be the exclusive property of Buyer, and Seller shall
cooperate in assigning, and hereby does assign, all right, title, and interest
in and to such BSC Intellectual Property to Buyer.&#160;&#160;All copyrightable
works developed by Seller, either alone or with others, related to BSC
Intellectual Property, are &#8220;works made for hire&#8221; and are hereby assigned to and
shall belong exclusively to Buyer, and any and all copyright rights to such
works, including the right to copy or reproduce the works, create further
derivative works, file for copyright registration, and renew such rights, are
hereby assigned to, and shall be the exclusive property of, Buyer.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;Seller
agrees to cooperate with Buyer in the preparation, prosecution, filing and
maintenance of the BSC Intellectual Property during the term of this Agreement
and thereafter, and Buyer agrees to pay Seller reasonable compensation for such
cooperation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;To
the extent there is jointly invented and jointly owned intellectual property,
each Party hereto agrees to cooperate with the other Party with the preparation,
prosecution, filing and maintenance of the intellectual property during the term
of this Agreement and thereafter beyond that provided by the
Agreement.&#160;&#160;Each Party agrees to pay the other Party reasonable
compensation for such cooperation beyond the term of this
Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;During
the term of this Agreement, and any extension thereof, Buyer hereby grants to
Seller a worldwide, royalty-free, non-exclusive license to use the BSC
Intellectual Property solely for the purpose of fulfilling its obligations
hereunder.&#160;&#160;No other license is granted by Buyer therein or in any
other of Buyer&#8217;s intellectual property.&#160;&#160;Buyer reserves to itself
exclusive ownership and rights in the BSC Intellectual Property, except to the
extent of the limited license granted in this section.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;Seller
agrees that there shall be no consideration provided by Buyer to Seller not
expressly contemplated in this Agreement for Seller&#8217;s manufacturing know-how and
other intellectual property used by Seller in the manufacture and delivery of
Product to Buyer.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Co-Branding</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All
labeling, packaging, materials for advertising and marketing, websites, and user
and technical documentation for Products (collectively, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Materials</font>&#8221;) will be co-branded
with both the Boston Scientific and Bovie names (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Co-Brand</font>&#8221;).&#160;&#160;Unless
otherwise mutually agreed to by the Parties in writing, the Co-Brand shall be
present on all Materials in a size and format to be mutually agreed upon by the
Parties, but in all cases so that each name is prominent and reasonably legible
to the naked eye.&#160;&#160;The Parties will work in good faith to agree to one
or more standard Co-Brand templates for use on the Materials, which Templates
shall specify the acceptable visual characteristics of the Co-Brand for use on
Materials, and as long as one of these templates is used, Buyer may use the
Co-Brand without the further prior approval of Seller.&#160;&#160;Any deviation
from the template will require the prior written approval of Seller, which
approval shall not be unreasonably withheld.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Buyer
will use Seller&#8217;s trademarks as adjectives and not as nouns or verbs, and not in
the plural or possessive form.&#160;&#160;In advertising and marketing
materials, Buyer shall distinguish Seller&#8217;s trademark from surrounding text by
using bold, italics or the appropriate visual tools, or by capitalization or the
use of quotation marks, and will use the proper trademark symbol in connection
with Seller&#8217;s trademarks.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller
hereby grants to Buyer a fully paid-up, royalty free license to use Seller&#8217;s
trademarks solely in connection with the marketing, distribution, import,
export, use, offer to sell and sale of the Products.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller
will take such actions as are reasonably necessary to prosecute and maintain its
trademarks and shall inform Buyer of any changes in or additions to any
trademark used in the Co-Brand materials.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except
as required under this Agreement, and as set forth in this Section 4.4
(Co-Branding), in no event will Seller be permitted to use Buyer&#8217;s trademarks
without the prior written consent of Buyer.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Combining
the Parties&#8217; trademarks is permitted only as mutually agreed to by the Parties
for purposes of the Co-Brand.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Insurance and
Indemnification.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline">5.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline"><font style="TEXT-DECORATION: underline">Insurance</font>.&#160; </font>Seller shall:
(a) during the term of this Agreement, maintain commercial general liability
insurance, naming Buyer as additional insured and loss-payee; and (b)
immediately notify Buyer in writing of any change or cancellation relating to
such policy.&#160;&#160;Prior to execution of this Agreement, Seller shall
provide Buyer with a certificate of insurance evidencing such
insurance.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Indemnification</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller
shall indemnify, defend and hold harmless Buyer and its Affiliates and their
respective directors, officers, employees and agents from and against any claim,
action, suit, demand, damage, expense<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>or losses (including
reasonable attorneys&#8217; fees) (collectively, "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Claims</font>") resulting from or in
any way relating to: (i) the gross negligence, intentional misconduct, or
violation of law by Seller or Seller Representatives in the performance of, or
its failure to perform, any of Seller&#8217;s obligations under this Agreement; (ii)
any material breach of Seller&#8217;s representations, warranties, covenants or
obligations under this Agreement, including Seller&#8217;s obligation to deliver
Product under this Agreement; or (iii) infringement or alleged infringement of
any third party intellectual property rights with respect to any Product
provided by Seller to Buyer hereunder to the extent that infringement is found
by a court of competent jurisdiction to result from the use or sale of a Bovie
Improvement or the incorporation of Bovie Intellectual Property into a
Product.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Buyer
shall indemnify, defend and hold harmless Seller and its Affiliates and their
respective directors, officers, employees and agents from and against any Claims
resulting from or in any way relating to:&#160;&#160;(i) the gross negligence,
intentional misconduct, or violation of law by Buyer in the performance of, or
its failure to perform, any of Buyer&#8217;s obligations under this Agreement; (ii)
any material breach of Buyer&#8217;s representations, warranties, covenants or
obligations under this Agreement, or (iii) infringement or alleged infringement
of any third party intellectual property rights with respect to any BSC
Intellectual Property (including Specifications or requirements provided by
Buyer to Seller hereunder), except to the extent that infringement is found by a
court of competent jurisdiction to result from Buyer&#8217;s use, manufacture, offer
to sell, or sale of Bovie&#8217;s Intellectual Property or Bovie&#8217;s Improvements
incorporated into a Product.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each
Party&#8217;s obligations to the other Party under this Section 5.2 are conditioned
upon the Party seeking indemnification:&#160;&#160;(i) providing notice to the
indemnifying Party of any Claims promptly, but not later than thirty (30) days
after the Party knows of such Claim; (ii) permitting the indemnifying Party to
assume full responsibility for the defense of such Claim; (iii) assisting the
indemnifying Party in defense of such Claim; and (iv) not compromising or
settling any such Claim without the indemnifying Party&#8217;s prior
consent.&#160;&#160;Notwithstanding the foregoing, a<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Party's failure to give
the notice specified in Section 5(c)(i), or delay in giving such notice, shall
not affect such Party's right to indemnification under this Section 5.2 except
to the extent that the indemnifying Party has been prejudiced by such failure or
delay.&#160;&#160;In addition, the indemnifying Party may not settle a claim
without the indemnified Party&#8217;s consent unless such settlement includes a full
release or license for both past and future sales of Product at no additional
cost to the indemnified Party.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Remedies</font><font style="DISPLAY: inline">.&#160;&#160;</font>Termination of this Agreement, or
the exercise of any other remedy, shall not be deemed to be an exclusive remedy
hereunder, and shall be in addition to any other remedies available at law or in
equity (including a Party&#8217;s right to obtain specific performance and other
equitable relief for other Party&#8217;s material breach).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">7.</font>&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Term.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline">7.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Term;
Termination</font><font style="DISPLAY: inline">.&#160;&#160;</font>The initial
term of this Agreement shall commence on the Effective Date and expire on the
fifth (5th) 12-month anniversary of the Product Launch Date of the
Product.&#160;&#160;This Agreement will automatically renew for additional
one-year periods, unless notice of cancellation is delivered by either Party at
least one hundred and eighty (180) days prior to the end of the then current
term.&#160;&#160;Notwithstanding the above, this Agreement shall
terminate:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;subject
to Section 7.1(b), sixty (60) days after notice of a material breach from one
Party to the other, but only if such breach remains uncured at the end of such
60-day period; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that this
Agreement shall terminate immediately upon notice of breach to a Party if the
same or similar material breach was the subject of a previous notice of breach
pursuant to which a 60-day cure period was previously provided to such
Party;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;subject
to the Force Majeure provisions of Section 7.3, immediately upon notice from
Buyer if:&#160;&#160;(i) Seller does not satisfy Buyer&#8217;s binding purchase order
requirements for any two (2) consecutive months; (ii) Buyer determines in good
faith that Five Percent (5%) or more of any particular Product manufactured and
delivered to Buyer during a calendar month is defective, or does not meet the
Specifications for such Product, anytime after the first ninety (90) days of the
term of this Agreement; (iii) Buyer believes in good faith that Seller's quality
assurance policies do not comply with Section 3;<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>or (iv) Buyer reasonably
determines that any material breach hereunder does or may negatively impact the
performance of any of Buyer&#8217;s Products, Buyer&#8217;s reputation, patient safety or
the safety of any other persons or the environment;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in
accordance with Section 7.3 or 7.4 hereof;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;immediately
upon notice from a Party if the other Party has become the subject of voluntary
or involuntary bankruptcy, receivership, or insolvency proceedings;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;following
one hundred and twenty (120) days written notice from Buyer of its intent to
terminate for convenience;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;immediately
upon notice from Seller if Buyer fails to make payments to Seller in accordance
with the provisions of Section 2.2, above.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Fulfillment Upon
Termination</font>.&#160;&#160;(a) Upon termination (except pursuant to Section
7.1(e), above) or expiration of this Agreement, Seller shall be obligated to
fulfill any then open binding purchase orders, and Buyer shall be obligated to
purchase (a) all Products on open binding purchase orders not yet purchased, and
(b) all then-existing Shelf Inventory; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that in no
event shall Buyer be required to purchase any Product (including work-in-process
or raw materials or Shelf Inventory) after any termination of this Agreement by
Buyer pursuant to Section 7.1(a), (b), (c) or (d) .</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b) Upon
termination pursuant to Section 7.1(e), above, in Contract Years One or Two, if
Buyer has not purchased the minimum quantity of Product units for Contract Years
One and Two, as set forth in Section 1.3, above, Buyer shall immediately
purchase or, at its election, pay for in cash the transfer price of the number
of Product units equal to the difference between Thirty-Five Hundred (3,500) and
the actual number of Product units purchased to that point in time by Buyer.
Upon termination pursuant to Section 7.1(e), above, after Contract Year Two,
Buyer shall be obligated to purchase (a) all Products on then open binding
purchase orders not yet purchased, and (b) all then-existing Shelf
Inventory.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Force
Majeure</font>.&#160;&#160;If a Party&#8217;s performance is delayed because of war or
similar unrest, terrorism, fire, act of God or other similar cause that is
beyond its control and which such Party could not have reasonably prevented,
such delay in performance shall not be considered a breach of this Agreement;
<font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font> that if such
delay continues for sixty (60) days or more, then:&#160;&#160;(a) the other
Party may upon notice cancel all or any portion of unfilled orders; and (b) that
other Party may immediately terminate this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Failure to
Supply</font>.&#160;&#160;If Seller fails to meet its binding supply obligations
under any binding purchase orders provided by Buyer pursuant to Section 1.3, and
such failure:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;remains
uncured for more
than&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**, then such
shortfall shall be sold to Buyer at a price discount
of&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;percent&#160;&#160;&#160;**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**
and this discount will remain in effect for three (3) consecutive months after
the failure to supply has been cured; and</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;results
in less than the specified number of Product units being delivered to Buyer for
any five (5) months, whether consecutive or not, at any time during the term of
this Agreement, then Buyer may terminate this Agreement immediately upon written
notice and initiate a manufacturing transfer pursuant to Section 7.5 hereof to
be completed by Seller at Seller&#8217;s expense.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Manufacturing
Transfer</font>.&#160;&#160;In the event of any termination of this Agreement,
Seller shall physically transfer to Buyer, at Buyers expense, all of Buyer&#8217;s
Property held by Seller.&#160;&#160;Buyer may purchase from Seller, all tooling
developed by Seller and not previously charged to Seller.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warranty</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
addition to any other representations and warranties of Seller herein, Seller
represents and warrants to Buyer that all Products supplied to Buyer hereunder
shall: (a) conform to the Product Specifications, (b) be manufactured, labeled,
packaged and tested in accordance with the applicable regulatory approvals
therefor and the applicable laws and regulations relating to the manufacture,
labeling, packaging and testing of Products, and (c)&#160;&#160;be free from
defects in design, materials and workmanship.&#160;&#160;Seller shall provide
all end-users of all Products a limited warranty that reasonable care has been
used in the design and manufacture of the Products.&#160;&#160;If a Product does
not conform to the warranties set forth above, Seller will replace the Product,
issue Buyer a refund, or issue Buyer a credit toward future purchases, solely at
Seller&#8217;s discretion.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Miscellaneous</font>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller
is an independent contractor of Buyer, and neither Party has the power to bind
the other.&#160;&#160;Subject to the limitations of Force Majeure set forth in
Section 7.3, above, time is of the essence in performance
hereunder.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither
Party shall assign this Agreement or its obligations hereunder, whether
voluntarily or involuntarily, without the express prior written consent of the
other Party, except that either Party hereto may assign all of its rights and
obligations under this Agreement to any purchaser, directly or indirectly, of
(a) in the case of Seller, all or substantially all of Seller&#8217;s assets (or
stock), and (b) in the case of Buyer, all or substantially all of Buyer&#8217;s
Oncology Business assets (or stock), without the other Party&#8217;s
consent.&#160;&#160;Any permitted assignee hereunder is deemed to have assumed
the assignor&#8217;s performance obligations in favor of the non-assigning
Party.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This
Agreement is fully binding upon either Party&#8217;s successors and permitted
assigns.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All
requests, approvals, consents and notices must be in writing and will be
effective as of the date actually received and, unless otherwise specified in
this Agreement, shall be sent as follows: (i) certified mail - return receipt
requested; (ii) a nationally recognized overnight delivery service that
guarantees overnight delivery and requires the signature of recipient; or (iii)
facsimile, transmission confirmed; to the addresses and fax numbers indicated on
the first page of this Agreement; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that a copy
is also sent one of the foregoing methods of subsection (i) or (ii),
above</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This
Agreement:&#160;&#160;(i) is governed by the laws of The State of New York,
without reference to its internal principles of conflicts of laws; (ii) together
with all Exhibits thereto (which are hereby incorporated into this Agreement) is
the entire and exclusive set of terms and conditions for transactions made with
respect to the Products; (iii) supersedes conflicting terms of purchase orders,
invoices or other documents issued under it; and (iv) may only be modified by a
writing signed by both Parties.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Headings
of the articles, sections and subsections of this Agreement, and the name of
this Agreement, are for reference purposes only and shall not limit or affect
the meaning or construction of the terms and conditions
hereof.&#160;&#160;Whenever the words &#8220;include&#8221;, &#8220;includes&#8221; or &#8220;including&#8221; are
used in this Agreement, they shall be deemed in each instance to be followed by
the words &#8220;without limitation.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
failure of either Party to enforce any right under this Agreement shall be
deemed a waiver thereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For
purposes of clarity, nothing in this Agreement shall restrict: as to Buyer, the
right to pursue alternative resection device technology or Dissimilar Devices
(defined below)&#160;from third parties or, as to Buyer or Seller, from
developing alternative resection device technology or Dissimilar Devices
internally or from selling any such Dissimilar Devices.&#160; As used herein, a
"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Dissimilar Device"</font> is a
medical device whose manufacture, use, importation, offer for sale, or sale,
would not, if performed by a party other than Buyer (or its licensee) infringe
BSC Intellectual Property.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All
obligations and rights which are by their nature continuing, including the
obligations contained in Sections 3.7 and 7.2 and Sections 4 through 6, and 8,
shall survive the expiration or termination of this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[BALANCE
OF THIS PAGE INTENTIONALLY LEFT BLANK]</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Additional Representations
and Warranties</font>.&#160;&#160;Each Party hereby represents and warrants to
the other that:&#160;&#160;(a) the execution and delivery of and performance
under this Agreement by such Party does not, and will not, conflict with or
violate any other agreement or obligations with third parties or any
restrictions of any kind or any law to which it is bound or subject; and (b) it
has the unrestricted right to disclose any information it submits to the other
Party, free of all claims of third parties, and that such disclosures do not
breach or conflict with any confidentiality provisions of any agreement to which
it is a party<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.
</font>Each Party hereto further hereby represents and warrants that (x) it owns
or has sufficient license and right to intellectual property used in connection
with or incorporated into the Product; and (y) the manufacture, use,
importation, offer for sale, and sale of the Product does not and will not
infringe the intellectual property rights of any third party.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ACCEPTANCE
OF AGREEMENT</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By
signing below the undersigned acknowledge and accept all terms and conditions of
this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <div align="left">
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <table cellpadding="0" cellspacing="0" width="95%">
                      <tr>
                        <td align="left" colspan="2" valign="top" width="45%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SELLER: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">BOVIE MEDICAL
      CORPORATION</font></font></div>
                        </td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" colspan="2" valign="top" width="45%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">BUYER:&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">BOSTON SCIENTIFIC
      CORPORATION</font></font></div>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="13%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
                        </td>
                        <td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/S/ Moshe Citronowicz</font></font></div>
                        </td>
                        <td valign="top" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="13%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
                        </td>
                        <td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="32%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Signature)</font></div>
                        </td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="32%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Signature)</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="13%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Print
      Name:</font></div>
                        </td>
                        <td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Moshe Citronowicz</font></font></div>
                        </td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="13%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Print
      Name:</font></div>
                        </td>
                        <td align="left" valign="top" width="32%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dave
      McClellan</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="13%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
                        </td>
                        <td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Vice President/COO</font></font></div>
                        </td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="13%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
                        </td>
                        <td align="left" valign="top" width="32%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">President,
      Oncology Division</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="13%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date
      Signed:</font></div>
                        </td>
                        <td align="left" valign="top" width="32%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10/06/06</font></div>
                        </td>
                        <td valign="top" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="13%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date
      Signed:</font></div>
                        </td>
                        <td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="13%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
                        </td>
                        <td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="32%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Signature)</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="13%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Print
      Name:</font></div>
                        </td>
                        <td align="left" valign="top" width="32%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ghislain
      Gackiere</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="13%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
                        </td>
                        <td align="left" valign="top" width="32%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Finance
      Director</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                      <tr>
                        <td valign="top" width="13%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="32%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="13%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date
      Signed:</font></div>
                        </td>
                        <td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                  </table>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">EXHIBIT
A: PRODUCT AND PRODUCT SPECIFICATIONS</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT A
Version A-1 to Exhibit 10.12 &#8211; Redacted</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="ex10-12a1a.jpg" alt=""></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">BOVIE
&#8211;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Resection
Device</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Product
Specifications</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">BOVIE MEDICAL
CORPORATION</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">CONFIDENTIAL</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">FOR INTERNAL USE
ONLY</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Table of
Contents</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">1</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">INTRODUCTION</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">4</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.1</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Purpose</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.2</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Scope</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">2</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">A</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">PPLICABLE
      DOCUMENTS</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">4</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.1</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Standards</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">3.0
      GENERAL DESCRIPTION</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">4</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1
      Concept Drawing</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2
      Application</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2.1
      Intended Use</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
                </td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2.2
      Intended Users</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3
      Quality System Requirements</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.1
      US Requirements</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
                </td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.2
      Canadian Requirements</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.3
      European Classifications</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
                </td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.4
      Quality System Requirements</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">4</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">PRODUCT
      DOCUMENT STRUCTURE</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">7</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">4.1</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Project
      Documentation</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">4.2</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Model Number
      Format</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">5</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">PRODUCT
      REQUIREMENTS</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">8</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.1</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Electrical and
      Mechanical</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.1<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font>Insulated
      Handle</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8</font></div>
                </td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.2<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font>Shaft
      and Electrode Tip</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.3<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font>Shipping
      and Handling</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
                </td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.4<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font>Sterilization</font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">6</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Protection
      Against Hazards</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">10</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">7</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Packaging</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">10</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Labeling</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.2</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Packaging
      Configuration</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr bgcolor="#ccffcc">
                <td align="left" valign="top" width="77%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.3</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Manufacturing</font></font></div>
                </td>
                <td align="right" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">List
of Tables</font></div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <table cellpadding="0" cellspacing="0" width="100%">
                    <tr bgcolor="#ccffcc">
                      <td align="left" valign="top" width="77%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Table
      One &#8211; Standards</font></div>
                      </td>
                      <td align="right" valign="top" width="8%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      4</font></div>
                      </td>
                    </tr>
                    <tr bgcolor="white">
                      <td align="left" valign="top" width="77%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Table
      Two &#8211; Device Classifications</font></div>
                      </td>
                      <td align="right" valign="top" width="8%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      6</font></div>
                      </td>
                    </tr>
                    <tr bgcolor="#ccffcc">
                      <td align="left" valign="top" width="77%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Table
      Three &#8211; Model Number Format</font></div>
                      </td>
                      <td align="right" valign="top" width="8%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      7</font></div>
                      </td>
                    </tr>
                    <tr bgcolor="white">
                      <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    </tr>
                    <tr bgcolor="white">
                      <td colspan="2" valign="top" width="77%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">List
      of Figures</font></div>
                      </td>
                    </tr>
                    <tr bgcolor="#ccffcc">
                      <td align="left" valign="top" width="77%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Figure
      One &#8211; Concept Drawing</font></div>
                      </td>
                      <td align="right" valign="top" width="8%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      5</font></div>
                      </td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div>&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">1</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">INTRODUCTION</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">1.1</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Purpose</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Product Specification defines preliminary product requirements and constitutes a
part of the Design Inputs for the Resection Device Project for Boston Scientific
Corporation (&#8220;BSC&#8221;).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">1.2</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Scope</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Product Specification sets forth the requirements, provided by BSC, for the
Resection Device, (the &#8220;Device&#8221;).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">2</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">APPLICABLE
      DOCUMENTS</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following is a list of all documents and other sources of information referenced
in this Product Specification.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">2.1</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Standards</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div>
        <div>
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <table cellpadding="0" cellspacing="0" width="100%">
                      <tr>
                        <td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Standard</font></font></div>
                        </td>
                        <td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160;&#160;&#160;</font></font></div>
                        </td>
                        <td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Version/Date</font></font></div>
                        </td>
                        <td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160;&#160;&#160;</font></font></div>
                        </td>
                        <td align="left" valign="top" width="56%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Description</font></font></div>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21
      CFR Part 820</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="56%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Medical
      Devices, Current Good Manufacturing Practices, Final Rule, Quality System
      Regulation.</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">HF-18</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2001</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="56%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AAMI/ANSI
      Electrosurgical Devices</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10993-1</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3;
      Date 8-1-03</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="56%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AAMI/ANSI/ISO
      Biological evaluation of medical devices &#8211; Part 1: Evaluation and
      Testing</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EN
      980</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2003</font></div>
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">04/16/2003</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="56%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Graphical
      symbols for use in the labeling of medical devices</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EN
      ISO 14971</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2000
      AMD 1 2003</font></div>
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">03/01/2003</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="56%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Medical
      devices &#8211; Application of risk management to risk management to medical
      devices (ISO 14971:2000)</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ISTA
      2A 2006</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="20%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2006</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="56%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Performance
      Test for Packaged-Products Weighing 150 lbs (68 kg) or
  Less</font></div>
                        </td>
                      </tr>
                  </table>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Table 1 -
Applicable Standards for Medical Devices (US)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 18pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.0</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">GENERAL
      DESCRIPTION</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device is a sterile, single use electrosurgical device intended to be used in
conjunction with an electrosurgical generator for the delivery of radiofrequency
(&#8220;RF&#8221;) current and sterile saline for hemostatic sealing and coagulation of soft
tissue in accordance with instructions and user procedures provided by
BSC.&#160;&#160;The device is not intended for any other unspecified uses<font style="DISPLAY: inline; FONT-STYLE: italic">.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 18pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.1</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Concept
      Drawing</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="ex10-12a1b.jpg" alt=""></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Figure 1
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 18pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.2</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Application</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.2.1</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Intended
      Use</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device is a sterile, single use electrosurgical device intended to be used in
conjunction with an electrosurgical generator for the delivery of radiofrequency
current and sterile saline for hemostatic sealing and coagulation of the soft
tissue in accordance with instructions and user procedures provided by BSC. The
device is not intended for any other unspecified uses<font style="DISPLAY: inline; FONT-STYLE: italic">.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 18pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.2.2</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;Intended
      Users</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Users of
this Device will be healthcare professionals such as medical doctors and nurses,
who are qualified and trained in electrosurgical procedures.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;Quality
      System Requirements</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device has the following classifications for FDA, CMDR, and MDD
classification.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div>
          <div align="center">
            <div style="TEXT-ALIGN: center" align="left">
              <div style="TEXT-ALIGN: center" align="left">
                <div style="TEXT-ALIGN: center" align="left">
                  <table cellpadding="0" cellspacing="0" width="80%" style="TEXT-ALIGN: center">
                      <tr style="TEXT-ALIGN: center;">
                        <td align="left" valign="bottom" width="23%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Device</font></font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="bottom" width="23%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">US Classification</font></font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="24%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Canada</font></font></div>
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Classification</font></font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="24%" style="BORDER-BOTTOM: black 2px solid">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">MDD</font></font></div>
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Classification</font></font></div>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td align="left" valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td align="left" valign="top" width="24%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td align="left" valign="top" width="24%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="23%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Resection
      Device</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="23%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">II</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="24%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">III</font></div>
                        </td>
                        <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        <td align="left" valign="top" width="24%">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">IIb</font></div>
                        </td>
                      </tr>
                  </table>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Table 2 -
Device Classifications</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.1</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;US
      Requirements</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To market
medical products, the Food and Drug Administration (FDA) must determine that a
medical device is substantially equivalent to similar marketed medical
devices.&#160;&#160;The Bovie Regulatory department intends to use the
dissecting sealer device manufactured by TissueLink as a predicate
device.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.1.1</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Classification</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device&#8217;s classification is Class II.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.1.2</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Safety
      and Effectiveness
requirements</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device will meet electrical safety requirements (ANSI/AAMI
HF-18:2001).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.1.3</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Quality
      System Requirements</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Quality
system requirements are specified as part of 21 CFR Part 820, Quality System
Regulation.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.2</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;Canadian
      Requirements</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To market
medical products in Canada, a license application must be presented to Health
Canada. Once the license application is approved, the medical product can be
labeled and made available for sale in the Canadian provinces.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.2.1</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Classification</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Class
III</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.2.2</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Safety
      and Effectiveness
requirements</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Safety
and effectiveness requirements closely correspond to the essential requirements
of the Medical Device Directive.&#160;&#160;A list of Health Canada recognized
standards has been issued as of April 11, 2002 in Policy on Recognition and Use
of Standards under Medical Device Regulations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.2.3</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Quality
      System Requirements</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Health
Canada requires manufacturers of Class II, III and IV device to demonstrate that
their devices are manufactured in accordance with internationally recognized
standards.&#160;&#160;Demonstration of compliance with the quality system
requirements will be required at the time an application is made for a medical
device license.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.3</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;European
      Classifications</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.3.1</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Classification</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device is classified IIb (Rule 9 ) in accordance with the Medical Devices
Directive Annex IX.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Reference:
Guidelines for the Classification of Medical Devices &#8211; MEDDEV 2.4/1 Rev. 8, July
2001)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.3.2</font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Conformance
      Assessment Route</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device assessment route will be via Annex II (full quality assurance
system).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td align="right" style="WIDTH: 18pt; BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.4</font></font></div>
                  </td>
                  <td align="left" style="BORDER-BOTTOM: black 2px solid">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;Quality
      System
Requirements</font></font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
Medical Corporation (&#8220;Bovie&#8221;) has been certified to ISO13485</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">4</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">PRODUCT
      DOCUMENT STRUCTURE</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">4.1</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Project Documentation</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Documents
will be in standard Bovie document format.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">4.2</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Model Number Format</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following table lists the Device&#8217;s model number and corresponding product /
catalog code.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div>
          <div align="center">
            <div align="center">
              <div style="MARGIN-LEFT: 81pt" align="left">
                <table cellpadding="0" cellspacing="0" width="70%">
                    <tr>
                      <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Catalog #</font></font></div>
                      </td>
                      <td valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="top" width="75%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Comments</font></font></div>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" width="23%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TBD</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="top" width="75%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Laparoscopic&#160;&#160;Monopolar
      Device</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" width="23%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TBD</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="top" width="75%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Open
      Abdominal Monopolar
Device</font></div>
                      </td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;Table
Three</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">PRODUCT
      REQUIREMENTS</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following section will describe requirements for the insulated handle and shaft
with electrode tip.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Electrical
      and Mechanical</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device hardware is comprised of two (2) major components: (i) an Insulated
Handle and (ii) a Shaft with Electrode Tip. RF energy is passed through the
Insulated Handle through the Shaft to the Electrode Tip by a powered lead from
an electrosurgical generator.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1.1</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Insulated
      Handle</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Insulated Handle encases the controlling mechanism for the flow of saline, and
activation and selection of the RF current for the Device.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.1
Insulated Handle and Power Cord Insulation Resistance</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
insulation of the Insulated Handle and Power Cord shall meet Requirements of
Section 4.2.5.4 Dielectric withstands of accessories ANSI/AAMI
HF-18:2001</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.2
Insulated Handle Ergonomics</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Insulated Handle shall be designed for comfortable and efficient hand
operation.&#160;&#160;It will incorporate an over-mold to give the body an
elegant feel and soft touch.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.3
Insulated Handle Electrical Cord</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Insulated Handle Electrical Cord shall be approximately ten (10) feet in length
and incorporate a 3-prong electrical plug.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.4
Insulated Handle Flow Control Mechanism</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device will have a flow control mechanism, either on the tubing or in the handle
itself so the flow can be regulated by the user within the sterile
field.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.5
Insulated Handle Tubing Length</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
tubing length should be approximately seven (7) feet in length and incorporate
an I.V. spike on the end to attach directly to a hanging IV bag.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.6
Insulated Handle Tubing Material</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
tubing material should be a material that will resist kinking but should not
have so strong a memory as to pull the probe off of the sterile
field.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.7
Insulated Handle Activation Buttons</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">The Device should have a Cut and Coagulation Mode. &#8220;Cut&#8221;/&#8221;Coag&#8221;
buttons must be easy to operate.</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.8
Insulated Handle Compatibility</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 54pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Insulated Handle should have compatibility with standard RF generators
      used for electrocautery and standard grounding
  pad.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 54pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Insulated Handle should have compatibility with standard 0.9% saline I.V.
      bag.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1.2</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Shaft
      and Electrode Tip</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Shaft
and Electrode Tip provide the actual working portion of this
system.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.1
Saline Flow Rate of Device</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Saline flow rate prior to use will be
**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.2
Device (Shaft) Length</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device should be straight and have two (2) lengths: one for laparoscopic
monopolar procedures (approximately thirty-two (32) cm) and one for open
monopolar procedures (approximately fourteen (14) cm).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.3
Shaft Configuration</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Shaft
will be hollow to allow for fluid to flow to the sintered stainless steel tip.
The inside diameter of the Shaft should be equal to the inside diameter of the
tubing that feeds fluid to the Shaft to minimize any flow restriction in the
fluid circuit.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.4
Tip Material</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Tip
shall be made of **&#160;&#160;&#160;&#160;&#160;&#160;&#160;**</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.5
Tip Strength</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
porous blade tip to shaft tensile bond strength (axial mode) must be greater
than **&#160;&#160;&#160;&#160;&#160;&#160;&#160;**</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;after
being subjected to a full-power simulated use duty cycle.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
porous blade tip to shaft bond strength in an flexural mode must be greater than
**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">. after being subjected to a full-power simulated use duty
cycle.</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.6
Tip performance</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 54pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
      will exert its best efforts to meet the design goal that tip cutting
      performance be superior to competitive devices with respect to cutting
      speed. Tip will have the ability to coagulate soft tissue when performed
      in a suitable simulated use
environment.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1.3</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Shipping
      and Handling</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1.3.1
Shipping Temperatures</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tropical
(Wet and Dry) Conditions and Winter (Frozen) Conditions per ISTA
2A.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1.3.2
Transportation Testing</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Final
Product Packaging Configuration for the Device shall meet the finished device
requirements after being subjected to Simulated Transportation Conditioning per
ISTA 2A.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1.4</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Sterilization</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.4.1
Withstand 2x ETO Sterilization.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.4.2
EN 550: 1994 &#8211; Sterilization of Medical Devices &#8211; Validation and routine control
of ethylene oxide sterilization.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.4.3
AAMI/ANSI/ISO 11135 -1994 Medical Devices &#8211; Validation and routine control of
ethylene oxide sterilization.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">6</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Protection
      Against Hazards</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
Hazard/Risk Analysis will be performed throughout the design
process.&#160;&#160;The Hazard/Risk Analysis will be documented and filed as
part of the design history file.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">7</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Packaging</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">7.1</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      &#160;Labeling</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;7.1.1
Package must be labeled in accordance with both BSC&#160;and Bovie Labeling
Standards.</font></div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
7.1.2 BSC&#160;and Bovie branding, including mutually approved trademarks, will
be on the Handle and/or the shaft.</font></div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
7.1.3 The Device is to have a three (3) year shelf life under normal storage
conditions.</font></div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">7.2</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Packaging Configuration</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 57.25pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Tip and Shaft protector shall be included into the
  Design.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 57.25pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Scratch Pad shall be packaged with the
Device.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td style="WIDTH: 57.25pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
              </td>
              <td style="WIDTH: 18pt">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
              </td>
              <td>
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Device will be packaged in a Sterile
Pouch.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div>
          <div align="center">
            <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
                <tr valign="top">
                  <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">7.3</font></div>
                  </td>
                  <td style="BORDER-BOTTOM: black 2px solid">
                    <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Manufacturing</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Final
assembly and packaging will be performed by Bovie.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
              </td>
              <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              </td>
              <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12-12</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">APPROVALS</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <div align="left">
                    <div align="left">
                      <div align="left">
                        <table cellpadding="0" cellspacing="0" width="100%">
                            <tr>
                              <td align="left" valign="top" width="22%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Author</font></div>
                              </td>
                              <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            </tr>
                            <tr>
                              <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="52%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
                              </td>
                              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                              </td>
                            </tr>
                            <tr>
                              <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sales
      &amp; Marketing</font></div>
                              </td>
                              <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            </tr>
                            <tr>
                              <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="52%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rick
      Pfahl</font></div>
                              </td>
                              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                              </td>
                            </tr>
                            <tr>
                              <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Regulatory</font></div>
                              </td>
                              <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            </tr>
                            <tr>
                              <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="52%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rick
      Kozloff</font></div>
                              </td>
                              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                              </td>
                            </tr>
                            <tr>
                              <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Quality</font></div>
                              </td>
                              <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            </tr>
                            <tr>
                              <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="52%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John
      Woody</font></div>
                              </td>
                              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                              </td>
                            </tr>
                            <tr>
                              <td align="left" valign="top" width="22%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Manufacturing</font></div>
                              </td>
                              <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            </tr>
                            <tr>
                              <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="52%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Lillian
      Eshem</font></div>
                              </td>
                              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                              </td>
                            </tr>
                            <tr>
                              <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Engineering</font></div>
                              </td>
                              <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            </tr>
                            <tr>
                              <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td valign="top" width="52%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fred
      Baron</font></div>
                              </td>
                              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                              <td align="left" valign="top" width="23%">
                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                              </td>
                            </tr>
                        </table>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">EXHIBIT
B:&#160;&#160;BUYER&#8217;S FORM OF PURCHASE ORDER</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURCHASE
ORDER</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" colspan="2" valign="top" width="41%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Boston
      Scientific</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporate
      Headquarters</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One
      Boston Scientific Place</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Natick,
      MA 01760</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">USA</font></div>
            </td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      1</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Purchase
      Order No.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6056307</font></div>
            </td>
          </tr>
          <tr>
            <td colspan="2" valign="top" width="41%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">This
      number must appear on all invoices, packages and
      correspondence</font></div>
            </td>
          </tr>
          <tr>
            <td colspan="2" valign="top" width="41%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="23%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ship
      to Address:</font></div>
            </td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td colspan="2" valign="top" width="41%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td colspan="2" valign="top" width="41%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="23%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Boston
      Scientific</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporate
      Headquarters</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One
      Boston Scientific Place</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Natick,
      MA 01760</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">USA</font></div>
            </td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td colspan="2" valign="top" width="41%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td colspan="2" valign="top" width="41%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="23%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bill
      to Address:</font></div>
            </td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td colspan="2" valign="top" width="41%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td colspan="2" valign="top" width="41%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="23%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Boston
      Scientific</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporate
      Headquarters</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One
      Boston Scientific Place</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Natick,
      MA 01760</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">USA</font></div>
            </td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td colspan="2" valign="top" width="41%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tax
      Exemption No.</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Telephone:</font></div>
            </td>
            <td align="left" valign="top" width="28%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5086478600</font></div>
            </td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">04-2695240</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FAX:</font></div>
            </td>
            <td align="left" valign="top" width="28%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5086479416</font></div>
            </td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date
      Ordered:</font></div>
            </td>
            <td align="left" valign="top" width="28%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOB</font></div>
            </td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Mode
      of&#160;&#160;Transportation</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9-28-2006</font></div>
            </td>
            <td align="left" valign="top" width="28%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">VNCR:
      FOB: Ship Point - Collect</font></div>
            </td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Buyer
      No.</font></div>
            </td>
            <td valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="23%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Confirm
      To:</font></div>
            </td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">06B
      NAT</font></div>
            </td>
            <td valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="23%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John
      Q. Public</font></div>
            </td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" colspan="2" valign="top" width="41%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Terms
      of Payment</font></div>
            </td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" colspan="2" valign="top" width="41%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Within
      45 days Due net</font></div>
            </td>
            <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
      </table>
    </div>
    <div>
      <div align="left">
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <div align="left">
                    <div align="left">
                      <table cellpadding="0" cellspacing="0" width="100%">
                          <tr>
                            <td colspan="8" valign="top" width="81%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                            <td align="left" valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                            <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                            <td align="left" colspan="2" valign="top" width="17%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" width="11%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item</font></div>
                            </td>
                            <td align="left" valign="top" width="11%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Port
      Number</font></div>
                            </td>
                            <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td align="left" colspan="2" valign="top" width="17%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Description</font></div>
                            </td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Quantity</font></div>
                            </td>
                            <td align="left" valign="top" width="6%" style="BORDER-BOTTOM: black 2px solid">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">UOM</font></div>
                            </td>
                            <td align="left" colspan="2" valign="top" width="17%" style="BORDER-BOTTOM: black 2px solid">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Due
      Date</font></div>
                            </td>
                            <td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unit
      Price</font></div>
                            </td>
                            <td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Taxable</font></div>
                            </td>
                            <td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revision
      Total</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td colspan="8" valign="top" width="81%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" width="11%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">00010</font></div>
                            </td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td align="left" colspan="2" valign="top" width="17%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Test
      Purchase Order)</font></div>
                            </td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td align="left" valign="top" width="11%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.00
      EA</font></div>
                            </td>
                            <td colspan="2" valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td align="left" valign="top" width="11%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">150.00/100</font></div>
                            </td>
                            <td align="left" valign="top" width="11%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Y</font></div>
                            </td>
                            <td align="left" valign="top" width="12%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.00</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td colspan="2" valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td align="left" colspan="4" valign="top" width="34%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance
      Due: 0.03</font></div>
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item
      Text:</font></div>
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">***
      Item Canceled ***</font></div>
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">***
      Item Canceled ***</font></div>
                            </td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td colspan="4" valign="top" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td align="left" colspan="2" valign="top" width="23%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TOTAL
      ORDER:</font></div>
                            </td>
                            <td align="left" valign="top" width="12%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.00</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td colspan="4" valign="top" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td align="left" colspan="2" valign="top" width="23%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CURRENCY:</font></div>
                            </td>
                            <td align="left" valign="top" width="12%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">USD</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td colspan="4" valign="top" width="34%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td colspan="2" valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td colspan="4" valign="top" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td align="left" colspan="3" valign="top" width="35%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Authorized
      Signature</font></div>
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">JOHN
      SMITH</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td colspan="4" valign="top" width="34%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td align="left" colspan="3" valign="top" width="35%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUYER</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td colspan="4" valign="top" width="34%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td colspan="3" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                      </table>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
changes or substitutions can be made to DSC specified components or he
processing of those components without prior notification and approval of the
purchasing department.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">VENDOR
COPY</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">EXHIBIT
C:&#160;&#160;NON-BINDING 12-MONTH FORECAST</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Surgical
Resection</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <div align="left">
                    <div align="left">
                      <div align="left">
                        <div align="left">
                          <div align="left">
                            <div align="left">
                              <div align="left">
                                <div align="left">
                                  <div align="left">
                                    <div align="left">
                                      <div align="left">
                                        <div align="left">
                                          <div align="left">
                                            <div align="left">
                                              <div align="left">
                                                <div align="left">
                                                  <div align="left">
                                                    <div align="left">
                                                      <div align="left">
                                                        <table cellpadding="0" cellspacing="0" width="100%">
                                                            <tr>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Year
      1 </font></div>
                                                              </td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                            </tr>
                                                            <tr>
                                                              <td valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">9</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">10</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">11</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Month </font></font></div>
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12</font></font></div>
                                                              </td>
                                                              <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Totals</font></font></div>
                                                              </td>
                                                            </tr>
                                                            <tr>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                              <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                            </tr>
                                                            <tr>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="7%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="7%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="7%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                              <td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                              <td align="left" valign="top" width="6%">
                                                                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;**</font></div>
                                                              </td>
                                                            </tr>
                                                        </table>
                                                      </div>
                                                    </div>
                                                  </div>
                                                </div>
                                              </div>
                                            </div>
                                          </div>
                                        </div>
                                      </div>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">EXHIBIT
D: LONG LEAD TIME COMPONENTS</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(To
be provided as set forth in Section 1.7(a))</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">EXHIBIT
E:&#160;&#160;TRANSFER PRICES</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <div align="left">
          <div align="left">
            <div align="left">
              <table cellpadding="0" cellspacing="0" width="100%">
                  <tr>
                    <td align="left" valign="top" width="65%" style="BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Units Purchased in Contract Years 1-2 (in
      aggregate)</font></font></div>
                    </td>
                    <td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price per Unit*</font></font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="65%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                    <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="top" width="33%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="65%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                    <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="top" width="33%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="65%" style="BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Units Purchased in Contract Years 3-5
      (annually)</font></font></div>
                    </td>
                    <td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price per Unit*</font></font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="65%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                    <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="top" width="33%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="65%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                    <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="top" width="33%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="65%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                    <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="top" width="33%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="65%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                    <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="top" width="33%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="65%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                    <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td align="left" valign="top" width="33%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;&#160;**</font></div>
                    </td>
                  </tr>
              </table>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*Note:
use of this Exhibit, including the determination of applicable pricing, is
subject to the provisions of Section 1.3 of the Agreement.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">EXHIBIT
F:&#160;&#160;SELLER&#8217;S VENDORS</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The
following list is tentative as of the Effective Date, and Seller reserves the
right to amend this list upon finalization and approval of the Specifications
and Bill-of-Materials for the Product.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">1.
**&#160;&#160;&#160;&#160;**</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">2.&#160;Mott
Corporation<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">&#160;</font>84
Spring Lane, Farmington, CT 06032, 860-747-6333.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">3.&#160;&#160;**&#160;&#160;&#160;&#160;**</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex10-12a1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-12a1a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!4@(=`P$1``(1`0,1`?_$`/H``0`"`@(#`0$`````
M```````)"@<(`08"`P4$"P$!``("`@,!``````````````@)!@<%"@$#!`(0
M```%`P($`04,!`<*!PP+``$"`P0%``8'$0@A$A,),4$B%)=843(C4Q65U1;6
M&0H:87$S&$)2)!=7=]>!0S0EMC>W.)@YD;'1<D0VEO#A\6*RLU1DE#556<&2
MPG-%=B='ATAX$0`!`@4"`@0)!P<(!0L#`P4!`@,`$00%!B$',1)!41,(87$B
M,M(4E%47@4)2DB.3"9%B<C,5%ABA@D-3TR14='.#LS0UL<&BLL+B8Z.5-C?1
M1"7P\7569(2D)O_:``P#`0`"$0,1`#\`OX4A"D(4A"D(4A"D(4A"D(4A"D(4
MA"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4
MA"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A&N.Y;='B[
M:U9)KMR%(G7D7P*HVM9T6=`]R74^2`O,C'-E3D*@R;B<HN':NB*!1XB8XD(;
M8>W.V>3;FWG]EV%L)IT2+U0L'LF4GI40-5&1Y$#RE'J`)&E-\-^\#V$Q<Y#F
M#Q76NS%+1M%)J:I8E,-I)`2A,QVCJI(0#TJ*4*KU92[LFZ>]YQ9S94K!XJMU
M-P)XZ$@8>/EWW0*;X(LM-SS5ZJ_7,3W_`$DFR0CX$"I[XSW6]L;+1!N\-/7.
MX%,EN.N+;3/IY&VE)"1U<Q6KK)BF_/\`\0K?O*;JI_%ZBFL%F2N;;-.RVZOE
M'#M7JA#A<4>GD2VGJ0(E/[:&]#)6Y]ED&T\JMHE[<=@-("3:79$LTXLTS'S:
M\BT,VE8QOHR3?,UF`"59`J952'$#$`Q>8T8^\;L_CNVSU!=<84ZBWUZW4*86
MHK[-380J:%GRBE05JE1)!&AD9"?G<<[SF;[[TUXQ[/D4[MYM#;#J*MI`:+S;
MRG$%+K:9("T%L$+0$A0404@IFJ52HPQ/^%(0I"%(0I"%(0I"%(0I"%(0I"%(
M0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"&@
MCX4A'3KLR)8%A-SNKWOBTK0;II]4ZMRW%$PH`F/@<`D';<Q@$`\@#7+VK'[]
M?'`U9:*KJW"929:6YK_-28QG(<TP_$63493=;=;F0)DU-0RSIU_:+3/Y(U*O
M/N1[-++ZI%\QQUR.DA$!:67$3ESB?3RI/F$>,2J4P\`$K@0_N<:VI9^[ON]>
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MP3.?RTDHR7;?>CP0_4(G=&,,GVX!A`#+QYK<N)!+QU,?_&<0Y$`_\5(P_HK'
M;CW/<V8256VY6VH(Z%]JT3_T'!^4QF]D_$ZVGK%A%]L5]H@>*FS35"1XYNLJ
M_(D^*-R<2[^]J>9GS2'M;*<;%7"^.";2W;T;.K1DW*PAJ5NU/,)HQCUR;3@F
MBX4.;3@`A6HLJV*W0Q!E=7<[8X[0($U.TY2^@#K4&R5I'A4@`=<27V\[WG=_
MW+JF[;8K^Q3WATR13UJ5TCBE?107@EIQ1Z$MN*4>@1N/_P"']8>Z'NA6HHDK
MQU'"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I".I7Y>]
MNXULNZ+_`+M?$CK;M"$?STP[-H(D9L$#+&31*(AU7+DX`FD0.*BIRE#B(5RM
MBLMPR*\4UBM2"Y<:MY+3:?SE&4SU`<5'H`)Z(QW+LJLV#XQ7Y?D+H9LENI7'
MWEGH0VDF0'2I1DE">*E$)&IBF1N2W`7AN5RQ<63;M<*D3>N%&=L074$S.UK7
M;K*#$P;(@#R`**)N==0`YEW!SJ&XFX6_;>8):=NL7I\<M205(2%/.2\IYX@<
M[BCX3HD<$H"4CA'66WNW@R3>_<&MSC(5J"'5E%,Q.:*6F23V3"!P\D&:U<7'
M"M9U5&"V[==VN@U:H+.G3E9)NV;-TCK.'#A8Y4D4$$4RF45664,!2E*`F,80
M``UK-7'$-(4ZZH):2"229``"9))T``U)/"-3LLO5+R*>G0I=0XH)2E()4I2C
M()2!,DDF0`$R=!%L;MO[3WVV?#[F3O)J5ME#)RD?.74T'E,K;T6T05^K]KJ'
M#4!=L$WBJSK0="N5S$X\FHU;]X;=)C<;+4TUH458U;0IME70ZM1':O#\U12E
M*.M"0KYTH["O<H[O=5L=MNNNR5L(SJ^EM^J1I.G:0#ZO2D_30%K6[K(..%&O
M("9$JC_$SH4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(
M4A"D(4A"D(4A"D(4A"D(4A"D(4A'4[OOVQ\?1QY>^KOMJSXPA#J"]N6;CH9`
MQ$^)Q3,_<(=42^X74:Y6TV*]7ZH%)9*2IJZDF7*RVMPZ]?*#+Y8QW),OQ7#J
M(W'*[E0VVA`)YZE]ME,AQD7%)G+P3,:#Y-[J^TG'XN6L)<<]D^40YB@VL6$6
M4CSJE_@?+LV>(BU""/@=$ZQ1\@C6\\;[L&ZE]Y7*VG8MM,KIJ7`%2_T;?:+!
M\"@DQ$;.OQ`.[SAY<8M=;5WVN1\VA9);)ZNW?++1'YR"L=4XT!R3WJ+^D!<-
M<38BMNV$#!RH2M[RKVYY`/$!5",B0@F"1A#B!3++`4?'F#QWMCO<[L5/RNY3
M=:FI7THIT)93XN=?:J/C"4_)$0,X_$]RZL*V-O<=H:%HCR7:UU=4YX^S:]70
MD]0*G`#QGTZ"9%W[[M\GBX3G\TW1%,'(`4T599V]DL"I@(B"8?5I&/>'+H.@
M\ZQQ,'OA'C6],?V-VJQOE50V>F=?3\^H!J%3Z_MBM(^1(ET2B(>:=[KO#YWS
MHNV35]/2+XM4931(`ZO[LEI9'0>92B1Q)UC4N1DI&7=*/I:0?2KU4QCJO))V
MX?NE#F'F,<[ATHJL<QC#J(B/$:VG3T]/2-!FE;0TR."4)"4CQ!(`B/-9<*^X
MOJJK@^Z_4J,RMQ:EJ)/6I1)/RF/QU[H^.%(0I"%(0I"'_>'^Z'$!_6`TCR"1
MJ.,2W;#^Y%=F()F$Q7FV:?71B)^X;1<7<,HNH\G,;G6.5!!8'JO.YDK33$0!
M9NH8QVA//1'E*9(T5M[^[S:\MI'LFPUE%-E;:2M;2`$MU<M2.4:(?/S5"06?
M)6)D*%B?=,[[60;<7*EP+=&J=K]NWEI::J'5%;]NF0E*@LS4Y2#Y[:B2TGRF
MB`DMJLT-G+9ZV;O6;A%VS>((NFCILJ19NY;.$RK(.$%DQ,FJBLD<#%,41`Q1
M`0JN!UIQEQ3+R2EY"BE22)$$&1!!U!!T(/"+SZ=]BJ8154RTN4SJ`M"TD*2I
M*A-*DD:%*@001H09B/?7XCVPI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I
M"%(0I"%(1&9W:?K4.T*7+;:<@HP-?%HC=_H":BG);2:KQ45'_2`3$C2S";3J
M&'S`-R\W"I']U?\`9GQ7:-P+8?\`4G^PYB!-XA(DF?S^S+DAQE.409_$-%_/
M=TJ$V5+IHS=*7UOLP3*F':&:Y<&P^&>8G2?+/2*K\>Q?2SUK&Q3-W)R+Y9-L
MRCXYNL]?/'"IN5)!JT;$57<+*&'0I2%$PCX!5F[[[%*RJHJ5H;IT`E2E$)2D
M#B5*,@`.DDQ0/24597U3=%0M.O5KJ@E#;:5+6M1X)2E(*E*/0`"3T18;[=?;
MD?8_?Q.>,_0Y$+P;`D_Q]CYZ!55+76.4#HW-<R0"9,MP)E-_)6@\WH8CU%-%
M@*5.`W>`[P;%]8=P?!7BJTJFFJJDZ!X<"RR>/9'Y[FG:>:GR)E5RG<Q[E=5A
M]73[L[NTP3D:).6^WKD33*T*:FI'`/C^B9,^Q/EKDZ$I;FXJ&46E0I"%(0I"
M%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"
M%(0I",9Y(S/BC#\<:4R=D*U+):`03IEG9=JV>N0T$=&48!SR3XXZ:`5%(XB.
M@>(A628[A^4Y;4>K8W0558[.1[-M12/TERY$^-2A&"YMN=M[MQ1FNSJ\V^UL
M2F`^\E*U?H-3+KAZ@A"B3IQB,'+G>1PI:XN6&)+,N;)\@0#D2EI,?J;;'4`3
M%*HF9X@\GG:7@.GHB',&H<Q>`U)/%.Z+F-RY7\JK*:VL'BA']X>EU'E*6TG^
M>J748@CN-^)9MA8>>DV[ME=?:P3`==_N=-/43'.E=0H<#(LMSZQQB,C+/=-W
M89+](:0US16*X583`5AC^.*UD>F;@!5KCE#2,P)P`1#5`[<!#^#KQJ2&+=V7
M:['.5VLIG;G6#YU4OF1/P-(Y&_K!?CB"VX??Y[P6<%=/;*YBPVM1,FZ!OD<D
M>A50X7'I^%M38\$:`7'=-SWA(*2UV7%.W/**F$RDC<,L_F7IQ$1,.KF1<.%O
M$?#72M[6^V6VTL"EM=.Q34PX(:0EM/Y$`"(@7K(;]D=8JXY!6U==7JXN5#KC
MRSXUN*4K^6/A5]T</"D(4A"D(4A'N;-G#U4B#-NN[74,!"(M45'"QSF'0I2)
MHE.<QA'P``UK\..-LH+CJDH0.))`'Y3'O9IJBI<#-.A;CJC()2"23X`-3&4X
M;`F<;B("D'A[)THD).H59I8UR'1.3^,188XJ2@?J$:QFKSG"Z`\M;=[:TN<I
M*J60?R<\Q&?6S:+=2\IY[7C=\?;(F%(H:DI(\"@W(_(87!@7-]IL5)2Y<0Y)
M@XU(HG6D)&R[@;LD"%]\==R9AT4"!_&.)0I09QAET?%-;KM;GJ@G1**AHJ/B
M'-,_)"\;1;IX_2FNO>.WNEHDB:G'**H0A('2I1;"4CPDB,35E,:ZA2$*0BTA
MVE\XR.4=O#RQ)]VJ]G,,S"%MMW3A455W%HRR"S^V2*'/YYAC>BX9E#4>5!!,
M-?)59_>GPJGQK/D7RA2$45W9+I2!(!]!"7OKS0X>M2E1?=^'ENK6YYLV[B=W
M<4[=<:J4TZ5J,U*I'DJ<I@3Q^RY761U(;0(E-J,D3ZA2$*0A2$*0A2$*0A2$
M*0A2$*0A2$*0A2$*0A2$*0A2$*0CT.FK5\V79O6S=XS=)'0<M'2*;ALY05*)
M5$5T%BG2624*.ABF`0$/&OVTZZRXEYE2D.I((4DD$$<""-01UB/344[%6PNF
MJD(=IG$E*D+`4E23H4J20001H01(QT&V\/XFLV34F[1QACZV)E4QSGEH"SK?
MB9'53]IR/6,>@X3*?7B!3``^Y7/7'+<JN],*.ZW*OJ:0#S'7W5HTX>2I1!^4
M1B%DVVV[QFO-TQVPV>@N:B27:>CIV7->,EMMI4`>D`RC(M8]&:PI"%(0I"%(
M0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"/B
M7#<MNVC%.9VZIZ'MJ%9D%1U+3LDSB8YN4`$1%5V^600*(Z<`YM1'PK[;?;;A
M=JI-%:V'JBL69)0VA2U'Q)2"8XJ]7VRXY;UW;(*NFH;8T)K=?=0TVD>%:RE(
M\&NO1$9^:N[5MNQN+J-Q^68S+<"/.0HVZ3Y(M--8.8-%KFE$>9RF!@#SF;5R
M00'@:I&X=W5]PLAY:F_%FT4!U^U^T?(\#*#H?`XM!\$0;W0_$/V4PKM*'#Q4
MY+>$S`]7'8T@.O&I=3-0G+5EIU)GHJ(E,R=U+=+E$CJ.MV9BL1V^XYT_0K#:
MG+-'0-P`KBZ90SN3*IR^)FH--1$>&F@!*C$>['MEC)347!EVZUZ?G5)^SGX&
M4<J)>!?/%=VY??\`=^L]2NBLU33X]:%S')0)(>*3T*JG2MV?66NQGKI+01V3
M4[-W)(KS%Q3$K/RSHPG<RDU(.Y20<''Q,L\?++N%!'])AK?]'14=OITTEO9:
M8I4CR4-H2A(\24@`?DB&5TN]UO=8NXWFIJ*NX.&:W7G%NN*/6I:RI2CXR8^7
M7U1QT*0A2$*0C[=OVS<=VR"<3:MOS=RRJPZ)1L!%/YA\H.H`/(TCD'"X@`B&
MOFZ!7Q5]RMUJIS57-]FFI1Q6ZM+:1_.40(Y:SV&^9#6)M]AHZJMKU<&V&EO.
M'Q(;2I1_)&\^,^V+N^R."+E;'[;'\6J8FLAD.7;02I4S:")RPK<)">,/(.H<
MS8A3>',%:5R/O([48\2VBO57U(^92H+@GU=H>5K\BS+JB5N#=Q3O&9J$O.6A
M%HH%$?:7!U+!EIJ&4]I4<.$V@#PG$@&.^RC#HE2<98S5(/E0,`K1./H%!@W$
M`'42A-W`9ZNH4P<!T9)C[@UHC(.^/5K);Q:SH0F6BZIPJ/W;7*!]X8F#AGX7
MMM;"7MP<G>=7/5J@82A/B[>HYR9_Z!)ZC&\%@=LK9S8734-C,][/D_\`IU_S
M<C<'./#B:,(HR@QXAK_@NM:7OO>/W;ODTBXBC9/S:5M+7_3DIS_IQ*C$.XQW
M;<1DX;&JZ50^?7ON5$_&T"W3_P#E1N):N,\<V,@1M9EA6;:J)"%3`MOVU#Q)
MA*4-"@HHR9HJJB`>4PB-:DN>29#>UER\5U95*)G]J\XO\@4H@?)$DK!@N$XH
MT&<9M%LM[8`']WIF6M!UE"$D^,DF.\:CY!$`]P.`!^H`KA8RJ/$P`<IB'`#D
M.`E,0X`8IBF#02F*;4IBB`\0&O()!F-"(\*2E0*5`%)&H/`Q5A[KV%[-Q+N+
MCI:R8]I"L,FVFG=\K!,$B-V#&X$I1Y%R;IBU2`J35O*@W37,F4`*"XJ"```Z
M!9OW7<QN^5;?N4MY<6\_;:HL(<425*:*$K0%*.JBB92"=>7E!X101^(-MCC.
MWF\S-PQ=ENEI+Y;Q5NL-@);;J`ZXTZI"1HA+O(EPI``[0K(`!D(P:DG$#X4A
M%A'LH6=*M;4S??K@JR4/,3ELVO&:Z@B[>0C-](RBI0'Q%J26;DU#Q$XAY*@5
MWR+O3.7.S6-$C5M,O/+ZTI<4E"!_.+:S\@BX[\+S&J]C'\HRUX*3;JBJI:5O
MZ*UL(<==(_1#S8G^<1T1.94*8M:A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$
M*0A2$*0A2$*0A2$*0A2$*0A2$*0CY,Y/0=L13R=N28BX"$CDA7?R\R_:QD:S
M1+XJ.7KQ5%NB7_G&#4:^JBH:VY52*&W,NOUCADE#:2M:CU!*02?R1QUVN]JL
M-O=NU[J6*.ULIYG'GG$M-H'6I:R$@>,Q%OFWNZ;?,>*NXC&<=,YDG6_62],B
MQ^K]G)KD#E)_C^1;J/)!+G\3-6BJ8EXE..M29PWNI9Y?T(J\C<9M%$J1Y5_:
MOD?Z)!"4F70M8(/%,0)W2_$7V>PUQRW8.S4Y+=4<PYVO[O1A0X?;N)*W!/I:
M94@CS5F(\[D[RNY21=J*6W9V*K99<^J+9:(GIYP5,!X%6=N9YD5500\3%2('
MN`%;\MW=$VZIV@FX5=TJ7I:D+:;$_`D-*D/`5'QQ#6]_B7[VUM05V2VV"AI9
MZ(++[ZI>%:JA`)ZR$)\`$95Q-WH[P;RK1GFS%T!)P*IRINYS'JSZ+F6)#&T,
MZ^19E[(,)(J11UZ95VQA`.!A'A6,93W/;0Y2K>PVY/M5H$TMU02MM7@[1M*5
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MN6.'@D:&C#*G8"?R'=F;)<>)@#C6RL,VBW`SQ256"WNFB/\`3N_9,`=?:+ES
M>)L+5X(T1NEWEMF-GVUHS*]4XNJ1I1TY]9JR>HLM$EN?0IXMHZU`1#CG#O+7
M].&=Q.!+%CK(CA$Z:5V7F"-PW*J3SB@LU@T3!`19QUU`%C/O)X<0&7&%]T.Q
M40159Q6N5M1Q+%/-ID'J4X?M5C]$-16KNI^)AEUT4Y;MI;4S:Z+4"KK)5%21
MJ)I9']W:/3)9J/DZ8FLFYGRMF66--91O^YKV?<XG2":DEEF+,1U\V/BDA2BX
MY,`'0"H(I@`<*E+CF'XOB-+ZGC5#34;$M>S0`I7Z:S-:SX5*)BO/.=SMP-R[
M@;IG=WKKG5SF.V=44(_T;0DTV.B3:$B6DHQE621@D*0A2$*0CNUB8UR%D^6)
M!XZLFY[VECF*46=M0KZ5.ES"!0.Z4:HG09I:CQ.J<A`\HUPU[R*PXW2FMR"L
MIJ.E'SGG$H!\0405'P)!/@C*\3P7,L[N(M6&VNNN=P)`Y*9EQTIGTK*$D(3^
M<LA/AB3'$/9_W#WL#20R9,VQB*(6%(ZK1TN%UW6"!^4QM(B&7)%-U>0>!5GY
M3@("!BAY8Y99WL<`LW,QCC-3=:L3`4D=@Q/]-P<Y'A2T1U$Q.3;C\-_>/*`W
M69Q4T..VY4B4+5ZU5<IX_8LJ[))EP"ZA*@9A21+63W%?::VK6`5HZNR/N/+,
MR@(**.+NE5&,(=4-!#IV[`#'MC(`8/V;A5R`AP,)JC9D_>FW.OI6U:UT]KI%
M:`,("G)>%UWF,_"@(\$HG=@'X>NP6(!NHR!FMR"Y(,RJK=+;)/@IZ?LTE/YK
MJW1+0SB0FS<?6)CN-3B+#LVV+.C$DRI%9VW"1T.B)"^]!3T%NB980]TXF']-
M:$N]_OF05!J[Y65-74$SYGG%N'Y.8F7R1,;&<-Q+#*(6[$K906VA2)<E,PVR
M)#KY$IGXS,QW"N(C)84A"D(4A"D(ZW>%WVS8%KSEZ7C,LK?M>VXY>4FIB05!
M%JR9-RZG.<P^<=10P@1-,H"=10Q2E`3"`#R-HM-QOMS8L]H96_<JAP(;;2)J
M4H_\PXDG0`$D@`F.$R3)+'B%AJLGR6I:H[%1,J=>><,DH0GB3UDF02D34I1"
M4@J($4Z=X>XV0W0YQN/(ZB*S&W$")V[8T4N/PL=:46JN+#TDNHE*^D5EU7;@
M`X%57$H<"A5M^TNWS&VN%T^/)(7<"2[4K'!;ZP.:7YJ``A/6E,^)CK6]Y/>J
MLWWW4K<T4E35E2!3T+2N+=(T5=GS#ASN*4IUR6@6LI&@$:N5LN-"1]2$A96Y
M)F)MV"8KR<W.R3*'B(YL7G</I*2<IM&31$OE47<*E*'DX\>%?-6UE+;J-VOK
M5I;HV&U.+6=`E"`5*4?``"8Y"TVJX7RZ4]FM+2W[G5OH9:;2)J6XXH(0A(ZU
M*(`\<71=K&#V>W;!%@8K1%%62A8H'MSO$`#IO[LF#C(W`Y(?0!41(_7,BB80
M`>@D3@'A5/>YV:.Y_F]?DRYBF>=Y64GBEAOR&AX#R@*4/I$QV==@=K*?9K::
MT8$WRJKJ:GYZI:>#E6\>TJ%`]*0XHH03KV:$QL)6`QN.%(0I"%(0I"%(0I"%
M(0I"%(0I"%(0I"%(1TJ^,D8^QG%A-9#O6U[)BSF$B3VYIN/ATG"@<12:@]72
M.[5`.(D2`YM..FE<S9<=OV25/J=@HZFLJ1Q2RVIP@=:N4'E'A,A&+97F^'8+
M0?M/,[I06N@)D%U3[;(4>I'.H%9Z9)!,M91TZQ=Q6!LF/RQ5@Y@QY=<L<PE2
MBHBZ8I>47,`"(@VCC."/'/*`<>F0VE<O>]OLXQMCUJ^VFOI:4<5K96$#QKER
MCY2(QK$]ZMI,ZJQ;\0R2S7"X$R#3-4TIU7Z+?,%J_FI,9FK#XV="D(QYD#+>
M+\4LT7^2L@6C8S9S_@IKFGH^*5=^=RB+1LY7(Z=`4WOA3(8"^72L@L.*9+E#
MI8QV@JZUQ/G=BTM83^D0))\$R)QAF8;BX%M]3)J\WO%NM3"_-]9?;:*^CR$J
M4%+ET\H,NF/G8]SEAO+*CA#&F3[(O=TU*8[EC;MQ1TA((I$T`RZD>DOZ:5N4
M3`'4Z?)KPUKZ+_A.7XLE*\CMM;1-*X*=:6E!/4%D<L_!.?@CXL-W7VTW#6MK
M![[:KH^V"5(IZAMQQ('%1;"N<)_.Y9>&,J5B\;`A2$*0A2$1U;NNXUB;;0#Z
MTH#T?)>7$RF3^JD6]*6&MI<2^:I>,TAU2LE2"(#Z"@!WA@X'!$!`]2!VI[OF
M4[BE%UK^:W8H=>W6G[1X=5.V9<P/]8J38Z.<@IB%_>+[Z>WNQX=QZS\E[W#2
M"/56ECL:94M#6/)GR$?U".9T_.[($*BM[GO=-FW<E,FD\HWD\D(Y-4RD9:48
M)XNSX8FOF$802"GHYUB%``](<"LY-IYR@U89@VV6&;=T8IL:I$-U!$EOK\M]
MS])PB8'YB>5`Z$Q2;NYO]NCO;<S7YU<G7:-*IM4C4VJ1GJ#;"3RDC^L<YW3\
MY9C7FL^C3,*0A2$24]KS<%<F)]QEM8^]/64L+,,@2V9^&55,+1">4:K_`%<G
MVR9M2(/T'I"-U#E`!4;JB4VO*02QV[RN!V[*=OJF_<@%\M+?;-.`>46P1VK1
M/2DIFH`\%)!'$SG!W#=X;WM]O10X?VRE8ED;PIJADGR`^4J]6J$C@EQ+G*VH
MB7,VM0,Y)Y;6E5>QV"(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A'SI:7B8".
M=2\[*1T+$L4C+/926>MHZ.:(D#4RKEZ\51;()E`.(F,`5]%+25==4)I*%IQZ
MJ69)0A)6M1Z@E())\0CXKC<K=:*-RXW:H9I;>TGF6Z\M+;:`.)4M9"4CPD@1
M&-GGNQ;><6B]A\=@^S1=3?J(A]7E`C;-;."D,`>E74[14!ZF170!]!0<E,&O
MGA4D<'[K>?9+R5>0<EGMBI'[4<]01X&4D<IE_6*01U&(*[M_B$;.8%VMMPSM
M<FOZ)@>KGLJ-*I'SJI:3SB?]0VZ#](1#%G+N1;HLVF>Q_P!<38WM-T"R7U7Q
MT*\&55JKYO0D9_JJ7#(?!\#!Z0DD;4?@PX:3`PKN\[:8:$/^J?M&Z)D>VJY.
M24.E#4@TG7AY)4/I161NMWVM^-T2[1_M(V7'W.8>JV[F8!2?FN/S-0YIH?M$
MH,_,&DM#%555U55UU%%EUCF5666.95994XB8ZBJIQ,=10YA$1,(B(C6\$I2A
M(0@`(`D`-``.``Z!$2777'G%.O*4IU1)))F23J22=22=2>F/"OU'KA2$*0C]
M3%@^E'C>/C&3N1D':A46K%@V6>/'*IQ`"I-VK8BBZRAA'@4I1$:]3S[-,TI^
MI6AMA(FI2B$I`ZR3(`>$F/II*.KKZA%'0M./5;BN5"&TE:U$\`E*02HGH`!,
M2(X1[7>Z'+H-9*<@6F([8<`13Y6O\RK:750.4#@9E:;0JLT<XE,`@#DK0@_Q
MJT#F?>6VUQ0JIJ)]=UN2=.2ED4`\/*?5)N7Z!6?!$S-K>X9OON*&ZVZTC>/6
M)<CVM?-#I21.:*1,WR?]*&0?I1+QACM*[:\<@VD+_P#EG,L^EH<_UD4-#VL1
M70!^!MJ)7**Z9#!X.W+DIO*70=*BAF'>HW$R#FI[%V-HH3I]D.T>(\+RQH?T
M$((ZYZQ8YMC^'CLEA0169=ZSDMW3J?6#V-*#^;3,JFH#J===!Z1+2)*+6M"U
M+'B4(&S+:@;3A&Q2%0BK<B6,,P3`A`(40:QZ""0GY2@`F$!,/E&H[7.[72]5
M2JZ\5+]56*XK=6IQ1GKQ42?DB;E@QO'L5MR+3C-#26^UH`"6J9EMEL2$AY+:
M4B<NF4X[%7'QS<*0A2$*0A2$*0A2$?!NBZ;<LFWI>[+NFHZW;:@&*TC,34JY
M3:,(]F@7F46764$`U'WI2AJ=0X@4H"80`?NMELN%YKVK5:F7*BXOK"&VT`J4
MI1X``?E)X`3)(`CB+_?[+BUFJ<AR*J9HK)2-*<>>=4$-MH3Q*B?R`"942$I!
M)`BJ]OYWW3FZ*Y5+-LIS(0N#+=?%4B(M0#M'EYR;43%+=%Q(`('!(HF'T%F?
M4K<GPAPZIAY+.=C-D*+;2W"[WA+;V:U").+'E)IT'^A:/7_6.#51\D>2-:!N
M]UWL[KOQ>SC6,+>I=JZ-V;31FA=8ZF8%54)XR_J&3HV/*4.T)Y8X:D)$)X4A
M$[?::V<K/'R&Z/(T08C!B*S?#\8_1T],?ZJ-I"^3(*DU%NQ`#-XX^FAE146+
M[Q,PPD[TN[B&6%;:8^[.H7(UZTGS4Z%--,=*M%.CH3RH/G*$6R_AZ=VIRIJT
M[\9I3$4C14FT-.)ESN:I<KN4CS6]6Z<\"LK<'F-J-@*H'Q<'"D(4A"D(4A"D
M(4A"D(4A"D(4A"D(4A"D(T9WK[V[-VF6D5LB1I<V6;C:+&M"S.N`$;)B!TBW
M)<HI&ZS.":K!H4@:*NU"]-/0`.<FZ]F]F;ONG=2XLJIL6IUCMZB6JCH>R9GH
MIQ0XGS6QY2I^2E44N]#WH\:[O6/=@T&Z[<&L;/JE'S:(&H]9J9:H82K@G13R
M@4(D`M:*J.5\O9%S?>,A?>3[HD+IN*0..BSQ3E9QS775*-AHY/E9Q,:V+P(B
MB0I?*.IA$PV?8OBF/X9:6[)C=,W36]L<$CREGI6XL^4M9Z5*)/0)"0CK^[@[
MD9INEDCV5YS7O5UX>)U6?(;3T-LMB2&FD\$H0`.DS423CMNNNS<(.VBZS1VV
M5(NV=-E5&[ENLD8#IK(+I&(JBJF<`$IBB!@$-0&N?<0AYLM.I"FE`@I(!!!X
M@@Z$'I!C#&*A^E>344RUMOH4%)4DE*DJ!F"")$$'4$:@Q<&[?%_9"R7M.QC=
M63%W<A<*R4U&MYM^8YY"X(.&F'D;$2[Y0_G+NE6S?I&5'4RW2ZAA$QA$:F=^
M[%8,<W2N5LQQ*6Z`%M9;3YK3CC:5N-I`X)!,PG@GFY1(`".R)W.LOS'..[Y8
M[]G"G'KPH/M)?<)+E0PR\MIEY9.JEE*>4K.J^3G))42>][K]R]I[6L2RV0)\
M47LXY!6)L:V15`CFY;H61,9JV`H#U"QK$/AWBH<$D"CIYYB`/";7;<W3<W*6
MK%0S11)DNI>E,,L@^4>KG5YK:>E1Z@2,L[P>^./[";>5&7W<I=NJYM4--.2J
MFJ*24IZPVCSWECS4`@>4I(-/3)F2[VR_>LYD'(4Z\N&Y[@>*NWCQVJ<Z;=,Y
MS&0CHU`QC)1\4Q3$$T&Z0%323*``'B(VTXYCEFQ.SLV&PL(I[:P@)2E(U)Z5
MK/%2U'52C,D\8ZV^<YUE.X^3U67YA5NUE\K'"I:UDR2)DI;;3.3;2`>5MM,D
MH2``([SMBCKSE=PN'(W'SN2C[K>Y!ME%@]B55T739N24;KR:ZIVYBF%@A&)+
M'<E-JF*!3@8!+J%<)N146BEP*[U-^0VY:T4#Q4E8!!/(0@"?SBLI"):\Q$M8
MRS8FCR>X[Q8W0X>Z^S?W;Q2AM;14%)2'4EQ1*2#R):"U.`^26PH*!3.+M0^(
M_K&J:H[1T<4A'YW;MHP:N7[]TW9,63=9V\>NUDVS1HU;IF5<.7+A8Q$D&Z"1
M!,<YA`I2@(B.E>QIIU]U+#"5+>6H)2E()4I1,@`!J23H`-28]-34T]'3N5=6
MXAJD:05K6M02A"4B:E*42`E*0"220`!,Q7UWQ=TR0FUI;%6V*76C(1,ZS"XL
MMLQ.C)3'*)DG#"R!4(52.C1$!`TCH"ZP?L.F710\\]EN[+3T2&LHW(:#E:0%
M-4*M4-](542T6OJ:\U/S^8^2*=^]3W^*RZ.5&`;%U*F+6DENHNR)I=>E,*11
M3`+370:C]8L?JN1,EK@X655<*JN'"JJZZZIUEUUE#JK++*F$ZJRRJ@F4554.
M81,8PB(B.HU-)"4MH#:`$H2```)``<``-`!T"*J7777W5//*4MY:BI2B2223
M,DDZDDZDG4F/77ZCUPI"%(0I"-YNW#CJ0R+N^Q01JW.K'V;(NK]G5P*<4FL?
M;;159N98Y-.GZ3+K-D2Z^)U`"M*]X3(*?']I[HIU0#]6VFF;'2I;R@#+KDV%
MJ/@$2N[E&&5F9]XW'T,(*J2VO*KWU:R0W3)*DDD<.9XM($^)6!%OCQ']=5/1
MV.H:#[@TA'%(0I"%(0I"%(0I"%(0I"%(0I".@9%RKC?$<$K<N3+VMVRH9(IS
M%=STD@S.Z$F@F2CV8F,]DG/'@DW344'R!7/8_B^1976BW8Y1U%95GYK2"H#P
MJ5YJ!X5$#PQA^:;@83MU:E7K.+I16RVI!DI]Q*"N70VCSW5?F-I4H]`B&_<#
MWDH&.].@-N=FGGW9>H@2_;Z068PY#:<H.8BUT%4Y)\4#<2&=JM@]U(0X#+K`
M^Z+6U')7;@U@8:T/JU,0ISQ./$%"?"$!?@4(K3WA_$MM-%VMHV7MIJZ@32*^
MN2I#(_.9I4D.+\!>4UX6R-(A=S'N,S5GR54E<JY!GKG`53*-88[D6-M1H";F
M*G&6ZQ]'B6A2#IH8$A4'34QA'C4P<1V^P[!J44N,4#%,924Y+F>7X5NJFM7B
MYI=0$5C;E;U;G[N7!5?GUXJZX<TTLE7)3-ZS`:IT<K*)=81S&6JB=8PG691J
MR%(0I"%(1E;%F#<N9LEB0V+,?W+>3H5027<Q<>K\D,!'Q-)S:X(Q$:0H<1%9
M8G#PUK%\FS3%,-I369-7T]&U*8"U#G5^@V)K6?T4F-A8#M1N+NA<!;,#L];<
MGRJ2E--GLF_"Z\J330Z9K6GP1,1@CLS2+CT*;W$WZ2.3'IK*V+CXZ;EYIQ$S
M:3NUZB9HB?P`X-&ZH>/*MX&J)6;][ZG;YZ/`*$N*U`J:J83XT,)/,?`5K3X4
M=$63;2_AFUCW973>6[!E&BC0V\A:_P!%VK6DH3T<P:;7T\KO`Q,;A[;5@W`K
M`C+%F.+=MIP"9$W$X#4)"YGPD)RB=]<4B+J67$^HB)>J"8"/`H!PJ(^6[C9K
MG+Y>R:X5%0W,D-\W(RG]%I$D"77RSZS%E.VVQ^U6TE(*;`K+1T3W*`I_E[2I
M<D)374.<SRI]7.$]20(SE6$QM>%(0I"%(0I"%(0I"%(0I",69BS1CC`UD260
M,G7$UM^!CR&*B4X@K)S+[D$R$1!1Q3`XDY1T8-")D#0OOCB4@&,&3XCAV0YQ
M>6[%C=.I^N<.O0AM/2MQ?!"$])/B`)(!P#<K<["MI,6>R_.JUNCM+(/*#JZ\
MN4TM,-CRG75="4\/.44I!4*J^\C?'D3=A<*C(YG5I8FBG@*VS8#=US$6.CS%
M1F[H71Y$Y:;.4PB4!`4&H&Y4@UYE#V=[1;+6#:V@#PY:K*742>JBGA/BVR#Y
MC8Z?G+XJ,I)%`/>6[U>9]X.\FE)<M^WS#DZ:@2N8)$P'JE29!U\SF/F-3Y6Q
M/F6O1VMTQ%2%(1)'V_=C$QN<NU"]KW9.XW!UJORC,/#`LU6OB4;&*<+5@E0`
MIC-0-I\H.B#HBG\&4>J<.2/&^^]=)MO:E6:S+0YFE4W]FG0BF0=.V<'7_5(/
MG'RB.4:S;[GW=2N6^>1)RC*&G&-K*![[99FDUKJ=?56#I-,Y>L.@R;3Y"3VB
MARVK(N+C82-CX:'8M8N)B63:.C(UB@FV9,&#)$C=HS:-TBE30;MT$RD(4H`!
M2AI58534U%;4N5E6M3M4ZLK6M1)4I2C-2E$ZDDDDD],=@*@H*&U4+-LMC3;%
MNIVDMM-H2$H;;0D)0A"1()2E(``&@`C]U>B/KA2$*0A2$*0A2$*0C$&4L_X6
MPFB@KE7)=IV4=T3JM6,M)$^5W:6O+UFL*U!S+.$>;ASD1$FOEK+<9P3,<R4I
M.,6ZJK$I,E*0@]FD]2G%20#X"J<:WSW>#;#;!"%9]?+?;''!-#;K@[98ZTL(
MYG5)_.""/#'0<>;S=KN5;B96C8F9[2F;FDE!1C8551_$O9);EY@;QY9EDP3>
MN3@`\J29C*&$.!1KG+_M!N7B]O7=;W9ZIFVMB:W!RN)0.M79J44@=)(`'7&)
M8=WF=B,^O+6.XKDMOJ;X^9-,J[1E;BI3Y6^W;;"U'H2DE1Z!&SM:VC>L*0A2
M$*0C2_>EO&M#:;C\[U4S2<R;<C9RA85F=8!4<."ATS3\V1,W6:6Y&*&U.<=#
M.5`!%/B)C$W#L[M'=MTK[V*>9G&Z=0-342T`X]DW/13JQP'!`\M6D@8Q=YWO
M*XYW>L0-2LMU6=5J%)H*.>JE#0U#X!FBG:/$Z%Q4FT:E2DU)LAY"O#*MYSU_
MW[-N[ANNY'IWTI)NS:F.80`B+9LD'P;1@R0*5)!!,`312*!2@`!5J5@L-IQB
MT,6*QLHI[93HY4(3_*2>*E*,U*4=5*))CKN9GF62;@9-5Y?EM4Y67^M=*W7%
MGB>`2D<$H0D!"$)`2A`"4@`".EUS$8O&V^SC:E=6ZS*C"UV2;N-L2%5;R.0[
MM(B86\-"E/S?)[14P=)6?FN046B6HB74RI@Y$S5JO=S="V;7XPNYO%#E[>!1
M2L3U<<^DH<0TWYRU>)(\I0B1?=J[OM_[P&?,V*E2XQBE*I+EPJP#RLLS_5H/
M`OO2*&D]!FX1R(5%N5PXL'!V,A7<*Q]GXXQE:B1!.<2H,H:WH!B1%%,/#J*]
M%$I2E#5194P`&IC<:IVV[[FN2<C8<J\AN54?"IQUU4R?`)F9Z$I$]`([%;SV
M(;4X+VKRF;;A5BMX$S)*&:>G0$@>$R``&JEJ(`FI6M1+>+NCN/=5ER3O)Z=T
MQLR'.YB,=6RJ?0D);A5M2N'"91%,TS,F3!P[4XCS"5,!Y$RU:WM)MI;]L<4;
MM#(2N[N@+JWAQ<=EP!X]FWYJ!U34=5&.N=WE-^KWO]N*_DE47&L9IRIFWTQ.
MC%.#HI0&G;/$!QY7TI(!Y$)EJA6T8CU%A;M`;7QA(*5W.7:Q,23N5!];&-&[
ME`Q3-;?3<%2GKF2ZA0$%)=VW]$;G+P]'25$!$%>$".]EN4*RM:VWM:P:>G4E
MZK(/%TB;3)ET(2>=0/SE)X%,7)?AP[#FUVJHWRR)HBMK4KIK:E22.5@*`J*D
M3'%U:2RV1_1I<()#@B<>H5Q:M'RIV=AK8AI.XKBE&$)!0K)Q)2TO)N4F<?',
M&J8JN'3MRL8B2**1"B(B(_H\:^JAH:RYUC5OM[2WJYY80AM`*E+4HR"4@:DD
MQQ]VNULL-L?O5ZJ&J6TTK2G'GG5!#;;:!-2EJ40``.N*PN_?N'SVX1_)8OQ8
MZ?6]A1B[4;O':9U6DMDE1N?E*\E`*)%&MM<Y>=NR'05@T47U'E3)9-L;L%0X
M$PWDN3)149BM`*4F2D4@/S4="GI:*<^;JE&DU*HC[W/?+NV\56_@F!..T>V+
M3A2M8)0[<2D^>[P*:>8FVP?.$EN^5)"(L:DW$`X]J""[E=%LV15<N7"J:#=N
MW3.LNX76.":*""*93*++*J&`I2E`3&,(``:U^5K0V@N.$);2"229``:DDG0`
M#4DZ"/:RR[4.IIZ=*EOK4$I2D$J4HF0``U)),@!J3$SNT_M)W1?K*.OC<8_E
M+!MQV";J/Q]%=%*]95J;E.FI.O%BKHVN@N4?V'35>B'O@1'2H?[I=ZFV6)YR
MR[?(:KKBF:552YFG0KI#:1(O$?2F&^KG$6;=WO\`#OOV6TS.5;T.OVBRN26W
M;VI"M=1H07UJ"DTJ5?0Y5O2\X-&4:W]Q^S]NF+LKV[B3`-J,8):Q;?.CD64:
M2TI+*R%R2*B"K.+?.)&0?%-(0\>B!UQ("8@HZ$A@YB"`;#[O5VW`R7%ZC*LZ
MJEOHKGYTB%(0@(:0"%+2$)3Y#BC),YZ(F-#,Z4[Z^.;,8'G]%MWM%0-TKMIH
MRFX.I>=>+E2X4E+2U.N+^T9;2"OE"?*=*2)H($=M;_B%\<@`F$"E`3&,(%*4
MH"8QC&'0I2E`!$QC".@`'$1KP2`)GA'Z2E2E!*1-1.@BU#VU-KO[MF%I+(N0
MVR$/D'([)&X9\9`"H+6A9#!L=[%0KU533T5;HF.^?%'3D.<J9N*-5D=XO<OX
MB9@WCU@4IZPV]9::Y=0_4*/*MQ('G"<FV^L`J&BXOX[C^PWP1VQ?S3,D)ILO
MO30J'^T\DT="VDK:963YBI<S[X,N4E*%:M1K)EC>+F+.#:Z<@67DAWMBV?6E
M=Z5A?SNL;6?73?U_W"L90"?(,:P04D&[9=(.<`1.W3:D.3K+'5,*9-D8MM)B
M6%N4UAO%N1DF[-52&I]14\EFFIFA*?:+40@D'3R@LK(/(@)',=';@=Y+<C=1
MFOS#&;TY@W=RMUQ%!^UD4KE57U]09R[!ML=HE*D^5Y"FDL@H[5U3A+:>E6-=
M%Y2EPLHW;7W$LE77E=P47<+C+<9:-Q04+D%=LDHX^1X1U>`.XXKE_P!,2)I`
M4!,/`%`]\7F+U;+134"ZC<3`+=2XND\KE9:GVG'*4$@=HXECE7RIG,JGIQY3
MP.,XO?LDKKRU0[);R7JX;@+'.S;,AI:EAFX*2"KL6%UA<:"G)$)1*9X!8\X;
M+(=R.\G&&)..3Q(X'=Q$Y+@\)/,3F3<`R"]KA87"]C;E39BO\H*0!DK8=E.W
M!74CD"%%7HG!6M=+[O%H;S!NH5=4_"IVW.7%-;,<WJ[2FDK9*I<@=F\@A4M4
M3/+S@HC=S7?8R9[;)^B1CR_XB*>]L61=JDKD]=J$5"FZD(YNT+!%*Z%-A4TN
MA(+G9*#L2ZU%&+%X4A"D(4A"D(4A"D(Q7EC-V*,'0)KCRK?4!9L<)3BU3DW9
M1E)0Y`$10AX9`%I657$0TY4$3Z>)M`XUE&+87E.:5HM^,43]6_/RBA/D('6X
MX9(0/"I0GT3,:_W!W3V^VKM)O.?W6DMM&0>0.+^U=(^:RRF;KJO`VA4N)D-8
MA#W%]XV=D_3[;VV6L%OL3=9O_.'>K5%W-K$$!(#F"M@IU8^-$==2*/#N3Z:"
M*)!X!,[;[NCT--V=QW#J>W?T/JM.2EL'J<>D%+\(;"!^>1%6>]/XE-UKNVLF
MR=!ZG2F:?VA6)2M\CAS,4P);:ZTJ>+IZVTF(9K\R-?F49]Q=.1+NG[SN!T8Q
ME).X))Q(+D*8=>BU(L<4&+8N@`5)$J:10```H`%2]L>/V/&J!-LQ^D8HZ!/!
M#2`D>-4M5*ZU*))Z3%9>6YKEN>7==^S*XUERN[A,W:AQ3B@#\U/,9(0.A"`E
M`Z`(Z77,1B\*0A2$<>'C2$;4X(V7;B=Q"K5>P+`D$+:<'`#WQ<Y5+>M%)/4.
M=5"3>I`I*BF4=1(R3<G_`$5K'-]X,`P!*D7VO;5<4C_=F9.OD]10DR1/K<*!
MX8D!M-W8MYMYG&WL1M#R;&LZUU2#3T@'24NK'VLAQ#"75>")O=O_`&AL,V!Z
M%.9IEW.7KE2!-4T(F5>#L-FN41$2>@HJA+3I2CIQ<K)I'\J%0QSOO7Y??>>B
MPYI-IMQF.T,G*E0Z^8CD;_F)*AT+BT[9_P##EVSQ#LKKN;4+R*]ID>P',Q0H
M5U<@/:OCPN+0A72S$KEMVQ;=G0S.W;2@(>V8&/3!)E#0,:TB8UJ0I2ET19LD
MD4""(%#4>741XB(U%VXW*XW>K77W5]ZIKG#-3CJU+6KQJ42?Y8L$LEALF,VU
MNS8[1TU#:61)#+#:&FDC\U"`E(\)E,],?9443134664(DDD0ZJJJARIII))E
M$QU%%#"!2)D*`B(B(``!QKXTI4M00@$K)D`-22>``ZXY1:T-(+CJ@EM()))D
M`!J22=``-23PB$?<=W@6%BWY(V;@JRK?O^*@'*K&3OBX))^G#RS]`P$<)VTS
MB^DHYCFZI3$!VHMRKB',F02<IS3-V^[IC]ZL;=WS:L?H:I](4BF:0DN(2>';
M*7,!9$CR!,T\%'FF!5IO5^)!1XIEC^-;4VRDN]OI%EMRNJ''`R\XG10ID-<I
M4VDS`=4N3A$T)Y.5:LX;+.Y=`[FKP/C"^;298[R`[:KO;9/'RJTC;]T@S2ZS
MV.;&>-T'<=,H(%.L1(YE2+)$-RG`Q>4V%[Q=W.NVXM`R6R52[A8D*"7@I`0Z
MSS&25GE)2MLF22H`%*B)B1F-J=V+OQ6C?/)#@N56]JSY<XVI=,6W5.4]5R#F
M6VGG2%MO!(4M*"5A:$JDH*3)4I=1EB?,*0A2$*0A2$*0A2$:@[L-YV*MJ-M'
M<7(\3N#($BU,K:N.(QTF$U*F,)B)OY,X%6""@4SE'G=+%\_E$J15#\`VSM;L
M_D^Z-Q"+>@L6%M4GJM:3V:.DI1P[1TC@A)TF"HI&L1P[P?>:P#N_6,O7IU-9
ME[S<Z6W-+';.DS`<=,E=@P"#-U8\J12VE:M(JL;A-Q^4=S%\.+VR7-&="F99
M&W[<9&51MRU(Q0X&+&P<>8YP2`0*`JKG$[AP<.90X\`"SK`MO<9VYLJ;-CK(
M2#(NNJD77UCY[BI"?YJ1)*1HD#6=`6\>]F>;XY2O)\WJBY(D4],B:::E:)GV
M;#9)D.'.LDN.$36HZ2P/6<1J.%(1)-L6[?=U[G)5G?%\I2-J8.C7?,ZE0(=K
M+7TLV4T5A;4%4GFLA.42.I'04T0U(ESJZ\D=][-^+7MO2KLME+=5FCB?)1YR
M*8$:./R/G=*&N*M"J2?.F]W4>YYD&^=Q:RG*DO6_:QASRW9%#M<I)U9I9CS)
M@I=J)%*-4HYG)A%I>U;5MRQ[<AK0M"&86];-O,$(R&AHMN1LQ8,FY>5-))(@
M!J8PZF.<VIU#B)C")A$1K+NETN-[N+UVNSSE1<:A96XXLDJ4H\22?R`<`)``
M`"+\L?Q^R8I9*7',<IF:.QT;*6F66DA*&T)&@`'Y23,J42I1*B3'8*^".8A2
M$*0A2$*0A2$*0C&V8<F0F&\77UE"X3D+%V5;DA-J)'-R^FNT$A)&QJ8Z@(KR
M<BHDW3`.(G4``XUD6(XY69?DU#C5`":FLJ$-S'S4D^6L^!"`I1\`,81N3G-L
MVTP.[9W>"!0VRB<>()ESK2)--#\YUPH;2!J5*$HI09%R#=65;VN/(-[2KJ8N
M6Z)-U)R#MVL=84_2%3'18MN<1!!@P1$$D$B`!$TR`!0`*N0Q^PVS&+-3V&SM
M)9M],TE"4I$IR$BH]:E'RE*.I)),=7C-LRR#<#*:W+\GJ'*F\USZG7%J),N8
MDA"9^:A`DE"!()2`D``1^K$R$FYRIC-O#&6)+K9!LQ.,4;F.5=-\:XXT&RB)
MR:G(HFJ("`AQ#2O5E*Z9O&+DY6`&D%!4%8/`I[)?,#/H(CZ=NFJU[<"QLVTJ
M%P5=Z,-%,^8.&H;Y""-00J1!'`ZQ>>X^7B/`!'W1`.(_W1JE*.UH.&O&%(\P
MI"-7-V&ZBQ=J>-G=WW(JWDKHDDG+2Q++(X*G(71-$(7EU*7F5;0L>90JCQSI
MRII^:750Y"FV9M;MC>]T,B1:K>%-VQLA5342FEEN?Y"XJ1#:.).IDD*(T+WA
M-_L4[O\`A+F17I2'[\\E2*&B"I.5+P`ZM4LMDA3SDI)3)(FM2$FH;ES+-\9O
MO^X,E9#EU9BYKA="LL<1,5G'M"")641$M1,8C")C41!-!$G`H!J.IC&,-KV*
MXM9<,L3&.V!D,VVG3(#YRE?.<6KYRUG52CQ.F@``ZY.XNX>5;IY?69OF52JI
MO=8Y,G4(;0-$,M(F0VTVGR4(&@&IFHDG&]9#&#QGK;CMVO\`W-Y*C,<V$S$H
MJ<CVY+C<I*&AK2M\BI2.IF65(&@`'-R((@/4<KB4A`XB)<&W"S^P[<8ZYD%\
M7P\EEH$=H^[+R6T#^52N"$S4>@';NRFS&7[YYNQAN)M<9+J:A0/8TE."`MYT
MCHUY4('E.+(0GB2+?6`<"6!MQQQ#XUQY']"/8@#F6EG)4QE[FG%B$*^G9EP0
MI>L[=&(`%*'P:"12ID`"E`*J>SK.;[N%D+N17]<WUZ(;$^S9;!\EML="1TGB
MI1*C,F.QWM#M'B&RN$TV$8<SRTC0YG7E`=M4OD#G?>4!JM4M`/)0@)0@!*1$
M$_=7WD!D&YE=N6.I<%;*LR2`^19-BJ!F]RWBQ.'3@DUTS:+Q5K+`(+`'F*OP
M'QZ!1&;G=@VB-@MHW!R!J5YK&_[JA0U985Q<(/!;P\WI#4OID14[^(#WEAF%
M]5LOA=3S8Q;'IW%Q!\FIK$'1@*'G-4JIA8X*J)_U2288ZE]%9,;#;6L`SNY7
M-5I8OB`508/7'RI=LL0NI(.T(Q1)2;D3&]Z"QDCE;MP'W[E9,OE&L!W,SJBV
MZPZJR6KDI]">1A!_I'U@AM'BF"I?4A*C&YM@MH+MO?N?;\%MO,FD<7VM6Z.#
M%(V07W/TI$(;'2ZM">F+GUNV]#6E;\):UO,4(R!MV*80D-'-B`1!E&QC9-FS
M;IE*`!HD@D4-?$1XCQJGZX5]9=:]ZYW!:G:ZH=4XXLZE2UDJ43XR8[-]DLUL
MQVSTM@LS26+314[;#+:1)*&VDA"$CQ)`'AXF/W/W[&+8O).3>-H^.CFJ[Y^_
M>KIMF;)FU2,NY=NG"QB)(-VZ)!,<YA`I2@(B->AAAZJ?134R%.5#B@E*4@E2
ME*,@E(&I).@`U)CZZRLI;?2.U]<XAFB9;4MQQ:@E"$(!4I:E$@)2E()))``$
MS%73N&;]I'<3<#O&&,Y%TPPE;L@=-1R@<[=7(\JS5$I9I^4HE/\`5ULJ018-
MC?M`T74#F$A4[+]@]C:?;^@3DF1-I<S*H;F`1,4B%#]6G_Q2/UJQP\Q)ES%5
M"W?*[W%;O+>',$P=YQG;"B>(*DDI-Q=09=LYP/JZ2)L-GC^M6.8I2W%Q4EX@
M1'ZX^/?2SYG%Q;)U(R4BZ08Q\>Q04=/'KUTJ5%LT:MD2G57<.%C@4A"@)C&$
M`"O4^^Q2L+J:E:6Z=M)4I2B`E*4B94HG0``3).@$?314=7<:MJ@H&G'JYYQ*
M&VT)*EK6HA*4I2D$J4HD```DDR$6:NW[V[(G!S",RWF6+8368WR*+V"@W2:3
MV/QDBJGS%!,!%1N[O`Y3Z+.`U*S_`&:(\W,H:N'?CO`56:/N8IB#JV<20HI<
M=22E=80>G@4L?11Q<\Y>DDB\_N?=S&W;5TC&XFY=.U4[D.I2MAA8"V[8DB8E
MQ2NL(/EN:AGS&CS<RSZ-]W<GMS##6:Q3A.097/EU9%Q'3%QM3HO8#'"IA,@L
M4ZA1.C*W:@'-R-RZI-#Z&6$3!TA_>R/=VN.7NLY1F3:Z;%`0MMHS2[5CB-.*
M&#TK/E+$PB0/./7WLN^[9-LJ>IV_VO>:KMPU)4V]4H(6Q;CJE0GJEVK3K)L3
M0RJ1=)4.S-9V1D7\Q(/I:5>N9*4E'CF0DI!ZL=R\?/GBQW#MXZ<*B91=PY74
M,<YS"(F,(B-6-4].Q2,(I:5"6Z9I`2A"0`E*4B24I`T`````X"*-:ZMK+E6.
MW&X.K>KWW%...+45+6M:BI:U*,RI2E$E1)F223'XZ]T?+$W/;(V%.+JDH;<=
MF2#%.THQ=.0QC:<JW,4US2C=0#MKODVBQ0U@8U4O,R3.&CM<`5TZ1"]2&?>0
MWQ;M=,]M[B+T[JZDIK'T']2@C5A"A_2K&CA!\A/D^<3RVF]Q;NCO9!6TV].Y
M5*4X\PL.6RD=3_O+J3--6X@__;MD39"A)YP!?ZM`[2;/<W#3UQ;=\WPEL$75
MGY3%]Z-8Q!J)_272ZD$\YF;<$P$YUWJ0&2(4/?&.`>6H:[;UE#;\_LU;<BD4
M+=RIU+*N"0'$^49]"3)1/0!.+1-]K9=[ULQE-JL(6J[OV&M0TE,^9:BPOR$R
MU*EB:`!Q)ETQ!_?]RVE</:'Q4QM-=J@\M?)%LVY=31,4_28R[4IZ=>/SR"'`
MY%GQ7:;LG/[])4H_JFA8K==:#O6W-^Z)4IFIMSSK*C.2V"TTE/*>D)Y2@RX*
M28JTS"^8]>?PZ[%2XZMM%10WNGIZI`ES-U8?J%N%Q/$%P+2\F?%"P8R38]HW
MW([[<3V%O&RM)3KRPX>.O;;;)1MO05LVOD!T9)!V2/<.FS9%TW?-EF@`9J)E
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M6<3UU!J+<84A"D(4A"D(Z-D/)F/\36T[N_)-W0EFVXR*859*;>IMBJG``$&S
M%OYSN1>GU\Q!NFHJ<?`HUS=@QN_93<46G':1ZKN"^"&TDR\*CYJ$CI4HA(Z3
M&*9GG6(;>61S(\VN-+;;,T-7'EA,S]%"=5N+/0AM*EGH28@YW+]X=\Z%_:NV
M.`]`;#SMSY/O!B51\H`@`"O;-J+\R+0-=>1>0ZAA#Q;%'0:FGMSW2F&@W<]R
M'^T<X^IL*DD>!Y\:J\*6I#_Q#%56^7XDE4^7K!L92=BSJDW.K0"X=/.IJ54T
MH\"ZCF/6PDZQ";>U^7IDBX'EUW]=,Y>%QOSB9U,7!(N))X<!,)@23.X.8K=L
M01\Q),")$#@4H!4R;-8[/CU`BUV*F8I+>@:-M("$^,RXD]*C,GI,5=93EV49
MM=W;_EU?57&\O&:GJAQ3BSX`5$\J1\U*9)2-$@".IURD8Y"D(4A#_P`']T?`
M/UC2/,I\(WEV]]O/<CN#]!E8ZUOJ'8[HP&->U^$<0[)5OXBK$0PIC.S?,'O#
M)(%;F'Q6*&HAI7/=_-O,"YZ6HJ?7KTD?[O32<4#U..3[-OPA2N<?0,2LV<[F
MV]>\1:KZ.@_9.+.'_?:X*904])9:D7WOS2AOLR>+@U(G2V\=KS;KA3Y.G+KC
MU,Q7TT%%Q\L7BW2^K;%ZD8B@*0]G)G5C2E(H7S3/3/5`TU`2^%0GS_O+9_F/
M:45K<%HLBYCLZ<GM5),Q)Q\R7PXAL-CH(,6O;-=P[9G;#L;ID#)R3*F^57;5
MB1ZLA8(,V:,$MR!&A?+ZND%/")(D446Z*3=NDDW;H)D20003(DBBDF4"D322
M3`J::9"AH`````5'A:UN++CA*G%&9),R2>)).I,39:::8:2RPE*&4`!*4@!(
M`T``&@`'`#A'LK\Q[(4A$#7='WU':A+;9,03(D<'(9IEVZXQR8IT4S@'-8,6
MZ1$!*HJ0?\:J$-P*(-O$5@"<7=HV3#G9;CY8S-`/-0L+'$_XE:3T`_J01Q':
M?0,5)]_3O7JI_6-C=N:F3I!1=ZII6H!XT#2ATD?[TH'@>P_K0(!ZG3%0<2V]
MHW;_`"U^9P6S4_;JM[.Q(W=$:.S$,5.6O2:8+,F4:V4U`#!%QKE1TX$->7F2
M*/[34(K=ZO.Z6QX6,.84%7>ZJ3S)GJBG;4%*61^>L!">N2S\V+$_PZ]G[CEN
MZ:MSZM"D8WCJ%<BR-':UYM2$-I/_`(3:U.N<9?9CY\Q9PJMV+U84A"D(4A"D
M(4A$0V]7N@VGB$LMC;`[B-O?*"8KL)6Z="/K-LA<`,DJ5)0A^E<EQ-CZZ(D$
M6B!P^%,<P"D,K]G.[5=,K+619NERBQLR4AG5-14#B)CBTT1\X^6H>:`"%Q7)
MWG^_ACVW*:C"=IULW3.@5-NU6BZ.B4-"$D&534)/!(FRV1]HI9!:BM]=MWW1
M?MQRUW7I/2ES7-..E'LM-S#M5X_>N%!$1,HLJ(\J:8>:FF4"II$`"D*4H``6
M&6JTVVQV]JU6=AJFMK"0E#;:0E*0.H#I/$DS).I))G%)N1Y)?LNO51D635;]
M=?*IPK=>>65N+4>DD]`X)2))2D!*0$@`=<KD(X2%(1,CL6[8LUD]2'RON$C7
MUNXV$J,C;]AK"M'W'>X")%6KJ9()2.(2U5B>=RZD=O"CH7IIB!S1&WL[R-%C
M27<7P)Q%1D6J':D24U3="@WT./#A/5#9X\RARBR_NH=Q6Z9TY3;@[PLNT>%2
M#E/0GF;J*W@4*>$@IBE(UEY+SP\WD00M5CR*BHR"C(^%A8]G$Q$4T;Q\9&1S
M=)HP8,6J946S1HU0*1%!N@D0"E*4```"J]*JJJ:ZI<K*QQ;M6ZLJ6M9*E*4H
MS*E$ZDDZDF+K;=;J"T4#-KM;+5/;:=M+;33:0AMM"``E"$I`"4I````D(^A7
MHC[(]2ZZ#5!9RY62;-FR2CAPX<*$10;H(D%159=90Q4TD4DRB8QC"`%`-1K]
M(0MU8;:25.*(``$R2=``!J23H`(];SS5.TI^H4E#"$E2E*("4I`F5*)T``!)
M)T`U,14[B>[-A'$\@^M?&$8XS1=+(ZK=V_BY!.)L5@Z3`0%+ZQ&;O%YHZ:O`
MP,D#H#H.B^H:#*#`.ZSF>4,(N62N)L]L6`4I6DKJ5`]/932&P1_6*"OS.F*_
M]YOQ#-KMO:MVQ8*PO)K\T2E3C3@:H6U#H]8Y5J>(.A[%LMG63LQ*(])7O-[E
M7+U16'L7#L4Q-^R9NX:ZY9=,-1]^]+=D<"H\H@'[(OA6^Z7N@[=-LA-76W=U
M[I4EQA`/\WL%R^L8AM</Q--[GJI3EMM6-L4AX(6Q5NJ'C6*QN?U1&:<3]ZB4
M^46;'-N)8TT6LHDDZN+'#]V@\9%,<`4=&MN>7=IODTRCJ)"/DCZ>&H\!P_*>
MYW2^KK>PVZN"I`)2U5I24JTT3VK024D]9;4/$-1L_;W\3VN]<:I-T,>8-"H@
M+J+<M:5HF=5^KU"EA8`UY0^@]4SH9M<4Y<QWFVS8Z_<8W.PNFVI'4A7303IN
M63LA2BO&RK!<J;R+DVHF`%$%B$.&H"`"40$8:91BF089=W+'DE,NFN+?S5:A
M23P6A0FE:%="DDCHX@B+2-O]Q<,W2QIG+<%KFJ^R/:<R)A2%B7,VZVH!;3J9
M^4A:01H1,$$Y(K'8S:%(1")WF,X!#6786`HAV4'UXO/KQ=R*1PZB=OP:YFUO
MM%RE'4$I*;ZJP`/`18Z^Y4SNZ%A?K=WKLZJD?8TB/5F"1H77!-U0\*&Y)G_X
MGCBK+\3'=3]F8S:=H[<X/6KDYZ]5@'44["BFG0KP./\`.L>%@'JBN[4_8IDC
M?3MIXS-DK=[C3JH=:+L-5]D65$Q1,0GU90YX?F'WO,:X7+30!]\4#>Y6CN\5
MD8QS:>X\JI55<$TB.L]L9.?^4'/EE$N.X_@RLW[QEC+B>:@M*EW%W30>K)FS
MX/\`>5,Z=(!BW354L=C"%(1A/<!GRP=M^-9C)>0'HIL6)?1HB&;'3^5[GG5B
M'%A!0Z)Q^$=.CEU.<?@T$@,H<0*4:S+`\%ONX>1,X[843>7JXX9]FRV/.<</
M0!T#BI4DC4QJ[>#=W$=D\(J<WR]V5*T.5EE)';53Y!Y&&0>*E$34H^2V@*6J
M24F*@&X?<#?VY3)<QDB_7IC+.CJ-8""15.:)M2WR*G.Q@8E(V@%10*;F55T!
M1RN)E#\3:!;)@.!V+;O'&L>L:)(2.9UT@<[[I'E.K/6>"4\$)DD:".M_O-O#
MEV]^<5.:Y:Z2XX2FG823V5+3@DML-`]"09J5+F<65+5JJ,&UFL:HC)6(L2WQ
MG#(%OXTQY$*2]RW"Z!)$GG$9QS),0,^F)9R!3$91,:@(J+*F\````!,8I1QW
M*\JLN%V&HR._NAJW4Z9GZ2U'S6T#YRUG1*1XS(`D9QMSMWE.ZF84>$8=3JJ;
MW6.2`X(;0-5O.JX(:;3Y2UG@-!-12#;YVI[7[(VK8Q8V/;":,A/O01?WQ>!V
MY4I"ZI[IB"BYQ$3*(13'G%)DVUY44@U'50ZAC5/;H;EWG<[)%WFY$MT")IIF
M)S2RU/0=16KSG%\5*_-"0.QYW?MA\6V!P5K%K&$O7=T)<KJPIDY5/RU)XE+3
M<REEN<D)U,UJ6I6`>XWN[1VV8F5MFTY(B>7\DLW4;:Q$3$,YMN#.(MIF\5B#
MJ*1VR9C(,1$//>&`P:E1.%9UW>]J%[AY2+E=&R<3MRPMZ?!YP:MTXZYF2G.I
ML2T*TF-0=]7O&-[);>JL>/OA.XU[;4W2@$<U,P?)>K".@I$VV)\7CS"8:6(J
M>JJJKJJ+KJJ++K*'6666.915954PG4554.(G444.81,81$1$=1JT=*4H2$(`
M"`)`#0`#@`.@#H$=>UQQQYQ3SRBIU1))))))U)).I).I)XQX5^H_$6G>UQM>
M#".%B9(NB.%MD?,+5E,.B.4^5W!6643.+;A=#%`[=6034!^Y)X\ZB9#!JD`!
M63WF-R_WSS`X[;7.;'[2I38D?)<J.#SG40@CLT'J"B-%1?QW"]AAM;MD,UOK
M/)FF1MH>4%"2V*+SJ9G4`I+@/;N#C-2$JU;$I0*C5$\(KN=T7?,-VOY7;3B6
M9`UJQ3KT7*=RQJX\EQ2[-4#'LU@Y2'16%BG"8"^.41*Y<EZ7$B9N>?\`W:-E
M/V2PUN+E+,KHZF=$RL?JFU#_`'A0/!Q8/V8.J$'FXJ'+3)W\^];^\574;(;>
M5,[!3N<MTJ6U:5#R#K1H4.+#2A]L1HXZ.2?(VKGA%J9D591R`"80*4!,8P@!
M2E`1,81'0```U$1$?`*\$@"9X1Y`*B$I$U&+'W;=V-1V'(!MN1SFR:1M\/(T
MTC:$1<)D&C3'-NN$.<UPS`O3$09W+(M3:@*HE&/;&T'E5.?DKV[P^]51EU<K
M;O"EK<LR'.1]QJ:E5;H/ZIOEF5,H5]']:O75($[K^Y-W5*+;6SHWLW6:;8RA
MQ@N4C-04H1;J=29FH>YY)14N(,P52-.V9'E<4KDQ7OI[I#5XSEL1[8IA50KH
MBT?=67F8J(:)&,=%S%6$)R$5$52`)5)7AYIA!L&NBP9/LGW9W6'FLKW)9`*2
M%,T*I'70A=3T:=#/WG2B,![U_?UIZFEJ-N]BZE12X"W57=$TZ:A35#H#J-%5
M6FADQT.Q`L<YU#G44.=110YE%%%#&.HHH<PF.<YS")CG.81$1$1$1'6IQ`!(
M"4@!($@!P`\$5'K6MQ9<<)4M1F2=22>))ZX\:\Q^8F.[>G;F>96<PV;<Z1*S
M'%[95&1M"S'I%&[[(+ANL51O(2J!RE4;684Y-0*.AY'P#1'4QXC[^=X)G%VW
ML-PIT+R50*'ZA,BFE!$BE!X&HUX\&NGR]$V6]S?N6U.?OTNZ.ZM.IK!$*#E)
M1K!2NX*29I<=20"FB!'#C4\!)J979'33:1[1))(C9@P9()((I)E2:LVC9$A4
MD4$B%Z:*""*90*4H`!2@``'"J\%*=J'2M14X^M1))FI2B=22=223J3Q,7:(1
M345,EIL-LTC2`E(`"$(2D22`!)*4@```2`$@(]Y3%,4JA#%.0X`8AR&`Q#%$
M-0,4Q1$I@$/<K\$$&2A(CKCW)4E:0I)!21H1J#$6V5M@EYP-_7!E3:5D"W+`
M?7<\&6O7$>08%O<F)[DERJJ./E)"+<Q\NUCG)EE3G(4S-04%3F%!5`IA+4F<
M7WUL]=8F,9W4H*BN9I$<E/74KA:K6FY`<A6%MJ6)``D.#F``6E9$X@5N!W1,
MEM.6U>>]WN[T=HJ;BYVM;:;@PFHM52[,J[1+2FGD-JYB5`%E10HDM.-))3'7
M+EP/W&\W_)\!DO(&WG&4$S+T5+KL&V%Y:^6;-7D*X3MIZ_8*O(9T<J8>>T>Q
MXAP$#\`"N1MV<=WS"^TK\<H+_<JU9F&*EX(IE*$Y%Y*5!+B=>"VW?%K..#O6
MTO?1W3[&SYU=\.L=I;$C5T%,IVN0@RYA3+<;*V5&0U9?ICU*T`C/)>W7@(FW
M1;;R1&:*W<S3:\W&1"N40OA?(S)H[9L[T5=@GZ,HNU;/UVZ;42=`C18Z8>>8
M51P4]X#.CN`,^*F2M+)IQ2R/JXI%*2I5.$SF`5)2LKGS%:0K@`F-N)[F6T:=
MF5;.I34AI=2FL5<>8>NJN*$+0BL*I<A*4.+;2T1V8:6I`\I1<C?2M'1+:%(0
MI"/0Z=-F+9P]>N6[-FT14<NW;M9-NU:MT2"HLNX<+&(D@BDF43&,80*4`U$:
M_;33K[B664J6\L@)2D$J).@``U))T`$>FHJ*>D87552T-4S:2I:UJ"4I2D3*
ME*)`2D#4DD`#4Q$-NG[LN.,:C)V=@5JSRA>R`K-%KK7,H7'L&Y+YAS-UD3I.
M[K<H'UT!N*;03!^W.&I:EAMCW6<@R+L[OG*EVVS&2@P)>M.#P@@I8!_/FN7S
M!QBN3?W\0O"L([?&]I$-WW*$S0:M4_V>PKA-)!"ZI23T-E+,Q^M5JF*^^7<W
M93SM<RUVY5O*6NR6.=46J;Q;IQ40BJ83"S@X=#IQL2T+P`"(IEY@`!,)AXU/
M#%,,QC"+:+5C%&U2TH`YBD36LCYSCAFM:O"HGP2&D4];C;J9]NQ?%9#GUSJ+
MA7DGD"U2:923/D993)MI`^BA(G(%4SK&*JRB->PI"%(1R4!,8I2@)C&,!2E*
M`B8QC#H4I2AJ)C"/@`>-"0!,\!'E*5*(2D$J/5$@>W?ML;C<]E8S;J$)BZQ7
M0)+%NJ^V[IDY?-%`$P+05M%(67D^<@:D.H#9N8=/A:T/G_>(V^P8KHVWC<[V
MF8["F*5!*AT./?JT>$#G6/HQ,/9GN1;T[MAJYU%*+#BKDCZU7)4A2T'I8I@.
MV=\"E!MH_P!;$\&W7MQ[<]OWH,R:`_G+OQJ!3C>%]-VT@5JY`>8%8*W!*I#0
MXIFTY%.19R73]L-0@W`[PFX&=\]('_V=9%?T%,2F8ZG'='')](FE!^A%M.S'
M<JV7V@[*Y*I/VYEC>OK=<E+@0KK8IM669?-5);H_K8WY#0```````````T``
M#@```<```K1?AZ8ET``)#0"%(\PI"%(1'EW#MXB&V'&'R):CY$<Q9!:NV-H(
M%$BBEMQ>@MY*\W20\W+Z`)^FR*8-%G8@/$J2@5OW8+:1>Y.2>NW1!_=*@4E3
MYU`=7Q13I/YTIN$>:CJ*DQ#3OE=Y)G8K!/V5C[J?B1>&UHI$B1-,UYKE8H='
M)/E8!$ENZR*6UB*FSITY?.G+YZX7=O7CA9V\=N53K.73IRH99PY<+*"915==
M8XF.8PB)C"(CQJTMIIMAM++*4H90D)2D"02`)``#0`#0#H$=>BHJ'ZNH75U2
MU.5+JRM:U$J4I2C-2E$S)422229DF9CL5D69<61;PMJQ+2CU)2Y;MF6$#"L4
M@$17?2"Y4$A4,`#TFZ(&%14X^:FF4QAX`-<?>;O;[!::F]W5P-6ZE94ZXH]"
M4"9EUD\$CB20!QCFL5QF\YGDE#BF/,J?O=PJ6V&4#YRW%!(GU)$YJ4=$I!4=
M`8N@[;L&6_MSPY9V*8`$5C0;$%Y^622Z1Y^Z'P%6G9I;4`.(NG?FI`;B1!-,
MG@4*I]W$S:OW!RZKR>NY@'ER:03/LF4Z-MCHT3J9<5%1Z8[..R6U-HV7VUMN
M`6CE4JE:YJAT"1J*I?E/O'I\I>B)ZI;2A/S8SG6$QM>%(0I"%(1TO(&1+(Q7
M:DI>^0[EB[3M>'2%5[+2S@J"(&Y3"FV;)^<N^?.!*()((E.LJ;@4HC7,6''[
MSD]T:LU@IG:JY.F24($SX23P2D?.4HA(&I(C&,PS/%L`L#^49C74]OL5,F:W
M75<HGT)2/.6XK@AM`4M1T2DF*X6\_N@WEF@LGCO"!I7'^+E@69R<\8PL;VO5
MN;5-1-55NJ8UN03@G_1T3^D+%'14X%$4@L+V?[M5HPXMW_,PU7Y,)*0WYU/3
MGB"`1]JX#\]0Y4GS4D@*BE'O-]_')=S0_ANUIJ+1@:N9#KY\BMK4\"%%)/J[
M"A_1H/:+!^T7RDMB)/\`[O[H^(_W:E1%=I,]3QA2/$?:MRVY^\)V*MBU8:1N
M&XIMXDPB(6):JO9&0>+F`J:#9LB4RAS"(ZB/O2E`1$0`!&OCN%PH;31.W*YO
M-L4#*"I;BU!*$I'$DG0?\YT&L<K9+'>,DNU/8K!3/5EXJG0VTRT@K<<6K0)2
ME())_D`F3(`F+&.Q_M?0N+CQ&4]PK2,NC(:8H2$!80]*1MJRW!3%5;NY<_GM
M;@N-`P`(%`#,VI_>]4X%4+7WO1WE:S)0[C&!+<IK"9H=J=4/5`X%+?2TT>O1
MQ8X\HFDW2]U?N'6S`U4^?;QML5V8IY7*>@T<IJ-0U2MXZHJ*A)D0-66E>;VB
M@%B9+_N_[P?H"HB19=PT'"%(1C_*&4;%PU9$UD/(T^TMRUH)#J.GKD>99RX.
M`@UC8QH35>1E7R@<B*"0&.<WD``$0Y[&<9O>7WEFP8\PNHN;ZI!(X`?.6M7!
M"$C52C(`>&0C#L]S[$]LL6JLRS6L;HK#2)FI:M5*4?-::0/*<=<.B&T@J4?`
M"15_WG=Q+(VY=[(6?:*K^P<+I+JHM[>:KF0F[O0*?X-]>CQLH(*)*`4#$CDC
M>C):^>*QP`P64[0;`8_MRRW=KJ&Z[,"`2Z1-M@RU33I(T(X%TCG5\WD&D40=
MYKOFYIOA5/8WCBGK1MFE12FG2KE>JT@Z+K%I.H,@13I/9(^<75`*$<52$B$\
M*0A2$;R;!]U$KMDS7$+2$BN7%]\O6-OY%BC&$[-)JNH9".NA)$QBD2D+=<N.
MH*@:&.U%5,>`AII;?/;&EW(PYU##:3DM$A3M(OYQ4!-;)/2ET"4CH%\JN@SE
M9W1=_KAL;N?3.5CZQ@ET=13W%HF:`A1Y6ZD`F0<IE*Y^8:EHN(^<)6]DU$U4
MTU4CE525(15)0A@,11-0H'34(8!$#%.40$!#Q`:J>4E2%%"P0L&1!Z".(CL=
M(6AU`<;(4VH`@C4$'4$'J(CSX!Q$0``XB(\```XB(B/```*\<=!QC]$@"9X1
M3/WM9F'.VYC)U[MG/I,"WF3VK:9BCJE]6K7$T4P61\-$Y!5%5UX!^WX\:M[V
M:Q#]R-N;;97$\M<ID//]?;/>6H'PH!"/YL=9KO2;F'=C?"^90POGM**DTM(>
MCU:EFTVH>!PA3O\`K#&J5;0B/D6!.RIC(S>&S)F%X@)?E)_#8]@U3$$!,C&I
M#/3YTS"'%,Z[YD34O#F3,`^%00[XV2!=7:,2:5^K0Y5.#PK/9-3\,DN'Q$'I
MBX3\+_!E-6S)-QZE,NV=9M[!(Z&QV]01X"5TXF.E*AT1.S4(XMDCHV2LD69B
M*R+AR)?\TW@;5MEBH^DGRX\RA]/-;L6+<!ZCV2?KB5)N@34ZJI@*'C7-XYCM
MWRN]4]@L3*G[G4K"4)'#PJ4>"4)$U*4=``28Q/.,WQG;G%JS,LOJ44E@H6BM
MQ:N)Z$H0GBMQQ4D-H3Y2U$`14,W?[L+PW89,<75+]>(LN%,XC[`LT%Q.W@H<
MRFHNW@%'HN;@E@*51VN`>(%3)\&F6K7MI]KK3M=CB;72<KMX>DJJJ):NN2\U
M/2&D:A"?&H^4HQUR>\AWA,D[P><KOUPYZ;&:8J;H*/FFEAF?G+EHJH=D%/+'
M3)"?(0F-3JVE$>8[%:-I7'?ESP5FVA$/)ZYKEDFT3"Q#!(RSI\^=J`1),A0X
M$(743*'-H1-,HF,(%`1#C[K=;?8[:_=[LZABVT[96XXHR2E*1,GQ]``U)(`F
M3'-XYCMZRV^TF-8Y3NU=\K7TM,LMB:EK69``=`Z5$R2E(*E$)!(MJ[&]F5O;
M3L?@,@5C,Y;NMJ@K?=SHD!0C8O,"Z-JP2QR@HG"1A].<P:"[<%%4P:`F4E6&
M]6[]?NE?94Y6SBM*HBF9.D^@O.`:%Q?0/F(/*/G$]B#NJ=V:S=WS#PJL#53N
M)<&TFNJ4ZA(\X4K"B)AELRYCIVS@[0@`(2C:[)61+5Q-8=TY'O60)&6S:,2Y
MEI-R;05#D1`"H,FJ8B'7?R#DY$$$PXJ+*%*'C6K<<Q^YY5?*;'K,V7+E5NA"
M!T"?%2CT)2)J4>A()B06<9I8-O,2K\TR=X,6.W4ZG75=)EYJ$#YSCBBE#:>*
MEJ2.F*9.XK.ET[C<N77E2ZSG36FG8H0D0"IE&UN6TS,=.%@6>HB`)LFPZJ&#
M3JN#J*#Q.-6_;?X3;-OL5I<8M8!0RB;BY2+KRM7'5>%1X#YJ0E/`1UEMZ-U[
M_O3N)<,^OY(<JG.5EJ<TT],@D,L(\"$^<1Y[A6LB:C&$*S.-5QOCV\]L1]R>
M>(Q.::G4QSCH65WWTH8OP+]-!UK"6SS"'*)YZ00T4+X^B)+"''0:TAOYN2G;
MO"'54:@,@N',Q3#I22G[1[_5).A^FI$2V[FVQ*M[MV6$7-!.&6;DJZXRT<"5
M?8TT^$ZAQ,E#CV*'2-0(MU$(1(A$TB$223*5---,H$333(`%(F0A0`I2$*``
M``&@`%52*4I2BI1)43,D\2>N.Q@A"&T!ML!+:0``!(`#0``:``<!$9_<JWAC
MMUQF2P['DR(Y>R6S=-8Q9`P&<VA:H@=M*70;0=4'[@PBVC]0_;"=4/V.@R.[
MNNTG[_Y&;[>FR<4MRP5@\'WN*&?"D>>[^;)/S](-=]_O)?!G!QB6+/A.XM[:
M4EM23Y5'2F:7:K\UQ1FW3S^?SN#]5(U5CG.H<ZBASJ**',HHHH83J**',)CJ
M'.81,<YS"(B(CJ(CK5G8`2`E(`2!(`<`.H10"M:W%EQPE3BC,DZDD\23TF/&
MO,?B/M6U.+VQ<<!<C5JR>N;>FXJ<;LI)$7$>[7B7R#]%L^;@8@KLUU$`*H0#
M!S$$0U"OCN-$BY6]^W.J6ANH96V5(,EI"TE)*3K)0!F#T&.4L=U=L5ZH[VPV
MTZ_1U33Z4.#F;6II:7`EQ,QS(44R4)B:21,1LEN`WI;A-R2BS7(-Z+-K5.L"
MJ%B6PF>"M)$2"84O2&"*JCF743YN!WJS@P#Q#2M>8)L]@6W:0[8:-*KF!(U+
MWVCYGQDH@!`/4VE`ZYQN[>#O/;Q;V+53YA<U(L!5--#3`L4B93ES-I)4Z1T%
M];A!U!$:IUL^(^QR4ICF*0A3'.<Q2$(4!,8QC"!2E*4`$3&,8=``.(C7@D`3
M.@$?I*5+4$(!*R9`#B3$ZFP3MDN912%S3N3@SM8H@MI6RL5R:0D<R8@(+M9N
M^&BA0,WC^!3H1I_/6#SG`%)HF>$^^G>/;I4O8=MX\%57E(J*U!T1T*;IE#BK
MB%.C1/!N9\H6P=T/N+O5ZZ;<[>RE+=`.5VBM;HDIWI2]6H.J6^!13'REC5X)
M3Y"YJ,U9JQUMUQQ)Y!R!)(P]OPR!&L=&M"HA(3,ATC!'6];\>!D@</G()\I"
M%Y2))E$YQ*0HB$.L-P[(-P,A;L-B;+M>\KF6M4^5M,_*==5K)(G,DS),@`5$
M"+/=S]S\+V8PI_,,O>336>F0$-M(Y>T><E]G3T[<QS+5*0`DE*05**4))%3+
M<]O#RUN<O:0GK@G)6!M!)<Z=K8^BI5XC`P,:0X^C^D(H*((RLRJ0`,X=JD$Y
MSB($`B8%(%INVVTN*[;V9NAH&&G[J4@O52T)+KJ^F1()0V/FMI,@-3-4R>O-
MOOWD]P]],H>NUWJWZ3'$K(I;>TZL4[#8/D\R04I=>(D7'EIYE&83RH"4#.7;
MOW796Q;G/'N./K',W!C3(=T,+6FK/DW3B39LG,ZJ5BSG(,KDZJD4^8O#IJ*]
M$2)K(E,"A1X"7"M_MKL7R;"J_(/5V6,BM],IYM]`"%*#0YE-N2`"TJ3,)YIE
M*B"DC4':O<T[P>X&![JV?"S6U-7A%XKVZ5ZC<4IU"%5"@VA]@*)+2VUE*E<D
MDK0%!8.A3:['@(A[E5=1V#84A"D(4A"D(UAW)[N<-;7+?&2R%.E=7&[;G5@+
M"A%&[N[9XX:E3.FQ,J0L=&BIP.[<BF@7B!1.8.4=E;=;4Y?N97^KV%CEMR%`
M.U+@*6&^L%4O+7+@A$U'ID-8T1O?WB]M-A;.:W,*L.7MQ!-/0,%*ZM\]!""0
M&VYZ%YPI0-0"I7DFM-NIW^9JW0.74.\?&L3&0J&!ICRW'BY6CU(IM4EKID]$
M7-Q.]``>4Y4VI#>\2`>(V+[8[%X=MJVFK91Z[DDO*JG4CF2>D,HU#2?")K/2
ML\(H\W_[WNY^^[[EMJ73:L&YO(M],M00L#@:IS150OP*"6@?-:2=3HS6ZHBC
M"D(4A'(`)A`I0$QC"!2E`!$QC&'0I2@'$3"(Z`'EH2`)GA'D)*CRI!*C$A>V
M_MJ[A<^@PG92*_FIQ^ZZ:H73>C1PA(R#4W'J6_:VJ$K(@H4/,56]%;&\B@UH
M/<+O%8#@I714SO[4OJ9CL:=0*$JZG7M4)ETA/.L=*1$RME.X_O'NYV5UKZ?]
M@8@Y(^M5J%)<<0>FGI?)=<F."E]DT9Z.&)Z=N?;TV[;=O0I=C;WU_OUJ4AC7
MS?"#:1=MW)0'F6@H82&B($-1U*9,BC@NG[8:@YN#OYG^?\](\_ZC8U?_`&U.
M2A)'4ZY/G=\()"#]`1;?LOW-MF=F>RN-+1_M?+$2/KM:E+BDJ'2PS+LF/`4I
M4Z/ZTQO1XUI.)70I"%(0I"%(1C?+V5;1PECFZLGWP^(RMZU(Q9\N7G*5S(NQ
M#IQT/'D-Q6DI9Z8B")`\3GU'0H"(9%B>+W7,LAI<;LJ"NOJG`D=2$\5N+ZD(
M3-2CU#KC"-Q]P,=VNPJX9UE+H:L]O8*U"8YG%\&V6P?.==64MH'TE3,@"13.
MS]FZ[MP^5;HRI>:NDA/.N2.C$U#G9V]`M1,G#P$>!_!M'-=`$V@"JJ)U#><<
M:M[P7#+5@.,4V,6@?8,)\M9$E.NJU<=5X5JZ/FIDD:`1UF]W]T\BWES^OS[)
M5?WNK<DVT"2BG83HRPW/YC:-)Z%2BI9\I1C#=9=&LHGW[06UD$4)/=!><:/5
M7!Y;>*6[M(P=-`!.VN6[4R'T`17-_(6AP`0Y2N!#Q*(06[V.YO,MO;6T.>2G
ME>K2D\3H66#+J_6+'66QT$1;W^'%L$&VG]]LF8^T5STUJ2L'0:IJ:L`]?ZAI
M4N`?/2DQ/-4'8MMA2$*0A2$:);M-_F']K;-U"*.$K\RJHW.,?C^#>I<\>J8O
M\G<W?)D!=*WV0F'FZ8E.[5*'F):#SAN_:S8G+-RWDUH2:'&`H<U4XD^6.D,(
M,BZKHG,(2>*IZ&)O>&[WNW&PM,Y:U+3=L_*#V=O86/LR?-55NCF%.B>O+)3R
MAYK<O*%9;<3NBR]N=NHUQY+N`ZS%JLJ:WK0C!5:6I;#=3S01BHSJ'`[D4P`%
M'2PJ.5OX1]-"A8[@&VF*;;VP6_'&`EY0':OKDI]X]:URX3X(3)">@=,48;S[
M];C;ZW\WK-ZPJI$*/J](U-%+3).G*TU,^5+13JRIU?SE2D!KQ6?QIB%(1LGM
MNVI9>W1706"QU!F)"M'":=R7Q+)K-K3ME$X<YA?/RIF]*?F2#5)F@"CA0=/-
M*74X:[W#W0Q/;2V&NR!\&L6DEJF007WCP\E,_)3/BXJ2!UDR!WALEW?=QM^;
M\+5AM(1;&U@5-:Z%)I:9)UFMR1YERU2RWS.*T\D)FH6@-I^R3$NU&%*I;[4+
MHR*_:E1N'(TRU1^57','PS"";_"DMZ%YATZ*1A45T`5E%!`-*UMTMYLIW0K.
M6N5ZMC[:IM4C:CR#J4X=.U<_.4))^8E.L[X.[WW6MO.[]:PY:&Q7YF\W*HN+
MR1VJI^<VPG44[/1R()4N0+BUD"6Y5:AB3$*0C'66,K6/A.P;@R3D292A;7MU
MKUW2YM%';URH/(RBHIIS`H_EI)<0301)Q,8=1T*!C!D.+8O>LROK&.V!DO7*
MH5(#@E(&JEK5P2A`U4H\!X2!&%;A;@XKM=B-9FV95*:6Q4;?,I7%:U'1#32.
M+CKBI)0@:DF9DD$BH_N\W?7]NROLTU.&6@[%A%ET;&L1NY.=A#,S&,7Y1D>4
M02D;D?I"'I#D2^:&B2?*F7C:KM1M/8MK;)ZG1`/WMX`U-21)3BOH(Z4,I/FH
MGKYRIJ.G78[QO>.R[O"Y8;G="JEQ2E4I-#0I42VR@D_:.2T<J7!^L=EH)(1)
M`UU'K:L1SCL5IVC=%^7%%VE9D!*W/<TVY*TBH.%9K/I%\N8-1*BW1*8W*0H"
M8YQT(0H"8P@`"-<?=+K;;';W;K>'VJ:VLIYEN.*"4)'A)_(!Q)T`)CF\=QN_
M9;>6,>QFDJ*Z]U2PAIAE!<<6H]`2D$Z#4G@D`DD`$QD_,FVS.&W\\.&7<>S%
MG(SY#&B'[A1A(Q;U5-,JJS-.4B'C^/+(()G`QVYE"K$+Q$NE8WB.XF%YV'?W
M4KV:M;!^T2`I"T@F044.)2KE)T"@.4]<9UN7LCNGL^JF^(MGJ;:U5C[%:BVX
MTL@`E`=96XWVB09J;*@L#4IE&#JS2-51P(:@(>Z&E(\C2+G^RZ^7>1MJV#;J
MD'`NI)>PHJ*DES&YU57UN@I`+J+F'43+K#&@<XCQ$QM:I^WBLK6/[G7JV4Z>
M6G%<M:!T!+LG0!X!SR'BCLX=V+*JC,]@L5OU8OM*U5I::<5.9*Z:=.HJ/TE=
MES'K)G'Y=Z^8"X/VRY4O=%P5":5@5;8M?4P`H>X[I_Q-'&1XE$QV17)W(Z<0
M(@80\*]NS>)G--R+99EIYJ,/AY[J#3/VBY_I2"/&H1\_>AW'3M9L9?\`*&UA
M%S52&EI>LU-5]BV1X6PI3IEKRMD]$4R^(\1$3"/$3".HF$?$1$>(B(U;YXN$
M=9<DDS/$QQ2/$7#^WQCHF--HF'8LS<6[^X8`;ZE0,7E.=[>*ZDRD8X#YP')'
M.$":#Q#ETX>%5*[]9`K(MU[O4A7,Q3O^K(_18'9F7@YPH_+'9,[G6&(PGNZ8
MW0E!15UM)Z\Z#QYZQ1>3/IT:4VG7A*7@C;N<FXBVH:5N*X))G#P4''NY68E7
MZQ&[*.C6")W+QXZ6.(%31;H)B8P^X%:HHJ*KN58U;Z!M;U:^XE#:$B:EK49)
M2`.)),A$C+K=;;8K947J\/MTUJI&5NO.N*"4-MMI*EK4HZ!*4@DF*H&_G>Y,
M;I[V&WK76=Q>%;/?K!:L483H+W._3YT#WA.H\/AW!!,5DW-J#5N;C\(<XU:-
ML9LS1[96;U^Y!#N8U:!VR]"&4G4,-GJ&A<4//4/HI3'7P[W?>DN>_F4FS6)3
ME/ME;7E>JM&:55+@FDUCZ?I*$PRV?U39U\M:XCUK?<0VC]#1HZ?NVK!BV7>O
MGKA%HS9M4CN'3MVY4*BW;-D$BF46776.!2$*`F,80``UKUNNM,-*??4E#*$E
M2E*(`2D"9))T``U)/`1[Z:FJ*RH;I*1"W:IU:4(0D%2E*40E*4I$RI2B0``"
M23(:Q:/[=.Q1IMUMIOE'(\>BXS7=D63E:+D35#'4&]3!0T$T-YX!//4S!\H+
M%'4FG0(/*4YE*T.\#O:[G]Q5C./+*<.I7/.$QZVXDR[17_A)/ZI)X^>=2`F^
MSN7]T^GV9L:,\S5E*]SK@P)(4`?V<PL3[!)U^W6"/6%CS?U*=`LKE&J,\3UB
MM[W:-V)KZO-/;A94@4]HV!((O[]>M%Q,E.WNFB(H0QC)FY%&5J)+B"A>("^.
M8!XHEJPWNL;6BQV<[A7ALBZU[933)4-6Z<G5S74*>(T/]6!+SS%)OXAW>%.5
MY*-E<8>!QVT/!=>M"IA^M`T9TT**4*(4-9OE0,BTDQ#)4OHK)C]#1HZ?NFS%
MDW6=O7KA!HS:MR&57<NG*I46[=!,H"91998X%*4.(B.E>MUUMAI3[R@EE"2I
M2B9`)`F23T``3,>^FIGZRH;I*5"G*EU:4(2D34I2B`E*0-222``-2=(N';&=
MM+/;'@BW[8=MDRWY<Z:%U9&>AH90]Q/FY!3ARJ<H"+.W&8E:IAQ`5"J*?WP:
MJ5WKW&=W(S=^Y-*)L=,2Q2)Z.R23-R7TG536?`4I^;'9+[J6Q]-L7M-1V*H;
M`RRN":JXKZ?6%I$F9R\RF1)H=!4%K^>8V0R3D*V<46'=>1[Q>EC[:L^&=S4H
MX$?/.FV)\"T;%\57K]R8B"!`XG54*4.(UKS';!<LIOE+CUH1SW&K>2V@=$SQ
M4>I*1-2CT)!,;LS?,;'M]B5PS7)'0S9+;3+>=5TD)'DH2.E;BBE"$\5+4D#C
M%+G/>:+IW`Y8N_*UVJ"$A<LB8[*/*H91M!0375"$@67,(\K:+8%(GKXJ*<QQ
MU,<1&X3!L/MF!XM28O:A]A3-R4N4BXX=7'5>%:IGP"21H!'6+W=W.OV\&X-Q
MS_(5'URN>)0W,E+#"?)981/YC38"?SCS+/E*)C#]9;&M84A"D(4A'9+0L^Z;
M_N.*M"RH"4N>YYMR5I%0D,T4>OWBYO(FBF`\J:9?..H82IID`3&,!0$:XZZW
M:V6*WNW6\/M4UM93S+<<4$I2/"3TG@`)DG0`F.<QO&<@S"]4^.XO1U%=?*I8
M0TRR@K<6H]0'`#BI1DE(!4H@`F+)6R+MD6UA0\5D[-Z<9>654P1>P]N%*F^M
M2PG&@*%5#J`9&?N1N;31R(>CMCA\"!C`"M5X;S]Y&XYB'<;PPN4>,&:7'M4O
MU(X2TU:9/T//6//($T1=QW6>XM8]KU4^=;I)8N6?)Y5LTVCE+0*X@ZS%14I/
M])+LVB/L@I0#L2,YIS38&`\?S62<D3*<5!1*0@BB42J24W)J%,+*$A&8F*=]
M*/U"\J9"^:4-3G$I"F,$?,.PZ^YU?F<>QYDNUKIU/!#:!YSCBN"4)&I/$Z``
MJ(!FGN=N=B&T6'U.:YI4II[53I\E(D77W2#R,,HF"MU9T`&@$U**4)4H5(-V
M6[&_MU^05+GN4ZL1:D2=PVL>QT'1UHVVXU0P`9540`B;V=?E(4SMT)0$X@!"
M`5,I2U:KM;M;8MKK"+;;@';HZ`:FI*9+>6.@<2EM,SR(GIQ,U$F.NQWAN\+E
MW>"S!5\O:E4^/TY4FBH4J);IFR>)X!;[@`+KI`*B`E("$I2-5ZV=$?XE][2^
MU^2R#E0NX"X6BJ%CXK=K)6X=9(Q27#?B[,Z21&IC<H*-;::._2%CEU`'!T2?
MQM(G]Z;<JFL.,?N)0+"KU<T`N@'5JF"IGFZB\I/*D'Y@6>J=C_X>6P]=F&?#
M=^\MJ1BUA<4*>8TJ*Y2"$A)Z4TR5]JLB<G"TGZ4K,%5R1>3"D(4A'K552025
M77531013.LLLL<J22*211.HJJH<2D333(41,81```-1K](0MQ80@%2U$``"9
M)/``=),?AQQMEM3SRDH:0DE2B0``!,DDZ``:DG0"(2-Y'=?C+2<2N-]LIXZX
MK@0ZK&8RH[2*^MV)7Y3$61LYF(]&>?MS#IZ8L`LB'`>0BX><$S-HNZY4W1#6
M0[CARGH3)3=$D\KJQT%]7%I)_JT_:$<2C@:MN\M^(-0XZ[485L:6:R[IFAZZ
M*`73M'@11HX/K3_7+FR#YB'1Y0K_`%U79<]\S\E=5Y3\M<]R3#@SF3FYMZO(
M2+Q8PB/,LY<'.?D('`I`T(0N@%````J=ULM=MLM"W;+0PU36]I,D-MI"4)'@
M`_E/$G4DF*?<@R*_97=W[_DM945UZJ5E;KSZU..+4>DJ42=.`'`"0```$=>K
M[XX6%(1QX>-(1O/MI[?.X#<D9G,Q\(%AX\7,4RE_7D@X9LW;?40.:W(?E)*7
M$H(%'E.F5-KKP,N6M*[B[\X)MV%TE0]Z]?T\*6G(4I)_\5SS&AU@DKZD&)7;
M']SK=_>TM7.DI?V3AJS,U]8E2$+3UT[7ZVH/44A+7074F+`VW#MV;>-NPLII
M"#-D6_VP%.-[7PW:OE&;D"B!E+?@@(:)@R@(ZD.!5G1?*L-0.W"[P&?9_P`]
M&M[]GV)7_P!O3E20H=3KD^=SPB:4'Z`BX793N8[-[,]G<VZ7]M9:B1]=KDH6
M4*UUIV)%ICCY*I+=']:8WQK1\2UA2$*0A2$*0A2$!$``1$0```1$1'0``.(B
M(CP``"G'0<8\$@"9T$5<.YUO#-G;(QL36/)`KBG&,LY1.[:*\S:\KS0(9G(S
M(G3,*;B*AA%1JQ\2F'JK!J"A-+,.[=M*,(QX93>FY91<F@>50UIZ<^4AO74+
M<T6YTCR4<4F="O?L[R2MV,T.WN+/<V`6.H4"M!\FLK$@H<>F#)33/E-,=!^T
M<$PXF46-2;B`49_VQ8&G=R6:+/Q7#"JW:RKSTZYY=,@F+!6G&B5Q.2AC:"0J
MQ6H=)N!N!W*J9?+6"[D9Q0[>8?5Y-624ZTCE9;/]*^O1M'BGY2I<$)4>B-P;
M$[27;>S<ZVX%;.9#%0[SU+P$PQ2M^4^Z>B83Y+8.BG5(2>,7/+1M2!L6UK>L
MRUF"47;EK0T?`PD>B``1K&QC9-JU3$0`.=3II@)SCQ.<1,/$1JGZ[72NO=SJ
M+Q<W"[<*IY3KBCQ4M9*B?`)G0=`T$=F[',>M.)V"BQBPLI8LM!3-L,MC@EMI
M(0D>$R&I.JC,G4QV*N/CFH4A'5+VOJS<;6U(WC?URP]I6Q$IBJ_FIMXDR9HA
MH(D2(90>=PZ6Y1!-%(IU53>:0HCPKE;+8[OD5Q;M-BIG:JY.F26VTE2CX=-`
M!TJ,D@:D@1CV4Y9C6$61[),NKJ:WV.G3-QY]80@=0$]5+5P2A(*U'1*2=(K^
M[M.[9<MV_*EB[:$GEH6TH55D]R9)("A=\L3F$JA[78',8EM,U2\"N%@.^$HZ
ME*@:IW;5]U>W6GL[WN,45=Q$E)HT&;"#T!Y7],H=*4R;Z"7!%/W>(_$0O>0]
MOBFQZ7+=9%`H7<G$\M6Z.DTR)RID$<%J"GR#,!E40LO7SV3>.I&2>.I"0?.%
M7;U^^<*NWCQTN<5%G+ITN=1=PX6.(F,<YA,81U$:F&RRS3,IIZ="6V$)"4I2
M`E*4C0!($@`!P`$A%8-55U5=4N5E:XX]6.K*EK6HK6M2C-2E*42I2B3,DDDG
M4F/RU[8^>/<V;.'CA!HS;KNW;I9-NU:MD5'#ERX6,!$D&Z"13JK+*G,`%*4!
M,81T`*_#CC;+:G75)0TD$E1(``&I))T``XDQ[F&'ZIY%-3(4Y4.*"4I2"I2E
M*,@E*1,DDD``"9.@B9[:)VF[HO@L9?NY,9&R;35!-Y'XX9J@VO*=2YBG2&X7
M0`<+6CER>*!=9`Y1T'T<=!&(&Z_>EMED+ECV[[.MNHFE56H3IVST]D/Z98/S
MC]D#P[0:19MW<_P]+[E08R[>PO6O'E`+;MR#RUCXT(]85KZJVH<4:U!&A#)D
MHV#K)L:S\;VU&6=8=MQ-J6O#I`C'0L*T39LT"Z`!U#%('.X<K"&JBR@G55-Y
MQS"(ZU`J\WN[Y%<7+O?*AVJN3IFMQQ14H^#P`="1)(&@`$7&8MBF-X38V,;Q
M*BI[?8J9,FV64!"$]9TU4I7%2U$K4=5$G6.UUQ<9!"D(^5.SL-;$+*W'<4FS
MAH*#CW4K+RT@L1NRCXYDB9=T[<K'$"D212((CY1\`XU]5#0UERK&K?;VUO5S
MSB4-H0)J4I1DE('63''7>[6RPVNHO5Y?:IK32,J=>=<4$H;;0"I2U*/```G_
M`)-8J3[[=YT]NMR$9K$*NXO$%GO7;>QH`QE$1E#@8Z*EX3C?FY#RTDD'P)!#
M^2-C`0//,J8UJ6R.T%#M?8>TJ@AW+*M"34NZ'DZ0PV?H(/G'YZ_*.@2!UWN]
MEWFKMW@,Q-/;E.4^W5M=6FAIR2.U,RDU;Z9R+KH\Q)_4MD('E%Q2M#ZW?$28
MR'BK%=\YION"QSCJ#<3UT7`Y!%JV2U(V9MRB7TN4E78E%*.B8](>===30I"A
MY3"4H\!D^3V7#[(_D.0/)8MC"9J)U*C\U"$\5K6=$I&I/@F1F>W^W^5[GY72
M87AE*NKOM8OE2D:)0GYSKJ^#;38\IQQ6B1UD@&V-L[V48[VG6JF+)-O<V49E
MDB6\+_=-B@X44,4JBT+;A%`,I$VXV6X%(`@JY$H*+"(\I25;;M[R7_=*YD.E
M5-C+*SV%*DZ2X!QZ6BW2.)\U$^5`E,J["O=K[KV&]WO'TFG2BNSRI:`K*]2?
M*),BIFF!U:ITG0`>6[(+=)/*E&).[2$9^YQ<0OVZ*SH+XL4L*HH4HG:R1I4_
M460,/$BAHLKE,=/$AQ#PK*NZOZS\7*<,*(:]2J>T`X*1R:`^#GY#XP(UW^(>
M*'^&NL-6A*JC]JT/8DC5#G:^4I)Z"6>U29="B(JHU9]'7[A2$6\.VFBJCLNP
MYU4S)]5I<2R?,&G.DI<TL)%"^Z0VG`:JB[Q:TKW@NW*09*:!\!#+>D=C;N/M
MN-]V;'.T24\R*DB?2#5/2(\!C0;O498Z;;$>$6+@-7!Y#)%Q(D4'4$T.M`6T
MFLF`Z:**'?J!KQ`4RCX#6].YWBW,Y=<S?3YH32-$CI,G7B#X`&A\IB(GXGNX
M7(QCVUU(O59<N-0`>@<U/3`CPDU!UZ@>F("*G3%0D=BL^WE[MNVUK5;%4,O<
MMQ0D`D"0:J<\Q)-H\#$#0WG%](U\!\*X^[5Z+5:JFYN2Y*:G<=,^$FT%7_-'
M.8S9W<AR.@L#,^VK:QEA,N,W7$MB7'I5%Z6&C&=N0,5#-^DWCX"'8QB(B)4D
M$&<6R2:D$1'E(FDFBAKJ.@``52?65+UQKW:M<U/OO*6>DE2U$GQDDQVNK90T
MUDM%/;6>5%'24S;2>A*4-("1X``E/R"*V?<IWYJ9DF)#!>)90Z>*;>D#(77<
M+)<0#(DXP6XMVZB1N4]HQ+E/X(.(/5R]4=4RIZV(]W78].(4;>:Y2T#E%0W-
MAI0_W5M0XD'^G6#K_5I/*/**HI'[[W>V<W*N;VU6WE04X!1O<M54(5_Q%]M7
M!)!UI&E#R!_3.#M#Y`;B(2I7Q7#"D(L,=L/88-LMH7<IF.&,2Y'B2<ABJTY)
M$`-!1[A+5"])=HJ7F3F'R1^:/2.`&;(CUA#J')TX#]Y/?#]HN/;=XB\#;T$H
MK7T']8H'6G0H<6TD2=(T6KR!Y(/-<IW$^Z3^PV*7>[<FF(O3B0Y:J1U.K#:A
MY-:Z@B8=6#.G29%M!#I'.I').+4+(M4C3/?5N;;;7\%S5RL%T37_`'4*UJX[
M8G,`G^7'K93TB=.ES%.=G;3,1<G\2F6Z28_M*V_LEMNYN5FS-N?2K]A4LGJI
M0X=FDB3<_I/*\@=2>90\V(R][#?1C8G:BIO=&I/[WW#FI;<@G7MUI/,^1.91
M3(FX>@K[-!\^*>[UZ[D7CN1D'*[U^_<KO7SQRH99R[>.E3KN7+A4XB=59=8Y
MC&,(ZB81&K:&66J=E%.PE*&$)"4I`D$I2)``#@`!(".MS5551753E;6+4Y5O
M.*6M:B2I2U$J4I1.I4HDDDZDF9C\U>R/GB7+M.;7@RCE-SF^[([K61B5V@:W
MTG*7,UG,A*DZS#E`X<BZ%KMC`[4\0*Y.W_3I%3O2;E_NSC*<,M3DKS=4GM2#
MJW2C17B+Q\@=:`YX(L7_``]MAAGF>KW2R%GFQ?'G$FG"AY+]P(YFY3T4FE3)
MY74X6?#*S75;\7HQ`!WBMR1W+^W-LMLO1*WCP8WKDHZ!Q^&>+)F/:EO+"4=.
MFV;J&?K$'7F.=N/#E'6=W=(V[#;%1N/<4?:.<U/23'!(/V[H\)(#23T`.#IT
MI_\`Q)][E/5=%L=8W9,L\E9<BD^<M0G2TY\"4DOK'25,'3EU@AJ;L5+PI"%(
M0I"-S=KVQC-VZ*0;N[>B3VGCTJH!)9(N9HY;P94R'`%D8!OHFXN:1`-0!-N(
M(E-P553K4&Y6]>&;:,*:N#HJK_+R*1E0+D^@NG4,I\*_*(\U"HDWL-W4=TM^
M:Q%19Z8V_#@K[2XU*%)8`!U#"=%5+GYK?D`Z..-\8LS[8]GF'-J\"+*Q(DTG
M=;Y`B5PY!GDV[BZ)H0*43H)K$3*E#Q/4`3$:-@*F'`3BH<.<:XMR-V\NW.KN
MVO;O9VM"IM4K9(9;\)$YN+EH5KF?HA(TB\W8ONV;:[!6GU;%*;M\@=0!47!\
M)55/=:0H"3+,]0RW)/2LK5Y49#SOGK&^W2P)#(>2YDD=&-@,A%QB`IJS=RRP
MD$S>&@6!E"'>/EQ#SAU!-$FIU#%(`C7`81@V0[@WUNP8ZR7*A6JUF8;91TN.
MJD>5(_*H^2D$D",SW9W<PK9?$7LPS>I#-&B:6FDR+]2[*:66&R05K/2=$H3-
M:U)2"8J6;J]V&1=UM^&N:[EQC+9B%':%DV2S5.,5;48NJ`\Q^(`_FWB29/2W
M9PYE#%`I`(F4I`M/VPVNQ_:^QBVVI/:7)T)-14*'EO+`_P"BVDD\B!H)S,U$
MD]>'O`]X3,^\#EIO>0K["Q4ZEIHJ)!/94S2C_P"8\L!/:NG51`"0E`2D:MUL
MR-!1M#M+VNWANKRDQLB!Z\9;4?T9.^[NZ!E6MMV^54"J"F(E%%::DM!29("/
MPBNIC?!D.(:UW3W+M.V&,KO5=RN7%R:*9B<E/.RTGTAM'G.*Z!H/*4D'?7=X
MV%R3?_/6L7M/.Q9&9.UU7RS334\]2/FEYR10R@^<J9/D(61<&QQCNT<3V1;F
M/+$B486UK6CDHV+8I``G$A-3+NW:V@&=2#]P8RRZIO.55.8P^-5,9#D%URF]
M5%_O;I>N=2X5K4?Y$I'S4I$DI2-`D`1V1,)PO'=O,5HL-Q2G32V&@9#;2!QT
MU4M9XJ<<42MQ9U4M1)XQW:N%C*H4A"D(K]=UG>A<:=R2&V#&TNYAXB-9-ARO
M+QZPH/)IY)MDW;>S4G*0@LA%-&"R:CT"B`N3J@D;S"&`\\>Z_L_;S;F]R<B:
M2]5N+/J3:A-+:4$I-00="M2@0W.?($\P\HB5/?X@7><O2+V]L5A-0NFMS#2?
MVJ\V>5;RW$A::,*&H90VI*G@".U4OLU>0A07!/4VHJ;A2$*0C8/`.U[-&Y6>
M"&Q;:;F09-UTTIFZY$31UI0!#ZB)Y2:53,CU@(`F!NB"SD^GFIC6!9UN7A^W
M5#ZYDU4EMY0);81Y;[OZ#8,Y3^>KE0.E0C<FT.PVYN]]W_9F!V]QZF0H!ZJ<
MFW24X.LW7B.6<M0V@+=5\U!BP[MB[7&$<)!&7-D5)OF'(S44717<VTTLN$>I
MB50HPEL+"=%\=!0OFN)#KGU#F(1(>`0%W)[S&9YD7+=CY5:<?5-/*VK^\.).
MGVCPU3,<4M<HZ"I47+;$]PK:[:Y+%\S-*,DS-$E<SZ/[DRL2/V-,9API(T<J
M.<S\I*&SH).R$(F0B:92IIIE*1-,A0(1,A``I2$(4`*0A2AH`!P`*C8I14HJ
M425$S)/$F)V(2EM`;0`E"0``!(`#0``<`(\J\1^H4A"D(4A"D(4A"D(BJ[H&
M\$V#<=EQ)8<J5#*>38YRD\=-%?Y7:%CK`HU?RFI.+:4G#<S9F.H'(0%50T$A
M!&3_`':]IAFM_.5WQHG&;:X"E*AY+]0)*2CPH;T6YT$\J3H3%?W?P[R!VKPP
M;=XG4!.>7QE06I!\NDH530XYIYKK_E-,G0I2''!(I035VJRR*&(#PXCX!2/,
M6H^U[M:'!>&0R'=4<#?)67FS&8=E7((.X&RP+Z3;<$(&*!D%WA%1?.B\!YU4
MR&XHA58_>6W-_?7+_P!@6MSFQVTJ4VF7FNU'!USPA,NS0>I*E#1<7]=P[80[
M4[9C,K^SR9MD:$/*"AY;%%+FIF-0"E2Y]NZ.M2$*U:$2=U&R)VP\`$1X``:B
M(\```\1$?``"G@Z8\$@"9X1&?NJ[F^&L"$DK6L-9IEG**'5;?)4.\`UI6\\*
M!BZW+<+<3I+*H*`',S9"JL(ZE.=$>-2.VP[MV7YR6[G?`JU8TJ1YW$_;NI_\
M%HZ@$<''))Z4A?"(-[_]^G;3:1#]AQ-3>0YVB:>R97.DIUZC^\U"9A12>++/
M,OYJU-'6*Y6>=RV8]R-Q!<&5;M=3!&QS##VZS#Y.M6WTS:@"</!H&]%14Y!T
M,NIU'*G\-0U6"X/MUB.WEO\`4,8I4M%0^T=5Y;SIZW'#J1U)$D#YJ1%+&[6^
M.Y6]EY_;&?7%RH0@GL:='V=+3CA)EA/DI,M"M7,ZKYZU1@>LXC4<*0C9+;GM
M1S)N?N((;&]O'^1FJZ:<_>TP59E:5O)'$.<7DETS>EO03U,1HV!5R?3WH%U,
M&N]P=T,1VVM_K>0U`];4DEJG;DI]T_FHGY*9Z%:^5`ZR=(W?LMW?-RM]KT+;
MA5$?V:VL"HK7IHI*<'CSNR/,N6H:;"W%?1Y9J%ES:EV_<,;8&[*>39DO[*A4
M2^E9!N!HF)XY8Y?AD;2B#&6:6^V`1Y06#J/3E]\MH/*%=&Z._&7[DN+H2LT.
M,$^32M*/ECH+[FBG3T\NC8/!$]8O%[OO<]VRV)9:NR6Q=\^"1S7"H0/LU'B*
M1DE2*=/1SCF>4-"YRGE&]]:/B6D*0A2$*0BNMW5]Z![NFGNV7&LJ4UJ6\[1/
ME":CU]2W!<;-3J)6BFLGP/%6^L4IW8`(E6>@!!X(CS6`]V'9Y-IHT;CY$T?V
MI4(/J;:A^J:4)%\@_/=$PCI2W,_/TI@_$`[SJ\AN;NQV$5`_=^C<!N;S:O\`
M>*E!F*0*'%JG4`79&2WQRG1KRH2ZF5%6T??M6UK@O>Y(2T+4B7D[<ER236(A
M(A@D*KM_(/%`2002('``$PZF,.A2$`3&$"@(A\-SN5!9K>]=;HZABW4[:G''
M%&24I2)DG_F'$F0&ICF,?L%XRF]TN.8_3N55ZK7T,LM-B:W'%F24@>,ZDR"1
M,D@`F+<&R+9M:^T_'R1'"+.6RQ=+)HM?]UE*57D6`.L6V()8Q>="`BE3\NI>
M47:Q>JI_`*2JK>?=ZY[HWXELK:Q:F6H4K/"8X=LX.EU8UUGR)/(GYQ5V*>ZS
MW:+#W?,.2EY+51N#7M(57U0UD?.%,PHZI8:)E,2[98[18\Q*-WJTO$IXA1[T
M^0$X[&&)L9(N"^E71>,A=CUKKYWR?:T89@V6$-/`7T]H'AX#_<F1W.["JHR2
MZY(M/V5-2(82K\]Y?,1]5K^6*O?Q/,P118+C^#-K'K%?<7*M:.GLZ5KLTGZ]
M09>(_)70JP.*68`!C"!2`)CF$"E*`"(F,/`I0`.(B(^2DP-3PC])!4H)&I)B
M[-M>L%;&&W?"]ANDS(/K?Q[;B,F@;WR$L]9$DI9(WAQ2DGJI?[E4V;EWQ&2[
M@7B]M&;+]>Z4'K0E7(V?E0E,=HS8;$G<%V9QG%*D%-926>G#H/$/+0'7A\CJ
MUB*L._W*89<W8Y:GVSGTJ(@YL+'@C%-JD$=9R1850Z'\'I.9-NX6`0X&!3F\
MNM6;;%8R<5VMM5"XGEJGV?67.OG?/:`'PA!2GP2E%!'>^SY.XG>#R&[T[G:6
MZEJO46".'9T8[`E/1)3J7%@C0\T^F<:;UMV(T1FG;C=UIV!GK$-[WT+DMH6I
M?]MSUP':-C/%THZ-D$G*JY6B8"JY*@8@',0@"<Q"B!0$VE8?N#:KI?<'NUFL
MO*;M54#S304>4%:T$`<QT$^`)T!E/2-H;*9'CV(;MX[E&5\XQRWW>F?J"A)6
MH-MN)45!`U5RR!*1Y1`(3K*)7M_?<U@\@6LYP_MMFI0T'/MUVU_9"%B[AE)*
M*<$Z:EL6RF](WDD6KTAC`^='32,HF/13U*8YAB[L7W<*VPW-.6[ALM^NL*!I
M:7F2X$+&H>>*24%23(MH!5(^6K4`18/WO._/:\OL"]M]DZE\VJK0I-?<.1;)
M<:4)&EI@L)="%B8?=4E!4G[-$TJ6HP;^'`.`!4THJHCFD(F%[9FQ,,NS#+/6
M68@#XOMV0,:S;>?HG`E^7%'JE'Y0<HGY05M6$<E\[74CQT3IZ"F10#1+[QV]
MO[ITB\'Q9V62U#?V[J3_`+LTH>:#T/.#ATMH/-HI2962]QGNG?$6Y-;M;A4T
M\$HGO[G3N`RKZAL^>H'C2LJX\0\Z.SU0AP&RN4I2%*0A2D(0H%*4H`4I2E``
M*4I0``*4H!H`!P`*KI)),SJ3%X24I2D)2`$@2`'`"/4X<-VC==V[72;-6J*K
MERY7.5)!NW03,JLNLJ<2D3222()C&$0``#4:_3;;CSB6FDE3JB``!,DDR``Z
M23H!'K>>9IF5U%0I**=M)4I2B`E*4B:E$G0``$DG0"*@&_7<VXW-9XFYN+>+
MGQW9QG%J8[9F./0/%-%Q*_N'I!YI7-S/TQ<"/O@;@B01'DJV38[;AO;C"&:.
MI0D7^K`?JE=/.H>2U/J92>7JYN=7SHZW_>XWT>WSW9JKG0N+.&VTJI;<@GR2
MTA7EU$N`54K':$\0WV2#YD:3UN2(N1W#'UB7+D^]K7Q]9[!22N6[IEG"1#1,
M!$#.':G*9=80_9M6:`'66./!-),QAX!7$WZ]V[&[-4WZ[+#=NI&5..*/4D<!
MUJ49)2.E1`Z8R7#L3O>=Y308?CC*G[W<:E#+2!TJ6>)ZDH$UK5P2A*E'01=(
MV_X7MO;[B.S,4VPF06EM1A"R4AR`5:<N!W_*9V<="!2B9:1D5#G*`_LTN1,/
M-(`!3SGF87'/,KK,HN1/:U#GD)Z&VDZ-MCP(0`#UF:CJ3'9WV>VQLFSVW5LV
M_L0!8HF!VKDI*?J%^4^^K0:N.%1`/FHY4#R4@1WB_;SA\=61=M^W`L5"%LZW
M9>Y))0Q@)JUB&*STZ1!$!U57Z0$('$3',`!Q&N%L5GJ\@O5)8Z!)565=0VT@
M>%:@F?B$YGJ`C*LOR:VX7BMQRZ\*"+9;:)ZI<,Y>2RA2R!X52Y4CI)`BD9E+
M(D]EK(UZ9+N98RTW>MPR4^\U'4K<'JYC-6*(>!6T<S!-!(H:`5-,````*N:Q
MFP46*X_1XY;A*CHZ=#2?#RC51\*U34H])),=6G/\SNVX>:W3-[XHJNESK''U
M]2>=1*4)ZDMHY6T#@$)2!H(Z%7.1A\>Q%%9PJF@W25776.5-%!!,ZJRJAAT*
MFDDF!CJ',/@``(C7Y6M#:2MPA*`)DDR`'62=!'L::=?<2RRE2W5&02D$DD\`
M`-23U1NCA?M];I<VJM%X?',A:%N.13,>Z\A%6M2*(V.8-7#9H]1^6Y,.0=2@
MW:J`8-.(`.M:>S#?C;/#$K15W!NKN"9_84LGUD]14D]FCP\ZQ+JGI$G=L>YW
MOUNBXV[;K*];K*N1-5<`:5H))\Y*5I[9W34=DTL'34#6)J]NG::PABP8^X<L
MN3YEO)L9)R5F_0/'6#'.B#SEZ%OE4,XG`2.`><_4.B?3B@6H<[@=Z;,\F#E!
MBJ1:+0J8YDGGJ5I/6[*3<^IH!0^F8M!V7_#TVMP$LWG<)9R7)4$*Y%I+=`VH
M?1IP2I^76^I2%?U(B51DR9QK1M'QS1JP8,D4VS-BR;I-&;1ND4")-VS9`B:*
M"*1``"E(4"@`:`%1A>>>J'55%0M3CZR2I2B5*43Q))F23TDQ/^EI:6AID4=$
MVVS2-)"4(0D(0A(T"4I2`E*0-````.$:E[K]YN*MJ-LG<W*\3N"_Y%J=2U<<
MQCI,)J54$#%2>R9P*J$%`IJ!Y[I8NI]!*D10_FAM3:W9_)]T;B&[<@L6)M4G
MJM:3V:!TI0-.T=(X(2=.*BD:Q'CO!]YK`.[[8R]>W$UF7/-DTMN:6.V=/0MT
MZ]@P#YSJQ,R*6TK5I%53<#N,RCN6OA>]\FSAGRJ76;V_`-`,WMZU8I145"1<
M)'@(D2('#JKGYW#@P<RAS#II9[@>W^-;=65-EQMD(09%UU6KKRP)<[BNGP)$
MDH&B0(Z_V\.]6>;X92O*,XJBZM,TT["/)IZ5HF8:8;X`<.99FXX1S+4H@2P5
M6;1J:,X[>]OF0]RF1HS'6/(X57"YDW,[.N4U`A;4@P5*1W-S+@H:)HHE$022
M`>JY5T33`3#PPO/<\L&W>/N9!?W)-IF&VP1VC[DO);;'23\Y7FH3-2M!&UMG
M-G<RWNS1C#<.9*GED*??4#V-*Q.2WWE#@D?-2/*<5)"`28MX[<=NN/\`;)C:
M-QU8+03`02/;DN-VFF$S=L^=(I'4Q*JD#AKIRMT"CTFR(`0G@(C5#N%N!?MR
M,B<R"^+EQ2RTDGLV&I^2V@?RJ5Q6J:CT`=C7939?#]B\(8PS$FYRDNIJ5@=M
M5U!$EO.D?D;;'DM(DA/23GNL&C;L*0A2$*0BI5W.\8SV/]W&0)J2:KEA<EF8
M7M;4B*9P:O6[B.9Q\HV16,'(=Q&RK)0BA`XD`Q!TT,41M1[MN24-^VJH*2G4
M/7+=S4[R)B:2%J4@D=2T*!!Z2#T@QUWN_;@MWQ#O$7>YUS:A;+V6ZVF<D>5:
M5-H0ZD*X%3;J%)4!JD%).B@3'O6^HAQ'U8."FKFEX^`MR)D9V<EG*;.,B(AF
MO(23]TJ.A$&C-J11=90P^0I1T#B/"OEK:VCMM*Y77!UMBB:25+<6H)0E(XE2
MB0`/''(VFT72^W%FT66G>J[I4+"&FFD*<<<6>"4(2"I1/4!$YNTOM&+N@B[[
MW1KG:H&Z+UEB2&><KI4HE!1,EZ3C0_\`)2CJ'.R9&ZGD.N4>8E0JW3[UC;1=
MLFVB0MS5*JYQ/DCH/J[:AKX''!+I"#HJ+6N[Q^'2Z^*?+-^%J;:\E:+2RN2S
MI,"L?0?(Z)LLGFZ%.I,T1.Q:=H6M8<!'6K9=O1%K6W$HE0CH2"8-XZ.:IE``
M^#;MB$(*A]-3G-J<YN)A$>-0DNMVNE\KW+G>*AVIN#IFMQQ16I1\)/0.@<`-
M`(MBQW&\?Q&SLX_B]'34%DIT\K;+#:6VT#P)2`)GI49E1U))CL=<='-PI"%(
M0I"%(0I"%(0I",-9^S;:6WG%-U94O%8OH$`S,6-C2JD3=W!/N2F3AX"/`X^>
MZD70``B`#TT@.H/FD&LOP3#+KGV44N,6D?;/K\M<B4M-#5QU4OFH3^4R2-2(
MUGN_NECVS>W]?GV1J'JM(W)IH$!=14*!#-.W/YSBM)_-0%+/DI,4S<MY3N[-
M>1;JR=?+XSZX[LDU7[K0QO1F+?@DPB8],PB"$;%,B$00(&FA"!KQ$1&WS%<9
MM6'8_2XW94<EOI6PE/6H\5+4>E:U$J4>L]4=9G<7/\BW0S2X9UE+I=O-P?+B
MOHH3P;:;'S6VD!+:$]"4CB9DXYK((PF)`>W'MD;[CL]-%+D:`YQUC))G>%X(
MJ`4495<KH2V[;:I3#YZ,Q(-SF7+Y6K=4/$0K1'>#W(<V]P98MRN6_P!R*F&"
M.*!R_:NCJ+:2`D]"U)/1$PNY5L6SO5NTVN]M\^&V-**NL2?-=4%_W>F/6EYQ
M)*QTM-N#I$6VRE*4I2$*4A"E`I"$*!2D*4``I2E#0"E*`:``>`558222I1F3
M'8E2E*$A"``D"0`T``Z`(U9W%[R,%;9(U0^0+I2=W2HW.K%V#;HHREVR)P((
MI=1B14J40T4.(!Z0\.BGH(B7F$-*V;M_M%FVY%0!8J4HM@4`NJ=FAA'7)1$W
M%#Z+84>N7&-!;T=Y;:C8RB4K+J]+E_*"6J"GY7:MPRTF@$!E!,OM'E(3]'F(
ME%=[<_W*LZ[@S2-NV^]6Q3C1R*J`6Q:[Y8DS,,CZEY+HN9($'CXJQ/?MVX-V
MOD,4_OAG[MKW=<)P(-W"N0+ID:9'MGDCLVU?^"R9I3+H6KF7T@IX13/OOWW]
MUMX5/6:SNJL&$+FGU6E6H//(.DJJI'*MR8XMH#;704KES&.JI`1"V%(1^M@P
M?2CUI&QC)W(R+]PDT8L&#99X]>.ES@FBV:M6Y%%W"ZRA@*4A"B8PCH`5ZGWV
M:9E514K2W3H25*4HA*4I&I*E&0``XDF4?324=7<*INBH6G'JUU80AMM)6M:E
M&24I2D%2E$Z``$DZ`1-QM![2\O</R7?^Y\'5OP@BW?1N*F#GHSTHD(%5)]<9
M%`>:#:'U`#,VYO2S!J!U$1\T89[L=Z>DH.TL6VW*_6:I76J$VD'@>P2?UBAT
M.*'9CH2L:Q:7W</P\KC>.PS#?7M*.U^2MNU-JY7W1Q'KCB=6$'I9;/;'@I;1
MT,^UHV?:M@V]&VG95O1-K6U#H%;1D)",D6$>T2*`!\&@@4I3*'$-3G-J<YA$
M3"(B(U!:ZW>Z7VO<NEYJ':FXO*FMQQ14I1\)/0.@#0#0`"+><<QK'\0LS&/8
MO1T]!8Z9'*TPPA+;:!X$I`U/$J,U*.JB29QV2N.CFX4A"D(4A&B_<'W,*;:L
M!2LE`O/1\B7VJK9UAB0Q>LP>.FYSRUQE*(#YL!&<QTQ\/2E$0'QK=FPFW*=Q
M<Z:IZY'-8*$!^IZE)!\AK_6KD#^8%GHB*/?%WR5LAM%45MI<Y,RNRC1T,O.;
M6I)+M3T_J&YE)X=JIH'0Q4.666<K+.'*RKAPX547<.%U#JKKKK',HLLLJ<3'
M5554,)C&$1$PB(C5KJ$(;0&VP$MI```$@`-``!H`!H!'7)===?=4^^I2WEJ*
ME*422HDS)).I).I)U)XQZZ_4>N+'O:FV<(V+:[?<CD.(`+UO!B<N.(]\E\+;
M-HNTQ(I/]%0O,A+7.F(](W`R;`0TTZY@"O;O0;N+O5R5MY8'?_P](L&K6DZ/
M/IU#4QQ0R?.'`N_H"+K_`,/WNU-XI84;UYE3_P#_`$UQ:(MS:QK34BQ(U'*1
MY+M2-$'BFGX?KE`305#V+.8>-(14H[FF:D,Q;IKJ0B7GI=M8S:HXYACIJ@HV
M5=PR[A6Y':`E\P06GW"R7,'$Q4"\1``JU+NXX<O$=LJ5=4CDN-R4:MR8D0EP
M`-)/B:"3+H*C'7=[\VZ#6Y._=P9M[O:62QH%N9D9I*V5*-0M,M-:A3B9](0G
MH`B/FM\Q#F-O-B>&QSAN@QC:;ED+VWXF6"\[M*/!(EO6J)))9-<=!`$W\@1N
MUTXZBN`>&M:HWMRX87MK<KHVODKW6O5V.OM7O(!'A2GF7_-B1W=.VU.Z>^]B
MQ]]KM;13U'KE7U"GI9.*"O`XX&V9=)<$6PL_Y&2Q%A+*62#*%04L^R)Z4CQU
M*366(Q50A4$P-YHG5E%D2%+Y1$`JKC!,?5E>9VS'@.9-76M(5^AS`N'Y$!1)
MCL);P9FWMUM;?LU*@E=NM;[K?`?:ALI82/"ITH2!TDRBD.Y<N'KEP\=JF6=.
MUUG3E8XB8ZKAPH99=4QA$1$RBIQ$1_35S;;;;+:66@$M(2``.@`2`^01U9:A
M]VJJ%U+ZBIYQ94HGB5*,R3X23,QZ:_<>F%(0I"%(1OOL*V9RFZS(HNY])]'8
M?LMRV<WM,HE41/,.-2K-K-AW6@%+(R:?G.%"B(M6NIO?G2`=&[X[O4NU^/\`
M94)0YEE8DBG;,CV8X&H<3]!!T2#YZ].`5*7?='[LUPW_`,T]9NR76=N+8M*J
MUX`@O*T*:-E?0XZ-5J$RTU-6BE-A5M&"@H:V(6*MRW8QE"P,&P;1<1$QR!&S
M&.CV:14&S1J@F`$3222(``'E\1XU5A75U9<ZQVX7!U;U<\LK<6LS4M2C,J)/
M$DQV'+1:;98;73V2RL-4MII64M,M-I"4-MH`2E"4C0``2CZM?+'(Q$]W7MS9
M\38@;X?M:1]'OC,+=TTDE&RPD>0V/T#`C,N/-T.B>XEA]!2'4-4O2-.):E)W
M7=MQE.6*RVYM\UEM*DJ0"/)<JCJV/"&A]H>I79SXQ7M^(-OHK;W;E&V]@>Y,
MIR-"DNE)DMFWI/*\K34&H5]@DS$T=M+5,5@ZLGBB"%(18*[06UHD;%2.Y^\8
MT0D9<KZV\6(.T#D,UB"F,UN*ZT.?E`3RBQ3,6QP`=$4UQ#4%`T@;WL-S345+
M>VMH<^P:*7:TI/%?G-,&7T!)Q8^D4?1BXK\.+8,4-`_OKDK']\J`NFM:5@CE
M:U145:9]+AFPVJ6B$O$$A8B=.H31:]$4W=ZRJO8^VN/L2/<'0D,MW8UA7/34
M`IS6Y;Q"SLP4P>^,DL[39I&_0I[E2@[J&,-WK<1R]OI"F+52J<$Q_2N_9M_*
M$EQ0\45^?B-;@.XKLDSBE&LIJ\AN"652,B:>G`?=\8*PPA7@5+IBKW5E<4-0
MI"+,_:QVD6O8>)H+/=X6^PDLDY$2-,6N]D6Z;M:TK+4$21`Q)%R&(QD9Y(HN
MU7!`!46ZJ28&``,`UQ=YO=6YWO*7\&M+ZV\=MY[-Y*"4A^H'ZSGEYR&CY"4G
M3F"E2)D1>?W!N[K8<2V]I=V\DHV7\VO*>VI5N)"S241T9+04)(<J`"ZIQ/E=
MFIM`(`4#+MJ(^-11BQF/2Y<MV;==V[<(-&C5%1PY=.54T&S9NB05%5UUU3$2
M112(43&,80*4`U$:_;;;CSB6F4J6ZH@!(!)).@``U))X`1ZGWV*5E=34K0W3
MMI*E+40E*4@3*E*,@`!J23(#4Q"KO'[KL#9X2N.MLZ[&Z+I+U&4ID]=(CNUX
M%3SB+IVLV4^#N*41'@#E0!8IFXE!?R3&VC[KM==BUD&XP736S12*,'E>='07
MB-6D'Z`^T/24=-7_`'EOQ!;1C8J,,V/4U77X30[<U`+IF#P4*5)TJ'!T.J!8
M2=4A[HKY75==S7Q<$G==XSTK<UR33D[N5FYMZO(2+YP<1$3K.7!SG$I0X%*&
MA"%`"E````J>=LM=MLM`U:[0PU36YE/*AMM(2A('4!_*>).I),4ZY!D5]RN\
M/Y!DM745UZJ5E;KSRU..+4>DJ42?`!P`D```!'7Z^^.&C9/;)M8R?NFO=*UK
M#CC-X5BNV&[KU?)'"W[3CUA,(KO%@$OI<@LDF;T=FD(K+F#^"0#'+KO<?<W&
MMLK,;G?'.:L6D]A3I([5]0Z$CYJ02.=P^2D=9D#O#8O8'.]_,H38<39*+8TM
M/K=:X#ZO2-JGY2SISN$`]FRD\[A'0D*4FV9MRVVXTVQ6`UL3'<;H=3I.;EN=
MZFD:?NZ8*F!%).7<D*&A"\2H-B:(MD_-(&HF,:K/<+<3(MR;ZJ]W]SR1,,LI
M)[)AN<PA`_ZRSY2SJ3P`[#&RNR.$;$X@WBF&L^6J2JFJ6`:BK>`D775#H&H;
M;3)#2=$B94I6?JP2-P0I"%(0I"%(1AW->`\4;A;5^I^6+39W+&(JG<QCH3*,
MIJ">G)TS/8.8:F3?1RYR:`<"&Z:H``'*8``*R[#<ZRC`;G^UL7JET]0H26G1
M3;B09\KC:II6)\)B8^:08UKNAM#M]O)8/W<W!M[=;1)45-+F4/,+(D5L/)DM
MM1&B@#RK$@M*@)1&G(=ES`KB3.YC\GY4CXLRP'",.:V'JR:7-J=%.14ADC"'
M+P*8Z1C!Y>:I%L=\+.&Z8-OVVV.5($N<=LD$]90'#\H!'@E$'JS\,7:5ZO+]
M'?;\S0%4^R/JJU`3U2'"P/$"4DCIG&]NWG9W@?;(U4'&MJ`:XG2?2?WO<:J<
MU=[Q,2`11N24402)&,E.(F09IMTC"/G`;A6D<_W;SC<AT#(JJ5O29IIV@6V$
MF<P>0$E:AT*<*B.@B)9;-]VS:;8RG)PFWSO+B9.5M20]5K$I%(=*4AI!UFAE
M+:3/R@8VAK6D;YA2$*0A2$*0A2$*0A2$*0CU++(MD5G+E9)NW;I*+N'"ZA$D
M4$$2&45665.)2)I))E$QC"(``!J-?I"%NK#;8*G%$``"9).@``U))X"/6ZZT
MPTI]]24,H25*4H@)2D"9))T``U).@&L5.NXMN^6W,95/;UJ/E1Q#C=X^C;43
M25/Z-<TN4YFLI>BR0"!%"/.GTF',',FS#FX"L<*M*[O^TZ-N,8%?=$#]Z[BA
M*WR1JRWYR*<'B.6?,[UN::A"3'7J[Z'>/=WQS\V;'WE?#FRN+:I`">6I=GRN
MUI'`AR7*Q,32SKH75B([*W_$,(4A$E&P+?3;.T)ID2%NRPI6ZHV]G4/*-Y*W
M73!O+L7L0V=M08N4I$4D7$<X(YYBB50#)*`8>4P&X1VWUV3N6Z[MOK+77-4M
M11)<04.A1;4EPI/,"B9"P1+42(EJ):S@[H7>OL?=SIKS;,@M#]PHKFMEU+E.
MMM+R%LI6GD4'))4VH+F"%`I5/105ID#<+W;LU9.:NK=Q'%I88MMP4Z2\LT>E
MF+\>HF,7@2;,W;LX(IBET'T1'KAJ.BP:Z!P6`]U;#<;=3<,J<-XN"=0A2>SI
MDGPMS*G/YZN7K1&8;R?B);G9TPY9MNV$XU9%@A3J%]M7+&G!\I2EC33[%'::
MF3O0(I)&2D9A^[E9>0?2LH_6.Y?24D[7?/WKA0=3KNWCI15PX6./B8YA$:E!
M3T]/2,)IJ1M#5,@22A"0E*0.`2D``#P`17U75]=<ZMRON3SM17.J*EN.+4MQ
M:CQ4M:B5*4>DDDGIC\5>Z/DA2$*0C9O:)GZ+VT9OM[*TS9J5[Q\8QE8U>,!9
M!M(LRRK;T;Y6A'+E)9NC*LOX'.``=,QR\Q!-S!KC=;!:G<;#*C%Z2L-$^ZM"
MPN1*%<AGR.`$$H5TRX$`R,I'>O=RW>H-CMTZ/<"YVU-THV&G6U-<R4N([5/+
MVK*E!20ZCHF!-)4GF3/F$Z"/>9VR'12,XLK,R*YB%%9).`M-<B:@AYY"+#>2
M0JE*/@;E+K[@5"=?=!W("R&ZVSE$]"77P2/%ZN9>*9BUYK\3+8Q325/6O)4N
MD"8#%&H`](!]=$_'(>*/U(=Y/:VJJ4BMJYE;$'7596V;8.0F@:AJ5"\E51U'
MAP*->ISNA[F)3S)JK.I74'GA_P`M.!_+'T-?B6["N+"5T&2H2>DTU*0/JUI/
M\D=X@>[3L[F%4D7L]?-LF5,4G4G+(D#H)B8=`%5:%6EP(4/$1'@`5PM=W5]V
MZ1)4RQ15(`X-U"9GQ!P-SC*;3^(=W;KDXENJJ[K0E1`F_1+*1/K+"GI>/@(W
M5QCGG#.9VPNL6Y*M&].0HF59Q$L@:7;E*&HF=PC@4)=J4`\JB!0K3F28-E^'
MN=GDUNJZ.?!2T'LS^BX)MJ^11B3^"[N;9[F,E[`[Y;KF1Q0TZGMDCK6PKE>0
M/"I`$9;K%8V+'B<Y$R'45.1)-,AE%%%#%(FFF0HF.<YS"!2$(4!$1'@`!7E*
M5*4$I!*B9`#4DGH$?E:T-H+CA"6T@DDF0`&I))X`=)BHWW%MRA-Q6X*7-`2'
MIF.L=$6LZR3(G$S20]&6YI^XT@T`I_EJ5(8$C_PFB"-6L=W_`&Z.W^!M"O;Y
M,@N!%143'E)F/LFC_HT2YAT+4N.NGWT-[T[S[P5*K0]VN&68&CHI'R'.57V]
M2.OMW0>572RAKPQH16\HB+&[FP7;(KN9SQ#P\NR.MCFR^C=>0US`8J#B+:K@
M$?;H*`&@N;B?E!(2^(-BK'_@\=,[Z;D)VXP=ZKI%@9!638I1TA9'ENRZFD^5
M/Z90.F)3]T38MS?+=FFMUQ:*L,MG+57!7S5-)5]G3S^E4.21+^K#JAYL6^V[
M=NS;H-&B"39JU02;-6R"94D&[=!,J2""*1`*1-)%(@%*4````-`JIUQQQYQ3
MKJBIU2B229DDF9))XDG4F.QXPPS3,HIJ="6Z=M(2E*0`E*4B24I`T`````T`
MCW5^(]L:A;X=Q37;5M_NJ\6SE-.\IU,]HX^:B;X9:YY=NN4C\I`,4_1@6)%7
MAS>&J12^)R@.V-EMOW-Q<[I;2XDFT,'MZI70&6R/)\;JN5L#CY1/`&(X=ZG>
M=C9#:"OR-EP)R6K!I+>GYQJ7DJDX!,'E80%O*/":$IXJ`-.-999RLJX<*J+N
M'"JBZZZQQ45666.*BJRIS")CJ**&$QA'B(C5N*$(;0&VP$MI```T``T``Z@(
MZU3SKK[JGWE%3RU%2E$S)),R23J23J2>,>NOU'KBQUV<,%*6QC>\L[33+I26
M17R=MVF=9/15.TK=75&1>HB8H&!*8GCB3AP,5D4=1`W"O?O<YLFY9#1X31KG
M3V]';/R.A?=`Y$GPMM:^-PCHBZW\-3:==BPJY[KW1KEK;RZ*:DF-12TZCVJQ
M/63SY*=.(8!U!CMG>,R@:U=O]JXV9K]-[E"\DC/2$5`ISV]9R:<J[*=,!YC(
MJR[ECQ\`$OZ:XKNCXT+GG=5D3J9LVVD/+IIVKY*$Z]8;#GY8R+\2G/#8-H*#
M":=<JF^W(%8!D33T8#JA+I!>4Q^2*S-6.Q1A"D(4A"D(S_MIV[WKN;RI"8VL
M]`Z**ZA'UTW$HD8\?:ELHJD"0F'IN!!4`@]-LCJ!G#@Q2!XB(8)N+G]FVXQA
M[(KNH%:1RLM`^6^\1Y+:?!TK5P0@%1Z`=P[';,Y/OGGU+A..(*6ED+JJ@@EN
MEIDD=H\L\)@>2VB8+CA2@2F2+B.'L1V3@S'=N8RQ]%DC+<MQH"*8B!!>RCY7
MX20FI9P4I3/)63<B*BRAO*(%+H0I2A4GEN5WG-L@J,DOSA<N%0J?YJ$C1+:!
M\U"!HD#QF9))[)NVVW6+[4X918-A[`8LU$W(<.=UPZN/.J`'.ZZJ:EJ/@2))
M2D#)M8W&=1\"Z[H@[)MFX+QN9\E&6]:\/(STW(+"`)M(R+:J/'BPZB',)44A
MT#Q,;0`XC7WVNV5MYN3%HMR"Y7U+R&FTCBI:U!*1^4QP^0WZU8M8JS);XZEB
MS4%,Y4/.'@AII!6M7R)!D.DZ12YW+YRF]Q>:+URI,F720FY$[>W(M903E@[4
MCQ,V@8E(!\T@HLB@=70``[A10W\*KA-N<*HMO\/H\8I.4K9;!=6!+M'E:NK/
MC5HGJ2$CHCK%;Y;JW7>?<ZZ9[<RI+54^4T[1,PQ2M^2PT/T4`%<M"XI:OG1@
M>LXC4D;);3MO,WN:S9:V-(X%F\,HM\LWK,)%U"$L^-52-+NP..A"NW0'*V;`
M(^<X6)Y`'37FZ6?4>W&&U61U$E58'9T[9_I'U@\B?T1(K7U(2>F4;O[O6S=T
MWSW0H,(HN=%M4KMJUX#]11MD%Y<^'.H$-M#I=6B>DY7,;<MV%M&WX2UK;CFT
M3;]NQ;&%AHQHF5)LQC8YNFU:-DB%```J:*8!KXB/$>(U4'<;A67:O>N=Q<4[
M7U#JG'%J,RI:R5*)\9,=F6R66UXW9Z7'[(RBGL]%3H99:0))0VVD(0D`=0`\
M)XG6/M5\<<I%</O3W8X?9AQ-9@*F%E;M@/YH41UY"R%Q3:J"JI0\-3LX9$!_
M55A7<[M:&,2NEW(';5%<EN?YK38('UG%12C^)YD#M7N/C^-!1]6HK0M[EZ.T
MJ7U!1^5#"!$+U3!BL6.#`(E$`\1`0#]8A0<8\@R(,7,=K^X##&0\#XZFK6N^
MU8EG#V=;\),0#Z:BHU]:DE#Q31@]B9-FY<(*-0;K(#TU!*":R>AR")1UJH;<
MO`\PL&<7"CN5)5.NO5;KC;J6UK2^AQ:E)6A0!!F#J)S29@@$1V8]A]X=LLQV
MELURL5RM]-34UMIV'J=QYIM=(XRTAM;3J%*24\I3Y*I<JTR4DD&<8TSGW(]K
M^%6KMNA>2&3KL1!4B%K8Z7;S8>DD#S4Y*XB'&`C$N?@8>LJL70=$C#PK(L*[
MN^Y68NH<<HU6VUF1+U6"WH>E#4NU6>KR0D_2$81NMWV]B-L*=QIBYHON0)F$
MTMN4EX<PZ'*D'U=L3X^6M8UDV>$5_P#='O\`\X[G57,,_D?J)C853^C8_M5V
MY1:/4?>IC=,IJD[N1<"AJ)%`3:%-Q*B4>-3MVSV)PO;9":MAOU[(I:U3R05)
M/3V*-4LCPB:Y<5F*?]^N]_NIOHXNVU;W[)PGF/+;Z5:@A8Z/6G=%U*O`H):!
MU2TDZQHU6ZHBE"D(D=V8]NW(FYEVQO&[2O[!PPFJ"BUQN&_2F[M(F?0[&SF3
MDFBB)Q`2GD%2^C)<>0%3@)0CWO!O_C^W#2[1:RBNR\B0:!FVQ/YU0H<#TAH'
MG/3RC6)K]V3N99GOC4M9)D0=M&V:53-0I,GJL`ZHHT*&H/!50H=DG7E[10*1
M9]Q;BC'^%[-B["QK;,?:]M1212)M620>D/7'(4JTE+/3`+J4E'8AS*N%C'4.
M/ET``"MC)LIOV87=V^9'4N5-Q=.JE'1(Z$(3YJ$)X)2D`#QSB][`=O</VQQI
MC$L(H6:&R4Z9!*!Y2U2\IUU9\IUU?%;BR5$],@`,AUC\9G"D(4A"D(4A"D(4
MA"D(4A"D(4A"D(4A"D(4A"D(4A"D(A$[K&]`EKP[S;)C.7+]99]JF.59J.<?
M"0,"X("B-FI+I#\%*3J1BG>@`@9)F()CQ7'EF=W7]GE7*K1N1D;1_9S"CZDV
ML:.NC0U!!XH;,PWT*<FKY@G5E^(#WG$6*VN[&X/4C]MU:!^U7FU:L,*$Q1@C
M@Z^)*?UFEDA!_6GEKNU/V*9(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(_=&2DG
M"OVTK#2+^(E&:A5F<E%O'$>_:K$$#$5;/&BB+A%0I@`0$I@$!KT5--35C"J:
ML;;=IEB2D+2%)4.HI4""/&(^R@N%?:ZI%=;'WJ>M;5-#C2U-K01P*5H(4DCH
M((,278-[KFY+%2+>'O5:-S/;:!03(G>"BS2ZFZ8``%!"[6*9W+KE`/\`IJ#L
MP^',7QJ.F:]U[;S*%JJ[.'+/<%&<V`%,GQL*,A_JU-CP&)Q;4_B"[V8`VBW9
M0IG)K*@2`K"I-4GJY:M`*U>'MT/$]!$?4W+]U;+.<[,?X]LVV&.);9G6JC*Y
MGD=,.9JYYJ/7)R.8E*6,TCD8F,=D$2+`BD*ZR8B05"D$Q3?-MSW8<5PF[HO]
MWJ5W6Y,*"F4K;#;+:AP64<RRM:>*>97*DZ\I(!'(;X_B`;A;JXR]AV-4+6/V
M2K045*VWE/5+S:A)30=*&@TVL3"PA'.M/DE825),5]2;B`,*1YBW5VZ=N9=O
M>W6`)+L@;7[D<&]\WJ90G*Y:GD&Q1@8%0>8PE+"0YR`<G#E<JK#IJ-52]X'<
M`Y[N`^:1?-8[?.FIY<%<I^U='^D<G(]*`CJCL8=R_9=.SNS-&+@UR99>@FNK
M)CRD]HG[!@ZF78LD<R>AU;O7&^=:.B6\>)SD2(=14Y$DDR&4444,4B::9"B8
MZASF$"D(0H"(B/``"O*4J4H)2"5$R`&I)/0(_*UH;07'"$MI!)),@`-223H`
M!Q,5(>XINB/N1SI(-[?D3.<88W.[M>QR(J&%G*+)+`2>NLI-"E.>:?)<J!Q#
M7T-%+W1UM5V`VT&WF$MKKVPG);@$O5,QY2`1]DQ/H[-)FH?UBE=0CKL=\_?I
M6]>ZSS-G?*\%LI72T0!/(Z0J3]5+0$OK$D*_J4-=),:!5O6(@1D/$N-+@S'D
MFS,8VLB96;O.>90S8P%YB-$5C\[^27X@`-HQ@FJX4$1``(F/&N`RG(Z#$<=K
M,DN9E1T;"G#^<1YJ!X5J(2/"1&:;=8/>-R<XMF#6%)5<[E5H93I,("C-;BN'
MDM-A3B]?-28NTX\L:!QE8MHX]MAN#:`LRWHNW8M/0`.9M&-4V_I"W*``9R[4
M(954W\)0YA\M4U7^]UV27NKO]R5S5U94+=6?"M1,AX$CR4CH``CM'89BEIP7
M$[=AMB1R6BV4;5.T.DI:0$\RNM2R"I1Z5$GIBLWW;\JA?FY_ZF,W)5HG$MKQ
M]M`1,PBF6?F-)Z>.(#[U<I7+5`^G`0;A5CG=5Q<V/;7]KO)(JKK4J>UX]DW]
MDT/%HM0_3,4:?B)[@?O;OM^[-,L*M^/4+=-(3D'W?[P^?');39E_5"(MZDQ$
M"(4A"D([/95F7-D2[+?L>S8EU.W1=$FVB(6*9D$RSIXZ/REU'WJ+=$FJBJIM
M"))%,<P@4HC7&WB[VZP6M^]7=U+%MIFRXXM7!*4_\I/!(&JB0!J8Y_%L8OF:
M9#1XKC5.NJOM>^EEEI`F5+4=/`$@34I1DE*05*(2"8N`;-]J=L;4<5,K49%:
MR5\3A6TID6ZTT_A)J<!(0*Q9J'*"R<#"E4,BT2'37SU3!SJ&JIO=W="Y;H9.
MNYO%3=E8)12,$Z-MS\Y0X%QR04L^)(\E(CL@=VGN_6+N^X`U8*8-OY55!+MQ
MJP-7GY:-H)$PPQ,H:3I/RG"`MQ4;;5JJ)$PI"(1^\'N5/;EJ0.VZUI$4Y6]$
MD+ER(+9311M:K1R!H.#7$A@$@SDHW%PH4?%%J4!#E4J9O=,VZ3<+F_N'<VYT
MU&2S23&A>4/M'!_HT'E!^DL]*8JT_$AWP59;!2;*V!Z5PN034W'E.J:5"IL,
M*D=.W=27%#Z#20='(KM5/Z*8H\B$.H<B:9#J**'*FFFF4QSJ'.8"D(0A0$QS
MG,(```&HC7@D)!4H@)`F2>`'68_2$+<6&VP5+49`#4DG@`.DF+9G;@VJAMQP
MHVF+HC2MLJ9.3:7!=W6(F+N#BQ(92WK3Z@<QDACVBW6=$`?\,6.4=>F4:JS[
MPNY_Q"S)5';7.;&+:5-,2)Y7%\'7Y=/,H<J#_5I!'G&.PUW*-@!LMM@W<[ZP
M&\^OB45%7S`<[#4B:>DGT%M"N=T3_7+4DSY$F)#ZT#$S(4A%:#O,6N]C=PUC
M72HFJ,?<^,VC5LN("*'I=OS,D@[;D-R@`*IIODCF#41T.`^6K&NZ%<V:G`:V
MV)([>FN*E$=/*ZV@I/B)2H#Q&*-OQ,;#4T.\=KOZPKU2NL:$)5\WFIWG0M(T
MX@.()$_G`Q$#4L8K@A2$<"`#Q$`$?T@%(\S(X0TT\.%(1S2/$=PL3'U[Y.N1
MC:&/;6FKPN61-HUAX)DJ]=&(`@!UUN0.DT:):ZG66,1),.)C`%<3>[[9L;MR
M[M?JEFDMS?G..*"4^(3U4H]"4@J/0#&2XGAV4YW>VL<P^@JKC>WCY#+""M1'
M2HRT2@?.6HI0GBH@18%V@]IRW+'4C,@;E!C[QNM$R;R-QLS4!W9\&N70Z1[D
M=!H6Z7Z)^/0)HP(8/.ZX<0@?NQWI;A>4N6+;KM*2V*FE=6H<K[@Z>Q3_`$*3
M](_:D<.3IN%[N'X>UEQ5;&7[V]C<K^DA;=M0>>D8/0:E7"J<']6/L`?.[82(
MFC001;(HMFR*3=LW230;MT$R(H(((D!-)%%%,I4TDDB%`I2E``*`:!4/%K6Z
MLN.$J<42229DDZDDG4DGB8LZ:::IVDL,)2AA"0E*4@!*4@2"4@:``:`#0#01
M[:_,>R%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"'C2$1R[XM_5D;;
MK2E+8L>:AKISA*H*LH>"9N$I%M9HJE,F>X;J]'%1%N=EKJW8J&*LX6`.8H)`
M8:D)LML7>MP[JU<[TR]2X6TH*<<4"@U$M0TS.1/-\]P#E0F<CS2$0J[U/>[Q
M;9/':BQ8K54M?NG4(*&6$*#B:.<P:BJY9I24<6V%$+<7*8#848JGS4U+7',2
MEP3TB[EYN:?NI26E'ZQW#V0D7RQW#MXZ6.(F46764$QA'W?<JSZCHZ6WTC5!
M0MH:HV4)0A"1)*$)$DI2!P``D(Z_=TNEQO=R?O%W><J+I5.J===<)4MQQ:BI
M:U*.I4I1))CYE?3'P0I"%(0I"%(1VNT[#O>_'I(VR;/N>[GRBA$BM;;@I*95
M!13WA3@P;+@F)O)S"`5Q=TOEFL;)J+S5TU(P!/F=<0V)#](B?R1D6/8CE66U
M0HL7MM=<:LJ`Y*9AQY4SP!#:52^6-W,>]K[>'?H(+N<?,K"CUS$U>7]/1\.L
MF0WB<\.S/)3A!+Y2F;D-^BM,W[O*;2V/F0W7KKGP/-IFU.`^`.*Y&_E"R(E+
MAO</[R&6A#K]G;M-(HCRZ]]MD@'I+*"X^)=1:!\$;S6'V33Z)+Y.SD0!T(9:
M-L.V1,7FY@YTRS,^Z*)BB77SO0BB`^2M*7SODIU1C=E/@74O?R]FTG^3M#$K
M,2_"[5Y+N=92)R$VZ&F)D>D!Y]8GX^P'BC;FU>TEM`M\B7RO$7U>K@F@G5N&
M\GC5(Y^.H^BVVA!)<G'@4W/^D1K55S[U6[%>H^J.T5&V>`:ITJ(_G/%TS\(E
M$C+!^'=W<K.A/[1I[K<WAQ-16*0"?T:9-.)>`S\9C-3/MZ;,6*((DP':+@`T
MU4?.)YZN;0--15<2YS?KT\:PU[?S=]Y?.J^52?`D-)'Y`V(VC2]SKNTTC0:1
MB=O6.M:ZA:ORJ>)C\TMVZ]F$NV,V4P3;3#F`2@O#R%Q1;HNOE*NTF"&`P>0?
M)7LI>\!O!2.!Q-[J%RZ'$-+'Y%-F/1<NYGW:+FP6',5HV@1YS+M2TH>)2'A&
M@>ZGM*XS@\=7?D'`TU<T).6E"R=R+69<4DG/0DO&Q#15^_91L@X11EXY^5H@
M<R(K+.B*'`""!=0,&]ML.]1D=;D%)8<X9IGJ*J>0R*AI!:<;6XH)2I:`2VM/
M,0%<J4$#764HB!O_`/AX8-:L+N.8[2U-=2W2W4KM2JBJ'`^R\VR@N.(:<4E+
MS;@0E11SK="CY)E,*%?,!U`!]WC4\HIVX1S2/$*0A2$*0C=?M^X&+G_<Q9<#
M)LQ=6A:)S7[>?.F)VRD3;RR"K*-7UT*(3,THV;B4=>9(QQT$"FK3>^^<'!-N
M:RNIE\MVJAZM3ZR(6Z"%+'^C;"USZ"$])$2C[GNT@W>WPMEJKFNTQRW'U^LF
M)I+5.4E#:NC[9XMM$'BE2S(@&+@P````%`"E```I0```H`&@``!P``#PJI@D
MDS/&.R(``)#0"%(\Q%YW1]T@81PT;&EK2'0R/F!H]B$C('$',#8_+Z-<<R(D
M,!D%Y$JOH+41\145.7BE4E^[/MG^^67?O'<V^;'K2M*S/@[4\6F_"$2[1?B2
MD^?$#._KOV-K=M#@]A>Y<TR-M;0Y3Y3%#YM2]H04J=GV#1_.<6-6XJR>'"K-
M(H*CFD(L`]GG;0=DRG]S5U1W(M))N[1QD5TEYY6!5.2Z+E;@8=2@Z63!@@?3
MB0B^G`W&"7>UW&2\ZQMQ:W)H;*7ZSE/SI399/Z(/:J'64=(BX/\`#;V.52TM
M7OCD#,G7@NDM@4->0&554IGPYB.P0J7`/="A.<6X)V-M:!F[FF5P;1-O1,C.
M2;@=/@6$4T6?.U.(@`B5!`V@:\1X5"RWT-1<Z]FVTB>:JJ'4-H'6I:@E(_*8
MM3O-VHK!9ZJ^7)7);J.F<?=5U-M(*UGY$I,4=,HWT_R=DB^\B2AA%]>UV3UR
MK%$QC=():1<.T&Q!-YW3:MU")D#R%(`5=+C5D8QO'J&P4WZBCI6F1X>1`23X
MU$$GPF.JOGV5UF=9M=LRKR?6[G<'ZE0^CVSBEA(\"`0D=0`CHE<W&(PI".2E
M,<Q2$*8YSF`I"$*)C',80`I2E*`F,8PCH`!Q$:\$@"9T`C])2I:@A`)43(`=
M)BSWVS-DO\QEI)YER3%D)EN^(P@Q$:[1#TBP;3>IE5(R$%`YF]PSB9BG>Z`!
MD$N1#@/5YJVN\?O+^^MU.(8ZZ3BM$Y]HM)TJ7TF7-IQ:;,PWT*5-?T97N=QG
MNN?"G'4[EYM3@;A75@=BVM/E4%(L`A&NJ:A\2+W`H1RM:'M)RPU%J+"H4A'3
MLA7W;N,+'NO(=VNP8VW9T'(3\NX'B8&K!`RO01+XJNG:@%21('$ZIRE#B-<O
M8+'<,EO=+8+4CGN%6\EI`\*C*9ZDI$U*/0`3T1C69999L$Q2X9CD+G966VTC
MC[JNGE;23RI'2M9DA">*E*"1J8I2YKRM<&<,J7OE.YE3FD[PG7<B1N8XF)&Q
M@&Z$/$-P$Q@(WBHQ))`@!P\S7Q$1&X[#L7H,,QBBQFW`"FI&$HG]-?%QP^%:
MRI1\<HZO>Z.X-XW3S^Z9[?%$UUQJUN!),PTW/E:93J9)::"&T^!,^),8MK)H
MP")6^UGM,-F7*`9BO.*%;&F*I!!RP2=I@+2YK^1Z;F*CRD4*)73&``2O'.FI
M>J"*8Z@<P5%[O-;IC$,9_=*T.RR.Z-D**3Y3-,9A:ICS5.ZMHZ>7G4.`BP;N
M#]WE6Y>>#<C)J?FPBP/)4V%CR*FO$ELMR/G(8T>=Z.;LD&84H1:"JM6+XH4A
M"D(CX[C^U^1W)8-ZMHM`>9'QF[=W5:;0H%!>;9*MBI7';:!C"7^4R3-`BK<N
MOGN6R9/X6M;[[O.Y5/MWFO)=5\F/7)*67U=#:@9M/'P(42E74A:CT1#GOK[#
MUF]NU7:8\WVF:6-Q=52($N9]!2!44R2?G.(2E;8^<ZTA/SIQ4N707:KK-G**
MK9RV540<-UTSHKH+HG,FLBLBH!5$E4E"B4Q3``E,`@/&K3D+0X@.-D*;4`00
M9@@Z@@C0@C4$<8Z\+S+M.ZIA]*D/H44J2H$*2H&1!!U!!T(.H.ACU5^H]<*0
MCZD)!S5RRK.#MV(DIV:D5B-V$3#L7,C(O%SCH1)LS:)JN%CB/D*4:^:LK:.W
M4RZVX.ML4;8FI;B@A"1UE2B`/E,<C:K3=+Y7M6JS4S]7<GE!+;3*%..+4>A*
M$`J4?`!$M>V_M&99R`JQN'.S\V);2/TG'U=;>BR60)1$3"(H*-@.K&VR"A2Z
M"9R99P34-6_N17W#[UF+6%*Z#"6_VK=1,=J9HI4'KGHMZ74@)0?ZR+$-D_PZ
M=PLO6U>=UW3CV/F2O5T\KE>Z/HE$RW33'2Z5.)GJSU3[83V]XAV\VV6V<46=
M'6XW433+)2HE],N*=53`/Y1.3K@#R$@H)@U`IC`DGKH0A0X5!;,L^RS/KB;C
ME%6Y4+!/(CS6F@>AMH>2@>$#F/SB3K%O&UVS>W.S=E%DV_MK-$T0.T=ESU#Y
M'SGWU3<</2`2$)X(2D:1FBL.C9\*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A
M2$*0A2$>M55)!)5==5-!!$AE5EECE2112(43'455.)2)ID*`B(B(``5^D(4X
ML(0"I9,@`)DD]``XQ^''&V6U.O*2AI()*B0``-223H`!J2>$1]Y^[EVVG!IG
ML.RGU,J7HUZB8VWC]5L_9-71-`!&7NDY_D-@`&'0X)'=+DTXI5OG!>[EN+F@
M15O,"V6=4CVU4"E1'6VS^L5X.8(2?I1#S=[OQ;(;5%VW4M6J_P"2MS'JU`4N
M(2H:2=JB>P1KQ""ZX)'[.(0-P7<XW(9O!]#0DNGB2R7751^0+&77;S#MHH44
MQ2F+M/R2SD3D'SRMO1$AU]X-30P/NW[>89R5=8R;K>4R/:U(!;2H:S;8\P>`
MK[17ABJ_>+OU;U;I=M;+54C'L7<F.PH5*2\M!$I/59D\HD<0WV*#THB.M111
M511550ZJJIS**JJ',HHJH<>8ZBBAQ$YSG,.HB(B(C6_TI2E(2D`)`D`-``.@
M1#!QQQU9<=45.*))),R2=223Q)/&/&O,?B%(1QX>-(1L9AK:7N%SXJB;&>,I
M^6B53D(>Z)%$L%:B!3"(<YI^7,T8+@701$J!EE!`!T*.E:^R_=/`<&21D=R8
M:J@/U*#VKY_U3?,H>-02/#&Z]L^[OO'NXM*L(L=946]1`-4XD,4J9])J'BAM
M4NI!4K31)B4C%/98N!T#9]FG+<=$$,4IUK>QY'*2KL!X"**MPSB;-HD8.(#T
MV:P>4#5&C*.^)0-%3&'6IQU4Y!VJ4$)\8:;*E'Y7$^*)Z[??AA7BH"*O<[(6
M:9)`)I[>V75^(U#X;0#T>2RL=2HD=QGVV]H6,@060QBC>LH@)#A+Y#?N+H6,
MJ3313Y-6]'@4M1\A&A0]W6H]9'WB-U\CYD+N1HZ94QR4J0R)'HYQ-T_*X8FM
M@W<D[N>#!+C5C3=*Y,CVMP<55$D=/9'EIQ\C(C=:%@(&VF2<;;D'#V_'(E*1
M&/@XQE$LDB%]Z1)JP0;H$(7R`!0`*TY65]?<7C47%]ZHJ#Q4XM2U'QJ423^6
M)06NS6>QTJ:&RTE-1T21(-L-(:0`.@(;2E('B$?7KY(Y*%(0I"%(0I"-.]^.
M:XO!VV/),XY<HEG;JA7U@VBQ,8O6?SUU,G$<)DDQ.4YB1D:HN[4,`"!2H^Z(
M`.W-CL-JLTW(MU&VDFBI7DU+ZNA+;*@O4_GK"4`=)5$:^]KNA;]J]B[W='W$
MBZW"E704B#+F6_5(4W,"8)#31<=41P".L@&G*`:``>X&E6WQUK#J9QS2/$*0
MA2$*0BS;V@L(EL;!$QEN49&1N#+LR<8U59+D53LJVU%F,7TC&`#=&2EC.U_*
M4Y`3$*K@[V.9F]9NSBM,N=!:F?+`.AJ'@%+GX4(Y$^`\PB]3\.+:P8IM/4[A
MW!KEO&15)[,J$B**F*D-R/&3CQ>7U%(;(B7"HIQ8I'2<CY"M7%%BW1D6]9$D
M7;%HQ+F7E79M!4%)`H`BT:IB8O7?/W)B(()@("HLH4OEKF<>L%SRB]TV/V9L
MNW*J=#:$]$SQ43T)2)J4>A()C%LUS*P;?8I7YGD[P8L5NIU/.JZ9)X(0/G..
M*(0VGBI:DIZ8IE[C\ZW)N-S!=V5+C,JC\M/3(0$0=3J)6]:[(QTH.#0T\S^2
M--#*F#@HX.H?^%5ONWN$V[;[$Z3&+=(]BB;JY2+KRM7'#^DKS1T)"4]$=9C>
MS=>][T[D7'/KT5)]:=*6&B9BGI4$AAA/1Y"-5$><X5KXJ,8,K-8U/&=MMN![
MEW(Y@M3%=M@=`)=R+NX)@$Q.C;UKL!(K-S*XZ"4!;MAY$2FX*N5$R>)JPG<3
M-[=MYB55D]QDKL4\K3<]77E:-MCQG51'FH"E=$;:V0VEO>]FY%OP&RS0*ASG
MJ'I3%/3-R+SRNCR4Z(!\YQ2$<51=`LJSX#'UHVU8UJL4XVW+3A8^!AF212E!
M%C&MB-D1.)2E!1=4"<ZAQ#4ZAC&'B(U3[>;O7W^[5-ZN:RY<*IY3KBCTJ623
M+J`X`<```-!'9PQ;&K1AN.4.*6!I+%EM]*VPR@="&TA(GUJ,IJ5Q4HE1U)C2
MGN:Y)-CG9_D0K=4R,E?BT1CR.,0PE.`7`Z%:6$!*(&`!@6#HNH>!C!6X^[?C
MHR#=BWEP3IJ$+JE_ZI,D?^:I!^0Q%_OSYLK"^[C>4L*Y:V[+9M[<C(R?5S/>
M'_=VWAXR(J/U:K'75A2$*0B9WM:;)_YPYYGN-R=$\UC6K)<V.X200YD;MN=@
MIYUP+H+$$CB`MUP71+4!(X>E\I43`:('>9WD_=^A7M]C;O\`^;JF_P"].).K
M#*A^J!'!UT>=TI;/6L2LW[A'==_?*[-[T9U3SQ6@?_\`Q[#B=*NJ;/Z]22)*
M8IU#R9S#CXEYK2@JR!5><78PI"%(1#MWELE2-MX/L/',<X,@GD>\57,X!#"4
MSF&M%LD_(T,)1#F24F'C8Y@'@/2"I;]T/':>XYG79!4)YE6^D`;\#CY*>;QA
MM*P/TC%;/XE^<5MDVLM.%T2RA%ZN2E/2TYF:1*7`CQ%Y;2B.'D"*U=6*11[&
M3L-8ENW.62[3Q;9+07,]=<FFS(L8AS-8M@35:4FY$Q`$4HZ(8D.NJ;R@3E#4
MQ@`<;R_*K5A6.5637E?+0TK95+I6K@AM'6M:B$I'AF=`8SS;+;O(=ULXM^!X
MNV5W6X/A`,B4-('E.O.$<&VFPI:SU)D)J(!N=82P_:>!L76CBNS&X)0UJQI&
MQW1R$*ZF)1<PN)><?B0//>RT@HHL?B(%Y@(70I2@%0&9Y;=,XR6KR>\*G5U3
MD^69Y6T#1MM,^"4)`2.N4SJ3'9KVLVWQ_:3`[=@.-(E;:!@)*R`%/.J\IY]R
M7%;KA4M75,)'DI`&5:Q>-@PI"%(0I"(UMUO;-Q%N-F']]V[)+XKR5(B*LI,Q
M$>C(6[<CH"\H.Y^WNLS_`,8GT#G=-ED5%=-5`4-QJ16U_>.RO;ZD19+@VFYX
MZWHAM:REUD?1:=DKR.I"TJ`X)*1I$'^\#W&=NMZ;D]E=E>58,W>U=>:;#E/4
MKEY[]/S(^T/SG6EH4KBL+5K$;KGLL9Z(\%-IE;$B[$3&Y7:XW>V<`0.7E%1F
M2WW)2J'U'@54P!IQ'C4AF^^)@Y9YG;7=4O\`T1V"A\BNU3IXTCQ1"=[\,+=E
M-3R4]_QY=+,^6HUB52TE-`IE@$ZZ!9&G&,]XP[*UN,7;=[F',$A/MTSE.M`6
M%#D@T5P#Q24GIE20="F8?*FU2-^D/&L'R7OBW!YI3.)6EMAPC1VI<[0CP]DV
M$)GXUJ$;<P/\,&RTM0BIW(R-VK:!!+%`R&0?`7WBXJ7A2RD^$1+%AS;AA+`<
M<$?BG'D!:ZAD2HNIE-MZ=<DB4I=!&1N*0,YEW7/XB45>37P*%1;R[</,\ZJ.
MWR>O?J4SFELGE:1^BTF3:?'RS\,6$;:[)[7;140I,`LU)0N%(2MX)[2I<`$O
MM*APJ>7/J*^7J`C-U87&U(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"
MD(ZY==X6I8L([N2]+D@[4@&)#*.YBX91G$QR)2E$VAG3U9%,RA@+YI`$3F'@
M`"-<C:[1=+W6(MUGIGZJN69);:0I:C\B03+K/`=,<)D&2X]B=K<O>3UU);[0
MT"5O5#J&6TR$_.64B?4!J>`!,1/9V[P>'+),]A<*V[(Y:FT@423N!\+BVK(0
M7*82@HFHY0^79I(!#71)!NF<.)5M.-2CPCNEY=>0BLS&H;M5&9$M)D]4$=1`
M/9MGQJ41THBO?=G\2';;%E.VS;&C>R"ZIF!4.<U-1)4#*8YD]N\/T4-I4/-=
ME$*N=][&XS<0HY;7W?SYG;"ZAC)V1:O-;UJ))"(\B+ADS4!S,`F`\#/EG)M>
M.H5,;"-F]OL`2ERR4*%W)(UJ'_M7R>L*4)-SZFTH$5?[L]Z+>C>5;C&5W=UJ
MQ+.E%2SIZ4#H2IM!YGI=;ZW3X1&I_AX5M&(]1S2$*0A2$92PYAG(>>K\BL=8
MS@E9RXI0PJ'$1,C&Q$>F8A74S./^0Z4;$L@.`J*F`1$1`A`,<Q2CC.79?8,'
MLCN09&^&;>U\JUJ/FMMIXK6KH2/"20D$C/\`;3;+,MV\LI\,P>D557A\S/0V
MTV".9Y]R1#;2)CF6>DA*0I:DI-D?;%VM,)880CKBR<W:9BR*D"2ZBLTUYK&A
M791*?DA;;7`4Y$4CET!Q(`J8WB5-+PJO'<GO-9EEZW+?C2EVC'S,`-G^\N)X
M?:.C5$_HM<LN!4KC%VVQ7<'VOVS:9O.=(;R3,D@*)>3_`'%E8D9,TRA)V1'Z
MRHYY\4MM\(D^;MV[1NBT:((M6K=,B+=LV230;H))ARD2112*1-),A0T`I0``
M"HUN...N%UU14ZHS)))))XDDZDQ.YEAFF933TZ$ML(2`E*0$I2!P``D`!T`"
M0CW5^(]L*0A2$*0A2$*0A2$=1ON_+0QE:4W?-]SS"VK5MYFH^E9>15!-!!(@
M>:DD0-573QR?0B*"13JK*&`A"B80"N6L=CNV275FRV1A=1<ZA82A"!,D]9Z`
MD#52C)*0"20!&.9;EN.8+CU5E>65;5%8*-LK==<,@`.``XK6HR2A"05K40E(
M)($5*-\6[^;W99-"2:D>1&,;2%S'8^MMR8"K`W5,4'MQRZ29C)?+<V*11,`"
M8&Z!2)`(B!S&M1V7VGHMK,<]7=*'<DJI+JGAPF/-:;)U[-N9EPYU$J($P!UW
MN]5WC[IWA<Y]=IP[3X-;^9N@IE&1Y21SU#H!EV[T@2-0V@(;!/*I2M)ZW)$6
MX4A"D(4A'9+-ME[>EW6M9\<'\ONJXH6W68Z"(%<34BVCDE#`''D3,XYA]P`&
MN.N]R9L]JJ;M4?J*6G<=5XFT%9_+*4<YC%CJLGR.@QRB_P![KZQFG1^D\XEM
M)/@!5,^"+QUBV=#X\LNU+$M]`K>%L^WHFW(U,I2E_DL2R19D4.!0`!67%(3G
M-XF.81'B-4LWR[U=_O-5>Z\\U95U"W5G\Y:BH@>`3D!T``1VJ\2QJVX;B]OQ
M.SI"+9;:-FG;$I>2T@(!,NE4N91Z22>F.T**)HIJ++*)HHHIG5565.5-))),
MHG4444.($(FF0HB(B(``!K7&I2I:@A`)63(`:DD\`!UF.><<;:;4ZZH):2"2
M29``:DDG0`#4D\(J_P#<MWO)Y\NC^:'&<FJ?$-DR9E)*30.)4+_NQD=1'Y33
MY=!4MV'$3$9`;@NKS+Z:=+2RGNZ;,*P6V?O7D;8&65C<D(/&F85(\AZG7-"Y
M+S1)''FG1!WX>].C=R_?#G!WU';JUODN.I,DU]4@E/:CKIV=4L3T6KF>E(M\
ML4M2@BOF/---191-%%,ZRRIR))))$,HJJJH8")I)IE`3'44.(`4H`(B(Z!7A
M2DH25K("`)DG0`#B2>@"/VVVXZXEII)4XH@``3))T``&I)/`"+7O;@VB?NVX
MI&Y[PCTTLMY+;,I*XP4(47-LP`D*YA[0`P@)DG"'4Z[X`$-71@(.O1*-5==X
M7=?XAY1^S+2X3BMN4I#4N#SO!Q_P@RY6_P`P<WSS'8/[E'=S^"6W_P"W<C9"
M=P[XA#E1,>52T\@IFD\"A/M'Q_6D(,^R28D=J/436B$_O82;E#%V$8A,YBM9
M*_;B>N2`;0IU(NWTDVX&+IYPE&1.(#KPJ9/<WIVUY+>:I0':-T+21XENDG_J
M"*O/Q0JUYK`<8MZ20P]=JA:A/0EIA*4S'3^M5%=*K`HI:A2$;B[*-I\YNNRR
MUMP0=QV/;;]&E\BW(@0Q09Q/5'H0C%<0%,)RX#)&10#B*9`46$!!/0=2;Q[H
MT6U^+*N`Y'+_`%$VZ1D_.7+5Q0_JVIA2NL\J.*M)+=UWN^77O`[A-V8AQG#Z
M+E>N-2!YC4_)90>';U!!0W]$!;A!""#;]MJVX.SK>A;4MF,:PUO6[&,X>&BV
M28)-6,<P0(W:MTB!Y")D#41U,8VHB(B(C53ERN-;=Z]ZZ7)Q3U?4.*<<6HS*
MEJ,R3\I\0X#2.Q[8[):L:LU+C]B8;IK-1,(99:0))0VVD)2D#P`:GB3,DDDF
M/MU\4<K"D(4A&B&__:5(;L,31L3:C]C'9"L>67N"TC2BAF\7+`Y:"TE(!\Z(
MFJ9D$BB4AD5A*)4UTB\^A!,(;OV(W4I]KLI<JKHA;EAK6@T_R":T25S(=2F8
MYN0S"D\2DF6H`B)G>_[N]9W@]O6;?8'FF<PM50I^D[4\K;O,CE=IUKD>3M`$
ME"Y2"T)YI)*B*]*7;HWGK3I8#^8VX$W`K]`9%:4MM.!*'-RBN:<&9&.%``X\
MP'$1#P`1X5/A?>!V?10FO_;3!;Y9\@0\7?%V?9\\_DBFUKN7=YER["S_`+JU
MB72OE[0NTP8'YW;]MV7+TS"B?!$]&P'8HAM0@Y:Z;T>Q=P9?N]HW9R;R,`ZT
M5:D(F8K@;=A7;A-)9VLX=:'>.N1,%3)D(0O(3F/!W?;>U>Z-:U;+.AUC$Z19
M4A*]%ON'3M7$@D)`3HVB9Y0229F0MO[H7=/9[OMKJ+_DSK%9N-<6TH<6W-35
M(R)*-.RM0!6I2Y%YWE2%%*$I'*GF7([4>HFM"D(4A"D(4A"D(4A"D(4A"D(4
MA"D(]+APW9HG<.UT&J"91,HLY6302(4H:B8ZBIB$*4`\1$=*_;;;CJPVTE2G
M#P`!)/R"/4^^Q3-EZI6AME(F5*(2`.LDD`1A"[MS^W2Q`/\`6S-^,(<Z8B!V
MZMXPKEX4P:^8+)B[=.^IYH^;R<P^Y6:6K;7<&]D?LNS7)U)Z0PX$_64D)EX9
MQJS(=]]E\4F,@RFQ4[@^::QE:Y]79MK4N>G#EG&LEV=TW9E:XJ)MLA3-WKIB
M(&1M*SK@>`80T_9NY1I#QRH&UX"580_36Q[5W9=W[F`IV@9I$'I?J&D_E2A3
MBQ\J8T7D/?X[L]A46V+Q4W%U/124=0H?(MY##9\861X8^G@;N2;<=P-]1V-[
M;6O"V[NFS.B0#*[H-NR:3:S5%1R9HRD(Z1DT"/CM43J%26Z7,!1`HB;A7S9Q
MW>-PL$LCF17!-)46ID)+JF'"I38)`YE)6A!*0H@$IG*<R`-8^_:7OM;+;OY6
MSA5E5<:+(JHJ%.BK92A#Y2"KD0XTZZD+*4E02ODG*0)5I&_M:*B7L*0A2$*0
MA2$*0A2$*0C$>7<\8AP1"?+V5[\@;/:'3449-'SGK34J*8"(IP\$T*O+RBG,
M&GP*)P`1#40K*\4P?+,WK/4<7H7ZMT$!2DB3:)]+CBI(0.GRE"?1.-<[C;M[
M<[36O]K;@7:DMS!22A"U<S[LN(981S/.GH\A!`/$B(6\^=Y>2<&?06W.QDHY
M#X1!*_L@)%<OC><``ZB;1:K"T;CR@(D,]76\?.1\E3#P;NATS816[@UI<7H3
M34IDG]%;ZAS'PAM*?`N*Q-WOQ,*UXNVG9BU)9:U2*^O`4YQ\YJD0>1.GFEYQ
MS\YKHB'#*.:,J9JG#W#E.^[AO23$QC(?*[XYF#`#?WJ+B$`1BHI$/XC=%,M2
MYQK#\8PZB%!C-%3T=-+7LT^4KPK69K6?"M1,5J9[N?N!N?=#><]NU9<ZZ9Y>
MU6>1N?0TTGE::3^:VA(\$8QK)(P.%(0I"%(0I"/MVU;4]>-PPMJ6O%NYNXKB
MDFD1"Q+%(RSM_(OEBH-FZ)"^4ZA^)AT*0H"8P@`"-?%<;C0VB@>NER=0S;Z=
MM3CBU&24H2)DGY/E)T&L<M8K'=LFO-+C]B8<JKS6/H99:;',MQQ:@E*4@=9/
M'@!J2`"8MX[)-HEN[3\8(Q9R-I+)EU(,I'(MS%*10RL@5+G2MV*6T$R<!!'5
M,FD`"'I"O,L8-3`4M46\VZ]PW1R0U*2IO'*52D4C/"29ZNK'2ZY($_1$D#@2
M>QKW6^[G9>[Y@J:%00]G%P0ARXU(D9N`3%,TKHIV"2E,I=HOF=4`5!*=T:T]
M$G84A"D(4A"D(4A"D(4A&#\^[AL8;;;&=7UDV<38-OA$(6#:F27N&Z),I.<D
M7`1IE$U':X\!44$2HH$'F4.4/'-<%P#)=Q+TFRXXP5N:%QQ4PTRCZ;JY'E'4
M-5*.B03&J]W=Y<$V2Q5S*LYJDLLZI883(U%4Z!,-,-D@J5TJ49(;3Y2U)$55
M=V^\_)V[*Z`<3ZQ[;Q]$.#FM+'<:Z5-%QY0$Y22LRIJ4)JXUTC?".#E`B0")
M$2D+KS6>;5;/XWM;;.SH0*B_.I';U2P.=76AL?T;0/!(,SQ6292Z_P#WBN\Y
MG/>$OW;791HL/IUGU2WMJ/9-\1VKQT[:H4#Y3B@`D>2VE"9@Z>5MJ(UPI"-X
M-J^P7-.ZR-D+FME2%LZQF#E6/+>%V^GD92LHB759A!LF#9=W)BU-H5=8.5%$
MP@43"?4H:7W-WSP[;"H;MMR#U7>G$A78,<O,A!X*<4HA*)\4IU4H:R`UB56P
M/=$W-W_HGKY9#36W%65EOURKYPAUT#5MA"$*6[R:!Q0`0@D#F*II&IV0+*F,
M;WQ=M@7!T!F[-N"4MR4,U.91JH\BG:C155L<Y2',W6%/G()BE-RF#4`'A6TK
M#>:3(;+2WV@YO4JMA#J.824$K2%`$=8G(^&(\YAB]RPG*KAB%XY/VI;:QVG=
MY#-)6TLH)22`2DRFF8!D1,`Z1U"N6C&XS-MTNV)L3/6'KQG2I#"V[D6U)*4,
MO^Q18I2S8KERKJ(?!M$CBJ/'@!*P_<&U55\P>[6BBGZY46]]")<2HH,@/"HZ
M?+&S]E<BM^);MXYDEV"3;*.\TCCO-YJ6TO(YE'P($U?)%V61FH>)B75P2DK'
M1T"R9'DW<R]>-VT6VCB)]<SY=^LH1LFU!'SNH)N73CK5-M/1U=55IH*9IQRM
M6OD2VE)*RN<N4)`F53TE*<=HJLNELMUM<O%?4,LVEIHNK>6M*6DM@<Q6IPD)
M"):\Q,I:SBNEO_[E)\H-YG"N`9!RSQXL*D?=]_I==G(7JF0YTW$1`!JFLRM1
M80T56,!5GQ?-`"(B/5L#V)[NHQEQG,<Z;2N_B2F*4R4FG)U"W>(4^/FI$TMG
M75<N6E[O?]]]6>,U.V&T3RV\.42W5UXYD.5H!(4TQP4BD5P4L@+?&DDM$AR&
M&I?Q6/"D(FK[66R4U[S,?N4RA$`:S+=>F4QC!R"("E<]QL5C$-=+ENJ405A+
M?<IB#74.5P]+S>]1\^'7>:WE%EHW-N\:=_\`R]0B58XDZLM*$^Q!'!QT'R^E
M+9EQ7I:%W!NZVK*;FSO;GE-/&J-V=L8<3I55+:I&I4D\6:=0^SGHX^)^:T>:
MQE5?,730I"(Q>ZYA*:RSMN3N2V63F2G,1W`%Y*1S1,5G+JW'#):,N,Z")"F5
M648-U$W0E+QZ2)QT$0`*DEW7<RH\6W#-NN*TMT5U8[`+49`.A06U,\`%$%`)
M^<H1!3\03:ZZ;A;)B]V-M;]TQZK]<+:!-2Z92"W4%(`));!0Z0/F-K.LA%5R
MK.8H"CON,<9WIF&^;?QUC^&<3ET7(]39L6B)1!%NF)@%S)2+C02,HN.1U5<+
MGT*FF41XCH`\'DF1V?$K*_D%^>2Q;*=!4I1XD]"$#YRUGR4I&I)C+\#P7)]R
M<KH\,Q"F757VM="$('!(^<XXK@AIM,U.+.B4@D]47%-K6W"T]KV)8;&]M=-]
M(ZA*WA<@HE2=7/=#E),K^15'3J$9H\@(M$A$>BW(4/?"81J2W-W#NNY>5/9#
M<9HI_,89G-++*2>5`Z.8^<M7SEDGA(#LH;![*8]L/MY3859.5VM_6UE3RR54
MU2@`MP](0F00T@D\C:4C57,3L96O8W3"D(4A"D(4A"D(4A"D(4A"D(4A"D(4
MA'.@CX`-(1T6[,GXVL-$[B]L@69::29!4,-PW-#1)Q*7744TGKQ%94>'@4HC
M7-VK&<BOBPBS4%95*)E]DRXO\I2D@?+&)Y#GN#XDT7LHO%LM[8$_[Q4LLF7@
M"U@GQ`$QJ)>W<PV:V3U$S973NQV0#"#2QX*9N(5!)KJ0C])HA#\PCX<SDH#[
MNE;6LW=RW=O,E"UFE:/SJAQMJ7C25%S\B#$=,I[\?=IQ::57\7!\#S*)AZHG
MXG`A+/BFZ!X91J->?>JQ:PZZ5@X=O>Y3E$P(.KEF(>UFB@!KRF.DR+<3LG-Y
M0Y>'Z:VO9^YUDK_*J^W:CID](9;<>4/E5V0_EB.F3_B?8'1\[>(XY<ZU8/DJ
MJ7F:5!ZC)L5*AXI1JC>/>;W!2Y3I6;8&-+,((FZ;AVA-72^(!N`:G=2$:Q,<
MGD'T?37Q`0X5M"T=T'`Z0A5WKKC6'J26V4_D"5JU_2B/N2?B:;OW%);QNT62
MVIU\I27JIP?*MQM$Q_HO&#&J=X]Q+>3>IU?3LW7!"-U/!I9[*&M-),HAH)"+
M0L<U?F*.O'G6.(^[6T+1L!M%9@.PLS#RQ\Y]3CY/R.+4G\B1$?<E[YW>4R=:
MC59164K*OF4B&:0`=04PVAP_SEDQJU<N1<@WFH96[[ZO&Z3G,)Q&X;FFID.8
M1$VI22#UP0@`81T````\E;,MV/V&SIY;314E*D#^B9;;_P"JD1H2^9MF.3J*
M\CNMQKU$S_O%2\]TS_I%JZ_DCIGF@.O`!'R\-1'_`(Q&N7UC&=3XHRYCC`V9
MLN2+>,QQC.\KL6<G`A7,=!O0BD=3`45'<TY20B&2)-=3&56(```CY!K%<ASC
M$,4IU5&0W*DI4)'!;B><^!+8)6H^!*28V)A6T>YFXM8BBPNQW*X.+,@IMA?9
M#PK>4`T@#I*UI`UUTBP;L%[;CG;]/-,QYBD(^4R>@S=-[<M>(5*]A+,!^B+=
MT^=R7(!9:XCMCG2**/\`)FQ#FY3*F$#E@9OIWAV\[H5XCB*'&\;4M)=><'*Y
M4<IFE*4?,:G)1YO+60)A(!!N*[HG<F>V?NS>Y.Y+K+^=(;4FFI62%LT?:)Y5
M+6Y*3M04$I')]FV%*DIQ1"DR[5%&+&84A"D(4A"D(4A"D(T=W\[K'&U3#03M
MN(MG61+SD5+:L5-ZD5PRCWA6QG4C<+YL8!*Z0AF@`8B1O,5<*)E-YO,%;IV+
MVO;W/R_U*X%2<?HVP]4E)DI29R0TD_-+BN*AJ$A1&LHBKWNN\"]L!MI^U;*E
M#F97-XTU"%@*0VOEYG*A:3,*2RF7*@^2IQ2`KR>:*F5\W[>>3+FD;QO^Y9>[
M+FEE3+/IB:>*O'1^81$J*/./3:M$0'1-%(I$DR\"E`.%6FV6QV?'+<W:+%3-
M4MM:$DMMI"0/"9:J4>E2B5$ZDDQUY<KR_)\YOCV29=75-POE0J:WGEE:CU`3
MT2D<$H2`A(T2D#2.HURL8W"D(4A"D(4A"D(4A%A_M,[/TK=@DMSV0(H?K#<+
M9RTQ5'ODA`8FW%RB@]N\$CAJ5[/E$Z+0PAJ1F!CEX+@(0$[TV[*J^M.VUA=_
MN%.H*K5I/GNC5+$_HM:*6.ER23YABYG\//NWMV:U)WUS"G__`#%8A2+4VL?J
MJ=0Y5UDC\]\30R>AGF6)AT$3?5"^+3X4A"D(4A"D(4A"D(4A&@>\;?[C/:Q'
M.;>8&:WSF!TU$T99#-T'HL)UD]6TG>;U`3&C&6I@.1L7^5N2AYH$(/4#>NT>
MQ.1[FU":]\+HL22KRZA2?*<D=44Z3YZN@K/D(Z23Y)B#WE>]]@^P=&NS49;N
MNXZVYMT2%^0Q,>2Y6+3JTC@4M#[5P<`A)[05=LSYOR9G^]7E^Y2N5U<,XX*9
M!FD;X"*@X[JG52B8&,3'T:,C43'$0(0.8YA$QS&.(F&RW$,,QS!+.BQXS3II
MZ).JCQ6XJ4BMQ9U6L]9T`T2``!%#.YNZF<;OY,YEF>5SE9=%CE0/-:9;F2&F
M&AY+3:23)*=29J45*)4<3UE,:[A2$21[#]@ER;GYMO>U\(R-MX-AGFCZ5(`M
M9&^'K54O5MZV3GT.1J`@)7C\H"1`-2)B*WO(\;W[Z6[;6B59K,6ZG-7D>2CB
MBF21HZ]+YW2VT=5><J2.,W.Z7W0[WOK=491E*7J+:RF<\MT>2Y6K0=:>F)U"
M>AY\`I;$T(F[YEIRUK7MVR;=AK2M*'86_;5O,$(R%AHQ`K=E'L6Q>5)%%,O_
M``F,81.<XB8PB81$:R;G<[A>;@]=;J\M^XU"RMQQ9FI2CQ)/_(.`$@``(OUL
M%@LN+66FQW':9JCLE&REIEEI/*AM"1()2/Y23,J)*E$DDQ4F[D=FJ69O*S$@
M)!*A<<C$7DT/RB4BJ5RP<>^7,GJ`<P$?=8AA#ASD,'DJU/N\W=-XVBM"P9KI
MVW*=76"RXI(G_-Y2/`1'7<[[6-+QGO+9(RH2:K'VJQ&D@14L-N*EUR<*TD_2
M!'1&C-;JB*,*0C*T[G7,]S61&XVN'*-\S-@Q!$$HZTI"XY%Q!MT6O!H@+(ZX
MD6;LPX(IJ<Y$@`.4`T"L7HL)Q"VWES(J"VT3-\=)*WTM(#A*O./,!,%7SB)$
M],XV%==V=S+YBS&$7B_76IQ*F"0W2.5+JF$A/F)Y"J12CYB53"-.4"48IK*(
MU["D(D,V"[(YC=->Q;BNIN\B\*6@_1-=$J4%&ZMTOTA*L2SX%P'*(K+ET%ZX
M((^B(#H'PAR!6@]\]YJ3;*S>H6Q2'<QJT'L4:$,I.G;NCJ']&D^>K\T*B9?=
M$[K5SW[RD7F_H<8VQMSJ35.ZI-4L2(HV%:>4H:O.`_9-G3RUHBU["0D1;4/%
MV];\:SAX.$8-8N(BH]$C=E'QS)$C=HT:H)@!$T4$2`4`#W*JYK:VKN-6[7U[
MBWJUY:EK6HS4I:C-2B3Q))G'8.M5JMMCME/9K.PW36JE90TRTVD)0VV@!*$)
M2-`$@`"/J5\T??"D(\3%*<IB'*4Y#E,0Y#E`Q#D,`E,4Q3`)3%,4=!`>`A7D
M$I(4DR4(\*2E:2A8!21(@Z@@\01$8&:.T[MQRK=#J[;>>W/BB0E':CV9C;.-
M'.+<>N7"@*N7#6&E6K@D.LL83#RM3IMP,;4$O)4E</[TFX.,6Q-JN"*:Z,-(
M"6UO\X=2`)`*<01V@&FJP5F7G1`_<[\/;9;<"_+R&SNUV/U;[A6\U1]FJG6I
M1FI2&74*[$G71I26P3,-QM!MMV@84VM1;QMC:#<+3\LBFA.WM<+@DE=,NBD(
M'*T,[*BW;1T<"H<WHS5)%(Q@`QP,8`&M:;B;LYCN;4H<R%Y*:!HDMT[0*&4$
M_.Y9DJ7+3G6I2@-!(&4;XV2[N&V&PE`XSA-*M5WJ$A+];4*#E4ZD:A'.$I2V
MW/7LVD(23(J"E`&-H:UI&^84A"D(4A"D(4A"D(4A"D(:"/A2$==N.\+2L]FI
M(7;=-N6LP2+S*/;BFXV%:D#34!,O(N6R8:@'#CQKD+?:+K=G0Q:J6HJ7SP2T
MVMQ7Y$`F.$O62XYC=,:S(KA14%(D:KJ'VF4#QJ<4D?RQI[?W<>V=X_%9)WEQ
MA<[Y`3E&/L:-DKJ6.H0=!2*\8-ODDIA\@G<%+^FMM6/N\[MWZ2FK4NF9/SJE
M:&1+KY5'G_(@GP1&_+N^OW;L/YD5&0M5]2F8[.A;=JB2.@+;3V/RET#PQI7?
MO>JQXP%PAC3#MUW(<HF!M(7?,QML-#AQ`ISLHU.?>::\1*)B\.&ON;CL7<YO
MS_*O([O2TZ>E+#:WE?666D_+(Q%_+OQ/\.I.=K",;KZUP'R5U;S=,@^$H:%0
MKY.8>.-,+Z[P&Z6Y3*)VHRQ]CMJ;F*08JWU9Z0(0>!1,\N-V_;"J4/$Q6Y0$
M?('A6W[)W3=L[<`;HNON#HX\[H;3]5I*3+P<Y\<1ERK\2#?J]J4FP-6BSTYG
M+LJ<ON#J\NI6ZDGPAM(\`C3R^MX>Z')'5)=V<LA/&RPB)X^.G%K=C./B!8ZW
M`BF90$.&@$XA6V[)M+MKCTC:K+0(<'!2VPZOZ[O.K^6(V97WD]^,U"D9#E5X
M<949EMM]5.W]U3]DW+P<NO3&N;MTZ?KJ.G[EP^=+&$ZKEXNJZ<*G'Q.HLN=1
M0YQ]T1$:V"TTTP@-,)2AL#0)``'B`D!&EJBJJ:MY515.+<J%F:E*45*)ZR22
M3\L>BOW'HCZL-!3EQ.TX^WX:6GGZI@(DRAHUY*.U#FX%(1LQ176,8WD``U&O
MEJZVBM[1?KWFF&!Q4XM*$CQE1`CDK;9[M>:D4=HI:BJJU&00RVMQ9)X`)0%*
M/R"-NL?=OC=[DCH*Q.&;@@V+@H'+)7LJQLYJ"8CH)Q2G'#60-R^4I4#&]P!K
M5-^WZVHQ[F357=AYY.G)3A509]4VPI/Y5`>&)%8=W.>\9FO(Y;\:K*6E6)AR
MM**-('614*0Y\@03U"-W;`[+&49(45\EY;LVU$3#\,RM2,D[M?D#0!T!P^&W
M67-QT'3F#7RCY=,W[OB8S3<R,<M595+'!3RT,)/R)[57_)$I\/\`PP\\KN1W
M.,AMMO;/G(I6W:M8'Z2_5D3^4B-V;$[/VURVBHJW<_R!D5V02F4+*3R=OQBA
M@#SB@QMQLQ=%2,/@4SDXA_&&M-7OO9[EW$E-J;H;>T>'(V75C^<Z5)GX>0>*
M)1XE^&_L/8DI7D3UWO50"">U?%.V3X$4R6U@>`ND^$QN=8>T?;-C/IFLS"./
M8UPD4A22#N!;SLK\'Q(8TK/_`"G('4`>/,*FNM:?OFZVX^1S%WO->XV2?)2Z
M6T:_F-<B)>"42:Q/NZ;&8/RJQK%K.R^D`!Q;"7W=.![6H[5R?3/FG.-AD446
MR*;=LBDW;HD!-)!!,B**1"@`%(FDF4I"$*`<``-`K`5K6XLN.$J<)F2222?"
M3&Y&FFF&PRPE*&4B02D``#J`$@!XH]E?F/9"D(4A"D(4A"D(4A"D(T'[A6U"
M7W48>8Q]G+MDLB6%*K7':39ZL1LRG"N&HM):WEW:@@FS4?MP*=!4_P`&5=(A
M3B4AC&+O/8/=&EVRRU;]V2HV"N:#3Y2"5-R/,AT)&J@DS"DC7E42)D`&(O?'
M[OEQW]VW:H\;4A.96E]512)60E#X4GD=IU+.B"XD)4VH^2%H2E12E14*I=\X
M]OK&<X\MK(-I3]G3C%8Z#B.N",=1RO.0PEYT#KIE1=H'TU(JD8Z9R\2F$!UJ
MT&RW^R9'1(N-AJV*NB6)A;2TK&O7(S2>L*`(X$1U^,JPO+,'NSECR^W5ENNS
M2BE3;[2FU3'2GF$EI/0I!4E0U22-8ZDW06>*E0:(K.USB`$1:I'<+&$1T`"I
M(E.<PB(^0*Y5Q:&DE;I"4#I)D/RF,>:IWWW`RPA:W5<`D$D^(#4QLYC+9=NA
MRZ=N:S,-7@:/<F*!)RX&'U3@@*?P5^4[C-&H+)?I2ZE:WR3>#;7%$J%WN]('
MTC]6TKMW/%R-<Y!_2E&],%[L6^^XJD*QK&KD:-9$GZAOU5B1Z>UJ2TE0\*"J
M)"\>=EG*,JF@YR=EFT+/(?BK&VM&2%W2"("`"`'=.U("/!0!'00**A?<,-:#
MO_?#QFE4IO&[75U9'!;RTL)/R)#JI>.1\$3(PS\,3/*]"'\ZR"W6T'SFJ5MR
MK<`\*E&F;GUR*AU$QH5O-VMFVEY6:8[)>*5[L)2VF%S1LL,>2)D$F[MR[9J-
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M5F+AD?'L8E@QBXQH@PC8UHVCX]BU3*BV9L6:)&[5JW2(`$20;H)E(4H<`*&E
M5*U#[U4^NJJ5*74.+*EJ)F5*49J43TDDDDQV2*.CI;=1M6^A;0S1,-I;;0@`
M)0A"0E"4@:!*4@``<`(_77JCZ84A"D(4A"D(4A'X)65C(.-?3,U(LHB(C&RK
MR1DY)TBR8,&B!1.LY=NW!TT&Z"1`U,8Q@``KWTM+4UM0BCHVUNU;B@E"$)*E
M*4>`2D3))Z@(^.X7"@M-"[<[H\U36YA!6XZZI*&VT)$RI:U$)2D#B20(@:WE
M]V$RGRIC?:T[,0GP[&8S"J@)5#>*2J-AL72>I"CQTDER`/E03]ZK4X=H>ZV$
M]GD.YB)JT4W0`Z#I!J5).O\`H4GP+5Q1%2G>9_$(4OM\*V%<(1Y2'KN4R)Z"
M*%"AH./]Y<$^EI`\EV((I&1D)A^\E99\\E)21<JO)"1D'*SQ\^=KG%19R[=N
M#J+N%U3F$3'.83"(\1J;M/3T](PBEI4(:IFTA*4(`2E*1H`E(D``.``E%3%=
M75MSK'+A<7G'ZYY96XXXI2UK6HS4I:U$J4HG4DDDGC'XZ]T?+''AXTA$P.Q#
MMH3.8#Q66,\1\C;F+`Z#^WK24$["?R!RJ`=-9\0Q2NH:TU"EXG\QR]*.B7(F
M/5&)N]_>,H\32[B^$.-U&3:I=?$E-4NFH2?-<?'5JAL^=-7DQ9%W3.X[=-QE
MT^X.[++U%@0Y7*>D,VZBOD9@K'G,TAEJK1QX'[/E0>T-DF$A(>VH>-M^WHMA
M"0<,S0CXJ)C&J+*/CV+8@)H-6C5`I$D44R!H``%5WUM;5W&K<KZ]U;U:\LJ6
MM9*E*4=25*.I)B[>U6JV6.VL6>S4[5+:J9M+;3+20AMM"1)*4)2`$@#H`CZE
M?-'WQ`;WGL)/U'&.-P$2R,JP19CCF\5T4Q$6B@.G,K:KUV8H>:BX,Y=M^<>`
M'Z9==3%`9T=S_,V`W<,$JER?*_6V`3YPY0AY*?".5"Y=7,>@Q41^)MM;5K>L
MN[]N:*J1+7[.K%)'F$*6[2K7U)5SO-\Q^<$)XD3@4J<<5'0I"%(0I"-[]DNQ
MZ]-UUUI23Y-];>'()\4EV7ET^DK(*(@"A[<M;K$$CV7<`(%55`#(LDS<YQ$_
M(F?2.\F]%GVNM9IV2BHRU]'V%/.82#IVKTM4MCYJ=%.$2&G,H2U[KG=6R?O`
MY`FNJTNT6V]([*KK)2+A&IIZ7F$EO*T"E2*&4GF7-7(A=K^PK"M'&%H0-AV)
M!L[=M6VV*4?$Q3$G*DBBGQ.JJ<=5'+QTJ)E%EE!,HLJ8QS")A$:JXOM]NN2W
M9^^7MY=1<ZA94M:CJ2>@#@$@:)2)!(````CL'XCB..X)CE)B>*4K='8*)H-M
M-(&@`XDGBI:S-2UJ)4M1*E$DDQV^N)C)(4A"D(4A"D(4A"D(4A"D(4A"D(>3
M4>`!Q$1X``>41'P``I`Z:GA&%\@;C<#8L35/D'+M@6PJB&IV#VY(Y67T`=!$
MD*R6=2RO'AYJ(\:S&P[>YQDZ@+#::ZI2>"DM+#?WB@$#Y51K#+]ZMI,!23E^
M16BA=3Q;74ME[Y&$%3Q^1!C1G(/=YVKVF"Z%IIWSDI^D)RI_(<#\BQ*ARCIH
M,G<BT<MR&\ATVRI1K=5A[J&YMT*5W4T5N8/'M'>T6/YC(6/D*Q$4\Q_$:V#Q
MX+:QY-UO=6F8'8,=@T2.MRI4VJ7A2TL1HQD+O2Y5E`<ML9XILVT$#B8K>2N>
M0DKLE"%$/-4!LU^0HU)4!\ABKEK=E@[GF+TO*YD=TK*MP<4,I0P@^":NU61X
MBDQ%',OQ.\_K^T8P:P6VW-$D)<J7':MT#H/*GU=L'P$+$:27WW!]X&017)*9
MJN.$9N`$IXZS$V%H-0(;4#)@I!M6K\Q#%'00.N8!"MRV38;::PA)IK/3O/)^
M?4%3ZI]<G"I,_$D1%O+.^+WCLP*TUV3UM-2K$BW1AND3+I$Z="'"/`I9C4F;
MN"?N5V9_<<Y,7`^.)A,]G)1]+.C<PZFU</UW"O$?TUM2CH*&W-=A;V&6&!\U
MM"4)_(D`1'>Z7J\7RI]<O574U=6?GO.K=7]9:E*_ECY%?7'&1P(@'B.GZZ1Y
MX\([M9V-LAY#=D86'8MW7D[.(`"-LV]*S.GG<G,H=@U7323*;Q,8P%+Y1"N&
MN^16"P-%^^5M)2-#I>=0W^3F4"3X!K&4XU@V9YE4"DQ.U7&Y5!,N6FIW7I:R
MU[-"@D`\29`=)C>/'?:PW?WWT%Y&S87'4>L;SG=^7"S9.4RAIJ(P\.$S+`<2
MCP`R1`$>`B'DTOD'>;VGL?,BGJWKA4`>;3-*4#_K'.S;_(H^(Q*G#>X)WC<L
MY':RVTUFHU'5==4(0H#K[%GMGI]04VGJ)$;VX\[*,&CT'&5LUR<@8#`+B)L&
M`;QJ)@\1(2;GE9!7@/`1!F&H>&E:1O\`WQZQ?,WB]G;0.A=2Z5G[MH('_F?E
MB6>&_A>VIKD>S_)WW2#Y35!3I;!\`?J"X?\`R!\D;SV!VT]G5@`FH7%:%Y/D
M^0?3[^E9&YA,<H!J8T<LNC"Z'$-1+Z-RAY`K2=][Q>[=])!N9HV3\VF0AG_I
M@%S_`*<2MQ#N/]VW$0%"P)N52)>77NN5,R/_``BI+&O2.RE&Y-KV19=D-"L+
M-M*VK49D3*D#:W8.-ADNF3WI#%8-D.<`T\NM:BN=ZO%Z=[>\5=35/3G-UQ;A
MG_.)B2UAQ3&,5IQ28S;J&WTP`'+3L-,B0X`AM*9_+':-=?&N,CGX4A"D(4A"
MD(4A"D(4A"D(4A"D(4A"D(4A'QIJW+>N1$K:XH&%GVY.;D0FXIA*HEYO?<J3
M]NN0O-IQT#C7V4=QN%N7VEO?>8</2VM2#^5)$<7<[)9;VT&;U1TM8R."7VFW
M4B?@6E0CYD38-B0"P.(*R;0A5P,!P6B;:A8Y4#AH(&!1FR1.!@$`XZZ\*^FJ
MOM\KD=G75M6\B7!;SBQ^12C'PV_#\2M#@>M-KMU*\#/F9IF6S/KFA`,X[:(B
M/B(UQ49%'P;HN:$LRVYZ[KE?HQ=OVU$OYR:D7!@(BSC8ULHZ=K&$P@`B5)(=
M`\3&T`.(U]ULMM;>+BQ:K<@NU]2ZEMM(U*EK(2D?E/R1Q%_OMJQBR5>1WQY-
M/9Z&G<?><49!#;22M:C/J`,ATG0:Q2WW,9PF-Q.:[YRK+&63;SLH=O;D<J<Q
M@AK4C1%I;\60!'0AD6!"J*Z:`9PHH;^%5PNW.&4F`8;18Q2A)<8;FZL?TCZ_
M*=6>N:M$]20D=$=8K?/=2Y;S;H77/K@5!FJ?*:=LF?8TK?D4[0ZN5L`KEH7%
M+5\Z,#UG$:CCR3345.1)(AU553E3323*8ZBBAS`4B:9"@)CG.80```-1$:\*
M4E*2I1`2!,DZ``<2?!'[0A;BPVV"IQ1```F23P``XDQ;O[>NV@FV_`,*VFF"
M;?(V0"MKOOQ4Q`]*9KNT.:&MM13B8"6_&JE(<@>:#I180\=:JCW\W&5N%G3R
MZ-PJQZ@FQ3"?DJ"3]H\!_P"*L3!X\@0.B.QGW.-CD;*;14K5S9",TO`35UQ(
M\M!6G[&F)UTIVR`H<.V4Z1QC>RM(Q+*%(0I"%(0I"%(1JKN7WC85VMPIW%^3
MI9&[7+8ZT%CR`40>77,&Y1Z*BK<3@E"QAU-`,[=BFGIKR`H8.4=G[<[1YCN9
M6!NR,=G:DJDY5.@I9;ZP#Q<7U(1,]?*-8T!OAWE-L-A;87LLJP]D*T%3%O8*
M5U3QEH2F<F6R>+KI2GCR!:ARFLQNGWR9FW3R:S:X)$UJ8[0<=2(QO;[M=.&3
M*0?@G,\Y#HKW+)@''J.`!%,W[))/RV.[9;+8AME3!R@;]:OZDR<JW4@N&?$-
M#4,H\"?*(\Y2HHQW][U>YF_E<IB[O&WX:A<V;=3J4&1+@I]6BJEWIYG!RI/Z
MM".G3.MOQ&2%(1]JW+;N"\)R,MFU863N*X9IVDQB86'9KOY*0=K#RIH-6K<A
MU5##XB.FA2@(B(``C7QW"XT%IHG+E<WFZ>@925+<<4$H2D<25&0'_/P&L<K9
M+'>,DNK%CL%*_67BI<"&F64*<<<6>"4I2"2?DT$R=`8L1[(^UM"X\-#Y3W&L
MHZYKY3%M)0&.3"E(6U:2Y>59!S<@^>UN*?;GT$$0YV+<P?WX^AB0"WF[S%9?
MP]C.WRW*:RF:':O5+SXX$-=+31'SM'%CZ`T-S?=:[A-LPTTV>[TM,UV4CE<8
MMQDY34BM"E53Q14/I,CR#F8;(_I52*9GRE*4H%*`%*4`*4I0`I2E*&A2E*&@
M`4`#0`#PJ'Q))F=28LW2E*4A*0`D"0`X`1S7B/,*0CIF0L?VEE2RKCQ[?40A
M.6I=4:K&3$<OJ7J(J"4Z:[=4OGMGK-P0BR"I=#I+$*8.(5S%@OUUQB\T]_LC
MI9NE*X%MK'01Q!'2E0FE23HI)(/&,9S+#\>S_&*W#\JITU5@KV2TZV=)@ZA2
M2-4K0H!;:QJA:0H:B*R6Y7M;YYQ'-R4GBV%D,Q8Y.LLO&.K>1(YO.*9B)SIL
MIVV4A*[>N6Z8<OI#`BZ:VG,)$A'D"R#;KO,8/E=&W39*\W:,@``6ETRIUJT!
M4T\?)2"=>5TI*>$U2YC19OAW"=VMN[H_78%2O9)AA4I32Z=(56-(U(0_3)\M
M:DB0YV$K2OSN5LGD$=LI85]0CM6/F;*NZ)?(F,19G)6U-,721RCH8IT'+)-0
MIBCX@(5O^FOEDK&@_1UE*ZP>"D/-J2?$0HB(9UV'Y9:ZA5)<[9<*>J22"AVG
M=;6".(*5H!'RB.SV9@[,N1'J4?8^*\@70Z5.!`")M297;D$1`.9P]%H1DU3#
MF#4ZJA"!Y1"N-O&:8A8&347JYT%,V!/RWVP3XD\W,H^``GP1SV,[4;F9E5IH
ML6L%WKGU&7V5*\I(\*EA'(@=96H`=)B5_;-V@;VGW\?<^Y612LVVTC(N?YOK
M>D&\A=<P7S%`;3$TR.M&6\U.`\J@('<NAXAJD/G5%W<?O8V6@8<MNW39K+B0
M1ZTZDI8;XB;;:I+=/5S!".GRQI%@VQGX<.47>K9ON]SR;;94D*_9].XERK=&
MAY77D%35.DZA7(IUSB/LSY46"K3M*V;$MR'M"S8*-MJV8!DE'P\)$MDVC%BT
M1+H4B:28!S*''4RBAA,HJ<1.<QC"(C`RZW6Y7RX.W:[ON5%R?65..+)4I2CU
MD]'0`-`)````1</CN.6+$K)38YC5(Q16.D:#;++20A"$)X``<2>*E&:E*)4H
ME1)/8JX^.:A2$*0A2$*0A2$*0A2$>"JB:"1UUU$T$4BB=198Y4DDR!XG.HH)
M2$*'NB.E?I"5.*"&P5+)T`$R?$!'X<<;9;+KRDH:2)DD@`#K).@$:X9&W@[8
M\4BNE>V:K$8OVY5!4AXR73N.;*=(-11/$6\$F^15,/``4(34?+6PL?VEW(RC
ME59[/6K841)Q;9:;UZ>=WD21XB8TIF?>1V+P`K;R;)[4W5H!FRT\*E\$=!9I
MNU<23P',D:QH9D7O+X&@.LVQS8M^9#=$!0J3V0(QLR$.<`$$E"J/CR$T=(3\
M1`S)(VGZ?#>./]T+.*Z3F0UU#0-3$TIYJAR73HD(;!\3BHB3FGXF&TMH*F,+
MM5UO#X!DXYR4;!/005EUXB?$%A!E&AV1.\3N4N<54+%@+!QFR-J":S:-<77-
ME*8HE$#R$ZJ$8(AKJ`D8)F`?+6\,?[I.W5MDY>GZZXO#B"L,-_5;'/\`(73$
M2\S_`!)M[;Z5-8K26FQTIX%#:JI\3$M7'R6CX"*=)C16_MU&X[*!E`OG-60Y
MINH(B:.)<3V)A^(CP"&A3QT4`<=/V.NE;LL6V.WN-`?L6ST#+@^?V25N?>.<
MZ_\`I1$_+]_]ZL[4?WIR>\5+)XMBH6TS]PR6V?\`H1@,YC*'.HH8QU%#&.=0
MXB=0YS")C'.<PB8QC".HB(ZB-9R`$@)3HD#0=`C4*UK6HK625$S).I)/$GPQ
MQ7F/S'&NGCPI'F.[V9C3(F1GJ<=8-BW=>;U4W*1"V;>E9D0'FY1%0[!JLDD0
MH^^,<Q2E\HA7#7C([!C[)J+[6TE&R!.;SJ&_R<R@3X`-3T1E.,X-FF9U2:+$
MK3<;E5*,@FFIW7C\O9I5R@=),@.DQO?C;M3;N;\,W7F[;M[&,8L.IW=\W`V*
M]3)YHB(0EOEFY+J<IM0*J5$!'@)BCKII#(N\_M58PI%'45%RJ1\VF:/*3_I'
M>S1+PI*NN1B6F$?A^=XC+2AVZ45'8Z%1U775"0L#P,TX?=G+@%I1U$C66_>-
M^RM8;#T=UEC+]R7*J40,O$V1$LK98&$.(IC*2IIQ^JF(\!$J2!M`U`0UX:+R
M'OBWM_F:Q:TT].GH74+4\KQ\B.S2#XU*$2\PG\,'$J/D?W`R.MK7`9J:HFD4
MR#X"Z]VZU#HF$-GITGIOQCC8'M'Q@#=2#PQ;4S(-Q`Q9:]BN+U?F.`Z@II<2
MKYBDH4W$!31)H/AY--&9#OMNKDG,FLO%2RPKYE/*G3+J^R"5$>-1B76%]T+N
M[8*$+M>,T-56(,P[6A5:N?7*H+C:3U<B$RZ(VVBXJ+A&:<?"QD?#QZ/[)C%,
MFT>S2X`'P;9HDBB3@`>!:U74U=56O&HK'7'GSQ4M14H^,J),2(H+=;[53"CM
M;#--1IX-M(2V@>)*`$CY!'[Z^>/LA2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2
M$*0A2$*0A2$*0A2$*0B#?N_[GRP\%%[8[3?"$G<:4?<^2UVRN@M8%%P+BW[:
M5Y#`)5I5ZV*\7*/]X22#005J:G=.VU];K7=R+HC^[TY4S1@CSG2).O"?0A)+
M:2/G*5TIBJC\1_?<6VU,;&8\[_?:U+=3<E)/FL!7-3TQD=%.K2'E@_,0WH0Y
MI7JJ>\4W0I")*.V!MN#..?6MWW`Q%Q86'18W9+`LGS-)2YA7,-IPAQ.0R:I?
M3&YWBQ/*DUY3<#AK';O)[AG"L%5:J!?+?+MS,(D?*0S+[=P=(\DAM)ZUS'")
MP=Q#9(;J;NMY%>&BO$L;+=6[,>0[4\Q]48,Q(CG27ECZ+7*=%B=K6JO8[!$*
M0A2$*0A2$=,OW(MB8NMUW=N1+L@K-MQD417E9Y^BQ0,8`$P(-2*&Z[YV<`\Q
M%$JBIQX%*(US%CQ^^9-<$6K'Z5^LN"^"&DE1\9EHE/6I1"1TD1C&79IB>!69
MS(<SN%);;,T/*=?<2A)/T4@^4M9^:A`4M7!*28@>W4=WF9FRR5F;8F"]O1I^
MHU<92GV9/EYTF("0ZEJP+@%$(A,^H\CEX"CC3B5)(V@U-_;'NHTE$6[QN0M-
M14B2A1-*/9)/4\X)%P]:&Y)ZU*&D5+[_`'XC5RNB7\9V+971T)FA5T?0/6%B
M4B:5A4TLCJ<>"G.D-MJD8A*FIN9N26?SUPRLC.3<JY4>24M+/%W\B_=*F$RB
M[MXY.HNNJ<1\3&&IET=%1VZE;H:!IMFC:2$H0A(2A*1P"4@``>**MKI=;G?+
M@]=KS4/55SJ%E;CKJU..+6=2I:U$J43UDQ\NOICCX4A&U&V?9YF;=+.D9V)!
MGC;3;.")3V0YU%PUM2&)S@"J:;H"<TS*%+J)6C7G4U#SQ3+YP:QW&W:Q#;.B
M+M[>#ET4F;=*V07W--"4S^S1_P"(N0ZN8Z1(#8WNV;F;]784V*4I9Q]"P'[@
M^%)I61/4!4IO.@3DRUS+X<W(GRA9ZVL;+L0;5(,$[2CQG[Y?-P3N'(LX@@I/
MR(F(4%F<:!0,G`PO,74K5`=3>*IU3>=5;.YN\.6;GUL[HYV%D0J;5(V2&D]2
ME]+KG6M7#YH2-(O;V"[L6W'=_M03C[/KF5NHE47%]*2^Y,":&N(89F-&D&9X
MN*<5K&W=:HB1L*0A2$*0A2$*0C@P`;3G*4^GASE`VGZN8!TKS,C@3'@I2KS@
M#'(<```X``:``<```\```T``KQQXQY&F@X0I"%(0I"%(0I"%(1Z'3ELQ;JNW
MKANS:($ZB[IVLFV;HD#0!.JNL8B29`$?$1`*_;33C[@:92I;JC(!())/@`U,
M>FHJ*>D954U2T-4Z!-2EJ"4I'65$@`>$F-8<C;U]J^+"KENS-EE"^0`_-$6[
M(_6V8%0@:BB+"VB2:J"@AX=7I@(^6ME8_LWN=DQ2;79JSL%?TCJ>P;EU\SW(
M"/T9QHG-.]%L%@(6F_Y1;#5H!FS3.>MO3'06Z8.E)ZN?E'AC0C(_>@P]#>D-
ML88TO2^7)0,5"2N%PPLZ',?3S%"I!\L2ZR0CXE.B@:MY8]W/LMK.5W)+C1T3
M9XH:"GW/%/[-L'Q*4(B/FWXFVV]L*Z?!;)<KJ^`>5RH4W1LD]!`';NJ'6%(;
M,:%9'[NVZ:\07;6B2RL7L%0$I!@(3Y;F"$$/X4M<BC]$%`\ADFJ(A6\L>[J6
MV5HY7+KZY<GQ_6N=FW]1D),O`I:HB-FWXC&_62<[&."V6*C4)#U=CMGAXW:D
MNIGX4-(C0Z_\]YKRHLHKD3*E]W:501$6DM<DDI&%UU`01B45T8M`H@/@1$H5
MO"Q8-AV,("+!;*&E(^<AI`7\JR"L_*HQ$K+]WMT,^=4YF5_NMP"OF.U+I:'B
M9"@TG^:@1B,``/``#]0:5E4:Z))XQS2/$*0C[EO6Q<MVOB1=JV].7-)*"4",
M+?B7\R\,)QT+HVCF[A;SA#APKXJ^Y6ZU,&INE0Q34P^<ZM+:?RK($<O9\?ON
M0U8H+!155;6F4FV&G'EZ\/);2I7\D;MXS[:&[[)70<?S;_4*+6%,1DLBR3>V
MQ(FIQZOR/H[N`0('B7T0#?HK3.1]XS:?'>9'[1]>J1/R*1!>F1T=IY+7_3B4
MF#=QOO&9ORO&R_LFA5+[2XN)II`]/8GFJ-.KL9Q(7C3LIQ"'0=9?S*^?G`R9
MEX7'D,E'H"7351$)^X/3%SZ&#0#@Q)J`^`5H3(^^/5+YFL3M"$"1DY5.%1\!
M[)KE'R=H8F1@_P"%_;FN2HW&R5UU4P5,V]D('A3ZQ4<Y.O3ZNGQ")!\:]O3:
M+B\6[B)Q%#7))MQ`Q9:_5G-Y.S'#0>H+:846B$S<P:AR-B@4?``K0N1;^;K9
M*%-U5U>IZ97S*8"G'BYFP'#\JSX8F-A'<V[NN"%#M!CM-6UJ#,.UY56*GU\C
MQ+(/Z+0ET2C<:,BXR%:)1\-&Q\0P1#E18Q;-M'LT2@``!4FS1-)$@``:<"UJ
M.IJJFL=+]8XXZ^KBI:BI1\9423$DZ&WV^UTR:.V,,T](GS4-(2V@>)*`$CY!
M'[J]$?9"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(
M4A"D(QAF?+%L8.QA>.4KO<$1AK1AUWXH"<I%Y.0,`(14,R`P_"/9:14303`-
M?./J/`!$,EP_%KEFF2TF,VI)-75NA,^A".*W%=24(!4?`)<91@>YVX5BVKP2
MY9[D2PFVVZF4YRS`4ZX?):91/BMUPI;2.M4SH"8I5Y-R)<N6L@7=DF[W9GEQ
M7E-O)N14$1%-$SD^C=BV`?V;*-:$3;H$#@1)(H!X5<7C=@MV+6&DQVTHY+?1
MLI;0.DRXJ/6I:IJ4>E1)CK`9WF=[W$S"XYMD3A=O-RJEO.'H',?)0GJ0V@);
M;3\U"4CHCHM<W&)1Q2$7`NWIAV!P_M7QJE%BU<R]_0S+(MU2S8Z2Q9"6N=JB
M\;H%73U!1O#Q1D&A/.$-4C&#03"%5-[^Y;799N;<55/,FDH7E4K*#,<J&5%)
M,CP+B^99_2`Z([(7<VVVM&W&P=D10=FNXW>F1<:IU)![1VJ0E:4\PXI9:[-H
M:G5!5IS&-W*TQ$IH4A"D(Z_=%UVQ9$(]N6\;AAK7M^-2,L^F9Z1:Q<:V3*4Q
MA%5V\522`P@4="@(F,/``$:^^V6NY7JM1;K13O5->X9);:0I:R?`E()\9X".
M'OV0V'%K6[?,EK*:@L["9K>?<0TVD<=5K($]-!.9X`$Q#WN2[O\`85IE?VSM
MUA2Y"GR@JW&^I]!U'V6Q5Y3D!>+C3>CR]Q&3.("43^B(#IP,H%2UV[[IM\NA
M1<MP'O4*'0^K-$*J%#31:]6VI^#G5X$F*V][_P`1[$\>2]8]F:87>\":?7JA
M*VZ-!U',TUY+U009$%78HZBL1`]E[.65L\7*I=65;SE[LDQ,?T1%VJ",3$(G
M,)O186&;`E&138NNG*BD43>)A,/&IO8GA6+X1;A;,7HVJ6FD.8I$UK(^<XX9
MK6?"HF71(14MN-NMN!NS>U7_`#ZYU-PKB3R!9DTTDF?(RRF332?`A(GQ5,ZQ
MB>LIC7D*0C[=MVU<5X3<?;5J0<K<EP2S@C6,A81BXDI)ZX4,!2IMVC5-14XZ
MCQ'30H<1$`XU\5PN-!::)RXW1YJGH&DE2W'%!"$@=)4H@#_GZ(Y:QV*]9+=&
M;)C]+45MWJ%A#;++:G'%J.@"4(!4?#IH-3I$Y6TKM&KJFC+[W2*BW1^`>L<2
M0[T!74\%2%O2=9J"5$@\`.R9'$PAJ!UPXDJ%>ZG>K;0'+)MF.9>J55SB=!T'
MU=M0U\#C@EU(.ABU?N[_`(=3KA8RS?E7(UY*T6EE?E'I`K7T&21PFRR2>A3J
M=41.];MN0%HPD=;=K0L7;MOQ#9-G%PL,R;QT:P;)AH1)LT:IIHIE\HZ!J81$
M1$1$1J$-PN-?=JURXW-YVHKW5%2W'%%:U$])4HDG_FX1;/9;)9\<M;%DL%*Q
M16>F0$-,LH2VVVD<`E"0`.LZ:F9.IC[5?''*0I"%(0I"%(0I"%(0I"%(0I"%
M(0TU\*0C%F0\X8=Q,@=QDG)EE68!--6\Y<$>UD#B8ACE!&+ZQY)P8Y"B)0(D
M83>2LGL&%9=E2PC';;65D^EMI2D=6JY<@^50C`,RW5VUV]:+N;7RV6R7S7ZA
MM+AF)CE:F7%$@:!*"3T1'QE#N^[9[-Z[6Q(^\,KR*9C$34BH_P"K5OG,`>:8
MTO<!47HI&_C),E?U5OK&NZ=N-=^5V^.4EKIR-0M?;._4:FF?C<3$.L\_$<V/
MQGGI\39N605J20"TWZM3D]9=J`')>%+"HCERAWA=QEV^D-,>05FXLCE.H1-R
MW9FNNX@3,)@`1D)LH1:2G(/B1B`E$-2F"I!XUW2]OK5RNW]^KN=0)$@J[!J?
MZ+?ED>-SQB(69Y^))O/D)73X;2VVPT1F`I*/6JB6LOM'_L@9?18!!X$1'9D3
M.N9<LNCN\D9.O6\#',)@;S$\^5C4A,&A@;Q*2J,6U*(<-$T2AI6_[!A.(XLV
M&L>MM'2`=+;20L^-9!6KY5&(89ENQN7N$^:C-;Y<[DH_->?<4V/T6@0TC^:@
M1B@``/``#]0:5E$:^))XQS2/$*0CDH"8Q2%`3'.(%(0H"8QC"(`!2E#43"(C
MX!0D`3.@$?I*5+(2D$J)EI&S&,]F^YW+OHZUDX:O-S&N3D*2<F8\;9@@*<0^
M%^5+A/&ME4RE'F'I"H82\0`:UQD>[FV^*<R;S=Z--0D?JVU]LYXN1KG(/CD/
M#&\L'[M&^FXG(YC&-7)=$M0`?>;]68D>GM:@M(4!Q\DJ,N`,2)XP[+N3)?T9
MYEO*%L68V.)3+PUI,W-US)2Z><F=^[&)B&ZH#Y2>DE&M`9+WP<;I.9G%;;4U
MC@X./J##?C"4\ZR/'R&)GX'^&-G%Q[.IW$OM#;6"?*9I$*JGI=16KL6DGPI+
MHB13&':OVD8]!LYF+6F,G2R)0YWE^3*[E@=74!$Y(&)+%Q/)J`:%536$/=$-
M:C_DO><W4O\`S-TE2S;:4G1-,V`J7^E7SK^J4^*)GX)W`^[QAH0_<J"IOMP2
M-5USQ4V3UAAD--2\"TK\9C?6U;'LNQ6!(JR;2MJT8U,H%*RMN#C85MH&G$R4
M<V;E.8=-1$VHB/$1K1MTO=YO;YJKS5U-74$^<\XMP_E63+Q");X_BF+XG1B@
MQ>W4-NHDB013,-LI^4-I2">LG4],=HKC(Y^%(0I"%(0I"%(0I"%(0I"%(0I"
M%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(16][N^YSZZW]';=;5?
M\]M8W<I2U\*MU-49.^G+0?18PXD-RJ)6Q&NA`Y1\':YP$.9(-+#>ZEMO^QK$
MYG]S1*XW%)13@C5%,%>4L=1>6G0_02"-%&*3?Q&-]3D^7,[-6!Z=CLJP[6E)
MT=KE(\ELR,B*5M1!']:XL'5L1#)4OHK)A2$*0B</L]9NRU)Y"G<(O;A7F<61
M%D2=S,H:4$72EL/V\I'MT`M]T<>NR8/59$_6;:F0YA`Y2E-J(PN[VF&8K36!
MC,V:<,Y,[6(94XCR0\DH43VJ>"E)"!RK\Z6A)$I6J?AN;I;AUV8U6UU56*J<
M!I[6[4H9=\LTSB76DI]76?*0VLNJYVIE$Y*2E*IDV&J@+%RD8FRKG?#V$(LT
MOE7(=LV8WY.H@UDY`AYA\&AQ`L9`M`<34D8W3$`!!`_&LJQC",MS.I]4QBWU
M-8Y.14A)[-/#SW52;1Q^<H1KO/\`=G;?:V@-PSZ\T-M:E-*''`7G./ZIA',\
M[P/ZMM40_P"=^\S#MDW<-MWL)Q*.1*JDG>^0DS,F"1].4CF-M1BX%Z\*`^<4
M7;AOY.9+R5++".Z#5.*169_7);;F#ZM2GF4?`M]0Y4]1"$+\"HK@W9_$RMS"
M7+9LU:5OOR(%;<!R-@]"FZ5M7.L=(+KC?A;Z(A=S!G_,.>ILT]E>_)R['`*&
M.S8.7'HT#%%,8P]*(@&96\1'$#FTU31`Y@]\81J86)X+B6#47J.+T+-*W+RE
M`3=7X7'53<7\JI#H`BL7<C>#<C=NZF[9_=JJX/3)0VI7*PU.>C+".5EH:R\A
M`)^<3&':RV-:0I"%(1(OM>[:N<]PGR;<UP-3XJQDZ,@X^LUS,EBS<VP4'F,I
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MD(4A"D(4A"D(4A"D(^=+3$1`,%I2>E8R$C&X<SB1EW[6,8(%_C+.WJJ#=(/T
MF,%?124=77OBFH6G'JE7!#:5+4?$E()/R"/AN-SMMGI%5]WJ&*6A1YSCSB&V
MT_I+64I'RF-(\G]R7:%B\5VR^3D;WED#*)FB,<L7%U*=1/F`4S2J'0MY(P'+
MRB!G@&`?)6YL:[N^Z^2\KB+::*E4`>TJU!D2/YAFZ=-=&Y1%O.^^WW<\$*F'
M;XFZ7!)([*W(55&8GH7D\M,-1(S>F#T1'AE#O5R"H.&>&L.MV9=#D0GLBRYG
M:W$-"+?5RWS(HIF*/\$T@H`_HK?V-=SFG1RNY==U+.DVJ1'*/%VKLR?'V0B&
M>>?B?UC@73;:XVAH2(2_<72M7@/JU.4I'B-0J?@B.C*/<`W:99])0G<N3<#$
MN0.0T'8A4K,CBHG-KT!4A2H2CA,@<`%9RJ<0\1&I`XUL3M9BW*NAM3+]4G^D
MJ9U"Y]<G)H!_10D=0B%V>=\#O"[A=HU=<BJJ2@<F.PH94;8!/FS8Y75#H^T<
M69<28T]=O'<@Y5>/W3E\\7,)UG;Q=5TY6.81$QE5USJ*J&,(ZB(B(UMIIEIA
ML,L)2AH<$I`2!X@)`1&ZIJJJL>545CBW:A9FI2U%2B>LDDDGPDQ^>O9'SPI"
M%(1V:U;+O&^I).'LFU;BNZ55.0A(^VX:0FG?,H;D()T8]NX,D03#IS&T*'E&
MN-NEYM%DIS5WFJIZ2E`/EO.(;3IX5D3\0UCG\?Q;)<LKA;<8M];<+@H@!NG9
M<>7J9":6TJ($^DB4;_XO[5&[3(16KR<MZ!Q;$N!*87-^3*:<H1(?$P6_!IR\
MFFH`?WMP5N;W=*T3DO>?VLL!4U15#]SJD]%,V2B?^E<+:"/"DJ$2_P`#_#^[
MPN8ANHNM'26&WK/G5SP#@3U]@P'G0?S7$MGKE$C>+>S'B."]&>9:R+==_O""
M4Z\3;B"%FP)Q#B*)UN>5FUTA\!$B[<P^(<M1\R;O?Y56\S6*V^EH6CP6\34.
M^,#R&P?`4J'CB:F`_AE[=VD(J-P[S7W>I&JFJ9*:-@^`JFZ\1T32MLGHE$CV
M,-J^WC#9$1QWB*S()Z@!>295BDIBX!,0.7J#/37RA+`H8!XB54-:CWDFYV?Y
M<3^W[K6/,J_HPLMM>+LF^5'_`$8FM@FP.S6VJ4G#L=ME+5(`D\IH/5&G3ZP]
MVCT^N2Q&?_(`>0.``'```/``#P`*P.-P<!(<(4A"D(4A"D(4A"D(4A"D(4A"
MD(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(UEW=[A8K
M;/@R[<CN5$5+@%N,%8T6H8O/*WA*I*I11`3,`BHUCM#.W/#@@@8/$0UV1M1@
M-5N-FM+C[8(H.;M:E8^8P@@K,^@KT0C\Y0Z`8T5WC=XZ#8[:FXYH\4*O)1V%
M"T3^MK'00T)=*&]7G-/U;:AQ(BF;,3$G<,O*3TV]7DIB:D'DK*R#HXJ.'TC(
M.%';QVNH;43JKN%3&$?=&K>Z2DIJ"D:H:-"6Z1EM*$)&@2A("4I`Z@`!'6:N
M=RKKS<JB[W-U;UQJGENNN*,U+<<45K6H])4HDD]9CYU?1'PPI"%(1E7#6:\D
M8"O=ED'%UPJV]<31%1FL84$7D?*1JYDSN8J7CG)3MG\>X,D43$,`"4Q0,0Q3
ME`P8QEV'8]G5F78<EIP_;UD*&I2I"Q.2VUC5*A,ZCB"0002(V#MGNCFVT.4M
M9A@=8JCO+:2@Z!;;K:B"IIUM0*7&U2$P1,$!22E0!&W^1NZ7N]R%$A#-[O@\
M?M3IE([<X]@2PTL\$"Z&,,Q(.YB19`<>.C51`?)J(5J;'^[-M18*KUQ=(]7N
M`^2*ISM$)_U:$MH5_/"HD?FG?X[QF8V[]F-7&EM#!$EJM['8NK_USBWG4?ZI
M3?5$?TS-S5QR3F9N&8E)Z8>G%1Y*S4@[E))TH8=3'</GRR[E8PCY3&&M[T=%
M1V^G31T#33%(@22AM*4(2.H)2`!\@B']TNUUO=:Y<KS4OU=Q=,UNO.+=<6>M
M2UE2E'PDF/F5],<?"D(4A&S^W?9_G/<U)D1QU:BR=MI+@E)WW/@M%6?&`!M%
M`&3.B<TF[3`!_D[,BZVOB!0XAK7/]V<*VXIBO(*I)N!3-%,U);Z^KR`?(2?I
MN%*>HDZ1OG9KNW;K;Y5P;PVWJ394KD[7/S:HVM=?M2#VBQK]FTEQ?6D#6+#.
MU_ME8.P$,?<UVH)9=R4V%-P2>N-@D6VX-V4I3<UMVLH=RU3514U$CEV9RX`0
M`Q.D/"H#;E=Y#-,Z[2VVHFU8ZJ8+;2CVSB=?UKPDH@CBA`0GB%<T7)[#]Q?:
MO:+L;WD2$Y%FR)*#]2V!3,+$M:>E)4D$'4.O%QP&11V?"))?<#R`&@`'```/
M``#R`%1WB;@$A(<(4A"D(4A"D(4A"D(4A#01\*0C#F2MPN#\/(JJY+RE9=I*
MI$$XQTC-M5)I0-!$`0@VAW,NN8^FA0(B/,/A67X[@.:9:L)QVV5E4DGSTMJ#
M8\;BI-CPS5&M,WWDVKVX;4O-[_;+>XD3[-QY)?/Z+""IY4^B2#.(X\G=Y+`E
MLF7:8TLV],G/$^H1-^Y*A95OG.7@10CF22?32B1AX\6)!_5P&I!XWW1<XN02
M[D=91VUHRFE,ZAT>`A!2V#_K#$*\Z_$LVDL953X1;;G?*@3`<7RT5.2.!"G`
MX^0>.M.GY-(CGRCW<-TE\@Y9V<>T\3Q:Q3)E^K4268G@3-S!YTY<?IY$U.40
M\]!L@8!#4!#PJ06-=U7;.RE+UV%5=*E.OVR^S;G_`*-KE)'@4M0ZXA;GOXBF
M_.5!=-C1H,?H%B7]V:#SX&O]/4]H`?SFVFU`Z@CA$>U]93R5D]\>2R+?MW7L
M\.<5.I<L_)2Q$C#IKZ.V=.%&K4HZ>]2(0OZ*WW9,9QW&V!3X_0TE&R!*3+2$
M3\92`5>,DF(<99N#G&=U9KLRN]QN=253G4U#KH2?S4K44H\20!'0?#PKG(P^
M.:0A2$<"(!Q$0`/T\*1YD3PC-N+MM^=\T+$)C+%=XW4W.<"#*M8E9I`I")N4
M17N"2]#AD0*(\>9<-/+XUAN2[A81AZ2<DN=)2N`>85A3I\32.9P_(F-I8'LE
MNQN:X$X-8+E7LDR[5#12P-9>54.<C*9=,W!*)*,6]F;,EP`V>97R#:6.V9S$
M.O$P:*]YW`5,0`QDS*)*Q<(W6XB&I7#@I1XZ&"H[9-WO<0H.9G%Z"JN#P!DM
MPBG:GUZA;A'@*$'Q1-[`?PS=RKQV=3N!=[?9J8D%33(565$ND$@M,)5T3#K@
M'&1B2+%7:GVG8Z%N\N"`G,K2Z)2B+F_)4QXGK``@8Z=N0I(N+.0VNO(Y!R`:
M<*CSD_>@W1R`*9H'V;72*Z*9'ERZBZYSK!\*.2)M;?\`X?\`W?<+**F[TE5?
M[BD>=7.GLI]8IV`TV1X'>UB02U[.M*R(Q*&LRV+?M.)1*4J4;;D/'PS,H%`"
M@/H\>W;IF.(!Q,("81XB(C6AKG=[K>JDUEXJ7ZJJ/%;KBG%?E42?DB85AQG'
M,5H4VS&:"CM]O2-&Z9EME'U6TI!/63J>F.QUQT<W"D(4A"D(4A"D(4A"D(4A
M"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A
M"D(JO=TK<N.:\YJ8]MU[UK!PRL_MYJ9%7G:S%XJ'(G=$R'*8R:A&BR!6"!@U
M#E0.8O!0=;.>[/MS^YN%"_7!$KY=TI=5,:MT\ILM]8Y@2XH=:D@^;%`O?WWR
M^)^ZBL.LSO-B.-*<IT\IFAZL)`JGM#(A"DAA!ZFU*&BXC#J2401A2$*0A2$*
M0A2$*0A2$9VPEMHS9N'EBQ>*;$EI]N18B+^X5D_DVU8CF'B>3N%[THY$2%XB
MF0RBXA[T@CH%81F6XN&X#2^LY17-,+(FEH'G>7^@TF:S/K(">M0C;>UNQNZ.
M\EQ%!@-IJ*MH*"7*@CLZ5GPNU"Y-IEQY02L_-03I$[NV_M$8PL(T=<V>98F5
M+F1!)Q]4V)5X^P&#D-#]-T!A2E+F!(W`06]';'T\Y$P5"+</O79)?`Y;<':-
MLMQF.W5)52H=:>*&9_F\RQT+!BV79/\`#FP7$BS?-VJ@7^]IDKU1OF;H&U<9
M+X.U,N!Y^S;5\YI0B7J)B8J!C6<-!QC"&B(Y`C:/BXMFW81[)NF&A$&C-JFD
MW;I%\A2E`*BA55=575"ZRM<<>JW%34M:BI2B>)4I1))\),6-VZW6^T4+5LM3
M#--;F4!+;32$MMH2."4(0`E('4`!'T*^>/MA2$*0A2$*0A2$>*AR))G55.1)
M),HG454,4B9"E#43'.<0*4H!XB(UY2E2U!*02H\`-3'Y6M#:"XX0E`$R29`#
MK),:D9:WU[6,,^D-[KRS`R4RWU`UN68<UX38J`!O@5$(3TEHR4YB\O\`*5D2
M@;@(A6UL5V1W-R_E<MEK?;HU?TM1]@W+K!<DI0Z?(2K3A$==P^]CL'MGSLW_
M`""D?N2.-/1'UQ^>ODD,<R&SI+[5:`#H2(C-RKWJ2%,X985Q"*A?A2(W#D>2
M%/74!*FLG;<`H8=0U`P`H_#00T$HU(W&.YT2$O9C=9'0EJD1/Q@NNC_D:^6(
M-;@?B?(2I=+MCCLQJ!47%S\BA34Y^76H\!!B-;*F_P"W8Y<]*0G\M34##NBB
MF>W[$`EFQ0(B.O1,>'Z4HZ)P_O[E4WZ:D5C&Q6UN*<JZ&U,OU:3/M:F=0N?7
M]I-"?YJ$Q"#/^]_W@]Q2XU=LAJJ2W."1IZ&5&U+J^QY75C_2.+/AC3QRX</'
M"KMXNN[=+G,HNZ=*J.'"RAQ$QU%5UC'54.<PZB)A$1&MM-MMLH#324I:2)``
M``#J`&@B-K]0_5.J?J5K<?625*42I2B>)),R2>LQZ:_<>F%(0I".2E,<Y4R%
M,<YS`4A"`)CG,/`"D*4!,8P^X'&O!(`F=`(_24*6H)0"5$\!&UV)=C^Z+-`M
MU[.Q+<36'<\IB7'=B06C`=(P`/63>SHLU'B?*;F#T=-83![T!K5^5;S[:8>%
M(N]UIU5:?Z)@]N[/J*6N8)/Z93+IE$@]O.ZOOQN:4.XWCU8BW.<*BJ'JC$M/
M*"W^3G$C,=FE9/0#$FF*NRL]53;/LTY>29G$$E%[=QU&>E&#7BH@>Y)XB28"
M7PYDV!M?((5'#)^^*RA2F<.M)6-0':M?+XCV+4S^5T1.?;_\,&I<0BJW.R)+
M2B`54]N:YSX4FI?"1X-*<^.),,4[`-I^(/1G$!BB'N"9;"!BW#?ACWC*F4#7
MX4B<N"L4T4X_]';(A4<LHWWW1RSF;KKHZQ1J_HJ;[!$NJ:)+4/TEJB<FWW=`
M[ONW'(]:<?IJRY(U]8KYUCL^L!Z;*#_HVD1N*W;H-$$FK1!%JV0(5-%LV230
M013(&A4TD4BD33(4/````"M2....K+CJBIQ1F2222>LDZF))LL,TS26*="6V
M$"24I`2D`<``)``=0CVU^(]L*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*
M0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0C3'?EN*)M
MOV\75<L:\3;WS=)#V;C]+F#K%GI=%0CB63)S%.)+?C`6=ZAJ'5(F4??5N#8[
M;]6X>?4UNJ$%5EI3ZQ5'H[)LB2#_`*5?*C]$J(X1&3O;;SHV4V;K[W1.A&55
MX-'0"?E!]U)"G@)S_N[7.[/ASI0D^=%/1995PJJX754777446765.915994P
MG5554,(F.HH<PB8PCJ(CJ-6TH0AM`;;`2A(``&@`&@`'0!T1UMG77'W5//**
MG5J)429DDF9))U))U),>NOU'KC+.#\+WMN`R7;N+;`9IN9V?7.*CIR)R1L+%
M-2@K)SDLL0IS(QT:WU,?0!.<PE(0#'.4!Q;-,PLV"8Y49-?5E-"PG0#5;BSH
MAM`,IK6=!T`342`"8V)M7MCE&\&;T6!XBV%W6K69J5,-LM)U=?=4`>5MM.ID
M"29)2"M2099LJ=F"[8*RTY;$^44+YO)@R!:4M:X(="VVTRX(0IED[;EB2#M%
MLJ)A$$DGH%(?3SEBB.@19QCO@6JNO!I,IMBJ*T+7)#S3A>+8Z"\CE22.LMS(
MZ$&46&Y_^&3D-IQA-QV^OJ+KDK34W:5]E-,EY0'E"F=[1:4GCRH>D%2U=3.0
MAJO6Q;RQQ<+ZU+]MB;M&XXU8Z+R(GH]>/>)F(.G.0JY"D<('\2*I"=,Y1`2F
M$!`:EW9[W:,AH$72QU+-7;W!-+C2@M)\<N!ZP9$'0@&*T,GQ+)L*O#M@RR@J
MK?>6%%*V7VU-K!'2`H#F2>A29I4)%)((,=4U`/$0_P"$*Y21C'I&.Q6Y:-V7
M@\2CK2MBX;H?K&Y4F5NPLE-.E#:@'*1"-;.5##J/N5\%PNMKM+)J+K4T],P.
M*G7$-I'RK($<U9<:R+(ZH46/4%975BC(-T[+CRR?`EM*E?R1OOB+M;[K\GJM
M7,U:S#%4`L<O5E<@/2-)`J(@!A.WMF/]-FU3\I@Y05(W(/\`'"M&97WF-KL;
M2INCJEW.N`T12IYDSZB\KE;`_1*SX(ESMSW">\#G3C;USH&K!:%'5VO7R.<L
MIS33(YWR>H+2V#]*);<'=I#;WC@S*7R6[ELRW&@"2JC:8`(6RTG!0`Q@2MU@
MJ9R_2*IPT>.EDSE]\F&NE16S3O59[D`728XAJT6]4P"W]I4$>%U0DDR_JT)(
MZ%18EM5^'9L[A1:N.<.5&2WE,B4O?8405TRIVR5N"?0\ZM*AQ;$Y1*'!P,);
M,4S@K;AXR`A8](J#&)AF+:-CFB10T!-NS9I(MTB_J*&M1IK:ZMN54NMN+SK]
M8X9J6XHK6H]94HDG\L3QM5HM5BM[=JLE,Q1VQE/*AIEM+3:!U)0@!(^01]6O
MECD84A"D(4A"D(\%%$T4SK+*$212*8ZBJIRII)D*&ICJ*'$"$*4`XB(@`5Y2
ME2U!"`2LF0`U)^2/PXXAI!==4$MI$R29``<22=`(TSS#W`=JN%A<M)_)L=<T
M^VYBFMG'Y2W?+=4H"(H++1ROR,P5`0T$'+M'E'@/'A6W\2V'W/S`)=H;:Y34
M*OZ:J^P1+K`6.T4/T$*G$9]R.^#L#MCVE/=KXS779O0TUOE5N\WT2IL]@V>@
MAQU$CH=8BQRWWHKUDC.6&$\7PUL-#`8B-PWXY4GY<>(@"R,)&*L8IH8`T$`5
M6=![H5)S%>Y[9J<)?S*Y/5+O2U3`--^(N+"EJ^1*(@'N)^)SD]:I=)M?8J:A
MIR)"HKE&H>\89;+;2#^DMX>"(Q,L;KMQ&;55OYQ\KW9,QZQU#?(#1^:$MI(J
MG`R2<!"@PC#)\H`'PB9S"`><(CQJ2.+;7X#AB4_N]:Z5E]('VJD]H\9=)=<Y
MES\1`Z@(@IN#W@]Y=T5K_?3(+A4T:B?[NESL:8`]`IV>S:E+35))Z23&O.@!
MX!6?1IJ.:1XA2$*0CDI3'.1,A3'.H8"$(0HF.<YAT*0A"@)C&,(Z``<1KP2`
M"HZ)'&/TE"EJ"$`E1,@!Q)/"-OL-[#]T><`:.[4QC*P]O.]#DNN]];2@>B)B
M@*[=24(21DDP`VH>BMUQ,'$-:U/EV]^VF%\S5TN33U>G^@I_MW9]1"/(0?TU
MIETQ(_;3NE[\[IANIL%BJ*:T.:BJK?[HQ+3RDET!QP:S'8MN3'`1*SB/LN6@
MP3;/\WY1E[A><#KVYC]LG!Q)!T`>DI/RJ+V3=EU$0$4VS4>&H#48,K[X5U?4
MIC#+8TPST.U1+BSX0T@I0GY5K\46![=?AC8Y2(;K-T;[45E3Q53T"0RT/`:A
MY*W%_P`UIH]1B3?$^T?;CA,B!L>8FM2-DD2)E^L,DR^L%R*'3T$%AFYPS]^B
MH8P<VB1DR`(CH4*C=E.ZVX69*4+]=:IRF)/V2%=DR`>CLV^5)'Z0)ZS$Z-ON
M[ILIM>E"L/QZWLUR`!ZPZCUBI)'3V[Y<<29Z^04@'@!&QW_T>`>0/U!Y*U[&
M[(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"
MD(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A%57NG[@39@W$O+(AWWI%F
M893<VDQ*BH)FSNZE5$U+OD="F$AU$7J1&(&\@-!T]\.MGO=DP,8EM^B\U:.6
M[W@A]4QJED3#".L`I)<E^?X(Z_\`W^]X3N1O*YB]M=Y\;QH*I$<I\E=42#5N
M:&1(<2&)]`9T\XSC,J1T07CDI3',4A"F.<Y@*0A0$QC&,(`4I2@`B8QA'0`#
MB(UX)"1,Z`1^DI4M00@$K)D`.),6K>VGM#_=WQ9]>;TC"(Y;R<S:OY9-<FKN
MU+6,!7,/:H:_L'BO,#I^`:#US%2-KT0JL/O%[K_O]DW[$L[A5BMM6I*"#Y+[
MW!Q[PI'F-?F@J'GF.P%W'N[E\&L!_>O)F`C<.^MH6Z%#RZ2ET4S2_FK5HZ^!
MKSE+9GV0,27U'&)R1TR\L<X_R*S*POZR+4O1FF`@DWN>`BYLB0".H@C\H-ES
M)`(^/*(:US%GR&_8^Z7[%6U5&Z>)9=6V3X^0B?RQB^383AV:4PI,NM5ON=,.
M":JG:?`\7:)5+Y)1C.,VI;989<'47@#$#%P4Q3`JA8%ME.!B<W((",>/$O,/
M_#61U.Z&X]8CLZF^W9:.HU3WIQ@U#W>]B[:[V]!B&.-/`@S3;Z:<QP_H_#&:
M(:WX&W&WH=O0</`M.'\EA8QE%MN'A\"Q003X:\.%8?65]=<'.VKWWGW?I.+4
ML_E428V?;+-9[*QZM9J2FI*;Z#+2&D_50E(_DCZ]?)')0I"%(0I"%(0TU\*0
MC7K,FZS;]@-!4<G9-MZ%DTR'.G;3-P,W=;@2"`<B5NQ!7DF03&'0#*D33UU\
M[@-9]B&U^>9RL#&[;4/4Q(F\H=FP)];J^5!\0)/@C3>Y7>!V?VD:4<YOE'35
MR02*9"NVJE2Z!3M<[H\:TI3^=$2&:.]$L;TR+P%C`J11!5)"[\DK`=0-0Y2.
M&EIPKGIE,`ZB7KOS!P#F3'B%2JP_N>H')4YS<IG0EBD$AXE/N"?CY6QX%=,5
MV;G?B<.*[6@VCL82-0FKN1F?`I-(PN7A'/4$<.9!U$129?W<;B\ZG7)DC*ER
MRD6N8QOJU&N0M^UDRFU#D+`0A6,>L``.FJQ53B'B8:E#B>U6W^$A)QZV4S54
MD?KECM7C_K7.98\22!U"*^MQ^\5O/NLM:<TO]<_0*)_NS:NPI0#T>KL!MI7C
M6E2NLF-<--/#A6PHTI'-(\0I"%(1P(@'B(!^L=*1YD3PC9O#^SG<GG0[=7'V
M*KC<0ZY@#ZT3K<+9M8I>(F4+-3@LFSPI0`=0;=8_DY=:UQEN[>WF%!2;]=*=
M-6D?J6SVSWB[-OF4G^?RCPQO7;?NT[V[K*0YB%@K5VU9_P!Z?3ZM2RZP^_R(
M6!TALK5T2G$J^'.RV0/0Y//&4S'_`&:KBT\:M>4H\.8S=Q=<XW$V@"``;HL`
M$0$>4X#H-1@R[OAGRZ;"+9U@/U9_E##9_)S.^-/1%@.VOX8J!V==NS?IG0JI
M+:G\J553Z>'0>2GF=9+&AB5'$&S?;7@T$%L?8IMQM,(%*'UGG$3W-<QSET'J
MEF)T[YPS.80`1!MT2:AKRU&/+-W=Q<U*D7VZ5"J11_4MGL69=79M\H5_/YCX
M8GYMSW:=D=JPAW$+!1(N2!_O+Z34U,^L//E:D>)KD3X(V<$1'Q&M;1O6.*0A
M2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A
M2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0C$6?<B_S283RGDLI1.O9E
MCW!-L2%TU4DT&"I(I,.8!+\))*)%X\.-97@N/_O5F5LQTZ(K*UIM1ZD%0YS\
MB`HQKG=[,_AWM=?\W2)O6RU5#S8ZW4MD-#Y7"@12*?OWDH_?2DBX4=R$D\=2
M#YTJ83*N7CU<[ETX4,/$3K+JF,(^Z-7-L,-4S"*:G2$L-H"4I'`)2``!X``!
M'5GK:RIN%8[7UBU.5;[BG%J.I4M9*E*)Z2223X8_)7MCY8F7[5^R\<C7(VW%
M9*ARJV%:+\X8^B)%#F;W9=S%7E--J-U0Y',';"Y1Y.8!(N^``X@B<!B'WF]X
M?W>MRL`QUXB^U:/[TM!U884/U8(U#CPXRU2UU%8(LS[@G=C.9WM&\V;TP5B5
MN=/[/:<3--75H/ZXI.BF*90TG,+?`&H:6#9&\:KPB[6%(0I"%(0I"%(0I"%(
M1\6XKDMZT8=[<-U3L1;<%')&6?3$[(M(N-:)E*)A,N\>JHH)\"CH`FU'R5]M
MOMUPNU6B@M;#M17.&26VT*6M1\"4@D_DCBKU?++C=M=O.05=-0VEE/,X\^XA
MII`'2I:RE(_+KT1%7G+N]X)L%1Y#XFAI;,,Z@*J02:)S6Y9*2Q0T*8LL];JR
M<HF!_*W:=,P<05J3N%=U#-KZE%7E+S5IH52/(?M:@C]!)"$'])<QTIB`6ZOX
MC>U&(+=MNWU-49'=D3':@FFH@H</M5I+KH_T;/*1P<B(7-O<DW3YI!W'FO3^
M;BV'/43&W,;%7MX%&ZG+\$^G^NO<3W4I=#!Z2FD;4?,`!TJ6&&=WC;+#BBH%
M'^T+DF1[6KD[(CI2U(-)\'D%0^E%<>Z7?;W[W.#E&;G^Q;$N8]7MP53S29:+
M?YE5*]!J.U2@S/D"<:'N'#AVX6=NUUG3IPH99PZ<JJ+N'"QQYCJKKJF.JLJ<
MPZB8PB(CXUNYMMMI`::2$M)$@````.``&@`ZA$2WWWZEY514K4X^M14I2B5*
M43J229DDGB3QCU5^X],*0A2$<:Z>/"D>8S[B3:[G[.2Z1,98NNFX&2BB:9IY
M1B,3;3<%1``47N&6%E%`0H#S"!53GY>(%&L&RK<O!<*03DESIF'@">R"N=XR
MZFD<R_!J`/#&WMN]A=WMU74IP>PU]92J(!?*.RIDSZ55#I0S(#4@+)EP!B5/
M#O9=N)\#22SKD]E!(CTU5[6QXW^59(2\Q1.W<W++(H1[542:@(HM')0'P,/C
M48LN[X-O8*J;";:M]>H#U4>1'C#*"5*'Z2T'K`B?VVOX8]ZJ@W7;KWUJD;,B
MJEMZ>V<XB:55+H2V@RF#R-.@'@H\8E7Q!L8VNX2*W7M+%<')3;<-0N>\TBW?
M<`J</A4G4R5PV8*:AP]%10`->'#A47\LWKW+S(J1=;F^W1J_H:<]@U+J(;D5
M#]-2HL!VX[J6P^UZ4.X]8*5^Z(_^YK`*M^?6E3P4EL_Z)#?@TC;8I2D*4A``
MA"%`I"%`"D(4H:%*4H:%*4H!H`!P`*U6229G4F)$I2E"0E(`2!(`:``=`CFO
M$>84A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A
M"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A'4;^L:V\FV
M5=&/KP9#(VQ>$*^@9MF14R"JC%^B9)0S=<NID'2!A!1)0.)%"E-Y*Y:Q7NXX
MW>::_6E?9W*D>2ZVJ4P%),Q,=(/!0Z02(QS+\4LF=8O7X?D;1>L5RI5L/(!*
M24."1*5#5*TZ*0H>:H`]$5W\K]FS-4'*OE\0WA:-]VX=94\8RN!ZK:USH-Q.
M(HMGHJMG$(Z63((%%8BZ0'$->F3PJ?F+][O#JVE0C*Z2KH;@$CG4TD/,D])3
M(AQ()^:4JE](Q3/N%^&CN=:K@Z[MU<K==K*5DMH?6:6J2F>B5S2IA2@-.8.(
M"CKR)&D:V8X[>6X:1S_8V)\DXUN6VH&5DF\C=%TMR)/K=:6:P7!6<>-KECCN
MXDKQ9NF*#=(R@+"X5)Y@`.M;%R#?S`:?!:W*<>N--4UK392RR24NJJ%"3:2R
ML)7R@GF4J7+RI5K&D<*[FV\=9N_:MOLVLE=16E]]+E55)`73HHVU3?6FI;*V
M><I!0VDJYRXI`*9&<6P[6M>W[)MR#M"U8MI"6W;<8TAX6*8I@DU8Q[)(J+=%
M,@>(@4NIC#J8YA$QA$1$:JVN=SK[S<7KM='5/7&H<4XXM1F5*49DG_F'`#0:
M1V$L?L-GQ:R4N.6"G;I;+1,(99:0))0V@!*4@>(:DZDS))))C[U?#'+PI"%(
M0I"%(0I"%(1I_N_WBV!M)LI*4FR%N*_;@2<IV18C5R1)W*KI!RGE994.=2+M
MMBJ(`JN)1,H?X-(#'$>7;6TVT=]W4O!IJ,^KV-@@U%21-*`?F('!;JAYJ9R`
M\I1`E.-W>0[RF(]W?&$UUS`K<MK$J%%0I4`MU0T+KIU+5,@RYW)$J/D-@JGR
MU8<^;F\Q[D[C5G\H76[D&B:ZBD/:K$ZK&TK=1,.A$(F%(H9`IR$X&<*]5RIX
MG4&K-L&VWQ';NWBAQJE0VZ4@./*`4^Z>M;DI_P`U,D#H2(H)W=WUW*WMO:KO
MG5P<>IPLEFE02BDIP>"660>4&6A6KF=5\Y9C`%9W&GH4A"D(4A&5\98+S%F5
M\G'XOQO=MYJ'4Z9G<1$.#1#8P#RF%[-KE1AV)2#XBJN0`K%\DS;$L08+^2W&
MEHT@3Y7%CG/Z+8FXK^:DQL/!=I]R=RZH4F"66X7-9,BIEI1:3U\[RI,M@=)6
MM(B4[#?9GR=<'HTEFR_H3'[`^AU;>M4A;JN82^/27?J"V@&!Q#AJ0SS3W.'&
M,F7=[W&Z#FI\-H7J]\<'7CV+/C"1-U7B(;\<3ZVT_#.SF\<E=NA=J6T49U-/
M2CUJIEU*62EAL^%*GI=(B5[#?;SVJX6%H]B,<M+ON%J*:A;FR&<EUR)5R`'P
MS9D[2)!L#@8.8HHM""4>(#KQJ+N7[^;G9B%,U=P524"ICL:7[!$NHJ2>T5U'
MF69]46#[:]S;8';$MU-OLK=RO#9!%3<"*ISF'SDMJ2&$'I!0RD@],]8W6111
M;(IMVZ23=NB0J:*""9$44DRAH4B228%33(4/````"M-K6MQ9<<)4X3,DF9)Z
MR3K$H&FFF&TLL)2AE(D$I```'``#0`=0CV5^8]D*0A2$*0A2$*0A2$*0A2$*
M0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*
M0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$-1\/)2$*0A2$*0A2$*0A2
M$*0CY,_.1EL04U<DTY(SA[?BI":E7:@@!&T=%M%7KQ<PB(``)-T3#_<KZZ"B
MJ;E7,VZC25U;[J&T)'$K6H)2/E)$<=>+M0V&TU5\NBPU;:.G<?=6>"6VD%:U
M'Q)23%*K<?G"X-Q&8[TRG/K+\LY)JI6_&JJG42@K69G.A`PS8AC&*DFU9`!E
M`+H!USJ''B81JXS;W#*#`,1H\8H0F;#8+JP)%QY6KKAZRI6@GP2$IX`1U?\`
M>W=.\;R[EW//;NI<JI\AALDD,4J"4L,I!)D$(D52T4X5KXJ,8-K-(U1"D([/
M:-DWC?\`,(V_8UK7!>$XX,4J43;<0^F7QN8>4#&;L$%SII\PZ<QN4H>4:XVZ
MWFTV*D57WJI8I*)/%;RTMI_*HB9\`UCG\<Q7)<ON2+/BM!67&Z+E)JG9<><,
MS*?*VE1E/I(D.DQ)CACM&;B\@>B262'<%AV!5Z:BB$NJ6X+M.@8WG`E`Q"XL
MVJPE#P=/$C%UXD$0$M1RS#O6;?6'FI\>2_=ZT3`+8[)@'PNN#F(_0;4#T'IB
M<NV7X=.\^8=G6YJY28W:52)2\?6*LIGK)AE7(DRZ'7FR)ZIF)1+5ACM<;6<4
M>B2$Y;KW+5R-^0YI3("R;N**X(<IP4:6JR*WA2$`2AH#@KHP<?.J*^8=YC<W
M*.9BBJ$6JW*TY*4%*Y=2GE3<G^@4#P18AMEW"]A-ONSJ[I1NY#>D2)=KR%,\
MP(,T4J`EF6@D'0\?SM8D,BXJ+A&+>+A8V/AXQHF"36.BF3:/8-DB@!2IMV;1
M-%NB0I0```I0``K05355-:^JIK'''JE1FI:U%:B>LJ422?&8F106ZWVJD106
MMAFFH6Q)#;2$MMI`X!*$`)2!U`"/WUZ(^R%(0I"%(0I"%(0I"%(0I"%(0I"%
M(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%
M(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%
M(1A;<=8]PY+P+EVP+3532N6[K!N.#A`66]&17D'C!4C=FJX$0*@F_-\`8YO-
M*"FH\-:S+;V]6_',YM-]NH)MU)7-..2$R$)4"5`=)3YTAJ9::QJ[>W%+SG.T
M61XACJDB^7&T5+#',KE"G%MD)05<$ASS"3H`J9TG%2YOLCW<.9`T6GMYR@#M
M-3I'%:W%V[,IN;E`XR*YDV'1$>(*`IR"'$!TXU::YO+M4VQZRJ_VWLB)B3H*
MOJ":I^"4^B.O,UW6>\0]6&A;P^^^L!4C.F6E'WBI-R_.Y^66LY1MIC+M![G+
MQ,W<7T]LS%,:H!#JEEI0+FGB)F-H8$XBW#.&(K%+Q`BKY(!\!$!K5F2=[#;>
MT!3=E1672H&@Y$=BU/PK=DJ7A#:OEB0V"_AQ;Y9(4/96[;;!1*`)[9T5+X$]
M9,TQ6@F6LE/HZB08D1Q5V=<`6@\;R62;IN[*ZZ)4C#$*BE:%MG7((&.99K#K
MK3+E$3!P3,^*40X&`P#I6@<G[V^=79E5/CM+26M!GY8F^Z!X"X`V#X>SGU2B
M9NW_`.&SM#C=2BNS6ON%_>0`>R,J2F*AJ2I+*E/*'YO;@2T4""1$G]AXUQ]B
MZ&3M_'5EVU94.D4I?0;;AV46FJ)0``4=*-DB+O%]`XJ+&.<?*-1KOF1W[)JL
MU^05E1659^<ZXI9'@2"9)'@2`/!$[<2P?#L#MHM&&6RAMEM'S*9E#05X5E("
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M@<2(X*_Y+8\7I45E]J$T],M?(E2@HS5(F7D@G@#&GWWSO;-]JJS_`)BO7[-U
MF/P5W.]TO?6:].,3^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?
M%_;GWFU]5ST(??.]LWVJK/\`F*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YW
MMF^U59_S%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"N
MYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWF
MU]5ST(??.]LWVJK/^8KU^S=/@KN=[I>^LUZ</B_MS[S:^JYZ$/OG>V;[55G_
M`#%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[Z
MS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(
M??.]LWVJK/\`F*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YWMF^U59_S%>OV
M;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+
M^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LW
MVJK/^8KU^S=/@KN=[I>^LUZ</B_MS[S:^JYZ$/OG>V;[55G_`#%>OV;I\%=S
MO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-K
MZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/\`
MF*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YWMF^U59_S%>OV;I\%=SO=+WUF
MO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^
M^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/^8KU^S=/
M@KN=[I>^LUZ</B_MS[S:^JYZ$/OG>V;[55G_`#%>OV;I\%=SO=+WUFO3A\7]
MN?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM
M56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/\`F*]?LW3X*[G>
MZ7OK->G#XO[<^\VOJN>A#[YWMF^U59_S%>OV;I\%=SO=+WUFO3A\7]N?>;7U
M7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7
MK]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/^8KU^S=/@KN=[I>^LUZ<
M/B_MS[S:^JYZ$/OG>V;[55G_`#%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\
M[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!
M7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/\`F*]?LW3X*[G>Z7OK->G#XO[<
M^\VOJN>A#[YWMF^U59_S%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:J
ML_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]
M]9KTX?%_;GWFU]5ST(??.]LWVJK/^8KU^S=/@KN=[I>^LUZ</B_MS[S:^JYZ
M$/OG>V;[55G_`#%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7
M[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?
M%_;GWFU]5ST(??.]LWVJK/\`F*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YW
MMF^U59_S%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"N
MYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWF
MU]5ST(??.]LWVJK/^8KU^S=/@KN=[I>^LUZ</B_MS[S:^JYZ$/OG>V;[55G_
M`#%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[Z
MS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(
M??.]LWVJK/\`F*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YWMF^U59_S%>OV
M;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+
M^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LW
MVJK/^8KU^S=/@KN=[I>^LUZ</B_MS[S:^JYZ$/OG>V;[55G_`#%>OV;I\%=S
MO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-K
MZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/\`
MF*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YWMF^U59_S%>OV;I\%=SO=+WUF
MO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH1N
M=M]W)X2W46*ZR5@*_8[(MD,KCD;2<S\8UDV;=*X8EK'/9&,%*59,'0JMFLLW
M.)@()!!0-!$0'3"\BQF^8I7BV9!3JIJY3:7`A123R*)`5Y)(U*3T]$9?8<BL
MV341N-C?3440<*"I((',D`D>4`=`H='3&<JX&.:A2$*0A2$*0C1K?IE[99AO
M&=JS^^""MR?QS(WFC%6RVN7&LCD]FE=YXJ0<)+(P\;"3BS)P$8BN'I!DBE`H
MB7FU-H.=X!9\VO5S=I\&<<;N262I90\&#V?,!(J4I$QS2TGX91A><77#[3;F
MG\S0VY;U/<J`MDO#M.4F82$JD9`ZR\$10_OV?A[/Z-L3_P"R)=7]GE;:_<+O
M$?XFK_\`4&_[:-7_`+Z[#_X>E]A7_91]^U=Y7X?F[[FM^U(VP,(,I&Y)B/@X
M]U/[7)JWX1%])N4VC0\K.2UAM8N(9"NJ4#N'"J:*0#S',``(UZ*O"^\+1TKE
M6[45RFVD%1"*Y*U$)$SRI2Z5*,N``)/0(]]+EVQ-74MTK;%$EQQ82"JC4E,R
M9":E-!*1/I)`'28EI3V$;'E4R*I;3]O*J2I"J)*IXMLXZ:B9R@8BB9RQ@E.0
MY1`0$!$!`=:U$=P,Z29&[7$$?^.YZ4;2&#X81,6N@(/_`(+?HQY?N";(?9,V
M^>JJT/HNO'Q!SGWO<?OW/2CS^XV&^ZZ#[EOT8?N";(?9,V^>JJT/HNGQ!SGW
MO<?OW/2A^XV&^ZZ#[EOT8U-W5PG:)V5P]K3.XG"&WJS4[UD'<=;$:QP='73/
M2RD>@#B0=H0=LVU*29(Q@4Y"K.CIE0(HJ0@FYC``Y=B;^\&;/.L8Y77%XL)!
M6HU10A,S(`J6M*>8ZR3.9`)E(1BV3L[58>TT]?Z*@9#RB$`4P6I4M20E"%*D
M-)F4@2!.9C2?]^S\/9_1MB?_`&1+J_L\K-_W"[Q'^)J__4&_[:,._?78?_#T
MOL*_[*/O6KO'[`=YW/;EGV_B_$CN>NN=BK<A&JFTRY&J;F6FGR$='-U'3G'Z
M39L19VX(45%#%(0!U,(`&M>BKPSO!45*Y65%56"G:;4M1]?09)2"29!Z9T'`
M:Q[Z;+=C*RI;I&*:E+[JTH2/45B:E$`"9:D-3Q.D2V_N";(@_P#ZF;?/559_
MT76H?B#G/O>X_?N>E&T_W&PWW70?<M^C''[@FR'V3-OGJJM#Z+I\0<Y][W'[
M]STH?N-AONN@^Y;]&'[@FR'V3-OGJJM#Z+I\0<Y][W'[]STH?N-AONN@^Y;]
M&'[@FR'V3-OGJJM#Z+I\0<Y][W'[]STH?N-AONN@^Y;]&(Q<T;BNQ5M_RC>.
M',HXAP]!W_84F6(N>):;69B;;,GYFJ#P$DI6'L5Y&O2]!R0>=%4Y>.FNH#6T
M;)C>_&0VIF\VJLK'+?4)YD*-<E)(F1YJG0H:CI`C6]XO^RMBN3UIN5)2(KF%
M<JTBB4H`R!\Y+1!T/08Q?^_9^'L_HVQ/_LB75_9Y7*?N%WB/\35_^H-_VT<;
M^^NP_P#AZ7V%?]E#]^S\/9_1MB?_`&1+J_L\I^X7>(_Q-7_Z@W_;0_?78?\`
MP]+["O\`LH?OV?A[/Z-L3_[(EU?V>4_<+O$?XFK_`/4&_P"VA^^NP_\`AZ7V
M%?\`91X*;[_P]229U3XWQ.!$R&.<?W1+K'0I"B8PZ!CO4=`"O(P'O$DR%35S
M_P#Y!O\`MH\'-MA@)FGI9#_^Q7_91+C;&R?87>%M6]=L!M3V_NX*Z8.(N.%=
M*8CM9JHYB)R/;R<:X4:N8=)PV.LS=$,*:A2G((Z&`!`0K4%5G&?T54Y1U%VN
M`?:<4A0]8<,E))2H3"I&1!U&D;4IL.PBKIFZIBV4)8=0E:3V"!-*@"#(IF-#
MP,?<_<$V0^R9M\]55H?1=>CX@YS[WN/W[GI1[_W&PWW70?<M^C#]P39#[)FW
MSU56A]%T^(.<^][C]^YZ4/W&PWW70?<M^C#]P39#[)FWSU56A]%T^(.<^][C
M]^YZ4/W&PWW70?<M^C$:^?,Z=CC;-E:YL*YAPYARWLB6>$6,]$,MKLI<#9I\
MLQ;29C^G+0=COXMUU8]ZF<>FJ;D$>4VA@$*V9C]AWUR>TM7NS5E:Y;GN;D4:
MY*">512?)4Z%#4'B(UW?+ULQCMT=L]VI*1NO9Y>9(HU*`YDA0\I+9!T(X&,.
M_OV?A[/Z-L3_`.R)=7]GE<S^X7>(_P`35_\`J#?]M'$_OKL/_AZ7V%?]E#]^
MS\/9_1MB?_9$NK^SRG[A=XC_`!-7_P"H-_VT/WUV'_P]+["O^RA^_9^'L_HV
MQ/\`[(EU?V>4_<+O$?XFK_\`4&_[:'[Z[#_X>E]A7_91W&#W=?A[IQ5)(+?V
MVP_5*F;JW#MRE85!/J?P5EGM@D32,GIYX"(<OEKXW\/[P[`)[2Y+E]"L2H_D
M#L?6SE6P[QEV=N1/Z=(I(_E:C>##F*.TGN$0ZV$L=[+\FJ`D*ZD?:=L8XD9I
M!`"@85G4"5F2;:)`4??*MR!_P#6"WF[[NXZKEOE3>J43E-Q;R4D]07/E/R&,
MSM%KVLOPG9J>T5)E.2$-%0'A3+F'RB,\_N";(?9,V^>JJT/HNN`^(.<^][C]
M^YZ4<Y^XV&^ZZ#[EOT8?N";(?9,V^>JJT/HNGQ!SGWO<?OW/2A^XV&^ZZ#[E
MOT8?N";(?9,V^>JJT/HNGQ!SGWO<?OW/2A^XV&^ZZ#[EOT8?N";(?9,V^>JJ
MT/HNGQ!SGWO<?OW/2A^XV&^ZZ#[EOT8U0W76YVF-E$!9]S;B=O>#[0A[[G'U
MN6RXC-OJ%VG>RT=&FEG;=5O:]K2J[,B;$@F!18I"&'@`B/"LMQ*IW<SBH>I<
M<N-<\]3MA:PJK+<DE7*#-;B0=>@3,8OE%/M=AS#51?Z"B::?64((I0N:@.8B
M2$*(TZ3&GUM;S.P!=MR6[:<%B_$CJ<NJ?A;9A&JFTNY&R;F8N"3:Q$6W4<N,
M?I-VQ%W[Q,@J*&*F0!YC"``(UF53A?>#HZ9RK?JJP,--J6H^OH,DH25*,@],
MR`.@U,8G3Y=L755#=*S34I>=<2A(]16)J40E(F6I"9(U.@B7']P39#[)FWSU
M56?]%UJ#X@YS[WN/W[GI1M3]QL-]UT'W+?HQQ^X)LA]DS;YZJK0^BZ?$'.?>
M]Q^_<]*'[C8;[KH/N6_1A^X)LA]DS;YZJK0^BZ?$'.?>]Q^_<]*'[C8;[KH/
MN6_1A^X)LA]DS;YZJK0^BZ?$'.?>]Q^_<]*'[C8;[KH/N6_1C\[S8AL6CFCA
M_(;5]N;!BS1.X=O7N,K*:M&J"91,HNY<KQJ:*"*90U$QC`4`\1K](SW/'%AM
MNZW)3A,@`^Z23U`!4S'Y7A.%-I*W+9;TH`F266P`.LF41^Y,S!V%,2R3R%NU
MILS<3+`YDW499^-(&_7":A!,4Z8J69;4XS%0AR"42]7F`W#2MA6RS;_7=I+]
M(;T&5<%./+:'_F+2?Y(P2XW;9"UN%FJ%H+R>(0REP_\`EH4/Y8UV?[\OP^;(
M0*CB?&$H/4.F;Y/VE36A`)X*<[ZRF29TSC[T2"81]S2LD;P'O#+\ZKJD:=->
MG_F=,<`YF^Q".%+3*\5"K_G;$?.^\!_#]_T(6'_LF+_9NO9\/>\)_CG_`&\>
MG'K_`'[V)_P3'L7_`'(^A';\_P`/H^6!%;$N,8K4Q"E6DMIDL"`B<V@B*C*S
M7O3*GXF$X%``KUN8!WAFT\R:RJ7X$UZ9_P`K@C]MYQL0X9&EID^.B5_S-G^6
M-V<")]EW<X_3A<(V=LZO2Y%4^H2TRX^M*#NY0`*8YRH6S<,)%3+LR1"B8X(H
MJ<A>(Z!6#Y`=Z\7;+]\>O+%,/Z3M7%-_*M"E)'@F1.,RL8V@R-SL;,U:7JCZ
M'9(2OY$+2E1^0&-N_P!P39#[)FWSU56A]%UA_P`0<Y][W'[]STHRO]QL-]UT
M'W+?HP_<$V0^R9M\]55H?1=/B#G/O>X_?N>E#]QL-]UT'W+?HP_<$V0^R9M\
M]55H?1=/B#G/O>X_?N>E#]QL-]UT'W+?HP_<$V0^R9M\]55H?1=/B#G/O>X_
M?N>E#]QL-]UT'W+?HP_<$V0^R9M\]55H?1=/B#G/O>X_?N>E#]QL-]UT'W+?
MHQ@3<AB#M:[2L:NLM9ZP!MULJRF\G'PJ+O\`F:@IJ3DYB45%-G%PT%"0#^8E
MGIR$.J8B")^FBF=0VA"B(9!C5YW5RZYBT6"X7)^M*2HCUE24I2GBI2E+"4CH
MU.I(`U,<%D-IVTQ:W&Z7RAM[-&%!,_5TJ)4K@$I2DJ4>G0:`$G01'A^_9^'L
M_HVQ/_LB75_9Y6Q?W"[Q'^)J_P#U!O\`MHP+]]=A_P##TOL*_P"RCL=H;Q/P
M_E[77;EG1&/L(-9:Z9J.@(QQ/[79FWH5.0E7*;-G\ISLQ8C2*B&9W"I2G<.5
M4T4]=3F`.-?/689WA*&D<K7JBN+32"M017)6J21,\J4NE2C+H`)/0(^BDRS8
MJLJFZ1IBB#KJPD%5&I"9J,A-2F@E(GTD@#I,2SAL%V0"`"&TW;X("`"`ABNS
MQ`0$-0$!"+T$!"M1?$#.?>]Q^_<]*-I?N-AGNN@^Y;]&'[@FR'V3-OGJJM#Z
M+I\0<Y][W'[]STH?N-AONN@^Y;]&'[@FR'V3-OGJJM#Z+I\0<Y][W'[]STH?
MN-AONN@^Y;]&'[@FR'V3-OGJJM#Z+I\0<Y][W'[]STH?N-AONN@^Y;]&'[@F
MR'V3-OGJJM#Z+I\0<Y][W'[]STH?N-AONN@^Y;]&->MS.*>UQM!QN7+.>=N&
M"[5L<\_%VP63CL$1UT.!F9@K@S!O\F6Y;<E(`14&I]5.GTRZ<1#4*R+%[MNI
MF-S_`&18+E7NUW9J7RFJ*!RIE,\RUI'2-)SC@,CM>VN*6_\`:E[M]$U1=HE$
MQ3!9YE3D)(03T<92B/K]^S\/9_1MB?Q`/]42ZO$1T#_]O/=K8?[A=XC_`!-7
M_P"H-_VT8)^^NP_^'I?85_V42ZP6Q[8C<D)#7%$;4MO[B)GXJ.FHM<^);4;G
M7CI5FB_9+'07B"+(&5;+E,)#E`Q1'00`0K3]1G6>TSZZ9Z[7`/-K*5#UAPR*
M20=0J1U'1&U6,,PFH914-6N@+2TA0/8($PH3&A3U&/J_N";(?9,V^>JJT/HN
MO5\0<Y][W'[]STH]O[C8;[KH/N6_1A^X)LA]DS;YZJK0^BZ?$'.?>]Q^_<]*
M'[C8;[KH/N6_1C/&-,38PPS;RMI8EL"T<;6NO*.IM>W[*@8ZW8=68>HM6[R3
M481B#=L=\Y09(D.J)><Q4B@(Z`%<!<[O=+U4BLN]0]4U02$A;BU+5RB9"9J)
M,@29#PF.;MUKMMHIS2VMAJGIBHJY6TA">8R!,D@"9`$SX(R#7'1]\*0A2$*0
MA2$5T/Q*7^J/AG^OQC_D;<M2/[L__N^M_P`@?]HB-`=X?_VK2?YX?[-<4ZL5
MQ5O3^4,;V_=Q71K5N"_;1@+B]"6]'>%AIR?814@HT7Y3]%RDW>"<AA`0`Q0U
M#36IEW5ZHI[74U%'+UMNG<6B>HYDH*A,=(F(B9;&F'[E3L54_5G'VTKEH>52
M@DR/7(QGS?#M`OS9-N$O+"%[HN'T8U75E\?7:HV%%C?>/Y!=8(.?:B'.@#LJ
M1!;OT"F,+9ZDH0>'*(X_@N8T&;XZS?*$A+I'*\W.9:=`',@],NE)Z4D'KCG,
MSQ2MPZ_/6:M!4V#S-+EHXT3Y*AT3Z%#H4"(L4=C;NKJ3Z-M[)=QUR]2<9MR1
M>W[(<Z\U6FV3<G\FQ5<#]R;5>68(%$(1=0W,X0)Z((BH1$#QRWUVG%.7<XQM
MJ3!/-5LI'FD\7T`?-)_6`<#Y?`JEOW9?<XOAO#L@<^V`E2NJ/G`<&5$_.`_5
MD\1Y'$)G:@J*429C7#==NDQ;L[PE=N<,L20-H2W6HHP\(V61+-WG<[DAPA;2
MMUNL8/2966<EY=0`2H)`=931-,PADN)8K=<ROC-BM*9ON&:E$'E;0/.<61P2
MD?E,@-2(Q[*,EMN)V9V\W14F6QY*1YSBSYJ$#I4H_D$R=`8_G4;N]V&4MYF;
MKJS?E>2,9]++*M+8ME!PH>!L"SVZRAXBTK?24'1)FP2-S+K"'4=NC*+J")C\
M+'</Q*U878VK%:4^0@36LCRW7"/*<7X3T#@E,DC01`/*LGN677EV\W17EK,D
M(!\EIL>:A/@'2>*C,GC&8<K;*)[!NQG#6YW)*3R*O+<7E(S#'-J.-6ZD7B2(
MM*7EE+FE6AQ*M\IW=+"U5:D,71&.*0XZ&<!IP]IS>GON=UN+6TI716VEF\X-
M>:H4XE/(D\.5M/,%'I7,<$QRUSP]^RX71Y)<04U=PJ9-(.G*PE"E<ZAQFM7*
M1U(D?G1K=ML_UB\!_P!<V-/\L(BLDR;_`-N7#_)/?[-48_CO_'Z'_.,_[1,?
MU%S>(_KJK&+*#'%(\0I"%(\CC'\YKNY?[R#=?_6&C_D]#59#M#_\;6G_`"W_
M`&U17_NI_P#(-T_S'_83&QW9"V@8#WD9ZR_9&X.RW%[6W:F(V]TP;%"?G;?%
ME-J7?#Q)G9W,`_CW"X&8NSD`ASB34VNFH!6-;Y9CD&&6"CKL=?#%2]6%M1*$
M+FGLU*E)8(&H&HUCG]FL4L>6WRKH[\R7J=JE"T@*4F2NT2F<TD$Z$Z'2+,?W
M%O;/_H$D?67DC[35&/X[[G>\$_<L^A$B_@KMU_@3]Z[Z</N+>V?_`$"2/K+R
M1]IJ?'?<[W@G[EGT(?!7;K_`G[UWTX\5.Q5VS%2'3/@.1$BA#$.'\Y>2`U*<
M!*8-0N;4-0&@WXW/!F+@F?\`H6?0CP=E-N2)&A5+_3.^G$KEM6]$VC;EOVI`
M-A9P5L0D3;L*S%55P+6)A&#>,C6PKKG476%!FU(43G,8YM-1$1&M3552]65+
ME74'F?=6I:CPFI1*B9#03),;0IJ=JDIVZ5@28:0E"1QDE(``F>H"/M5Z(]T*
M0A2$?SVN]S_O,]Q?_-QQ_HWMBK$-C_\`XQMW^N_VRX@=O)_\C7#_`%/^Q1';
M.RSM"P5O-W&Y%QUGZVI.Y[6M[$+V[8EG%W',6TLA.HW5;T61RH[A7+5RND#&
M05+TS&Y.8P&TU`*^3>S,+]A>-TURQ]U+56Y6!M14A*YI+:U2DH$#4#7C'T[0
M8I9<NR&HM]\;4Y3-TA6D!:D25SI$YI()T)TBS1]PKVT_Z([N]:]_?351A^/V
MYO\`C&?N&O1B1OP/V[_PKOW[OI1P;L*=M,Q3%_FDO`O,40YBY8OX#%U`0YBC
M\LCH8OB'Z:\_'[<W_&,_<->C'CX'[=_X5W[]WTHU-W-?AU-LTKCNYI?;1<^1
M,=Y(AH60D[?A[GN4][V;<3]BV5<I0TF66;A/1ORF*71(Y1=F!`YP,*1P#2LM
MQ?O'9.U<FF<G:IJFVK6$K4A'9.(!,N9/*>17+QY2G7A,1B^1[`XZY0..XZ[4
M4]P0@E*5K[1M9`GRGF',)\)A6G&1BFY!3=Q67<+*X;9F9BT[L@'_`%XZ>MZ2
M>0T[$23-42]9C*QRK9ZV715((<Q#AKX#PX5,Y]BFK:=5/5(0]2.)D4+2%)4D
M]!29@B(DL/5%&^FHIEK:JFU3"DDI4DCJ4)$&+\_96WHY"WE;47K_`"](!/90
MQ'>2V.[ANH4D475WQ813"7MNX99)`J:(3:S%T=N[4*4H.%6PK"',H8`K_P![
ML*MV&98ENSI[.UUC(>0WQ#:N8I6A,]>4$32.@*Y>`B<6SV7U^78N5W57/<J5
MXM+7TN#E"D+5+YQ!DKK(GQ,3`5IR-L0I"%(16-_$W_YD=JG]<MY?Z/W%2A[K
M_P#QR[?Y)O\`VHB./>-_X-;/\VY_LHJG;?/]8#`O]=V(_P#2';E2QR'_`-OU
M_P#D:C_8KB,5B_X[0_YUC_:HC^I(/B/ZQ_XZJMBRN.*0A2$*0BD_^('W@Y5N
MS<_([58:[)J!PUC&U[6<SEJ1#UQ',+VO*Y&`SCR4NDC<R1YEM$,G*#9HV6,=
MJF)3J`3J'$U3>[O6'6FCQ9.5O,H<O54ZX$N*`46FT'E"43\TJ()41Y1T$Y"(
M=;ZY9<ZO)%8RRZM%HIFT%2$D@..+',2N7G!(("09@:F4S$77;MVC-=[6ZRP<
M`R5P/+2MF59S]SW?-Q"#967;6Q:T>+^0;PZ;HAVA).27.BV354(H1#K"H)#\
MG(;:>XV7KPC$ZC(&FTO52"A#:5$\I6LR!5+7E2)J($B92F)SC6V`XJG,<G8L
M3CA:IE!2W%)`Y@A`F0F>DSH`3.4YR,I1</MWL(]MB":)MGF++SNE<J1$U)"X
M\IWJJ[74*!>=<R<5)Q3)%100X@FD0@:Z`4`J&]3O_N74+*D5;+29\$,-2'@\
MI*C^4F)94^Q^WC".5=,\Z9<5O.3/A\DI'Y`([#]Q?VS?Z!9#UF9'^TU?-\=]
MSO>"?N6?0CW_``5VZ_P)^]=].-(-^787VW--OU_WMM"L/(43F^UF+67M.R(B
M[)>[(N^13D&B4A;@Q%SO':C=XXCE55$%T7*0D53#G`Q1$*SG`=_<E7D-/0YA
M44Z[&ZHI<=4VEM36ADOF0!,!4@04F8.DC&&9OLACR+$_6XHQ4)O+20I#:5J6
M'-1-'*LF1()(((U&LXKN1?;"[ED%*1T[!;3<ZPL[#/&\G#3,2T81\K$R3-4J
M[1_'/VLZDZ9NVRY`,11,Q3%,'C4C'=T=LGVE4[]WH%L+24J2HDI4DZ$$%$B"
M.(,:#:VXW$9<2^S:ZU#Z""E20`I)&H((5,$'I$7[MH\OEZ=VR8-E,_1$G!YI
M7QQ;J63(V:02:RZ5VLF@,91>3;H'412?OU6WI"H$$2<ZHZ<-*K^S!FST^45[
M6/K2Y9!4K[%23-/9DS2$DZR`,A/H$3EQ5VZOXW1.WQ"D7@TZ.V"A)7.!)1('
M293/CC8FL;CGX4A"D(^3/ST):L',7-<DHQ@[>MZ,?34Y,R3@C6/BHF,;*/)"
M0>N51*F@V:-43'.81T`H5[J>G?JWT4M,A3E0XH)2E(F5*49``=))T$>I]]FE
M874U"DHIVTE2E$R"4@3))Z@-3'\]ONK]PJ=WY9\=N(%Z]:8`QB^DX3#=O*@9
MN610,8K:5R'+-1T'Y:NPS<#)%/J9JP!)(/.%036(;3[=L8#CX34)2<@JDI54
M+XR/%+*3]%N>LO.7,\)1`[<[/'LWOA4PHBQ4RBFG1PF.!=4/I+EI]%,AUQG_
M`+0O:B2WRKWME7-!9Z`V_6[&S=IVX\B5SQTK>>273,S9)S#N1+H>%L(5P=.C
M<2.'O2;CJ4%P#'MX=V3@B6+39.S<R%Q27%A0FEMD&<E#Z3LN5/2$S5QY8YW:
MG;`9HIZYW?G;L3:5(04Z*<>(E-)^BU.9ZU23PG$8F[#;%D7:#G6^<"Y/::3-
MJOA/$3:"2B<7>-IOC'5MZ[H8YP#G8S#$`,8GOF[@JB)]#IF"MHXEE%MS&PL7
M^UG[!U/E)/G-N#SVU>%)_*)*&AC7&48W<,4O;UCN0^V:5Y*AYKB#YBT^!0_(
M9@ZB+9W8O[EY\_60WVF9NN4SO-F-X?7&T_++E%[DO&\0V(F$>LX4T.^NVR6R
M8$7$1,J[CP(L/,=)8PQ'WWVQ&/UQRZQM2LE2O[9"1HR\H\0.AMTZCH2N:>!2
M(E%LMN*;Y1C%KRY.\4Z/LE*XO-)'`GI6V./2I,CQ"HL45'&-_0I"%(0I"((O
MQ$O^[^;_`->&.?\`S,]6^^[E_P#(1_R+W_9C26_O_L4?YUK_`+447/<_YQ?_
M`"@J=QX1"R/ZFN%_\SN)OZLK"_R5B:JJO?\`QJL_S3O^T5%E]G_X12_Y9K_J
M)C)=<7'(PI"%(0I"%(0I"%(0I"*Z'XE+_5'PS_7XQ_R-N6I']V?_`-WUO^0/
M^T1&@.\/_P"U:3_/#_9KBF[CW_.'CW_\_65_E/%5,^X_\.J/\N[_`-141)H/
M^(4_^G;_`.NF/Z(_<-V`XYW]X*-94\5M`9/M5BXEL09%*B!G=L7&JS2$T9)"
M0.J]M.X3()HOV_$0*!5D_A$RZUS;=;@W+;^_>NT\W+6\H)J&9Z+1/SD]3B)D
MH/C!T)B?&>X+;\YLGJ;\D7)I)4P[TH7+@>M"M`H?*-1'\]K*V*\G[=<JW+C#
M)$+*V)DW',\1M(-`65;/&#]FHF[BIR$DFYB"NQ>)@D[8/4#<JJ1B*$-[EB%I
MNMKR.TM72VK146NI;F#*8(.BDJ2>!&J5I/`S!B!]TMERL%S<MMP0IFXTZY$<
M""-4J21Q!T4E0XB1$78^T+W283=#@2X[7W`7A$0V;=OEL+3%^7%,N4(]&]<8
MP[81+E!4QN1,'<4BET)OE#0KCD7\'``6$.\.U3^+9`U58\RM=CN+O*TA()[)
M]1_4>)1U:\$T_-UF)M3N6SDEC<IKZZE%YH&^9U:B`'&4C]=XT\'/#)7SHJ]]
MT3N"73OTSY(R[%\^88)QZ_DH/#%I&.HDW/&%5]'=WW*M!$"GN.[N@"PB<!,U
M9BD@4?-.)I2[6;>4F`X^EEQ*57ZH2E52YT\W$-)/T&YR_.5-75$;=R<[J<WO
MBG4*4FRL**:='1R\"ZH?37Q_-3)/7/;WLP]K)?=A>C+<3G.`<$VW6%+D5@(.
M01.DCF>[XQQK\F%*<"F<6+`.D@&24+YKQ<`:E$2@N)<.WJW53B5"K'+$X/WE
MJ$>6H<:9M0\[P.K'F#YH\L_-C*MH=LU916)O]Z0?W>87Y*2-*AP'S?"VD^>?
MG'R>N)%_Q,K9NSPGM,:,VZ#1HUR7?#9JU;))H-FS9"S8Y)!NW02*5)%!%(@%
M(0H`4I0``#0*UOW8E*7?+NM9)6:5HDG4DEQ4R3TF-@=XM*46>UH0`$"H<``T
M``;3(`15EVV?ZQ>`_P"N;&G^6$14J\F_]N7#_)/?[-41IQW_`(_0_P"<9_VB
M8_J+F\1_756,64&.*1XA2$*1Y'&/YS7=R_WD&Z_^L-'_`">AJLAVA_\`C:T_
MY;_MJBO_`'4_^0;I_F/^PF/H]L79GE3>ME;(=B8GSX]V_3-HX^2NR2N-@C<J
MRLY&J7#'Q`0I@MFX;<<E(1R[*OJHJ=/S.!>;00]>Z&:6G"+335]WMZ;BR]4%
MM*#R>2KD*N;RT+'`2T`.O&/WMQB-SS"Z5%%:ZY5"\TQSE8Y_*'.$\OD+0>)G
MJ9>")L/N#MYW_P`RRX__`&+*_P#:C6D/C_A/_P#3#7Y:?^PC<?P.R[_^HG/R
M/_VT/N#MYW_S++C_`/8LK_VHT^/^$_\`],-?EI_["'P.R[_^HG/R/_VT9$Q#
MV/\`=SCK+6+<A3O<.G[JA+#R-9%Z3-KJL\GE2N2*M:YHR<D8!0SS)+MH5.99
ML3MC"JDJF`*><0Q=2CQMXWRP^XVBKMU/CC;3]13.MI7-CR%.(4D+T9!\DD'0
M@Z:$1]]JV:RJWW2FKWK\XZRQ4-N*1)[RTH6%%.KQ'E`2U!&NH,681XB(_IJ,
M<2*CBD(4A"D(_GM=[G_>9[B_^;CC_1O;%6(;'_\`QC;O]=_MEQ`[>3_Y&N'^
MI_V*(W&_#9?ZXV7O_P#/DE_ES:-8;WE__9E'_P#R*?\`9.1EG=Z_]W57^0/^
MT1%U^H0Q,6%(1\Z8=MH^(E7[U=-LS91D@[=N5CE31;MFS199==50P@4B:21!
M,81'0`"O:PA3CR&T`E:E``=9)D!'K=6EMI3BS)"4DD]0`UC^5;=+U"2NBYY%
MJ(F:R%R3[YL80`!,W=RSQP@80`1`!%)0*M=I4*:I6FU^>EI`/C"0#%952M+E
M2XXGS5.*(\142(N'?AG8A5OMRW&3ABJ@C*YJAV"9S$`$#'AK*8**E2/XF4($
MH7G#^"`E]VH;]YUX*R2VL:<R*)1\/E.'T8ECW=6BG'[@]K)58D?5;'_UBRK4
M98D1"D(4A%8W\3?_`)D=JG]<MY?Z/W%2A[K_`/QR[?Y)O_:B(X]XW_@UL_S;
MG^RBJ=M\_P!8#`O]=V(_](=N5+'(?_;]?_D:C_8KB,5B_P".T/\`G6/]JB/Z
MD@^(_K'_`(ZJMBRN.*0A2$*0C^?GWSXUS&]R[-P.2@7Y0@,9RC?3F\YJ[LR/
M(D8>8I>(F0-X:AP\:L*V(<2YME0\OS7'TGQAP_\`UB">]#:F]Q*WF^<AE0\1
M;'_TCO/X?QVV:]R"SB.%B)'>XIRNS:E.(@*[H8F/<@@GH`ZGZ#90_P"H@U\/
M>#0I6VKQ2)A-6P3X!S$3_*1'V[%J2G<)D*,ITKX'CY0?^0&+Z=0#B;\*0CKU
MVW9;UAVM<=[7;*)0EK6E"2=QW',+IN%D(J$AV:K^3D%DFB+ATHDT9H'.8$R'
M.(%X`(U]-'25-PJVZ&C07*MY:4(2)`J4H@)&LAJ3+4Q\]754]#2N5E6H(IFD
M%:U&<DI2)DZ3.@$]!$>8=XWMF"`"&[S'H@(`(#\EWQQ`>(#_`-5:V)\&MS_<
M]1]9KTXP+XM;<^]:?\CGH1O)B+,&-<]8^M_*V(;NC[ZQY=2;M6W[IBTGR+&4
M38/G,:[,@G(M63PH(/FBB8\Z1>)!TU#C6"WBS7.P7%RTWAE3%Q:(YT*D2F8"
MA.1(U!!XQFEJNUNOE`W=+2ZEZ@=!Y%B8"I$@RF`>((X1DFN,CD84A"D(J0]_
M+N3FEWTCL6PE<0_)4>HD;<9<<2XT*_D$S).F&*&[I$P@=HR$".9H`'SE@3:F
MTY%BC+WN_P"V?8MISN^-_;*']S0H<!P+Y!Z3P:\$U]*8BQOCN&7EJPJS.?9)
M/][6D\3Q#`/4.+GADD\#%=W:]AB`SYF^Q\:7=DRR</63*R!7=[9&OVYH:UH2
MW+4CA(XF56CV<=LVCNX';4!08-0,)E7*A1$`(4Y@D9E-ZJ,?L3]SHZ5^LK4)
MDTRTA2U+<.B9A()"`=5JZ$@],HT'C=H8OEY9MU74LTE&I4W'75I0E"!JJ140
M"HC1(Z2>H&/Z`>'MS';BP-C&R\08NW.;9+:L2PH-K`V_$MLS8]U(W;E$RSQZ
ML$X4SR4DW1SN'3@WGKN%3G-Q,-5[WG&-R;_='[Q=+7<W:^H<*UJ-.]Q/`#R=
M$I$@D<``!$Z;3D>WUCMK-IMMRMK=$P@)2D5#7`=)\K4DZD])),1O]W"WMA^^
MO!:DI9FZW:ZSW$XI:/IG&$TIF3'B"MRQY4U',QC26>!.@<8^X0)SLC'YBM9$
MJ9@Y2*+".RMH*G/<#OO8UMINJL<JU!+Z?5WCR'@EY(Y.*/G2\Y$QJ0F->[J,
M81FME[6CN=M%_I05,J]8:\L<5,J/-P5\WJ7(Z`F*:&.\A7MB._+4R7CN??6I
M?EBSK.X+:GHU;E<QLM'*\R9@,F;IN6JP<R2Z0B9)P@<Q#:D,.LT;C;J&\4#M
MLN+:7J!]LH6@\%)/_(>D'B"`>(B(]!7UEJK6KC0.%JN86%(4.(4/^4=!'`B8
MX&/Z*/;DWT6=OTV\PF28TS.*R1;A6=MYCLI%0.I;-ZIM0,J[9HF,98;;N4B9
MG<<J;Q2,9(1%1$]5R;DX'6X#D2[:[S+MKLUT[I^>W/@3PYT>:L=<CP(B?6WV
M:TF;V%%P;DFX-R0^W]!R7$?F+\Y!ZICB#&_=:^C.H4A"D(@B_$2_[OYO_7AC
MG_S,]6^^[E_\A'_(O?\`9C26_O\`[%'^=:_[447/<_YQ?_*"IW'A$+(_J:X7
M_P`SN)OZLK"_R5B:JJO?_&JS_-._[1467V?_`(12_P"6:_ZB8R77%QR,*0A2
M$*0A2$*0A2$*0BO/^(ZMZX;CVG8=:6Y;T]<;M'.S)=9I;\+)SCI%`+/N0@KJ
MMHMJ[620`Y@#G,4"ZB`:ZC4BN[;44]-EM8NI<;;0:`B:U)2)]HC2:B!.-"]X
M%A^HQ>D33MK<4*T&24E1EV:]9)!BG_C_`!=E%/(%@**8PR4FFG?=F****6!=
MY$TTR7-%F.HH<T,!2$(4!$1$0``#4:F+<+K:C;Z@"JIB33N?TK?T%?G1%&@M
MMR%>P335$NW;_HG/II_-C^HDV`0;-@'@(-T`$!\0'I$JK)?GGQF+)D^:/%$0
MG=G[8EO;[,8'O&P&45!;G,>QJRMCW"J5)FA?4.W*HX7QQ=3P`*`MGIA$T:[5
MU]!=B`"((JJUN':/=&HP.Z>I7!2W,7J%?:HXEI1T#S8ZQ\](\Y/YP$:IW2VW
M8S6V^MT*4HR.G3]FKAVB1J6EGJ/S%'S5>`F*+#K$^>+.EI^#<8PS#;LRU&5M
M2Y6"%DWLS<<A%_19F!DC,HP$WC)1=MRK)"91!;D`1Y@T&IX)N]@K&6WTU5&X
MP>5Q!+K1'":5IFK0R.AT(B%2[7>J1U;*J:K;>',A8#;@/&2DF2=1,:C4&)#>
MV7VN\E[U\SI)9`MJ[\?X#L!XPD<HW',0LM;4C/)&/UVMAVB:69-CJS,ZFF(+
MN2%.1@TYE!U4,D4VNMS]T[9A%E*K>ZS49!4)(80E25I3T%USE)\E/0DZK5IP
MF1GVW.VMQS&[@5[;K%C8(+RU)4@JZ0TCF`\I72=0E,SQD#?SLFR;3QO:%MV#
M8EOQEJV;:$.Q@+:MV';$:1L1$QR)4&K1J@F```%(74QC:G4.(G.(F,(C7Y75
MU7<ZQVX5[BG:UY96M:C-2E$S))__`$`-!I$YJ*CI;=2-T-$VEJD:0$H0D2"4
MC0`#_P#4^)UBN9^)3MJY;EP_M:1MJVKBN19KDZ^U72-NP4M.JM4CVDQ(15RE
M%,W9VZ9SAH4QP*`CP#C4C^[/54M->;JJI=;:2:5J16I*9_:*X<Q$_DB/W>'I
MZBHM5L%.VXX14NSY$J5+R!QY0915[VY8RR:VW"X)<.<9Y';-T,PXW67<.+"N
MU!N@BG=T2=19=96'(DBBF0!$QC"!2@&HCI4ILDNEK5CM>E-53%1HWI`.MDG[
M-7`<T1NQ^W7%-^HE*IZ@)%6SJ6E@?K$_FQ_3@-XC^NJOXL<,<4CQ"D(4CR.,
M?SR>['CS(<MW%-U$C$X]OV6CG60$5&LC%V7<\C'ND_J_#EZC9ZRBEVKA/F`0
MYB',&H:58KM+<;<SMS:FWJBG0X*?4*<0"/+5Q!4"(@3NA05[N?7-QIA]39?T
M(;60?(3P(208^+V_MT^XWM\9'O;)-A[;K@R%(WQ92=DO(V[[.R1&LF+-.;8S
M@/6JL-#==1R*S$J8E/YG(81\:]VX6*8WN';6+;7W-NG;8?[4%MQE1)Y2F1YE
M2E(STCTX+D]_P.X/7"AM[C[CS/9D+;=``Y@J8Y4SG,2B6+\PGO?]A.W_`)FS
M5]#5J7^'?!??SGUJ;THVA\><R]RH^K4>C#\PGO?]A.W_`)FS5]#4_AWP7W\Y
M]:F]*'QYS+W*CZM1Z,>"GXA7?`1,YPV)6^(E(8P!\C9KXB4HB`<(;7CI7D=W
M?!29?MYSZU-Z4>#OSF0$_P!BM_5J/1BTQ@>_YK*N%<4Y,N2#3MFX+]L"UKMF
MK>2(]32A).=B&L@\BTTY$B;\A&2ZXI@"Q04#E\X-:BI?[>Q:;W5VRF67:>GJ
M'&TK,O*2E1`5IIJ!/33JB2]CKWKI9J6XU".S??80M2-?)*D@D:ZZ$RUUC+-<
M1'*PI"%(10'[T]@7_-=R?<+)0M@WU-1K@N.O1Y*'LZY)2.<=/'5M)J=!\PC'
M#5;IJ%$IN4X\I@$!XA5@NR=PM[&VEN;?J&$.CMIA3B$D?;+X@J!$07W@H:Y[
M<.O<98?6V>RD4MK4#]DC@0"(P=L1W*[E]@F4+FRIC?;].WG,7392]CO(Z\[!
MR.G'-X]>7C9DSMN,-'M'/I95XLA0YC"3D,/#72N=SW&<9W`M;5IN5Q;89:?#
MH+;K,R0E29'F)$I*,<-A.19%@UR<NENH%O/.,ELAQIV0!4%3'*`9S$2N?F!>
MX#[&=H_]A<U_\M:F_A[V]]]/?>TT;.^.V=^Z&ONZB.#?B!>X$)3`79K:!3"4
M0*8;$S68"FTX&$O,7F`!\FH:T'=[V]G_`,:>^]IH?';._=#7W=1&LF?NYCW:
MMW5HS.+66)[YL&SKK9GCYV'PU@G)$7+3\,^3,@O%.[JF6\U,DCI!$QTUBLU6
MI5TC"0VI1$!RC']L=H\/K$75=6Q45K*IH54U3*DH4-0H-I*4S2=1S!4CJ(QV
M^[B[I952+MJ*5YBC=$E)IZ9T*4DZ2*U!2I'@>4B8TX1KMM^[,O<!SU+QK8<*
M2V'+6<J)`]O3,X?4MC',S"4#N4;;7ZEWRIRICJ1-%D`'_CE#B&1Y#O3M[8&5
M*]>16U8!DW3?:%1ZBL?9I\)*M.J.`L6T6=7QU*?4U4E,3JY4?9@#KY/UBO$$
M_+%W/8SL]LG8WMXM;!%F2+BX%6+I]<5Y7<];D:.[OO::Z)IJ<.S3.J5BT$K=
M)NT;@<_0:()D$QC`)A@YG>95V=Y&[?JU(;2H!#;8,PVTF?*F?2=25'2:B3(<
M(F1A>)T>%V!JR4BBX4DJ<61(N.*ES*ET#0!(Z$@"9XQM_6'1ED*0A2$5I_Q*
MMM7+<N%=K:-M6U<5R+-<PW@LZ1MV"E9U9JB>PETR+.4HIH[4;I'4'E`QP`HF
MX`.M2:[LU534M[NJJEUMI)HVP"M24@GM1PYB)Q'?O#TU146>VBG;<<(JG">5
M)41]GT\H,5:\!8QR<WSW@IPXQED=NW0S5B===PO85VHH(((Y`MY159=96'*D
MBBDF43&.80*4H"(B`!4J<@NEK58*]*:JF*C1/@`.MDD]DO0#FXQ&BQVZXB^4
M1535`2*Q@DEI8'ZU'YL?T[1\1_6/_'57D6/QQ2$*0A2$5Z^\UVEK^WCSUO[B
M-NRL&OEZV[53M*[K"FGB4*GD&"C'+AY"/X:=<CZ`TN>'([5;@DZ%)!TW$A04
M3.F'/(G9;=VWX93N8YD8<%G<=[1MU(YNR6H`*"DC4H5(&:9E)GH0=-#;N[6U
MV6OHO]@*#=6VN1;2CR]JD$E)2HZ!:9D25($2U!&M72$PAO\`-D^7;7R;&X+S
MMC#)&.YKY2@+A2QI/ST65P1)9J[1%Y%QLQ;T]"23%95!P0%%6SANH8HB(#K4
MIW[YM_F]H=M;M?055MJ4<JT=LA"I<09*4E:%`R(T!!`B-;-FSG#[JU<FZ*MI
MKA3KFE78J4)\#J`I*DD3!U(()$2]6Y^(5WY0#)*/O3:I85RRJ""1%GXVAEFT
M%US@`?RI>-(I)))G7+Q$"<A-1U*`!PK3U3W=L!J%ERBNU0TT3P[2G<`\`/D\
M/#KUQM:GWYS=A`166QAQT#CR/MD^$C7C\D=B_,8[PO8PL7_ZF6OHZOG_`(<,
M-]]/_P#^O_\`6/?\?\L]T,?^?_\`2-;-R/>2[B&Z?&EVXAA<'M\<6=?\5(6Q
M<ZF.<89*N"Z9."DTCH2D&UGI1-\FP2?L%!17.W:D<BD8W*H0##62XULQMSBE
MS9O#]<:FLIUA:.V?90A*DZI44IE.1U$U$3X@QCV0[MY]DUN=M3-$*>D?24+[
M)EY:U).BDA1G*8T,DSETB-#<%]K_`'V[@Y>.CK*VYW_`1+U5%-6\LDPSO'=G
M1C=0`,9XYDKG18N7:2*8\PI,T'*YO`I!$:SZ_;I8%CS*G*ZY4[CR1^K94'G"
M>H)02!/K44CPQA%EVWS:_.I;H[>^AHG]8ZDM-@=9*Y$RZD@GP1?HV7;<4-I.
MUW#FWHDRE<;O'%K!'S5P-T%&S:9N&2?O)N??-$%C&628GEI)8K<I_/!`I.;0
M=:K_`,VR167Y56Y$4%M%2[-*"9E*$@)0">OE2)]$YQ./#\?3BV-4EA"^T53M
M24H"04HDJ40.KF)EX)1M!6*QDL*0B*SNQ;X[DV?8"<Q6(X"Y+GW`Y5;/H''2
M-O6S-7$C9K'0J$YD&8&+CWJ+?Y$06Y8])42^DOSI\#)IJZ;8VDP6FS'(`]>'
M&FL>I"%O%:TH[0\4LIYB">8CRR.")\"1&L=T<SJ,3L9:M2''+[5`I:Y4*7V8
M^<ZKE!`Y1YH/%1'0#%"E'$V=KVN=)$N,,MW'=MX3Y2=5W8]X+R<]<=P2'G+.
MWKN**"KR2D70F465.`<QQ,8P!J-3[5=[#0TI4:JC;HV6^AUL)0A`X`!7!(&@
M`\`B$";7>JRH"?5JIRJ=7TMN34M1Z24\23J3%N;`GX<[;&&'K"4W%3V5)#-#
MR":R&02V5>T;$6K&3KX/2EH*':*6[(G50@B*E:F<"L?TE1(RH<I3`4(@Y!WD
M,H_;-0,<;I$V1+A#7:-%3BDC3F4>=.JO.E+R00-93B5-CV`QS]DL&_KJ57<H
M!=[-P)0%'7E2.0Z)\V<]2">F,O?ES^WO_P"F9\]9,5]D*X?^)#</Z-O^Y5_:
M1RO\/^!]==]ZG^SA^7/[>_\`Z;GSUDQ7V0I_$AN']&W_`'*O[2'\/^!]==]Z
MG^SB(_NM=E./VKV+;N;-I[?(E\X[CU48/*%I3*Q[SO"WGC]UTX:[XL8:(:.7
MENKJJ%:.T00,=HJ9-7F%,Y^GM[:;>US+*]RR9::9BY*',PXD=FVL`>4VKF40
M%C523/RA,2F!/5FYVSR,9HF[QC`J'Z!)Y7D*/:.))/DN)Y4@E'S5"7DF1X$R
MCHV![@]QVQ+<);V7K8Q?EJ4M%Z9"`RO8R%C7BDVO:Q'#DBCYH"9X4S<D[$'#
MTJ-7,412<$Y1^#44`=D;@8]C>>XZY9ZJJI$U@FMATNMS:=`T/G3Y5>:L=(,^
M($:_P:_9!A-^;NM-352J4^2\WV;DG&R=1YLN9/G(/0=.!,?T.,<W_;.5;#M+
M)%FN73NU[U@F%PPBSYB[BWX,I!$JI4)"-?)(O(^0:G$4ET%2%.DJ0Q1#4*KJ
MN5OJK37O6VM`%4PX4*D0H3!XA0F"#Q!&A&L3VM]?372A:N%(2:9Y`4F8*3(]
M!!D01P(.H,=TKX8^R%(1!M^(.@YRX-A+=A;T'-7`_#-F/%O0(&)D)I]T4TIS
MJ+>AQC9TYZ*?,',?EY2ZAJ-;V[O#[%/GY<J'$-M^HO":U!(GY.DU$"<:7WX9
M>?P<(80MQ?KC1DE)49>5T`$Q2#_FKRIP_P#TMR;P$!_S>WAY!U_^"_HJ<G[5
MM/\`BZ7[YOTHAI^S+E_AJG[IST8L-VMWY=^]IVQ;=JLMG5L.6=LP$-;S1PYL
M7-'I+AM"QS:-07<`F!4P662;`8P%`"@81T#2HZU>P>`5=4[5N7ET+=<4L@.T
MT@5$J('@$XWU3;W9Q2TS=*BTM%#:$I!+=1,A(`!/ATC[OY@7N`^QG:/_`&%S
M7_RUZ/X>]O??3WWM-'N^.V=^Z&ONZB'Y@7N`^QG:/_87-?\`RT_A[V]]]/?>
MTT/CMG?NAK[NHB?CMA;N,M[TMN4QEW-&-X_%EW1^5+JL=O;<9%W-$-EH.#AK
M6D6,L+6Z_P#&9E7;B;7()R_`B"0`7B!JC]NEB%GPG)$6>R5*JNC52-NE:E(4
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M:!Z$/CW@G57_`'!]*./S#_;V^(W!^IY?Z>I_#GN)UV[V@>A#X]X)U5_W!]*.
M0_$0=O</!'<'ZGE_IVG\.>XG7;O:!Z$/CW@G57_<'THY_,0]O?XG<'ZGE_IV
MG\.>X?7;O:!Z$/CW@G57_<'TH\?S#_;V^(W!^IY?Z>I_#GN)UV[V@>A#X]X)
MU5_W!]*'YA_M[?$;@_4\O]/4_ASW$Z[=[0/0A\>\$ZJ_[@^E#\P_V]OB-P?J
M>7^GJ?PY[B==N]H'H0^/>"=5?]P?2A^8?[>WQ&X/U/+_`$]3^'/<3KMWM`]"
M'Q[P3JK_`+@^E'E^8A[>_P`3N#]3R_T[3^'/</KMWM`]"'Q[P3JK_N#Z4/S$
M/;X^)W!^IY?Z=I_#GN)UV[V@>A#X]X)U5_W!]*'YB'M\?$[@_4\O].T_ASW$
MZ[=[0/0A\>\$ZJ_[@^E#\Q#V^/B=P?J>7^G:?PY[B==N]H'H0^/>"=5?]P?2
MA^8A[?'Q.X/U/+_3M/X<]Q.NW>T#T(?'O!.JO^X/I1X_F'^WM\3N#]3R_P!/
M4_ASW$Z[=[0/0A\>\$ZJ_P"X/I0_,/\`;V^(W!^IY?Z>I_#GN)UV[V@>A#X]
MX)U5_P!P?2A^8?[>WQ&X/U/+_3U/X<]Q.NW>T#T(?'O!.JO^X/I0_,/]O;XC
M<'ZGE_IZG\.>XG7;O:!Z$/CW@G57_<'TH\@_$0]O<.`([@_4\O\`3M/X<]Q.
MNW>T#T(?'O!.JO\`N#Z4/S$/;X^)W!^IY?Z=I_#GN)UV[V@>A#X]X)U5_P!P
M?2A^8A[?'Q.X/U/+_3M/X<]Q.NW>T#T(?'O!.JO^X/I0_,0]OCXG<'ZGE_IV
MG\.>XG7;O:!Z$/CW@G57_<'THX_,0=O?XK<)ZGW'T]3^'/<3KMWM`]"'Q[P3
MJK_N#Z4/S#_;V'Q1W"#_`/P^X^GJ?PY[B==N]H'H0^/>"=5?]P?2CC\P_P!O
M;XC<'ZGE_IZG\.>XG7;O:!Z$/CW@G57_`'!]*'YA_M[?$;@_4\O]/4_ASW$Z
M[=[0/0A\>\$ZJ_[@^E#\P_V]OB-P?J>7^GJ?PY[B==N]H'H0^/>"=5?]P?2A
M^8?[>WQ&X/U/+_3U/X<]Q.NW>T#T(?'O!.JO^X/I1R'XB#M[AX([@_4\O].T
M_ASW$Z[=[0/0A\>\$ZJ_[@^E'/YB'M[_`!.X/U/+_3M/X<]Q.NW>T#T(?'O!
M.JO^X/I1X_F'^WM\1N#]3R_T]3^'/<3KMWM`]"'Q[P3JK_N#Z4/S#_;V^(W!
M^IY?Z>I_#GN)UV[V@>A#X]X)U5_W!]*'YA_M[?$;@_4\O]/4_ASW$Z[=[0/0
MA\>\$ZJ_[@^E#\P_V]OB-P?J>7^GJ?PY[B==N]H'H0^/>"=5?]P?2A^8?[>W
MQ&X/U/+_`$]3^'/<3KMWM`]"'Q[P3JK_`+@^E'/YB#M[_%;A/4^X^GJ?PY[B
M==N]H'H0^/>"=5?]P?2CT*?B%^W:J83JL,^*''0!.IA@QS"`<``3&FQ$=`K]
M#N[;C`2"K>!_F?\`NQX._&`DS*:Z?^7_`.]'A^82[=/_`,-SSZE1^FJ?P[[C
M_3H/:?\`NQX^.^`_1K?9_P#O1[T_Q#G;R1+R)-=P"1!'7E2PVJF74=-1T).`
M&HZ5X/=TW%.I-O)_S'_<C]#?G`QP%</_`/'_`.]'G^8@[>P^*.X3U/N/IZO'
M\.>XG7;O:!Z$/CW@G57_`'!]*./S#_;V^(W!^IY?Z>I_#GN)UV[V@>A#X]X)
MU5_W!]*'YA_M[?$;@_4\O]/4_ASW$Z[=[0/0A\>\$ZJ_[@^E#\P_V]OB-P?J
M>7^GJ?PY[B==N]H'H0^/>"=5?]P?2CD/Q$';V#P1W!^IY?Z=I_#GN)UV[V@>
MA#X]8)U5_P!P?2CG\Q#V]_B=P?J>7^G:?PY[B==N]H'H0^/>"=5?]P?2CQ_,
M/]O;XC<'ZGE_IZG\.>XG7;O:!Z$/CW@G57_<'TH?F'^WM\1N#]3R_P!/4_AS
MW$Z[=[0/0A\>\$ZJ_P"X/I0_,/\`;V^(W!^IY?Z>I_#GN)UV[V@>A#X]X)U5
M_P!P?2CD/Q#_`&]@\$=P?J>7^GJ?PY[B==N]H'H0^/>"=5?]P?2CG\Q#V^/B
M=P?J>7^G:?PY[B==N]H'H0^/>"=5?]P?2CQ_,/\`;V^(W!^[_F>7#B/C_P#C
MOE&G\.>XG7;O:!Z$/CU@?57?<'TH?F'^WM\1N#]3R_T]3^'/<3KMWM`]"'Q[
MP3JK_N#Z4/S#_;V^(W!^IY?Z>I_#GN)UV[V@>A#X]X)U5_W!]*.0_$0=O8/!
M'<'ZGE_IVG\.>XG7;O:!Z$/CW@G57_<'THY_,0]OCXG<'ZGE_IVG\.>XG7;O
M:!Z$/CW@G57_`'!]*'YB'M\?$[@_4\O].T_ASW$Z[=[0/0A\>\$ZJ_[@^E#\
MQ#V^/B=P?J>7^G:?PY[B==N]H'H0^/>"=5?]P?2A^8A[?'Q.X/U/+_3M/X<]
MQ.NW>T#T(?'O!.JO^X/I1)9M#W@XAWNXK?9BPH6[BVA'WE,V(X"];=-;$Q\N
M03"'DGPIQQW3P3L?1IU#D5Y_.-S!H'+6L<QPV\8-=DV:^=CZXIE+H[)?.GE4
M5`:R&LTF8\4;$Q3++5F5L5=K/VOJB7E-GM$\BN9(23I,Z24-?'&TE8I&30I"
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M3E/;(>RP]3E/;(>RP]3E/;(>RQWNV_\`W>;_`*N?X2K_`-5__=WO$O?_`/K7
G\;_Q>6O@JOUG])P^?Q__`&C[:;]7_1\?F</_`-X[!7S1]$*0C__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex10-12a1b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-12a1b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!?P)8`P$1``(1`0,1`?_$`(T``0`"`@,!`0$!````
M```````&"`4'`0,$`@H)"P$!`````````````````````!````8!`@($"@<&
M`P<#!0$```$"`P0%!A$'$@@A$Y@),2(45M;7&%AX&4$R%;:W.#GP46%Q(Q:!
MD22AL<'1X4(E\3-34D,T11<F$0$`````````````````````_]H`#`,!``(1
M`Q$`/P#]-G=_<AO(UFO)#RIY?F7)ARGY;EF3[$[<7N291DO+IM!?9#D-[:XY
M"G6MU>75IA\NQMK:SFOK>D27W7'GGG%+6HU&9F%P/ER=WI[A_)GV7]D?0<`^
M7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>
MGN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\
MF?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?
MV1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!
MP#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<
MG=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>
MX?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9
M]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9
M'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`
M/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=
MWI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A
M_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV
M7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?
M0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^
M7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>
MGN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\
MF?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?
MV1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!
MP#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<
MG=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>
MX?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9
M]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9
M'T'`/ER=WI[A_)GV7]D?0<!6[G(Y`.0_&>4/FIR3'.2;E&Q_(L>Y;]\+VAOJ
M3EMV;JKFDNZ?;+)[&IN*BT@X8Q-K;2LGQFWXTAE:'F7FTK0HE)(R"P/=K?I_
M<FWPY[4_=*M`7<``````````````````````````````````````````````
M```````````````````````````````````````````````````5;YX_R4\X
M/PM\P/X39:`@_=K?I_<FWPY[4_=*M`7<````````````````````````````
M````````````````````````````````````````````````````````````
M``'63S*G#92ZV;R4\:FB6DW$HXC3QF@CXB3Q$9:Z::@/O4@'(```*M\\?Y*>
M<'X6^8'\)LM`0?NUOT_N3;X<]J?NE6@+N```````````````````````````
M```````````````````````````````````````````````````````````!
MX`&'N[RKH(#EC:2.H80I+;:$H6]*DR73X&(D**V2GY4R0L^%MM"5+6H^@@%8
M<TW(R;R^P3?5<F%B;+D1E::1^79-T2I2#-$+.X-)PY'?9+,67]*FIG%QT-*_
MUCI%T@(\]6TF05J;"+(9:@,2E)+(JZZ76_9U@V:"X4W&*6=53U=I%4E/!7P2
MN)Y+,B>\=#B3#8-#F.Z6*.+^WJBVW*P]*3<;NZG'K&#FU:VM;*&6WZQ^NJ8&
M6PFV]5&_&;C3"(NEAT_&,+!4]S67T!FSJ9;<V&_Q<+K?$E2%H/A<8?:6E#L>
M0ROQ5MK2E:%$9&1&`[V;*OD2I,&/.AOS81-G,B-267)44GB-3)R6$+-UCK2+
M5/$1:_0`QF299C.'USMOE5]4X]6,_7FV\Z/!8-1_5;;5(6CKGEF6B4(XEJ/H
M(C,!2SG`W=PW*>4GFXQRK=MBE67*3S!W%#.F4UA#ILEK&MI<L.1,QZV>9*)9
M(B\7]1!*2XCPFG0!E^[6_3^Y-OASVI^Z5:`NX```````````````````````
M````````````````````````````````````````````````````````````
M```(MDF5UF.^1Q7%>6WMLIYJAQV*['^U[M^.A+D@H4=YQ'^FAH42Y#Y_TH[?
MC+/I21AH6TNYD^=]HR)OEMJXN9#8L:MQLX54VPG2UJ,"5-X8IOPVCTM<DE$4
M>&DS2@^-26C#&5\.5+E08==#<DN.,*.LKJIZ1!4=?+5_J9$6<^7EM!C<Y6OE
M=S(+[5N>DF$H:,M0\4C'TT*K'-L)F5["L<@7$G*+[R`RP&*Q&K)'#6X'BS2E
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MI^=:6E)7Q%LH><:BDI;[ZNK5JE1!83NUOT_N3;X<]J?NE6@+N```````````
M````````````````````````````````````````````````````````````
M`````````````>`!#LDRHJM:*JICM6N2R6%2&*];Y1HE=#1T.W.03=%)JZ>-
M]*E$;CZO$92M6N@5_EPO[PL6H<-#N2VLYYFR>R%3DJHE7+<<W64*@R8;I2L-
MVLB&XMHR9<\LNR-3+9N(6_(4$H=KJ5%=/K8+U3/.&J(C+]P;F+&:QJA;JW.O
MB45!5I4F%**K<+_35C.L**9FY+6X^X:9`2"AQE=ZPZPTQ84^&37#D3'9KSJ<
MNW$>6GA=GY!+4EN57TDA'0F-XCLAHR2:6(^C2PD>4,1I3F.X#61XS4>Q>;G6
ML5E!-1H.(T3T9Z:DV6NK03=G*-B`A!&G4I"UD2B:61!IW<3":+,<KFM0>HJI
M;LRGQQR5'9;.!.DM26\IR.1<0$.1F;'R.!`81UIN-2F'3+JG6U'J81/'3W$E
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MN3;X<]J?NE6@+N``````````````````````````````````````````````
M````````````````````````````````````#C7]O]_^0#6V4YHMH["KQ^5"
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MWWG$*,B,XQM_S`8/<['SM=H;R]R>?*OIUK3U)L1'.*+352KZ?5LI*'61UI;>
M7".67"MXW%*-!'T&>@"=[?X!@M(E[.V,7QZ/EUPY;RK;,GZV"K)'HC]G82"A
MOY$^RJQ35Q&7C2VP3J8[2->%):GJ&I^<^VJ;SD=YO;&ELZZX@.\KO,(AN=5S
M8MA"=4WM1EZ'$HDQ'7F5FA9&1D2CX3Z`$:[M;]/[DV^'/:G[I5H"[@``````
M````````````````````````````````````````````````````````````
M``````````````#@ST(_HZ-=3TT+]_\`E_D`U)D.8E:QYK539.5.,Q'_`"*X
MS&.A3TN?+-?4_P!MX)&;0ZY:74M_^BJ2VEQ+2OZ;"77S-3`=V,8:;[<&7=5J
M:JIKEE)QO"DK2^S7.Z\?VUDKR7'$W.4/K6:SXEN,Q5*/A4XZ9N@,KEN<Q:%3
MU9`<@2+WR=+[IV$LH=/1QG-2;L<AGEQ'&CGH?5,-DJ3*47"VCAXEH""1\A@T
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M5MNMQ>,^I"'#21-JC*6ADW'5+?`3K*UHAS[9,="6&*;;B>AEEI"4)838SD1V
MDQB;+1">"LX3(M-"2G^`")[MY!1UV*XM@:["*YDMWD.WL"%0Q%>4V+L>#D5+
M.FRG($9+S\>I8B0%F](<2EAIO4U*(B`4;R3>7!\>IZ.#G.:[B[_[Q2&F8U%L
MOMBS"QR+A.0-QTRJVEBX%C]A+F7605BW&>MDV<B[DI2LY1E'AK/@#9>_.*9'
M4\E7.[E-[C$+`3S+E.W;L'<&BR:^7*J;UK8[*$9#,N5TJW\=192[)2T\,!UY
M@VVTJ-9J49$&PN[6_3^Y-OASVI^Z5:`NX```````````````````````````
M````````````````````````````````````````````````````#$V]Y54,
M0YUM-8A1]22@W%&;K[JC)*(\6.@E/RY3BS(DMMI6M1GH1`-$9YG%@<['(%Y!
MF46'Y1/53PZMF63&<9;;/HXZRM5`21?8V/STI-+ZU/)?27BN]4DU$8;*QG$W
MFGXEWD34,K*''\GHJ2`E)4F'05M]4<6I;X4(=L5L'P2)AI):DZH;X&S-*@U_
ME>\$25*GT6)/2.IA2'8-OEA--LPFI31$4FKQN3.)$6TMFS7PN/MI?:C'T$AU
MPN`@U)5S*VD9)FCC+C+>F.ON6DB3*M<AL[%XR2[82\FNC5:/6S[G0:V$UCAE
MHA*#224@)=%QK(GT+L)$<ZN,^LREV-M+.B;7Q'P$B5.L-+B;Q*5_[;K*4J^A
M1@/8Q#QR)!>FHG662QJMF9)4WB%8TW51W(CA]<;606JD5<:2VMLTK3'6TZ:M
M/"8#Q.6><_V;=9Y08MC>V\%G%KNXBV]Y(+,,[DR&8#RZIA]3Z50HB)$U""=;
M=D2.%)Z$1&`F3%%2-9+A<_.)K]RJ?BS\R!*RJ4E^I5E#$BFLW#:@/$W30[.%
M'8-^#HUUK:4OJ;/Q#,@F)33SG(*S[-)3N(X[)^TI%OHI,2\NVT+:A0JPU)+R
MN%6FXIYU]/B&\2$I,]%`.ZSIXF47V84DI^8Q#G8;3TTJ1`D>2SF"FR[YUQR%
M)2E9L/$RZ@TN:&9*+^`#%+PK"]L\,RN925\>MD*Q^R79Y%/E*DWUFMN$Z:'+
M3([-UVQEN]:9\!..&A"CT0DN@@&2V^VEV\VW;D2\3PW'*2]N&FUY+D4&JB-Y
M%D<Q2&#D2KZ^-H[:W===82HSD.KTX4D1$22(@U+SQEIR4\X/PM\P/X39;_O`
M0CNUOT_N3;X<]J?NE6@+N```````````````````````````````````````
M``````````````````````````````````````.IYYJ.TMY]UMEEI)K<==6E
MIIM!>%;BUJ2A"2+PF9Z`-4W6Y;2E'$QSJ%$XKJD7<YB6]&4X9?4IJ>&A5KD4
MDM=4]6EN/J6AN]!D`\%1CN33IGVMU+D&P<(TJRO+FXMCD3;;B5(<1C^.15*J
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M1YSD:*VBL;:=DY_:#+E]&88E'+:JED51$7%FJ4IKJV"ZM1='@`23.4D]6U6/
MM((_[BOJRI6RVDDF5<EPYUJILB+A+J*V$ZO^1`(!F6-YRYBF6X+3UL:WK,@-
M]%);>6QX[E)76<LY%G#L(4A32I:ZY*U^2=4O1\E$A1M\/$8?=?F64_9WV3D^
MV$XR@/K@)XDG81;./7.);@7#,9J#/9CM6#;1.I:6ZMUA7BJ/4M0&:5NY306O
M]?17E8VPRXMPG8T9IMEJ.V;BN%"I#;G`A#9Z$2"Z="+IZ`$'J=P<NRV]R67M
MCA-A*AVB:%,/-,XC2\9Q:/%15-.+.'">:3D%\MF0^OC0RRA!+Z#<(ND!+X6T
M#%K+8N-S[^9N-:QWVY42NL&4U^%U,EM25MJK<2C.*@O+9<07"[-5*=Z-2,C`
M;E(O]G@_@7\SU\("KO/'^2GG!^%OF!_";+0$'[M;]/[DV^'/:G[I5H"[@```
M````````````````````````````````````````````````````````````
M```````````X_?\`P_;_```:KS;=FEQ)URKKZ^RRW(T-+==J:4HS-?3M)T+R
MK+LKLGH>+X="U/4CGRFY#Y$HHS+ZTF@!J53&XV:E+N<RL:BJQQESRN,RUY?0
MX;30TMD7%-LKHH5_F4II9J4<E,6GA+0HC;6XGPALC#J_$Z&'(S";:RF6&#*(
MF^R!O^VZ=UI\FFB>K8TY45:X3[SA-LO/DHWS,C:-9&E2@^Z?<:?N++GQ]NZ]
MUK'("EPY.X-_!DQ:Z19H6XS,K<:H)91+6SE5;C9D_)DHCQ&G2)*"D>/P!D["
M%08:3%U8IF99E\UXXE*=@ZS(N;2R<XW40:6,LFX-2RV2E*6IEMM##.IJ/0M`
M'JQ[`H3<F;D.3Q*^TRBZD(G6"C82Y6P%MM-L185=$<XF-8,=M+:I)IZ]Y2>)
M2NG0@V*22(B))$1)\"2(B+0OH(BT(@%2]ZS/(=V-N\(+1Q-C7MI<:2GK%LPI
M^2UDR^?ZO73B*GQOJU$?1U;QZ]!](6U_W?Q^C^&G1X-`$*E%]H9]6LF1+CXU
MC\JU<U,R-JSR"2JKJW$EIXVM?76*3_=QD`FOAU_AT?[>G_:0#D!\FE*O"E)_
M1TD1_P"\!SH7[?Q_]`'(``JWSQ_DIYP?A;Y@?PFRT!!^[6_3^Y-OASVI^Z5:
M`NX`````````````````````````````````````````````````````````
M``````````````#Y4I*$J6M24(01J4I1DE*4I+52E*/H21$72`U+=;PXU#M"
MH*EYJSN7FNMB=<]Y!52B)\HCB(%B\@T6\EF4HFULPR?=2M24F1&HM0@D^]RO
M)I*X/7S92UZ)52T[<ROAMI49))4IN'(BWDQO51&9RIE4P:=24A:>@!DCV]E0
M:K[1NK.KIT5K;CU9"<D,PHE:ZOQEN%+KXT:!CQDE:R<^R([,]S0M9Z]3,!Y%
M/LL1HUJ3;]_Y`IENMR3*X\EK'X4DEI*.SA>)<;\^VM>)LS9?7ULI1ZFJ7P*,
MR##5&$3]T+J)D&32IUA6U$KKH$VQ<0XS#EM*-M:L:K(__AX-N1$:%V#:9#L$
MC-N/)<=XG6PL!:VM1AE-&0U%4:$$U74E'6M=9.LI1]$:OKHVI*==5]9:S/A0
MDE..*))*,!X,;QV:W->R;)UM2,FFLFPB.PZMZMQZN-:UHK*CK"2HW'$FDY<C
M0E2'2Z-$$D@$X`<'X#`5$QQ+>6\XFY,Q*EKB;3[=X73D9*U::R'-&;.Q>29'
MT$942$ZI+Z3(S^C4+,V.5XY5&2)MO"0\HBX8S;J9$I9ZFDB1'C]:\M1GT::`
M,9AZ79KV1Y&]'=C_`&[=**O*2VZU(^PZ>(Q55QFTZ2%M,RGV)$MM)I(])6I^
M$!-@```````5;YX_R4\X/PM\P/X39:`@_=K?I_<FWPY[4_=*M`7<````````
M``````````````````````````````````````````````````````````'!
M_P"/^`"+7V9XWC<JO@6UEU=G:FLJ^IA0["XMY:&T+6Z^Q4T\2?8KBLI;/C>Z
MKJD:>,HN@!\XAG6&[@5K]OA&3TF4UT2PF5$Z326,:>FOMZ]SJIU38H96IZNM
M(3O0['?2V\WKXR2U(!(Y<N+!C/2YTJ-"BQVU.R),MYJ/&8:1TK<>>>4AMMM!
M>%2C(B`5[O,Y;S=#3E._'>Q.5Y>52U8%+K(&0_8[BRN<JR*2_P"12(NWN/FT
M?0DT_:3I%PKZHR401B7AS67O0*M^*<Z59QCE0EVC"Z^<Q1,/)_\`]59MQ?))
MF)4#\MI!5=)#.+(DK0DY*BZMTHX3#"6LBI').-8)*?RW&F(K32<PRIYLJ^NN
M8SZV+")`7#98FY2RM)&9]6I#$9:>#KEF2DD',K"LQHLILLZO+=S=&L32(0SC
M-FN!2,X],@RYLMR?C<'@:H3<DP76V7E2S)]1L)43R2XB4'3C-18[I/0\MO')
M+6/2(_65[)L3*Q4N(]TG754*6VQ-KJ;@+@D2W$-R[,R\7JXII)8;DN;JJQ&I
M;=6R:6R6Q6U%3`:(WY\QPNJA5==%:3H3CBBX2Z"0VDC4HR2DS`8C&\?L%SCR
MK*S:>R62TMJ)";6E^#BT!XF^LJZIS1/6//DVDY4C3B?66A:(2E(">:``#@_`
M?_+7Z`&HJK9/"J?)]P<KB?;:I^YN05N397'=NIRH,FVJ<?KL8A*C1T.(.+&:
MJJQM/4I5U7&:E</$HS`;&KL>HZ@M*VI@0SU(^-F,VEPS(M-3=-)N&?\`$S`9
M@````````!5OGC_)3S@_"WS`_A-EH"#]VM^G]R;?#GM3]TJT!=P`````````
M``````````````````````````````````````````````````````'!@,=:
M6U;31%3K2:S!BI42.L>5H;CBM2;88;+5U^0Z9:(;0E2U'T$1GT`--W^XUE8*
MD1:1#]/#9+_4S5E#^VB;62>%:_+S^Q<4:<2>J7;`W9!DHN"*LST(-<0(5SDK
M\JIQN*4E,E]"KF8^<U=,XZ?BE*R&?8D=SF4IM&I)*P-N&2"X45[J4I2`S]AR
MZMPER\[PO(%4.^A18R6<^4TM%=>M5_C1<3S.GAFVWD.'.(2<=*9!.RJY"C5!
M6QPI:`1RKR^QW&I(<B?4VLK-%Y">'Y55S"*%BNT.2PU&60Q(C#I$5];U$$RE
M1)ZTON/QW&)3!L(=-`#-.3:2/&L+V[)3.+U-2WDEJQHEU\\5H9"F<%Q**VM:
M$K>O[!DYSC!$E<U];*.GB42@D+5+DN1-IQIZP*AR'(F*W+MU;6M2U*>A5D];
M\:FP"DE+X$H;3$@.Q2?))DF/'>?4@GI6JPV,[C$>FKE.2<RR.OJ:R+JO_545
M;`AQ(R"2A*2B4<9$6.PTG1*4&DB(M.DP&I%OY3F$]W'(EE,MZ)Q,:5"A9!7,
M,26HCG6.(O,X?@)AHE4C^B5U=,<=B5/-)+EF<;H<#=EQ>U>`XM]I9#:/R(]7
M&:95+?::596LPR)MIF/$ALLMNS9CIZ(::;))?N)*3,@Q^.4<V98(S#*$-'>O
MQUMU%8A?6Q<5JY*4*7"94A:V)-M)22?*I22\;3JVS)LC-83\````````````
M````!5OGC_)3S@_"WS`_A-EH"#]VM^G]R;?#GM3]TJT!=P``````````````
M````````````````````````````````````````````````?#BT-H6XXM#;
M:$FI:UJ)"$)+I4I:E&24I27AU/P`-37>YS*WFZW$HQW$Z1J4>;U+S\1SIX>.
MLB,&F5<DD_\`[J39A%],CH,@&JITN1)F>6V\]ZYME*<AM-199NMQY2]/]`JV
MJFEI1)2I1$Y74+2I!$G5^41$HP$VHMM;&X1%D90HZNM95UL3'X*&8CB"<,U>
M.S$<<AU!.$?C$VI^:O4^.26IH`;NKZZ#51&H-=$8A1&2(FV([9-MIZ"(S,B(
MC4L].E1])_2`\%WD-1C\=N1:2R94^OJX<1I#DB?8/EIPQJ^`PE<J8^9J+H0D
M^$CU5HDC,!3S*,UN\1W+W/5%I$5\3-=JJG,7Z:;,>5819]#=M8<Y>368+,BL
MHY=M2W3"'3=>,^&O;ZU24MF9!+:V9CN=N8S113=<C6FX#%I8UKYG&6[4[:5\
M-V!$E$VER+.AL9`422T;+JV5J:2:5*Z2(-UXS9UL&COLTLYC<>+=WUQ:O3GM
M$MJJX,LZ+'R82236IMZCJ8RT(21FMUU1D1J69@-6Y5E%AD,LR=CR&&8;["JS
M'_)4SI,.6LDNU[]K6J5U-SF\]&BX%0L^HKVS\JFGXA)`;@@JIL%Q1,R6P_7\
M2&I=BAQX[:ZLKJ:E'6-NR&TF_=W<V29-EP$HW%Z)3HDBT",4%?/S*3D-QE<9
M$>TA/6E%1T1/')KZ"OE1N)B6YXI-/9'.B24E,=3JEDR-EM1I2:EA-<'DG+Q/
M'W%:\;-8Q!=,SUXGJWBKWE'_`!4[%4?^("5@````````````````*M\\?Y*>
M<'X6^8'\)LM`0?NUOT_N3;X<]J?NE6@+N```````````````````````````
M`````````````````````````````````'_M`:_RC<2DQPWHJ%G9VS:T,JKX
MBTJ*/(<22VVILA).)8>6A1&EA*7)*TF2DMFG50#4UW+N[YU"LQE/UT5YKRR#
MB-<PT_:RXB%J-4Q53(/R6'$9X5&J?;*..V;?0PE9)4`5%-<Y0VY&I(D:OH9*
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MMU3/Q62*WSAU11#BVM7Y9.143'29AO*=B17E-:EQ-):<2M*DNI,B-`"/L,WL
MW'\8JJZ]GU]S@QR:6K8BU\2;75DO&)$S'Y33N-]8PQ/MM8*U.6LY4&OK#,GH
MB5&EHUAL3#9T?"6:ZYW'K:^)-EM2&<=OJ":K(<4)V<I+JZVGFN-HMI&1Y$[X
MZWGVS>L7B4EM75H2D!MJCI;&ZL&,LRN.F/*8)2L:QQ:FWF<99<2ZT<Z0I)<#
M^1SXSNCKA:HC(,V6CZ7%N!D:!*49%G#:>@OM:I>X2+Q24]CU::S+3HXEK29G
M]/3_`!`>?!"TJK%+>I149'D)04'T=5$*R=439'TD:2?X_!T=("<`````````
M````````*M\\?Y*><'X6^8'\)LM`0?NUOT_N3;X<]J?NE6@+N```````````
M```````````````````````````````````````````````"/7^3TF,1BDW$
MUJ.:]28CH)3TV6X1:=7$B-\3\A9Z^`BZ/I,!INTS#)LKBNR(KK6#X>G4I%W8
M27694E/%P\"9<-YJ2\ZH]=(U:ZAQ1EPJG,+(VE!A*UIJ%):K<2J[!-JIC5-I
M*@P'LP=BO+XE/5-.^VW0X!4/+/7RRP0E;NO$F+(<7UIALBAVSCI)4C)E-3E2
M'BENTC+\J76.22X5)E7MA/XK3,;-M:2,GIIIC-J0DV(S!EJ8;4)*4)224DE*
M$I)*$DE)$E)%H24ET)2DOH^@!";'-F"?D5V.1D7]E%+2<\4I$.@I>C7K;V\4
MEYB(ELM%*::2_*4G4TM'H>@5OO\`=&-96+K..L,[LY-6.*6_:R#53[/X,ZV1
M\;Z7%N+1<SH2?K.FZ\\73J_%;4:2"*4V(95NE:HNILD\_L&EK0G*+]EV!MCC
MNI%QL8KC[/5KR1QOA(B-"4PU'PF\[-2?$06DQ/:JAQR0U;V+LC*,G0@D%?W+
M;1JB((N!,:DK6B.!10FD>*AMA.J4>+Q&1%H&T.GP_P`]-2^GZ/WF0#3%]LM2
MNVDK)\&EE@&7R9D"Q?L*^([,QZSGP'EFB9?8DU85=?837HC[T9<IER+-6P\:
M#>-*4D0</8U(E29<R?ME7R;NTEQY-O(C9''8Q2WL(C3,*-<6D5Q29LDVX<5D
MB4[7OR$);2@N+@29A+JW$Y#]A'O,JDQ+.?!T^Q:F%'4SCV-:(-!KKH[QJ=F6
M1I\4YKI)<X3X6D,H,TF$[_G_`+?V_>`@F(N)=3E5VXHU)GY):*)PB+A7"ITM
MUD52#\*DJ8A=!F>G3]`#UX$A:<2IEK3HJ0W*F>`RT3.G2IB#T41*Z4/D`F``
M```````````````"K?/'^2GG!^%OF!_";+0$'[M;]/[DV^'/:G[I5H"[@```
M````````````````````````````````````````````````````/'.GPJR,
M[-L);$**P1&Y(DNI::0:C)*4FI:B(UK49$E)=*C,B(M3(!IRQW)M\A?DU>WE
M=Y9U*EM3;^::6X%;P]#IO&LR1%>83XQMNGUZ2^LT7TA`":J8;J;.1*1FEY,<
M6W]N6O7NX^N6@S2]#HX+*7+#+GV3T_IQ4'$21EQK2G4R"=U.%9#D$EBVR&3+
MK4((C9>D=0J^2@RX>"KA,]958BP2?`;1/32(BU=29:@-NU%+5T,;R.JALPV3
M6;CIH)2WI+RCU7(F2'#5(ER7-?&<<6M1_O\```QUYEE72.H@GY197+Z..)15
M;)S+1])J)).J929(AQ2,S,WGU-MZ)/0S,M#"OV>[G1X,LJ3(9,RVOY1I;A;3
M;?/+G7#SBRZQMO*;R.:?(VU-J(UMHZKQ#XO&3J8#4,I.7[B2TXU;Q2E1(AI)
MG9_;J4F#C=,E3G'KN+F$?2*;A.*)3L5M2W%&9F:-3,P%A,4V-AM1H*LV<@V;
M$(VW*_"Z6,==A%2ILDFT2H!:/7\E@TD9.RS4GBZ4H2`W\RTVPVAEEMMEEI"6
MVFFD);:;;07"E#;:")*$)(M"(N@B(!V``````#!9+<HQ^CL[A9<9PHKBV&O#
MU\M1=7#C)(E$I2GY2THT+I/4!#IK4S%]NHU2A:57DV-%HX^II4E5]D+Y1UF2
MD^*;4>7,6LU=.C;?$?@,!L"L@MU==`K&5+6S70HL%E3A\3BFHC#<=M3AD1$:
MU(;(ST+34![@````````````````%6^>/\E/.#\+?,#^$V6@(/W:WZ?W)M\.
M>U/W2K0%W```````````````````````````````````````````````````
M`-2+PGH``-8Y%N;5USIUU$R>17"GE14M1#>77L2DD2EQWI,./-E3IK;9FHXD
M%B7)21<3B&FN)U`:PM&WYTU4S/["7:649M4IC#*:3"AG7QCXTF_?6;<Y='AU
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M77)(RE0V&)#ME7-S4+09O^4$:/"NPCJ)4<!L3`MB)Q1%(LF%X%CLLC5+H:>Q
M3,SK)4K,U*/-<Y92E45E]7C+@51--:GX[JU<2C"S5#CM)C%<S4X]5PJBN821
M-Q83"&4$?3Q*<-/C.N*,]34HS49])F9F`S1?M_P_V`.0```````0"\45[E='
MCC:E+BTAM9;?$E)FT1LK<9QJ"XLD&27I5HVN4E/$7$W"61]!D1AS.4F[SNL@
M)5UD7$(2[N:25)X4W-NAVNJ6G/%4761JPY3IH,R/1YI7[@$^````````````
M``````%6^>/\E/.#\+?,#^$V6@(/W:WZ?W)M\.>U/W2K0%W`````````````
M`````````````````````````````````````!QKT:@(G?YC34*U1G%N3K5+
M"I)54'JU2FXY%TRYSCKC46K@)/ZS\EQIHB^D_``TE>Y/<9*VERRL44V/O(4I
MF)!\I7Y>UX#5&:(XEI?I0I/";Z_(JLC_`.]TBU`?%%7V]FDXF(5;U?"6V4=^
M\-UMJ4[&4>JXZ[YEGJ(45*T\1PJAGJ]=>)[B4:@&U*+;:FKDL.6A-6\AITI;
M49QDFZ:+*X>B2S7+6Z4R8T>I)E2U2).A%XY:%H&Q''&VVUNNK0VTTE;CKCAI
M0AMMM/&IQ:EF24(0DM3,ST(NDP&M[3/>NC2G\<*"FLA$OR_,KY\X&*UR6]24
MMAY:FGKIQ)D:=&3)GB+0W",]`%:+?=)VP=FVF#.1[9VO6IBPWGW!3Y%B&/+6
M1ZL8?2+2VF5+5JI+*&D&\X9Z?U"/0!B*/9S)]PK*OR!+UD2OM6+96FZ&XL(Y
M.0V\6*2GX\/!L)?4F+C]4<LTK2Y,(DJ2DC\G5T`+A8CMYC>&'(E5S#\Z\L"(
M[?)[J0NTR.W67_=-M)&KW5%IXK+?5L-ET)01$`G'^7^'[?0`Y````````UT_
M;^&O_`!'\DOHV-T\NUD-JE*:ZIF%!9,BDV5C*6EB!71B,CU>F2'$H+H,DD9J
M/Q4F`B\4SP3%+"\N?_(9#9OE9VQ,=+MID5CU,2!3P$F9K-AA740HJ"U-+39'
MTF:C,,[B-%(I:Q2[%Q$B]MY#EOD$M)%H]:2B2:VFCU5_I(#24QV$D>B6FRT(
MO`02L``````````````````5;YX_R4\X/PM\P/X39:`@_=K?I_<FWPY[4_=*
MM`7<``````````````````````````````````````````````'R:B(E&9Z$
MDM3,^@B+PF9Z^`B+Z?``\#%O4RG4LQK2ND/++5#3$V,ZZHND]4MMNJ4HM$GX
M"^@!YKN_I<>BE+N[*'7,+433/E+R4.2WS^I&AL:]=,DK,]$M-I4M1GT$`TSN
M%N>UCE1'M,FM3V[QZTDG7TS4GJ2SW+IZV''D5M'7.=:U2..LLJ6I;I.RD-:J
M4B.:>(!!*&GS',D$NEQG[!I)+S4Q$W)FG6X2G#4EQNS7!L&W+G++H]344NP0
M;!'KU+;"M'##=E)M=40C.5?2)&4V3JDN2'K754-3J23HKR(U.>4&1IT)4A;R
M]/"?00#9:&T-I0VA*4(;2E*$((DH2E):))*"(DD1$707T`(C;9A$B2W*FFB/
MY'?(+5RLKEM$S!U-22=N;-TRA4[!&@]>L4;AZ&2&UJT(PT!F.X<)$XJN<X>Y
M&5J4LX6#8RIYO#:IU/C)=MY9).3?.15(U6MTC;+0_P"DSKJ`UBQ69AN[9H\M
M;C9R[7OFVU6Q)3U3LUASB#0GJ[*R@J<7EMC$+0C@UIOG]#DM*=4D%F\2V<IZ
MB1!NLHE_WCDD!)%7/RX3%?CN.%I_^/B6*QM:RD91X"=,GI:]-5O*,P&XR(B\
M!$7\OW`.0````````#70!XY\Z'60Y5A/D-184-AR1)DO*)#3+#:36XM:SZ-"
M27@^D^CPF`@%+%F978,9A?QUPJF$:W\0I)2.K<BM+;4A626R5:&FRF,J/J&E
M:>2L*Z?ZBE&0<UAN9O>1,A-!)Q&@<D*QI*R\;(+=1+BN9(;9D1)JH+)N-P-=
M>O6M4@B)*65*#90```````````````````*M\\?Y*><'X6^8'\)LM`0?NUOT
M_N3;X<]J?NE6@+N````````````````````````````````````````````X
MU_AT?O\`^@"$2LR\JEOU>)UR\EGQG5,3I;3Y1<?J7F]#=8L+GJWT.S6_IC14
M2'DJT)PFDF2@%+MI]TY>ZVYVY%;O-N?BE9`QJ?\`8^,[+5#+^)*K_L]Z2S.O
M,WFV%F[>V=I8<*#C0W5QXW4&3B&5DKB(-O[L6NT=7@EG75M?10/*8BZRLOZE
MEFC9J)I-J5%?J+R`46;97$1S^HS#KEOR77-.,FVE+=2$#V$B9/ENW^/[IY/#
M5N',=39PY=7EM:S.RF`W76,NM=L,-R!U7DDYR3!92IU#:$,O/I<2PZDM$F&^
M%PZZJ8I,UQN/'RC#8KCM@[62V%6UGC;;R'&9=[A[TQ#]C"E13-29L$C)2D$L
MFR2X1H6&YX\AB6PS+C/-R(LEEN1'D,K2XR^P\A+K+S+B3-*VG&E$I)D9D9'J
M`Q-YDE1CS32[*2:7Y2^J@5\9IR9:63^FI1ZZMC)=F3'?W\"#)!$:E&E)&9!J
M/+LR?:CNN9-/<Q2L)GKO[7IY<5W+IL9Q7"VN^MT/%6XO#?7HGA0[Q.*U;2^M
M:B;`5\N,PO<I<8Q#&X$REK);?E,/#,.BK>R:XCNF:?M*><OR14"!(X2)RWN5
MPXSFFJ&G72-"@VOA6P.L8CSA46'6/<"UX+CLN2Y$EDG0R+,\G6B-;9:Z1_6C
MI*+6I46B&#+I`6;A08=;$8@5T2+!@Q6B9BPX;#4:+'93]5IF.RE#33:?W)(B
M`>H``````````<&>@".91EN/8;6';Y'9QJV(;\>)'ZY9=?.FRG4LQ($&/KUL
MN9)>5HA"",_"H]$D9D$>8IK3*GX]IES2(--'=9G56((=1(03K)]9&GY/,;-3
M%A,:,B<1%:,XD=>FJGU()T!XY[Z]Q)+E-6.K+"HDA3>0V[*C2G(GF%Z+QVI>
M(RZRM2XG2=(3XKA%U*#/5P!LUMIMEMMEE"&FFD(;:;;22$-MMI)*$-I3H2$(
M06A$701`.P```````````````````%6^>/\`)3S@_"WS`_A-EH"#]VM^G]R;
M?#GM3]TJT!=P`````````````````````````````````````````\`"/W^3
MTF,L,/7,YN*<QU4>!&22GI]C)2CK#CU\%E*Y,QXD=)I0D]/IT+I`5-N\WSC-
MJ>7FV<XMNAMIM!5NS'%X?1U9_P#]%R6IAK<2]DF8OU$QVUQK&%,-J>16P/\`
MR3C)$M];9'U1AM2G=FWV$45]L]F4?(,%MHD23#;8CU[5BNBZI1N-XI:(CQ(4
M*R5HE"$S(ZDM^,9^/H`Q]GM]L!D=&F^OL5JR?1*7$EV,UB9#S55ZDDD[$LYT
M1QJ_LKS4B\5Q;RE)TX=6S(!K^3M3MHS8Q+"9B46%()AYFK1ES]KFN7NPW31Q
MH@XVB4M<&&^9)-;;[QH6@RXD=!D`VOQ6%55)=6O,Z>IB,--(<>FXAB]=%80D
MD,,0*HH;J8<=+:22AE/C$6B2(!'\4O<SJ;Z1:(Q/*+?`LI4\JS.545M7<4E^
MP\;"L@;J&9IE:T>3P>%;ZV6FW4R&NN-LR?/0/<G*;/$J>UB//P\)Q.%93Y%/
MD>3$VJ=]BR"*9Y#1XVE9S9CT"2\M"#?X4)0:2)"B(B`:#E;]5==4VV51Z?)L
M5I;>-3LX7F.7-DO<'>65>6+==%CXQ4I:F7&/XZEUQMY*TPDFXR9.-L)+5P!)
M\2VBSW.9*;?)G).%TCCJI">O8;<RF4XYXBI%7535SXM'(=:,R.PLCG6:D]"4
M-$:>$+:XIA>-85`77XW6-0&GW/*)\HUNRK2WF&6BI]S;2W'[&WG+(]#>D.N.
M:>*1DDB(@E&G[?XZ_P`@'(``````````\TF9&A1W9<V0Q%C,)-;TA]U#3+:"
M\*EN.&E)$`@BLDO,E4;.&PTQJXSX%Y9<L.I@F7%H:J:K4;,FW/A2?"XHVXYG
MIXRBU(!YWJ_$,/0Y9Y),7=W-FP["=G7*4VEQ9M2$FF16U56TTI#,%XCT5&BL
MI;4GZ_$9<1A@,8Q/(+BI15Y(4BAQ"#86[=/C#,QP[6SQ]=I+>HHN13VW>MB0
M8=6MIE,%I:EFV@DO.*T-*@W)'BQX;#,6(PQ%BQVTLQXT=EMEAAI"22VTPTTE
M+;3:$EH22(B(@'>`````````````````````JWSQ_DIYP?A;Y@?PFRT!!^[6
M_3^Y-OASVI^Z5:`NX```````````````````````````````````````#CIU
M_A]/\/\`F`A^29:W3NM5-7!7D&53FC=K<=B/(9=4REQ+2K.VEK2XW34<=U1$
MY*=2>I^(TEUTTMF%+=K<[R>RWMW2NLJC1,POJ";88G6382+;^W<.Q^L?C)=K
ML>8I*/(I]:[96RG3F/V++:I26&S1)5P*82&\L_W'M&L=L)=BAC$L=;865K;3
M47,!IZ.I*C7$:L<@J<=FK7*;2:#:KX,QQ:#/61%(C=2$0Y;G+7`MHH$>VB2I
MUKEV39+=8)C"(#%1<2Z"=,2NL?F0$$F/1UYL:2W''2;1!BOMMN%UI$E02>OQ
MF\R7-%9/4VL55LEMZIRG+&8ZW\=AQVE&2*+`H#RVV9MY5ND;;UPZA7#JIM6J
MBZIH)Y!EUE9Y7"P"M8O+%"EM7.8VTIQ5-&E(U2ZJSR-SK)%[/:<,R5$AJ432
MTFV\Y%,TF82"/B<&(XO(LNLROK&$V[+5/MC:BTM*TVA3KSE=6K7Y#6QX[:#,
MWG#6]PIU4X9ZF`UMF6^%=!@NO4$J+`J4L=>K,KE"&Z]V(ITF&YN-5DI^$NY@
MO.D;;=E*=AU+BS3Y,]-6?4&%1\NDYIN3=0<0QK'[>7E60)\L9R#(8DF3?8[7
M+9=ZC+\A1*CQ6=O\95J95Z)T>-,LG"_T=3P(5((+I;;[*TN&OQ,COY1YEGS5
M)4T)Y19L()%754\=+$*IQBMU7%HJUDR4LS:+KGW%J6ZM1GT!NO3_`-?IZ`'(
M``````````XU_P"G^>G_`!`0JPS!*YDBFQ>`K)KN*YU,WJ7?)Z*D>UT-%[=F
MV\Q&E((]3B,)D3M#29LI0KK"#P)Q9C55]GUPQ<.04*F=5()%=B5(AE/6./L5
M[SRFE$PE.IORUNK(BUU3H0#Z.\OLF23.'Q4UE.I.G]W7,1Q+;[1I3HO&:-WJ
M9%@GA,^KE228B*T2MI,EM6I!F:/$*JF?78*.1:W;Z=)-[;.^663NOUD-N*(F
MX4?7P-,I0VDNC0!*="_<`Y``````````````````````%6^>/\E/.#\+?,#^
M$V6@(/W:WZ?W)M\.>U/W2K0%W```````````````````````````````````
M```!QK_O_B`TU=9Q?Y39R,2VJ1%>D1'_`"7)=P;!A4K%L44G_P!^'7L(=9/*
M<H0D]2B-.(C,&9'(>1T(4$YQ+#:C$(LEJ"J;/LK-Y$N]R*XD)G9!D,Y*#24V
MWGDVRA:D$9DRPRVS$BH/JX[+31$@@@V3[#;>Y+DLC-4QK?&<QF-LM3LGP^ZL
M,<MK!J.DT,-SG(#J6I/`@].(T=8HB(C4?"G0-;W>UNV^-W#<N2S8[A9BPPF>
MR6?9!+NJ7'8K"N)%YD+LU3C;-?%66K:9!ON.N$1-)XB)20R++ASY+C<A5M9O
MW##)V*(#2HN8YM&0I9L14M(6C^PMO6-5=2RIQEY]LU+,R6MQQP(=S";T85RZ
M[?U^:[[6/]NX-)L(^.U6(8M#F*QZ*^<)^7'CY385D<IDRO;C1%$J,RTW$7IU
M9MODHB`?FX[U/OTJJ@VQL-H.5F@N[7-,QDHP9>Z65TBL2V\VLJERE55U.VYP
M9[CLLNS"-'0IJNL+)#<."\29+3;:D$TX'Z((]CEVXL>FK,>B'DL&GI<;TM;M
MUV)MEC+S5'6/)DI*P:D?W?;QG5=8F7/;FN-KT4U$CK3UQ!EJ#"4Y!<3HN&7$
MC*\V@24N76]-_5'8X=A5FXOAEHV]I;!^1#O<[CQ-$%-D.S'HQ&772NKX8IA:
MW",$QW`*=530,2#5*E.V-S<64IRQR#);J1IY;>Y%</F<JUMIJDEQ+69(;026
MVDMM(0VD)D```````````"-7F555$IJ,^MV7:2=/(Z6M:.9:RU&>A=7%;/5M
MHU:$;KAH;3KTJ(!'_LC)\I,W,EEJQ^D61FG&J.6XBQEMF1EU=[D$=33S3:B+
MQF81M:^!3RD\2#!_<==`).-8%2LV\F`DXQ1:I+$'':3I4>EA8H04..9*(S-E
MDG'E&1^+J8#U0\/=GR&+/-)R<AG1W428E6ALV,7J9+:B=:=AU:C45A-BN?4E
MR^L=2I/$TEDS,@$[_;_@`$1%X`````````````````````````%6^>/\E/.#
M\+?,#^$V6@(/W:WZ?W)M\.>U/W2K0%W`````````````````````````````
M````````'3(D,Q679$EYN/'8:6\_(><0TRRRTDUN.NNN&3;;3:",U*,R(B+I
M`:V>.SW$)34=R72X(ZDT.34&[#N<O97T*37F7!)JL=>071(/@D2T'JV2632X
MX$_JJFLHZ^+54\&+6UL)HF8L*&RAB.PVGIT0V@B+4U'J9GTJ49F9F9@,@`U?
MG>X,?'E+IJYY"KMR/ULF3Y.[.8H8[S;AQGG(,9*I=Q>3UMFFOJXY*E3%)-6B
M6D+60:WQ+!\NRM"+/(XTW":)^6FS9HY[T6PSJ\DGTIN\SF1S?JZ^T<(RZF$P
MI]NN;(D(/B+H"5[A[G[-<MN)OY'GF156(5;CNC1/G(L<ERBT<-MMJ#3U41N;
MD657LQYQ"&V([3[RUK21%T@/XU]Z;N#N3NGRN5>;S<;@X#M?)S6,UCN-WC=A
M_P#U.QFJI[9<:VRR`ZU$CX*3<;76G=0[/0I>KRD="`'Y#-Y-@]T>9W?G;S9G
M9[&G\JS/)MS)+1LI0Z=30U2<FEG8Y)EU@A#C5)BU3%0MV5)>T+1/`V3CJD-J
M#_1NK\'R#)X5776#CE-B=;!KJ]B(U%<J4/18$&/$6FGH%*4_7QY*V5&B18J5
M*0RHB2PP9`-ZU-57TE=$JJJ(S!KX31,QHK"";::06IGH1>%2U&:E*/4U*,S,
MS,P&1``````````&-M;>LHX:["VG1X$-M24&](62"4XX9(:893]=^0\LR2AM
M!*<<4>B2,S(@$-.9EV5&::ME[#Z%9Z?:MC'2K);!DS,N.OJ7B4W2M+3TI<ED
MJ1H>O4MF0`1XM@9E%AL2K+(K-!NE$C:VV5W1FHTG*DN/+)QN&3B>%3[[C$1I
M6B36DS21@.BR+)_ZF52_LBH41<.*TDMPUO)_^F\O&RCORS,R\9F.33/3H9KT
MU,)Q`KX-7%:A5T2/"B,%PM1HS2&6FR(M#T0@B+B/3I/I,_I`>P``````````
M`````````````````%6^>/\`)3S@_"WS`_A-EH"#]VM^G]R;?#GM3]TJT!=P
M```````````````````````````````````&*N+JMH(#UE:RFXL1DTI-2B4M
MQUUP^%F-&802GI,N0X9(;:;2I:U'H1&8"&QJBSS)UNQRV(J!0-.MR*G#G#2I
M<E;2R<CV66<*E(E/H425LP",X["B)3O6NDCJ@V/^W[?Y``#5NXF<V]&J!C&%
M4_\`<>?9"9M5<):C14T$+ZLG*<JEIU\AHZ[I-*2(WI;VC323,S-(>6EQS'=L
M:>=EV<9+#D6$1B38Y#F^2RH];`AF^23G.1?*G_):B&LTDG7B-Q:"2@U&E*$I
M#5BMV]R]Y5G`Y?Z%%#A[BNKD[Y;@U<QBF>8,S2MW;O"GCAW&7O&@]69DHX=;
MKH9*>+0C"!Q=F]ML)WVPRYRZ78[B9E0X9D.<'EV:.IR7-+7,9-U2XU22*>M;
M8ZBG@4]?8ST0H59&C1(JWR=476-DZ0?.X6T^-<UT7(L-W`P!%]@4+.HUVQ6V
M%K:4U<[:P*MF'Y9;7N-V,27/)!.+;>K8*UDH]4/R$=)`-W[+\LNRFPT>4>VV
MW.&XM8V*E.65G08[`JGY3CAJ4[HXVEZ:I#CBU&:WWY$ESB_JNN'H8#?V@```
M````````-9(W`1D\ZSI=O?(;R93RO(;JXDOFU1TLDR5JVO@_UEK((DGPICIZ
ME1D9&Z6BM`]OV31XR191E]N5I:Q]4-W5P3:&H3KZ>$X>-U+9+CURI))X$HCI
M<F/EHE;CID0#K*;E>5]%6V_A]"OPV\^.AS))[1]/%653R7(]2VM/U7I9..$6
MFC/3T!)J/'*G'FG45T8R?E*)R?8R75S+2S?(B+K[*QD&N7+=(BT3Q*-*$^*D
MDI(B(,]_```````````````````````````````5;YX_R4\X/PM\P/X39:`@
M_=K?I_<FWPY[4_=*M`7<`````````````````````````````````",C\`"-
MY%DL+'VF$K;?GVD]:V*>D@D3EE:R2(C4VPVI24MQVN(C=?<-#+"/&4HBTU#%
M5.-3)5BSDN6N,S;QHE'65L=2G*7&&G4FDVJY"TH.99K0>C\YQ).*UX6TMM^*
M83D``0O(,CDHF%C6.>3/Y*_&3+>>EI6JLQVM6YU9V]P;:FS6H]%>2Q"6AR6X
MG3B;:)QU`5RO=[Z'#5Y+CFTM#.W>SRKCR+7/LG=EMU^(XXN/7^7N6&X&>N,J
MKHBFH&BX]37H?DDP:$-,-H,C`:HQ+;K-[U&*[]\WN>8[D3=E8Q)=3M._"9H]
ME-IJ>6U,L*>W;CVZVYM]G3#++77V-JXZT@W#;89;X4N&%E8^[O\`?3*XVTL6
M5<5C:%-,Y%!KT*ARR;0HD-TCUB4:E8C+)O1N9)<4P7_8T]IP@,#@&QMZK+,F
MW%W1N(LV[R6KI\>AXM1.RGH5#C-3(F3UU=SE\LF;S,+"ZMIJI,U1-U]>24-1
M6HO4,\3H68B18T*.S%B1V8D:.VEIB,PVAIEEM!:)0VVV1(0DBZ-"`>D`````
M``````'!D1D9'X#(R/\`D?A`5(QO:G<+"MP*Z?00Z!^NA%E58C*'9ST)ZQQ:
M^E?;%9`RVGCM]=<VF,6IJ1&<0M'7(/I4R1J`6(J\0BQIC=Q=2Y&29`DCX+2R
M0V34#B+QVZ6L;UA4S"B(B,FB-UPDD;CCBBX@$P``````````````````````
M```````````5;YX_R4\X/PM\P/X39:`@_=K?I_<FWPY[4_=*M`7<````````
M````````````````````````U\/\/^6H#5.[&Y*-N:>I;KX#UYF&7W43%<(Q
MYB/+?^T[Z<2U%(L#ALO.P:&JC-KDSI:B)MAAL]3XC21A&L#OOL[)':C.JJ76
M;@7#9F5W/=3(@733*]3@8_)274PZV.K7JXZ-#5]9>JS(S#??A`<:E_EX?#IX
M-?#X/``@LW.8CW7Q,4B2,LM$H<2W]F$2J5B3PGU:9]ZHTU[;27?%<)I;KB-#
M(TD8#0<D['&VK,\UDUN4S),E-C9XMAQW5O8R[:6V@DQ;V!71G)ELN.YHU%;?
M>APR82DN#Q3,!JRGQKFAS_!LJQBGPS#-AZ[<?+\GN+ZXRY3>49#4XI=.PX$2
M#68G2.QJ\LI<QZ`@WE2I*XK#KO5EQ=5XP6-3R^8K=.4DG<VSM=U%XZ_!ETU5
ME/DZ</K9]8SU$&?&PV$VU329D,E+-IR8F6XV:S-)D?2`WK'C1XK+46*PQ&C,
MI)MF.PRAEEI"?`EMIHDMMH+Z-"(B`>@`````````````````````````````
M``````````````````````%6^>/\E/.#\+?,#^$V6@(/W:WZ?W)M\.>U/W2K
M0%W``````````````````````````````!Y9DV)7QW9<Z2Q$BLI-;LB2ZAEE
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M5PI]KDC!J:+QW$VR$N$1IZK4]`FK&'SIK26LBO'E0R(B3C^+M.8Q0MI)'#U3
MJXC[E[8DE)FE9.3$1GDEJ<9/@`2RLIZNECHB5%="K8K9<*6(4=J,WIKKTH9;
M02C_`(GTZ_S`9,``````````````````````````````````````````````
M`````````%6^>/\`)3S@_"WS`_A-EH"#]VM^G]R;?#GM3]TJT!=P````````
M```````````````````'!GT:ZEX#/_K_`"`0.7FA2Y;M7B$$\EL6EFW)EMN=
M5C]8LCT44ZV)*FG'D]/]%@G'->A7#TF`YBX9Y9):M,OG'D5@VKCCPUM]3C]:
MKH-/D54:EMO/-J,]'GS<</7HTT(!.B/_`)=/1TEJ?^/^`"$V&9(7,>J,7A+R
M2Y94IJ24=PFJBJ=(BZ+:W-*H[+B#UU9;ZQ[4C(TD8"*V&VM]D=E7WF09U=L3
MJ\E+ATU(4>-BT.4HU+9F*KGVW7+.=!4:39=D+425I)1(^@!)Z#;K&L?8AMI8
ME74J"TEMFSR*6Y<3^(G#>-[CE<3+<A;ZE+-Q"$KXE'TZ=`"=@```````````
M````````````````````````````````````````````````JWSQ_DIYP?A;
MY@?PFRT!!^[6_3^Y-OASVI^Z5:`NX`````````````````````````:_2`C-
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M\"$D1&9F>IF?29])@/<`````````````````````````````````````````
M`````````````````````*M\\?Y*><'X6^8'\)LM`0?NUOT_N3;X<]J?NE6@
M+N```````````````````````?\`#P@,5;7=511%3K>?'@1B42$N/KT4ZXKH
M0S'93Q/RGUGT);;2I:C\!&`B!2\JRO4J]N1A]"H]%6,YA!Y/9-&1ZG!KGN-F
MC8<+ZKDCCD<*M2::46H"34F.5./-.HK8Q(=DJ)V;/D.N2K*Q>T/B?GSWU+DR
MG#4HS+B5PIU\4DET`/9:6M;2PW9]M.CU\-GI<D2WDM-Z^-HA!F>KCCFGBH3J
MI1]!$9]`"'?:.594?!21WL5HUF?%>VT8CO)S1]&M/2O=%>VO3H>F>.9'JEDN
MA0"14>,5./DZN$RX[.E&2I]M.=7,MK!?1JJ98/<3[B-2U)LC2TD]>%):@)`1
M:?M]'[@'(```````````````````````````````````````````````````
M````````````*M\\?Y*><'X6^8'\)LM`0?NUOT_N3;X<]J?NE6@+N```````
M`````````````:_\P'4Z\TPVX\^XVRTTDUN//*2VTVA):J6MQ9DA*2+PF9Z$
M`@1Y;8Y`X<;"(3<R.2C2_E-HAYK'X_"OA64!M/4RKYXB\'4FAC][Q&7"89*H
MP^%`F%;V<F3D.0:*([JVZM;D5*]24W50VTE#IXZNDN%A*5&1^,I0"6+6AE"E
MN*2VTT@U+<6I*$(0DM5+6M1I2E*2(S,_H(!`W<NFW+BXF$0&[8T+6U(R&<IU
MC&83B%&AQ+,A!$_=2&U='5Q2X.C1;J-2`>ZKPZ.S+;M[Z6]DM^V?$U86"&TQ
M:XSTU125:.*)5(+3ZZ24^KIXG#U`3(``````````````````````````````
M`````````````````````````````````````%6^>/\`)3S@_"WS`_A-EH"#
M]VM^G]R;?#GM3]TJT!=P``````````````````-0$0M,MC1ICE/217LDR%O@
M)VKKEH2Q6]:DU-/9!:*2N%21U_6)*^.4ZC4V67>$R(,<UB$JY>:GYQ.;N%MK
M2]'QZ&AR-C$!PNE)*BK4J1=R$=&KLLU(4>JD--D?"03UM"&T);;0E#:$DAM"
M")*$H21$E*$)(DI21%H1%T$`BMQET*OEG45T:3D.1&A+B:.JZM;T=#FI-2;B
M6ZI$*D@*470[(6A2]#)I#JRX##%MXK99`M$K.)C4IE+G6L8M5+>:Q^,?0:4S
MW5$U+R!]M22U4\3;!F1FEE)&9&$\:9:8:;98;;99:0EMIII"6VFFT%HA#;:"
M2E"$ET$1:$1`.W]OV_D`````````````````````````````````````````
M````````````````````````````JWSQ_DIYP?A;Y@?PFRT!!^[6_3^Y-OAS
MVI^Z5:`NX```````````````#C4OW@,!>9/3X^EHI\@U2Y71"K(K:Y=G.69D
MDD1(3!+>=U4>AJT)!?29`(T4/+,J,E6KS^(42SU35UCY'DE@R9$9%86K6J*9
MM2="4W&UD>,9=:VHM3"95536TD-%?4PH\"&TI:R9CH)*5..*XG7W5GJX]*?7
MJIQQ:E..*,S4HS/4!Y+O)*?'F4/6DI+2WCX(L1M*Y$^<X>I$S"A-$J1(69F1
M>*DR+7I,@$80WEN6:^4*DX70.:D3++C2LLL&C21HZU[A>BT+:M?&)).R--4Z
MMGHH@F%12U5%$*!40FH48W%/.$WQK=DOK2DG)4R2\IR3.F/$DN-YU;CJ]-5*
M,!E0````````````````````````````````````````````````````````
M```````````````5;YX_R4\X/PM\P/X39:`@_=K?I_<FWPY[4_=*M`7<````
M``````````'CGSX-9#?GV4R+`@QD<<F9,?:C16$&I*"4Z^\I#;9&M1$6I])F
M1>$P$(.UR;*?Z>.1W<<I%]!Y+<Q%(M)C9F9&=%CTE"78[?27#(GDV?0?#'4D
MTN`,[1XI4T*W)4=MZ9:2=/+;JR=5.MI9D6AD[,>,W$-']#;?"VGZ"`9R5+B0
M(S\R=*CPX<9M3TF5+?:CQH[*/&6Z^^ZI#3+2"\)J,DD0"#'>Y!E&C>(QOLRH
M<+QLNNXKB?*&E$>KF/43Z6Y$WI^K)E$S'/0E-H?;42@&9I,0JJ5YR?K(L[F0
M7^KO+5TYEF_X/$2\LN"(P6FA-LI0A)=!$`E0````````````````````````
M``````````````````````````````````````````````````JWSQ_DIYP?
MA;Y@?PFRT!!^[6_3^Y-OASVI^Z5:`NX```````````#C4M-3Z"(C,]="+0OI
MU\`""2LQ782':W#8*<@G-.&Q)LENJCXU5O$HT**9:(0YY6\T9'JS%2ZO4C29
MI,!W5V'DN8Q<Y1/5DMTPKK89OLDQ2TKI^!5'3<;K$>0A)\/E3QO2S(S(G$H,
MT`)H?1KX?W_RT_G]`"$3<S:D3':G%H2LEM65]7)<CNDU1U*]=-;6XX5LMK3X
M399)U\^$RX2/34/F%AZIDEBUS*<G([..XB1#@=2;&-4SZ=%)76TZEN)E2V5D
M7#+E=:^2D\31,\1I`3K0OI_?K^[^6O[S(!R`````````````````````````
M``````````````````````````````````````````````````"K?/'^2GG!
M^%OF!_";+0$'[M;]/[DV^'/:G[I5H"[@````````#@ST_P`R_P`?]P"*W>75
MU0^FL8:D75\\@UL4%0A,FP4CIT?E:J3'K89Z'J](6VCH,D\2N@!ARQR[R7A>
MS*:B/7&9+3B5(^ZF`:2,E);NK3A9E7"M.A;2$LQ3Z2-+A=("<Q8L>$PU$B1V
M(L9A!(:8CMH::;01$7"VTA))21?P`8.ZRRII76H2U/V%Q)(U0Z*J:.;;RD__
M`")C(-*8T8OI>?4TR6A^/KH1A@_L+(,I+CRV2=35+41IQ6DE+)3K?A)%[>-&
MAZ9J1F2V8W5,'H6JG"U(!-H-?"K(K,*NBQX,2.DD,QHK+;+#:2\!);;))%_Q
M,!Z]/^@#D```````````````````````````````````````````````````
M`````````````````````````!5OGC_)3S@_"WS`_A-EH"#]VM^G]R;?#GM3
M]TJT!=P``````<&>FG\3T`8FYOJF@BIEVTQN*TXX3,=&BWI,Q]1&I,:##82[
M+G2EI(S)MI"UF1&>FA&8")ZY;E9]!/X50.?2HF'<ML&CTUT3_7A4#:RZ-3Z]
M_3Z$'TD$JIJ"HQ^.J+4PFXJ'7#>DO<3CLN;(47C29TQY;DJ;)7J>KCJU*_B`
M[;6XK*.&J?:S6(,1*TMI<=,S4Z\LE&W&C,MDIZ7+>X3)MEI*W%F6B2,^@!#S
MD99EFA0$/X;C[FNL^8PTO*;!KP:PJ]PG8M*VLB,TN2"=?TX3ZI)F>@2BDQRH
MQ]IU%9%ZMZ2KK)LY]QR596#W@-^?/D*<E2G?W<2C2DNA)$6A`,WI^W\O!_N`
M<@``````````````````````````````````````````````````````````
M`````````````````````JWSQ_DIYP?A;Y@?PFRT!!^[6_3^Y-OASVI^Z5:`
MNX`````Z)$EB(RY)E/M1H[*%+>??6EIII"2U4M;CAI0A*2+74^@!`_[JMLC4
MJ/A,%M</4T.Y;=,O-T;1)4:5*J8*5QYN1/),N@T+8B]'2_KXJ@S-/B4"LE*M
M9;\J]R!ULVGKVW4AZ8AI2B<5%KV6T-PZ>!UA$HF(K;3?%XRB4LS4825UQMA"
MGG5H:;;2:W''%DAM*2Z34M:CX4I27[^@!`UY;.O5KB8-"9LD$I33^3V)/-8S
M#4DU)<*-U9MR[^4WPGHU&-+6O0M]O4C`9*IQ&'$F(M[62_D>0D@T_;%F39^2
M)7P&MBEKFR*%20S4GZK*>L61$;KCJ_',)=H6NO[?1_R`<@``````````````
M````````````````````````````````````````````````````````````
M```````"K?/'^2GG!^%OF!_";+0$'[M;]/[DV^'/:G[I5H"[@``&`@]CFC7E
MCU/C4)S)KIE9LRF8:R;JZITCX5?;%N9+B17&C^LPCK)!?2@M2,!T,8?(M'V[
M#-9R+R0VI+T>D92MG&X"R\!I@K4:K)U.A?U))J+74R2G4!.TI)"4I024)01)
M2DB)*4H+Q4I21:$DDEIX.CZ`$1M<QC1ICE-217<COFS)+M;7+03%?J>G%<62
MC.)6D@NDVU&I\R,C)O0]0&/;Q&?>.)EYO8(LDDLG&,<KR=CX]&-)D9%)0:BD
M7+A'IJ;Y]61^!`">M,M,MMLM-H:::0EMIIM"6VVVT))*$-MHT0A"4D1$1$1$
M0#M(M```````````````````````````````````````````````````````
M``````````````````````````````%6^>/\E/.#\+?,#^$V6@(/W:WZ?W)M
M\.>U/W2K0%W`$<O,HJ*#J6YK[CL^4?#!J(#+DZWL'-#T1$KHQ+D.IZ#U69);
M21&:E$1&9!@OLS(\K(U9`\YC=$OI3C53-,KB:T9H419%?PUD<5M:?KPZY22^
MA<MYM2FP$QKJZ!51&8%;"BP(4=)(8BPV&X[#:4EX$,M)0E)EIT]!:@/!>9)4
M8\AE5E*X7Y*^JA08[;DNRGOF2N!B!71D.2I;SAIT(D)/4^@!&_),IROQK5V1
MB&/K+HJ*^2DLILFM?_VMS%6IJACN)T,V()KDZ:&<IL^)H!,*NHJZ6(B!4P(M
M=#;^JQ%90T@S,BXEKX2XG'%_]RU&:E'TF9F`R0``````````````````````
M````````````````````````````````````````````````````````````
M`````*M\\?Y*><'X6^8'\)LM`:][N*7%@=WKR>3)LEB)%C\N&U3C\F2ZAAAE
M"<2K3-;CKAI0A/\`,R`6`R?/ITR.NMQ8Y-8[9-.QX%_(K5S;)UQY"DIE8QBS
MI%(LU,EXZ)$PH\`M",U.)U(PTG36.0;$[A8/"R^PM+C#]W77\7CVV3K3?YC1
M9XPV=G#=O,NB1V8Z:G*XC;C;=<2"CPY;*$1U*):B,+B3IT.LBOSK&4Q"AL(X
MWY4IY+#+9:Z$2G%Z$7$9D1%J9F9Z$1F`A'VYD>4EP8K$.EJ%=!Y3=Q5]?(;,
M_KT=&X3;KR5%TI?D]6WX#)"R`9ZCQ2KI'7)J?*;&XDH-$R]M'O++601FG5LG
MU%PQ8WB%HTR3;6B4ZD9EJ`DQ?X]'1^X!R```````````````````````````
M````````````````````````````````````````````````````````````
M``JWSQ_DIYP?A;Y@?PFRT!47D?PW.I?))R995"LYF5XM$Y;=GU%MXT[&I7X#
M[&&0TR["IM(S!/V$J4M27"2^HW&C0:$<2%\"0NC4N8Y9I.SPO%,\Q_,F3;@S
M)+=0Y!FJ-@E+*+D$_(EHH[NN:-U1I2XZLR,S-DT+Z2#6VZ^S&\>[F1[=7M]9
M8_6Q=N[AO(ZC&:2RF?V_;9$E266+/+Y,V*J>35=%4M3+$!A;I*6I!2"UZP@L
M_`PUM4EBTR:<O)K6-HJ)Y0SU%-5+2DB_\-2FZ^S'61EIU[RWY2B(N)T]"T";
M%_E_+P`.0```````````````````````````````````````````````````
M````````````````````````````````````````5;YX_P`E/.#\+?,#^$V6
M@(/W:WZ?W)M\.>U/W2K0%W``````````````````````````````````````
M```````````````````````````````````````````````````````````%
M6^>/\E/.#\+?,#^$V6@(/W:WZ?W)M\.>U/W2K0%W````````````````````
M````````````````````````````````````````````````````````````
M`````````````````%6^>/\`)3S@_"WS`_A-EH"HO=]<S.W&+\CG*;CMECO,
M%+L*383;2KF2<=Y2.:W+:)Z5`QB!&D+J,GQ;9:XQK(:\W6U=3-KY<J%*;T=8
M=<:4E:@N%[6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@"MG.9S1[:7G)_S64L+&>8MB9<<MF^=5$>N.3[FVQ^I9DV&V&41&';2_OMD
8:VBHZUMUXC?F39,>)%:)3CSK;:5*(/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex10-12logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-12logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*P!\`P$1``(1`0,1`?_$`(@```$%`0`#````````
M``````D`!08("@<"`P0!`0`````````````````````0```%`P$'`P$$`P@3
M``````,$!08'`0(("0`3%!46%Q@1$AD*(2,D)R4F.C%!(F)#MBAX@=$R,S5%
MM7:&-W>W.$AHF+@Y&A$!`````````````````````/_:``P#`0`"$0,1`#\`
MW\;`M@P[_5$1PUH4R3TO7+$O4\=+.3^4;V3Y_--!_/Y"#E-/#<^/Y.P@YB2>
MY@"-Y.PJXSX=M@`8-+;38GIZ>NP3+Z@Z)$O1[:...H/IQR?(.-LYG,@VS$[I
MAA+DU_.V)I^::@U74Z!@7)$;O<[@15&J(9:!8H:M)@`!#%E.M;Z6FZ%A[0V3
M1XOK#L8#'=+A0!VHON5GME?7&N:K=<:;:PLHI)14T`S6^EM]1T<Z9O+WUK2E
M?<'7UV"8;`M@K+DME=%N+0,*!2&>K>O9!Y"1%C=%K7(F25BXYGU++M3VZ$,0
M*&QP;C"6T4<P:652^REU0B!$3T]1+P[;@LUL"V!;`J5]?MI]M*_;2M/W]@6P
M+8%L"V#XE!33D@J(>55`DF$@JVT%.*!L`D5#K?=2VR@A@R($#96^ZOI3UK]M
M=@]Y<R7.`!&B@X)HL/9:*`8+BV#@#!W4];1`A@KK@Q++J?N5I6M*[!BH^KM(
MWJ<Q:*Z:$HJ2.(H9/R*1#5T88N75TJ\VZ<:0+%%*'-E3Q4%2(W";T"\4$8.T
M6VVMUE]*5MJ'1M:_%)X:<!"--8)NR,[,]U+%Y[,EO..$=0M4*S*S&:WI`>:4
MD%9#Q_N;"8PD^*I'*O(PE@WF>6J5M-X`<#M#O3[`AP=L@-0>FIUJ4:/."Z"H
M/YBX99:XKA9T3PQD)SJC379<+K<<2R\V+!\@.)JGTI8-,-J+<2W@KB>6'!)K
M=YN^T:T0,("MH3W-"2DG1^U>=*]HXJ)1B.L=]0AQ.2!,C<=$$^ITAPXL6O*,
MF5'\OLQA#&C*&PY%;RI)P0B@=1RY2Y7($*`&;1+A!!+@&M-VH#AO$TJYI8Q:
MQ\"9=1)EZ\)WR&(QIGVS4USKP;-B)TNE>+8[NR"5Q&?;4>;)C^.(X.I095&;
M!0\F*X1<:\_8.:4%$"H.&K-"T!./5,^G2=3*<YR56_DXYHS,/67&[(DDE",Q
M()%PX\MUNO9I5+O<Q?'`*ZWC5QH/IX9.&MO,^\02\>V@E`(:^'$VLEM>!DZ.
MZQ>^[<%\0\67%.SUA10DB2%9,GF:GJ`W'4E73`Z%MV*#TDB/6:D2H0,)R&IJ
M)A-M4RHF]"%`W8(8>,J.M&T^]=7&;3\B4%P(&"^I-C6NIDC8XH+M>:2S8XET
MH<E,@G2A#54Q?+JT3GW$79Z>G*I=NF$HJ*&,,<OLJ;L!%#"I6C[BNW<Q-137
M*AG(>3IXD?&2`,IJL%J8W+TYRX<8:ZF`RED6D,HN]5P9[7OMS-R.D1#'!340
MRJ7I)@P>J;/`FC!4E>`%E/IOEEU17G9K=X+H+V>JQC1BUDHGDH#8+S=*T\+8
MU33DC3BUCB:@*B^</*(),\A-!+",6U$K0<4E:/?ZC7C7B!JHD^:(=A%&*N*9
MY8C2(F^=-<"379/?;68*,;.TMI?4F55'6JI)(<U[;J5W=E];_2O[FP2)EOAE
M2.VDQYQX\&L_6>M!7#HSK9;@270VE8"P2X*\9,74,V>2SX5HME;:W!"WTI=2
MM/W:;!*=@6P9G]/=KP[J_3YJ`Y1YBMEO3XDX]9E2;AYC?C=)U07C$,&1?$22
MW@!'P)#JIQ3&493E]96#1T\X5(H?/A@E[2A(<N6"N!V#FNISI]+&%CHPYGO3
MSD"4<9(#<.H#AHR<Q<5HH?[H;6/;N:3XR#8:*WY%18Z+JM$%AJ0;R&3D9<)(
M@))/7B"D%4R#^&&J9"=ZV^F1G7J931A<Y8B:F/3+96%TV.*2"ZJ_IT=X*Y*Z
M*L+$4JX!0!OH<%*Y9D*(7;L8.^@I]1#]3-EU+JTLNI4.FZF&`FHUJZM)FXN2
M<M8YX7X:=;-M[32/'\COC(7("4[VJ;X]%;2,75(BB*/6BWR9ZM#5+AS*B-<H
M@%3%UMP1>XJ8"59,:1JS'$XZ=V9^G@DL8I,VG/&A3'--A.3W">;+2G?%:UIK
MC+$C\>222"Y#;0DIMI+I5AT=7,IQHF9/*5]QVEMH=E:@Y.C`"=L^-13$_.3,
M>/VI`<0X'HZZK8^8[IS[2I4DI\3>YU!(53DF2B[6NGE6.V&BT#K=2AD1'3#B
ML<-'DRTR9'+!B7E+@973$>IZ\,.9EPNFO%+&_)]1E$M-[.CR;G_D509EMF/I
M-=KOZ$-3NTW+'"J^S3UB=L+9.X*K4YJ&IT3B]H9I.,4J+:%(\R=%#*MB7:&S
MZP[+,G(U0TE0VHD/F.7L^2L-K<OAH2]&3J.KS4<ZR276X@%U=691\.XJ;OO$
M3PC9?=\72P2V@7$>>"F:J=G+">L%'$80.4R?&BYWP'E9B`2E97L0'[!2JM5.
MQR<8T]*[))I(D_Q^G$TNQ6$.I!!N+5$T,H6,$P@N)-`UK>'TROC480M7?,IO
M15&CDA..D'&?3^Q#.3&4-W')'DA4<#=)N.8YA36>J-1.D!^.&2E%,14I#(KI
M8KQ1400T(,4IO`CNE=@+GQA#F9J6Y"R=%$#+;.U!)N4YK2"#0R,7#R[$_+UB
M<'JB-%;+*4$I11VCK:Q)!!,%/E1B89(,(8UN1J4M`J$<TW,%\X\#,[=3#-.<
MXX@<2(,Z))OF!;"9F02ZMNF"FFW''+<@JEAY)4800R,AJ%I5\!@6VECB99[B
MM]];O2^VE`XQ].VM)&J4M9J:K&53?294F1RY).*"8,17X0*NMMXUP(V&@SW@
MEL"(T5:".);2O6.NPP5@Z4"L-JEZ?:,,)<(8-7#`2C3`P#RVQ(RMU+IHGN4X
MC6(GRLFEN.R!(AA1#&:;3939:MCG2R;H6V63;#7:K6?:XS#J(FK`B?:>,K1Q
M($/*!PR/>&+<!L-@6P8)\_M-#66TN\ZY^SPT9U!XOV$<EG6>DN3H?8A1#?*P
MBNI=45-P.5N.^#7*"<LD9LAN%3/&D%412IE72RR@(4KPWLJ8-A+\(/JNI+NG
M-F8HZPV)B3!9YT.%L(E\K$V8\(\`9"\86B]&RXY5AJ5KU1136\670`!QEH@=
M#Y7>!Q%I*ZT.ZX,#XZIFJ:[\5)EQ)P7Q6:[*?F<&<;P34"-AI(JK&(IAQ@'%
MGD:G,DBIS;/)SB<I$D.$;O()9(P6J;L3#HMX]M"]@!H.%Y`Y\Y6::.9>GCCM
MD7,Z#FBWL_9-48F42+2QAOA=V1(J\Q9C=2WZT'`U7Z[6\XFH6<[W+T44!3*&
M%8%*"%-6*-:A>T4.?2;JKYU1!KJXEZ5SZ*8P+$43LAJTI+#\C^.Y+0WX$R#;
M:G8\UV6,,[95=:$"MDCL6E1%!1+DK;#5HUUH(1>GK38+2SOJ$R_-.IJ5TF,(
MW>Q(VD&.(:.3]EOD8]F5?*`D4-2\5H!-2,XOCL1>;B$N28Y>O$<T<4%@P,EI
M*<HV5M*FS-MX(8<RBO4MR0BG4S?FCWE`YX@?,U/B#3,Q8591),?++*;SZ,"-
MMS+-C)GR(4IZ&RX"^CB--5&J:;JNF%E0FD7V6`E!S8-`PI[%&K9JQS/JO92Z
M6[.CG$1<=D%QT?#!F9(:,EM:,&0I#J,4J1V;9);[AE)WO1THC8;[O&2$MH(A
MDD86G`H%;C*D4(!CF`0Z,Z]1?/W3WU<\/,!LN9?B',&#LZ$E.`:,DMF$"^/D
MCQ0]U=<5F>13K$1!>;Q;[A;-'82*4NXL00V(24:UM&L%*5H:"D.KY/6H<B:S
M.DUANY\@H/58W>V0L6Y$QPW&M`CM:+21G<FRBY6.QJ2\5,S>Y7;*?2Y0J*-[
M2*RVR0Q@Q<):5"%#`$"`X^J'E?GUI[8!R'EXA+>($F.6#R5BK(S>5X<F=MHC
MP).Z1&&Q6269`!/(-6/-<V@6N<R85!#YM4L4:AA6@6D_2^MP?)">0F5N:>C'
M%^395T0<SY7F7&A_OV6.HHL>3E9IA(/MA]`'$1BH+?EAF*3:/@V@%[2YL\>5
MP[0P[MX`+??[Z`"?Z0U%RT4=.>:!X'DK'5G-.W,![A**9+<)25)+C&7K8CA:
MXR=)K;.G^*4PJCBD;R]@9:\@,-8,&+?4>ZT2VP,"G:/VKCD)FQD/JI,+*<"#
MF2P=/YYI+$25R,6RZVHE'2;==L\(+]?[I,/-\/E0"*G"$7%S81:P>P(@#O+:
MU%N]1-@]F"N=&<&L==..2.,4KQ]A;@_&<G+L10C>YH$!G&;9Y66FG)2NX)#?
MEKA?+7;S%9-2:Z3L+(R47$4JF+QP1%"VXM6\8*)?_3T^_CD\@^R13O-YU>"G
M=7MT_P#Q_P!SRWJSR%[>=0]><3T+]YT#SSF7-_NN/W/V;`5O0\S[(Y:QYE1"
MCWDP^],A<3,Q<G8\>9%V+0BF\C$7*DY/U9AQQV7&Q!#9IJ$6V:JVRE]*W6EJ
MH%0:TLMW/N"M?U6&/,%2_I8O=Y/EOHYF?&#(42IF+*N53@!Y!6Y.?DCMUJ&X
MM:5P`-ZTN@O=HJ2F(.D`UO#$N(V';@ZWDK+[`$OF)%,DPO\`4LZ&;FEPU>$D
MK^-L"Q<G.0^:OJF')'8")*C.>K8*'1KMP.JWNQVIPM0[+JW"7K9?[/<+3U#:
M9/\`,L7P4C1^[I'31UA2<\O1M$$7I".CIRT[U>2Y@<Q)C(9%J%E`R1W(A4DI
MFE!6,!CA<&@$#YH3U"`OMJ&1C.+]L@TT/ZLZ?_,W,C8.!8P8>QO)GU6NIE$6
M7[.">R.\HJ?LPQJF+R\Z6WSHFYEV!7,SSK>/-I<0#JM8AL96.$JA4&%!LM)#
MTK9[R_J&&FA`P.TL,7LP,:S[(Q4:Z=E>^>YRM$;Y3`74\72RV['+(,==/1=7
M7.[%,=O-`B5=I-!#,W6#6\V<1(M99;4Q42P`=Z9O[69K$_[!#O\`EO%/8&O7
M(_:+=!+_`#OCW_R&#V!HULOVF#0PI_&B2O\`8\BGK_:V`R7U*]]EVB'GG;;=
M;=<&U8EL$I;=2M0[JY!1")2V^E*^MEU;+[:^E?M]*TK^_L#=I.?L\N./]11[
M_P`WWSL`XOHL?_6-.O\`76?O^YF"M@'MI)QX[I;5OJXXN8)<<X^)!.SFSFB0
M+5&M,*+C<*]FZEHZ8!4O2HV_4CYFP"REOK6MPE-@+A]'RK)I[2"+I90\7,*+
M<R<FU*7B(8E*FDA1,`,U8`)'P/L$+#BIBF7'MMNI3U#%MKL!FO-'%/O)XY]+
MJ'_$]XX]8]"H'97R<[*^2W2'5?'\'UKT[^'WO"[[JG]'>[C?X.P8K,5NRGGT
M_>GNUG=3O!F5R#XD/D"^6;G'?]S<P\B>Z/\`0U[8;_\`PEU-^@N"X'@ON=@,
M?3EGGQ@EW'\B^[O><;I_YONK>1<EY19Q_P`?WBG_`$'_`"WW7IP?4WZP;GV\
M']YZ[!V?ZF7H#Q[QC[B^)O*/(5(Y=WD\F/*7GV_0N6^!_BS^O'>?^[W_`#3]
M6_?P''?R6P,>(?3_`)KXD<[\[.O/25NGOFP[F=U>BNU2_O?`OM__`$;^]^_W
M'6'5'Y@=$<?N_N>+V`1V1_C!\X^-/&^1W47;87<=TOE_^5KV\LG7W>,?3_Y6
M]J?[YPW$_P`/@.?>W^0V"_FLYV]^0W`+F_2_5_;DIVY\5/)_YT.,X-_^O:WH
MG\C^TGKN>8]U?P'KU!Z?9Q.P7'P4Z8[OY=\X\L.J_%-.[G>8/=[Y=MQSQV\N
M[0="_DMXW\LWO3W:'\1UY[^._2'#;`&;"CQF^;;*_E'D;U-TVD;WM)\N/R+;
MSJ6$MUYO];_E'VAW^ZX_<_=;OE&\^ZXC8'K5?\;_`)C,/^J>[/5?=DQ_KJ^5
MWR@YCWI.;_XT>SGY,=+<;[NFO\5\=N=S^$]FP2G7/[>>0^BCP/77/^=M[MU[
M/*/YE>&[CM7B.VW4?Y:]0\3PO"=U/Q?/=_N?N.8;!YYM]B_C?R]ZY\E_7NV?
MYYY+?(OT-U!U!CYS_P"6WQU_@]Z^;>WHOIW]6.E>D>3?H[W[!;+"SL%\,+:Y
M=YT='=)I>]\;ODN[#\7T'*'#=D^JOSW\0.$W_4FY_`\;PV__`!/";!5GZ=KQ
MU\5<A^B^^'"=02QS;XUOE.\;."Z`BSC^5]_OTUY=[K=\'R7\?RK@N#^\W^P,
MFA-XZ>?N;'17<WJ/R20_=XM_*AS3F/<":MU\G7D#^575N]WF^]GZ+YQSO>?=
M[G8&7'GI+SBU#>C/)SFW>4UW1_\`GC[V]@^%YJY>*\J>_GZE>1_#>S?]G?QG
H%\SX?[_>;`4+\KOA#_Y$>U'D!_UB\AY%Y9_]Z/R:;S_23O-_$V#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>8
<FILENAME>v167911_ex10-13.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizer 4.0.6.4-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FIRST
AMENDMENT TO DISTRIBUTION AGREEMENT</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">This
First Amendment to Distribution Agreement</font> (&#8220;Amendment&#8221;) is made and
entered into as of this 23rd day of August 2007 (&#8220;Amendment Effective Date&#8221;) by
and between Boston Scientific Corporation, One Boston Scientific Place, Natick,
MA 01760 (&#8220;BSC&#8221;) and Bovie Medical Corporation, 7100 30<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font> Avenue
N, St. Petersburg, FL 33710 (&#8220;Bovie&#8221;).</font></div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RECITALS:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS,
the Parties entered into that certain Distribution Agreement dated as of October
6, 2006 (the &#8220;Agreement&#8221;);</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS,
capitalized terms used but not otherwise defined herein have the meaning set
forth in the Agreement (defined below);</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS,
pursuant to the terms of the Agreement set forth in Section 9.5(iv), the Parties
may modify the Agreement only by a writing signed by both
Parties;&#160;&#160;and</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS,
the Parties have negotiated new terms respecting (i) pricing of Product
manufactured by Bovie&#160;&#160;prior to the Product Launch Date, other than
(a) Product ordered on the Initial Purchase Order or (b) Product ordered by BSC
prior to the Product Launch Date for customer training and customer sampling
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(&#8220;Pre-Launch
Product&#8221;), (ii) the addition of **&#160;&#160;&#160;&#160;**, and the removal of
&#8220;Mott,&#8221; as the primary vendor for the Product&#8217;s porous
tip**&#160;&#160;&#160;&#160;** assembled to it (each being a separate component
and collectively referred to herein as the
**&#160;&#160;&#160;&#160;**&#160;&#160;and each set of one porous tip and
**&#160;&#160;&#160;&#160;** being referred to herein as a
**&#160;&#160;&#160;&#160;**, and (iii) Seller&#8217;s obligations under Section 3.2
(Seller&#8217;s Vendors) particularly directed to &#8220;Mott.&#8221;</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOW,
THEREFORE, in consideration of the foregoing recitals (which are incorporated
herein and made a part hereof) and other good and valuable consideration, the
sufficiency of which is hereby acknowledged, the Parties agree as
follows.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 18pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment</font>.&#160;&#160;As
      of the Amendment Effective Date, the following modifications to the
      Agreement shall apply:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment to Section
      1.3</font>.&#160;&#160;Section 1.3 of the Agreement (Ordering) is hereby
      amended as follows:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
seventh sentence of Section 1.3(b) of the Agreement (Ordering) is hereby amended
by deleting it in its entirety and replacing it with the following: &#8220;Pre-Launch
Product shall not accrue to the 3,500 unit minimum purchase requirement for the
first two (2) Contract Years.&#8221;</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment to Section
      2</font>.&#160;&#160;Section 2 of the Agreement (Pricing; Payment;
      Continuous Improvement) is hereby amended by adding a new Section 2.6 to
      the Agreement with the following
language:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Section
2.6&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Pre-Launch
Product</font>.&#160;&#160;From time to time prior to the Product Launch Date,
Seller may manufacture Pre-Launch Product (defined below) and Buyer shall
reimburse Seller for such Pre-Launch Product at the Unit Price set forth
below.&#160;&#160;Buyer will issue an open purchase order for
**&#160;&#160;&#160;&#160;&#160;**of Pre-Launch Product against which Seller
will invoice Buyer for Pre-Launch Product manufactured in furtherance of
creating commercially saleable Product.&#160;&#160;Notwithstanding anything in
this Agreement, Seller will not charge Buyer for, and Buyer will not reimburse
Seller for, any Pre-Launch Product in excess of
**&#160;&#160;&#160;&#160;**&#160;&#160;units, unless such additional units have
been ordered by Buyer in advance pursuant to a purchase order from Buyer to
Seller.&#160;&#160;The following formula sets forth the unit pricing for
Pre-Launch Product:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Page 1 of
3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Unit
Price = **&#160;&#160;&#160;&#160;** * <font style="DISPLAY: inline; FONT-WEIGHT: bold">1.15</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Where (i)
**&#160;&#160;&#160;&#160;**&#160;&#160;is the fixed price of the pencil handle
and packaging, (ii) **&#160;&#160;&#160;&#160;** is
**&#160;&#160;&#160;&#160;**&#160;&#160;(defined below in Section 3.2) transfer
price for the **&#160;&#160;&#160;&#160;** up to a maximum of $15.00
per&#160;&#160;**&#160;&#160;&#160;&#160;**&#160;&#160;(provided, that such
$15.00 cap only applies to the first
**&#160;&#160;&#160;&#160;**&#160;&#160;units of Pre-Launch Product), net of all
discounts, and (iii) <font style="DISPLAY: inline; FONT-WEIGHT: bold">1.15</font> reflects Seller&#8217;s markup
of **&#160;&#160;&#160;&#160;**&#160;&#160;&#160;Seller shall not charge Buyer
any labor costs related to the manufacture of Pre-Launch Product.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
purposes of this Agreement, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Pre-Launch Product</font>&#8221; means
Product manufactured by Seller prior to the Product Launch Date, other than (a)
Product ordered on the Initial Purchase Order or (b) Product ordered by Buyer
prior to the Product Launch Date for customer training and customer
sampling.&#8221;</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
purposes of this Agreement, **&#160;&#160;&#160;&#160;** means collectively the
Product&#8217;s porous tip and tube assembled to it.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment to Section
      3.2</font>.&#160;&#160;Section 3.2 of the Agreement (Seller&#8217;s Vendors) is
      hereby amended as follows:</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 54pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">by
      adding the following language to subclause (a) of the eighth sentence
      thereof: &#8220;or **&#160;&#160;&#160;&#160;** **&#160;&#160;&#160;&#160;**
      immediately after Mott Corporation (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Mott</font>&#8221;);
    and</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 54pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">by
      deleting all references to Mott in the tenth sentence thereof and
      replacing each occurrence with
  **&#160;&#160;&#160;&#160;**</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment to Exhibit
      F</font>.&#160;&#160;Exhibit F to the Agreement (Seller&#8217;s Vendors) is
      hereby amended by adding **&#160;&#160;&#160;&#160;** as a vendor thereto
      and deleting Mott as a vendor therefrom, and by adding
      **&#160;&#160;&#160;&#160;**&#160;&#160;as a vendor
    thereto.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Product
      Pricing</font>.&#160;&#160;In addition to the amendments to the Agreement
      set forth above, for the purposes of clarity, notwithstanding Section
      1.3(f) of the Agreement or Section 1.a. of this Amendment, the transfer
      prices for Products set forth in Exhibit E of the Agreement shall (a)
      remain the same as set forth on the Effective Date despite any changes
      that may occur to the Specifications because of the use of
      **&#160;&#160;&#160;&#160;**&#160;&#160;but shall remain subject to price
      adjustments otherwise in accordance with the Agreement, including but not
      limited to Sections 1.3(f) and 2.1 therein, and (b) only apply to Product
      ordered on the Initial Purchase Order (even though ordered before the
      Product Launch Date) or subsequent orders for Product after the Product
      Launch Date (and not before such
time).</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Approval and Qualification
of Chand Eisenmann</font>.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Buyer
      shall reasonably cooperate with Seller to promptly approve
      **&#160;&#160;&#160;&#160;** as a vendor of the
      **&#160;&#160;&#160;&#160;**&#160;&#160;&#160;Seller will be solely
      responsible for any and all of Seller&#8217;s labor, materials or other expenses
      associated with phasing in **&#160;&#160;&#160;&#160;** as a vendor of the
      **&#160;&#160;&#160;&#160;** to the extent required for Seller to comply
      with the Specifications Revision Level Number A-2 approved by Seller on
      April 4, 2007.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b.</font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Seller
      acknowledges and agrees that Buyer&#8217;s consent to qualify and approve
      **&#160;&#160;&#160;&#160;** as the primary vendor of the
      **&#160;&#160;&#160;&#160;**&#160;&#160;in no way modifies or waives any
      of Seller&#8217;s obligations with respect to Quality Assurance, or otherwise,
      set forth in the Agreement, except as expressly amended
      herein.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Page 2 of
3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Selection of Seller&#8217;s
Vendors</font>.&#160;&#160;Notwithstanding anything in this Amendment, Seller
reserves the right to select or change its vendors, subject to Buyer&#8217;s prior
written approval, in accordance with the provisions of Section 3.2 (Seller&#8217;s
Vendors) of the Agreement.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Effect on
Agreement</font>.&#160;&#160;Except as expressly stated herein, the terms and
conditions of the Agreement are ratified and confirmed, and shall remain in full
force and effect.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">IN WITNESS WHEREOF,</font> the
Parties have hereby executed this Amendment as of the date first written
above.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="top" width="30%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BOSTON
      SCIENTIFIC</font></div>
            </td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BOVIE
      MEDICAL</font></div>
            </td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="30%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CORPORATION</font></div>
            </td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CORPORATION</font></div>
            </td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/S/ David McClellan</font></font></div>
            </td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/S/ Moshe Citronowicz</font></font></div>
            </td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="30%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Signature</font></div>
            </td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Signature</font></div>
            </td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">David McClellan</font></font></div>
            </td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Moshe Citronowicz</font></font></div>
            </td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="30%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Printed
      Name</font></div>
            </td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Printed
      Name</font></div>
            </td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">President of Oncology</font></font></div>
            </td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Vice President COO</font></font></div>
            </td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="30%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title</font></div>
            </td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title</font></div>
            </td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7-5-07</font></font></div>
            </td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7-6-09</font></font></div>
            </td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="30%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
            </td>
            <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
            </td>
            <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Page 3 of
3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>9
<FILENAME>v167911_ex10-14.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizer 4.0.6.4-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="top" width="48%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><img src="ex10-14logo.jpg" alt=""></font></div>
              </td>
              <td valign="top" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="48%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporation</font></div>
              </td>
              <td align="left" nowrap valign="top" width="52%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TERMINATION,
      PURCHASE AND LICENSE AGREEMENT</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Termination, Purchase and License Agreement ("Agreement") is made as of
____________________, 2008 ("Effective Date"), by and between Boston Scientific
Corporation, One Boston Scientific Place, Natick, MA 01760 ("Seller"), and Bovie
Medical Corporation, 7100 30<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>
Avenue-North, St. Petersburg, FL&#160;&#160;33710 ("Buyer") for the purpose of
purchase and sale of certain rights and assets related to the Program (as
defined in Section 1.1) and use of the rights and assets in the development,
manufacture and sale of the Product (as defined in Section 1.2); assignments and
licenses for certain intellectual property of the Parties; and termination of
that certain Distribution Agreement between the Parties dated as of October 6,
2006, as amended on August 23, 2007 (the &#8220;Distribution Agreement&#8221;), all in
accordance with this Agreement.&#160;&#160;Buyer and Seller are herein referred
to collectively as &#8220;Parties&#8221; and individually as a &#8220;Party.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Times New Roman">MAILING
ADDRESSES AND FAX NUMBERS FOR NOTICES, ETC. UNDER
AGREEMENT</font></font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div>
        <div align="left">
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="top" width="49%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Buyer</font>:</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bovie
      Medical Corporation</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7100
      30<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>
      Avenue North</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">St.
      Petersburg, FL 33710</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Attn:&#160;&#160;Moshe
      Citronowicz, COO</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;(727)
      344-3876</font></div>
                    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                  </td>
                  <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="49%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">with copy
      to</font>:</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bovie
      Medical Corporation</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7100
      30<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>
      Avenue North</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">St.
      Petersburg, FL 33710</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Attn:
      General Counsel</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;(727)
      344-3876</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="49%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Seller</font>:</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Boston
      Scientific Corporation</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100
      Boston Scientific Way</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Marlborough,
      Massachusetts&#160;&#160;01752</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Attn:&#160;&#160;Michael
      Phalen, President Endoscopy</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;(508)
      683-5316</font></div>
                    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                  </td>
                  <td align="left" valign="top" width="2%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160;&#160;</font></font></div>
                  </td>
                  <td align="left" valign="top" width="49%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">with copy
      to</font>:</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Boston
      Scientific Corporation</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One
      Boston Scientific Place</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Natick,
      Massachusetts&#160;&#160;01760-1537</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Attn:&#160;&#160;General
      Counsel</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;(508)
      650-8956</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>NOW, THEREFORE, for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereto agree as follows:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">1</font><font style="DISPLAY: inline">.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Purchase and
Sale</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Program</font>.&#160;&#160;For
purposes of this Agreement, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Program</font>&#8221; means the SEER
Sintered Tip Resection Device, BSC Project # M0380.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Product</font>.&#160;&#160;For
purposes of this Agreement, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Product</font>&#8221; means any medical
device having a sintered, conductive metal tip in accordance with the Product
Specifications attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> (Revisions
A-1 &amp; A-2) for use in the Field.&#160;&#160;Product specifically does not
include any generator or generator accessories.&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Field</font>&#8221; means liver, pancreatic
and kidney tumor, orthopedic, and blood vessel sealing, therapy by delivery of
RF current and sterile saline for resection, hemostatic sealing and coagulation
of soft tissue in open surgery and/or laparoscopic surgery.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Assets</font>.&#160;&#160;At
the closing, and upon the terms and conditions of this Agreement, Seller hereby
sells, transfers, conveys, assigns and delivers to Buyer, and Buyer purchases
from Seller, free and clear of any and all liabilities, obligations, liens and
encumbrances, all right, title and interest in and to the following Program
assets of Seller (collectively, the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Purchased Assets</font>&#8221;), wherever
located, :</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All
equipment, machinery, prototypes, tooling, supplies, and other personal property
of the Seller predominantly related to the Program and the design, development
and manufacture of the Product, including all records related thereto, as set
forth on <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit
X</font> hereto;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="33%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUYER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
                <td valign="top" width="33%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page&#160;1&#160;of
      8</font></div>
                </td>
                <td align="right" valign="top" width="33%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SELLER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all
of Seller&#8217;s rights and interest in and under the contracts, licenses, leases and
other agreements and instruments predominantly related to the Program and the
design, development and manufacture of the Product, as set forth on<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit X</font> hereto,
together with true, complete and accurate copies of the same<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font>(the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Transferred
Contracts</font>&#8221;);</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to
the extent assignable, approvals, clearances, authorizations, licenses and
registrations required by any governmental authority, predominantly related to
the Program and to permit the design, development, pre-clinical and clinical
testing, manufacturing, labeling, sale, distribution, and promotion of the
Product as set forth on <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit X</font> hereto,
together with true, complete and accurate copies of the same (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Transferred
Permits</font>&#8221;);</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all
scientific, clinical, technical, marketing, pre-sales and other data,
predominantly related to the Program and the design, development and manufacture
of the Product, including, without limitation, files, formulas, compositions,
computer discs and tapes (and reasonable use of the means to access or convert
them to a form useable by Buyer, if necessary), laboratory notebooks, design
histories, operating manuals and procedures, instructions for use, device
history records, bills of materials, and manufacturing, inspection and quality
control records and procedures, as set forth on <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit X</font>
hereto;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline">the Generated Product IP (as defined in Section
2.1)</font>, together with true, complete and accurate copies of the documents
pertaining thereto including, without limitation, documents used by Seller (or
its counsel) in the preparation and prosecution of the patents comprising the
Generated Product IP, except as to the excluded document categories set forth on
<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit X</font>
hereto;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000">all guarantees,
warranties, indemnities and similar rights in favor of Seller with respect to
any Purchased Asset; and</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000">all rights to causes of
action, lawsuits, judgments, claims and demands of any nature available to, or
being pursued by, Seller, with respect to the Purchased Assets, whether arising
by way of counterclaim or otherwise.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline">1.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Delivery of Purchased
Assets.</font><font style="DISPLAY: inline">&#160;&#160;No later than _____ (_)
business days after the closing, Seller shall </font><font style="DISPLAY: inline">package and ship (or cause to be packaged and shipped)
to Buyer all tangible personal property elements of the Purchased Assets not in
Buyer&#8217;s possession and custody as of the closing, at Seller&#8217;s
expense.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Assignment of Intellectual
Property; Cross-Licenses.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Assignment of Generated
Product IP</font>.&#160;&#160;At the closing, and upon the terms and conditions
of this Agreement, Seller hereby sells, transfers, conveys and assigns to Buyer,
and Buyer purchases from Seller, free and clear of any and all liabilities,
obligations, liens and encumbrances, all right, title and interest in and to any
and all Intellectual Property Rights (as defined below) generated in the
performance of the Program and as a result of development work on the Product by
or on behalf of either Party (collectively, the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Generated Product IP</font>&#8221;),
including but not limited to:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 72pt"></font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;&#160;**</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 72pt"></font>(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;US2007/0156134,
filed December 29, 2005, **&#160;&#160;&#160;**</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 72pt"></font>(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;U.S.
Patent #7,282,051, filed February 4, 2004, issued October 16, 2007, and
continuation 11/550,374 (US2007/0123848); and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 72pt"></font>(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;**&#160;&#160;&#160;**
..</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
purposes of this Agreement, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Intellectual Property Rights</font>&#8221;
means intellectual property or proprietary rights of any description worldwide
including without limitation (i) rights in any patent, patent registration,
patent application, copyrights, industrial designs, trademarks, (ii) trade
secrets, moral rights, shop rights and publicity rights, (iii) inventions,
discoveries, know-how, techniques, methodologies, designs or data, whether or
not patented, patentable or copyrightable, (iv) rights to sue for and remedies
against past, present and future infringements or misappropriations thereof, and
rights of priority and protection of interests therein under the laws of any
jurisdiction worldwide and all tangible embodiments thereof, and (v) goodwill
related to any of the foregoing.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUYER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
                <td valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page&#160;2&#160;of
      8</font></div>
                </td>
                <td align="right" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SELLER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">License to Generated Product
IP</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.&#160;&#160;</font>At
the closing, and upon the terms and conditions of this Agreement, Buyer hereby
grants to Seller a non-exclusive, fully paid up, royalty-free, worldwide,
perpetual, irrevocable license to the Generated Product IP solely to make, have
made, use, offer for sale, sell, have sold, import and export any Seller
Products.&#160;&#160;For purposes of this Agreement, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Seller Products</font>&#8221; means any
product or device of Seller, provided however, such product or device shall be
for use in applications outside of a Product for the Field.&#160;&#160;As of
January 1, 2016, the license granted to Seller under this Section 2.2 shall
cease to include the limitation in the previous sentence, i.e., &#8220;for use in
applications outside of a Product for the Field.&#8221;&#160;&#160;The license granted
to Seller hereunder is not sublicensable, but is transferable by Seller to a
buyer only in connection with the sale of all or substantially all of the assets
relating to any Seller Product.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; TEXT-DECORATION: underline">2.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">License to Existing Product
Patents</font>.&#160;&#160;At the closing, and upon the terms and conditions of
this Agreement, Seller hereby grants to Buyer a non-exclusive, fully paid up,
royalty-free, worldwide, perpetual, irrevocable license to Existing Product
Patents solely to make, have made, use, offer for sale, sell, have sold, import
and export the Product for use in the Field.&#160;&#160;For purposes of this
Agreement, &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Existing Product
Patents</font>&#8221; shall include any of Seller&#8217;s invention disclosures, trade
secrets and patent applications (but not to the extent of disclosing non-public
details of such disclosures, trade secrets, or patent applications), and issued
and issuing patents existing as of the Effective Date, including continuations
and foreign counterparts thereof obtained thereafter, necessary for the
non-infringing manufacture, use and sale of the Product.&#160;&#160;The
foregoing license is not sublicensable but is transferable by Buyer to a buyer
only in connection with the sale of all or substantially all of the assets
relating to the Product.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Termination of Distribution
Agreement and Releases.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Termination.</font>&#160;&#160;The
Distribution Agreement is hereby terminated as of the Effective
Date.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Releases</font>.&#160;&#160;Each
Party, along with its employees, officers, directors, affiliates,
subcontractors, agents, successors or assigns, hereby releases and discharges
the other Party, along with its employees, officers, directors, affiliates,
subcontractors, agents, successors or assigns, of any and all obligations,
liabilities and claims, whether known or unknown, accrued or not accrued,
contingent or otherwise, arising prior to the Effective Date, directly or
indirectly, out of or related to, the Distribution Agreement, the performance of
the Distribution Agreement or the termination of the Distribution
Agreement.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Confidential
Information</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Confidential
Information</font>.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Confidential Information</font>"
means all proprietary information disclosed by or on behalf of either Party
hereto (a &#8220;Disclosing Party&#8221;) to the other Party hereto (a &#8220;Receiving Party&#8221;),
or any of the Disclosing Party&#8217;s or Receiving Party&#8217;s employees, officers,
directors, affiliates, subcontractors, agents, successors or assigns
(collectively &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Representatives</font>&#8221; and together
with the Disclosing Party, the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Disclosing Group</font>&#8221; or together
with the Receiving Party, the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Receiving Group</font>&#8221;), including
information relating to the matters that are the subject of this Agreement,
including the terms, existence and nature of this Agreement, or relating to the
Disclosing Party&#8217;s other past, present or future research, technology, know-how,
ideas, concepts, designs, products, markets, customer information, computer
programs, prototypes, processes, machines, articles of manufacture, compositions
of matter, business plans and operations, technical information, drawings, or
specifications; except information which is:&#160;&#160;(i) at the time of
disclosure, or thereafter becomes lawfully part of the public domain through no
act or omission by the Receiving Party; (ii) lawfully in the possession of
Receiving Party prior to disclosure by or on behalf of Disclosing Party, as
shown by written records; (iii) lawfully disclosed to the Receiving Party by a
third party which did not acquire the same under an obligation of
confidentiality from or through the Disclosing Group; or (iv) independently
developed by the Receiving Party without use of Confidential Information, as
shown by written records.&#160;&#160;If a Receiving Party believes in good faith
that it is required by law to disclose any Confidential Information, it shall
provide notice to the Disclosing Party, prior to making such disclosure so as to
allow Disclosing Party time to undertake legal or other action, to prevent such
disclosure or otherwise obtain confidential treatment of such
disclosure.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUYER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
                <td valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page&#160;3&#160;of
      8</font></div>
                </td>
                <td align="right" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SELLER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A
Receiving Party shall not, without the prior consent of the Disclosing Party,
disclose any Confidential Information to anyone for any reason at any time or
use any Confidential Information for any purpose except as requested by the
Disclosing Party.&#160;&#160;The Receiving Party shall limit dissemination of
Confidential Information to only those of the Receiving Group having a "need to
know."&#160;&#160;A Receiving Party shall not, except as permitted under this
Agreement:&#160;&#160;(i) appropriate or use a Disclosing Party&#8217;s Confidential
Information in Receiving Party&#8217;s own manufacture of products for itself or for
any third party or for any other purpose; or (ii) obtain any title to, or any
interest or license in, any Confidential Information of a Disclosing
Party.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither
Party shall issue a press release or other public announcement concerning this
Agreement (or any term sheet, bids, negotiations or other related information),
the transactions contemplated herein, or the relationship between the Parties
without the prior written approval of an authorized representative of the other
Party, which such approval the other Party shall not unreasonably withhold or
delay, provided however, a Party may issue a press release, public announcement
or disclosure of this Agreement if required by the regulations of a securities
exchange on which such Party&#8217;s securities are listed if (i) it gives the other
Party prompt notice of such requirement and (ii) it cooperates with the other
Party with respect to reasonable requests for revisions to any announcement or
reasonable requests for confidential treatment of certain sections of this
Agreement.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither
Party shall:&#160;&#160;(i) disclose to the other Party any confidential or
proprietary information belonging to any third party without the consent of such
third party; nor (ii) represent as being unrestricted any designs, plans,
models, samples, or other writings or products that the Disclosing Party knows
or has reason to know are covered by Intellectual Property Rights of a third
party.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Indemnification.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Buyer
shall indemnify, defend and hold harmless Seller <font style="DISPLAY: inline; COLOR: #000000">and its affiliates and their respective
directors, officers, employees and agents from and against </font>any claim,
action, suit, demand, damage, expense or losses (including reasonable attorneys&#8217;
fees) by a third party (collectively, "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Claims</font>") resulting from or to
the extent relating to: (i) Buyer&#8217;s manufacture, use, sale and marketing of the
Product, including but not limited to Claims relating to personal injury; or
(ii) infringement or alleged infringement of any third party Intellectual
Property Rights with respect to the sale of the Product.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; TEXT-DECORATION: underline">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Seller shall
</font>indemnify, defend and hold harmless Buyer <font style="DISPLAY: inline; COLOR: #000000">and its affiliates and their respective
directors, officers, employees and agents from and against </font>any Claims
resulting from or to the extent relating to Seller&#8217;s material breach of this
Agreement including, without limitation, any material inaccuracy of Seller&#8217;s
representations or warranties, or material breach of Seller&#8217;s covenants, under
Section 7 hereof.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Either
Party&#8217;s (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">indemnifying
Party</font>&#8221;) obligations to the other Party (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">indemnified Party</font>&#8221;) under this
Section 5 are conditioned upon the indemnified Party:&#160;&#160;(i) providing
written notice to the indemnifying Party of any Claims promptly, but not later
than fifteen (15) calendar days after the indemnified Party knows of such Claim;
(ii) permitting the indemnifying Party to assume full responsibility for the
defense of such Claim; (iii) assisting the indemnifying Party in defense of such
Claim at the indemnifying Party&#8217;s expense; and (iv) not compromising or settling
any such Claim without the indemnifying Party&#8217;s prior written
consent.&#160;&#160;Indemnifying Party may not settle a Claim without the
indemnified Party&#8217;s prior written consent, which consent shall not be
unreasonably withheld or delayed, unless such settlement includes a full release
of the indemnified Party from all liability and without any condition of future
consideration.&#160;&#160;Notwithstanding the foregoing, the indemnified Party&#8217;s
failure to give the notice specified in this Section or delay in giving such
notice, shall not affect the indemnified Party&#8217;s right to indemnification under
this Section except to the extent that indemnifying Party has been prejudiced by
such failure or delay.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Remedies.&#160;&#160;</font>Termination
of this Agreement, or the exercise of any other remedy, shall not be deemed to
be an exclusive remedy hereunder, and shall be in addition to any other remedies
available at law or in equity (including a Party&#8217;s right to obtain specific
performance and other equitable relief for other Party&#8217;s material breach
hereof).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Representations and
Warranties; Covenants</font>.&#160;&#160;Each Party hereby represents and
warrants to the other that:&#160;&#160;(a)&#160;the execution and delivery of
and performance under this Agreement by such Party does not, and will not,
conflict with or violate any other agreement or obligations with third parties
or any restrictions of any kind or any law to which it is bound or subject; and
(b) it has the unrestricted right to disclose any information it submits to the
other Party, free of all claims of third parties, and that such disclosures do
not breach or conflict with any confidentiality provisions of any agreement to
which it is a party.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUYER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
                <td valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page&#160;4&#160;of
      8</font></div>
                </td>
                <td align="right" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SELLER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Purchased
Assets</font>.&#160;&#160;Seller hereby represents and warrants to Buyer that
Seller has good title to the Purchased Assets, and that the Purchased Assets
transferred or otherwise conveyed hereunder to Buyer are and shall be <font style="DISPLAY: inline; COLOR: #000000">free and clear of any and all
</font>liabilities, obligations, liens and encumbrances.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; COLOR: #000000">7.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; COLOR: #000000; TEXT-DECORATION: underline">Further
Assurances</font><font style="DISPLAY: inline; COLOR: #000000">.&#160;&#160;Following the closing,
Seller shall, from time to time, execute and deliver such additional
instruments, documents, conveyances or assurances, and take such other actions
as shall be reasonably necessary, or otherwise reasonably requested by the
Buyer, to confirm and assure the rights and obligations provided for in this
Agreement and to render effective the consummation of the transactions
contemplated hereby.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; COLOR: #000000">7.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; COLOR: #000000; TEXT-DECORATION: underline">Authorization</font><font style="DISPLAY: inline; COLOR: #000000">. Each Party has the corporate power and
authority to execute and deliver this Agreement, to perform fully its
obligations hereunder, and to consummate the transactions contemplated thereby.
The execution and delivery by each Party of this Agreement, and the consummation
of the transactions contemplated hereby, have been duly authorized by all
requisite corporate action of each Party.&#160;&#160;This Agreement constitutes
legal, valid and binding obligations of each Party, enforceable against it in
accordance with the terms and conditions hereof.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; COLOR: #000000">7.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; COLOR: #000000; TEXT-DECORATION: underline">Litigation</font><font style="DISPLAY: inline; COLOR: #000000">. There is no action, claim, demand,
suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry
or investigation of any nature, civil, criminal, regulatory or otherwise, in law
or in equity, pending or threatened against Seller in connection with the
Purchased Assets, and Seller does not know or have reason to be aware of any
basis for the same.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; COLOR: #000000">7.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; COLOR: #000000; TEXT-DECORATION: underline">Brokers,
Finders</font><font style="DISPLAY: inline; COLOR: #000000">. All negotiations
relating to this Agreement have been carried on without the participation of any
person acting on behalf of Seller or its affiliates in such manner as to give
rise to any valid claim against the Buyer for any brokerage or finder's
commission, fee or similar compensation, or for any bonus payable to any
officer, director, employee, agent or sales representative of or consultant to
Seller or their respective affiliates upon consummation of the transactions
contemplated hereby.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; COLOR: #000000">7.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; COLOR: #000000; TEXT-DECORATION: underline">Liability
for Transfer Taxes</font><font style="DISPLAY: inline; COLOR: #000000">. In the
event any sales (including, without limitation, bulk sales), use, value-added,
documentary, stamp, registration, transfer, conveyance, excise, recording,
license and other similar taxes and fees (collectively, "Transfer Taxes"),
arising out of or in connection with or attributable to the transactions
effected pursuant to this Agreement are due, the Parties shall agree as to which
Party shall prepare any required returns or notices and the Parties shall evenly
split the cost of preparing such returns and the amount of any Transfer Taxes
due.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">8.</font>&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Miscellaneous</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except
as specifically set forth in Sections 2.2 and 2.3 neither Party shall assign
this Agreement or its obligations hereunder, whether voluntarily or
involuntarily, without the express prior written consent of the other
Party.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This
Agreement is fully binding upon the Parties&#8217; successors and permitted
assigns.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All
requests, approvals, consents and notices must be in writing and will be
effective as of the date actually received and, unless otherwise specified in
this Agreement, shall be sent as follows: (i) certified mail - return receipt
requested; (ii) a nationally recognized overnight delivery service that
guarantees overnight delivery and requires the signature of recipient; or (iii)
facsimile, transmission confirmed; to the addresses and fax numbers indicated on
the first page of this Agreement; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that in the
case of a facsimile transmission a copy is also sent one of the foregoing
methods of subsection (i) or (ii), above.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This
Agreement:&#160;&#160;(i) is governed by the laws of The State of New York,
without reference to its internal principles of conflicts of laws, any disputes
shall be brought exclusively in a federal or state court residing in New York,
and the parties agree without objection to the jurisdiction and venue of such
court; (ii) together with all Exhibits thereto (which are hereby incorporated
into this Agreement) is the entire and exclusive set of terms and conditions and
supersedes all prior agreements and understandings, both written and oral,
between the Parties with respect to the subject matter of this Agreement and
termination of the Distribution Agreement; and (iii) may only be modified by a
writing signed by both Parties.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Headings
of the articles, sections and subsections of this Agreement, and the name of
this Agreement, are for reference purposes only and shall not limit or affect
the meaning or construction of the terms and conditions
hereof.&#160;&#160;Whenever the words &#8220;include&#8221;, &#8220;includes&#8221; or &#8220;including&#8221; are
used in this Agreement, they shall be deemed in each instance to be followed by
the words &#8220;without limitation.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUYER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
                <td valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page&#160;5&#160;of
      8</font></div>
                </td>
                <td align="right" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SELLER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
failure of either Party to enforce any right under this Agreement shall be
deemed a waiver thereof.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All
obligations and rights which are by their nature continuing, including the
obligations contained in Sections 2.2, 2.3, 4, 5, 7, and 8 shall survive the
expiration or termination of this Agreement.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Times New Roman">ACCEPTANCE
OF AGREEMENT</font></font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By
signing below the undersigned acknowledge and accept all terms and conditions of
this Agreement.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <div align="left">
                    <div align="left">
                      <div align="left">
                        <div align="left">
                          <div align="left">
                            <div align="left">
                              <table cellpadding="0" cellspacing="0" width="100%">
                                  <tr>
                                    <td align="left" colspan="3" valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUYER:&#160;&#160;&#160;BOVIE
      MEDICAL CORPORATION&#160;</font></td>
                                    <td align="left" colspan="3" valign="top" width="4%" style="PADDING-BOTTOM: 2px">

                                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SELLER:&#160;&#160;BOSTON
      SCIENTIFIC CORPORATION</font></div>
                                    </td>
                                  </tr>
                                  <tr>
                                    <td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                    <td align="left" valign="top" width="21%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                    <td align="left" valign="top" width="28%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                    <td align="left" valign="top" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                    <td align="left" valign="top" width="19%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                    <td align="left" valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                  </tr>
                                  <tr>
                                    <td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
                                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By</font></div>
                                    </td>
                                    <td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid">
                                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/S/
      Moshe Citronowicz</font></font></font></div>
                                    </td>
                                    <td align="left" valign="top" width="28%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                    <td align="left" valign="top" width="4%" style="PADDING-BOTTOM: 2px">
                                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
                                    </td>
                                    <td align="left" valign="top" width="19%" style="BORDER-BOTTOM: black 2px solid">
                                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/S/
      Michael P. Phalen</font></font></font></div>
                                    </td>
                                    <td align="left" valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                  </tr>
                                  <tr>
                                    <td align="left" colspan="2" valign="top" width="24%">
                                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Signature)</font></div>
                                    </td>
                                    <td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                    <td align="left" colspan="2" valign="top" width="23%">
                                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Signature)</font></div>
                                    </td>
                                    <td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                  </tr>
                              </table>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="top" width="11%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Print
      Name:</font></div>
              </td>
              <td align="left" valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/S/ Moshe Citronowicz</font></font></div>
              </td>
              <td valign="top" width="66%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="top" width="19%" style="PADDING-LEFT: 0pt">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Print
      Name:</font></div>
              </td>
              <td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/S/ Michael P. Phalen</font></font></div>
              </td>
              <td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="8%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
                </td>
                <td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Vice President / COO</font></font></div>
                </td>
                <td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td align="left" valign="top" width="11%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:&#160;&#160;Title:</font></div>
                </td>
                <td align="left" nowrap valign="top" width="14%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Pres, Oncology</font></font></div>
                </td>
                <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" nowrap valign="top" width="12%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date
      signed:</font></div>
                </td>
                <td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4-29-08</font></font></div>
                </td>
                <td valign="top" width="26%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td align="left" valign="top" width="11%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date
      signed:</font></div>
                </td>
                <td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4-30-08</font></font></div>
                </td>
                <td valign="top" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUYER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
                <td valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page&#160;6&#160;of
      8</font></div>
                </td>
                <td align="right" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SELLER:
      <font style="DISPLAY: inline">________</font></font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          </div>
        </div><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit X: Purchased
Assets</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sect
1.3a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Equipment, machinery, prototypes, tooling, supplies, and other personal property
predominantly related to the Program</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Prototypes</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12
      assembled prototypes in trays</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60
      porous tips w/o powder coat</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20
      short samples &#8211; blue powder coat</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20
      laser and resistance welded samples</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1
      laparoscopic prototype</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3
      bipolar prototypes</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Any
      prototype from **&#160;&#160;**</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Bovie)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Any
      prototype with **&#160;&#160;&#160;**</font></div>
                </td>
                <td valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Bovie)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Any
      packaging prototypes</font></div>
                </td>
                <td valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Bovie)</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">PDM Project
Files</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>See 1.3d, below</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Equipment</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>None</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Tooling and
Molds</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" colspan="3" valign="top" width="78%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">All
      of BSC&#8217;s right, title and interest in component tooling with
      Mott</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Handle
      Molds&#160;&#160;&#160;&#160;-9 tools</font></div>
                </td>
                <td valign="top" width="17%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;**</font></div>
                </td>
                <td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Packaging
      Molds</font></div>
                </td>
                <td align="left" valign="top" width="17%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;**</font></div>
                </td>
                <td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Components and Test
Fixtures</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Any
      components with **&#160;&#160;&#160;**</font></div>
                </td>
                <td valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Bovie)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Any
      components with **&#160;&#160;**</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Bovie)</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sect.
1.3b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller&#8217;s right and interest in
and under the contracts, licenses, leases and other agreements and instruments
predominantly related to the Program</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Contracts</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Mott
      letter with terms and Conditions</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PO&#8217;s
      to Mott</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Mott
      quotes</font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section
1.3c)&#160;&#160;&#160;&#160;&#160;&#160;Approvals, clearances, authorizations,
license and registrations required by any governmental authority, predominantly
related to the Program</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section
1.3d)&#160;&#160;&#160;&#160;&#160;Clinical, technical, marketing, pre-sales and
other data, predominantly related to the Program and the design, development and
manufacture of the Product</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="top" width="26%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUYER:
      <font style="DISPLAY: inline">________</font></font></div>
                  </td>
                  <td valign="top" width="26%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page&#160;7&#160;of
      8</font></div>
                  </td>
                  <td align="right" valign="top" width="26%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SELLER:
      <font style="DISPLAY: inline">________</font></font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div><br>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          </div>
        </div><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Product and Marketing
Specifications</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Product
      Spec attached as part of contract</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Bovie)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Drawings</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Bovie)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Customer
      Input</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BSC
      PDM Files</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Design
      History File</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Bovie)</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Technical Documents,
Testing, Notebook Entries, Schedules and Activities</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BSC
      PDM Files</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Personal
      Files</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Network
      Drives</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Mott
      Documents</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;**
      Documents</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;**Documents</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Meeting Minutes,
Presentations, Trip Reports, Quality Documents, Design
Control</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BSC
      PDM Files</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Personal
      Files</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Network
      Drives</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Mott
      Documents</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">**&#160;&#160;&#160;**
      Documents</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Animal and Bench Testing,
Regulatory Documents, Physician Feedback</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Video
      and Photos</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Includes
      **&#160;&#160;&#160;** demo</font></div>
                </td>
                <td valign="top" width="39%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BSCPDMFiles</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Personal
      Files</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Network
      Drives</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Marketing Data, Customer
Input</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Personal
      Files</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Network
      Drives</font></div>
                </td>
                <td align="left" valign="top" width="39%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(BSC)</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.3e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Generated
Product IP</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Excluded Document
Categories</font></font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Only documents or portions thereof, to
the extent they incorporate attorney-client privileged legal analysis, prepared
in response to BSC&#8217;s request to its internal or external counsel, related to the
General Product IP.&#160;&#160;Nothwithstanding the foregoing, patent search
results and drafts of unfiled patent applications shall not be
excluded.</font></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
        <div>
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="top" width="26%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUYER:
      <font style="DISPLAY: inline">________</font></font></div>
                  </td>
                  <td valign="top" width="26%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page&#160;8&#160;of
      8</font></div>
                  </td>
                  <td align="right" valign="top" width="26%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SELLER:
      <font style="DISPLAY: inline">________</font></font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT A
Version A-1 to Exhibit 10.14 &#8211; Redacted</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="ex10-14a1a.jpg" alt=""></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">BOVIE
&#8211;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Resection
Device</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Product
Specifications</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">BOVIE MEDICAL
CORPORATION</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">CONFIDENTIAL</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">FOR INTERNAL USE
ONLY</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Table of
Contents</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">1</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">INTRODUCTION</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.1</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Purpose</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.2</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Scope</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">2</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">A</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">PPLICABLE
      DOCUMENTS</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.1</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Standards</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">3.0
      GENERAL DESCRIPTION</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1
      Concept Drawing</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2
      Application</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2.1
      Intended Use</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2.2
      Intended Users</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3
      Quality System Requirements</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.1
      US Requirements</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.2
      Canadian Requirements</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.3
      European Classifications</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.4
      Quality System Requirements</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">4</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">PRODUCT
      DOCUMENT STRUCTURE</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">4.1</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Project
      Documentation</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">4.2</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Model Number
      Format</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">5</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">PRODUCT
      REQUIREMENTS</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">8</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.1</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Electrical and
      Mechanical</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.1<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font>Insulated
      Handle</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.2<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font>Shaft
      and Electrode Tip</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.3<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font>Shipping
      and Handling</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.4<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font>Sterilization</font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">6</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Protection
      Against Hazards</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">7</font>&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Packaging</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Labeling</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.2</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Packaging
      Configuration</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.3</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Manufacturing</font></font></div>
              </td>
              <td align="right" valign="top" width="8%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11</font></div>
              </td>
            </tr>
        </table>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">List
of Tables</font></div>
    <div>
      <div align="left">
        <div align="left">
          <div align="left">
            <div align="left">
              <table cellpadding="0" cellspacing="0" width="100%">
                  <tr bgcolor="#ccffcc">
                    <td align="left" valign="top" width="77%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Table
      One &#8211; Standards</font></div>
                    </td>
                    <td align="right" valign="top" width="8%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      4</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="white">
                    <td align="left" valign="top" width="77%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Table
      Two &#8211; Device Classifications</font></div>
                    </td>
                    <td align="right" valign="top" width="8%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      6</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td align="left" valign="top" width="77%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Table
      Three &#8211; Model Number Format</font></div>
                    </td>
                    <td align="right" valign="top" width="8%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      7</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="white">
                    <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr bgcolor="white">
                    <td colspan="2" valign="top" width="77%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">List
      of Figures</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td align="left" valign="top" width="77%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Figure
      One &#8211; Concept Drawing</font></div>
                    </td>
                    <td align="right" valign="top" width="8%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      5</font></div>
                    </td>
                  </tr>
              </table>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div>&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">INTRODUCTION</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">1.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Purpose</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Product Specification defines preliminary product requirements and constitutes a
part of the Design Inputs for the Resection Device Project for Boston Scientific
Corporation (&#8220;BSC&#8221;).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">1.2</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Scope</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Product Specification sets forth the requirements, provided by BSC, for the
Resection Device, (the &#8220;Device&#8221;).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">2</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">APPLICABLE
      DOCUMENTS</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following is a list of all documents and other sources of information referenced
in this Product Specification.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">2.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Standards</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <table cellpadding="0" cellspacing="0" width="100%">
                    <tr>
                      <td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Standard</font></font></div>
                      </td>
                      <td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160;&#160;&#160;</font></font></div>
                      </td>
                      <td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Version/Date</font></font></div>
                      </td>
                      <td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160;&#160;&#160;</font></font></div>
                      </td>
                      <td align="left" valign="top" width="56%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Description</font></font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21
      CFR Part 820</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="56%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Medical
      Devices, Current Good Manufacturing Practices, Final Rule, Quality System
      Regulation.</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">HF-18</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2001</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="56%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AAMI/ANSI
      Electrosurgical Devices</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10993-1</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3;
      Date 8-1-03</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="56%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AAMI/ANSI/ISO
      Biological evaluation of medical devices &#8211; Part 1: Evaluation and
      Testing</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EN
      980</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2003</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">04/16/2003</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="56%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Graphical
      symbols for use in the labeling of medical devices</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EN
      ISO 14971</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2000
      AMD 1 2003</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">03/01/2003</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="56%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Medical
      devices &#8211; Application of risk management to risk management to medical
      devices (ISO 14971:2000)</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ISTA
      2A 2006</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2006</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="56%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Performance
      Test for Packaged-Products Weighing 150 lbs (68 kg) or
  Less</font></div>
                      </td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Table 1 -
Applicable Standards for Medical Devices (US)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 18pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.0</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">GENERAL
      DESCRIPTION</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device is a sterile, single use electrosurgical device intended to be used in
conjunction with an electrosurgical generator for the delivery of radiofrequency
(&#8220;RF&#8221;) current and sterile saline for hemostatic sealing and coagulation of soft
tissue in accordance with instructions and user procedures provided by
BSC.&#160;&#160;The device is not intended for any other unspecified uses<font style="DISPLAY: inline; FONT-STYLE: italic">.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 18pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.1</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Concept
      Drawing</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="ex10-14a1b.jpg" alt=""></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Figure 1
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 18pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.2</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Application</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.2.1</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Intended
      Use</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device is a sterile, single use electrosurgical device intended to be used in
conjunction with an electrosurgical generator for the delivery of radiofrequency
current and sterile saline for hemostatic sealing and coagulation of the soft
tissue in accordance with instructions and user procedures provided by BSC. The
device is not intended for any other unspecified uses<font style="DISPLAY: inline; FONT-STYLE: italic">.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 18pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.2.2</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;Intended
      Users</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Users of
this Device will be healthcare professionals such as medical doctors and nurses,
who are qualified and trained in electrosurgical procedures.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;Quality
      System Requirements</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device has the following classifications for FDA, CMDR, and MDD
classification.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <div>
        <div align="center">
          <div style="TEXT-ALIGN: center" align="left">
            <div style="TEXT-ALIGN: center" align="left">
              <div style="TEXT-ALIGN: center" align="left">
                <table cellpadding="0" cellspacing="0" width="80%" style="TEXT-ALIGN: center">
                    <tr style="TEXT-ALIGN: center;">
                      <td align="left" valign="bottom" width="23%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Device</font></font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="bottom" width="23%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">US Classification</font></font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="24%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Canada</font></font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Classification</font></font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="24%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">MDD</font></font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Classification</font></font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="top" width="24%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="top" width="24%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="23%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Resection
      Device</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="23%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">II</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="24%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">III</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="24%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">IIb</font></div>
                      </td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Table 2 -
Device Classifications</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.1</font></div>
              </td>
              <td align="left" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;US
      Requirements</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To market
medical products, the Food and Drug Administration (FDA) must determine that a
medical device is substantially equivalent to similar marketed medical
devices.&#160;&#160;The Bovie Regulatory department intends to use the
dissecting sealer device manufactured by TissueLink as a predicate
device.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.1.1</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Classification</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device&#8217;s classification is Class II.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.1.2</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Safety
      and Effectiveness
requirements</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device will meet electrical safety requirements (ANSI/AAMI
HF-18:2001).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.1.3</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Quality
      System Requirements</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Quality
system requirements are specified as part of 21 CFR Part 820, Quality System
Regulation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.2</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;Canadian
      Requirements</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To market
medical products in Canada, a license application must be presented to Health
Canada. Once the license application is approved, the medical product can be
labeled and made available for sale in the Canadian provinces.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.2.1</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Classification</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Class
III</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.2.2</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Safety
      and Effectiveness
requirements</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Safety
and effectiveness requirements closely correspond to the essential requirements
of the Medical Device Directive.&#160;&#160;A list of Health Canada recognized
standards has been issued as of April 11, 2002 in Policy on Recognition and Use
of Standards under Medical Device Regulations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.2.3</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Quality
      System Requirements</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Health
Canada requires manufacturers of Class II, III and IV device to demonstrate that
their devices are manufactured in accordance with internationally recognized
standards.&#160;&#160;Demonstration of compliance with the quality system
requirements will be required at the time an application is made for a medical
device license.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.3</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;European
      Classifications</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.3.1</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Classification</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device is classified IIb (Rule 9 ) in accordance with the Medical Devices
Directive Annex IX.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Reference:
Guidelines for the Classification of Medical Devices &#8211; MEDDEV 2.4/1 Rev. 8, July
2001)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 9pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.3.2</font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Conformance
      Assessment Route</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device assessment route will be via Annex II (full quality assurance
system).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 18pt; BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">3.3.4</font></font></div>
                </td>
                <td align="left" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;Quality
      System
Requirements</font></font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
Medical Corporation (&#8220;Bovie&#8221;) has been certified to ISO13485</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">4</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">PRODUCT
      DOCUMENT STRUCTURE</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">4.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Project Documentation</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Documents
will be in standard Bovie document format.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">4.2</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Model Number Format</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following table lists the Device&#8217;s model number and corresponding product /
catalog code.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <div>
        <div align="center">
          <div align="center">
            <div style="MARGIN-LEFT: 81pt" align="left">
              <table cellpadding="0" cellspacing="0" width="70%">
                  <tr>
                    <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Catalog #</font></font></div>
                    </td>
                    <td valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td valign="top" width="75%" style="BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Comments</font></font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="top" width="23%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TBD</font></div>
                    </td>
                    <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td valign="top" width="75%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Laparoscopic&#160;&#160;Monopolar
      Device</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="top" width="23%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TBD</font></div>
                    </td>
                    <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                    <td valign="top" width="75%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Open
      Abdominal Monopolar
Device</font></div>
                    </td>
                  </tr>
              </table>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;Table
Three</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">PRODUCT
      REQUIREMENTS</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following section will describe requirements for the insulated handle and shaft
with electrode tip.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Electrical
      and Mechanical</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device hardware is comprised of two (2) major components: (i) an Insulated
Handle and (ii) a Shaft with Electrode Tip. RF energy is passed through the
Insulated Handle through the Shaft to the Electrode Tip by a powered lead from
an electrosurgical generator.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Insulated
      Handle</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Insulated Handle encases the controlling mechanism for the flow of saline, and
activation and selection of the RF current for the Device.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.1
Insulated Handle and Power Cord Insulation Resistance</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
insulation of the Insulated Handle and Power Cord shall meet Requirements of
Section 4.2.5.4 Dielectric withstands of accessories ANSI/AAMI
HF-18:2001</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.2
Insulated Handle Ergonomics</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Insulated Handle shall be designed for comfortable and efficient hand
operation.&#160;&#160;It will incorporate an over-mold to give the body an
elegant feel and soft touch.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.3
Insulated Handle Electrical Cord</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Insulated Handle Electrical Cord shall be approximately ten (10) feet in length
and incorporate a 3-prong electrical plug.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.4
Insulated Handle Flow Control Mechanism</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device will have a flow control mechanism, either on the tubing or in the handle
itself so the flow can be regulated by the user within the sterile
field.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.5
Insulated Handle Tubing Length</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
tubing length should be approximately seven (7) feet in length and incorporate
an I.V. spike on the end to attach directly to a hanging IV bag.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.6
Insulated Handle Tubing Material</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
tubing material should be a material that will resist kinking but should not
have so strong a memory as to pull the probe off of the sterile
field.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.7
Insulated Handle Activation Buttons</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">The Device should have a Cut and Coagulation Mode. &#8220;Cut&#8221;/&#8221;Coag&#8221;
buttons must be easy to operate.</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.8
Insulated Handle Compatibility</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 54pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Insulated Handle should have compatibility with standard RF generators
      used for electrocautery and standard grounding
  pad.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 54pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Insulated Handle should have compatibility with standard 0.9% saline I.V.
      bag.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1.2</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Shaft
      and Electrode Tip</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Shaft
and Electrode Tip provide the actual working portion of this
system.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.1
Saline Flow Rate of Device</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Saline flow rate prior to use will be
**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.2
Device (Shaft) Length</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device should be straight and have two (2) lengths: one for laparoscopic
monopolar procedures (approximately thirty-two (32) cm) and one for open
monopolar procedures (approximately fourteen (14) cm).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.3
Shaft Configuration</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Shaft
will be hollow to allow for fluid to flow to the sintered stainless steel tip.
The inside diameter of the Shaft should be equal to the inside diameter of the
tubing that feeds fluid to the Shaft to minimize any flow restriction in the
fluid circuit.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.4
Tip Material</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Tip
shall be made of **&#160;&#160;&#160;&#160;&#160;&#160;&#160;**</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.5
Tip Strength</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
porous blade tip to shaft tensile bond strength (axial mode) must be greater
than **&#160;&#160;&#160;&#160;&#160;&#160;&#160;**</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;after
being subjected to a full-power simulated use duty cycle.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
porous blade tip to shaft bond strength in an flexural mode must be greater than
**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">. after being subjected to a full-power simulated use duty
cycle.</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.6
Tip performance</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 54pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
      will exert its best efforts to meet the design goal that tip cutting
      performance be superior to competitive devices with respect to cutting
      speed. Tip will have the ability to coagulate soft tissue when performed
      in a suitable simulated use
environment.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1.3</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Shipping
      and Handling</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1.3.1
Shipping Temperatures</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tropical
(Wet and Dry) Conditions and Winter (Frozen) Conditions per ISTA
2A.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1.3.2
Transportation Testing</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Final
Product Packaging Configuration for the Device shall meet the finished device
requirements after being subjected to Simulated Transportation Conditioning per
ISTA 2A.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1.4</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Sterilization</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.4.1
Withstand 2x ETO Sterilization.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.4.2
EN 550: 1994 &#8211; Sterilization of Medical Devices &#8211; Validation and routine control
of ethylene oxide sterilization.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.4.3
AAMI/ANSI/ISO 11135 -1994 Medical Devices &#8211; Validation and routine control of
ethylene oxide sterilization.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">6</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Protection
      Against Hazards</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
Hazard/Risk Analysis will be performed throughout the design
process.&#160;&#160;The Hazard/Risk Analysis will be documented and filed as
part of the design history file.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">7</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Packaging</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">7.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      &#160;Labeling</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;7.1.1
Package must be labeled in accordance with both BSC&#160;and Bovie Labeling
Standards.</font></div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
7.1.2 BSC&#160;and Bovie branding, including mutually approved trademarks, will
be on the Handle and/or the shaft.</font></div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
7.1.3 The Device is to have a three (3) year shelf life under normal storage
conditions.</font></div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">7.2</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Packaging Configuration</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 57.25pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Tip and Shaft protector shall be included into the
  Design.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 57.25pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Scratch Pad shall be packaged with the
Device.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 57.25pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Device will be packaged in a Sterile
Pouch.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">7.3</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;
      Manufacturing</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Final
assembly and packaging will be performed by Bovie.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Author</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Document
      Number</font></font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Rev</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-1</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Page</font></font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12-12</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Title:&#160;&#160;</font>Product
      Specification: Resection
Device</font></font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">APPROVALS</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <div align="left">
                    <div align="left">
                      <table cellpadding="0" cellspacing="0" width="100%">
                          <tr>
                            <td align="left" valign="top" width="22%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Author</font></div>
                            </td>
                            <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="52%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
                            </td>
                            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sales
      &amp; Marketing</font></div>
                            </td>
                            <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="52%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rick
      Pfahl</font></div>
                            </td>
                            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Regulatory</font></div>
                            </td>
                            <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="52%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rick
      Kozloff</font></div>
                            </td>
                            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Quality</font></div>
                            </td>
                            <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="52%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John
      Woody</font></div>
                            </td>
                            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" width="22%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Manufacturing</font></div>
                            </td>
                            <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="52%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Lillian
      Eshem</font></div>
                            </td>
                            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                            </td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Engineering</font></div>
                            </td>
                            <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          </tr>
                          <tr>
                            <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td valign="top" width="52%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fred
      Baron</font></div>
                            </td>
                            <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                            <td align="left" valign="top" width="23%">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                            </td>
                          </tr>
                      </table>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="27%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Document Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="18%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="12%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="100%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT A
Version A-2 to Exhibit 10.14 &#8211; REDACTED</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><img src="ex10-14a2a.jpg" alt=""><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">BOVIE
&#8211;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Resection
Device</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Product
Specifications</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">BOVIE MEDICAL
CORPORATION</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">CONFIDENTIAL</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">FOR INTERNAL USE
ONLY</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="27%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Document Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="18%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="12%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="100%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Table of
Contents</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">1&#160;&#160;&#160;&#160;&#160;INTRODUCTION</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.1&#160;&#160;&#160;&#160;&#160;&#160;Purpose</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.2&#160;&#160;&#160;&#160;&#160;&#160;Scope</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">2&#160;&#160;&#160;&#160;&#160;&#160;APPLICABLE
      DOCUMENTS</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.1&#160;&#160;&#160;&#160;&#160;&#160;Standards</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">3.0
      GENERAL DESCRIPTION</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">4</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1
      Concept Drawing</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2
      Application</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2.1
      Intended Use</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2.2
      Intended Users</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3
      Quality System Requirements</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.1
      US Requirements</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.2
      Canadian Requirements</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.3
      European Classifications</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3.4
      Quality System Requirements</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">4&#160;&#160;&#160;&#160;&#160;&#160;PRODUCT
      DOCUMENT STRUCTURE</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.1&#160;&#160;&#160;&#160;&#160;&#160;Project
      Documentation</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.2&#160;&#160;&#160;&#160;&#160;&#160;Model
      Number Format</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">5&#160;&#160;&#160;&#160;&#160;&#160;PRODUCT
      REQUIREMENTS</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">7</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1
      <font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Electrical and
      Mechanical</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="tabdatabeginip">5.1.1 Insulated Handle</a></font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.2
      Shaft and Electrode Tip</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.3
      Shipping and Handling</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1.4
      Sterilization</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">6&#160;&#160;&#160;&#160;&#160;&#160;Protection
      Against Hazards</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">7&#160;&#160;&#160;&#160;&#160;&#160;Packaging</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.1&#160;&#160;&#160;&#160;&#160;&#160;Labeling</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="lineip">7.2&#160;&#160;&#160;&#160;&#160;&#160;Packaging
      Configuration</a></font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td valign="top" width="77%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="77%">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.3&#160;&#160;&#160;&#160;&#160;&#160;Manufacturing</font></div>
              </td>
              <td align="right" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>
              </td>
            </tr>
        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="27%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Document Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="18%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="12%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="100%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div>
      <div align="left">
        <div align="left">
          <div align="left">
            <div align="left">
              <table cellpadding="0" cellspacing="0" width="100%">
                  <tr bgcolor="white">
                    <td align="left" colspan="2" valign="top" width="74%">
                      <div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">List
      of Tables</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td align="left" valign="top" width="74%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Table
      One &#8211; Standards</font></div>
                    </td>
                    <td align="right" valign="top" width="11%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      4</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="white">
                    <td align="left" valign="top" width="74%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Table
      Two &#8211; Device Classifications</font></div>
                    </td>
                    <td align="right" valign="top" width="11%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      6</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td align="left" valign="top" width="74%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Table
      Three &#8211; Model Number Format</font></div>
                    </td>
                    <td align="right" valign="top" width="11%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      7</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="white">
                    <td valign="top" width="74%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  </tr>
                  <tr bgcolor="white">
                    <td colspan="2" valign="top" width="74%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">List
      of Figures</font></div>
                    </td>
                  </tr>
                  <tr bgcolor="#ccffcc">
                    <td align="left" valign="top" width="74%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Figure
      One &#8211; Concept Drawing</font></div>
                    </td>
                    <td align="right" valign="top" width="11%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page
      5</font></div>
                    </td>
                  </tr>
              </table>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="23%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="17%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Document Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="15%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="10%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="86%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">INTRODUCTION</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">1.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Purpose</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Product Specification defines preliminary product requirements and constitutes a
part of the Design Inputs for the Resection Device Project for Boston Scientific
Corporation (&#8220;BSC&#8221;).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">1.2</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Scope</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
Product Specification sets forth the requirements, provided by BSC, for the
Resection Device, (the &#8220;Device&#8221;).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">2</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">APPLICABLE
      DOCUMENTS</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following is a list of all documents and other sources of information referenced
in this Product Specification.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">2.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Standards</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <table cellpadding="0" cellspacing="0" width="100%">
                    <tr>
                      <td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Standard</font></div>
                      </td>
                      <td valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="16%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Version/Date</font></div>
                      </td>
                      <td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="top" width="60%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Description</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21
      CFR Part 820</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="top" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Medical
      Devices, Current Good Manufacturing Practices, Final Rule, Quality System
      Regulation.</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">HF-18</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="16%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2001</font></div>
                      </td>
                      <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AAMI/ANSI
      Electrosurgical Devices</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10993-1</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="16%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3;
      Date 8-1-03</font></div>
                      </td>
                      <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AAMI/ANSI/ISO
      Biological evaluation of medical devices &#8211; Part 1: Evaluation and
      Testing</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EN
      980</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="16%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2003</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">04/16/2003</font></div>
                      </td>
                      <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Graphical
      symbols for use in the labeling of medical devices</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EN
      ISO 14971</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="16%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2000
      AMD 1 2003</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">03/01/2003</font></div>
                      </td>
                      <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Medical
      devices &#8211; Application of risk management to risk management to medical
      devices (ISO 14971:2000)</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ISTA
      2A 2006</font></div>
                      </td>
                      <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="16%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2006</font></div>
                      </td>
                      <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Performance
      Test for Packaged-Products Weighing 150 lbs (68 kg) or
  Less</font></div>
                      </td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Table 1 -
Applicable Standards for Medical Devices (US)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.0
GENERAL DESCRIPTION</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device is a sterile, single use electrosurgical device intended to be used in
conjunction with an electrosurgical generator for the delivery of radiofrequency
(&#8220;RF&#8221;) current and sterile saline for hemostatic sealing and coagulation of soft
tissue in accordance with instructions and user procedures provided by
BSC.&#160;&#160;The device is not intended for any other unspecified uses<font style="DISPLAY: inline; FONT-STYLE: italic">.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="27%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Document Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="18%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="12%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="100%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.1
Concept Drawing</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="ex10-14a2b.jpg" alt=""></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Figure
1</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.2
Application</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.2.1
Intended Use</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device is a sterile, single use electrosurgical device intended to be used in
conjunction with an electrosurgical generator for the delivery of radiofrequency
current and sterile saline for hemostatic sealing and coagulation of the soft
tissue in accordance with instructions and user procedures provided by BSC. The
device is not intended for any other unspecified uses<font style="DISPLAY: inline; FONT-STYLE: italic">.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.2.2
Intended Users</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Users of
this Device will be healthcare professionals such as medical doctors and nurses,
who are qualified and trained in electrosurgical procedures.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="27%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Document Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="18%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="12%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="100%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3
Quality System Requirements</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device has the following classifications for FDA, CMDR, and MDD
classification.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <div>
        <div align="center">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <div style="TEXT-ALIGN: center" align="left">
                    <table cellpadding="0" cellspacing="0" width="80%" style="TEXT-ALIGN: center">
                        <tr style="TEXT-ALIGN: center;">
                          <td align="left" valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Device</font></div>
                          </td>
                          <td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          <td align="left" nowrap valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">US
      Classification</font></div>
                          </td>
                          <td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          <td align="left" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Canada</font></div>
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
                              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Classification</font></div>
                            </div>
                          </td>
                          <td align="left" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                          </td>
                          <td align="left" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">MDD</font></div>
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Classification</font></div>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" width="20%">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Resection
      Device</font></div>
                          </td>
                          <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          <td align="left" valign="top" width="14%">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">II</font></div>
                          </td>
                          <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          <td align="left" valign="top" width="14%">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">III</font></div>
                          </td>
                          <td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                          <td align="left" valign="top" width="46%">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">IIb</font></div>
                          </td>
                        </tr>
                    </table>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Table 2 -
Device Classifications</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.1
US Requirements</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To market
medical products, the Food and Drug Administration (FDA) must determine that a
medical device is substantially equivalent to similar marketed medical
devices.&#160;&#160;The Bovie Regulatory department intends to use the
dissecting sealer device manufactured by TissueLink as a predicate
device.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.1.1
Classification</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device&#8217;s classification is Class II.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.1.2
Safety and Effectiveness requirements</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device will meet electrical safety requirements (ANSI/AAMI
HF-18:2001).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.1.3
Quality System Requirements</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Quality
system requirements are specified as part of 21 CFR Part 820, Quality System
Regulation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.2
Canadian Requirements</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To market
medical products in Canada, a license application must be presented to Health
Canada. Once the license application is approved, the medical product can be
labeled and made available for sale in the Canadian provinces.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.2.1
Classification</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Class
III</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.2.2
Safety and Effectiveness requirements</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Safety
and effectiveness requirements closely correspond to the essential requirements
of the Medical Device Directive.&#160;&#160;A list of Health Canada recognized
standards has been issued as of April 11, 2002 in Policy on Recognition and Use
of Standards under Medical Device Regulations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="27%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Document Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="18%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="12%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="100%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.2.3
Quality System Requirements</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Health
Canada requires manufacturers of Class II, III and IV device to demonstrate that
their devices are manufactured in accordance with internationally recognized
standards.&#160;&#160;Demonstration of compliance with the quality system
requirements will be required at the time an application is made for a medical
device license.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.3
European Classifications</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.3.1
Classification</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device is classified IIb (Rule 9 ) in accordance with the Medical Devices
Directive Annex IX.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Reference:
Guidelines for the Classification of Medical Devices &#8211; MEDDEV 2.4/1 Rev. 8, July
2001)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.3.2
Conformance Assessment Route</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device assessment route will be via Annex II (full quality assurance
system).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">3.3.4
Quality System Requirements</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
Medical Corporation (&#8220;Bovie&#8221;) has been certified to ISO13485</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">4</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">PRODUCT
      DOCUMENT STRUCTURE</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">4.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Project
      Documentation</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Documents
will be in standard Bovie document format.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">4.2</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Model
      Number Format</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following table lists the Device&#8217;s model number and corresponding product /
catalog code.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <div>
        <div align="center">
          <div align="center">
            <div align="center">
              <table cellpadding="0" cellspacing="0" width="60%">
                  <tr>
                    <td valign="top" width="14%" style="BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Catalog
      #</font></div>
                    </td>
                    <td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="top" width="85%" style="BORDER-BOTTOM: black 2px solid">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Comments</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="top" width="14%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TBD</font></div>
                    </td>
                    <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="top" width="85%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Laparoscopic&#160;&#160;Monopolar
      Device</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td valign="top" width="14%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TBD</font></div>
                    </td>
                    <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    <td valign="top" width="85%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Open
      Abdominal Monopolar
Device</font></div>
                    </td>
                  </tr>
              </table>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 171pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Table
Three</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">PRODUCT
      REQUIREMENTS</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following section will describe requirements for the insulated handle and shaft
with electrode tip.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="27%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Document Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="18%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="12%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="100%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Electrical
      and Mechanical</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device hardware is comprised of two (2) major components: (i) an Insulated
Handle and (ii) a Shaft with Electrode Tip. RF energy is passed through the
Insulated Handle through the Shaft to the Electrode Tip by a powered lead from
an electrosurgical generator.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 18pt">
                </td>
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Insulated
      Handle</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Insulated_Handle_Insulation_Resistance" /><a name="Insulated_Handle_Ergonomics">The Insulated Handle encases the controlling
mechanism for the flow of saline, and activation and selection of the RF current
for the Device.</a></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.1
Insulated Handle and Power Cord Insulation Resistance</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
insulation of the Insulated Handle and Power Cord shall meet Requirements of
Section 4.2.5.4 Dielectric withstands of accessories ANSI/AAMI
HF-18:2001</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.2
Insulated Handle Ergonomics</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Insulated Handle shall be designed for comfortable and efficient hand
operation.&#160;&#160;It will incorporate an over-mold to give the body an
elegant feel and soft touch.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Insulated_Handle_Smooth_Closing_Action">5.1.1.3 Insulated Handle Electrical
Cord</a></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Insulated Handle Electrical Cord shall be approximately ten (10) feet in length
and incorporate a 3-prong electrical plug.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.4
Insulated Handle Flow Control Mechanism</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device will have a flow control mechanism in the handle so the flow can be
regulated by the user within the sterile field.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Insulated_Handle_Limited_Lateral_Movemen" /><a name="Insulated_Handle_Material">5.1.1.5 Insulated Handle Tubing
Length</a></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
tubing length should be approximately ten (10) feet in length and incorporate an
I.V. spike on the end to attach directly to a hanging IV bag.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.6
Insulated Handle Tubing Material</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
tubing material should be a material that will resist kinking but should not
have so strong a memory as to pull the probe off of the sterile
field.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Insulated_Handle_Material_Cleaning">5.1.1.7 Insulated Handle Activation
Buttons</a></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device should have an activation button. The activation button must be easy to
operate.<a name="Insulated_Handle_Spring_Loaded" /><a name="Insulated_Handle_Cancelable_Ratchet_Rele" /></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.8
Insulated Handle Compatibility</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="27%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Document Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="18%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="12%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="100%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 54pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Insulated Handle should have compatibility with standard RF generators
      used for electrocautery and standard grounding
  pad.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 54pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Insulated Handle should have compatibility with standard 0.9% saline I.V.
      bag.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 18pt">
                </td>
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps"><a name="insulated_handle_dimensions">5.1.2</a></font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Shaft
      and Electrode Tip</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Shaft
and Electrode Tip provide the actual working portion of this
system.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.1
Saline Flow Rate of Device</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Saline flow rate prior to use will be
**&#160;&#160;&#160;&#160;&#160;&#160;&#160;**.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.2
Device (Shaft) Length</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Device should be straight and have two (2) lengths: one for laparoscopic
monopolar procedures (approximately thirty-two (32) cm) and one for open
monopolar procedures (approximately fourteen (14) cm).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.3
Shaft Configuration</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Shaft
will be hollow to allow for fluid to flow to the sintered stainless steel tip.
The inside diameter of the Shaft should be equal to the inside diameter of the
tubing that feeds fluid to the Shaft to minimize any flow restriction in the
fluid circuit.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.4
Tip Material</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Tip
shall be made of **&#160;&#160;&#160;&#160;&#160;&#160;&#160;**.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.5
Tip Strength</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
porous blade tip to shaft tensile bond strength (axial mode) must be greater
than **&#160;&#160;&#160;&#160;&#160;&#160;&#160;** after being subjected to a
full-power simulated use duty cycle.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
porous blade tip to shaft bond strength in an flexural mode must be greater than
**&#160;&#160;&#160;&#160;&#160;&#160;&#160;** after being subjected to a
full-power simulated use duty cycle.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.6
Tip performance</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 54pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bovie
      will exert its best efforts to meet the design goal that tip cutting
      performance be superior to competitive devices with respect to cutting
      speed. Tip will have the ability to coagulate soft tissue when performed
      in a suitable simulated use
environment.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="27%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Document Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="18%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="12%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-STYLE: normal">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="100%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 18pt">
                </td>
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps"><a name="common_accessory_requirements" /><a name="operating_environments">5.1.3</a></font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Shipping
      and Handling</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1.3.1
Shipping Temperatures</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tropical
(Wet and Dry) Conditions and Winter (Frozen) Conditions per ISTA
2A.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1.3.2
Transportation Testing</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Final
Product Packaging Configuration for the Device shall meet the finished device
requirements after being subjected to Simulated Transportation Conditioning per
ISTA 2A.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 18pt">
                </td>
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">5.1.4</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Sterilization</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.4.1
Withstand 2x ETO Sterilization.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.4.2
EN 550: 1994 &#8211; Sterilization of Medical Devices &#8211; Validation and routine control
of ethylene oxide sterilization.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.4.3
AAMI/ANSI/ISO 11135 -1994 Medical Devices &#8211; Validation and routine control of
ethylene oxide sterilization.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps"><a name="operating_environment_temperature" /><a name="protection_against_hazards">6</a></font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Protection
      Against Hazards</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
Hazard/Risk Analysis will be performed throughout the design
process.&#160;&#160;The Hazard/Risk Analysis will be documented and filed as
part of the design history file.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 27pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps"><a name="hazard_drop">7</a></font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Packaging</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">7.1</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">&#160;&#160;Labeling</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 30pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.1.1
      Package must be labeled in accordance with both BSC&#160;and Bovie
      Labeling Standards.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 30pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td>
              <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.1.2
      BSC&#160;and Bovie branding, including mutually approved trademarks, will
      be on the Handle and/or the shaft.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;7.1.3
The Device is to have a three (3) year shelf life under normal storage
conditions.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps"><a name="packaging_configuration">7.2</a></font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Packaging
      Configuration</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="Packaging_Configuration_Standard_Kit"><br></a></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 57.25pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Tip and Shaft protector shall be included into the
  Design.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 57.25pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Scratch Pad shall be packaged with the
Device.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td style="WIDTH: 57.25pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></div>
            </td>
            <td style="WIDTH: 18pt">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
            </td>
            <td>
              <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Device will be packaged in a Sterile
Pouch.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td style="WIDTH: 36pt; BORDER-BOTTOM: black 2px solid">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">7.3</font></div>
                </td>
                <td style="BORDER-BOTTOM: black 2px solid">
                  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">Manufacturing</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Final
assembly and packaging will be performed by
Bovie.&#160;&#160;&#160;</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="27%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Author</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
            </td>
            <td valign="top" width="20%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline; FONT-STYLE: normal">Document
      Number</font></font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
            <td valign="top" width="18%" style="BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Rev</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level
      A-2</font></div>
            </td>
            <td valign="top" width="12%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-TOP: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Page</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11-11</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" colspan="5" valign="top" width="100%" style="BORDER-RIGHT: black 0.75pt solid; BORDER-LEFT: black 0.75pt solid; BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title:&#160;&#160;</font>Product
      Specification: Resection Device</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">APPROVALS</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <div align="left">
                    <div align="left">
                      <div align="left">
                        <div align="left">
                          <div align="left">
                            <div align="left">
                              <div align="left">
                                <div align="left">
                                  <div align="left">
                                    <div align="left">
                                      <div align="left">
                                        <div align="left">
                                          <table cellpadding="0" cellspacing="0" width="100%">
                                              <tr>
                                                <td align="left" valign="top" width="22%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Author</font></div>
                                                </td>
                                                <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                              </tr>
                                              <tr>
                                                <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="52%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas
      Feldhaus</font></div>
                                                </td>
                                                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                                                </td>
                                              </tr>
                                              <tr>
                                                <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                              </tr>
                                              <tr>
                                                <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sales
      &amp; Marketing</font></div>
                                                </td>
                                                <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                              </tr>
                                              <tr>
                                                <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="52%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rick
      Pfahl</font></div>
                                                </td>
                                                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                                                </td>
                                              </tr>
                                              <tr>
                                                <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                              </tr>
                                              <tr>
                                                <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Regulatory</font></div>
                                                </td>
                                                <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                              </tr>
                                              <tr>
                                                <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="52%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rick
      Kozloff</font></div>
                                                </td>
                                                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                                                </td>
                                              </tr>
                                              <tr>
                                                <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                              </tr>
                                              <tr>
                                                <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Quality</font></div>
                                                </td>
                                                <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                              </tr>
                                              <tr>
                                                <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="52%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John
      Woody</font></div>
                                                </td>
                                                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                                                </td>
                                              </tr>
                                              <tr>
                                                <td align="left" valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                              </tr>
                                              <tr>
                                                <td align="left" valign="top" width="22%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Manufacturing</font></div>
                                                </td>
                                                <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                              </tr>
                                              <tr>
                                                <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="52%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Lillian
      Eshem</font></div>
                                                </td>
                                                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                                                </td>
                                              </tr>
                                              <tr>
                                                <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                                <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                                              </tr>
                                              <tr>
                                                <td align="left" valign="top" width="22%" style="PADDING-BOTTOM: 2px">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Engineering</font></div>
                                                </td>
                                                <td valign="top" width="52%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                              </tr>
                                              <tr>
                                                <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td valign="top" width="52%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fred
      Baron</font></div>
                                                </td>
                                                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                                                <td align="left" valign="top" width="23%">
                                                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font></div>
                                                </td>
                                              </tr>
                                          </table>
                                        </div>
                                      </div>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BOVIE
MEDICAL CONFIDENTIAL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS
DOCUMENT IS THE PROPERTY OF BOVIE MEDICALCORPORATION AND MUST BE ACCOUNTED
FOR.&#160;&#160;INFORMATION HEREIN IS CONFIDENTIAL.&#160;&#160;DO NOT REPRODUCE,
USE, OR CONVEY ANY PORTION OF THIS DOCUMENT TO UNAUTHORIZED PERSONS, WITHOUT
PROPER AUTHORIZATION.</font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex10-14a1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-14a1a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!4@(=`P$1``(1`0,1`?_$`/H``0`"`@(#`0$`````
M```````)"@<(`08"`P4$"P$!``("`@,!``````````````@)!@<%"@$#!`(0
M```%`P($`04,!`<*!PP+``$"`P0%``8'$0@A$A,),4$B%)=843(C4Q65U1;6
M&0H:87$S&$)2)!=7=]>!0S0EMC>W.)@YD;'1<D0VEO#A\6*RLU1DE#556<&2
MPG-%=B='ATAX$0`!`@4"`@0)!P<(!0L#`P4!`@,`$00%!B$',1)!41,(87$B
M,M(4E%47@4)2DB.3"9%B<C,5%ABA@D-3TR14='.#LS0UL<&BLL+B8Z.5-C?1
M1"7P\7569(2D)O_:``P#`0`"$0,1`#\`OX4A"D(4A"D(4A"D(4A"D(4A"D(4
MA"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4
MA"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A&N.Y;='B[
M:U9)KMR%(G7D7P*HVM9T6=`]R74^2`O,C'-E3D*@R;B<HN':NB*!1XB8XD(;
M8>W.V>3;FWG]EV%L)IT2+U0L'LF4GI40-5&1Y$#RE'J`)&E-\-^\#V$Q<Y#F
M#Q76NS%+1M%)J:I8E,-I)`2A,QVCJI(0#TJ*4*KU92[LFZ>]YQ9S94K!XJMU
M-P)XZ$@8>/EWW0*;X(LM-SS5ZJ_7,3W_`$DFR0CX$"I[XSW6]L;+1!N\-/7.
MX%,EN.N+;3/IY&VE)"1U<Q6KK)BF_/\`\0K?O*;JI_%ZBFL%F2N;;-.RVZOE
M'#M7JA#A<4>GD2VGJ0(E/[:&]#)6Y]ED&T\JMHE[<=@-("3:79$LTXLTS'S:
M\BT,VE8QOHR3?,UF`"59`J952'$#$`Q>8T8^\;L_CNVSU!=<84ZBWUZW4*86
MHK[-380J:%GRBE05JE1)!&AD9"?G<<[SF;[[TUXQ[/D4[MYM#;#J*MI`:+S;
MRG$%+K:9("T%L$+0$A0404@IFJ52HPQ/^%(0I"%(0I"%(0I"%(0I"%(0I"%(
M0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"&@
MCX4A'3KLR)8%A-SNKWOBTK0;II]4ZMRW%$PH`F/@<`D';<Q@$`\@#7+VK'[]
M?'`U9:*KJW"929:6YK_-28QG(<TP_$63493=;=;F0)DU-0RSIU_:+3/Y(U*O
M/N1[-++ZI%\QQUR.DA$!:67$3ESB?3RI/F$>,2J4P\`$K@0_N<:VI9^[ON]>
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MP3.?RTDHR7;?>CP0_4(G=&,,GVX!A`#+QYK<N)!+QU,?_&<0Y$`_\5(P_HK'
M;CW/<V8256VY6VH(Z%]JT3_T'!^4QF]D_$ZVGK%A%]L5]H@>*FS35"1XYNLJ
M_(D^*-R<2[^]J>9GS2'M;*<;%7"^.";2W;T;.K1DW*PAJ5NU/,)HQCUR;3@F
MBX4.;3@`A6HLJV*W0Q!E=7<[8X[0($U.TY2^@#K4&R5I'A4@`=<27V\[WG=_
MW+JF[;8K^Q3WATR13UJ5TCBE?107@EIQ1Z$MN*4>@1N/_P"']8>Z'NA6HHDK
MQU'"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I".I7Y>]
MNXULNZ+_`+M?$CK;M"$?STP[-H(D9L$#+&31*(AU7+DX`FD0.*BIRE#B(5RM
MBLMPR*\4UBM2"Y<:MY+3:?SE&4SU`<5'H`)Z(QW+LJLV#XQ7Y?D+H9LENI7'
MWEGH0VDF0'2I1DE">*E$)&IBF1N2W`7AN5RQ<63;M<*D3>N%&=L074$S.UK7
M;K*#$P;(@#R`**)N==0`YEW!SJ&XFX6_;>8):=NL7I\<M205(2%/.2\IYX@<
M[BCX3HD<$H"4CA'66WNW@R3>_<&MSC(5J"'5E%,Q.:*6F23V3"!P\D&:U<7'
M"M9U5&"V[==VN@U:H+.G3E9)NV;-TCK.'#A8Y4D4$$4RF45664,!2E*`F,80
M``UK-7'$-(4ZZH):2"229``"9))T``U)/"-3LLO5+R*>G0I=0XH)2E()4I2C
M()2!,DDF0`$R=!%L;MO[3WVV?#[F3O)J5ME#)RD?.74T'E,K;T6T05^K]KJ'
M#4!=L$WBJSK0="N5S$X\FHU;]X;=)C<;+4TUH458U;0IME70ZM1':O#\U12E
M*.M"0KYTH["O<H[O=5L=MNNNR5L(SJ^EM^J1I.G:0#ZO2D_30%K6[K(..%&O
M("9$JC_$SH4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(
M4A"D(4A"D(4A"D(4A"D(4A"D(4A'4[OOVQ\?1QY>^KOMJSXPA#J"]N6;CH9`
MQ$^)Q3,_<(=42^X74:Y6TV*]7ZH%)9*2IJZDF7*RVMPZ]?*#+Y8QW),OQ7#J
M(W'*[E0VVA`)YZE]ME,AQD7%)G+P3,:#Y-[J^TG'XN6L)<<]D^40YB@VL6$6
M4CSJE_@?+LV>(BU""/@=$ZQ1\@C6\\;[L&ZE]Y7*VG8MM,KIJ7`%2_T;?:+!
M\"@DQ$;.OQ`.[SAY<8M=;5WVN1\VA9);)ZNW?++1'YR"L=4XT!R3WJ+^D!<-
M<38BMNV$#!RH2M[RKVYY`/$!5",B0@F"1A#B!3++`4?'F#QWMCO<[L5/RNY3
M=:FI7THIT)93XN=?:J/C"4_)$0,X_$]RZL*V-O<=H:%HCR7:UU=4YX^S:]70
MD]0*G`#QGTZ"9%W[[M\GBX3G\TW1%,'(`4T599V]DL"I@(B"8?5I&/>'+H.@
M\ZQQ,'OA'C6],?V-VJQOE50V>F=?3\^H!J%3Z_MBM(^1(ET2B(>:=[KO#YWS
MHNV35]/2+XM4931(`ZO[LEI9'0>92B1Q)UC4N1DI&7=*/I:0?2KU4QCJO))V
MX?NE#F'F,<[ATHJL<QC#J(B/$:VG3T]/2-!FE;0TR."4)"4CQ!(`B/-9<*^X
MOJJK@^Z_4J,RMQ:EJ)/6I1)/RF/QU[H^.%(0I"%(0I"'_>'^Z'$!_6`TCR"1
MJ.,2W;#^Y%=F()F$Q7FV:?71B)^X;1<7<,HNH\G,;G6.5!!8'JO.YDK33$0!
M9NH8QVA//1'E*9(T5M[^[S:\MI'LFPUE%-E;:2M;2`$MU<M2.4:(?/S5"06?
M)6)D*%B?=,[[60;<7*EP+=&J=K]NWEI::J'5%;]NF0E*@LS4Y2#Y[:B2TGRF
MB`DMJLT-G+9ZV;O6;A%VS>((NFCILJ19NY;.$RK(.$%DQ,FJBLD<#%,41`Q1
M`0JN!UIQEQ3+R2EY"BE22)$$&1!!U!!T(/"+SZ=]BJ8154RTN4SJ`M"TD*2I
M*A-*DD:%*@001H09B/?7XCVPI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I
M"%(0I"%(1&9W:?K4.T*7+;:<@HP-?%HC=_H":BG);2:KQ45'_2`3$C2S";3J
M&'S`-R\W"I']U?\`9GQ7:-P+8?\`4G^PYB!-XA(DF?S^S+DAQE.409_$-%_/
M=TJ$V5+IHS=*7UOLP3*F':&:Y<&P^&>8G2?+/2*K\>Q?2SUK&Q3-W)R+Y9-L
MRCXYNL]?/'"IN5)!JT;$57<+*&'0I2%$PCX!5F[[[%*RJHJ5H;IT`E2E$)2D
M#B5*,@`.DDQ0/24597U3=%0M.O5KJ@E#;:5+6M1X)2E(*E*/0`"3T18;[=?;
MD?8_?Q.>,_0Y$+P;`D_Q]CYZ!55+76.4#HW-<R0"9,MP)E-_)6@\WH8CU%-%
M@*5.`W>`[P;%]8=P?!7BJTJFFJJDZ!X<"RR>/9'Y[FG:>:GR)E5RG<Q[E=5A
M]73[L[NTP3D:).6^WKD33*T*:FI'`/C^B9,^Q/EKDZ$I;FXJ&46E0I"%(0I"
M%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"
M%(0I",9Y(S/BC#\<:4R=D*U+):`03IEG9=JV>N0T$=&48!SR3XXZ:`5%(XB.
M@>(A628[A^4Y;4>K8W0558[.1[-M12/TERY$^-2A&"YMN=M[MQ1FNSJ\V^UL
M2F`^\E*U?H-3+KAZ@A"B3IQB,'+G>1PI:XN6&)+,N;)\@0#D2EI,?J;;'4`3
M%*HF9X@\GG:7@.GHB',&H<Q>`U)/%.Z+F-RY7\JK*:VL'BA']X>EU'E*6TG^
M>J748@CN-^)9MA8>>DV[ME=?:P3`==_N=-/43'.E=0H<#(LMSZQQB,C+/=-W
M89+](:0US16*X583`5AC^.*UD>F;@!5KCE#2,P)P`1#5`[<!#^#KQJ2&+=V7
M:['.5VLIG;G6#YU4OF1/P-(Y&_K!?CB"VX??Y[P6<%=/;*YBPVM1,FZ!OD<D
M>A50X7'I^%M38\$:`7'=-SWA(*2UV7%.W/**F$RDC<,L_F7IQ$1,.KF1<.%O
M$?#72M[6^V6VTL"EM=.Q34PX(:0EM/Y$`"(@7K(;]D=8JXY!6U==7JXN5#KC
MRSXUN*4K^6/A5]T</"D(4A"D(4A'N;-G#U4B#-NN[74,!"(M45'"QSF'0I2)
MHE.<QA'P``UK\..-LH+CJDH0.))`'Y3'O9IJBI<#-.A;CJC()2"23X`-3&4X
M;`F<;B("D'A[)THD).H59I8UR'1.3^,188XJ2@?J$:QFKSG"Z`\M;=[:TN<I
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M5$5T%BG2624*.ABF`0$/&OVTZZRXEYE2D.I((4DD$$<""-01UB/344[%6PNF
MJD(=IG$E*D+`4E23H4J20001H01(QT&V\/XFLV34F[1QACZV)E4QSGEH"SK?
MB9'53]IR/6,>@X3*?7B!3``^Y7/7'+<JN],*.ZW*OJ:0#S'7W5HTX>2I1!^4
M1B%DVVV[QFO-TQVPV>@N:B27:>CIV7->,EMMI4`>D`RC(M8]&:PI"%(0I"%(
M0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"/B
M7#<MNVC%.9VZIZ'MJ%9D%1U+3LDSB8YN4`$1%5V^600*(Z<`YM1'PK[;?;;A
M=JI-%:V'JBL69)0VA2U'Q)2"8XJ]7VRXY;UW;(*NFH;8T)K=?=0TVD>%:RE(
M\&NO1$9^:N[5MNQN+J-Q^68S+<"/.0HVZ3Y(M--8.8-%KFE$>9RF!@#SF;5R
M00'@:I&X=W5]PLAY:F_%FT4!U^U^T?(\#*#H?`XM!\$0;W0_$/V4PKM*'#Q4
MY+>$S`]7'8T@.O&I=3-0G+5EIU)GHJ(E,R=U+=+E$CJ.MV9BL1V^XYT_0K#:
MG+-'0-P`KBZ90SN3*IR^)FH--1$>&F@!*C$>['MEC)347!EVZUZ?G5)^SGX&
M4<J)>!?/%=VY??\`=^L]2NBLU33X]:%S')0)(>*3T*JG2MV?66NQGKI+01V3
M4[-W)(KS%Q3$K/RSHPG<RDU(.Y20<''Q,L\?++N%!'])AK?]'14=OITTEO9:
M8I4CR4-H2A(\24@`?DB&5TN]UO=8NXWFIJ*NX.&:W7G%NN*/6I:RI2CXR8^7
M7U1QT*0A2$*0C[=OVS<=VR"<3:MOS=RRJPZ)1L!%/YA\H.H`/(TCD'"X@`B&
MOFZ!7Q5]RMUJIS57-]FFI1Q6ZM+:1_.40(Y:SV&^9#6)M]AHZJMKU<&V&EO.
M'Q(;2I1_)&\^,^V+N^R."+E;'[;'\6J8FLAD.7;02I4S:")RPK<)">,/(.H<
MS8A3>',%:5R/O([48\2VBO57U(^92H+@GU=H>5K\BS+JB5N#=Q3O&9J$O.6A
M%HH%$?:7!U+!EIJ&4]I4<.$V@#PG$@&.^RC#HE2<98S5(/E0,`K1./H%!@W$
M`'42A-W`9ZNH4P<!T9)C[@UHC(.^/5K);Q:SH0F6BZIPJ/W;7*!]X8F#AGX7
MMM;"7MP<G>=7/5J@82A/B[>HYR9_Z!)ZC&\%@=LK9S8734-C,][/D_\`IU_S
M<C<'./#B:,(HR@QXAK_@NM:7OO>/W;ODTBXBC9/S:5M+7_3DIS_IQ*C$.XQW
M;<1DX;&JZ50^?7ON5$_&T"W3_P#E1N):N,\<V,@1M9EA6;:J)"%3`MOVU#Q)
MA*4-"@HHR9HJJB`>4PB-:DN>29#>UER\5U95*)G]J\XO\@4H@?)$DK!@N$XH
MT&<9M%LM[8`']WIF6M!UE"$D^,DF.\:CY!$`]P.`!^H`KA8RJ/$P`<IB'`#D
M.`E,0X`8IBF#02F*;4IBB`\0&O()!F-"(\*2E0*5`%)&H/`Q5A[KV%[-Q+N+
MCI:R8]I"L,FVFG=\K!,$B-V#&X$I1Y%R;IBU2`J35O*@W37,F4`*"XJ"```Z
M!9OW7<QN^5;?N4MY<6\_;:HL(<425*:*$K0%*.JBB92"=>7E!X101^(-MCC.
MWF\S-PQ=ENEI+Y;Q5NL-@);;J`ZXTZI"1HA+O(EPI``[0K(`!D(P:DG$#X4A
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MN`%;\MW=$VZIV@FX5=TJ7I:D+:;$_`D-*D/`5'QQ#6]_B7[VUM05V2VV"AI9
MZ(++[ZI>%:JA`)ZR$)\`$95Q-WH[P;RK1GFS%T!)P*IRINYS'JSZ+F6)#&T,
MZ^19E[(,)(J11UZ95VQA`.!A'A6,93W/;0Y2K>PVY/M5H$TMU02MM7@[1M*5
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MN6.'@D:&C#*G8"?R'=F;)<>)@#C6RL,VBW`SQ256"WNFB/\`3N_9,`=?:+ES
M>)L+5X(T1NEWEMF-GVUHS*]4XNJ1I1TY]9JR>HLM$EN?0IXMHZU`1#CG#O+7
M].&=Q.!+%CK(CA$Z:5V7F"-PW*J3SB@LU@T3!`19QUU`%C/O)X<0&7&%]T.Q
M40159Q6N5M1Q+%/-ID'J4X?M5C]$-16KNI^)AEUT4Y;MI;4S:Z+4"KK)5%21
MJ)I9']W:/3)9J/DZ8FLFYGRMF66--91O^YKV?<XG2":DEEF+,1U\V/BDA2BX
MY,`'0"H(I@`<*E+CF'XOB-+ZGC5#34;$M>S0`I7Z:S-:SX5*)BO/.=SMP-R[
M@;IG=WKKG5SF.V=44(_T;0DTV.B3:$B6DHQE621@D*0A2$*0CNUB8UR%D^6)
M!XZLFY[VECF*46=M0KZ5.ES"!0.Z4:HG09I:CQ.J<A`\HUPU[R*PXW2FMR"L
MIJ.E'SGG$H!\0405'P)!/@C*\3P7,L[N(M6&VNNN=P)`Y*9EQTIGTK*$D(3^
M<LA/AB3'$/9_W#WL#20R9,VQB*(6%(ZK1TN%UW6"!^4QM(B&7)%-U>0>!5GY
M3@("!BAY8Y99WL<`LW,QCC-3=:L3`4D=@Q/]-P<Y'A2T1U$Q.3;C\-_>/*`W
M69Q4T..VY4B4+5ZU5<IX_8LJ[))EP"ZA*@9A21+63W%?::VK6`5HZNR/N/+,
MR@(**.+NE5&,(=4-!#IV[`#'MC(`8/V;A5R`AP,)JC9D_>FW.OI6U:UT]KI%
M:`,("G)>%UWF,_"@(\$HG=@'X>NP6(!NHR!FMR"Y(,RJK=+;)/@IZ?LTE/YK
MJW1+0SB0FS<?6)CN-3B+#LVV+.C$DRI%9VW"1T.B)"^]!3T%NB980]TXF']-
M:$N]_OF05!J[Y65-74$SYGG%N'Y.8F7R1,;&<-Q+#*(6[$K906VA2)<E,PVR
M)#KY$IGXS,QW"N(C)84A"D(4A"D(ZW>%WVS8%KSEZ7C,LK?M>VXY>4FIB05!
M%JR9-RZG.<P^<=10P@1-,H"=10Q2E`3"`#R-HM-QOMS8L]H96_<JAP(;;2)J
M4H_\PXDG0`$D@`F.$R3)+'B%AJLGR6I:H[%1,J=>><,DH0GB3UDF02D34I1"
M4@J($4Z=X>XV0W0YQN/(ZB*S&W$")V[8T4N/PL=:46JN+#TDNHE*^D5EU7;@
M`X%57$H<"A5M^TNWS&VN%T^/)(7<"2[4K'!;ZP.:7YJ``A/6E,^)CK6]Y/>J
MLWWW4K<T4E35E2!3T+2N+=(T5=GS#ASN*4IUR6@6LI&@$:N5LN-"1]2$A96Y
M)F)MV"8KR<W.R3*'B(YL7G</I*2<IM&31$OE47<*E*'DX\>%?-6UE+;J-VOK
M5I;HV&U.+6=`E"`5*4?``"8Y"TVJX7RZ4]FM+2W[G5OH9:;2)J6XXH(0A(ZU
M*(`\<71=K&#V>W;!%@8K1%%62A8H'MSO$`#IO[LF#C(W`Y(?0!41(_7,BB80
M`>@D3@'A5/>YV:.Y_F]?DRYBF>=Y64GBEAOR&AX#R@*4/I$QV==@=K*?9K::
MT8$WRJKJ:GYZI:>#E6\>TJ%`]*0XHH03KV:$QL)6`QN.%(0I"%(0I"%(0I"%
M(0I"%(0I"%(0I"%(1TJ^,D8^QG%A-9#O6U[)BSF$B3VYIN/ATG"@<12:@]72
M.[5`.(D2`YM..FE<S9<=OV25/J=@HZFLJ1Q2RVIP@=:N4'E'A,A&+97F^'8+
M0?M/,[I06N@)D%U3[;(4>I'.H%9Z9)!,M91TZQ=Q6!LF/RQ5@Y@QY=<L<PE2
MBHBZ8I>47,`"(@VCC."/'/*`<>F0VE<O>]OLXQMCUJ^VFOI:4<5K96$#QKER
MCY2(QK$]ZMI,ZJQ;\0R2S7"X$R#3-4TIU7Z+?,%J_FI,9FK#XV="D(QYD#+>
M+\4LT7^2L@6C8S9S_@IKFGH^*5=^=RB+1LY7(Z=`4WOA3(8"^72L@L.*9+E#
MI8QV@JZUQ/G=BTM83^D0))\$R)QAF8;BX%M]3)J\WO%NM3"_-]9?;:*^CR$J
M4%+ET\H,NF/G8]SEAO+*CA#&F3[(O=TU*8[EC;MQ1TA((I$T`RZD>DOZ:5N4
M3`'4Z?)KPUKZ+_A.7XLE*\CMM;1-*X*=:6E!/4%D<L_!.?@CXL-W7VTW#6MK
M![[:KH^V"5(IZAMQQ('%1;"N<)_.Y9>&,J5B\;`A2$*0A2$1U;NNXUB;;0#Z
MTH#T?)>7$RF3^JD6]*6&MI<2^:I>,TAU2LE2"(#Z"@!WA@X'!$!`]2!VI[OF
M4[BE%UK^:W8H=>W6G[1X=5.V9<P/]8J38Z.<@IB%_>+[Z>WNQX=QZS\E[W#2
M"/56ECL:94M#6/)GR$?U".9T_.[($*BM[GO=-FW<E,FD\HWD\D(Y-4RD9:48
M)XNSX8FOF$802"GHYUB%``](<"LY-IYR@U89@VV6&;=T8IL:I$-U!$EOK\M]
MS])PB8'YB>5`Z$Q2;NYO]NCO;<S7YU<G7:-*IM4C4VJ1GJ#;"3RDC^L<YW3\
MY9C7FL^C3,*0A2$24]KS<%<F)]QEM8^]/64L+,,@2V9^&55,+1">4:K_`%<G
MVR9M2(/T'I"-U#E`!4;JB4VO*02QV[RN!V[*=OJF_<@%\M+?;-.`>46P1VK1
M/2DIFH`\%)!'$SG!W#=X;WM]O10X?VRE8ED;PIJADGR`^4J]6J$C@EQ+G*VH
MB7,VM0,Y)Y;6E5>QV"(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A'SI:7B8".
M=2\[*1T+$L4C+/926>MHZ.:(D#4RKEZ\51;()E`.(F,`5]%+25==4)I*%IQZ
MJ69)0A)6M1Z@E())\0CXKC<K=:*-RXW:H9I;>TGF6Z\M+;:`.)4M9"4CPD@1
M&-GGNQ;><6B]A\=@^S1=3?J(A]7E`C;-;."D,`>E74[14!ZF170!]!0<E,&O
MGA4D<'[K>?9+R5>0<EGMBI'[4<]01X&4D<IE_6*01U&(*[M_B$;.8%VMMPSM
M<FOZ)@>KGLJ-*I'SJI:3SB?]0VZ#](1#%G+N1;HLVF>Q_P!<38WM-T"R7U7Q
MT*\&55JKYO0D9_JJ7#(?!\#!Z0DD;4?@PX:3`PKN\[:8:$/^J?M&Z)D>VJY.
M24.E#4@TG7AY)4/I161NMWVM^-T2[1_M(V7'W.8>JV[F8!2?FN/S-0YIH?M$
MH,_,&DM#%555U55UU%%EUCF5666.95994XB8ZBJIQ,=10YA$1,(B(C6\$I2A
M(0@`(`D`-``.``Z!$2777'G%.O*4IU1)))F23J22=22=2>F/"OU'KA2$*0C]
M3%@^E'C>/C&3N1D':A46K%@V6>/'*IQ`"I-VK8BBZRAA'@4I1$:]3S[-,TI^
MI6AMA(FI2B$I`ZR3(`>$F/II*.KKZA%'0M./5;BN5"&TE:U$\`E*02HGH`!,
M2(X1[7>Z'+H-9*<@6F([8<`13Y6O\RK:750.4#@9E:;0JLT<XE,`@#DK0@_Q
MJT#F?>6VUQ0JIJ)]=UN2=.2ED4`\/*?5)N7Z!6?!$S-K>X9OON*&ZVZTC>/6
M)<CVM?-#I21.:*1,WR?]*&0?I1+QACM*[:\<@VD+_P#EG,L^EH<_UD4-#VL1
M70!^!MJ)7**Z9#!X.W+DIO*70=*BAF'>HW$R#FI[%V-HH3I]D.T>(\+RQH?T
M$((ZYZQ8YMC^'CLEA0169=ZSDMW3J?6#V-*#^;3,JFH#J===!Z1+2)*+6M"U
M+'B4(&S+:@;3A&Q2%0BK<B6,,P3`A`(40:QZ""0GY2@`F$!,/E&H[7.[72]5
M2JZ\5+]56*XK=6IQ1GKQ42?DB;E@QO'L5MR+3C-#26^UH`"6J9EMEL2$AY+:
M4B<NF4X[%7'QS<*0A2$*0A2$*0A2$?!NBZ;<LFWI>[+NFHZW;:@&*TC,34JY
M3:,(]F@7F46764$`U'WI2AJ=0X@4H"80`?NMELN%YKVK5:F7*BXOK"&VT`J4
MI1X``?E)X`3)(`CB+_?[+BUFJ<AR*J9HK)2-*<>>=4$-MH3Q*B?R`"942$I!
M)`BJ]OYWW3FZ*Y5+-LIS(0N#+=?%4B(M0#M'EYR;43%+=%Q(`('!(HF'T%F?
M4K<GPAPZIAY+.=C-D*+;2W"[WA+;V:U").+'E)IT'^A:/7_6.#51\D>2-:!N
M]UWL[KOQ>SC6,+>I=JZ-V;31FA=8ZF8%54)XR_J&3HV/*4.T)Y8X:D)$)X4A
M$[?::V<K/'R&Z/(T08C!B*S?#\8_1T],?ZJ-I"^3(*DU%NQ`#-XX^FAE146+
M[Q,PPD[TN[B&6%;:8^[.H7(UZTGS4Z%--,=*M%.CH3RH/G*$6R_AZ=VIRIJT
M[\9I3$4C14FT-.)ESN:I<KN4CS6]6Z<\"LK<'F-J-@*H'Q<'"D(4A"D(4A"D
M(4A"D(4A"D(4A"D(4A"D(T9WK[V[-VF6D5LB1I<V6;C:+&M"S.N`$;)B!TBW
M)<HI&ZS.":K!H4@:*NU"]-/0`.<FZ]F]F;ONG=2XLJIL6IUCMZB6JCH>R9GH
MIQ0XGS6QY2I^2E44N]#WH\:[O6/=@T&Z[<&L;/JE'S:(&H]9J9:H82K@G13R
M@4(D`M:*J.5\O9%S?>,A?>3[HD+IN*0..BSQ3E9QS775*-AHY/E9Q,:V+P(B
MB0I?*.IA$PV?8OBF/X9:6[)C=,W36]L<$CREGI6XL^4M9Z5*)/0)"0CK^[@[
MD9INEDCV5YS7O5UX>)U6?(;3T-LMB2&FD\$H0`.DS423CMNNNS<(.VBZS1VV
M5(NV=-E5&[ENLD8#IK(+I&(JBJF<`$IBB!@$-0&N?<0AYLM.I"FE`@I(!!!X
M@@Z$'I!C#&*A^E>344RUMOH4%)4DE*DJ!F"")$$'4$:@Q<&[?%_9"R7M.QC=
M63%W<A<*R4U&MYM^8YY"X(.&F'D;$2[Y0_G+NE6S?I&5'4RW2ZAA$QA$:F=^
M[%8,<W2N5LQQ*6Z`%M9;3YK3CC:5N-I`X)!,PG@GFY1(`".R)W.LOS'..[Y8
M[]G"G'KPH/M)?<)+E0PR\MIEY9.JEE*>4K.J^3G))42>][K]R]I[6L2RV0)\
M47LXY!6)L:V15`CFY;H61,9JV`H#U"QK$/AWBH<$D"CIYYB`/";7;<W3<W*6
MK%0S11)DNI>E,,L@^4>KG5YK:>E1Z@2,L[P>^./[";>5&7W<I=NJYM4--.2J
MFJ*24IZPVCSWECS4`@>4I(-/3)F2[VR_>LYD'(4Z\N&Y[@>*NWCQVJ<Z;=,Y
MS&0CHU`QC)1\4Q3$$T&Z0%323*``'B(VTXYCEFQ.SLV&PL(I[:P@)2E(U)Z5
MK/%2U'52C,D\8ZV^<YUE.X^3U67YA5NUE\K'"I:UDR2)DI;;3.3;2`>5MM,D
MH2``([SMBCKSE=PN'(W'SN2C[K>Y!ME%@]B55T739N24;KR:ZIVYBF%@A&)+
M'<E-JF*!3@8!+J%<)N146BEP*[U-^0VY:T4#Q4E8!!/(0@"?SBLI"):\Q$M8
MRS8FCR>X[Q8W0X>Z^S?W;Q2AM;14%)2'4EQ1*2#R):"U.`^26PH*!3.+M0^(
M_K&J:H[1T<4A'YW;MHP:N7[]TW9,63=9V\>NUDVS1HU;IF5<.7+A8Q$D&Z"1
M!,<YA`I2@(B.E>QIIU]U+#"5+>6H)2E()4I1,@`!J23H`-28]-34T]'3N5=6
MXAJD:05K6M02A"4B:E*42`E*0"220`!,Q7UWQ=TR0FUI;%6V*76C(1,ZS"XL
MMLQ.C)3'*)DG#"R!4(52.C1$!`TCH"ZP?L.F710\\]EN[+3T2&LHW(:#E:0%
M-4*M4-](542T6OJ:\U/S^8^2*=^]3W^*RZ.5&`;%U*F+6DENHNR)I=>E,*11
M3`+370:C]8L?JN1,EK@X655<*JN'"JJZZZIUEUUE#JK++*F$ZJRRJ@F4554.
M81,8PB(B.HU-)"4MH#:`$H2```)``<``-`!T"*J7777W5//*4MY:BI2B2223
M,DDZDDZDG4F/77ZCUPI"%(0I"-YNW#CJ0R+N^Q01JW.K'V;(NK]G5P*<4FL?
M;;159N98Y-.GZ3+K-D2Z^)U`"M*]X3(*?']I[HIU0#]6VFF;'2I;R@#+KDV%
MJ/@$2N[E&&5F9]XW'T,(*J2VO*KWU:R0W3)*DDD<.9XM($^)6!%OCQ']=5/1
MV.H:#[@TA'%(0I"%(0I"%(0I"%(0I"%(0I".@9%RKC?$<$K<N3+VMVRH9(IS
M%=STD@S.Z$F@F2CV8F,]DG/'@DW344'R!7/8_B^1976BW8Y1U%95GYK2"H#P
MJ5YJ!X5$#PQA^:;@83MU:E7K.+I16RVI!DI]Q*"N70VCSW5?F-I4H]`B&_<#
MWDH&.].@-N=FGGW9>H@2_;Z068PY#:<H.8BUT%4Y)\4#<2&=JM@]U(0X#+K`
M^Z+6U')7;@U@8:T/JU,0ISQ./$%"?"$!?@4(K3WA_$MM-%VMHV7MIJZ@32*^
MN2I#(_.9I4D.+\!>4UX6R-(A=S'N,S5GR54E<JY!GKG`53*-88[D6-M1H";F
M*G&6ZQ]'B6A2#IH8$A4'34QA'C4P<1V^P[!J44N,4#%,924Y+F>7X5NJFM7B
MYI=0$5C;E;U;G[N7!5?GUXJZX<TTLE7)3-ZS`:IT<K*)=81S&6JB=8PG691J
MR%(0I"%(1E;%F#<N9LEB0V+,?W+>3H5027<Q<>K\D,!'Q-)S:X(Q$:0H<1%9
M8G#PUK%\FS3%,-I369-7T]&U*8"U#G5^@V)K6?T4F-A8#M1N+NA<!;,#L];<
MGRJ2E--GLF_"Z\J330Z9K6GP1,1@CLS2+CT*;W$WZ2.3'IK*V+CXZ;EYIQ$S
M:3NUZB9HB?P`X-&ZH>/*MX&J)6;][ZG;YZ/`*$N*U`J:J83XT,)/,?`5K3X4
M=$63;2_AFUCW973>6[!E&BC0V\A:_P!%VK6DH3T<P:;7T\KO`Q,;A[;5@W`K
M`C+%F.+=MIP"9$W$X#4)"YGPD)RB=]<4B+J67$^HB)>J"8"/`H!PJ(^6[C9K
MG+Y>R:X5%0W,D-\W(RG]%I$D"77RSZS%E.VVQ^U6TE(*;`K+1T3W*`I_E[2I
M<D)374.<SRI]7.$]20(SE6$QM>%(0I"%(0I"%(0I"%(0I",69BS1CC`UD260
M,G7$UM^!CR&*B4X@K)S+[D$R$1!1Q3`XDY1T8-")D#0OOCB4@&,&3XCAV0YQ
M>6[%C=.I^N<.O0AM/2MQ?!"$])/B`)(!P#<K<["MI,6>R_.JUNCM+(/*#JZ\
MN4TM,-CRG75="4\/.44I!4*J^\C?'D3=A<*C(YG5I8FBG@*VS8#=US$6.CS%
M1F[H71Y$Y:;.4PB4!`4&H&Y4@UYE#V=[1;+6#:V@#PY:K*742>JBGA/BVR#Y
MC8Z?G+XJ,I)%`/>6[U>9]X.\FE)<M^WS#DZ:@2N8)$P'JE29!U\SF/F-3Y6Q
M/F6O1VMTQ%2%(1)'V_=C$QN<NU"]KW9.XW!UJORC,/#`LU6OB4;&*<+5@E0`
MIC-0-I\H.B#HBG\&4>J<.2/&^^]=)MO:E6:S+0YFE4W]FG0BF0=.V<'7_5(/
MG'RB.4:S;[GW=2N6^>1)RC*&G&-K*![[99FDUKJ=?56#I-,Y>L.@R;3Y"3VB
MARVK(N+C82-CX:'8M8N)B63:.C(UB@FV9,&#)$C=HS:-TBE30;MT$RD(4H`!
M2AI58534U%;4N5E6M3M4ZLK6M1)4I2C-2E$ZDDDDD],=@*@H*&U4+-LMC3;%
MNIVDMM-H2$H;;0D)0A"1()2E(``&@`C]U>B/KA2$*0A2$*0A2$*0C$&4L_X6
MPFB@KE7)=IV4=T3JM6,M)$^5W:6O+UFL*U!S+.$>;ASD1$FOEK+<9P3,<R4I
M.,6ZJK$I,E*0@]FD]2G%20#X"J<:WSW>#;#;!"%9]?+?;''!-#;K@[98ZTL(
MYG5)_.""/#'0<>;S=KN5;B96C8F9[2F;FDE!1C8551_$O9);EY@;QY9EDP3>
MN3@`\J29C*&$.!1KG+_M!N7B]O7=;W9ZIFVMB:W!RN)0.M79J44@=)(`'7&)
M8=WF=B,^O+6.XKDMOJ;X^9-,J[1E;BI3Y6^W;;"U'H2DE1Z!&SM:VC>L*0A2
M$*0C2_>EO&M#:;C\[U4S2<R;<C9RA85F=8!4<."ATS3\V1,W6:6Y&*&U.<=#
M.5`!%/B)C$W#L[M'=MTK[V*>9G&Z=0-342T`X]DW/13JQP'!`\M6D@8Q=YWO
M*XYW>L0-2LMU6=5J%)H*.>JE#0U#X!FBG:/$Z%Q4FT:E2DU)LAY"O#*MYSU_
MW[-N[ANNY'IWTI)NS:F.80`B+9LD'P;1@R0*5)!!,`312*!2@`!5J5@L-IQB
MT,6*QLHI[93HY4(3_*2>*E*,U*4=5*))CKN9GF62;@9-5Y?EM4Y67^M=*W7%
MGB>`2D<$H0D!"$)`2A`"4@`".EUS$8O&V^SC:E=6ZS*C"UV2;N-L2%5;R.0[
MM(B86\-"E/S?)[14P=)6?FN046B6HB74RI@Y$S5JO=S="V;7XPNYO%#E[>!1
M2L3U<<^DH<0TWYRU>)(\I0B1?=J[OM_[P&?,V*E2XQBE*I+EPJP#RLLS_5H/
M`OO2*&D]!FX1R(5%N5PXL'!V,A7<*Q]GXXQE:B1!.<2H,H:WH!B1%%,/#J*]
M%$I2E#5194P`&IC<:IVV[[FN2<C8<J\AN54?"IQUU4R?`)F9Z$I$]`([%;SV
M(;4X+VKRF;;A5BMX$S)*&:>G0$@>$R``&JEJ(`FI6M1+>+NCN/=5ER3O)Z=T
MQLR'.YB,=6RJ?0D);A5M2N'"91%,TS,F3!P[4XCS"5,!Y$RU:WM)MI;]L<4;
MM#(2N[N@+JWAQ<=EP!X]FWYJ!U34=5&.N=WE-^KWO]N*_DE47&L9IRIFWTQ.
MC%.#HI0&G;/$!QY7TI(!Y$)EJA6T8CU%A;M`;7QA(*5W.7:Q,23N5!];&-&[
ME`Q3-;?3<%2GKF2ZA0$%)=VW]$;G+P]'25$!$%>$".]EN4*RM:VWM:P:>G4E
MZK(/%TB;3)ET(2>=0/SE)X%,7)?AP[#FUVJHWRR)HBMK4KIK:E22.5@*`J*D
M3'%U:2RV1_1I<()#@B<>H5Q:M'RIV=AK8AI.XKBE&$)!0K)Q)2TO)N4F<?',
M&J8JN'3MRL8B2**1"B(B(_H\:^JAH:RYUC5OM[2WJYY80AM`*E+4HR"4@:DD
MQQ]VNULL-L?O5ZJ&J6TTK2G'GG5!#;;:!-2EJ40``.N*PN_?N'SVX1_)8OQ8
MZ?6]A1B[4;O':9U6DMDE1N?E*\E`*)%&MM<Y>=NR'05@T47U'E3)9-L;L%0X
M$PWDN3)149BM`*4F2D4@/S4="GI:*<^;JE&DU*HC[W/?+NV\56_@F!..T>V+
M3A2M8)0[<2D^>[P*:>8FVP?.$EN^5)"(L:DW$`X]J""[E=%LV15<N7"J:#=N
MW3.LNX76.":*""*93*++*J&`I2E`3&,(``:U^5K0V@N.$);2"229``:DDG0`
M#4DZ"/:RR[4.IIZ=*EOK4$I2D$J4HF0``U)),@!J3$SNT_M)W1?K*.OC<8_E
M+!MQV";J/Q]%=%*]95J;E.FI.O%BKHVN@N4?V'35>B'O@1'2H?[I=ZFV6)YR
MR[?(:KKBF:552YFG0KI#:1(O$?2F&^KG$6;=WO\`#OOV6TS.5;T.OVBRN26W
M;VI"M=1H07UJ"DTJ5?0Y5O2\X-&4:W]Q^S]NF+LKV[B3`-J,8):Q;?.CD64:
M2TI+*R%R2*B"K.+?.)&0?%-(0\>B!UQ("8@HZ$A@YB"`;#[O5VW`R7%ZC*LZ
MJEOHKGYTB%(0@(:0"%+2$)3Y#BC),YZ(F-#,Z4[Z^.;,8'G]%MWM%0-TKMIH
MRFX.I>=>+E2X4E+2U.N+^T9;2"OE"?*=*2)H($=M;_B%\<@`F$"E`3&,(%*4
MH"8QC&'0I2E`!$QC".@`'$1KP2`)GA'Z2E2E!*1-1.@BU#VU-KO[MF%I+(N0
MVR$/D'([)&X9\9`"H+6A9#!L=[%0KU533T5;HF.^?%'3D.<J9N*-5D=XO<OX
MB9@WCU@4IZPV]9::Y=0_4*/*MQ('G"<FV^L`J&BXOX[C^PWP1VQ?S3,D)ILO
MO30J'^T\DT="VDK:963YBI<S[X,N4E*%:M1K)EC>+F+.#:Z<@67DAWMBV?6E
M=Z5A?SNL;6?73?U_W"L90"?(,:P04D&[9=(.<`1.W3:D.3K+'5,*9-D8MM)B
M6%N4UAO%N1DF[-52&I]14\EFFIFA*?:+40@D'3R@LK(/(@)',=';@=Y+<C=1
MFOS#&;TY@W=RMUQ%!^UD4KE57U]09R[!ML=HE*D^5Y"FDL@H[5U3A+:>E6-=
M%Y2EPLHW;7W$LE77E=P47<+C+<9:-Q04+D%=LDHX^1X1U>`.XXKE_P!,2)I`
M4!,/`%`]\7F+U;+134"ZC<3`+=2XND\KE9:GVG'*4$@=HXECE7RIG,JGIQY3
MP.,XO?LDKKRU0[);R7JX;@+'.S;,AI:EAFX*2"KL6%UA<:"G)$)1*9X!8\X;
M+(=R.\G&&)..3Q(X'=Q$Y+@\)/,3F3<`R"]KA87"]C;E39BO\H*0!DK8=E.W
M!74CD"%%7HG!6M=+[O%H;S!NH5=4_"IVW.7%-;,<WJ[2FDK9*I<@=F\@A4M4
M3/+S@HC=S7?8R9[;)^B1CR_XB*>]L61=JDKD]=J$5"FZD(YNT+!%*Z%-A4TN
MA(+G9*#L2ZU%&+%X4A"D(4A"D(4A"D(Q7EC-V*,'0)KCRK?4!9L<)3BU3DW9
M1E)0Y`$10AX9`%I657$0TY4$3Z>)M`XUE&+87E.:5HM^,43]6_/RBA/D('6X
MX9(0/"I0GT3,:_W!W3V^VKM)O.?W6DMM&0>0.+^U=(^:RRF;KJO`VA4N)D-8
MA#W%]XV=D_3[;VV6L%OL3=9O_.'>K5%W-K$$!(#F"M@IU8^-$==2*/#N3Z:"
M*)!X!,[;[NCT--V=QW#J>W?T/JM.2EL'J<>D%+\(;"!^>1%6>]/XE-UKNVLF
MR=!ZG2F:?VA6)2M\CAS,4P);:ZTJ>+IZVTF(9K\R-?F49]Q=.1+NG[SN!T8Q
ME).X))Q(+D*8=>BU(L<4&+8N@`5)$J:10```H`%2]L>/V/&J!-LQ^D8HZ!/!
M#2`D>-4M5*ZU*))Z3%9>6YKEN>7==^S*XUERN[A,W:AQ3B@#\U/,9(0.A"`E
M`Z`(Z77,1B\*0A2$<>'C2$;4X(V7;B=Q"K5>P+`D$+:<'`#WQ<Y5+>M%)/4.
M=5"3>I`I*BF4=1(R3<G_`$5K'-]X,`P!*D7VO;5<4C_=F9.OD]10DR1/K<*!
MX8D!M-W8MYMYG&WL1M#R;&LZUU2#3T@'24NK'VLAQ#"75>")O=O_`&AL,V!Z
M%.9IEW.7KE2!-4T(F5>#L-FN41$2>@HJA+3I2CIQ<K)I'\J%0QSOO7Y??>>B
MPYI-IMQF.T,G*E0Z^8CD;_F)*AT+BT[9_P##EVSQ#LKKN;4+R*]ID>P',Q0H
M5U<@/:OCPN+0A72S$KEMVQ;=G0S.W;2@(>V8&/3!)E#0,:TB8UJ0I2ET19LD
MD4""(%#4>741XB(U%VXW*XW>K77W5]ZIKG#-3CJU+6KQJ42?Y8L$LEALF,VU
MNS8[1TU#:61)#+#:&FDC\U"`E(\)E,],?9443134664(DDD0ZJJJARIII))E
M$QU%%#"!2)D*`B(B(``!QKXTI4M00@$K)D`-22>``ZXY1:T-(+CJ@EM()))D
M`!J22=``-23PB$?<=W@6%BWY(V;@JRK?O^*@'*K&3OBX))^G#RS]`P$<)VTS
MB^DHYCFZI3$!VHMRKB',F02<IS3-V^[IC]ZL;=WS:L?H:I](4BF:0DN(2>';
M*7,!9$CR!,T\%'FF!5IO5^)!1XIEC^-;4VRDN]OI%EMRNJ''`R\XG10ID-<I
M4VDS`=4N3A$T)Y.5:LX;+.Y=`[FKP/C"^;298[R`[:KO;9/'RJTC;]T@S2ZS
MV.;&>-T'<=,H(%.L1(YE2+)$-RG`Q>4V%[Q=W.NVXM`R6R52[A8D*"7@I`0Z
MSS&25GE)2MLF22H`%*B)B1F-J=V+OQ6C?/)#@N56]JSY<XVI=,6W5.4]5R#F
M6VGG2%MO!(4M*"5A:$JDH*3)4I=1EB?,*0A2$*0A2$*0A2$:@[L-YV*MJ-M'
M<7(\3N#($BU,K:N.(QTF$U*F,)B)OY,X%6""@4SE'G=+%\_E$J15#\`VSM;L
M_D^Z-Q"+>@L6%M4GJM:3V:.DI1P[1TC@A)TF"HI&L1P[P?>:P#N_6,O7IU-9
ME[S<Z6W-+';.DS`<=,E=@P"#-U8\J12VE:M(JL;A-Q^4=S%\.+VR7-&="F99
M&W[<9&51MRU(Q0X&+&P<>8YP2`0*`JKG$[AP<.90X\`"SK`MO<9VYLJ;-CK(
M2#(NNJD77UCY[BI"?YJ1)*1HD#6=`6\>]F>;XY2O)\WJBY(D4],B:::E:)GV
M;#9)D.'.LDN.$36HZ2P/6<1J.%(1)-L6[?=U[G)5G?%\I2-J8.C7?,ZE0(=K
M+7TLV4T5A;4%4GFLA.42.I'04T0U(ESJZ\D=][-^+7MO2KLME+=5FCB?)1YR
M*8$:./R/G=*&N*M"J2?.F]W4>YYD&^=Q:RG*DO6_:QASRW9%#M<I)U9I9CS)
M@I=J)%*-4HYG)A%I>U;5MRQ[<AK0M"&86];-O,$(R&AHMN1LQ8,FY>5-))(@
M!J8PZF.<VIU#B)C")A$1K+NETN-[N+UVNSSE1<:A96XXLDJ4H\22?R`<`)``
M`"+\L?Q^R8I9*7',<IF:.QT;*6F66DA*&T)&@`'Y23,J42I1*B3'8*^".8A2
M$*0A2$*0A2$*0C&V8<F0F&\77UE"X3D+%V5;DA-J)'-R^FNT$A)&QJ8Z@(KR
M<BHDW3`.(G4``XUD6(XY69?DU#C5`":FLJ$-S'S4D^6L^!"`I1\`,81N3G-L
MVTP.[9W>"!0VRB<>()ESK2)--#\YUPH;2!J5*$HI09%R#=65;VN/(-[2KJ8N
M6Z)-U)R#MVL=84_2%3'18MN<1!!@P1$$D$B`!$TR`!0`*N0Q^PVS&+-3V&SM
M)9M],TE"4I$IR$BH]:E'RE*.I)),=7C-LRR#<#*:W+\GJ'*F\USZG7%J),N8
MDA"9^:A`DE"!()2`D``1^K$R$FYRIC-O#&6)+K9!LQ.,4;F.5=-\:XXT&RB)
MR:G(HFJ("`AQ#2O5E*Z9O&+DY6`&D%!4%8/`I[)?,#/H(CZ=NFJU[<"QLVTJ
M%P5=Z,-%,^8.&H;Y""-00J1!'`ZQ>>X^7B/`!'W1`.(_W1JE*.UH.&O&%(\P
MI"-7-V&ZBQ=J>-G=WW(JWDKHDDG+2Q++(X*G(71-$(7EU*7F5;0L>90JCQSI
MRII^:750Y"FV9M;MC>]T,B1:K>%-VQLA5342FEEN?Y"XJ1#:.).IDD*(T+WA
M-_L4[O\`A+F17I2'[\\E2*&B"I.5+P`ZM4LMDA3SDI)3)(FM2$FH;ES+-\9O
MO^X,E9#EU9BYKA="LL<1,5G'M"")641$M1,8C")C41!-!$G`H!J.IC&,-KV*
MXM9<,L3&.V!D,VVG3(#YRE?.<6KYRUG52CQ.F@``ZY.XNX>5;IY?69OF52JI
MO=8Y,G4(;0-$,M(F0VTVGR4(&@&IFHDG&]9#&#QGK;CMVO\`W-Y*C,<V$S$H
MJ<CVY+C<I*&AK2M\BI2.IF65(&@`'-R((@/4<KB4A`XB)<&W"S^P[<8ZYD%\
M7P\EEH$=H^[+R6T#^52N"$S4>@';NRFS&7[YYNQAN)M<9+J:A0/8TE."`MYT
MCHUY4('E.+(0GB2+?6`<"6!MQQQ#XUQY']"/8@#F6EG)4QE[FG%B$*^G9EP0
MI>L[=&(`%*'P:"12ID`"E`*J>SK.;[N%D+N17]<WUZ(;$^S9;!\EML="1TGB
MI1*C,F.QWM#M'B&RN$TV$8<SRTC0YG7E`=M4OD#G?>4!JM4M`/)0@)0@!*1$
M$_=7WD!D&YE=N6.I<%;*LR2`^19-BJ!F]RWBQ.'3@DUTS:+Q5K+`(+`'F*OP
M'QZ!1&;G=@VB-@MHW!R!J5YK&_[JA0U985Q<(/!;P\WI#4OID14[^(#WEAF%
M]5LOA=3S8Q;'IW%Q!\FIK$'1@*'G-4JIA8X*J)_U2288ZE]%9,;#;6L`SNY7
M-5I8OB`508/7'RI=LL0NI(.T(Q1)2;D3&]Z"QDCE;MP'W[E9,OE&L!W,SJBV
MZPZJR6KDI]">1A!_I'U@AM'BF"I?4A*C&YM@MH+MO?N?;\%MO,FD<7VM6Z.#
M%(V07W/TI$(;'2ZM">F+GUNV]#6E;\):UO,4(R!MV*80D-'-B`1!E&QC9-FS
M;IE*`!HD@D4-?$1XCQJGZX5]9=:]ZYW!:G:ZH=4XXLZE2UDJ43XR8[-]DLUL
MQVSTM@LS26+314[;#+:1)*&VDA"$CQ)`'AXF/W/W[&+8O).3>-H^.CFJ[Y^_
M>KIMF;)FU2,NY=NG"QB)(-VZ)!,<YA`I2@(B->AAAZJ?134R%.5#B@E*4@E2
ME*,@E(&I).@`U)CZZRLI;?2.U]<XAFB9;4MQQ:@E"$(!4I:E$@)2E()))``$
MS%73N&;]I'<3<#O&&,Y%TPPE;L@=-1R@<[=7(\JS5$I9I^4HE/\`5ULJ018-
MC?M`T74#F$A4[+]@]C:?;^@3DF1-I<S*H;F`1,4B%#]6G_Q2/UJQP\Q)ES%5
M"W?*[W%;O+>',$P=YQG;"B>(*DDI-Q=09=LYP/JZ2)L-GC^M6.8I2W%Q4EX@
M1'ZX^/?2SYG%Q;)U(R4BZ08Q\>Q04=/'KUTJ5%LT:MD2G57<.%C@4A"@)C&$
M`"O4^^Q2L+J:E:6Z=M)4I2B`E*4B94HG0``3).@$?314=7<:MJ@H&G'JYYQ*
M&VT)*EK6HA*4I2D$J4HD```DDR$6:NW[V[(G!S",RWF6+8368WR*+V"@W2:3
MV/QDBJGS%!,!%1N[O`Y3Z+.`U*S_`&:(\W,H:N'?CO`56:/N8IB#JV<20HI<
M=22E=80>G@4L?11Q<\Y>DDB\_N?=S&W;5TC&XFY=.U4[D.I2MAA8"V[8DB8E
MQ2NL(/EN:AGS&CS<RSZ-]W<GMS##6:Q3A.097/EU9%Q'3%QM3HO8#'"IA,@L
M4ZA1.C*W:@'-R-RZI-#Z&6$3!TA_>R/=VN.7NLY1F3:Z;%`0MMHS2[5CB-.*
M&#TK/E+$PB0/./7WLN^[9-LJ>IV_VO>:KMPU)4V]4H(6Q;CJE0GJEVK3K)L3
M0RJ1=)4.S-9V1D7\Q(/I:5>N9*4E'CF0DI!ZL=R\?/GBQW#MXZ<*B91=PY74
M,<YS"(F,(B-6-4].Q2,(I:5"6Z9I`2A"0`E*4B24I`T`````X"*-:ZMK+E6.
MW&X.K>KWW%...+45+6M:BI:U*,RI2E$E1)F223'XZ]T?+$W/;(V%.+JDH;<=
MF2#%.THQ=.0QC:<JW,4US2C=0#MKODVBQ0U@8U4O,R3.&CM<`5TZ1"]2&?>0
MWQ;M=,]M[B+T[JZDIK'T']2@C5A"A_2K&CA!\A/D^<3RVF]Q;NCO9!6TV].Y
M5*4X\PL.6RD=3_O+J3--6X@__;MD39"A)YP!?ZM`[2;/<W#3UQ;=\WPEL$75
MGY3%]Z-8Q!J)_272ZD$\YF;<$P$YUWJ0&2(4/?&.`>6H:[;UE#;\_LU;<BD4
M+=RIU+*N"0'$^49]"3)1/0!.+1-]K9=[ULQE-JL(6J[OV&M0TE,^9:BPOR$R
MU*EB:`!Q)ETQ!_?]RVE</:'Q4QM-=J@\M?)%LVY=31,4_28R[4IZ=>/SR"'`
MY%GQ7:;LG/[])4H_JFA8K==:#O6W-^Z)4IFIMSSK*C.2V"TTE/*>D)Y2@RX*
M28JTS"^8]>?PZ[%2XZMM%10WNGIZI`ES-U8?J%N%Q/$%P+2\F?%"P8R38]HW
MW([[<3V%O&RM)3KRPX>.O;;;)1MO05LVOD!T9)!V2/<.FS9%TW?-EF@`9J)E
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M6<3UU!J+<84A"D(4A"D(Z-D/)F/\36T[N_)-W0EFVXR*859*;>IMBJG``$&S
M%OYSN1>GU\Q!NFHJ<?`HUS=@QN_93<46G':1ZKN"^"&TDR\*CYJ$CI4HA(Z3
M&*9GG6(;>61S(\VN-+;;,T-7'EA,S]%"=5N+/0AM*EGH28@YW+]X=\Z%_:NV
M.`]`;#SMSY/O!B51\H`@`"O;-J+\R+0-=>1>0ZAA#Q;%'0:FGMSW2F&@W<]R
M'^T<X^IL*DD>!Y\:J\*6I#_Q#%56^7XDE4^7K!L92=BSJDW.K0"X=/.IJ54T
MH\"ZCF/6PDZQ";>U^7IDBX'EUW]=,Y>%QOSB9U,7!(N))X<!,)@23.X.8K=L
M01\Q),")$#@4H!4R;-8[/CU`BUV*F8I+>@:-M("$^,RXD]*C,GI,5=93EV49
MM=W;_EU?57&\O&:GJAQ3BSX`5$\J1\U*9)2-$@".IURD8Y"D(4A#_P`']T?`
M/UC2/,I\(WEV]]O/<CN#]!E8ZUOJ'8[HP&->U^$<0[)5OXBK$0PIC.S?,'O#
M)(%;F'Q6*&HAI7/=_-O,"YZ6HJ?7KTD?[O32<4#U..3[-OPA2N<?0,2LV<[F
MV]>\1:KZ.@_9.+.'_?:X*904])9:D7WOS2AOLR>+@U(G2V\=KS;KA3Y.G+KC
MU,Q7TT%%Q\L7BW2^K;%ZD8B@*0]G)G5C2E(H7S3/3/5`TU`2^%0GS_O+9_F/
M:45K<%HLBYCLZ<GM5),Q)Q\R7PXAL-CH(,6O;-=P[9G;#L;ID#)R3*F^57;5
MB1ZLA8(,V:,$MR!&A?+ZND%/")(D446Z*3=NDDW;H)D20003(DBBDF4"D322
M3`J::9"AH`````5'A:UN++CA*G%&9),R2>)).I,39:::8:2RPE*&4`!*4@!(
M`T``&@`'`#A'LK\Q[(4A$#7='WU':A+;9,03(D<'(9IEVZXQR8IT4S@'-8,6
MZ1$!*HJ0?\:J$-P*(-O$5@"<7=HV3#G9;CY8S-`/-0L+'$_XE:3T`_J01Q':
M?0,5)]_3O7JI_6-C=N:F3I!1=ZII6H!XT#2ATD?[TH'@>P_K0(!ZG3%0<2V]
MHW;_`"U^9P6S4_;JM[.Q(W=$:.S$,5.6O2:8+,F4:V4U`#!%QKE1TX$->7F2
M*/[34(K=ZO.Z6QX6,.84%7>ZJ3S)GJBG;4%*61^>L!">N2S\V+$_PZ]G[CEN
MZ:MSZM"D8WCJ%<BR-':UYM2$-I/_`(3:U.N<9?9CY\Q9PJMV+U84A"D(4A"D
M(4A$0V]7N@VGB$LMC;`[B-O?*"8KL)6Z="/K-LA<`,DJ5)0A^E<EQ-CZZ(D$
M6B!P^%,<P"D,K]G.[5=,K+619NERBQLR4AG5-14#B)CBTT1\X^6H>:`"%Q7)
MWG^_ACVW*:C"=IULW3.@5-NU6BZ.B4-"$D&534)/!(FRV1]HI9!:BM]=MWW1
M?MQRUW7I/2ES7-..E'LM-S#M5X_>N%!$1,HLJ(\J:8>:FF4"II$`"D*4H``6
M&6JTVVQV]JU6=AJFMK"0E#;:0E*0.H#I/$DS).I))G%)N1Y)?LNO51D635;]
M=?*IPK=>>65N+4>DD]`X)2))2D!*0$@`=<KD(X2%(1,CL6[8LUD]2'RON$C7
MUNXV$J,C;]AK"M'W'>X")%6KJ9()2.(2U5B>=RZD=O"CH7IIB!S1&WL[R-%C
M27<7P)Q%1D6J':D24U3="@WT./#A/5#9X\RARBR_NH=Q6Z9TY3;@[PLNT>%2
M#E/0GF;J*W@4*>$@IBE(UEY+SP\WD00M5CR*BHR"C(^%A8]G$Q$4T;Q\9&1S
M=)HP8,6J946S1HU0*1%!N@D0"E*4```"J]*JJJ:ZI<K*QQ;M6ZLJ6M9*E*4H
MS*E$ZDDZDF+K;=;J"T4#-KM;+5/;:=M+;33:0AMM"``E"$I`"4I````D(^A7
MHC[(]2ZZ#5!9RY62;-FR2CAPX<*$10;H(D%159=90Q4TD4DRB8QC"`%`-1K]
M(0MU8;:25.*(``$R2=``!J23H`(];SS5.TI^H4E#"$E2E*("4I`F5*)T``!)
M)T`U,14[B>[-A'$\@^M?&$8XS1=+(ZK=V_BY!.)L5@Z3`0%+ZQ&;O%YHZ:O`
MP,D#H#H.B^H:#*#`.ZSF>4,(N62N)L]L6`4I6DKJ5`]/932&P1_6*"OS.F*_
M]YOQ#-KMO:MVQ8*PO)K\T2E3C3@:H6U#H]8Y5J>(.A[%LMG63LQ*(])7O-[E
M7+U16'L7#L4Q-^R9NX:ZY9=,-1]^]+=D<"H\H@'[(OA6^Z7N@[=-LA-76W=U
M[I4EQA`/\WL%R^L8AM</Q--[GJI3EMM6-L4AX(6Q5NJ'C6*QN?U1&:<3]ZB4
M^46;'-N)8TT6LHDDZN+'#]V@\9%,<`4=&MN>7=IODTRCJ)"/DCZ>&H\!P_*>
MYW2^KK>PVZN"I`)2U5I24JTT3VK024D]9;4/$-1L_;W\3VN]<:I-T,>8-"H@
M+J+<M:5HF=5^KU"EA8`UY0^@]4SH9M<4Y<QWFVS8Z_<8W.PNFVI'4A7303IN
M63LA2BO&RK!<J;R+DVHF`%$%B$.&H"`"40$8:91BF089=W+'DE,NFN+?S5:A
M23P6A0FE:%="DDCHX@B+2-O]Q<,W2QIG+<%KFJ^R/:<R)A2%B7,VZVH!;3J9
M^4A:01H1,$$Y(K'8S:%(1")WF,X!#6786`HAV4'UXO/KQ=R*1PZB=OP:YFUO
MM%RE'4$I*;ZJP`/`18Z^Y4SNZ%A?K=WKLZJD?8TB/5F"1H77!-U0\*&Y)G_X
MGCBK+\3'=3]F8S:=H[<X/6KDYZ]5@'44["BFG0KP./\`.L>%@'JBN[4_8IDC
M?3MIXS-DK=[C3JH=:+L-5]D65$Q1,0GU90YX?F'WO,:X7+30!]\4#>Y6CN\5
MD8QS:>X\JI55<$TB.L]L9.?^4'/EE$N.X_@RLW[QEC+B>:@M*EW%W30>K)FS
MX/\`>5,Z=(!BW354L=C"%(1A/<!GRP=M^-9C)>0'HIL6)?1HB&;'3^5[GG5B
M'%A!0Z)Q^$=.CEU.<?@T$@,H<0*4:S+`\%ONX>1,X[843>7JXX9]FRV/.<</
M0!T#BI4DC4QJ[>#=W$=D\(J<WR]V5*T.5EE)';53Y!Y&&0>*E$34H^2V@*6J
M24F*@&X?<#?VY3)<QDB_7IC+.CJ-8""15.:)M2WR*G.Q@8E(V@%10*;F55T!
M1RN)E#\3:!;)@.!V+;O'&L>L:)(2.9UT@<[[I'E.K/6>"4\$)DD:".M_O-O#
MEV]^<5.:Y:Z2XX2FG823V5+3@DML-`]"09J5+F<65+5JJ,&UFL:HC)6(L2WQ
MG#(%OXTQY$*2]RW"Z!)$GG$9QS),0,^F)9R!3$91,:@(J+*F\````!,8I1QW
M*\JLN%V&HR._NAJW4Z9GZ2U'S6T#YRUG1*1XS(`D9QMSMWE.ZF84>$8=3JJ;
MW6.2`X(;0-5O.JX(:;3Y2UG@-!-12#;YVI[7[(VK8Q8V/;":,A/O01?WQ>!V
MY4I"ZI[IB"BYQ$3*(13'G%)DVUY44@U'50ZAC5/;H;EWG<[)%WFY$MT")IIF
M)S2RU/0=16KSG%\5*_-"0.QYW?MA\6V!P5K%K&$O7=T)<KJPIDY5/RU)XE+3
M<REEN<D)U,UJ6I6`>XWN[1VV8F5MFTY(B>7\DLW4;:Q$3$,YMN#.(MIF\5B#
MJ*1VR9C(,1$//>&`P:E1.%9UW>]J%[AY2+E=&R<3MRPMZ?!YP:MTXZYF2G.I
ML2T*TF-0=]7O&-[);>JL>/OA.XU[;4W2@$<U,P?)>K".@I$VV)\7CS"8:6(J
M>JJJKJJ+KJJ++K*'6666.915954PG4554.(G444.81,81$1$=1JT=*4H2$(`
M"`)`#0`#@`.@#H$=>UQQQYQ3SRBIU1))))))U)).I).I)XQX5^H_$6G>UQM>
M#".%B9(NB.%MD?,+5E,.B.4^5W!6643.+;A=#%`[=6034!^Y)X\ZB9#!JD`!
M63WF-R_WSS`X[;7.;'[2I38D?)<J.#SG40@CLT'J"B-%1?QW"]AAM;MD,UOK
M/)FF1MH>4%"2V*+SJ9G4`I+@/;N#C-2$JU;$I0*C5$\(KN=T7?,-VOY7;3B6
M9`UJQ3KT7*=RQJX\EQ2[-4#'LU@Y2'16%BG"8"^.41*Y<EZ7$B9N>?\`W:-E
M/V2PUN+E+,KHZF=$RL?JFU#_`'A0/!Q8/V8.J$'FXJ'+3)W\^];^\574;(;>
M5,[!3N<MTJ6U:5#R#K1H4.+#2A]L1HXZ.2?(VKGA%J9D591R`"80*4!,8P@!
M2E`1,81'0```U$1$?`*\$@"9X1Y`*B$I$U&+'W;=V-1V'(!MN1SFR:1M\/(T
MTC:$1<)D&C3'-NN$.<UPS`O3$09W+(M3:@*HE&/;&T'E5.?DKV[P^]51EU<K
M;O"EK<LR'.1]QJ:E5;H/ZIOEF5,H5]']:O75($[K^Y-W5*+;6SHWLW6:;8RA
MQ@N4C-04H1;J=29FH>YY)14N(,P52-.V9'E<4KDQ7OI[I#5XSEL1[8IA50KH
MBT?=67F8J(:)&,=%S%6$)R$5$52`)5)7AYIA!L&NBP9/LGW9W6'FLKW)9`*2
M%,T*I'70A=3T:=#/WG2B,![U_?UIZFEJ-N]BZE12X"W57=$TZ:A35#H#J-%5
M6FADQT.Q`L<YU#G44.=110YE%%%#&.HHH<PF.<YS")CG.81$1$1$1'6IQ`!(
M"4@!($@!P`\$5'K6MQ9<<)4M1F2=22>))ZX\:\Q^8F.[>G;F>96<PV;<Z1*S
M'%[95&1M"S'I%&[[(+ANL51O(2J!RE4;684Y-0*.AY'P#1'4QXC[^=X)G%VW
ML-PIT+R50*'ZA,BFE!$BE!X&HUX\&NGR]$V6]S?N6U.?OTNZ.ZM.IK!$*#E)
M1K!2NX*29I<=20"FB!'#C4\!)J979'33:1[1))(C9@P9()((I)E2:LVC9$A4
MD4$B%Z:*""*90*4H`!2@``'"J\%*=J'2M14X^M1))FI2B=22=223J3Q,7:(1
M345,EIL-LTC2`E(`"$(2D22`!)*4@```2`$@(]Y3%,4JA#%.0X`8AR&`Q#%$
M-0,4Q1$I@$/<K\$$&2A(CKCW)4E:0I)!21H1J#$6V5M@EYP-_7!E3:5D"W+`
M?7<\&6O7$>08%O<F)[DERJJ./E)"+<Q\NUCG)EE3G(4S-04%3F%!5`IA+4F<
M7WUL]=8F,9W4H*BN9I$<E/74KA:K6FY`<A6%MJ6)``D.#F``6E9$X@5N!W1,
MEM.6U>>]WN[T=HJ;BYVM;:;@PFHM52[,J[1+2FGD-JYB5`%E10HDM.-))3'7
M+EP/W&\W_)\!DO(&WG&4$S+T5+KL&V%Y:^6;-7D*X3MIZ_8*O(9T<J8>>T>Q
MXAP$#\`"N1MV<=WS"^TK\<H+_<JU9F&*EX(IE*$Y%Y*5!+B=>"VW?%K..#O6
MTO?1W3[&SYU=\.L=I;$C5T%,IVN0@RYA3+<;*V5&0U9?ICU*T`C/)>W7@(FW
M1;;R1&:*W<S3:\W&1"N40OA?(S)H[9L[T5=@GZ,HNU;/UVZ;42=`C18Z8>>8
M51P4]X#.CN`,^*F2M+)IQ2R/JXI%*2I5.$SF`5)2LKGS%:0K@`F-N)[F6T:=
MF5;.I34AI=2FL5<>8>NJN*$+0BL*I<A*4.+;2T1V8:6I`\I1<C?2M'1+:%(0
MI"/0Z=-F+9P]>N6[-FT14<NW;M9-NU:MT2"HLNX<+&(D@BDF43&,80*4`U$:
M_;33K[B664J6\L@)2D$J).@``U))T`$>FHJ*>D87552T-4S:2I:UJ"4I2D3*
ME*)`2D#4DD`#4Q$-NG[LN.,:C)V=@5JSRA>R`K-%KK7,H7'L&Y+YAS-UD3I.
M[K<H'UT!N*;03!^W.&I:EAMCW6<@R+L[OG*EVVS&2@P)>M.#P@@I8!_/FN7S
M!QBN3?W\0O"L([?&]I$-WW*$S0:M4_V>PKA-)!"ZI23T-E+,Q^M5JF*^^7<W
M93SM<RUVY5O*6NR6.=46J;Q;IQ40BJ83"S@X=#IQL2T+P`"(IEY@`!,)AXU/
M#%,,QC"+:+5C%&U2TH`YBD36LCYSCAFM:O"HGP2&D4];C;J9]NQ?%9#GUSJ+
MA7DGD"U2:923/D993)MI`^BA(G(%4SK&*JRB->PI"%(1R4!,8I2@)C&,!2E*
M`B8QC#H4I2AJ)C"/@`>-"0!,\!'E*5*(2D$J/5$@>W?ML;C<]E8S;J$)BZQ7
M0)+%NJ^V[IDY?-%`$P+05M%(67D^<@:D.H#9N8=/A:T/G_>(V^P8KHVWC<[V
MF8["F*5!*AT./?JT>$#G6/HQ,/9GN1;T[MAJYU%*+#BKDCZU7)4A2T'I8I@.
MV=\"E!MH_P!;$\&W7MQ[<]OWH,R:`_G+OQJ!3C>%]-VT@5JY`>8%8*W!*I#0
MXIFTY%.19R73]L-0@W`[PFX&=\]('_V=9%?T%,2F8ZG'='')](FE!^A%M.S'
M<JV7V@[*Y*I/VYEC>OK=<E+@0KK8IM669?-5);H_K8WY#0```````````T``
M#@```<```K1?AZ8ET``)#0"%(\PI"%(1'EW#MXB&V'&'R):CY$<Q9!:NV-H(
M%$BBEMQ>@MY*\W20\W+Z`)^FR*8-%G8@/$J2@5OW8+:1>Y.2>NW1!_=*@4E3
MYU`=7Q13I/YTIN$>:CJ*DQ#3OE=Y)G8K!/V5C[J?B1>&UHI$B1-,UYKE8H='
M)/E8!$ENZR*6UB*FSITY?.G+YZX7=O7CA9V\=N53K.73IRH99PY<+*"915==
M8XF.8PB)C"(CQJTMIIMAM++*4H90D)2D"02`)``#0`#0#H$=>BHJ'ZNH75U2
MU.5+JRM:U$J4I2C-2E$S)422229DF9CL5D69<61;PMJQ+2CU)2Y;MF6$#"L4
M@$17?2"Y4$A4,`#TFZ(&%14X^:FF4QAX`-<?>;O;[!::F]W5P-6ZE94ZXH]"
M4"9EUD\$CB20!QCFL5QF\YGDE#BF/,J?O=PJ6V&4#YRW%!(GU)$YJ4=$I!4=
M`8N@[;L&6_MSPY9V*8`$5C0;$%Y^622Z1Y^Z'P%6G9I;4`.(NG?FI`;B1!-,
MG@4*I]W$S:OW!RZKR>NY@'ER:03/LF4Z-MCHT3J9<5%1Z8[..R6U-HV7VUMN
M`6CE4JE:YJAT"1J*I?E/O'I\I>B)ZI;2A/S8SG6$QM>%(0I"%(1TO(&1+(Q7
M:DI>^0[EB[3M>'2%5[+2S@J"(&Y3"FV;)^<N^?.!*()((E.LJ;@4HC7,6''[
MSD]T:LU@IG:JY.F24($SX23P2D?.4HA(&I(C&,PS/%L`L#^49C74]OL5,F:W
M75<HGT)2/.6XK@AM`4M1T2DF*X6\_N@WEF@LGCO"!I7'^+E@69R<\8PL;VO5
MN;5-1-55NJ8UN03@G_1T3^D+%'14X%$4@L+V?[M5HPXMW_,PU7Y,)*0WYU/3
MGB"`1]JX#\]0Y4GS4D@*BE'O-]_')=S0_ANUIJ+1@:N9#KY\BMK4\"%%)/J[
M"A_1H/:+!^T7RDMB)/\`[O[H^(_W:E1%=I,]3QA2/$?:MRVY^\)V*MBU8:1N
M&XIMXDPB(6):JO9&0>+F`J:#9LB4RAS"(ZB/O2E`1$0`!&OCN%PH;31.W*YO
M-L4#*"I;BU!*$I'$DG0?\YT&L<K9+'>,DNU/8K!3/5EXJG0VTRT@K<<6K0)2
ME())_D`F3(`F+&.Q_M?0N+CQ&4]PK2,NC(:8H2$!80]*1MJRW!3%5;NY<_GM
M;@N-`P`(%`#,VI_>]4X%4+7WO1WE:S)0[C&!+<IK"9H=J=4/5`X%+?2TT>O1
MQ8X\HFDW2]U?N'6S`U4^?;QML5V8IY7*>@T<IJ-0U2MXZHJ*A)D0-66E>;VB
M@%B9+_N_[P?H"HB19=PT'"%(1C_*&4;%PU9$UD/(T^TMRUH)#J.GKD>99RX.
M`@UC8QH35>1E7R@<B*"0&.<WD``$0Y[&<9O>7WEFP8\PNHN;ZI!(X`?.6M7!
M"$C52C(`>&0C#L]S[$]LL6JLRS6L;HK#2)FI:M5*4?-::0/*<=<.B&T@J4?`
M"15_WG=Q+(VY=[(6?:*K^P<+I+JHM[>:KF0F[O0*?X-]>CQLH(*)*`4#$CDC
M>C):^>*QP`P64[0;`8_MRRW=KJ&Z[,"`2Z1-M@RU33I(T(X%TCG5\WD&D40=
MYKOFYIOA5/8WCBGK1MFE12FG2KE>JT@Z+K%I.H,@13I/9(^<75`*$<52$B$\
M*0A2$;R;!]U$KMDS7$+2$BN7%]\O6-OY%BC&$[-)JNH9".NA)$QBD2D+=<N.
MH*@:&.U%5,>`AII;?/;&EW(PYU##:3DM$A3M(OYQ4!-;)/2ET"4CH%\JN@SE
M9W1=_KAL;N?3.5CZQ@ET=13W%HF:`A1Y6ZD`F0<IE*Y^8:EHN(^<)6]DU$U4
MTU4CE525(15)0A@,11-0H'34(8!$#%.40$!#Q`:J>4E2%%"P0L&1!Z".(CL=
M(6AU`<;(4VH`@C4$'4$'J(CSX!Q$0``XB(\```XB(B/```*\<=!QC]$@"9X1
M3/WM9F'.VYC)U[MG/I,"WF3VK:9BCJE]6K7$T4P61\-$Y!5%5UX!^WX\:M[V
M:Q#]R-N;;97$\M<ID//]?;/>6H'PH!"/YL=9KO2;F'=C?"^90POGM**DTM(>
MCU:EFTVH>!PA3O\`K#&J5;0B/D6!.RIC(S>&S)F%X@)?E)_#8]@U3$$!,C&I
M#/3YTS"'%,Z[YD34O#F3,`^%00[XV2!=7:,2:5^K0Y5.#PK/9-3\,DN'Q$'I
MBX3\+_!E-6S)-QZE,NV=9M[!(Z&QV]01X"5TXF.E*AT1.S4(XMDCHV2LD69B
M*R+AR)?\TW@;5MEBH^DGRX\RA]/-;L6+<!ZCV2?KB5)N@34ZJI@*'C7-XYCM
MWRN]4]@L3*G[G4K"4)'#PJ4>"4)$U*4=``28Q/.,WQG;G%JS,LOJ44E@H6BM
MQ:N)Z$H0GBMQQ4D-H3Y2U$`14,W?[L+PW89,<75+]>(LN%,XC[`LT%Q.W@H<
MRFHNW@%'HN;@E@*51VN`>(%3)\&F6K7MI]KK3M=CB;72<KMX>DJJJ):NN2\U
M/2&D:A"?&H^4HQUR>\AWA,D[P><KOUPYZ;&:8J;H*/FFEAF?G+EHJH=D%/+'
M3)"?(0F-3JVE$>8[%:-I7'?ESP5FVA$/)ZYKEDFT3"Q#!(RSI\^=J`1),A0X
M$(743*'-H1-,HF,(%`1#C[K=;?8[:_=[LZABVT[96XXHR2E*1,GQ]``U)(`F
M3'-XYCMZRV^TF-8Y3NU=\K7TM,LMB:EK69``=`Z5$R2E(*E$)!(MJ[&]F5O;
M3L?@,@5C,Y;NMJ@K?=SHD!0C8O,"Z-JP2QR@HG"1A].<P:"[<%%4P:`F4E6&
M]6[]?NE?94Y6SBM*HBF9.D^@O.`:%Q?0/F(/*/G$]B#NJ=V:S=WS#PJL#53N
M)<&TFNJ4ZA(\X4K"B)AELRYCIVS@[0@`(2C:[)61+5Q-8=TY'O60)&6S:,2Y
MEI-R;05#D1`"H,FJ8B'7?R#DY$$$PXJ+*%*'C6K<<Q^YY5?*;'K,V7+E5NA"
M!T"?%2CT)2)J4>A()B06<9I8-O,2K\TR=X,6.W4ZG75=)EYJ$#YSCBBE#:>*
MEJ2.F*9.XK.ET[C<N77E2ZSG36FG8H0D0"IE&UN6TS,=.%@6>HB`)LFPZJ&#
M3JN#J*#Q.-6_;?X3;-OL5I<8M8!0RB;BY2+KRM7'5>%1X#YJ0E/`1UEMZ-U[
M_O3N)<,^OY(<JG.5EJ<TT],@D,L(\"$^<1Y[A6LB:C&$*S.-5QOCV\]L1]R>
M>(Q.::G4QSCH65WWTH8OP+]-!UK"6SS"'*)YZ00T4+X^B)+"''0:TAOYN2G;
MO"'54:@,@N',Q3#I22G[1[_5).A^FI$2V[FVQ*M[MV6$7-!.&6;DJZXRT<"5
M?8TT^$ZAQ,E#CV*'2-0(MU$(1(A$TB$223*5---,H$333(`%(F0A0`I2$*``
M``&@`%52*4I2BI1)43,D\2>N.Q@A"&T!ML!+:0``!(`#0``:``<!$9_<JWAC
MMUQF2P['DR(Y>R6S=-8Q9`P&<VA:H@=M*70;0=4'[@PBVC]0_;"=4/V.@R.[
MNNTG[_Y&;[>FR<4MRP5@\'WN*&?"D>>[^;)/S](-=]_O)?!G!QB6+/A.XM[:
M4EM23Y5'2F:7:K\UQ1FW3S^?SN#]5(U5CG.H<ZBASJ**',HHHH83J**',)CJ
M'.81,<YS"(B(CJ(CK5G8`2`E(`2!(`<`.H10"M:W%EQPE3BC,DZDD\23TF/&
MO,?B/M6U.+VQ<<!<C5JR>N;>FXJ<;LI)$7$>[7B7R#]%L^;@8@KLUU$`*H0#
M!S$$0U"OCN-$BY6]^W.J6ANH96V5(,EI"TE)*3K)0!F#T&.4L=U=L5ZH[VPV
MTZ_1U33Z4.#F;6II:7`EQ,QS(44R4)B:21,1LEN`WI;A-R2BS7(-Z+-K5.L"
MJ%B6PF>"M)$2"84O2&"*JCF743YN!WJS@P#Q#2M>8)L]@6W:0[8:-*KF!(U+
MWVCYGQDH@!`/4VE`ZYQN[>#O/;Q;V+53YA<U(L!5--#3`L4B93ES-I)4Z1T%
M];A!U!$:IUL^(^QR4ICF*0A3'.<Q2$(4!,8QC"!2E*4`$3&,8=``.(C7@D`3
M.@$?I*5+4$(!*R9`#B3$ZFP3MDN912%S3N3@SM8H@MI6RL5R:0D<R8@(+M9N
M^&BA0,WC^!3H1I_/6#SG`%)HF>$^^G>/;I4O8=MX\%57E(J*U!T1T*;IE#BK
MB%.C1/!N9\H6P=T/N+O5ZZ;<[>RE+=`.5VBM;HDIWI2]6H.J6^!13'REC5X)
M3Y"YJ,U9JQUMUQQ)Y!R!)(P]OPR!&L=&M"HA(3,ATC!'6];\>!D@</G()\I"
M%Y2))E$YQ*0HB$.L-P[(-P,A;L-B;+M>\KF6M4^5M,_*==5K)(G,DS),@`5$
M"+/=S]S\+V8PI_,,O>336>F0$-M(Y>T><E]G3T[<QS+5*0`DE*05**4))%3+
M<]O#RUN<O:0GK@G)6!M!)<Z=K8^BI5XC`P,:0X^C^D(H*((RLRJ0`,X=JD$Y
MSB($`B8%(%INVVTN*[;V9NAH&&G[J4@O52T)+KJ^F1()0V/FMI,@-3-4R>O-
MOOWD]P]],H>NUWJWZ3'$K(I;>TZL4[#8/D\R04I=>(D7'EIYE&83RH"4#.7;
MOW796Q;G/'N./K',W!C3(=T,+6FK/DW3B39LG,ZJ5BSG(,KDZJD4^8O#IJ*]
M$2)K(E,"A1X"7"M_MKL7R;"J_(/5V6,BM],IYM]`"%*#0YE-N2`"TJ3,)YIE
M*B"DC4':O<T[P>X&![JV?"S6U-7A%XKVZ5ZC<4IU"%5"@VA]@*)+2VUE*E<D
MDK0%!8.A3:['@(A[E5=1V#84A"D(4A"D(UAW)[N<-;7+?&2R%.E=7&[;G5@+
M"A%&[N[9XX:E3.FQ,J0L=&BIP.[<BF@7B!1.8.4=E;=;4Y?N97^KV%CEMR%`
M.U+@*6&^L%4O+7+@A$U'ID-8T1O?WB]M-A;.:W,*L.7MQ!-/0,%*ZM\]!""0
M&VYZ%YPI0-0"I7DFM-NIW^9JW0.74.\?&L3&0J&!ICRW'BY6CU(IM4EKID]$
M7-Q.]``>4Y4VI#>\2`>(V+[8[%X=MJVFK91Z[DDO*JG4CF2>D,HU#2?")K/2
ML\(H\W_[WNY^^[[EMJ73:L&YO(M],M00L#@:IS150OP*"6@?-:2=3HS6ZHBC
M"D(4A'(`)A`I0$QC"!2E`!$QC&'0I2@'$3"(Z`'EH2`)GA'D)*CRI!*C$A>V
M_MJ[A<^@PG92*_FIQ^ZZ:H73>C1PA(R#4W'J6_:VJ$K(@H4/,56]%;&\B@UH
M/<+O%8#@I714SO[4OJ9CL:=0*$JZG7M4)ETA/.L=*1$RME.X_O'NYV5UKZ?]
M@8@Y(^M5J%)<<0>FGI?)=<F."E]DT9Z.&)Z=N?;TV[;=O0I=C;WU_OUJ4AC7
MS?"#:1=MW)0'F6@H82&B($-1U*9,BC@NG[8:@YN#OYG^?\](\_ZC8U?_`&U.
M2A)'4ZY/G=\()"#]`1;?LOW-MF=F>RN-+1_M?+$2/KM:E+BDJ'2PS+LF/`4I
M4Z/ZTQO1XUI.)70I"%(0I"%(1C?+V5;1PECFZLGWP^(RMZU(Q9\N7G*5S(NQ
M#IQT/'D-Q6DI9Z8B")`\3GU'0H"(9%B>+W7,LAI<;LJ"NOJG`D=2$\5N+ZD(
M3-2CU#KC"-Q]P,=VNPJX9UE+H:L]O8*U"8YG%\&V6P?.==64MH'TE3,@"13.
MS]FZ[MP^5;HRI>:NDA/.N2.C$U#G9V]`M1,G#P$>!_!M'-=`$V@"JJ)U#><<
M:M[P7#+5@.,4V,6@?8,)\M9$E.NJU<=5X5JZ/FIDD:`1UF]W]T\BWES^OS[)
M5?WNK<DVT"2BG83HRPW/YC:-)Z%2BI9\I1C#=9=&LHGW[06UD$4)/=!><:/5
M7!Y;>*6[M(P=-`!.VN6[4R'T`17-_(6AP`0Y2N!#Q*(06[V.YO,MO;6T.>2G
ME>K2D\3H66#+J_6+'66QT$1;W^'%L$&VG]]LF8^T5STUJ2L'0:IJ:L`]?ZAI
M4N`?/2DQ/-4'8MMA2$*0A2$:);M-_F']K;-U"*.$K\RJHW.,?C^#>I<\>J8O
M\G<W?)D!=*WV0F'FZ8E.[5*'F):#SAN_:S8G+-RWDUH2:'&`H<U4XD^6.D,(
M,BZKHG,(2>*IZ&)O>&[WNW&PM,Y:U+3=L_*#V=O86/LR?-55NCF%.B>O+)3R
MAYK<O*%9;<3NBR]N=NHUQY+N`ZS%JLJ:WK0C!5:6I;#=3S01BHSJ'`[D4P`%
M'2PJ.5OX1]-"A8[@&VF*;;VP6_'&`EY0':OKDI]X]:URX3X(3)">@=,48;S[
M];C;ZW\WK-ZPJI$*/J](U-%+3).G*TU,^5+13JRIU?SE2D!KQ6?QIB%(1LGM
MNVI9>W1706"QU!F)"M'":=R7Q+)K-K3ME$X<YA?/RIF]*?F2#5)F@"CA0=/-
M*74X:[W#W0Q/;2V&NR!\&L6DEJF007WCP\E,_)3/BXJ2!UDR!WALEW?=QM^;
M\+5AM(1;&U@5-:Z%)I:9)UFMR1YERU2RWS.*T\D)FH6@-I^R3$NU&%*I;[4+
MHR*_:E1N'(TRU1^57','PS"";_"DMZ%YATZ*1A45T`5E%!`-*UMTMYLIW0K.
M6N5ZMC[:IM4C:CR#J4X=.U<_.4))^8E.L[X.[WW6MO.[]:PY:&Q7YF\W*HN+
MR1VJI^<VPG44[/1R()4N0+BUD"6Y5:AB3$*0C'66,K6/A.P;@R3D292A;7MU
MKUW2YM%';URH/(RBHIIS`H_EI)<0301)Q,8=1T*!C!D.+8O>LROK&.V!DO7*
MH5(#@E(&JEK5P2A`U4H\!X2!&%;A;@XKM=B-9FV95*:6Q4;?,I7%:U'1#32.
M+CKBI)0@:DF9DD$BH_N\W?7]NROLTU.&6@[%A%ET;&L1NY.=A#,S&,7Y1D>4
M02D;D?I"'I#D2^:&B2?*F7C:KM1M/8MK;)ZG1`/WMX`U-21)3BOH(Z4,I/FH
MGKYRIJ.G78[QO>.R[O"Y8;G="JEQ2E4I-#0I42VR@D_:.2T<J7!^L=EH)(1)
M`UU'K:L1SCL5IVC=%^7%%VE9D!*W/<TVY*TBH.%9K/I%\N8-1*BW1*8W*0H"
M8YQT(0H"8P@`"-<?=+K;;';W;K>'VJ:VLIYEN.*"4)'A)_(!Q)T`)CF\=QN_
M9;>6,>QFDJ*Z]U2PAIAE!<<6H]`2D$Z#4G@D`DD`$QD_,FVS.&W\\.&7<>S%
MG(SY#&B'[A1A(Q;U5-,JJS-.4B'C^/+(()G`QVYE"K$+Q$NE8WB.XF%YV'?W
M4KV:M;!^T2`I"T@F044.)2KE)T"@.4]<9UN7LCNGL^JF^(MGJ;:U5C[%:BVX
MTL@`E`=96XWVB09J;*@L#4IE&#JS2-51P(:@(>Z&E(\C2+G^RZ^7>1MJV#;J
MD'`NI)>PHJ*DES&YU57UN@I`+J+F'43+K#&@<XCQ$QM:I^WBLK6/[G7JV4Z>
M6G%<M:!T!+LG0!X!SR'BCLX=V+*JC,]@L5OU8OM*U5I::<5.9*Z:=.HJ/TE=
MES'K)G'Y=Z^8"X/VRY4O=%P5":5@5;8M?4P`H>X[I_Q-'&1XE$QV17)W(Z<0
M(@80\*]NS>)G--R+99EIYJ,/AY[J#3/VBY_I2"/&H1\_>AW'3M9L9?\`*&UA
M%S52&EI>LU-5]BV1X6PI3IEKRMD]$4R^(\1$3"/$3".HF$?$1$>(B(U;YXN$
M=9<DDS/$QQ2/$7#^WQCHF--HF'8LS<6[^X8`;ZE0,7E.=[>*ZDRD8X#YP')'
M.$":#Q#ETX>%5*[]9`K(MU[O4A7,Q3O^K(_18'9F7@YPH_+'9,[G6&(PGNZ8
MW0E!15UM)Z\Z#QYZQ1>3/IT:4VG7A*7@C;N<FXBVH:5N*X))G#P4''NY68E7
MZQ&[*.C6")W+QXZ6.(%31;H)B8P^X%:HHJ*KN58U;Z!M;U:^XE#:$B:EK49)
M2`.)),A$C+K=;;8K947J\/MTUJI&5NO.N*"4-MMI*EK4HZ!*4@DF*H&_G>Y,
M;I[V&WK76=Q>%;/?K!:L483H+W._3YT#WA.H\/AW!!,5DW-J#5N;C\(<XU:-
ML9LS1[96;U^Y!#N8U:!VR]"&4G4,-GJ&A<4//4/HI3'7P[W?>DN>_F4FS6)3
ME/ME;7E>JM&:55+@FDUCZ?I*$PRV?U39U\M:XCUK?<0VC]#1HZ?NVK!BV7>O
MGKA%HS9M4CN'3MVY4*BW;-D$BF46776.!2$*`F,80``UKUNNM,-*??4E#*$E
M2E*(`2D"9))T``U)/`1[Z:FJ*RH;I*1"W:IU:4(0D%2E*40E*4I$RI2B0``"
M23(:Q:/[=.Q1IMUMIOE'(\>BXS7=D63E:+D35#'4&]3!0T$T-YX!//4S!\H+
M%'4FG0(/*4YE*T.\#O:[G]Q5C./+*<.I7/.$QZVXDR[17_A)/ZI)X^>=2`F^
MSN7]T^GV9L:,\S5E*]SK@P)(4`?V<PL3[!)U^W6"/6%CS?U*=`LKE&J,\3UB
MM[W:-V)KZO-/;A94@4]HV!((O[]>M%Q,E.WNFB(H0QC)FY%&5J)+B"A>("^.
M8!XHEJPWNL;6BQV<[A7ALBZU[933)4-6Z<G5S74*>(T/]6!+SS%)OXAW>%.5
MY*-E<8>!QVT/!=>M"IA^M`T9TT**4*(4-9OE0,BTDQ#)4OHK)C]#1HZ?NFS%
MDW6=O7KA!HS:MR&57<NG*I46[=!,H"91998X%*4.(B.E>MUUMAI3[R@EE"2I
M2B9`)`F23T``3,>^FIGZRH;I*5"G*EU:4(2D34I2B`E*0-222``-2=(N';&=
MM+/;'@BW[8=MDRWY<Z:%U9&>AH90]Q/FY!3ARJ<H"+.W&8E:IAQ`5"J*?WP:
MJ5WKW&=W(S=^Y-*)L=,2Q2)Z.R23-R7TG536?`4I^;'9+[J6Q]-L7M-1V*H;
M`RRN":JXKZ?6%I$F9R\RF1)H=!4%K^>8V0R3D*V<46'=>1[Q>EC[:L^&=S4H
MX$?/.FV)\"T;%\57K]R8B"!`XG54*4.(UKS';!<LIOE+CUH1SW&K>2V@=$SQ
M4>I*1-2CT)!,;LS?,;'M]B5PS7)'0S9+;3+>=5TD)'DH2.E;BBE"$\5+4D#C
M%+G/>:+IW`Y8N_*UVJ"$A<LB8[*/*H91M!0375"$@67,(\K:+8%(GKXJ*<QQ
MU,<1&X3!L/MF!XM28O:A]A3-R4N4BXX=7'5>%:IGP"21H!'6+W=W.OV\&X-Q
MS_(5'URN>)0W,E+#"?)981/YC38"?SCS+/E*)C#]9;&M84A"D(4A'9+0L^Z;
M_N.*M"RH"4N>YYMR5I%0D,T4>OWBYO(FBF`\J:9?..H82IID`3&,!0$:XZZW
M:V6*WNW6\/M4UM93S+<<4$I2/"3TG@`)DG0`F.<QO&<@S"]4^.XO1U%=?*I8
M0TRR@K<6H]0'`#BI1DE(!4H@`F+)6R+MD6UA0\5D[-Z<9>654P1>P]N%*F^M
M2PG&@*%5#J`9&?N1N;31R(>CMCA\"!C`"M5X;S]Y&XYB'<;PPN4>,&:7'M4O
MU(X2TU:9/T//6//($T1=QW6>XM8]KU4^=;I)8N6?)Y5LTVCE+0*X@ZS%14I/
M])+LVB/L@I0#L2,YIS38&`\?S62<D3*<5!1*0@BB42J24W)J%,+*$A&8F*=]
M*/U"\J9"^:4-3G$I"F,$?,.PZ^YU?F<>QYDNUKIU/!#:!YSCBN"4)&I/$Z``
MJ(!FGN=N=B&T6'U.:YI4II[53I\E(D77W2#R,,HF"MU9T`&@$U**4)4H5(-V
M6[&_MU^05+GN4ZL1:D2=PVL>QT'1UHVVXU0P`9540`B;V=?E(4SMT)0$X@!"
M`5,I2U:KM;M;8MKK"+;;@';HZ`:FI*9+>6.@<2EM,SR(GIQ,U$F.NQWAN\+E
MW>"S!5\O:E4^/TY4FBH4J);IFR>)X!;[@`+KI`*B`E("$I2-5ZV=$?XE][2^
MU^2R#E0NX"X6BJ%CXK=K)6X=9(Q27#?B[,Z21&IC<H*-;::._2%CEU`'!T2?
MQM(G]Z;<JFL.,?N)0+"KU<T`N@'5JF"IGFZB\I/*D'Y@6>J=C_X>6P]=F&?#
M=^\MJ1BUA<4*>8TJ*Y2"$A)Z4TR5]JLB<G"TGZ4K,%5R1>3"D(4A'K552025
M77531013.LLLL<J22*211.HJJH<2D333(41,81```-1K](0MQ80@%2U$``"9
M)/``=),?AQQMEM3SRDH:0DE2B0``!,DDZ``:DG0"(2-Y'=?C+2<2N-]LIXZX
MK@0ZK&8RH[2*^MV)7Y3$61LYF(]&>?MS#IZ8L`LB'`>0BX><$S-HNZY4W1#6
M0[CARGH3)3=$D\KJQT%]7%I)_JT_:$<2C@:MN\M^(-0XZ[485L:6:R[IFAZZ
M*`73M'@11HX/K3_7+FR#YB'1Y0K_`%U79<]\S\E=5Y3\M<]R3#@SF3FYMZO(
M2+Q8PB/,LY<'.?D('`I`T(0N@%````J=ULM=MLM"W;+0PU36]I,D-MI"4)'@
M`_E/$G4DF*?<@R*_97=W[_DM945UZJ5E;KSZU..+4>DJ42=.`'`"0```$=>K
M[XX6%(1QX>-(1O/MI[?.X#<D9G,Q\(%AX\7,4RE_7D@X9LW;?40.:W(?E)*7
M$H(%'E.F5-KKP,N6M*[B[\X)MV%TE0]Z]?T\*6G(4I)_\5SS&AU@DKZD&)7;
M']SK=_>TM7.DI?V3AJS,U]8E2$+3UT[7ZVH/44A+7074F+`VW#MV;>-NPLII
M"#-D6_VP%.-[7PW:OE&;D"B!E+?@@(:)@R@(ZD.!5G1?*L-0.W"[P&?9_P`]
M&M[]GV)7_P!O3E20H=3KD^=SPB:4'Z`BX793N8[-[,]G<VZ7]M9:B1]=KDH6
M4*UUIV)%ICCY*I+=']:8WQK1\2UA2$*0A2$*0A2$!$``1$0```1$1'0``.(B
M(CP``"G'0<8\$@"9T$5<.YUO#-G;(QL36/)`KBG&,LY1.[:*\S:\KS0(9G(S
M(G3,*;B*AA%1JQ\2F'JK!J"A-+,.[=M*,(QX93>FY91<F@>50UIZ<^4AO74+
M<T6YTCR4<4F="O?L[R2MV,T.WN+/<V`6.H4"M!\FLK$@H<>F#)33/E-,=!^T
M<$PXF46-2;B`49_VQ8&G=R6:+/Q7#"JW:RKSTZYY=,@F+!6G&B5Q.2AC:"0J
MQ6H=)N!N!W*J9?+6"[D9Q0[>8?5Y-624ZTCE9;/]*^O1M'BGY2I<$)4>B-P;
M$[27;>S<ZVX%;.9#%0[SU+P$PQ2M^4^Z>B83Y+8.BG5(2>,7/+1M2!L6UK>L
MRUF"47;EK0T?`PD>B``1K&QC9-JU3$0`.=3II@)SCQ.<1,/$1JGZ[72NO=SJ
M+Q<W"[<*IY3KBCQ4M9*B?`)G0=`T$=F[',>M.)V"BQBPLI8LM!3-L,MC@EMI
M(0D>$R&I.JC,G4QV*N/CFH4A'5+VOJS<;6U(WC?URP]I6Q$IBJ_FIMXDR9HA
MH(D2(90>=PZ6Y1!-%(IU53>:0HCPKE;+8[OD5Q;M-BIG:JY.F26VTE2CX=-`
M!TJ,D@:D@1CV4Y9C6$61[),NKJ:WV.G3-QY]80@=0$]5+5P2A(*U'1*2=(K^
M[M.[9<MV_*EB[:$GEH6TH55D]R9)("A=\L3F$JA[78',8EM,U2\"N%@.^$HZ
ME*@:IW;5]U>W6GL[WN,45=Q$E)HT&;"#T!Y7],H=*4R;Z"7!%/W>(_$0O>0]
MOBFQZ7+=9%`H7<G$\M6Z.DTR)RID$<%J"GR#,!E40LO7SV3>.I&2>.I"0?.%
M7;U^^<*NWCQTN<5%G+ITN=1=PX6.(F,<YA,81U$:F&RRS3,IIZ="6V$)"4I2
M`E*4C0!($@`!P`$A%8-55U5=4N5E:XX]6.K*EK6HK6M2C-2E*42I2B3,DDDG
M4F/RU[8^>/<V;.'CA!HS;KNW;I9-NU:MD5'#ERX6,!$D&Z"13JK+*G,`%*4!
M,81T`*_#CC;+:G75)0TD$E1(``&I))T``XDQ[F&'ZIY%-3(4Y4.*"4I2"I2E
M*,@E*1,DDD``"9.@B9[:)VF[HO@L9?NY,9&R;35!-Y'XX9J@VO*=2YBG2&X7
M0`<+6CER>*!=9`Y1T'T<=!&(&Z_>EMED+ECV[[.MNHFE56H3IVST]D/Z98/S
MC]D#P[0:19MW<_P]+[E08R[>PO6O'E`+;MR#RUCXT(]85KZJVH<4:U!&A#)D
MHV#K)L:S\;VU&6=8=MQ-J6O#I`C'0L*T39LT"Z`!U#%('.X<K"&JBR@G55-Y
MQS"(ZU`J\WN[Y%<7+O?*AVJN3IFMQQ14H^#P`="1)(&@`$7&8MBF-X38V,;Q
M*BI[?8J9,FV64!"$]9TU4I7%2U$K4=5$G6.UUQ<9!"D(^5.SL-;$+*W'<4FS
MAH*#CW4K+RT@L1NRCXYDB9=T[<K'$"D212((CY1\`XU]5#0UERK&K?;VUO5S
MSB4-H0)J4I1DE('63''7>[6RPVNHO5Y?:IK32,J=>=<4$H;;0"I2U*/```G_
M`)-8J3[[=YT]NMR$9K$*NXO$%GO7;>QH`QE$1E#@8Z*EX3C?FY#RTDD'P)!#
M^2-C`0//,J8UJ6R.T%#M?8>TJ@AW+*M"34NZ'DZ0PV?H(/G'YZ_*.@2!UWN]
MEWFKMW@,Q-/;E.4^W5M=6FAIR2.U,RDU;Z9R+KH\Q)_4MD('E%Q2M#ZW?$28
MR'BK%=\YION"QSCJ#<3UT7`Y!%JV2U(V9MRB7TN4E78E%*.B8](>===30I"A
MY3"4H\!D^3V7#[(_D.0/)8MC"9J)U*C\U"$\5K6=$I&I/@F1F>W^W^5[GY72
M87AE*NKOM8OE2D:)0GYSKJ^#;38\IQQ6B1UD@&V-L[V48[VG6JF+)-O<V49E
MDB6\+_=-B@X44,4JBT+;A%`,I$VXV6X%(`@JY$H*+"(\I25;;M[R7_=*YD.E
M5-C+*SV%*DZ2X!QZ6BW2.)\U$^5`E,J["O=K[KV&]WO'TFG2BNSRI:`K*]2?
M*),BIFF!U:ITG0`>6[(+=)/*E&).[2$9^YQ<0OVZ*SH+XL4L*HH4HG:R1I4_
M460,/$BAHLKE,=/$AQ#PK*NZOZS\7*<,*(:]2J>T`X*1R:`^#GY#XP(UW^(>
M*'^&NL-6A*JC]JT/8DC5#G:^4I)Z"6>U29="B(JHU9]'7[A2$6\.VFBJCLNP
MYU4S)]5I<2R?,&G.DI<TL)%"^Z0VG`:JB[Q:TKW@NW*09*:!\!#+>D=C;N/M
MN-]V;'.T24\R*DB?2#5/2(\!C0;O498Z;;$>$6+@-7!Y#)%Q(D4'4$T.M`6T
MFLF`Z:**'?J!KQ`4RCX#6].YWBW,Y=<S?3YH32-$CI,G7B#X`&A\IB(GXGNX
M7(QCVUU(O59<N-0`>@<U/3`CPDU!UZ@>F("*G3%0D=BL^WE[MNVUK5;%4,O<
MMQ0D`D"0:J<\Q)-H\#$#0WG%](U\!\*X^[5Z+5:JFYN2Y*:G<=,^$FT%7_-'
M.8S9W<AR.@L#,^VK:QEA,N,W7$MB7'I5%Z6&C&=N0,5#-^DWCX"'8QB(B)4D
M$&<6R2:D$1'E(FDFBAKJ.@``52?65+UQKW:M<U/OO*6>DE2U$GQDDQVNK90T
MUDM%/;6>5%'24S;2>A*4-("1X``E/R"*V?<IWYJ9DF)#!>)90Z>*;>D#(77<
M+)<0#(DXP6XMVZB1N4]HQ+E/X(.(/5R]4=4RIZV(]W78].(4;>:Y2T#E%0W-
MAI0_W5M0XD'^G6#K_5I/*/**HI'[[W>V<W*N;VU6WE04X!1O<M54(5_Q%]M7
M!)!UI&E#R!_3.#M#Y`;B(2I7Q7#"D(L,=L/88-LMH7<IF.&,2Y'B2<ABJTY)
M$`-!1[A+5"])=HJ7F3F'R1^:/2.`&;(CUA#J')TX#]Y/?#]HN/;=XB\#;T$H
MK7T']8H'6G0H<6TD2=(T6KR!Y(/-<IW$^Z3^PV*7>[<FF(O3B0Y:J1U.K#:A
MY-:Z@B8=6#.G29%M!#I'.I').+4+(M4C3/?5N;;;7\%S5RL%T37_`'4*UJX[
M8G,`G^7'K93TB=.ES%.=G;3,1<G\2F6Z28_M*V_LEMNYN5FS-N?2K]A4LGJI
M0X=FDB3<_I/*\@=2>90\V(R][#?1C8G:BIO=&I/[WW#FI;<@G7MUI/,^1.91
M3(FX>@K[-!\^*>[UZ[D7CN1D'*[U^_<KO7SQRH99R[>.E3KN7+A4XB=59=8Y
MC&,(ZB81&K:&66J=E%.PE*&$)"4I`D$I2)``#@`!(".MS5551753E;6+4Y5O
M.*6M:B2I2U$J4I1.I4HDDDZDF9C\U>R/GB7+M.;7@RCE-SF^[([K61B5V@:W
MTG*7,UG,A*DZS#E`X<BZ%KMC`[4\0*Y.W_3I%3O2;E_NSC*<,M3DKS=4GM2#
MJW2C17B+Q\@=:`YX(L7_``]MAAGF>KW2R%GFQ?'G$FG"AY+]P(YFY3T4FE3)
MY74X6?#*S75;\7HQ`!WBMR1W+^W-LMLO1*WCP8WKDHZ!Q^&>+)F/:EO+"4=.
MFV;J&?K$'7F.=N/#E'6=W=(V[#;%1N/<4?:.<U/23'!(/V[H\)(#23T`.#IT
MI_\`Q)][E/5=%L=8W9,L\E9<BD^<M0G2TY\"4DOK'25,'3EU@AJ;L5+PI"%(
M0I"-S=KVQC-VZ*0;N[>B3VGCTJH!)9(N9HY;P94R'`%D8!OHFXN:1`-0!-N(
M(E-P553K4&Y6]>&;:,*:N#HJK_+R*1E0+D^@NG4,I\*_*(\U"HDWL-W4=TM^
M:Q%19Z8V_#@K[2XU*%)8`!U#"=%5+GYK?D`Z..-\8LS[8]GF'-J\"+*Q(DTG
M=;Y`B5PY!GDV[BZ)H0*43H)K$3*E#Q/4`3$:-@*F'`3BH<.<:XMR-V\NW.KN
MVO;O9VM"IM4K9(9;\)$YN+EH5KF?HA(TB\W8ONV;:[!6GU;%*;M\@=0!47!\
M)55/=:0H"3+,]0RW)/2LK5Y49#SOGK&^W2P)#(>2YDD=&-@,A%QB`IJS=RRP
MD$S>&@6!E"'>/EQ#SAU!-$FIU#%(`C7`81@V0[@WUNP8ZR7*A6JUF8;91TN.
MJD>5(_*H^2D$D",SW9W<PK9?$7LPS>I#-&B:6FDR+]2[*:66&R05K/2=$H3-
M:U)2"8J6;J]V&1=UM^&N:[EQC+9B%':%DV2S5.,5;48NJ`\Q^(`_FWB29/2W
M9PYE#%`I`(F4I`M/VPVNQ_:^QBVVI/:7)T)-14*'EO+`_P"BVDD\B!H)S,U$
MD]>'O`]X3,^\#EIO>0K["Q4ZEIHJ)!/94S2C_P"8\L!/:NG51`"0E`2D:MUL
MR-!1M#M+VNWANKRDQLB!Z\9;4?T9.^[NZ!E6MMV^54"J"F(E%%::DM!29("/
MPBNIC?!D.(:UW3W+M.V&,KO5=RN7%R:*9B<E/.RTGTAM'G.*Z!H/*4D'?7=X
MV%R3?_/6L7M/.Q9&9.UU7RS334\]2/FEYR10R@^<J9/D(61<&QQCNT<3V1;F
M/+$B486UK6CDHV+8I``G$A-3+NW:V@&=2#]P8RRZIO.55.8P^-5,9#D%URF]
M5%_O;I>N=2X5K4?Y$I'S4I$DI2-`D`1V1,)PO'=O,5HL-Q2G32V&@9#;2!QT
MU4M9XJ<<42MQ9U4M1)XQW:N%C*H4A"D(K]=UG>A<:=R2&V#&TNYAXB-9-ARO
M+QZPH/)IY)MDW;>S4G*0@LA%-&"R:CT"B`N3J@D;S"&`\\>Z_L_;S;F]R<B:
M2]5N+/J3:A-+:4$I-00="M2@0W.?($\P\HB5/?X@7><O2+V]L5A-0NFMS#2?
MVJ\V>5;RW$A::,*&H90VI*G@".U4OLU>0A07!/4VHJ;A2$*0C8/`.U[-&Y6>
M"&Q;:;F09-UTTIFZY$31UI0!#ZB)Y2:53,CU@(`F!NB"SD^GFIC6!9UN7A^W
M5#ZYDU4EMY0);81Y;[OZ#8,Y3^>KE0.E0C<FT.PVYN]]W_9F!V]QZF0H!ZJ<
MFW24X.LW7B.6<M0V@+=5\U!BP[MB[7&$<)!&7-D5)OF'(S44717<VTTLN$>I
MB50HPEL+"=%\=!0OFN)#KGU#F(1(>`0%W)[S&9YD7+=CY5:<?5-/*VK^\.).
MGVCPU3,<4M<HZ"I47+;$]PK:[:Y+%\S-*,DS-$E<SZ/[DRL2/V-,9API(T<J
M.<S\I*&SH).R$(F0B:92IIIE*1-,A0(1,A``I2$(4`*0A2AH`!P`*C8I14HJ
M425$S)/$F)V(2EM`;0`E"0``!(`#0``<`(\J\1^H4A"D(4A"D(4A"D(BJ[H&
M\$V#<=EQ)8<J5#*>38YRD\=-%?Y7:%CK`HU?RFI.+:4G#<S9F.H'(0%50T$A
M!&3_`':]IAFM_.5WQHG&;:X"E*AY+]0)*2CPH;T6YT$\J3H3%?W?P[R!VKPP
M;=XG4!.>7QE06I!\NDH530XYIYKK_E-,G0I2''!(I035VJRR*&(#PXCX!2/,
M6H^U[M:'!>&0R'=4<#?)67FS&8=E7((.X&RP+Z3;<$(&*!D%WA%1?.B\!YU4
MR&XHA58_>6W-_?7+_P!@6MSFQVTJ4VF7FNU'!USPA,NS0>I*E#1<7]=P[80[
M4[9C,K^SR9MD:$/*"AY;%%+FIF-0"E2Y]NZ.M2$*U:$2=U&R)VP\`$1X``:B
M(\```\1$?``"G@Z8\$@"9X1&?NJ[F^&L"$DK6L-9IEG**'5;?)4.\`UI6\\*
M!BZW+<+<3I+*H*`',S9"JL(ZE.=$>-2.VP[MV7YR6[G?`JU8TJ1YW$_;NI_\
M%HZ@$<''))Z4A?"(-[_]^G;3:1#]AQ-3>0YVB:>R97.DIUZC^\U"9A12>++/
M,OYJU-'6*Y6>=RV8]R-Q!<&5;M=3!&QS##VZS#Y.M6WTS:@"</!H&]%14Y!T
M,NIU'*G\-0U6"X/MUB.WEO\`4,8I4M%0^T=5Y;SIZW'#J1U)$D#YJ1%+&[6^
M.Y6]EY_;&?7%RH0@GL:='V=+3CA)EA/DI,M"M7,ZKYZU1@>LXC4<*0C9+;GM
M1S)N?N((;&]O'^1FJZ:<_>TP59E:5O)'$.<7DETS>EO03U,1HV!5R?3WH%U,
M&N]P=T,1VVM_K>0U`];4DEJG;DI]T_FHGY*9Z%:^5`ZR=(W?LMW?-RM]KT+;
MA5$?V:VL"HK7IHI*<'CSNR/,N6H:;"W%?1Y9J%ES:EV_<,;8&[*>39DO[*A4
M2^E9!N!HF)XY8Y?AD;2B#&6:6^V`1Y06#J/3E]\MH/*%=&Z._&7[DN+H2LT.
M,$^32M*/ECH+[FBG3T\NC8/!$]8O%[OO<]VRV)9:NR6Q=\^"1S7"H0/LU'B*
M1DE2*=/1SCF>4-"YRGE&]]:/B6D*0A2$*0BNMW5]Z![NFGNV7&LJ4UJ6\[1/
ME":CU]2W!<;-3J)6BFLGP/%6^L4IW8`(E6>@!!X(CS6`]V'9Y-IHT;CY$T?V
MI4(/J;:A^J:4)%\@_/=$PCI2W,_/TI@_$`[SJ\AN;NQV$5`_=^C<!N;S:O\`
M>*E!F*0*'%JG4`79&2WQRG1KRH2ZF5%6T??M6UK@O>Y(2T+4B7D[<ER236(A
M(A@D*KM_(/%`2002('``$PZF,.A2$`3&$"@(A\-SN5!9K>]=;HZABW4[:G''
M%&24I2)DG_F'$F0&ICF,?L%XRF]TN.8_3N55ZK7T,LM-B:W'%F24@>,ZDR"1
M,D@`F+<&R+9M:^T_'R1'"+.6RQ=+)HM?]UE*57D6`.L6V()8Q>="`BE3\NI>
M47:Q>JI_`*2JK>?=ZY[HWXELK:Q:F6H4K/"8X=LX.EU8UUGR)/(GYQ5V*>ZS
MW:+#W?,.2EY+51N#7M(57U0UD?.%,PHZI8:)E,2[98[18\Q*-WJTO$IXA1[T
M^0$X[&&)L9(N"^E71>,A=CUKKYWR?:T89@V6$-/`7T]H'AX#_<F1W.["JHR2
MZY(M/V5-2(82K\]Y?,1]5K^6*O?Q/,P118+C^#-K'K%?<7*M:.GLZ5KLTGZ]
M09>(_)70JP.*68`!C"!2`)CF$"E*`"(F,/`I0`.(B(^2DP-3PC])!4H)&I)B
M[-M>L%;&&W?"]ANDS(/K?Q[;B,F@;WR$L]9$DI9(WAQ2DGJI?[E4V;EWQ&2[
M@7B]M&;+]>Z4'K0E7(V?E0E,=HS8;$G<%V9QG%*D%-926>G#H/$/+0'7A\CJ
MUB*L._W*89<W8Y:GVSGTJ(@YL+'@C%-JD$=9R1850Z'\'I.9-NX6`0X&!3F\
MNM6;;%8R<5VMM5"XGEJGV?67.OG?/:`'PA!2GP2E%!'>^SY.XG>#R&[T[G:6
MZEJO46".'9T8[`E/1)3J7%@C0\T^F<:;UMV(T1FG;C=UIV!GK$-[WT+DMH6I
M?]MSUP':-C/%THZ-D$G*JY6B8"JY*@8@',0@"<Q"B!0$VE8?N#:KI?<'NUFL
MO*;M54#S304>4%:T$`<QT$^`)T!E/2-H;*9'CV(;MX[E&5\XQRWW>F?J"A)6
MH-MN)45!`U5RR!*1Y1`(3K*)7M_?<U@\@6LYP_MMFI0T'/MUVU_9"%B[AE)*
M*<$Z:EL6RF](WDD6KTAC`^='32,HF/13U*8YAB[L7W<*VPW-.6[ALM^NL*!I
M:7F2X$+&H>>*24%23(MH!5(^6K4`18/WO._/:\OL"]M]DZE\VJK0I-?<.1;)
M<:4)&EI@L)="%B8?=4E!4G[-$TJ6HP;^'`.`!4THJHCFD(F%[9FQ,,NS#+/6
M68@#XOMV0,:S;>?HG`E^7%'JE'Y0<HGY05M6$<E\[74CQT3IZ"F10#1+[QV]
MO[ITB\'Q9V62U#?V[J3_`+LTH>:#T/.#ATMH/-HI2962]QGNG?$6Y-;M;A4T
M\$HGO[G3N`RKZAL^>H'C2LJX\0\Z.SU0AP&RN4I2%*0A2D(0H%*4H`4I2E``
M*4I0``*4H!H`!P`*KI)),SJ3%X24I2D)2`$@2`'`"/4X<-VC==V[72;-6J*K
MERY7.5)!NW03,JLNLJ<2D3222()C&$0``#4:_3;;CSB6FDE3JB``!,DDR``Z
M23H!'K>>9IF5U%0I**=M)4I2B`E*4B:E$G0``$DG0"*@&_7<VXW-9XFYN+>+
MGQW9QG%J8[9F./0/%-%Q*_N'I!YI7-S/TQ<"/O@;@B01'DJV38[;AO;C"&:.
MI0D7^K`?JE=/.H>2U/J92>7JYN=7SHZW_>XWT>WSW9JKG0N+.&VTJI;<@GR2
MTA7EU$N`54K':$\0WV2#YD:3UN2(N1W#'UB7+D^]K7Q]9[!22N6[IEG"1#1,
M!$#.':G*9=80_9M6:`'66./!-),QAX!7$WZ]V[&[-4WZ[+#=NI&5..*/4D<!
MUJ49)2.E1`Z8R7#L3O>=Y308?CC*G[W<:E#+2!TJ6>)ZDH$UK5P2A*E'01=(
MV_X7MO;[B.S,4VPF06EM1A"R4AR`5:<N!W_*9V<="!2B9:1D5#G*`_LTN1,/
M-(`!3SGF87'/,KK,HN1/:U#GD)Z&VDZ-MCP(0`#UF:CJ3'9WV>VQLFSVW5LV
M_L0!8HF!VKDI*?J%^4^^K0:N.%1`/FHY4#R4@1WB_;SA\=61=M^W`L5"%LZW
M9>Y))0Q@)JUB&*STZ1!$!U57Z0$('$3',`!Q&N%L5GJ\@O5)8Z!)565=0VT@
M>%:@F?B$YGJ`C*LOR:VX7BMQRZ\*"+9;:)ZI<,Y>2RA2R!X52Y4CI)`BD9E+
M(D]EK(UZ9+N98RTW>MPR4^\U'4K<'JYC-6*(>!6T<S!-!(H:`5-,````*N:Q
MFP46*X_1XY;A*CHZ=#2?#RC51\*U34H])),=6G/\SNVX>:W3-[XHJNESK''U
M]2>=1*4)ZDMHY6T#@$)2!H(Z%7.1A\>Q%%9PJF@W25776.5-%!!,ZJRJAAT*
MFDDF!CJ',/@``(C7Y6M#:2MPA*`)DDR`'62=!'L::=?<2RRE2W5&02D$DD\`
M`-23U1NCA?M];I<VJM%X?',A:%N.13,>Z\A%6M2*(V.8-7#9H]1^6Y,.0=2@
MW:J`8-.(`.M:>S#?C;/#$K15W!NKN"9_84LGUD]14D]FCP\ZQ+JGI$G=L>YW
MOUNBXV[;K*];K*N1-5<`:5H))\Y*5I[9W34=DTL'34#6)J]NG::PABP8^X<L
MN3YEO)L9)R5F_0/'6#'.B#SEZ%OE4,XG`2.`><_4.B?3B@6H<[@=Z;,\F#E!
MBJ1:+0J8YDGGJ5I/6[*3<^IH!0^F8M!V7_#TVMP$LWG<)9R7)4$*Y%I+=`VH
M?1IP2I^76^I2%?U(B51DR9QK1M'QS1JP8,D4VS-BR;I-&;1ND4")-VS9`B:*
M"*1``"E(4"@`:`%1A>>>J'55%0M3CZR2I2B5*43Q))F23TDQ/^EI:6AID4=$
MVVS2-)"4(0D(0A(T"4I2`E*0-````.$:E[K]YN*MJ-LG<W*\3N"_Y%J=2U<<
MQCI,)J54$#%2>R9P*J$%`IJ!Y[I8NI]!*D10_FAM3:W9_)]T;B&[<@L6)M4G
MJM:3V:!TI0-.T=(X(2=.*BD:Q'CO!]YK`.[[8R]>W$UF7/-DTMN:6.V=/0MT
MZ]@P#YSJQ,R*6TK5I%53<#N,RCN6OA>]\FSAGRJ76;V_`-`,WMZU8I145"1<
M)'@(D2('#JKGYW#@P<RAS#II9[@>W^-;=65-EQMD(09%UU6KKRP)<[BNGP)$
MDH&B0(Z_V\.]6>;X92O*,XJBZM,TT["/)IZ5HF8:8;X`<.99FXX1S+4H@2P5
M6;1J:,X[>]OF0]RF1HS'6/(X57"YDW,[.N4U`A;4@P5*1W-S+@H:)HHE$022
M`>JY5T33`3#PPO/<\L&W>/N9!?W)-IF&VP1VC[DO);;'23\Y7FH3-2M!&UMG
M-G<RWNS1C#<.9*GED*??4#V-*Q.2WWE#@D?-2/*<5)"`28MX[<=NN/\`;)C:
M-QU8+03`02/;DN-VFF$S=L^=(I'4Q*JD#AKIRMT"CTFR(`0G@(C5#N%N!?MR
M,B<R"^+EQ2RTDGLV&I^2V@?RJ5Q6J:CT`=C7939?#]B\(8PS$FYRDNIJ5@=M
M5U!$EO.D?D;;'DM(DA/23GNL&C;L*0A2$*0BI5W.\8SV/]W&0)J2:KEA<EF8
M7M;4B*9P:O6[B.9Q\HV16,'(=Q&RK)0BA`XD`Q!TT,41M1[MN24-^VJH*2G4
M/7+=S4[R)B:2%J4@D=2T*!!Z2#T@QUWN_;@MWQ#O$7>YUS:A;+V6ZVF<D>5:
M5-H0ZD*X%3;J%)4!JD%).B@3'O6^HAQ'U8."FKFEX^`MR)D9V<EG*;.,B(AF
MO(23]TJ.A$&C-J11=90P^0I1T#B/"OEK:VCMM*Y77!UMBB:25+<6H)0E(XE2
MB0`/''(VFT72^W%FT66G>J[I4+"&FFD*<<<6>"4(2"I1/4!$YNTOM&+N@B[[
MW1KG:H&Z+UEB2&><KI4HE!1,EZ3C0_\`)2CJ'.R9&ZGD.N4>8E0JW3[UC;1=
MLFVB0MS5*JYQ/DCH/J[:AKX''!+I"#HJ+6N[Q^'2Z^*?+-^%J;:\E:+2RN2S
MI,"L?0?(Z)LLGFZ%.I,T1.Q:=H6M8<!'6K9=O1%K6W$HE0CH2"8-XZ.:IE``
M^#;MB$(*A]-3G-J<YN)A$>-0DNMVNE\KW+G>*AVIN#IFMQQ16I1\)/0.@<`-
M`(MBQW&\?Q&SLX_B]'34%DIT\K;+#:6VT#P)2`)GI49E1U))CL=<='-PI"%(
M0I"%(0I"%(0I",-9^S;:6WG%-U94O%8OH$`S,6-C2JD3=W!/N2F3AX"/`X^>
MZD70``B`#TT@.H/FD&LOP3#+KGV44N,6D?;/K\M<B4M-#5QU4OFH3^4R2-2(
MUGN_NECVS>W]?GV1J'JM(W)IH$!=14*!#-.W/YSBM)_-0%+/DI,4S<MY3N[-
M>1;JR=?+XSZX[LDU7[K0QO1F+?@DPB8],PB"$;%,B$00(&FA"!KQ$1&WS%<9
MM6'8_2XW94<EOI6PE/6H\5+4>E:U$J4>L]4=9G<7/\BW0S2X9UE+I=O-P?+B
MOHH3P;:;'S6VD!+:$]"4CB9DXYK((PF)`>W'MD;[CL]-%+D:`YQUC))G>%X(
MJ`4495<KH2V[;:I3#YZ,Q(-SF7+Y6K=4/$0K1'>#W(<V]P98MRN6_P!R*F&"
M.*!R_:NCJ+:2`D]"U)/1$PNY5L6SO5NTVN]M\^&V-**NL2?-=4%_W>F/6EYQ
M)*QTM-N#I$6VRE*4I2$*4A"E`I"$*!2D*4``I2E#0"E*`:``>`558222I1F3
M'8E2E*$A"``D"0`T``Z`(U9W%[R,%;9(U0^0+I2=W2HW.K%V#;HHREVR)P((
MI=1B14J40T4.(!Z0\.BGH(B7F$-*V;M_M%FVY%0!8J4HM@4`NJ=FAA'7)1$W
M%#Z+84>N7&-!;T=Y;:C8RB4K+J]+E_*"6J"GY7:MPRTF@$!E!,OM'E(3]'F(
ME%=[<_W*LZ[@S2-NV^]6Q3C1R*J`6Q:[Y8DS,,CZEY+HN9($'CXJQ/?MVX-V
MOD,4_OAG[MKW=<)P(-W"N0+ID:9'MGDCLVU?^"R9I3+H6KF7T@IX13/OOWW]
MUMX5/6:SNJL&$+FGU6E6H//(.DJJI'*MR8XMH#;704KES&.JI`1"V%(1^M@P
M?2CUI&QC)W(R+]PDT8L&#99X]>.ES@FBV:M6Y%%W"ZRA@*4A"B8PCH`5ZGWV
M:9E514K2W3H25*4HA*4I&I*E&0``XDF4?324=7<*INBH6G'JUU80AMM)6M:E
M&24I2D%2E$Z``$DZ`1-QM![2\O</R7?^Y\'5OP@BW?1N*F#GHSTHD(%5)]<9
M%`>:#:'U`#,VYO2S!J!U$1\T89[L=Z>DH.TL6VW*_6:I76J$VD'@>P2?UBAT
M.*'9CH2L:Q:7W</P\KC>.PS#?7M*.U^2MNU-JY7W1Q'KCB=6$'I9;/;'@I;1
MT,^UHV?:M@V]&VG95O1-K6U#H%;1D)",D6$>T2*`!\&@@4I3*'$-3G-J<YA$
M3"(B(U!:ZW>Z7VO<NEYJ':FXO*FMQQ14I1\)/0.@#0#0`"+><<QK'\0LS&/8
MO1T]!8Z9'*TPPA+;:!X$I`U/$J,U*.JB29QV2N.CFX4A"D(4A&B_<'W,*;:L
M!2LE`O/1\B7VJK9UAB0Q>LP>.FYSRUQE*(#YL!&<QTQ\/2E$0'QK=FPFW*=Q
M<Z:IZY'-8*$!^IZE)!\AK_6KD#^8%GHB*/?%WR5LAM%45MI<Y,RNRC1T,O.;
M6I)+M3T_J&YE)X=JIH'0Q4.666<K+.'*RKAPX547<.%U#JKKKK',HLLLJ<3'
M5554,)C&$1$PB(C5KJ$(;0&VP$MI```$@`-``!H`!H!'7)===?=4^^I2WEJ*
ME*422HDS)).I).I)U)XQZZ_4>N+'O:FV<(V+:[?<CD.(`+UO!B<N.(]\E\+;
M-HNTQ(I/]%0O,A+7.F(](W`R;`0TTZY@"O;O0;N+O5R5MY8'?_P](L&K6DZ/
M/IU#4QQ0R?.'`N_H"+K_`,/WNU-XI84;UYE3_P#_`$UQ:(MS:QK34BQ(U'*1
MY+M2-$'BFGX?KE`305#V+.8>-(14H[FF:D,Q;IKJ0B7GI=M8S:HXYACIJ@HV
M5=PR[A6Y':`E\P06GW"R7,'$Q4"\1``JU+NXX<O$=LJ5=4CDN-R4:MR8D0EP
M`-)/B:"3+H*C'7=[\VZ#6Y._=P9M[O:62QH%N9D9I*V5*-0M,M-:A3B9](0G
MH`B/FM\Q#F-O-B>&QSAN@QC:;ED+VWXF6"\[M*/!(EO6J)))9-<=!`$W\@1N
MUTXZBN`>&M:HWMRX87MK<KHVODKW6O5V.OM7O(!'A2GF7_-B1W=.VU.Z>^]B
MQ]]KM;13U'KE7U"GI9.*"O`XX&V9=)<$6PL_Y&2Q%A+*62#*%04L^R)Z4CQU
M*366(Q50A4$P-YHG5E%D2%+Y1$`JKC!,?5E>9VS'@.9-76M(5^AS`N'Y$!1)
MCL);P9FWMUM;?LU*@E=NM;[K?`?:ALI82/"ITH2!TDRBD.Y<N'KEP\=JF6=.
MUUG3E8XB8ZKAPH99=4QA$1$RBIQ$1_35S;;;;+:66@$M(2``.@`2`^01U9:A
M]VJJ%U+ZBIYQ94HGB5*,R3X23,QZ:_<>F%(0I"%(1OOL*V9RFZS(HNY])]'8
M?LMRV<WM,HE41/,.-2K-K-AW6@%+(R:?G.%"B(M6NIO?G2`=&[X[O4NU^/\`
M94)0YEE8DBG;,CV8X&H<3]!!T2#YZ].`5*7?='[LUPW_`,T]9NR76=N+8M*J
MUX`@O*T*:-E?0XZ-5J$RTU-6BE-A5M&"@H:V(6*MRW8QE"P,&P;1<1$QR!&S
M&.CV:14&S1J@F`$3222(``'E\1XU5A75U9<ZQVX7!U;U<\LK<6LS4M2C,J)/
M$DQV'+1:;98;73V2RL-4MII64M,M-I"4-MH`2E"4C0``2CZM?+'(Q$]W7MS9
M\38@;X?M:1]'OC,+=TTDE&RPD>0V/T#`C,N/-T.B>XEA]!2'4-4O2-.):E)W
M7=MQE.6*RVYM\UEM*DJ0"/)<JCJV/"&A]H>I79SXQ7M^(-OHK;W;E&V]@>Y,
MIR-"DNE)DMFWI/*\K34&H5]@DS$T=M+5,5@ZLGBB"%(18*[06UHD;%2.Y^\8
MT0D9<KZV\6(.T#D,UB"F,UN*ZT.?E`3RBQ3,6QP`=$4UQ#4%`T@;WL-S345+
M>VMH<^P:*7:TI/%?G-,&7T!)Q8^D4?1BXK\.+8,4-`_OKDK']\J`NFM:5@CE
M:U145:9]+AFPVJ6B$O$$A8B=.H31:]$4W=ZRJO8^VN/L2/<'0D,MW8UA7/34
M`IS6Y;Q"SLP4P>^,DL[39I&_0I[E2@[J&,-WK<1R]OI"F+52J<$Q_2N_9M_*
M$EQ0\45^?B-;@.XKLDSBE&LIJ\AN"652,B:>G`?=\8*PPA7@5+IBKW5E<4-0
MI"+,_:QVD6O8>)H+/=X6^PDLDY$2-,6N]D6Z;M:TK+4$21`Q)%R&(QD9Y(HN
MU7!`!46ZJ28&``,`UQ=YO=6YWO*7\&M+ZV\=MY[-Y*"4A^H'ZSGEYR&CY"4G
M3F"E2)D1>?W!N[K8<2V]I=V\DHV7\VO*>VI5N)"S241T9+04)(<J`"ZIQ/E=
MFIM`(`4#+MJ(^-11BQF/2Y<MV;==V[<(-&C5%1PY=.54T&S9NB05%5UUU3$2
M112(43&,80*4`U$:_;;;CSB6F4J6ZH@!(!)).@``U))X`1ZGWV*5E=34K0W3
MMI*E+40E*4@3*E*,@`!J23(#4Q"KO'[KL#9X2N.MLZ[&Z+I+U&4ID]=(CNUX
M%3SB+IVLV4^#N*41'@#E0!8IFXE!?R3&VC[KM==BUD&XP736S12*,'E>='07
MB-6D'Z`^T/24=-7_`'EOQ!;1C8J,,V/4U77X30[<U`+IF#P4*5)TJ'!T.J!8
M2=4A[HKY75==S7Q<$G==XSTK<UR33D[N5FYMZO(2+YP<1$3K.7!SG$I0X%*&
MA"%`"E````J>=LM=MLM`U:[0PU36YE/*AMM(2A('4!_*>).I),4ZY!D5]RN\
M/Y!DM745UZJ5E;KSRU..+4>DJ42?`!P`D```!'7Z^^.&C9/;)M8R?NFO=*UK
M#CC-X5BNV&[KU?)'"W[3CUA,(KO%@$OI<@LDF;T=FD(K+F#^"0#'+KO<?<W&
MMLK,;G?'.:L6D]A3I([5]0Z$CYJ02.=P^2D=9D#O#8O8'.]_,H38<39*+8TM
M/K=:X#ZO2-JGY2SISN$`]FRD\[A'0D*4FV9MRVVXTVQ6`UL3'<;H=3I.;EN=
MZFD:?NZ8*F!%).7<D*&A"\2H-B:(MD_-(&HF,:K/<+<3(MR;ZJ]W]SR1,,LI
M)[)AN<PA`_ZRSY2SJ3P`[#&RNR.$;$X@WBF&L^6J2JFJ6`:BK>`D775#H&H;
M;3)#2=$B94I6?JP2-P0I"%(0I"%(1AW->`\4;A;5^I^6+39W+&(JG<QCH3*,
MIJ">G)TS/8.8:F3?1RYR:`<"&Z:H``'*8``*R[#<ZRC`;G^UL7JET]0H26G1
M3;B09\KC:II6)\)B8^:08UKNAM#M]O)8/W<W!M[=;1)45-+F4/,+(D5L/)DM
MM1&B@#RK$@M*@)1&G(=ES`KB3.YC\GY4CXLRP'",.:V'JR:7-J=%.14ADC"'
M+P*8Z1C!Y>:I%L=\+.&Z8-OVVV.5($N<=LD$]90'#\H!'@E$'JS\,7:5ZO+]
M'?;\S0%4^R/JJU`3U2'"P/$"4DCIG&]NWG9W@?;(U4'&MJ`:XG2?2?WO<:J<
MU=[Q,2`11N24402)&,E.(F09IMTC"/G`;A6D<_W;SC<AT#(JJ5O29IIV@6V$
MF<P>0$E:AT*<*B.@B)9;-]VS:;8RG)PFWSO+B9.5M20]5K$I%(=*4AI!UFAE
M+:3/R@8VAK6D;YA2$*0A2$*0A2$*0A2$*0CU++(MD5G+E9)NW;I*+N'"ZA$D
M4$$2&45665.)2)I))E$QC"(``!J-?I"%NK#;8*G%$``"9).@``U))X"/6ZZT
MPTI]]24,H25*4H@)2D"9))T``U).@&L5.NXMN^6W,95/;UJ/E1Q#C=X^C;43
M25/Z-<TN4YFLI>BR0"!%"/.GTF',',FS#FX"L<*M*[O^TZ-N,8%?=$#]Z[BA
M*WR1JRWYR*<'B.6?,[UN::A"3'7J[Z'>/=WQS\V;'WE?#FRN+:I`">6I=GRN
MUI'`AR7*Q,32SKH75B([*W_$,(4A$E&P+?3;.T)ID2%NRPI6ZHV]G4/*-Y*W
M73!O+L7L0V=M08N4I$4D7$<X(YYBB50#)*`8>4P&X1VWUV3N6Z[MOK+77-4M
M11)<04.A1;4EPI/,"B9"P1+42(EJ):S@[H7>OL?=SIKS;,@M#]PHKFMEU+E.
MMM+R%LI6GD4'))4VH+F"%`I5/105ID#<+W;LU9.:NK=Q'%I88MMP4Z2\LT>E
MF+\>HF,7@2;,W;LX(IBET'T1'KAJ.BP:Z!P6`]U;#<;=3<,J<-XN"=0A2>SI
MDGPMS*G/YZN7K1&8;R?B);G9TPY9MNV$XU9%@A3J%]M7+&G!\I2EC33[%'::
MF3O0(I)&2D9A^[E9>0?2LH_6.Y?24D[7?/WKA0=3KNWCI15PX6./B8YA$:E!
M3T]/2,)IJ1M#5,@22A"0E*0.`2D``#P`17U75]=<ZMRON3SM17.J*EN.+4MQ
M:CQ4M:B5*4>DDDGIC\5>Z/DA2$*0C9O:)GZ+VT9OM[*TS9J5[Q\8QE8U>,!9
M!M(LRRK;T;Y6A'+E)9NC*LOX'.``=,QR\Q!-S!KC=;!:G<;#*C%Z2L-$^ZM"
MPN1*%<AGR.`$$H5TRX$`R,I'>O=RW>H-CMTZ/<"YVU-THV&G6U-<R4N([5/+
MVK*E!20ZCHF!-)4GF3/F$Z"/>9VR'12,XLK,R*YB%%9).`M-<B:@AYY"+#>2
M0JE*/@;E+K[@5"=?=!W("R&ZVSE$]"77P2/%ZN9>*9BUYK\3+8Q325/6O)4N
MD"8#%&H`](!]=$_'(>*/U(=Y/:VJJ4BMJYE;$'7596V;8.0F@:AJ5"\E51U'
MAP*->ISNA[F)3S)JK.I74'GA_P`M.!_+'T-?B6["N+"5T&2H2>DTU*0/JUI/
M\D=X@>[3L[F%4D7L]?-LF5,4G4G+(D#H)B8=`%5:%6EP(4/$1'@`5PM=W5]V
MZ1)4RQ15(`X-U"9GQ!P-SC*;3^(=W;KDXENJJ[K0E1`F_1+*1/K+"GI>/@(W
M5QCGG#.9VPNL6Y*M&].0HF59Q$L@:7;E*&HF=PC@4)=J4`\JB!0K3F28-E^'
MN=GDUNJZ.?!2T'LS^BX)MJ^11B3^"[N;9[F,E[`[Y;KF1Q0TZGMDCK6PKE>0
M/"I`$9;K%8V+'B<Y$R'45.1)-,AE%%%#%(FFF0HF.<YS"!2$(4!$1'@`!7E*
M5*4$I!*B9`#4DGH$?E:T-H+CA"6T@DDF0`&I))X`=)BHWW%MRA-Q6X*7-`2'
MIF.L=$6LZR3(G$S20]&6YI^XT@T`I_EJ5(8$C_PFB"-6L=W_`&Z.W^!M"O;Y
M,@N!%143'E)F/LFC_HT2YAT+4N.NGWT-[T[S[P5*K0]VN&68&CHI'R'.57V]
M2.OMW0>572RAKPQH16\HB+&[FP7;(KN9SQ#P\NR.MCFR^C=>0US`8J#B+:K@
M$?;H*`&@N;B?E!(2^(-BK'_@\=,[Z;D)VXP=ZKI%@9!638I1TA9'ENRZFD^5
M/Z90.F)3]T38MS?+=FFMUQ:*L,MG+57!7S5-)5]G3S^E4.21+^K#JAYL6^V[
M=NS;H-&B"39JU02;-6R"94D&[=!,J2""*1`*1-)%(@%*4````-`JIUQQQYQ3
MKJBIU2B229DDF9))XDG4F.QXPPS3,HIJ="6Z=M(2E*0`E*4B24I`T`````T`
MCW5^(]L:A;X=Q37;5M_NJ\6SE-.\IU,]HX^:B;X9:YY=NN4C\I`,4_1@6)%7
MAS>&J12^)R@.V-EMOW-Q<[I;2XDFT,'MZI70&6R/)\;JN5L#CY1/`&(X=ZG>
M=C9#:"OR-EP)R6K!I+>GYQJ7DJDX!,'E80%O*/":$IXJ`-.-999RLJX<*J+N
M'"JBZZZQQ45666.*BJRIS")CJ**&$QA'B(C5N*$(;0&VP$MI```T``T``Z@(
MZU3SKK[JGWE%3RU%2E$S)),R23J23J2>,>NOU'KBQUV<,%*6QC>\L[33+I26
M17R=MVF=9/15.TK=75&1>HB8H&!*8GCB3AP,5D4=1`W"O?O<YLFY9#1X31KG
M3V]';/R.A?=`Y$GPMM:^-PCHBZW\-3:==BPJY[KW1KEK;RZ*:DF-12TZCVJQ
M/63SY*=.(8!U!CMG>,R@:U=O]JXV9K]-[E"\DC/2$5`ISV]9R:<J[*=,!YC(
MJR[ECQ\`$OZ:XKNCXT+GG=5D3J9LVVD/+IIVKY*$Z]8;#GY8R+\2G/#8-H*#
M":=<JF^W(%8!D33T8#JA+I!>4Q^2*S-6.Q1A"D(4A"D(S_MIV[WKN;RI"8VL
M]`Z**ZA'UTW$HD8\?:ELHJD"0F'IN!!4`@]-LCJ!G#@Q2!XB(8)N+G]FVXQA
M[(KNH%:1RLM`^6^\1Y+:?!TK5P0@%1Z`=P[';,Y/OGGU+A..(*6ED+JJ@@EN
MEIDD=H\L\)@>2VB8+CA2@2F2+B.'L1V3@S'=N8RQ]%DC+<MQH"*8B!!>RCY7
MX20FI9P4I3/)63<B*BRAO*(%+H0I2A4GEN5WG-L@J,DOSA<N%0J?YJ$C1+:!
M\U"!HD#QF9))[)NVVW6+[4X918-A[`8LU$W(<.=UPZN/.J`'.ZZJ:EJ/@2))
M2D#)M8W&=1\"Z[H@[)MFX+QN9\E&6]:\/(STW(+"`)M(R+:J/'BPZB',)44A
MT#Q,;0`XC7WVNV5MYN3%HMR"Y7U+R&FTCBI:U!*1^4QP^0WZU8M8JS);XZEB
MS4%,Y4/.'@AII!6M7R)!D.DZ12YW+YRF]Q>:+URI,F720FY$[>W(M903E@[4
MCQ,V@8E(!\T@HLB@=70``[A10W\*KA-N<*HMO\/H\8I.4K9;!=6!+M'E:NK/
MC5HGJ2$CHCK%;Y;JW7>?<ZZ9[<RI+54^4T[1,PQ2M^2PT/T4`%<M"XI:OG1@
M>LXC4D;);3MO,WN:S9:V-(X%F\,HM\LWK,)%U"$L^-52-+NP..A"NW0'*V;`
M(^<X6)Y`'37FZ6?4>W&&U61U$E58'9T[9_I'U@\B?T1(K7U(2>F4;O[O6S=T
MWSW0H,(HN=%M4KMJUX#]11MD%Y<^'.H$-M#I=6B>DY7,;<MV%M&WX2UK;CFT
M3;]NQ;&%AHQHF5)LQC8YNFU:-DB%```J:*8!KXB/$>(U4'<;A67:O>N=Q<4[
M7U#JG'%J,RI:R5*)\9,=F6R66UXW9Z7'[(RBGL]%3H99:0))0VVD(0D`=0`\
M)XG6/M5\<<I%</O3W8X?9AQ-9@*F%E;M@/YH41UY"R%Q3:J"JI0\-3LX9$!_
M55A7<[M:&,2NEW(';5%<EN?YK38('UG%12C^)YD#M7N/C^-!1]6HK0M[EZ.T
MJ7U!1^5#"!$+U3!BL6.#`(E$`\1`0#]8A0<8\@R(,7,=K^X##&0\#XZFK6N^
MU8EG#V=;\),0#Z:BHU]:DE#Q31@]B9-FY<(*-0;K(#TU!*":R>AR")1UJH;<
MO`\PL&<7"CN5)5.NO5;KC;J6UK2^AQ:E)6A0!!F#J)S29@@$1V8]A]X=LLQV
MELURL5RM]-34UMIV'J=QYIM=(XRTAM;3J%*24\I3Y*I<JTR4DD&<8TSGW(]K
M^%6KMNA>2&3KL1!4B%K8Z7;S8>DD#S4Y*XB'&`C$N?@8>LJL70=$C#PK(L*[
MN^Y68NH<<HU6VUF1+U6"WH>E#4NU6>KR0D_2$81NMWV]B-L*=QIBYHON0)F$
MTMN4EX<PZ'*D'U=L3X^6M8UDV>$5_P#='O\`\X[G57,,_D?J)C853^C8_M5V
MY1:/4?>IC=,IJD[N1<"AJ)%`3:%-Q*B4>-3MVSV)PO;9":MAOU[(I:U3R05)
M/3V*-4LCPB:Y<5F*?]^N]_NIOHXNVU;W[)PGF/+;Z5:@A8Z/6G=%U*O`H):!
MU2TDZQHU6ZHBE"D(D=V8]NW(FYEVQO&[2O[!PPFJ"BUQN&_2F[M(F?0[&SF3
MDFBB)Q`2GD%2^C)<>0%3@)0CWO!O_C^W#2[1:RBNR\B0:!FVQ/YU0H<#TAH'
MG/3RC6)K]V3N99GOC4M9)D0=M&V:53-0I,GJL`ZHHT*&H/!50H=DG7E[10*1
M9]Q;BC'^%[-B["QK;,?:]M1212)M620>D/7'(4JTE+/3`+J4E'8AS*N%C'4.
M/ET``"MC)LIOV87=V^9'4N5-Q=.JE'1(Z$(3YJ$)X)2D`#QSB][`=O</VQQI
MC$L(H6:&R4Z9!*!Y2U2\IUU9\IUU?%;BR5$],@`,AUC\9G"D(4A"D(4A"D(4
MA"D(4A"D(4A"D(4A"D(4A"D(4A"D(A$[K&]`EKP[S;)C.7+]99]JF.59J.<?
M"0,"X("B-FI+I#\%*3J1BG>@`@9)F()CQ7'EF=W7]GE7*K1N1D;1_9S"CZDV
ML:.NC0U!!XH;,PWT*<FKY@G5E^(#WG$6*VN[&X/4C]MU:!^U7FU:L,*$Q1@C
M@Z^)*?UFEDA!_6GEKNU/V*9(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(_=&2DG
M"OVTK#2+^(E&:A5F<E%O'$>_:K$$#$5;/&BB+A%0I@`0$I@$!KT5--35C"J:
ML;;=IEB2D+2%)4.HI4""/&(^R@N%?:ZI%=;'WJ>M;5-#C2U-K01P*5H(4DCH
M((,278-[KFY+%2+>'O5:-S/;:!03(G>"BS2ZFZ8``%!"[6*9W+KE`/\`IJ#L
MP^',7QJ.F:]U[;S*%JJ[.'+/<%&<V`%,GQL*,A_JU-CP&)Q;4_B"[V8`VBW9
M0IG)K*@2`K"I-4GJY:M`*U>'MT/$]!$?4W+]U;+.<[,?X]LVV&.);9G6JC*Y
MGD=,.9JYYJ/7)R.8E*6,TCD8F,=D$2+`BD*ZR8B05"D$Q3?-MSW8<5PF[HO]
MWJ5W6Y,*"F4K;#;+:AP64<RRM:>*>97*DZ\I(!'(;X_B`;A;JXR]AV-4+6/V
M2K045*VWE/5+S:A)30=*&@TVL3"PA'.M/DE825),5]2;B`,*1YBW5VZ=N9=O
M>W6`)+L@;7[D<&]\WJ90G*Y:GD&Q1@8%0>8PE+"0YR`<G#E<JK#IJ-52]X'<
M`Y[N`^:1?-8[?.FIY<%<I^U='^D<G(]*`CJCL8=R_9=.SNS-&+@UR99>@FNK
M)CRD]HG[!@ZF78LD<R>AU;O7&^=:.B6\>)SD2(=14Y$DDR&4444,4B::9"B8
MZASF$"D(0H"(B/``"O*4J4H)2"5$R`&I)/0(_*UH;07'"$MI!)),@`-223H`
M!Q,5(>XINB/N1SI(-[?D3.<88W.[M>QR(J&%G*+)+`2>NLI-"E.>:?)<J!Q#
M7T-%+W1UM5V`VT&WF$MKKVPG);@$O5,QY2`1]DQ/H[-)FH?UBE=0CKL=\_?I
M6]>ZSS-G?*\%LI72T0!/(Z0J3]5+0$OK$D*_J4-=),:!5O6(@1D/$N-+@S'D
MFS,8VLB96;O.>90S8P%YB-$5C\[^27X@`-HQ@FJX4$1``(F/&N`RG(Z#$<=K
M,DN9E1T;"G#^<1YJ!X5J(2/"1&:;=8/>-R<XMF#6%)5<[E5H93I,("C-;BN'
MDM-A3B]?-28NTX\L:!QE8MHX]MAN#:`LRWHNW8M/0`.9M&-4V_I"W*``9R[4
M(954W\)0YA\M4U7^]UV27NKO]R5S5U94+=6?"M1,AX$CR4CH``CM'89BEIP7
M$[=AMB1R6BV4;5.T.DI:0$\RNM2R"I1Z5$GIBLWW;\JA?FY_ZF,W)5HG$MKQ
M]M`1,PBF6?F-)Z>.(#[U<I7+5`^G`0;A5CG=5Q<V/;7]KO)(JKK4J>UX]DW]
MDT/%HM0_3,4:?B)[@?O;OM^[-,L*M^/4+=-(3D'W?[P^?');39E_5"(MZDQ$
M"(4A"D([/95F7-D2[+?L>S8EU.W1=$FVB(6*9D$RSIXZ/REU'WJ+=$FJBJIM
M"))%,<P@4HC7&WB[VZP6M^]7=U+%MIFRXXM7!*4_\I/!(&JB0!J8Y_%L8OF:
M9#1XKC5.NJOM>^EEEI`F5+4=/`$@34I1DE*05*(2"8N`;-]J=L;4<5,K49%:
MR5\3A6TID6ZTT_A)J<!(0*Q9J'*"R<#"E4,BT2'37SU3!SJ&JIO=W="Y;H9.
MNYO%3=E8)12,$Z-MS\Y0X%QR04L^)(\E(CL@=VGN_6+N^X`U8*8-OY55!+MQ
MJP-7GY:-H)$PPQ,H:3I/RG"`MQ4;;5JJ)$PI"(1^\'N5/;EJ0.VZUI$4Y6]$
MD+ER(+9311M:K1R!H.#7$A@$@SDHW%PH4?%%J4!#E4J9O=,VZ3<+F_N'<VYT
MU&2S23&A>4/M'!_HT'E!^DL]*8JT_$AWP59;!2;*V!Z5PN034W'E.J:5"IL,
M*D=.W=27%#Z#20='(KM5/Z*8H\B$.H<B:9#J**'*FFFF4QSJ'.8"D(0A0$QS
MG,(```&HC7@D)!4H@)`F2>`'68_2$+<6&VP5+49`#4DG@`.DF+9G;@VJAMQP
MHVF+HC2MLJ9.3:7!=W6(F+N#BQ(92WK3Z@<QDACVBW6=$`?\,6.4=>F4:JS[
MPNY_Q"S)5';7.;&+:5-,2)Y7%\'7Y=/,H<J#_5I!'G&.PUW*-@!LMM@W<[ZP
M&\^OB45%7S`<[#4B:>DGT%M"N=T3_7+4DSY$F)#ZT#$S(4A%:#O,6N]C=PUC
M72HFJ,?<^,VC5LN("*'I=OS,D@[;D-R@`*IIODCF#41T.`^6K&NZ%<V:G`:V
MV)([>FN*E$=/*ZV@I/B)2H#Q&*-OQ,;#4T.\=KOZPKU2NL:$)5\WFIWG0M(T
MX@.()$_G`Q$#4L8K@A2$<"`#Q$`$?T@%(\S(X0TT\.%(1S2/$=PL3'U[Y.N1
MC:&/;6FKPN61-HUAX)DJ]=&(`@!UUN0.DT:):ZG66,1),.)C`%<3>[[9L;MR
M[M?JEFDMS?G..*"4^(3U4H]"4@J/0#&2XGAV4YW>VL<P^@JKC>WCY#+""M1'
M2HRT2@?.6HI0GBH@18%V@]IRW+'4C,@;E!C[QNM$R;R-QLS4!W9\&N70Z1[D
M=!H6Z7Z)^/0)HP(8/.ZX<0@?NQWI;A>4N6+;KM*2V*FE=6H<K[@Z>Q3_`$*3
M](_:D<.3IN%[N'X>UEQ5;&7[V]C<K^DA;=M0>>D8/0:E7"J<']6/L`?.[82(
MFC001;(HMFR*3=LW230;MT$R(H(((D!-)%%%,I4TDDB%`I2E``*`:!4/%K6Z
MLN.$J<42229DDZDDG4DGB8LZ:::IVDL,)2AA"0E*4@!*4@2"4@:``:`#0#01
M[:_,>R%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"'C2$1R[XM_5D;;
MK2E+8L>:AKISA*H*LH>"9N$I%M9HJE,F>X;J]'%1%N=EKJW8J&*LX6`.8H)`
M8:D)LML7>MP[JU<[TR]2X6TH*<<4"@U$M0TS.1/-\]P#E0F<CS2$0J[U/>[Q
M;9/':BQ8K54M?NG4(*&6$*#B:.<P:BJY9I24<6V%$+<7*8#848JGS4U+7',2
MEP3TB[EYN:?NI26E'ZQW#V0D7RQW#MXZ6.(F46764$QA'W?<JSZCHZ6WTC5!
M0MH:HV4)0A"1)*$)$DI2!P``D(Z_=TNEQO=R?O%W><J+I5.J===<)4MQQ:BI
M:U*.I4I1))CYE?3'P0I"%(0I"%(1VNT[#O>_'I(VR;/N>[GRBA$BM;;@I*95
M!13WA3@P;+@F)O)S"`5Q=TOEFL;)J+S5TU(P!/F=<0V)#](B?R1D6/8CE66U
M0HL7MM=<:LJ`Y*9AQY4SP!#:52^6-W,>]K[>'?H(+N<?,K"CUS$U>7]/1\.L
MF0WB<\.S/)3A!+Y2F;D-^BM,W[O*;2V/F0W7KKGP/-IFU.`^`.*Y&_E"R(E+
MAO</[R&6A#K]G;M-(HCRZ]]MD@'I+*"X^)=1:!\$;S6'V33Z)+Y.SD0!T(9:
M-L.V1,7FY@YTRS,^Z*)BB77SO0BB`^2M*7SODIU1C=E/@74O?R]FTG^3M#$K
M,2_"[5Y+N=92)R$VZ&F)D>D!Y]8GX^P'BC;FU>TEM`M\B7RO$7U>K@F@G5N&
M\GC5(Y^.H^BVVA!)<G'@4W/^D1K55S[U6[%>H^J.T5&V>`:ITJ(_G/%TS\(E
M$C+!^'=W<K.A/[1I[K<WAQ-16*0"?T:9-.)>`S\9C-3/MZ;,6*((DP':+@`T
MU4?.)YZN;0--15<2YS?KT\:PU[?S=]Y?.J^52?`D-)'Y`V(VC2]SKNTTC0:1
MB=O6.M:ZA:ORJ>)C\TMVZ]F$NV,V4P3;3#F`2@O#R%Q1;HNOE*NTF"&`P>0?
M)7LI>\!O!2.!Q-[J%RZ'$-+'Y%-F/1<NYGW:+FP6',5HV@1YS+M2TH>)2'A&
M@>ZGM*XS@\=7?D'`TU<T).6E"R=R+69<4DG/0DO&Q#15^_91L@X11EXY^5H@
M<R(K+.B*'`""!=0,&]ML.]1D=;D%)8<X9IGJ*J>0R*AI!:<;6XH)2I:`2VM/
M,0%<J4$#764HB!O_`/AX8-:L+N.8[2U-=2W2W4KM2JBJ'`^R\VR@N.(:<4E+
MS;@0E11SK="CY)E,*%?,!U`!]WC4\HIVX1S2/$*0A2$*0C=?M^X&+G_<Q9<#
M)LQ=6A:)S7[>?.F)VRD3;RR"K*-7UT*(3,THV;B4=>9(QQT$"FK3>^^<'!-N
M:RNIE\MVJAZM3ZR(6Z"%+'^C;"USZ"$])$2C[GNT@W>WPMEJKFNTQRW'U^LF
M)I+5.4E#:NC[9XMM$'BE2S(@&+@P````%`"E```I0```H`&@``!P``#PJI@D
MDS/&.R(``)#0"%(\Q%YW1]T@81PT;&EK2'0R/F!H]B$C('$',#8_+Z-<<R(D
M,!D%Y$JOH+41\145.7BE4E^[/MG^^67?O'<V^;'K2M*S/@[4\6F_"$2[1?B2
MD^?$#._KOV-K=M#@]A>Y<TR-M;0Y3Y3%#YM2]H04J=GV#1_.<6-6XJR>'"K-
M(H*CFD(L`]GG;0=DRG]S5U1W(M))N[1QD5TEYY6!5.2Z+E;@8=2@Z63!@@?3
MB0B^G`W&"7>UW&2\ZQMQ:W)H;*7ZSE/SI399/Z(/:J'64=(BX/\`#;V.52TM
M7OCD#,G7@NDM@4->0&554IGPYB.P0J7`/="A.<6X)V-M:!F[FF5P;1-O1,C.
M2;@=/@6$4T6?.U.(@`B5!`V@:\1X5"RWT-1<Z]FVTB>:JJ'4-H'6I:@E(_*8
MM3O-VHK!9ZJ^7)7);J.F<?=5U-M(*UGY$I,4=,HWT_R=DB^\B2AA%]>UV3UR
MK%$QC=():1<.T&Q!-YW3:MU")D#R%(`5=+C5D8QO'J&P4WZBCI6F1X>1`23X
MU$$GPF.JOGV5UF=9M=LRKR?6[G<'ZE0^CVSBEA(\"`0D=0`CHE<W&(PI".2E
M,<Q2$*8YSF`I"$*)C',80`I2E*`F,8PCH`!Q$:\$@"9T`C])2I:@A`)43(`=
M)BSWVS-DO\QEI)YER3%D)EN^(P@Q$:[1#TBP;3>IE5(R$%`YF]PSB9BG>Z`!
MD$N1#@/5YJVN\?O+^^MU.(8ZZ3BM$Y]HM)TJ7TF7-IQ:;,PWT*5-?T97N=QG
MNN?"G'4[EYM3@;A75@=BVM/E4%(L`A&NJ:A\2+W`H1RM:'M)RPU%J+"H4A'3
MLA7W;N,+'NO(=VNP8VW9T'(3\NX'B8&K!`RO01+XJNG:@%21('$ZIRE#B-<O
M8+'<,EO=+8+4CGN%6\EI`\*C*9ZDI$U*/0`3T1C69999L$Q2X9CD+G966VTC
MC[JNGE;23RI'2M9DA">*E*"1J8I2YKRM<&<,J7OE.YE3FD[PG7<B1N8XF)&Q
M@&Z$/$-P$Q@(WBHQ))`@!P\S7Q$1&X[#L7H,,QBBQFW`"FI&$HG]-?%QP^%:
MRI1\<HZO>Z.X-XW3S^Z9[?%$UUQJUN!),PTW/E:93J9)::"&T^!,^),8MK)H
MP")6^UGM,-F7*`9BO.*%;&F*I!!RP2=I@+2YK^1Z;F*CRD4*)73&``2O'.FI
M>J"*8Z@<P5%[O-;IC$,9_=*T.RR.Z-D**3Y3-,9A:ICS5.ZMHZ>7G4.`BP;N
M#]WE6Y>>#<C)J?FPBP/)4V%CR*FO$ELMR/G(8T>=Z.;LD&84H1:"JM6+XH4A
M"D(CX[C^U^1W)8-ZMHM`>9'QF[=W5:;0H%!>;9*MBI7';:!C"7^4R3-`BK<N
MOGN6R9/X6M;[[O.Y5/MWFO)=5\F/7)*67U=#:@9M/'P(42E74A:CT1#GOK[#
MUF]NU7:8\WVF:6-Q=52($N9]!2!44R2?G.(2E;8^<ZTA/SIQ4N707:KK-G**
MK9RV540<-UTSHKH+HG,FLBLBH!5$E4E"B4Q3``E,`@/&K3D+0X@.-D*;4`00
M9@@Z@@C0@C4$<8Z\+S+M.ZIA]*D/H44J2H$*2H&1!!U!!T(.H.ACU5^H]<*0
MCZD)!S5RRK.#MV(DIV:D5B-V$3#L7,C(O%SCH1)LS:)JN%CB/D*4:^:LK:.W
M4RZVX.ML4;8FI;B@A"1UE2B`/E,<C:K3=+Y7M6JS4S]7<GE!+;3*%..+4>A*
M$`J4?`!$M>V_M&99R`JQN'.S\V);2/TG'U=;>BR60)1$3"(H*-@.K&VR"A2Z
M"9R99P34-6_N17W#[UF+6%*Z#"6_VK=1,=J9HI4'KGHMZ74@)0?ZR+$-D_PZ
M=PLO6U>=UW3CV/F2O5T\KE>Z/HE$RW33'2Z5.)GJSU3[83V]XAV\VV6V<46=
M'6XW433+)2HE],N*=53`/Y1.3K@#R$@H)@U`IC`DGKH0A0X5!;,L^RS/KB;C
ME%6Y4+!/(CS6F@>AMH>2@>$#F/SB3K%O&UVS>W.S=E%DV_MK-$T0.T=ESU#Y
M'SGWU3<</2`2$)X(2D:1FBL.C9\*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A
M2$*0A2$>M55)!)5==5-!!$AE5EECE2112(43'455.)2)ID*`B(B(``5^D(4X
ML(0"I9,@`)DD]``XQ^''&V6U.O*2AI()*B0``-223H`!J2>$1]Y^[EVVG!IG
ML.RGU,J7HUZB8VWC]5L_9-71-`!&7NDY_D-@`&'0X)'=+DTXI5OG!>[EN+F@
M15O,"V6=4CVU4"E1'6VS^L5X.8(2?I1#S=[OQ;(;5%VW4M6J_P"2MS'JU`4N
M(2H:2=JB>P1KQ""ZX)'[.(0-P7<XW(9O!]#0DNGB2R7751^0+&77;S#MHH44
MQ2F+M/R2SD3D'SRMO1$AU]X-30P/NW[>89R5=8R;K>4R/:U(!;2H:S;8\P>`
MK[17ABJ_>+OU;U;I=M;+54C'L7<F.PH5*2\M!$I/59D\HD<0WV*#THB.M111
M511550ZJJIS**JJ',HHJH<>8ZBBAQ$YSG,.HB(B(C6_TI2E(2D`)`D`-``.@
M1#!QQQU9<=45.*))),R2=223Q)/&/&O,?B%(1QX>-(1L9AK:7N%SXJB;&>,I
M^6B53D(>Z)%$L%:B!3"(<YI^7,T8+@701$J!EE!`!T*.E:^R_=/`<&21D=R8
M:J@/U*#VKY_U3?,H>-02/#&Z]L^[OO'NXM*L(L=946]1`-4XD,4J9])J'BAM
M4NI!4K31)B4C%/98N!T#9]FG+<=$$,4IUK>QY'*2KL!X"**MPSB;-HD8.(#T
MV:P>4#5&C*.^)0-%3&'6IQU4Y!VJ4$)\8:;*E'Y7$^*)Z[??AA7BH"*O<[(6
M:9)`)I[>V75^(U#X;0#T>2RL=2HD=QGVV]H6,@060QBC>LH@)#A+Y#?N+H6,
MJ3313Y-6]'@4M1\A&A0]W6H]9'WB-U\CYD+N1HZ94QR4J0R)'HYQ-T_*X8FM
M@W<D[N>#!+C5C3=*Y,CVMP<55$D=/9'EIQ\C(C=:%@(&VF2<;;D'#V_'(E*1
M&/@XQE$LDB%]Z1)JP0;H$(7R`!0`*TY65]?<7C47%]ZHJ#Q4XM2U'QJ423^6
M)06NS6>QTJ:&RTE-1T21(-L-(:0`.@(;2E('B$?7KY(Y*%(0I"%(0I"-.]^.
M:XO!VV/),XY<HEG;JA7U@VBQ,8O6?SUU,G$<)DDQ.4YB1D:HN[4,`"!2H^Z(
M`.W-CL-JLTW(MU&VDFBI7DU+ZNA+;*@O4_GK"4`=)5$:^]KNA;]J]B[W='W$
MBZW"E704B#+F6_5(4W,"8)#31<=41P".L@&G*`:``>X&E6WQUK#J9QS2/$*0
MA2$*0BS;V@L(EL;!$QEN49&1N#+LR<8U59+D53LJVU%F,7TC&`#=&2EC.U_*
M4Y`3$*K@[V.9F]9NSBM,N=!:F?+`.AJ'@%+GX4(Y$^`\PB]3\.+:P8IM/4[A
MW!KEO&15)[,J$B**F*D-R/&3CQ>7U%(;(B7"HIQ8I'2<CY"M7%%BW1D6]9$D
M7;%HQ+F7E79M!4%)`H`BT:IB8O7?/W)B(()@("HLH4OEKF<>L%SRB]TV/V9L
MNW*J=#:$]$SQ43T)2)J4>A()C%LUS*P;?8I7YGD[P8L5NIU/.JZ9)X(0/G..
M*(0VGBI:DIZ8IE[C\ZW)N-S!=V5+C,JC\M/3(0$0=3J)6]:[(QTH.#0T\S^2
M--#*F#@HX.H?^%5ONWN$V[;[$Z3&+=(]BB;JY2+KRM7'#^DKS1T)"4]$=9C>
MS=>][T[D7'/KT5)]:=*6&B9BGI4$AAA/1Y"-5$><X5KXJ,8,K-8U/&=MMN![
MEW(Y@M3%=M@=`)=R+NX)@$Q.C;UKL!(K-S*XZ"4!;MAY$2FX*N5$R>)JPG<3
M-[=MYB55D]QDKL4\K3<]77E:-MCQG51'FH"E=$;:V0VEO>]FY%OP&RS0*ASG
MJ'I3%/3-R+SRNCR4Z(!\YQ2$<51=`LJSX#'UHVU8UJL4XVW+3A8^!AF212E!
M%C&MB-D1.)2E!1=4"<ZAQ#4ZAC&'B(U3[>;O7W^[5-ZN:RY<*IY3KBCTJ623
M+J`X`<```-!'9PQ;&K1AN.4.*6!I+%EM]*VPR@="&TA(GUJ,IJ5Q4HE1U)C2
MGN:Y)-CG9_D0K=4R,E?BT1CR.,0PE.`7`Z%:6$!*(&`!@6#HNH>!C!6X^[?C
MHR#=BWEP3IJ$+JE_ZI,D?^:I!^0Q%_OSYLK"^[C>4L*Y:V[+9M[<C(R?5S/>
M'_=VWAXR(J/U:K'75A2$*0B9WM:;)_YPYYGN-R=$\UC6K)<V.X200YD;MN=@
MIYUP+H+$$CB`MUP71+4!(X>E\I43`:('>9WD_=^A7M]C;O\`^;JF_P"].).K
M#*A^J!'!UT>=TI;/6L2LW[A'==_?*[-[T9U3SQ6@?_\`Q[#B=*NJ;/Z]22)*
M8IU#R9S#CXEYK2@JR!5><78PI"%(1#MWELE2-MX/L/',<X,@GD>\57,X!#"4
MSF&M%LD_(T,)1#F24F'C8Y@'@/2"I;]T/':>XYG79!4)YE6^D`;\#CY*>;QA
MM*P/TC%;/XE^<5MDVLM.%T2RA%ZN2E/2TYF:1*7`CQ%Y;2B.'D"*U=6*11[&
M3L-8ENW.62[3Q;9+07,]=<FFS(L8AS-8M@35:4FY$Q`$4HZ(8D.NJ;R@3E#4
MQ@`<;R_*K5A6.5637E?+0TK95+I6K@AM'6M:B$I'AF=`8SS;+;O(=ULXM^!X
MNV5W6X/A`,B4-('E.O.$<&VFPI:SU)D)J(!N=82P_:>!L76CBNS&X)0UJQI&
MQW1R$*ZF)1<PN)><?B0//>RT@HHL?B(%Y@(70I2@%0&9Y;=,XR6KR>\*G5U3
MD^69Y6T#1MM,^"4)`2.N4SJ3'9KVLVWQ_:3`[=@.-(E;:!@)*R`%/.J\IY]R
M7%;KA4M75,)'DI`&5:Q>-@PI"%(0I"(UMUO;-Q%N-F']]V[)+XKR5(B*LI,Q
M$>C(6[<CH"\H.Y^WNLS_`,8GT#G=-ED5%=-5`4-QJ16U_>.RO;ZD19+@VFYX
MZWHAM:REUD?1:=DKR.I"TJ`X)*1I$'^\#W&=NMZ;D]E=E>58,W>U=>:;#E/4
MKEY[]/S(^T/SG6EH4KBL+5K$;KGLL9Z(\%-IE;$B[$3&Y7:XW>V<`0.7E%1F
M2WW)2J'U'@54P!IQ'C4AF^^)@Y9YG;7=4O\`T1V"A\BNU3IXTCQ1"=[\,+=E
M-3R4]_QY=+,^6HUB52TE-`IE@$ZZ!9&G&,]XP[*UN,7;=[F',$A/MTSE.M`6
M%#D@T5P#Q24GIE20="F8?*FU2-^D/&L'R7OBW!YI3.)6EMAPC1VI<[0CP]DV
M$)GXUJ$;<P/\,&RTM0BIW(R-VK:!!+%`R&0?`7WBXJ7A2RD^$1+%AS;AA+`<
M<$?BG'D!:ZAD2HNIE-MZ=<DB4I=!&1N*0,YEW7/XB45>37P*%1;R[</,\ZJ.
MWR>O?J4SFELGE:1^BTF3:?'RS\,6$;:[)[7;140I,`LU)0N%(2MX)[2I<`$O
MM*APJ>7/J*^7J`C-U87&U(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"
MD(ZY==X6I8L([N2]+D@[4@&)#*.YBX91G$QR)2E$VAG3U9%,RA@+YI`$3F'@
M`"-<C:[1=+W6(MUGIGZJN69);:0I:C\B03+K/`=,<)D&2X]B=K<O>3UU);[0
MT"5O5#J&6TR$_.64B?4!J>`!,1/9V[P>'+),]A<*V[(Y:FT@423N!\+BVK(0
M7*82@HFHY0^79I(!#71)!NF<.)5M.-2CPCNEY=>0BLS&H;M5&9$M)D]4$=1`
M/9MGQJ41THBO?=G\2';;%E.VS;&C>R"ZIF!4.<U-1)4#*8YD]N\/T4-I4/-=
ME$*N=][&XS<0HY;7W?SYG;"ZAC)V1:O-;UJ))"(\B+ADS4!S,`F`\#/EG)M>
M.H5,;"-F]OL`2ERR4*%W)(UJ'_M7R>L*4)-SZFTH$5?[L]Z+>C>5;C&5W=UJ
MQ+.E%2SIZ4#H2IM!YGI=;ZW3X1&I_AX5M&(]1S2$*0A2$92PYAG(>>K\BL=8
MS@E9RXI0PJ'$1,C&Q$>F8A74S./^0Z4;$L@.`J*F`1$1`A`,<Q2CC.79?8,'
MLCN09&^&;>U\JUJ/FMMIXK6KH2/"20D$C/\`;3;+,MV\LI\,P>D557A\S/0V
MTV".9Y]R1#;2)CF6>DA*0I:DI-D?;%VM,)880CKBR<W:9BR*D"2ZBLTUYK&A
M791*?DA;;7`4Y$4CET!Q(`J8WB5-+PJO'<GO-9EEZW+?C2EVC'S,`-G^\N)X
M?:.C5$_HM<LN!4KC%VVQ7<'VOVS:9O.=(;R3,D@*)>3_`'%E8D9,TRA)V1'Z
MRHYY\4MM\(D^;MV[1NBT:((M6K=,B+=LV230;H))ARD2112*1-),A0T`I0``
M"HUN...N%UU14ZHS)))))XDDZDQ.YEAFF933TZ$ML(2`E*0$I2!P``D`!T`"
M0CW5^(]L*0A2$*0A2$*0A2$=1ON_+0QE:4W?-]SS"VK5MYFH^E9>15!-!!(@
M>:DD0-573QR?0B*"13JK*&`A"B80"N6L=CNV275FRV1A=1<ZA82A"!,D]9Z`
MD#52C)*0"20!&.9;EN.8+CU5E>65;5%8*-LK==<,@`.``XK6HR2A"05K40E(
M)($5*-\6[^;W99-"2:D>1&,;2%S'8^MMR8"K`W5,4'MQRZ29C)?+<V*11,`"
M8&Z!2)`(B!S&M1V7VGHMK,<]7=*'<DJI+JGAPF/-:;)U[-N9EPYU$J($P!UW
MN]5WC[IWA<Y]=IP[3X-;^9N@IE&1Y21SU#H!EV[T@2-0V@(;!/*I2M)ZW)$6
MX4A"D(4A'9+-ME[>EW6M9\<'\ONJXH6W68Z"(%<34BVCDE#`''D3,XYA]P`&
MN.N]R9L]JJ;M4?J*6G<=5XFT%9_+*4<YC%CJLGR.@QRB_P![KZQFG1^D\XEM
M)/@!5,^"+QUBV=#X\LNU+$M]`K>%L^WHFW(U,I2E_DL2R19D4.!0`!67%(3G
M-XF.81'B-4LWR[U=_O-5>Z\\U95U"W5G\Y:BH@>`3D!T``1VJ\2QJVX;B]OQ
M.SI"+9;:-FG;$I>2T@(!,NE4N91Z22>F.T**)HIJ++*)HHHIG5565.5-))),
MHG4444.($(FF0HB(B(``!K7&I2I:@A`)63(`:DD\`!UF.><<;:;4ZZH):2"2
M29``:DDG0`#4D\(J_P#<MWO)Y\NC^:'&<FJ?$-DR9E)*30.)4+_NQD=1'Y33
MY=!4MV'$3$9`;@NKS+Z:=+2RGNZ;,*P6V?O7D;8&65C<D(/&F85(\AZG7-"Y
M+S1)''FG1!WX>].C=R_?#G!WU';JUODN.I,DU]4@E/:CKIV=4L3T6KF>E(M\
ML4M2@BOF/---191-%%,ZRRIR))))$,HJJJH8")I)IE`3'44.(`4H`(B(Z!7A
M2DH25K("`)DG0`#B2>@"/VVVXZXEII)4XH@``3))T``&I)/`"+7O;@VB?NVX
MI&Y[PCTTLMY+;,I*XP4(47-LP`D*YA[0`P@)DG"'4Z[X`$-71@(.O1*-5==X
M7=?XAY1^S+2X3BMN4I#4N#SO!Q_P@RY6_P`P<WSS'8/[E'=S^"6W_P"W<C9"
M=P[XA#E1,>52T\@IFD\"A/M'Q_6D(,^R28D=J/436B$_O82;E#%V$8A,YBM9
M*_;B>N2`;0IU(NWTDVX&+IYPE&1.(#KPJ9/<WIVUY+>:I0':-T+21XENDG_J
M"*O/Q0JUYK`<8MZ20P]=JA:A/0EIA*4S'3^M5%=*K`HI:A2$;B[*-I\YNNRR
MUMP0=QV/;;]&E\BW(@0Q09Q/5'H0C%<0%,)RX#)&10#B*9`46$!!/0=2;Q[H
MT6U^+*N`Y'+_`%$VZ1D_.7+5Q0_JVIA2NL\J.*M)+=UWN^77O`[A-V8AQG#Z
M+E>N-2!YC4_)90>';U!!0W]$!;A!""#;]MJVX.SK>A;4MF,:PUO6[&,X>&BV
M28)-6,<P0(W:MTB!Y")D#41U,8VHB(B(C53ERN-;=Z]ZZ7)Q3U?4.*<<6HS*
MEJ,R3\I\0X#2.Q[8[):L:LU+C]B8;IK-1,(99:0))0VVD)2D#P`:GB3,DDDF
M/MU\4<K"D(4A&B&__:5(;L,31L3:C]C'9"L>67N"TC2BAF\7+`Y:"TE(!\Z(
MFJ9D$BB4AD5A*)4UTB\^A!,(;OV(W4I]KLI<JKHA;EAK6@T_R":T25S(=2F8
MYN0S"D\2DF6H`B)G>_[N]9W@]O6;?8'FF<PM50I^D[4\K;O,CE=IUKD>3M`$
ME"Y2"T)YI)*B*]*7;HWGK3I8#^8VX$W`K]`9%:4MM.!*'-RBN:<&9&.%``X\
MP'$1#P`1X5/A?>!V?10FO_;3!;Y9\@0\7?%V?9\\_DBFUKN7=YER["S_`+JU
MB72OE[0NTP8'YW;]MV7+TS"B?!$]&P'8HAM0@Y:Z;T>Q=P9?N]HW9R;R,`ZT
M5:D(F8K@;=A7;A-)9VLX=:'>.N1,%3)D(0O(3F/!W?;>U>Z-:U;+.AUC$Z19
M4A*]%ON'3M7$@D)`3HVB9Y0229F0MO[H7=/9[OMKJ+_DSK%9N-<6TH<6W-35
M(R)*-.RM0!6I2Y%YWE2%%*$I'*GF7([4>HFM"D(4A"D(4A"D(4A"D(4A"D(4
MA"D(]+APW9HG<.UT&J"91,HLY6302(4H:B8ZBIB$*4`\1$=*_;;;CJPVTE2G
M#P`!)/R"/4^^Q3-EZI6AME(F5*(2`.LDD`1A"[MS^W2Q`/\`6S-^,(<Z8B!V
MZMXPKEX4P:^8+)B[=.^IYH^;R<P^Y6:6K;7<&]D?LNS7)U)Z0PX$_64D)EX9
MQJS(=]]E\4F,@RFQ4[@^::QE:Y]79MK4N>G#EG&LEV=TW9E:XJ)MLA3-WKIB
M(&1M*SK@>`80T_9NY1I#QRH&UX"580_36Q[5W9=W[F`IV@9I$'I?J&D_E2A3
MBQ\J8T7D/?X[L]A46V+Q4W%U/124=0H?(MY##9\861X8^G@;N2;<=P-]1V-[
M;6O"V[NFS.B0#*[H-NR:3:S5%1R9HRD(Z1DT"/CM43J%26Z7,!1`HB;A7S9Q
MW>-PL$LCF17!-)46ID)+JF'"I38)`YE)6A!*0H@$IG*<R`-8^_:7OM;+;OY6
MSA5E5<:+(JHJ%.BK92A#Y2"KD0XTZZD+*4E02ODG*0)5I&_M:*B7L*0A2$*0
MA2$*0A2$*0C$>7<\8AP1"?+V5[\@;/:'3449-'SGK34J*8"(IP\$T*O+RBG,
M&GP*)P`1#40K*\4P?+,WK/4<7H7ZMT$!2DB3:)]+CBI(0.GRE"?1.-<[C;M[
M<[36O]K;@7:DMS!22A"U<S[LN(981S/.GH\A!`/$B(6\^=Y>2<&?06W.QDHY
M#X1!*_L@)%<OC><``ZB;1:K"T;CR@(D,]76\?.1\E3#P;NATS816[@UI<7H3
M34IDG]%;ZAS'PAM*?`N*Q-WOQ,*UXNVG9BU)9:U2*^O`4YQ\YJD0>1.GFEYQ
MS\YKHB'#*.:,J9JG#W#E.^[AO23$QC(?*[XYF#`#?WJ+B$`1BHI$/XC=%,M2
MYQK#\8PZB%!C-%3T=-+7LT^4KPK69K6?"M1,5J9[N?N!N?=#><]NU9<ZZ9Y>
MU6>1N?0TTGE::3^:VA(\$8QK)(P.%(0I"%(0I"/MVU;4]>-PPMJ6O%NYNXKB
MDFD1"Q+%(RSM_(OEBH-FZ)"^4ZA^)AT*0H"8P@`"-?%<;C0VB@>NER=0S;Z=
MM3CBU&24H2)DGY/E)T&L<M8K'=LFO-+C]B8<JKS6/H99:;',MQQ:@E*4@=9/
M'@!J2`"8MX[)-HEN[3\8(Q9R-I+)EU(,I'(MS%*10RL@5+G2MV*6T$R<!!'5
M,FD`"'I"O,L8-3`4M46\VZ]PW1R0U*2IO'*52D4C/"29ZNK'2ZY($_1$D#@2
M>QKW6^[G9>[Y@J:%00]G%P0ARXU(D9N`3%,TKHIV"2E,I=HOF=4`5!*=T:T]
M$G84A"D(4A"D(4A"D(4A&#\^[AL8;;;&=7UDV<38-OA$(6#:F27N&Z),I.<D
M7`1IE$U':X\!44$2HH$'F4.4/'-<%P#)=Q+TFRXXP5N:%QQ4PTRCZ;JY'E'4
M-5*.B03&J]W=Y<$V2Q5S*LYJDLLZI883(U%4Z!,-,-D@J5TJ49(;3Y2U)$55
M=V^\_)V[*Z`<3ZQ[;Q]$.#FM+'<:Z5-%QY0$Y22LRIJ4)JXUTC?".#E`B0")
M$2D+KS6>;5;/XWM;;.SH0*B_.I';U2P.=76AL?T;0/!(,SQ6292Z_P#WBN\Y
MG/>$OW;791HL/IUGU2WMJ/9-\1VKQT[:H4#Y3B@`D>2VE"9@Z>5MJ(UPI"-X
M-J^P7-.ZR-D+FME2%LZQF#E6/+>%V^GD92LHB759A!LF#9=W)BU-H5=8.5%$
MP@43"?4H:7W-WSP[;"H;MMR#U7>G$A78,<O,A!X*<4HA*)\4IU4H:R`UB56P
M/=$W-W_HGKY9#36W%65EOURKYPAUT#5MA"$*6[R:!Q0`0@D#F*II&IV0+*F,
M;WQ=M@7!T!F[-N"4MR4,U.91JH\BG:C155L<Y2',W6%/G()BE-RF#4`'A6TK
M#>:3(;+2WV@YO4JMA#J.824$K2%`$=8G(^&(\YAB]RPG*KAB%XY/VI;:QVG=
MY#-)6TLH)22`2DRFF8!D1,`Z1U"N6C&XS-MTNV)L3/6'KQG2I#"V[D6U)*4,
MO^Q18I2S8KERKJ(?!M$CBJ/'@!*P_<&U55\P>[6BBGZY46]]")<2HH,@/"HZ
M?+&S]E<BM^);MXYDEV"3;*.\TCCO-YJ6TO(YE'P($U?)%V61FH>)B75P2DK'
M1T"R9'DW<R]>-VT6VCB)]<SY=^LH1LFU!'SNH)N73CK5-M/1U=55IH*9IQRM
M6OD2VE)*RN<N4)`F53TE*<=HJLNELMUM<O%?4,LVEIHNK>6M*6DM@<Q6IPD)
M"):\Q,I:SBNEO_[E)\H-YG"N`9!RSQXL*D?=]_I==G(7JF0YTW$1`!JFLRM1
M80T56,!5GQ?-`"(B/5L#V)[NHQEQG,<Z;2N_B2F*4R4FG)U"W>(4^/FI$TMG
M75<N6E[O?]]]6>,U.V&T3RV\.42W5UXYD.5H!(4TQP4BD5P4L@+?&DDM$AR&
M&I?Q6/"D(FK[66R4U[S,?N4RA$`:S+=>F4QC!R"("E<]QL5C$-=+ENJ405A+
M?<IB#74.5P]+S>]1\^'7>:WE%EHW-N\:=_\`R]0B58XDZLM*$^Q!'!QT'R^E
M+9EQ7I:%W!NZVK*;FSO;GE-/&J-V=L8<3I55+:I&I4D\6:=0^SGHX^)^:T>:
MQE5?,730I"(Q>ZYA*:RSMN3N2V63F2G,1W`%Y*1S1,5G+JW'#):,N,Z")"F5
M648-U$W0E+QZ2)QT$0`*DEW7<RH\6W#-NN*TMT5U8[`+49`.A06U,\`%$%`)
M^<H1!3\03:ZZ;A;)B]V-M;]TQZK]<+:!-2Z92"W4%(`));!0Z0/F-K.LA%5R
MK.8H"CON,<9WIF&^;?QUC^&<3ET7(]39L6B)1!%NF)@%S)2+C02,HN.1U5<+
MGT*FF41XCH`\'DF1V?$K*_D%^>2Q;*=!4I1XD]"$#YRUGR4I&I)C+\#P7)]R
M<KH\,Q"F757VM="$('!(^<XXK@AIM,U.+.B4@D]47%-K6W"T]KV)8;&]M=-]
M(ZA*WA<@HE2=7/=#E),K^15'3J$9H\@(M$A$>BW(4/?"81J2W-W#NNY>5/9#
M<9HI_,89G-++*2>5`Z.8^<M7SEDGA(#LH;![*8]L/MY3859.5VM_6UE3RR54
MU2@`MP](0F00T@D\C:4C57,3L96O8W3"D(4A"D(4A"D(4A"D(4A"D(4A"D(4
MA'.@CX`-(1T6[,GXVL-$[B]L@69::29!4,-PW-#1)Q*7744TGKQ%94>'@4HC
M7-VK&<BOBPBS4%95*)E]DRXO\I2D@?+&)Y#GN#XDT7LHO%LM[8$_[Q4LLF7@
M"U@GQ`$QJ)>W<PV:V3U$S973NQV0#"#2QX*9N(5!)KJ0C])HA#\PCX<SDH#[
MNE;6LW=RW=O,E"UFE:/SJAQMJ7C25%S\B#$=,I[\?=IQ::57\7!\#S*)AZHG
MXG`A+/BFZ!X91J->?>JQ:PZZ5@X=O>Y3E$P(.KEF(>UFB@!KRF.DR+<3LG-Y
M0Y>'Z:VO9^YUDK_*J^W:CID](9;<>4/E5V0_EB.F3_B?8'1\[>(XY<ZU8/DJ
MJ7F:5!ZC)L5*AXI1JC>/>;W!2Y3I6;8&-+,((FZ;AVA-72^(!N`:G=2$:Q,<
MGD'T?37Q`0X5M"T=T'`Z0A5WKKC6'J26V4_D"5JU_2B/N2?B:;OW%);QNT62
MVIU\I27JIP?*MQM$Q_HO&#&J=X]Q+>3>IU?3LW7!"-U/!I9[*&M-),HAH)"+
M0L<U?F*.O'G6.(^[6T+1L!M%9@.PLS#RQ\Y]3CY/R.+4G\B1$?<E[YW>4R=:
MC59164K*OF4B&:0`=04PVAP_SEDQJU<N1<@WFH96[[ZO&Z3G,)Q&X;FFID.8
M1$VI22#UP0@`81T````\E;,MV/V&SIY;314E*D#^B9;;_P"JD1H2^9MF.3J*
M\CNMQKU$S_O%2\]TS_I%JZ_DCIGF@.O`!'R\-1'_`(Q&N7UC&=3XHRYCC`V9
MLN2+>,QQC.\KL6<G`A7,=!O0BD=3`45'<TY20B&2)-=3&56(```CY!K%<ASC
M$,4IU5&0W*DI4)'!;B><^!+8)6H^!*28V)A6T>YFXM8BBPNQW*X.+,@IMA?9
M#PK>4`T@#I*UI`UUTBP;L%[;CG;]/-,QYBD(^4R>@S=-[<M>(5*]A+,!^B+=
MT^=R7(!9:XCMCG2**/\`)FQ#FY3*F$#E@9OIWAV\[H5XCB*'&\;4M)=><'*Y
M4<IFE*4?,:G)1YO+60)A(!!N*[HG<F>V?NS>Y.Y+K+^=(;4FFI62%LT?:)Y5
M+6Y*3M04$I')]FV%*DIQ1"DR[5%&+&84A"D(4A"D(4A"D(T=W\[K'&U3#03M
MN(MG61+SD5+:L5-ZD5PRCWA6QG4C<+YL8!*Z0AF@`8B1O,5<*)E-YO,%;IV+
MVO;W/R_U*X%2<?HVP]4E)DI29R0TD_-+BN*AJ$A1&LHBKWNN\"]L!MI^U;*E
M#F97-XTU"%@*0VOEYG*A:3,*2RF7*@^2IQ2`KR>:*F5\W[>>3+FD;QO^Y9>[
M+FEE3+/IB:>*O'1^81$J*/./3:M$0'1-%(I$DR\"E`.%6FV6QV?'+<W:+%3-
M4MM:$DMMI"0/"9:J4>E2B5$ZDDQUY<KR_)\YOCV29=75-POE0J:WGEE:CU`3
MT2D<$H2`A(T2D#2.HURL8W"D(4A"D(4A"D(4A%A_M,[/TK=@DMSV0(H?K#<+
M9RTQ5'ODA`8FW%RB@]N\$CAJ5[/E$Z+0PAJ1F!CEX+@(0$[TV[*J^M.VUA=_
MN%.H*K5I/GNC5+$_HM:*6.ER23YABYG\//NWMV:U)WUS"G__`#%8A2+4VL?J
MJ=0Y5UDC\]\30R>AGF6)AT$3?5"^+3X4A"D(4A"D(4A"D(4A&@>\;?[C/:Q'
M.;>8&:WSF!TU$T99#-T'HL)UD]6TG>;U`3&C&6I@.1L7^5N2AYH$(/4#>NT>
MQ.1[FU":]\+HL22KRZA2?*<D=44Z3YZN@K/D(Z23Y)B#WE>]]@^P=&NS49;N
MNXZVYMT2%^0Q,>2Y6+3JTC@4M#[5P<`A)[05=LSYOR9G^]7E^Y2N5U<,XX*9
M!FD;X"*@X[JG52B8&,3'T:,C43'$0(0.8YA$QS&.(F&RW$,,QS!+.BQXS3II
MZ).JCQ6XJ4BMQ9U6L]9T`T2``!%#.YNZF<;OY,YEF>5SE9=%CE0/-:9;F2&F
M&AY+3:23)*=29J45*)4<3UE,:[A2$21[#]@ER;GYMO>U\(R-MX-AGFCZ5(`M
M9&^'K54O5MZV3GT.1J`@)7C\H"1`-2)B*WO(\;W[Z6[;6B59K,6ZG-7D>2CB
MBF21HZ]+YW2VT=5><J2.,W.Z7W0[WOK=491E*7J+:RF<\MT>2Y6K0=:>F)U"
M>AY\`I;$T(F[YEIRUK7MVR;=AK2M*'86_;5O,$(R%AHQ`K=E'L6Q>5)%%,O_
M``F,81.<XB8PB81$:R;G<[A>;@]=;J\M^XU"RMQQ9FI2CQ)/_(.`$@``(OUL
M%@LN+66FQW':9JCLE&REIEEI/*AM"1()2/Y23,J)*E$DDQ4F[D=FJ69O*S$@
M)!*A<<C$7DT/RB4BJ5RP<>^7,GJ`<P$?=8AA#ASD,'DJU/N\W=-XVBM"P9KI
MVW*=76"RXI(G_-Y2/`1'7<[[6-+QGO+9(RH2:K'VJQ&D@14L-N*EUR<*TD_2
M!'1&C-;JB*,*0C*T[G7,]S61&XVN'*-\S-@Q!$$HZTI"XY%Q!MT6O!H@+(ZX
MD6;LPX(IJ<Y$@`.4`T"L7HL)Q"VWES(J"VT3-\=)*WTM(#A*O./,!,%7SB)$
M],XV%==V=S+YBS&$7B_76IQ*F"0W2.5+JF$A/F)Y"J12CYB53"-.4"48IK*(
MU["D(D,V"[(YC=->Q;BNIN\B\*6@_1-=$J4%&ZMTOTA*L2SX%P'*(K+ET%ZX
M((^B(#H'PAR!6@]\]YJ3;*S>H6Q2'<QJT'L4:$,I.G;NCJ']&D^>K\T*B9?=
M$[K5SW[RD7F_H<8VQMSJ35.ZI-4L2(HV%:>4H:O.`_9-G3RUHBU["0D1;4/%
MV];\:SAX.$8-8N(BH]$C=E'QS)$C=HT:H)@!$T4$2`4`#W*JYK:VKN-6[7U[
MBWJUY:EK6HS4I:C-2B3Q))G'8.M5JMMCME/9K.PW36JE90TRTVD)0VV@!*$)
M2-`$@`"/J5\T??"D(\3%*<IB'*4Y#E,0Y#E`Q#D,`E,4Q3`)3%,4=!`>`A7D
M$I(4DR4(\*2E:2A8!21(@Z@@\01$8&:.T[MQRK=#J[;>>W/BB0E':CV9C;.-
M'.+<>N7"@*N7#6&E6K@D.LL83#RM3IMP,;4$O)4E</[TFX.,6Q-JN"*:Z,-(
M"6UO\X=2`)`*<01V@&FJP5F7G1`_<[\/;9;<"_+R&SNUV/U;[A6\U1]FJG6I
M1FI2&74*[$G71I26P3,-QM!MMV@84VM1;QMC:#<+3\LBFA.WM<+@DE=,NBD(
M'*T,[*BW;1T<"H<WHS5)%(Q@`QP,8`&M:;B;LYCN;4H<R%Y*:!HDMT[0*&4$
M_.Y9DJ7+3G6I2@-!(&4;XV2[N&V&PE`XSA-*M5WJ$A+];4*#E4ZD:A'.$I2V
MW/7LVD(23(J"E`&-H:UI&^84A"D(4A"D(4A"D(4A"D(:"/A2$==N.\+2L]FI
M(7;=-N6LP2+S*/;BFXV%:D#34!,O(N6R8:@'#CQKD+?:+K=G0Q:J6HJ7SP2T
MVMQ7Y$`F.$O62XYC=,:S(KA14%(D:KJ'VF4#QJ<4D?RQI[?W<>V=X_%9)WEQ
MA<[Y`3E&/L:-DKJ6.H0=!2*\8-ODDIA\@G<%+^FMM6/N\[MWZ2FK4NF9/SJE
M:&1+KY5'G_(@GP1&_+N^OW;L/YD5&0M5]2F8[.A;=JB2.@+;3V/RET#PQI7?
MO>JQXP%PAC3#MUW(<HF!M(7?,QML-#AQ`ISLHU.?>::\1*)B\.&ON;CL7<YO
MS_*O([O2TZ>E+#:WE?666D_+(Q%_+OQ/\.I.=K",;KZUP'R5U;S=,@^$H:%0
MKY.8>.-,+Z[P&Z6Y3*)VHRQ]CMJ;F*08JWU9Z0(0>!1,\N-V_;"J4/$Q6Y0$
M?('A6W[)W3=L[<`;HNON#HX\[H;3]5I*3+P<Y\<1ERK\2#?J]J4FP-6BSTYG
M+LJ<ON#J\NI6ZDGPAM(\`C3R^MX>Z')'5)=V<LA/&RPB)X^.G%K=C./B!8ZW
M`BF90$.&@$XA6V[)M+MKCTC:K+0(<'!2VPZOZ[O.K^6(V97WD]^,U"D9#E5X
M<949EMM]5.W]U3]DW+P<NO3&N;MTZ?KJ.G[EP^=+&$ZKEXNJZ<*G'Q.HLN=1
M0YQ]T1$:V"TTTP@-,)2AL#0)``'B`D!&EJBJJ:MY515.+<J%F:E*45*)ZR22
M3\L>BOW'HCZL-!3EQ.TX^WX:6GGZI@(DRAHUY*.U#FX%(1LQ176,8WD``U&O
MEJZVBM[1?KWFF&!Q4XM*$CQE1`CDK;9[M>:D4=HI:BJJU&00RVMQ9)X`)0%*
M/R"-NL?=OC=[DCH*Q.&;@@V+@H'+)7LJQLYJ"8CH)Q2G'#60-R^4I4#&]P!K
M5-^WZVHQ[F357=AYY.G)3A509]4VPI/Y5`>&)%8=W.>\9FO(Y;\:K*6E6)AR
MM**-('614*0Y\@03U"-W;`[+&49(45\EY;LVU$3#\,RM2,D[M?D#0!T!P^&W
M67-QT'3F#7RCY=,W[OB8S3<R,<M595+'!3RT,)/R)[57_)$I\/\`PP\\KN1W
M.,AMMO;/G(I6W:M8'Z2_5D3^4B-V;$[/VURVBHJW<_R!D5V02F4+*3R=OQBA
M@#SB@QMQLQ=%2,/@4SDXA_&&M-7OO9[EW$E-J;H;>T>'(V75C^<Z5)GX>0>*
M)1XE^&_L/8DI7D3UWO50"">U?%.V3X$4R6U@>`ND^$QN=8>T?;-C/IFLS"./
M8UPD4A22#N!;SLK\'Q(8TK/_`"G('4`>/,*FNM:?OFZVX^1S%WO->XV2?)2Z
M6T:_F-<B)>"42:Q/NZ;&8/RJQK%K.R^D`!Q;"7W=.![6H[5R?3/FG.-AD446
MR*;=LBDW;HD!-)!!,B**1"@`%(FDF4I"$*`<``-`K`5K6XLN.$J<)F2222?"
M3&Y&FFF&PRPE*&4B02D``#J`$@!XH]E?F/9"D(4A"D(4A"D(4A"D(T'[A6U"
M7W48>8Q]G+MDLB6%*K7':39ZL1LRG"N&HM):WEW:@@FS4?MP*=!4_P`&5=(A
M3B4AC&+O/8/=&EVRRU;]V2HV"N:#3Y2"5-R/,AT)&J@DS"DC7E42)D`&(O?'
M[OEQW]VW:H\;4A.96E]512)60E#X4GD=IU+.B"XD)4VH^2%H2E12E14*I=\X
M]OK&<X\MK(-I3]G3C%8Z#B.N",=1RO.0PEYT#KIE1=H'TU(JD8Z9R\2F$!UJ
MT&RW^R9'1(N-AJV*NB6)A;2TK&O7(S2>L*`(X$1U^,JPO+,'NSECR^W5ENNS
M2BE3;[2FU3'2GF$EI/0I!4E0U22-8ZDW06>*E0:(K.USB`$1:I'<+&$1T`"I
M(E.<PB(^0*Y5Q:&DE;I"4#I)D/RF,>:IWWW`RPA:W5<`D$D^(#4QLYC+9=NA
MRZ=N:S,-7@:/<F*!)RX&'U3@@*?P5^4[C-&H+)?I2ZE:WR3>#;7%$J%WN]('
MTC]6TKMW/%R-<Y!_2E&],%[L6^^XJD*QK&KD:-9$GZAOU5B1Z>UJ2TE0\*"J
M)"\>=EG*,JF@YR=EFT+/(?BK&VM&2%W2"("`"`'=.U("/!0!'00**A?<,-:#
MO_?#QFE4IO&[75U9'!;RTL)/R)#JI>.1\$3(PS\,3/*]"'\ZR"W6T'SFJ5MR
MK<`\*E&F;GUR*AU$QH5O-VMFVEY6:8[)>*5[L)2VF%S1LL,>2)D$F[MR[9J-
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M5F+AD?'L8E@QBXQH@PC8UHVCX]BU3*BV9L6:)&[5JW2(`$20;H)E(4H<`*&E
M5*U#[U4^NJJ5*74.+*EJ)F5*49J43TDDDDQV2*.CI;=1M6^A;0S1,-I;;0@`
M)0A"0E"4@:!*4@``<`(_77JCZ84A"D(4A"D(4A'X)65C(.-?3,U(LHB(C&RK
MR1DY)TBR8,&B!1.LY=NW!TT&Z"1`U,8Q@``KWTM+4UM0BCHVUNU;B@E"$)*E
M*4>`2D3))Z@(^.X7"@M-"[<[H\U36YA!6XZZI*&VT)$RI:U$)2D#B20(@:WE
M]V$RGRIC?:T[,0GP[&8S"J@)5#>*2J-AL72>I"CQTDER`/E03]ZK4X=H>ZV$
M]GD.YB)JT4W0`Z#I!J5).O\`H4GP+5Q1%2G>9_$(4OM\*V%<(1Y2'KN4R)Z"
M*%"AH./]Y<$^EI`\EV((I&1D)A^\E99\\E)21<JO)"1D'*SQ\^=KG%19R[=N
M#J+N%U3F$3'.83"(\1J;M/3T](PBEI4(:IFTA*4(`2E*1H`E(D``.``E%3%=
M75MSK'+A<7G'ZYY96XXXI2UK6HS4I:U$J4HG4DDDGC'XZ]T?+''AXTA$P.Q#
MMH3.8#Q66,\1\C;F+`Z#^WK24$["?R!RJ`=-9\0Q2NH:TU"EXG\QR]*.B7(F
M/5&)N]_>,H\32[B^$.-U&3:I=?$E-4NFH2?-<?'5JAL^=-7DQ9%W3.X[=-QE
MT^X.[++U%@0Y7*>D,VZBOD9@K'G,TAEJK1QX'[/E0>T-DF$A(>VH>-M^WHMA
M"0<,S0CXJ)C&J+*/CV+8@)H-6C5`I$D44R!H``%5WUM;5W&K<KZ]U;U:\LJ6
MM9*E*4=25*.I)B[>U6JV6.VL6>S4[5+:J9M+;3+20AMM"1)*4)2`$@#H`CZE
M?-'WQ`;WGL)/U'&.-P$2R,JP19CCF\5T4Q$6B@.G,K:KUV8H>:BX,Y=M^<>`
M'Z9==3%`9T=S_,V`W<,$JER?*_6V`3YPY0AY*?".5"Y=7,>@Q41^)MM;5K>L
MN[]N:*J1+7[.K%)'F$*6[2K7U)5SO-\Q^<$)XD3@4J<<5'0I"%(0I"-[]DNQ
MZ]-UUUI23Y-];>'()\4EV7ET^DK(*(@"A[<M;K$$CV7<`(%55`#(LDS<YQ$_
M(F?2.\F]%GVNM9IV2BHRU]'V%/.82#IVKTM4MCYJ=%.$2&G,H2U[KG=6R?O`
MY`FNJTNT6V]([*KK)2+A&IIZ7F$EO*T"E2*&4GF7-7(A=K^PK"M'&%H0-AV)
M!L[=M6VV*4?$Q3$G*DBBGQ.JJ<=5'+QTJ)E%EE!,HLJ8QS")A$:JXOM]NN2W
M9^^7MY=1<ZA94M:CJ2>@#@$@:)2)!(````CL'XCB..X)CE)B>*4K='8*)H-M
M-(&@`XDGBI:S-2UJ)4M1*E$DDQV^N)C)(4A"D(4A"D(4A"D(4A"D(4A"D(>3
M4>`!Q$1X``>41'P``I`Z:GA&%\@;C<#8L35/D'+M@6PJB&IV#VY(Y67T`=!$
MD*R6=2RO'AYJ(\:S&P[>YQDZ@+#::ZI2>"DM+#?WB@$#Y51K#+]ZMI,!23E^
M16BA=3Q;74ME[Y&$%3Q^1!C1G(/=YVKVF"Z%IIWSDI^D)RI_(<#\BQ*ARCIH
M,G<BT<MR&\ATVRI1K=5A[J&YMT*5W4T5N8/'M'>T6/YC(6/D*Q$4\Q_$:V#Q
MX+:QY-UO=6F8'8,=@T2.MRI4VJ7A2TL1HQD+O2Y5E`<ML9XILVT$#B8K>2N>
M0DKLE"%$/-4!LU^0HU)4!\ABKEK=E@[GF+TO*YD=TK*MP<4,I0P@^":NU61X
MBDQ%',OQ.\_K^T8P:P6VW-$D)<J7':MT#H/*GU=L'P$+$:27WW!]X&017)*9
MJN.$9N`$IXZS$V%H-0(;4#)@I!M6K\Q#%'00.N8!"MRV38;::PA)IK/3O/)^
M?4%3ZI]<G"I,_$D1%O+.^+WCLP*TUV3UM-2K$BW1AND3+I$Z="'"/`I9C4F;
MN"?N5V9_<<Y,7`^.)A,]G)1]+.C<PZFU</UW"O$?TUM2CH*&W-=A;V&6&!\U
MM"4)_(D`1'>Z7J\7RI]<O574U=6?GO.K=7]9:E*_ECY%?7'&1P(@'B.GZZ1Y
MX\([M9V-LAY#=D86'8MW7D[.(`"-LV]*S.GG<G,H=@U7323*;Q,8P%+Y1"N&
MN^16"P-%^^5M)2-#I>=0W^3F4"3X!K&4XU@V9YE4"DQ.U7&Y5!,N6FIW7I:R
MU[-"@D`\29`=)C>/'?:PW?WWT%Y&S87'4>L;SG=^7"S9.4RAIJ(P\.$S+`<2
MCP`R1`$>`B'DTOD'>;VGL?,BGJWKA4`>;3-*4#_K'.S;_(H^(Q*G#>X)WC<L
MY':RVTUFHU'5==4(0H#K[%GMGI]04VGJ)$;VX\[*,&CT'&5LUR<@8#`+B)L&
M`;QJ)@\1(2;GE9!7@/`1!F&H>&E:1O\`WQZQ?,WB]G;0.A=2Z5G[MH('_F?E
MB6>&_A>VIKD>S_)WW2#Y35!3I;!\`?J"X?\`R!\D;SV!VT]G5@`FH7%:%Y/D
M^0?3[^E9&YA,<H!J8T<LNC"Z'$-1+Z-RAY`K2=][Q>[=])!N9HV3\VF0AG_I
M@%S_`*<2MQ#N/]VW$0%"P)N52)>77NN5,R/_``BI+&O2.RE&Y-KV19=D-"L+
M-M*VK49D3*D#:W8.-ADNF3WI#%8-D.<`T\NM:BN=ZO%Z=[>\5=35/3G-UQ;A
MG_.)B2UAQ3&,5IQ28S;J&WTP`'+3L-,B0X`AM*9_+':-=?&N,CGX4A"D(4A"
MD(4A"D(4A"D(4A"D(4A"D(4A'QIJW+>N1$K:XH&%GVY.;D0FXIA*HEYO?<J3
M]NN0O-IQT#C7V4=QN%N7VEO?>8</2VM2#^5)$<7<[)9;VT&;U1TM8R."7VFW
M4B?@6E0CYD38-B0"P.(*R;0A5P,!P6B;:A8Y4#AH(&!1FR1.!@$`XZZ\*^FJ
MOM\KD=G75M6\B7!;SBQ^12C'PV_#\2M#@>M-KMU*\#/F9IF6S/KFA`,X[:(B
M/B(UQ49%'P;HN:$LRVYZ[KE?HQ=OVU$OYR:D7!@(BSC8ULHZ=K&$P@`B5)(=
M`\3&T`.(U]ULMM;>+BQ:K<@NU]2ZEMM(U*EK(2D?E/R1Q%_OMJQBR5>1WQY-
M/9Z&G<?><49!#;22M:C/J`,ATG0:Q2WW,9PF-Q.:[YRK+&63;SLH=O;D<J<Q
M@AK4C1%I;\60!'0AD6!"J*Z:`9PHH;^%5PNW.&4F`8;18Q2A)<8;FZL?TCZ_
M*=6>N:M$]20D=$=8K?/=2Y;S;H77/K@5!FJ?*:=LF?8TK?D4[0ZN5L`KEH7%
M+5\Z,#UG$:CCR3345.1)(AU553E3323*8ZBBAS`4B:9"@)CG.80```-1$:\*
M4E*2I1`2!,DZ``<2?!'[0A;BPVV"IQ1```F23P``XDQ;O[>NV@FV_`,*VFF"
M;?(V0"MKOOQ4Q`]*9KNT.:&MM13B8"6_&JE(<@>:#I180\=:JCW\W&5N%G3R
MZ-PJQZ@FQ3"?DJ"3]H\!_P"*L3!X\@0.B.QGW.-CD;*;14K5S9",TO`35UQ(
M\M!6G[&F)UTIVR`H<.V4Z1QC>RM(Q+*%(0I"%(0I"%(1JKN7WC85VMPIW%^3
MI9&[7+8ZT%CR`40>77,&Y1Z*BK<3@E"QAU-`,[=BFGIKR`H8.4=G[<[1YCN9
M6!NR,=G:DJDY5.@I9;ZP#Q<7U(1,]?*-8T!OAWE-L-A;87LLJP]D*T%3%O8*
M5U3QEH2F<F6R>+KI2GCR!:ARFLQNGWR9FW3R:S:X)$UJ8[0<=2(QO;[M=.&3
M*0?@G,\Y#HKW+)@''J.`!%,W[))/RV.[9;+8AME3!R@;]:OZDR<JW4@N&?$-
M#4,H\"?*(\Y2HHQW][U>YF_E<IB[O&WX:A<V;=3J4&1+@I]6BJEWIYG!RI/Z
MM".G3.MOQ&2%(1]JW+;N"\)R,MFU863N*X9IVDQB86'9KOY*0=K#RIH-6K<A
MU5##XB.FA2@(B(``C7QW"XT%IHG+E<WFZ>@925+<<4$H2D<25&0'_/P&L<K9
M+'>,DNK%CL%*_67BI<"&F64*<<<6>"4I2"2?DT$R=`8L1[(^UM"X\-#Y3W&L
MHZYKY3%M)0&.3"E(6U:2Y>59!S<@^>UN*?;GT$$0YV+<P?WX^AB0"WF[S%9?
MP]C.WRW*:RF:':O5+SXX$-=+31'SM'%CZ`T-S?=:[A-LPTTV>[TM,UV4CE<8
MMQDY34BM"E53Q14/I,CR#F8;(_I52*9GRE*4H%*`%*4`*4I0`I2E*&A2E*&@
M`4`#0`#PJ'Q))F=28LW2E*4A*0`D"0`X`1S7B/,*0CIF0L?VEE2RKCQ[?40A
M.6I=4:K&3$<OJ7J(J"4Z:[=4OGMGK-P0BR"I=#I+$*8.(5S%@OUUQB\T]_LC
MI9NE*X%MK'01Q!'2E0FE23HI)(/&,9S+#\>S_&*W#\JITU5@KV2TZV=)@ZA2
M2-4K0H!;:QJA:0H:B*R6Y7M;YYQ'-R4GBV%D,Q8Y.LLO&.K>1(YO.*9B)SIL
MIVV4A*[>N6Z8<OI#`BZ:VG,)$A'D"R#;KO,8/E=&W39*\W:,@``6ETRIUJT!
M4T\?)2"=>5TI*>$U2YC19OAW"=VMN[H_78%2O9)AA4I32Z=(56-(U(0_3)\M
M:DB0YV$K2OSN5LGD$=LI85]0CM6/F;*NZ)?(F,19G)6U-,721RCH8IT'+)-0
MIBCX@(5O^FOEDK&@_1UE*ZP>"D/-J2?$0HB(9UV'Y9:ZA5)<[9<*>J22"AVG
M=;6".(*5H!'RB.SV9@[,N1'J4?8^*\@70Z5.!`")M297;D$1`.9P]%H1DU3#
MF#4ZJA"!Y1"N-O&:8A8&347JYT%,V!/RWVP3XD\W,H^``GP1SV,[4;F9E5IH
ML6L%WKGU&7V5*\I(\*EA'(@=96H`=)B5_;-V@;VGW\?<^Y612LVVTC(N?YOK
M>D&\A=<P7S%`;3$TR.M&6\U.`\J@('<NAXAJD/G5%W<?O8V6@8<MNW39K+B0
M1ZTZDI8;XB;;:I+=/5S!".GRQI%@VQGX<.47>K9ON]SR;;94D*_9].XERK=&
MAY77D%35.DZA7(IUSB/LSY46"K3M*V;$MR'M"S8*-MJV8!DE'P\)$MDVC%BT
M1+H4B:28!S*''4RBAA,HJ<1.<QC"(C`RZW6Y7RX.W:[ON5%R?65..+)4I2CU
MD]'0`-`)````1</CN.6+$K)38YC5(Q16.D:#;++20A"$)X``<2>*E&:E*)4H
ME1)/8JX^.:A2$*0A2$*0A2$*0A2$>"JB:"1UUU$T$4BB=198Y4DDR!XG.HH)
M2$*'NB.E?I"5.*"&P5+)T`$R?$!'X<<;9;+KRDH:2)DD@`#K).@$:X9&W@[8
M\4BNE>V:K$8OVY5!4AXR73N.;*=(-11/$6\$F^15,/``4(34?+6PL?VEW(RC
ME59[/6K841)Q;9:;UZ>=WD21XB8TIF?>1V+P`K;R;)[4W5H!FRT\*E\$=!9I
MNU<23P',D:QH9D7O+X&@.LVQS8M^9#=$!0J3V0(QLR$.<`$$E"J/CR$T=(3\
M1`S)(VGZ?#>./]T+.*Z3F0UU#0-3$TIYJAR73HD(;!\3BHB3FGXF&TMH*F,+
MM5UO#X!DXYR4;!/005EUXB?$%A!E&AV1.\3N4N<54+%@+!QFR-J":S:-<77-
ME*8HE$#R$ZJ$8(AKJ`D8)F`?+6\,?[I.W5MDY>GZZXO#B"L,-_5;'/\`(73$
M2\S_`!)M[;Z5-8K26FQTIX%#:JI\3$M7'R6CX"*=)C16_MU&X[*!E`OG-60Y
MINH(B:.)<3V)A^(CP"&A3QT4`<=/V.NE;LL6V.WN-`?L6ST#+@^?V25N?>.<
MZ_\`I1$_+]_]ZL[4?WIR>\5+)XMBH6TS]PR6V?\`H1@,YC*'.HH8QU%#&.=0
MXB=0YS")C'.<PB8QC".HB(ZB-9R`$@)3HD#0=`C4*UK6HK625$S).I)/$GPQ
MQ7F/S'&NGCPI'F.[V9C3(F1GJ<=8-BW=>;U4W*1"V;>E9D0'FY1%0[!JLDD0
MH^^,<Q2E\HA7#7C([!C[)J+[6TE&R!.;SJ&_R<R@3X`-3T1E.,X-FF9U2:+$
MK3<;E5*,@FFIW7C\O9I5R@=),@.DQO?C;M3;N;\,W7F[;M[&,8L.IW=\W`V*
M]3)YHB(0EOEFY+J<IM0*J5$!'@)BCKII#(N\_M58PI%'45%RJ1\VF:/*3_I'
M>S1+PI*NN1B6F$?A^=XC+2AVZ45'8Z%1U775"0L#P,TX?=G+@%I1U$C66_>-
M^RM8;#T=UEC+]R7*J40,O$V1$LK98&$.(IC*2IIQ^JF(\!$J2!M`U`0UX:+R
M'OBWM_F:Q:TT].GH74+4\KQ\B.S2#XU*$2\PG\,'$J/D?W`R.MK7`9J:HFD4
MR#X"Z]VZU#HF$-GITGIOQCC8'M'Q@#=2#PQ;4S(-Q`Q9:]BN+U?F.`Z@II<2
MKYBDH4W$!31)H/AY--&9#OMNKDG,FLO%2RPKYE/*G3+J^R"5$>-1B76%]T+N
M[8*$+M>,T-56(,P[6A5:N?7*H+C:3U<B$RZ(VVBXJ+A&:<?"QD?#QZ/[)C%,
MFT>S2X`'P;9HDBB3@`>!:U74U=56O&HK'7'GSQ4M14H^,J),2(H+=;[53"CM
M;#--1IX-M(2V@>)*`$CY!'[Z^>/LA2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2
M$*0A2$*0A2$*0A2$*0B#?N_[GRP\%%[8[3?"$G<:4?<^2UVRN@M8%%P+BW[:
M5Y#`)5I5ZV*\7*/]X22#005J:G=.VU];K7=R+HC^[TY4S1@CSG2).O"?0A)+
M:2/G*5TIBJC\1_?<6VU,;&8\[_?:U+=3<E)/FL!7-3TQD=%.K2'E@_,0WH0Y
MI7JJ>\4W0I")*.V!MN#..?6MWW`Q%Q86'18W9+`LGS-)2YA7,-IPAQ.0R:I?
M3&YWBQ/*DUY3<#AK';O)[AG"L%5:J!?+?+MS,(D?*0S+[=P=(\DAM)ZUS'")
MP=Q#9(;J;NMY%>&BO$L;+=6[,>0[4\Q]48,Q(CG27ECZ+7*=%B=K6JO8[!$*
M0A2$*0A2$=,OW(MB8NMUW=N1+L@K-MQD417E9Y^BQ0,8`$P(-2*&Z[YV<`\Q
M%$JBIQX%*(US%CQ^^9-<$6K'Z5^LN"^"&DE1\9EHE/6I1"1TD1C&79IB>!69
MS(<SN%);;,T/*=?<2A)/T4@^4M9^:A`4M7!*28@>W4=WF9FRR5F;8F"]O1I^
MHU<92GV9/EYTF("0ZEJP+@%$(A,^H\CEX"CC3B5)(V@U-_;'NHTE$6[QN0M-
M14B2A1-*/9)/4\X)%P]:&Y)ZU*&D5+[_`'XC5RNB7\9V+971T)FA5T?0/6%B
M4B:5A4TLCJ<>"G.D-MJD8A*FIN9N26?SUPRLC.3<JY4>24M+/%W\B_=*F$RB
M[MXY.HNNJ<1\3&&IET=%1VZE;H:!IMFC:2$H0A(2A*1P"4@``>**MKI=;G?+
M@]=KS4/55SJ%E;CKJU..+6=2I:U$J43UDQ\NOICCX4A&U&V?9YF;=+.D9V)!
MGC;3;.")3V0YU%PUM2&)S@"J:;H"<TS*%+J)6C7G4U#SQ3+YP:QW&W:Q#;.B
M+M[>#ET4F;=*V07W--"4S^S1_P"(N0ZN8Z1(#8WNV;F;]784V*4I9Q]"P'[@
M^%)I61/4!4IO.@3DRUS+X<W(GRA9ZVL;+L0;5(,$[2CQG[Y?-P3N'(LX@@I/
MR(F(4%F<:!0,G`PO,74K5`=3>*IU3>=5;.YN\.6;GUL[HYV%D0J;5(V2&D]2
ME]+KG6M7#YH2-(O;V"[L6W'=_M03C[/KF5NHE47%]*2^Y,":&N(89F-&D&9X
MN*<5K&W=:HB1L*0A2$*0A2$*0C@P`;3G*4^GASE`VGZN8!TKS,C@3'@I2KS@
M#'(<```X``:``<```\```T``KQQXQY&F@X0I"%(0I"%(0I"%(1Z'3ELQ;JNW
MKANS:($ZB[IVLFV;HD#0!.JNL8B29`$?$1`*_;33C[@:92I;JC(!())/@`U,
M>FHJ*>D954U2T-4Z!-2EJ"4I'65$@`>$F-8<C;U]J^+"KENS-EE"^0`_-$6[
M(_6V8%0@:BB+"VB2:J"@AX=7I@(^6ME8_LWN=DQ2;79JSL%?TCJ>P;EU\SW(
M"/T9QHG-.]%L%@(6F_Y1;#5H!FS3.>MO3'06Z8.E)ZN?E'AC0C(_>@P]#>D-
ML88TO2^7)0,5"2N%PPLZ',?3S%"I!\L2ZR0CXE.B@:MY8]W/LMK.5W)+C1T3
M9XH:"GW/%/[-L'Q*4(B/FWXFVV]L*Z?!;)<KJ^`>5RH4W1LD]!`';NJ'6%(;
M,:%9'[NVZ:\07;6B2RL7L%0$I!@(3Y;F"$$/X4M<BC]$%`\ADFJ(A6\L>[J6
MV5HY7+KZY<GQ_6N=FW]1D),O`I:HB-FWXC&_62<[&."V6*C4)#U=CMGAXW:D
MNIGX4-(C0Z_\]YKRHLHKD3*E]W:501$6DM<DDI&%UU`01B45T8M`H@/@1$H5
MO"Q8-AV,("+!;*&E(^<AI`7\JR"L_*HQ$K+]WMT,^=4YF5_NMP"OF.U+I:'B
M9"@TG^:@1B,``/``#]0:5E4:Z))XQS2/$*0C[EO6Q<MVOB1=JV].7-)*"4",
M+?B7\R\,)QT+HVCF[A;SA#APKXJ^Y6ZU,&INE0Q34P^<ZM+:?RK($<O9\?ON
M0U8H+!155;6F4FV&G'EZ\/);2I7\D;MXS[:&[[)70<?S;_4*+6%,1DLBR3>V
MQ(FIQZOR/H[N`0('B7T0#?HK3.1]XS:?'>9'[1]>J1/R*1!>F1T=IY+7_3B4
MF#=QOO&9ORO&R_LFA5+[2XN)II`]/8GFJ-.KL9Q(7C3LIQ"'0=9?S*^?G`R9
MEX7'D,E'H"7351$)^X/3%SZ&#0#@Q)J`^`5H3(^^/5+YFL3M"$"1DY5.%1\!
M[)KE'R=H8F1@_P"%_;FN2HW&R5UU4P5,V]D('A3ZQ4<Y.O3ZNGQ")!\:]O3:
M+B\6[B)Q%#7))MQ`Q9:_5G-Y.S'#0>H+:846B$S<P:AR-B@4?``K0N1;^;K9
M*%-U5U>IZ97S*8"G'BYFP'#\JSX8F-A'<V[NN"%#M!CM-6UJ#,.UY56*GU\C
MQ+(/Z+0ET2C<:,BXR%:)1\-&Q\0P1#E18Q;-M'LT2@``!4FS1-)$@``:<"UJ
M.IJJFL=+]8XXZ^KBI:BI1\9423$DZ&WV^UTR:.V,,T](GS4-(2V@>)*`$CY!
M'[J]$?9"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(
M4A"D(QAF?+%L8.QA>.4KO<$1AK1AUWXH"<I%Y.0,`(14,R`P_"/9:14303`-
M?./J/`!$,EP_%KEFF2TF,VI)-75NA,^A".*W%=24(!4?`)<91@>YVX5BVKP2
MY9[D2PFVVZF4YRS`4ZX?):91/BMUPI;2.M4SH"8I5Y-R)<N6L@7=DF[W9GEQ
M7E-O)N14$1%-$SD^C=BV`?V;*-:$3;H$#@1)(H!X5<7C=@MV+6&DQVTHY+?1
MLI;0.DRXJ/6I:IJ4>E1)CK`9WF=[W$S"XYMD3A=O-RJEO.'H',?)0GJ0V@);
M;3\U"4CHCHM<W&)1Q2$7`NWIAV!P_M7QJE%BU<R]_0S+(MU2S8Z2Q9"6N=JB
M\;H%73U!1O#Q1D&A/.$-4C&#03"%5-[^Y;799N;<55/,FDH7E4K*#,<J&5%)
M,CP+B^99_2`Z([(7<VVVM&W&P=D10=FNXW>F1<:IU)![1VJ0E:4\PXI9:[-H
M:G5!5IS&-W*TQ$IH4A"D(Z_=%UVQ9$(]N6\;AAK7M^-2,L^F9Z1:Q<:V3*4Q
MA%5V\522`P@4="@(F,/``$:^^V6NY7JM1;K13O5->X9);:0I:R?`E()\9X".
M'OV0V'%K6[?,EK*:@L["9K>?<0TVD<=5K($]-!.9X`$Q#WN2[O\`85IE?VSM
MUA2Y"GR@JW&^I]!U'V6Q5Y3D!>+C3>CR]Q&3.("43^B(#IP,H%2UV[[IM\NA
M1<MP'O4*'0^K-$*J%#31:]6VI^#G5X$F*V][_P`1[$\>2]8]F:87>\":?7JA
M*VZ-!U',TUY+U009$%78HZBL1`]E[.65L\7*I=65;SE[LDQ,?T1%VJ",3$(G
M,)O186&;`E&138NNG*BD43>)A,/&IO8GA6+X1;A;,7HVJ6FD.8I$UK(^<XX9
MK6?"HF71(14MN-NMN!NS>U7_`#ZYU-PKB3R!9DTTDF?(RRF332?`A(GQ5,ZQ
MB>LIC7D*0C[=MVU<5X3<?;5J0<K<EP2S@C6,A81BXDI)ZX4,!2IMVC5-14XZ
MCQ'30H<1$`XU\5PN-!::)RXW1YJGH&DE2W'%!"$@=)4H@#_GZ(Y:QV*]9+=&
M;)C]+45MWJ%A#;++:G'%J.@"4(!4?#IH-3I$Y6TKM&KJFC+[W2*BW1^`>L<2
M0[T!74\%2%O2=9J"5$@\`.R9'$PAJ!UPXDJ%>ZG>K;0'+)MF.9>J55SB=!T'
MU=M0U\#C@EU(.ABU?N[_`(=3KA8RS?E7(UY*T6EE?E'I`K7T&21PFRR2>A3J
M=41.];MN0%HPD=;=K0L7;MOQ#9-G%PL,R;QT:P;)AH1)LT:IIHIE\HZ!J81$
M1$1$1J$-PN-?=JURXW-YVHKW5%2W'%%:U$])4HDG_FX1;/9;)9\<M;%DL%*Q
M16>F0$-,LH2VVVD<`E"0`.LZ:F9.IC[5?''*0I"%(0I"%(0I"%(0I"%(0I"%
M(0TU\*0C%F0\X8=Q,@=QDG)EE68!--6\Y<$>UD#B8ACE!&+ZQY)P8Y"B)0(D
M83>2LGL&%9=E2PC';;65D^EMI2D=6JY<@^50C`,RW5VUV]:+N;7RV6R7S7ZA
MM+AF)CE:F7%$@:!*"3T1'QE#N^[9[-Z[6Q(^\,KR*9C$34BH_P"K5OG,`>:8
MTO<!47HI&_C),E?U5OK&NZ=N-=^5V^.4EKIR-0M?;._4:FF?C<3$.L\_$<V/
MQGGI\39N605J20"TWZM3D]9=J`')>%+"HCERAWA=QEV^D-,>05FXLCE.H1-R
MW9FNNX@3,)@`1D)LH1:2G(/B1B`E$-2F"I!XUW2]OK5RNW]^KN=0)$@J[!J?
MZ+?ED>-SQB(69Y^))O/D)73X;2VVPT1F`I*/6JB6LOM'_L@9?18!!X$1'9D3
M.N9<LNCN\D9.O6\#',)@;S$\^5C4A,&A@;Q*2J,6U*(<-$T2AI6_[!A.(XLV
M&L>MM'2`=+;20L^-9!6KY5&(89ENQN7N$^:C-;Y<[DH_->?<4V/T6@0TC^:@
M1B@``/``#]0:5E$:^))XQS2/$*0CDH"8Q2%`3'.(%(0H"8QC"(`!2E#43"(C
MX!0D`3.@$?I*5+(2D$J)EI&S&,]F^YW+OHZUDX:O-S&N3D*2<F8\;9@@*<0^
M%^5+A/&ME4RE'F'I"H82\0`:UQD>[FV^*<R;S=Z--0D?JVU]LYXN1KG(/CD/
M#&\L'[M&^FXG(YC&-7)=$M0`?>;]68D>GM:@M(4!Q\DJ,N`,2)XP[+N3)?T9
MYEO*%L68V.)3+PUI,W-US)2Z><F=^[&)B&ZH#Y2>DE&M`9+WP<;I.9G%;;4U
MC@X./J##?C"4\ZR/'R&)GX'^&-G%Q[.IW$OM#;6"?*9I$*JGI=16KL6DGPI+
MHB13&':OVD8]!LYF+6F,G2R)0YWE^3*[E@=74!$Y(&)+%Q/)J`:%536$/=$-
M:C_DO><W4O\`S-TE2S;:4G1-,V`J7^E7SK^J4^*)GX)W`^[QAH0_<J"IOMP2
M-5USQ4V3UAAD--2\"TK\9C?6U;'LNQ6!(JR;2MJT8U,H%*RMN#C85MH&G$R4
M<V;E.8=-1$VHB/$1K1MTO=YO;YJKS5U-74$^<\XMP_E63+Q");X_BF+XG1B@
MQ>W4-NHDB013,-LI^4-I2">LG4],=HKC(Y^%(0I"%(0I"%(0I"%(0I"%(0I"
M%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(16][N^YSZZW]';=;5?
M\]M8W<I2U\*MU-49.^G+0?18PXD-RJ)6Q&NA`Y1\':YP$.9(-+#>ZEMO^QK$
MYG]S1*XW%)13@C5%,%>4L=1>6G0_02"-%&*3?Q&-]3D^7,[-6!Z=CLJP[6E)
MT=KE(\ELR,B*5M1!']:XL'5L1#)4OHK)A2$*0B</L]9NRU)Y"G<(O;A7F<61
M%D2=S,H:4$72EL/V\I'MT`M]T<>NR8/59$_6;:F0YA`Y2E-J(PN[VF&8K36!
MC,V:<,Y,[6(94XCR0\DH43VJ>"E)"!RK\Z6A)$I6J?AN;I;AUV8U6UU56*J<
M!I[6[4H9=\LTSB76DI]76?*0VLNJYVIE$Y*2E*IDV&J@+%RD8FRKG?#V$(LT
MOE7(=LV8WY.H@UDY`AYA\&AQ`L9`M`<34D8W3$`!!`_&LJQC",MS.I]4QBWU
M-8Y.14A)[-/#SW52;1Q^<H1KO/\`=G;?:V@-PSZ\T-M:E-*''`7G./ZIA',\
M[P/ZMM40_P"=^\S#MDW<-MWL)Q*.1*JDG>^0DS,F"1].4CF-M1BX%Z\*`^<4
M7;AOY.9+R5++".Z#5.*169_7);;F#ZM2GF4?`M]0Y4]1"$+\"HK@W9_$RMS"
M7+9LU:5OOR(%;<!R-@]"FZ5M7.L=(+KC?A;Z(A=S!G_,.>ILT]E>_)R['`*&
M.S8.7'HT#%%,8P]*(@&96\1'$#FTU31`Y@]\81J86)X+B6#47J.+T+-*W+RE
M`3=7X7'53<7\JI#H`BL7<C>#<C=NZF[9_=JJX/3)0VI7*PU.>C+".5EH:R\A
M`)^<3&':RV-:0I"%(1(OM>[:N<]PGR;<UP-3XJQDZ,@X^LUS,EBS<VP4'F,I
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MD(4A"D(4A"D(4A"D(^=+3$1`,%I2>E8R$C&X<SB1EW[6,8(%_C+.WJJ#=(/T
MF,%?124=77OBFH6G'JE7!#:5+4?$E()/R"/AN-SMMGI%5]WJ&*6A1YSCSB&V
MT_I+64I'RF-(\G]R7:%B\5VR^3D;WED#*)FB,<L7%U*=1/F`4S2J'0MY(P'+
MRB!G@&`?)6YL:[N^Z^2\KB+::*E4`>TJU!D2/YAFZ=-=&Y1%O.^^WW<\$*F'
M;XFZ7!)([*W(55&8GH7D\M,-1(S>F#T1'AE#O5R"H.&>&L.MV9=#D0GLBRYG
M:W$-"+?5RWS(HIF*/\$T@H`_HK?V-=SFG1RNY==U+.DVJ1'*/%VKLR?'V0B&
M>>?B?UC@73;:XVAH2(2_<72M7@/JU.4I'B-0J?@B.C*/<`W:99])0G<N3<#$
MN0.0T'8A4K,CBHG-KT!4A2H2CA,@<`%9RJ<0\1&I`XUL3M9BW*NAM3+]4G^D
MJ9U"Y]<G)H!_10D=0B%V>=\#O"[A=HU=<BJJ2@<F.PH94;8!/FS8Y75#H^T<
M69<28T]=O'<@Y5>/W3E\\7,)UG;Q=5TY6.81$QE5USJ*J&,(ZB(B(UMIIEIA
ML,L)2AH<$I`2!X@)`1&ZIJJJL>545CBW:A9FI2U%2B>LDDDGPDQ^>O9'SPI"
M%(1V:U;+O&^I).'LFU;BNZ55.0A(^VX:0FG?,H;D()T8]NX,D03#IS&T*'E&
MN-NEYM%DIS5WFJIZ2E`/EO.(;3IX5D3\0UCG\?Q;)<LKA;<8M];<+@H@!NG9
M<>7J9":6TJ($^DB4;_XO[5&[3(16KR<MZ!Q;$N!*87-^3*:<H1(?$P6_!IR\
MFFH`?WMP5N;W=*T3DO>?VLL!4U15#]SJD]%,V2B?^E<+:"/"DJ$2_P`#_#^[
MPN8ANHNM'26&WK/G5SP#@3U]@P'G0?S7$MGKE$C>+>S'B."]&>9:R+==_O""
M4Z\3;B"%FP)Q#B*)UN>5FUTA\!$B[<P^(<M1\R;O?Y56\S6*V^EH6CP6\34.
M^,#R&P?`4J'CB:F`_AE[=VD(J-P[S7W>I&JFJ9*:-@^`JFZ\1T32MLGHE$CV
M,-J^WC#9$1QWB*S()Z@!>295BDIBX!,0.7J#/37RA+`H8!XB54-:CWDFYV?Y
M<3^W[K6/,J_HPLMM>+LF^5'_`$8FM@FP.S6VJ4G#L=ME+5(`D\IH/5&G3ZP]
MVCT^N2Q&?_(`>0.``'```/``#P`*P.-P<!(<(4A"D(4A"D(4A"D(4A"D(4A"
MD(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(UEW=[A8K
M;/@R[<CN5$5+@%N,%8T6H8O/*WA*I*I11`3,`BHUCM#.W/#@@@8/$0UV1M1@
M-5N-FM+C[8(H.;M:E8^8P@@K,^@KT0C\Y0Z`8T5WC=XZ#8[:FXYH\4*O)1V%
M"T3^MK'00T)=*&]7G-/U;:AQ(BF;,3$G<,O*3TV]7DIB:D'DK*R#HXJ.'TC(
M.%';QVNH;43JKN%3&$?=&K>Z2DIJ"D:H:-"6Z1EM*$)&@2A("4I`Z@`!'6:N
M=RKKS<JB[W-U;UQJGENNN*,U+<<45K6H])4HDD]9CYU?1'PPI"%(1E7#6:\D
M8"O=ED'%UPJV]<31%1FL84$7D?*1JYDSN8J7CG)3MG\>X,D43$,`"4Q0,0Q3
ME`P8QEV'8]G5F78<EIP_;UD*&I2I"Q.2VUC5*A,ZCB"0002(V#MGNCFVT.4M
M9A@=8JCO+:2@Z!;;K:B"IIUM0*7&U2$P1,$!22E0!&W^1NZ7N]R%$A#-[O@\
M?M3IE([<X]@2PTL\$"Z&,,Q(.YB19`<>.C51`?)J(5J;'^[-M18*KUQ=(]7N
M`^2*ISM$)_U:$MH5_/"HD?FG?X[QF8V[]F-7&EM#!$EJM['8NK_USBWG4?ZI
M3?5$?TS-S5QR3F9N&8E)Z8>G%1Y*S4@[E))TH8=3'</GRR[E8PCY3&&M[T=%
M1V^G31T#33%(@22AM*4(2.H)2`!\@B']TNUUO=:Y<KS4OU=Q=,UNO.+=<6>M
M2UE2E'PDF/F5],<?"D(4A&S^W?9_G/<U)D1QU:BR=MI+@E)WW/@M%6?&`!M%
M`&3.B<TF[3`!_D[,BZVOB!0XAK7/]V<*VXIBO(*I)N!3-%,U);Z^KR`?(2?I
MN%*>HDZ1OG9KNW;K;Y5P;PVWJ394KD[7/S:HVM=?M2#VBQK]FTEQ?6D#6+#.
MU_ME8.P$,?<UVH)9=R4V%-P2>N-@D6VX-V4I3<UMVLH=RU3514U$CEV9RX`0
M`Q.D/"H#;E=Y#-,Z[2VVHFU8ZJ8+;2CVSB=?UKPDH@CBA`0GB%<T7)[#]Q?:
MO:+L;WD2$Y%FR)*#]2V!3,+$M:>E)4D$'4.O%QP&11V?"))?<#R`&@`'```/
M``#R`%1WB;@$A(<(4A"D(4A"D(4A"D(4A#01\*0C#F2MPN#\/(JJY+RE9=I*
MI$$XQTC-M5)I0-!$`0@VAW,NN8^FA0(B/,/A67X[@.:9:L)QVV5E4DGSTMJ#
M8\;BI-CPS5&M,WWDVKVX;4O-[_;+>XD3[-QY)?/Z+""IY4^B2#.(X\G=Y+`E
MLF7:8TLV],G/$^H1-^Y*A95OG.7@10CF22?32B1AX\6)!_5P&I!XWW1<XN02
M[D=91VUHRFE,ZAT>`A!2V#_K#$*\Z_$LVDL953X1;;G?*@3`<7RT5.2.!"G`
MX^0>.M.GY-(CGRCW<-TE\@Y9V<>T\3Q:Q3)E^K4268G@3-S!YTY<?IY$U.40
M\]!L@8!#4!#PJ06-=U7;.RE+UV%5=*E.OVR^S;G_`*-KE)'@4M0ZXA;GOXBF
M_.5!=-C1H,?H%B7]V:#SX&O]/4]H`?SFVFU`Z@CA$>U]93R5D]\>2R+?MW7L
M\.<5.I<L_)2Q$C#IKZ.V=.%&K4HZ>]2(0OZ*WW9,9QW&V!3X_0TE&R!*3+2$
M3\92`5>,DF(<99N#G&=U9KLRN]QN=253G4U#KH2?S4K44H\20!'0?#PKG(P^
M.:0A2$<"(!Q$0`/T\*1YD3PC-N+MM^=\T+$)C+%=XW4W.<"#*M8E9I`I")N4
M17N"2]#AD0*(\>9<-/+XUAN2[A81AZ2<DN=)2N`>85A3I\32.9P_(F-I8'LE
MNQN:X$X-8+E7LDR[5#12P-9>54.<C*9=,W!*)*,6]F;,EP`V>97R#:6.V9S$
M.O$P:*]YW`5,0`QDS*)*Q<(W6XB&I7#@I1XZ&"H[9-WO<0H.9G%Z"JN#P!DM
MPBG:GUZA;A'@*$'Q1-[`?PS=RKQV=3N!=[?9J8D%33(565$ND$@M,)5T3#K@
M'&1B2+%7:GVG8Z%N\N"`G,K2Z)2B+F_)4QXGK``@8Z=N0I(N+.0VNO(Y!R`:
M<*CSD_>@W1R`*9H'V;72*Z*9'ERZBZYSK!\*.2)M;?\`X?\`W?<+**F[TE5?
M[BD>=7.GLI]8IV`TV1X'>UB02U[.M*R(Q*&LRV+?M.)1*4J4;;D/'PS,H%`"
M@/H\>W;IF.(!Q,("81XB(C6AKG=[K>JDUEXJ7ZJJ/%;KBG%?E42?DB85AQG'
M,5H4VS&:"CM]O2-&Z9EME'U6TI!/63J>F.QUQT<W"D(4A"D(4A"D(4A"D(4A
M"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A
M"D(JO=TK<N.:\YJ8]MU[UK!PRL_MYJ9%7G:S%XJ'(G=$R'*8R:A&BR!6"!@U
M#E0.8O!0=;.>[/MS^YN%"_7!$KY=TI=5,:MT\ILM]8Y@2XH=:D@^;%`O?WWR
M^)^ZBL.LSO-B.-*<IT\IFAZL)`JGM#(A"DAA!ZFU*&BXC#J2401A2$*0A2$*
M0A2$*0A2$9VPEMHS9N'EBQ>*;$EI]N18B+^X5D_DVU8CF'B>3N%[THY$2%XB
MF0RBXA[T@CH%81F6XN&X#2^LY17-,+(FEH'G>7^@TF:S/K(">M0C;>UNQNZ.
M\EQ%!@-IJ*MH*"7*@CLZ5GPNU"Y-IEQY02L_-03I$[NV_M$8PL(T=<V>98F5
M+F1!)Q]4V)5X^P&#D-#]-T!A2E+F!(W`06]';'T\Y$P5"+</O79)?`Y;<':-
MLMQF.W5)52H=:>*&9_F\RQT+!BV79/\`#FP7$BS?-VJ@7^]IDKU1OF;H&U<9
M+X.U,N!Y^S;5\YI0B7J)B8J!C6<-!QC"&B(Y`C:/BXMFW81[)NF&A$&C-JFD
MW;I%\A2E`*BA55=575"ZRM<<>JW%34M:BI2B>)4I1))\),6-VZW6^T4+5LM3
M#--;F4!+;32$MMH2."4(0`E('4`!'T*^>/MA2$*0A2$*0A2$>*AR))G55.1)
M),HG454,4B9"E#43'.<0*4H!XB(UY2E2U!*02H\`-3'Y6M#:"XX0E`$R29`#
MK),:D9:WU[6,,^D-[KRS`R4RWU`UN68<UX38J`!O@5$(3TEHR4YB\O\`*5D2
M@;@(A6UL5V1W-R_E<MEK?;HU?TM1]@W+K!<DI0Z?(2K3A$==P^]CL'MGSLW_
M`""D?N2.-/1'UQ^>ODD,<R&SI+[5:`#H2(C-RKWJ2%,X985Q"*A?A2(W#D>2
M%/74!*FLG;<`H8=0U`P`H_#00T$HU(W&.YT2$O9C=9'0EJD1/Q@NNC_D:^6(
M-;@?B?(2I=+MCCLQJ!47%S\BA34Y^76H\!!B-;*F_P"W8Y<]*0G\M34##NBB
MF>W[$`EFQ0(B.O1,>'Z4HZ)P_O[E4WZ:D5C&Q6UN*<JZ&U,OU:3/M:F=0N?7
M]I-"?YJ$Q"#/^]_W@]Q2XU=LAJJ2W."1IZ&5&U+J^QY75C_2.+/AC3QRX</'
M"KMXNN[=+G,HNZ=*J.'"RAQ$QU%5UC'54.<PZB)A$1&MM-MMLH#324I:2)``
M``#J`&@B-K]0_5.J?J5K<?625*42I2B>)),R2>LQZ:_<>F%(0I".2E,<Y4R%
M,<YS`4A"`)CG,/`"D*4!,8P^X'&O!(`F=`(_24*6H)0"5$\!&UV)=C^Z+-`M
MU[.Q+<36'<\IB7'=B06C`=(P`/63>SHLU'B?*;F#T=-83![T!K5^5;S[:8>%
M(N]UIU5:?Z)@]N[/J*6N8)/Z93+IE$@]O.ZOOQN:4.XWCU8BW.<*BJ'JC$M/
M*"W^3G$C,=FE9/0#$FF*NRL]53;/LTY>29G$$E%[=QU&>E&#7BH@>Y)XB28"
M7PYDV!M?((5'#)^^*RA2F<.M)6-0':M?+XCV+4S^5T1.?;_\,&I<0BJW.R)+
M2B`54]N:YSX4FI?"1X-*<^.),,4[`-I^(/1G$!BB'N"9;"!BW#?ACWC*F4#7
MX4B<N"L4T4X_]';(A4<LHWWW1RSF;KKHZQ1J_HJ;[!$NJ:)+4/TEJB<FWW=`
M[ONW'(]:<?IJRY(U]8KYUCL^L!Z;*#_HVD1N*W;H-$$FK1!%JV0(5-%LV230
M013(&A4TD4BD33(4/````"M2....K+CJBIQ1F2222>LDZF))LL,TS26*="6V
M$"24I`2D`<``)``=0CVU^(]L*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*
M0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0C3'?EN*)M
MOV\75<L:\3;WS=)#V;C]+F#K%GI=%0CB63)S%.)+?C`6=ZAJ'5(F4??5N#8[
M;]6X>?4UNJ$%5EI3ZQ5'H[)LB2#_`*5?*C]$J(X1&3O;;SHV4V;K[W1.A&55
MX-'0"?E!]U)"G@)S_N[7.[/ASI0D^=%/1995PJJX754777446765.915994P
MG5554,(F.HH<PB8PCJ(CJ-6TH0AM`;;`2A(``&@`&@`'0!T1UMG77'W5//**
MG5J)429DDF9))U))U),>NOU'KC+.#\+WMN`R7;N+;`9IN9V?7.*CIR)R1L+%
M-2@K)SDLL0IS(QT:WU,?0!.<PE(0#'.4!Q;-,PLV"8Y49-?5E-"PG0#5;BSH
MAM`,IK6=!T`342`"8V)M7MCE&\&;T6!XBV%W6K69J5,-LM)U=?=4`>5MM.ID
M"29)2"M2099LJ=F"[8*RTY;$^44+YO)@R!:4M:X(="VVTRX(0IED[;EB2#M%
MLJ)A$$DGH%(?3SEBB.@19QCO@6JNO!I,IMBJ*T+7)#S3A>+8Z"\CE22.LMS(
MZ$&46&Y_^&3D-IQA-QV^OJ+KDK34W:5]E-,EY0'E"F=[1:4GCRH>D%2U=3.0
MAJO6Q;RQQ<+ZU+]MB;M&XXU8Z+R(GH]>/>)F(.G.0JY"D<('\2*I"=,Y1`2F
M$!`:EW9[W:,AH$72QU+-7;W!-+C2@M)\<N!ZP9$'0@&*T,GQ+)L*O#M@RR@J
MK?>6%%*V7VU-K!'2`H#F2>A29I4)%)((,=4U`/$0_P"$*Y21C'I&.Q6Y:-V7
M@\2CK2MBX;H?K&Y4F5NPLE-.E#:@'*1"-;.5##J/N5\%PNMKM+)J+K4T],P.
M*G7$-I'RK($<U9<:R+(ZH46/4%975BC(-T[+CRR?`EM*E?R1OOB+M;[K\GJM
M7,U:S#%4`L<O5E<@/2-)`J(@!A.WMF/]-FU3\I@Y05(W(/\`'"M&97WF-KL;
M2INCJEW.N`T12IYDSZB\KE;`_1*SX(ESMSW">\#G3C;USH&K!:%'5VO7R.<L
MIS33(YWR>H+2V#]*);<'=I#;WC@S*7R6[ELRW&@"2JC:8`(6RTG!0`Q@2MU@
MJ9R_2*IPT>.EDSE]\F&NE16S3O59[D`728XAJT6]4P"W]I4$>%U0DDR_JT)(
MZ%18EM5^'9L[A1:N.<.5&2WE,B4O?8405TRIVR5N"?0\ZM*AQ;$Y1*'!P,);
M,4S@K;AXR`A8](J#&)AF+:-CFB10T!-NS9I(MTB_J*&M1IK:ZMN54NMN+SK]
M8X9J6XHK6H]94HDG\L3QM5HM5BM[=JLE,Q1VQE/*AIEM+3:!U)0@!(^01]6O
MECD84A"D(4A"D(\%%$T4SK+*$212*8ZBJIRII)D*&ICJ*'$"$*4`XB(@`5Y2
ME2U!"`2LF0`U)^2/PXXAI!==4$MI$R29``<22=`(TSS#W`=JN%A<M)_)L=<T
M^VYBFMG'Y2W?+=4H"(H++1ROR,P5`0T$'+M'E'@/'A6W\2V'W/S`)=H;:Y34
M*OZ:J^P1+K`6.T4/T$*G$9]R.^#L#MCVE/=KXS779O0TUOE5N\WT2IL]@V>@
MAQU$CH=8BQRWWHKUDC.6&$\7PUL-#`8B-PWXY4GY<>(@"R,)&*L8IH8`T$`5
M6=![H5)S%>Y[9J<)?S*Y/5+O2U3`--^(N+"EJ^1*(@'N)^)SD]:I=)M?8J:A
MIR)"HKE&H>\89;+;2#^DMX>"(Q,L;KMQ&;55OYQ\KW9,QZQU#?(#1^:$MI(J
MG`R2<!"@PC#)\H`'PB9S"`><(CQJ2.+;7X#AB4_N]:Z5E]('VJD]H\9=)=<Y
MES\1`Z@(@IN#W@]Y=T5K_?3(+A4T:B?[NESL:8`]`IV>S:E+35))Z23&O.@!
MX!6?1IJ.:1XA2$*0CDI3'.1,A3'.H8"$(0HF.<YAT*0A"@)C&,(Z``<1KP2`
M"HZ)'&/TE"EJ"$`E1,@!Q)/"-OL-[#]T><`:.[4QC*P]O.]#DNN]];2@>B)B
M@*[=24(21DDP`VH>BMUQ,'$-:U/EV]^VF%\S5TN33U>G^@I_MW9]1"/(0?TU
MIETQ(_;3NE[\[IANIL%BJ*:T.:BJK?[HQ+3RDET!QP:S'8MN3'`1*SB/LN6@
MP3;/\WY1E[A><#KVYC]LG!Q)!T`>DI/RJ+V3=EU$0$4VS4>&H#48,K[X5U?4
MIC#+8TPST.U1+BSX0T@I0GY5K\46![=?AC8Y2(;K-T;[45E3Q53T"0RT/`:A
MY*W%_P`UIH]1B3?$^T?;CA,B!L>8FM2-DD2)E^L,DR^L%R*'3T$%AFYPS]^B
MH8P<VB1DR`(CH4*C=E.ZVX69*4+]=:IRF)/V2%=DR`>CLV^5)'Z0)ZS$Z-ON
M[ILIM>E"L/QZWLUR`!ZPZCUBI)'3V[Y<<29Z^04@'@!&QW_T>`>0/U!Y*U[&
M[(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"
MD(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A%57NG[@39@W$O+(AWWI%F
M893<VDQ*BH)FSNZE5$U+OD="F$AU$7J1&(&\@-!T]\.MGO=DP,8EM^B\U:.6
M[W@A]4QJED3#".L`I)<E^?X(Z_\`W^]X3N1O*YB]M=Y\;QH*I$<I\E=42#5N
M:&1(<2&)]`9T\XSC,J1T07CDI3',4A"F.<Y@*0A0$QC&,(`4I2@`B8QA'0`#
MB(UX)"1,Z`1^DI4M00@$K)D`.),6K>VGM#_=WQ9]>;TC"(Y;R<S:OY9-<FKN
MU+6,!7,/:H:_L'BO,#I^`:#US%2-KT0JL/O%[K_O]DW[$L[A5BMM6I*"#Y+[
MW!Q[PI'F-?F@J'GF.P%W'N[E\&L!_>O)F`C<.^MH6Z%#RZ2ET4S2_FK5HZ^!
MKSE+9GV0,27U'&)R1TR\L<X_R*S*POZR+4O1FF`@DWN>`BYLB0".H@C\H-ES
M)`(^/*(:US%GR&_8^Z7[%6U5&Z>)9=6V3X^0B?RQB^383AV:4PI,NM5ON=,.
M":JG:?`\7:)5+Y)1C.,VI;989<'47@#$#%P4Q3`JA8%ME.!B<W((",>/$O,/
M_#61U.Z&X]8CLZF^W9:.HU3WIQ@U#W>]B[:[V]!B&.-/`@S3;Z:<QP_H_#&:
M(:WX&W&WH=O0</`M.'\EA8QE%MN'A\"Q003X:\.%8?65]=<'.VKWWGW?I.+4
ML_E428V?;+-9[*QZM9J2FI*;Z#+2&D_50E(_DCZ]?)')0I"%(0I"%(0TU\*0
MC7K,FZS;]@-!4<G9-MZ%DTR'.G;3-P,W=;@2"`<B5NQ!7DF03&'0#*D33UU\
M[@-9]B&U^>9RL#&[;4/4Q(F\H=FP)];J^5!\0)/@C3>Y7>!V?VD:4<YOE'35
MR02*9"NVJE2Z!3M<[H\:TI3^=$2&:.]$L;TR+P%C`J11!5)"[\DK`=0-0Y2.
M&EIPKGIE,`ZB7KOS!P#F3'B%2JP_N>H')4YS<IG0EBD$AXE/N"?CY6QX%=,5
MV;G?B<.*[6@VCL82-0FKN1F?`I-(PN7A'/4$<.9!U$129?W<;B\ZG7)DC*ER
MRD6N8QOJU&N0M^UDRFU#D+`0A6,>L``.FJQ53B'B8:E#B>U6W^$A)QZV4S54
MD?KECM7C_K7.98\22!U"*^MQ^\5O/NLM:<TO]<_0*)_NS:NPI0#T>KL!MI7C
M6E2NLF-<--/#A6PHTI'-(\0I"%(1P(@'B(!^L=*1YD3PC9O#^SG<GG0[=7'V
M*KC<0ZY@#ZT3K<+9M8I>(F4+-3@LFSPI0`=0;=8_DY=:UQEN[>WF%!2;]=*=
M-6D?J6SVSWB[-OF4G^?RCPQO7;?NT[V[K*0YB%@K5VU9_P!Z?3ZM2RZP^_R(
M6!TALK5T2G$J^'.RV0/0Y//&4S'_`&:KBT\:M>4H\.8S=Q=<XW$V@"``;HL`
M$0$>4X#H-1@R[OAGRZ;"+9U@/U9_E##9_)S.^-/1%@.VOX8J!V==NS?IG0JI
M+:G\J553Z>'0>2GF=9+&AB5'$&S?;7@T$%L?8IMQM,(%*'UGG$3W-<QSET'J
MEF)T[YPS.80`1!MT2:AKRU&/+-W=Q<U*D7VZ5"J11_4MGL69=79M\H5_/YCX
M8GYMSW:=D=JPAW$+!1(N2!_O+Z34U,^L//E:D>)KD3X(V<$1'Q&M;1O6.*0A
M2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A
M2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0C$6?<B_S283RGDLI1.O9E
MCW!-L2%TU4DT&"I(I,.8!+\))*)%X\.-97@N/_O5F5LQTZ(K*UIM1ZD%0YS\
MB`HQKG=[,_AWM=?\W2)O6RU5#S8ZW4MD-#Y7"@12*?OWDH_?2DBX4=R$D\=2
M#YTJ83*N7CU<[ETX4,/$3K+JF,(^Z-7-L,-4S"*:G2$L-H"4I'`)2``!X``!
M'5GK:RIN%8[7UBU.5;[BG%J.I4M9*E*)Z2223X8_)7MCY8F7[5^R\<C7(VW%
M9*ARJV%:+\X8^B)%#F;W9=S%7E--J-U0Y',';"Y1Y.8!(N^``X@B<!B'WF]X
M?W>MRL`QUXB^U:/[TM!U884/U8(U#CPXRU2UU%8(LS[@G=C.9WM&\V;TP5B5
MN=/[/:<3--75H/ZXI.BF*90TG,+?`&H:6#9&\:KPB[6%(0I"%(0I"%(0I"%(
M1\6XKDMZT8=[<-U3L1;<%')&6?3$[(M(N-:)E*)A,N\>JHH)\"CH`FU'R5]M
MOMUPNU6B@M;#M17.&26VT*6M1\"4@D_DCBKU?++C=M=O.05=-0VEE/,X\^XA
MII`'2I:RE(_+KT1%7G+N]X)L%1Y#XFAI;,,Z@*J02:)S6Y9*2Q0T*8LL];JR
M<HF!_*W:=,P<05J3N%=U#-KZE%7E+S5IH52/(?M:@C]!)"$'])<QTIB`6ZOX
MC>U&(+=MNWU-49'=D3':@FFH@H</M5I+KH_T;/*1P<B(7-O<DW3YI!W'FO3^
M;BV'/43&W,;%7MX%&ZG+\$^G^NO<3W4I=#!Z2FD;4?,`!TJ6&&=WC;+#BBH%
M'^T+DF1[6KD[(CI2U(-)\'D%0^E%<>Z7?;W[W.#E&;G^Q;$N8]7MP53S29:+
M?YE5*]!J.U2@S/D"<:'N'#AVX6=NUUG3IPH99PZ<JJ+N'"QQYCJKKJF.JLJ<
MPZB8PB(CXUNYMMMI`::2$M)$@````.``&@`ZA$2WWWZEY514K4X^M14I2B5*
M43J229DDGB3QCU5^X],*0A2$<:Z>/"D>8S[B3:[G[.2Z1,98NNFX&2BB:9IY
M1B,3;3<%1``47N&6%E%`0H#S"!53GY>(%&L&RK<O!<*03DESIF'@">R"N=XR
MZFD<R_!J`/#&WMN]A=WMU74IP>PU]92J(!?*.RIDSZ55#I0S(#4@+)EP!B5/
M#O9=N)\#22SKD]E!(CTU5[6QXW^59(2\Q1.W<W++(H1[542:@(HM')0'P,/C
M48LN[X-O8*J;";:M]>H#U4>1'C#*"5*'Z2T'K`B?VVOX8]ZJ@W7;KWUJD;,B
MJEMZ>V<XB:55+H2V@RF#R-.@'@H\8E7Q!L8VNX2*W7M+%<')3;<-0N>\TBW?
M<`J</A4G4R5PV8*:AP]%10`->'#A47\LWKW+S(J1=;F^W1J_H:<]@U+J(;D5
M#]-2HL!VX[J6P^UZ4.X]8*5^Z(_^YK`*M^?6E3P4EL_Z)#?@TC;8I2D*4A``
MA"%`I"%`"D(4H:%*4H:%*4H!H`!P`*U6229G4F)$I2E"0E(`2!(`:``=`CFO
M$>84A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A
M"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A'4;^L:V\FV
M5=&/KP9#(VQ>$*^@9MF14R"JC%^B9)0S=<NID'2!A!1)0.)%"E-Y*Y:Q7NXX
MW>::_6E?9W*D>2ZVJ4P%),Q,=(/!0Z02(QS+\4LF=8O7X?D;1>L5RI5L/(!*
M24."1*5#5*TZ*0H>:H`]$5W\K]FS-4'*OE\0WA:-]VX=94\8RN!ZK:USH-Q.
M(HMGHJMG$(Z63((%%8BZ0'$->F3PJ?F+][O#JVE0C*Z2KH;@$CG4TD/,D])3
M(AQ()^:4JE](Q3/N%^&CN=:K@Z[MU<K==K*5DMH?6:6J2F>B5S2IA2@-.8.(
M"CKR)&D:V8X[>6X:1S_8V)\DXUN6VH&5DF\C=%TMR)/K=:6:P7!6<>-KECCN
MXDKQ9NF*#=(R@+"X5)Y@`.M;%R#?S`:?!:W*<>N--4UK392RR24NJJ%"3:2R
ML)7R@GF4J7+RI5K&D<*[FV\=9N_:MOLVLE=16E]]+E55)`73HHVU3?6FI;*V
M><I!0VDJYRXI`*9&<6P[6M>W[)MR#M"U8MI"6W;<8TAX6*8I@DU8Q[)(J+=%
M,@>(@4NIC#J8YA$QA$1$:JVN=SK[S<7KM='5/7&H<4XXM1F5*49DG_F'`#0:
M1V$L?L-GQ:R4N.6"G;I;+1,(99:0))0V@!*4@>(:DZDS))))C[U?#'+PI"%(
M0I"%(0I"%(1I_N_WBV!M)LI*4FR%N*_;@2<IV18C5R1)W*KI!RGE994.=2+M
MMBJ(`JN)1,H?X-(#'$>7;6TVT=]W4O!IJ,^KV-@@U%21-*`?F('!;JAYJ9R`
M\I1`E.-W>0[RF(]W?&$UUS`K<MK$J%%0I4`MU0T+KIU+5,@RYW)$J/D-@JGR
MU8<^;F\Q[D[C5G\H76[D&B:ZBD/:K$ZK&TK=1,.A$(F%(H9`IR$X&<*]5RIX
MG4&K-L&VWQ';NWBAQJE0VZ4@./*`4^Z>M;DI_P`U,D#H2(H)W=WUW*WMO:KO
MG5P<>IPLEFE02BDIP>"660>4&6A6KF=5\Y9C`%9W&GH4A"D(4A&5\98+S%F5
M\G'XOQO=MYJ'4Z9G<1$.#1#8P#RF%[-KE1AV)2#XBJN0`K%\DS;$L08+^2W&
MEHT@3Y7%CG/Z+8FXK^:DQL/!=I]R=RZH4F"66X7-9,BIEI1:3U\[RI,M@=)6
MM(B4[#?9GR=<'HTEFR_H3'[`^AU;>M4A;JN82^/27?J"V@&!Q#AJ0SS3W.'&
M,F7=[W&Z#FI\-H7J]\<'7CV+/C"1-U7B(;\<3ZVT_#.SF\<E=NA=J6T49U-/
M2CUJIEU*62EAL^%*GI=(B5[#?;SVJX6%H]B,<M+ON%J*:A;FR&<EUR)5R`'P
MS9D[2)!L#@8.8HHM""4>(#KQJ+N7[^;G9B%,U=P524"ICL:7[!$NHJ2>T5U'
MF69]46#[:]S;8';$MU-OLK=RO#9!%3<"*ISF'SDMJ2&$'I!0RD@],]8W6111
M;(IMVZ23=NB0J:*""9$44DRAH4B228%33(4/````"M-K6MQ9<<)4X3,DF9)Z
MR3K$H&FFF&TLL)2AE(D$I```'``#0`=0CV5^8]D*0A2$*0A2$*0A2$*0A2$*
M0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*
M0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$-1\/)2$*0A2$*0A2$*0A2
M$*0CY,_.1EL04U<DTY(SA[?BI":E7:@@!&T=%M%7KQ<PB(``)-T3#_<KZZ"B
MJ;E7,VZC25U;[J&T)'$K6H)2/E)$<=>+M0V&TU5\NBPU;:.G<?=6>"6VD%:U
M'Q)23%*K<?G"X-Q&8[TRG/K+\LY)JI6_&JJG42@K69G.A`PS8AC&*DFU9`!E
M`+H!USJ''B81JXS;W#*#`,1H\8H0F;#8+JP)%QY6KKAZRI6@GP2$IX`1U?\`
M>W=.\;R[EW//;NI<JI\AALDD,4J"4L,I!)D$(D52T4X5KXJ,8-K-(U1"D([/
M:-DWC?\`,(V_8UK7!>$XX,4J43;<0^F7QN8>4#&;L$%SII\PZ<QN4H>4:XVZ
MWFTV*D57WJI8I*)/%;RTMI_*HB9\`UCG\<Q7)<ON2+/BM!67&Z+E)JG9<><,
MS*?*VE1E/I(D.DQ)CACM&;B\@>B262'<%AV!5Z:BB$NJ6X+M.@8WG`E`Q"XL
MVJPE#P=/$C%UXD$0$M1RS#O6;?6'FI\>2_=ZT3`+8[)@'PNN#F(_0;4#T'IB
M<NV7X=.\^8=G6YJY28W:52)2\?6*LIGK)AE7(DRZ'7FR)ZIF)1+5ACM<;6<4
M>B2$Y;KW+5R-^0YI3("R;N**X(<IP4:6JR*WA2$`2AH#@KHP<?.J*^8=YC<W
M*.9BBJ$6JW*TY*4%*Y=2GE3<G^@4#P18AMEW"]A-ONSJ[I1NY#>D2)=KR%,\
MP(,T4J`EF6@D'0\?SM8D,BXJ+A&+>+A8V/AXQHF"36.BF3:/8-DB@!2IMV;1
M-%NB0I0```I0``K05355-:^JIK'''JE1FI:U%:B>LJ422?&8F106ZWVJD106
MMAFFH6Q)#;2$MMI`X!*$`)2!U`"/WUZ(^R%(0I"%(0I"%(0I"%(0I"%(0I"%
M(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%
M(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%
M(1A;<=8]PY+P+EVP+3532N6[K!N.#A`66]&17D'C!4C=FJX$0*@F_-\`8YO-
M*"FH\-:S+;V]6_',YM-]NH)MU)7-..2$R$)4"5`=)3YTAJ9::QJ[>W%+SG.T
M61XACJDB^7&T5+#',KE"G%MD)05<$ASS"3H`J9TG%2YOLCW<.9`T6GMYR@#M
M-3I'%:W%V[,IN;E`XR*YDV'1$>(*`IR"'$!TXU::YO+M4VQZRJ_VWLB)B3H*
MOJ":I^"4^B.O,UW6>\0]6&A;P^^^L!4C.F6E'WBI-R_.Y^66LY1MIC+M![G+
MQ,W<7T]LS%,:H!#JEEI0+FGB)F-H8$XBW#.&(K%+Q`BKY(!\!$!K5F2=[#;>
MT!3=E1672H&@Y$=BU/PK=DJ7A#:OEB0V"_AQ;Y9(4/96[;;!1*`)[9T5+X$]
M9,TQ6@F6LE/HZB08D1Q5V=<`6@\;R62;IN[*ZZ)4C#$*BE:%MG7((&.99K#K
MK3+E$3!P3,^*40X&`P#I6@<G[V^=79E5/CM+26M!GY8F^Z!X"X`V#X>SGU2B
M9NW_`.&SM#C=2BNS6ON%_>0`>R,J2F*AJ2I+*E/*'YO;@2T4""1$G]AXUQ]B
MZ&3M_'5EVU94.D4I?0;;AV46FJ)0``4=*-DB+O%]`XJ+&.<?*-1KOF1W[)JL
MU^05E1659^<ZXI9'@2"9)'@2`/!$[<2P?#L#MHM&&6RAMEM'S*9E#05X5E("
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M@<2(X*_Y+8\7I45E]J$T],M?(E2@HS5(F7D@G@#&GWWSO;-]JJS_`)BO7[-U
MF/P5W.]TO?6:].,3^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?
M%_;GWFU]5ST(??.]LWVJK/\`F*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YW
MMF^U59_S%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"N
MYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWF
MU]5ST(??.]LWVJK/^8KU^S=/@KN=[I>^LUZ</B_MS[S:^JYZ$/OG>V;[55G_
M`#%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[Z
MS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(
M??.]LWVJK/\`F*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YWMF^U59_S%>OV
M;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+
M^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LW
MVJK/^8KU^S=/@KN=[I>^LUZ</B_MS[S:^JYZ$/OG>V;[55G_`#%>OV;I\%=S
MO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-K
MZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/\`
MF*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YWMF^U59_S%>OV;I\%=SO=+WUF
MO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^
M^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/^8KU^S=/
M@KN=[I>^LUZ</B_MS[S:^JYZ$/OG>V;[55G_`#%>OV;I\%=SO=+WUFO3A\7]
MN?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM
M56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/\`F*]?LW3X*[G>
MZ7OK->G#XO[<^\VOJN>A#[YWMF^U59_S%>OV;I\%=SO=+WUFO3A\7]N?>;7U
M7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7
MK]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/^8KU^S=/@KN=[I>^LUZ<
M/B_MS[S:^JYZ$/OG>V;[55G_`#%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\
M[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!
M7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/\`F*]?LW3X*[G>Z7OK->G#XO[<
M^\VOJN>A#[YWMF^U59_S%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:J
ML_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]
M]9KTX?%_;GWFU]5ST(??.]LWVJK/^8KU^S=/@KN=[I>^LUZ</B_MS[S:^JYZ
M$/OG>V;[55G_`#%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7
M[-T^"NYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?
M%_;GWFU]5ST(??.]LWVJK/\`F*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YW
MMF^U59_S%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"N
MYWNE[ZS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWF
MU]5ST(??.]LWVJK/^8KU^S=/@KN=[I>^LUZ</B_MS[S:^JYZ$/OG>V;[55G_
M`#%>OV;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[Z
MS7IP^+^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(
M??.]LWVJK/\`F*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YWMF^U59_S%>OV
M;I\%=SO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+
M^W/O-KZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LW
MVJK/^8KU^S=/@KN=[I>^LUZ</B_MS[S:^JYZ$/OG>V;[55G_`#%>OV;I\%=S
MO=+WUFO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-K
MZKGH0^^=[9OM56?\Q7K]FZ?!7<[W2]]9KTX?%_;GWFU]5ST(??.]LWVJK/\`
MF*]?LW3X*[G>Z7OK->G#XO[<^\VOJN>A#[YWMF^U59_S%>OV;I\%=SO=+WUF
MO3A\7]N?>;7U7/0A]\[VS?:JL_YBO7[-T^"NYWNE[ZS7IP^+^W/O-KZKGH1N
M=M]W)X2W46*ZR5@*_8[(MD,KCD;2<S\8UDV;=*X8EK'/9&,%*59,'0JMFLLW
M.)@()!!0-!$0'3"\BQF^8I7BV9!3JIJY3:7`A123R*)`5Y)(U*3T]$9?8<BL
MV341N-C?3440<*"I((',D`D>4`=`H='3&<JX&.:A2$*0A2$*0C1K?IE[99AO
M&=JS^^""MR?QS(WFC%6RVN7&LCD]FE=YXJ0<)+(P\;"3BS)P$8BN'I!DBE`H
MB7FU-H.=X!9\VO5S=I\&<<;N262I90\&#V?,!(J4I$QS2TGX91A><77#[3;F
MG\S0VY;U/<J`MDO#M.4F82$JD9`ZR\$10_OV?A[/Z-L3_P"R)=7]GE;:_<+O
M$?XFK_\`4&_[:-7_`+Z[#_X>E]A7_91]^U=Y7X?F[[FM^U(VP,(,I&Y)B/@X
M]U/[7)JWX1%])N4VC0\K.2UAM8N(9"NJ4#N'"J:*0#S',``(UZ*O"^\+1TKE
M6[45RFVD%1"*Y*U$)$SRI2Z5*,N``)/0(]]+EVQ-74MTK;%$EQQ82"JC4E,R
M9":E-!*1/I)`'28EI3V$;'E4R*I;3]O*J2I"J)*IXMLXZ:B9R@8BB9RQ@E.0
MY1`0$!$!`=:U$=P,Z29&[7$$?^.YZ4;2&#X81,6N@(/_`(+?HQY?N";(?9,V
M^>JJT/HNO'Q!SGWO<?OW/2CS^XV&^ZZ#[EOT8?N";(?9,V^>JJT/HNGQ!SGW
MO<?OW/2A^XV&^ZZ#[EOT8U-W5PG:)V5P]K3.XG"&WJS4[UD'<=;$:QP='73/
M2RD>@#B0=H0=LVU*29(Q@4Y"K.CIE0(HJ0@FYC``Y=B;^\&;/.L8Y77%XL)!
M6HU10A,S(`J6M*>8ZR3.9`)E(1BV3L[58>TT]?Z*@9#RB$`4P6I4M20E"%*D
M-)F4@2!.9C2?]^S\/9_1MB?_`&1+J_L\K-_W"[Q'^)J__4&_[:,._?78?_#T
MOL*_[*/O6KO'[`=YW/;EGV_B_$CN>NN=BK<A&JFTRY&J;F6FGR$='-U'3G'Z
M39L19VX(45%#%(0!U,(`&M>BKPSO!45*Y65%56"G:;4M1]?09)2"29!Z9T'`
M:Q[Z;+=C*RI;I&*:E+[JTH2/45B:E$`"9:D-3Q.D2V_N";(@_P#ZF;?/559_
MT76H?B#G/O>X_?N>E&T_W&PWW70?<M^C''[@FR'V3-OGJJM#Z+I\0<Y][W'[
M]STH?N-AONN@^Y;]&'[@FR'V3-OGJJM#Z+I\0<Y][W'[]STH?N-AONN@^Y;]
M&'[@FR'V3-OGJJM#Z+I\0<Y][W'[]STH?N-AONN@^Y;]&(Q<T;BNQ5M_RC>.
M',HXAP]!W_84F6(N>):;69B;;,GYFJ#P$DI6'L5Y&O2]!R0>=%4Y>.FNH#6T
M;)C>_&0VIF\VJLK'+?4)YD*-<E)(F1YJG0H:CI`C6]XO^RMBN3UIN5)2(KF%
M<JTBB4H`R!\Y+1!T/08Q?^_9^'L_HVQ/_LB75_9Y7*?N%WB/\35_^H-_VT<;
M^^NP_P#AZ7V%?]E#]^S\/9_1MB?_`&1+J_L\I^X7>(_Q-7_Z@W_;0_?78?\`
MP]+["O\`LH?OV?A[/Z-L3_[(EU?V>4_<+O$?XFK_`/4&_P"VA^^NP_\`AZ7V
M%?\`91X*;[_P]229U3XWQ.!$R&.<?W1+K'0I"B8PZ!CO4=`"O(P'O$DR%35S
M_P#Y!O\`MH\'-MA@)FGI9#_^Q7_91+C;&R?87>%M6]=L!M3V_NX*Z8.(N.%=
M*8CM9JHYB)R/;R<:X4:N8=)PV.LS=$,*:A2G((Z&`!`0K4%5G&?T54Y1U%VN
M`?:<4A0]8<,E))2H3"I&1!U&D;4IL.PBKIFZIBV4)8=0E:3V"!-*@"#(IF-#
MP,?<_<$V0^R9M\]55H?1=>CX@YS[WN/W[GI1[_W&PWW70?<M^C#]P39#[)FW
MSU56A]%T^(.<^][C]^YZ4/W&PWW70?<M^C#]P39#[)FWSU56A]%T^(.<^][C
M]^YZ4/W&PWW70?<M^C$:^?,Z=CC;-E:YL*YAPYARWLB6>$6,]$,MKLI<#9I\
MLQ;29C^G+0=COXMUU8]ZF<>FJ;D$>4VA@$*V9C]AWUR>TM7NS5E:Y;GN;D4:
MY*">512?)4Z%#4'B(UW?+ULQCMT=L]VI*1NO9Y>9(HU*`YDA0\I+9!T(X&,.
M_OV?A[/Z-L3_`.R)=7]GE<S^X7>(_P`35_\`J#?]M'$_OKL/_AZ7V%?]E#]^
MS\/9_1MB?_9$NK^SRG[A=XC_`!-7_P"H-_VT/WUV'_P]+["O^RA^_9^'L_HV
MQ/\`[(EU?V>4_<+O$?XFK_\`4&_[:'[Z[#_X>E]A7_91W&#W=?A[IQ5)(+?V
MVP_5*F;JW#MRE85!/J?P5EGM@D32,GIYX"(<OEKXW\/[P[`)[2Y+E]"L2H_D
M#L?6SE6P[QEV=N1/Z=(I(_E:C>##F*.TGN$0ZV$L=[+\FJ`D*ZD?:=L8XD9I
M!`"@85G4"5F2;:)`4??*MR!_P#6"WF[[NXZKEOE3>J43E-Q;R4D]07/E/R&,
MSM%KVLOPG9J>T5)E.2$-%0'A3+F'RB,\_N";(?9,V^>JJT/HNN`^(.<^][C]
M^YZ4<Y^XV&^ZZ#[EOT8?N";(?9,V^>JJT/HNGQ!SGWO<?OW/2A^XV&^ZZ#[E
MOT8?N";(?9,V^>JJT/HNGQ!SGWO<?OW/2A^XV&^ZZ#[EOT8?N";(?9,V^>JJ
MT/HNGQ!SGWO<?OW/2A^XV&^ZZ#[EOT8U0W76YVF-E$!9]S;B=O>#[0A[[G'U
MN6RXC-OJ%VG>RT=&FEG;=5O:]K2J[,B;$@F!18I"&'@`B/"LMQ*IW<SBH>I<
M<N-<\]3MA:PJK+<DE7*#-;B0=>@3,8OE%/M=AS#51?Z"B::?64((I0N:@.8B
M2$*(TZ3&GUM;S.P!=MR6[:<%B_$CJ<NJ?A;9A&JFTNY&R;F8N"3:Q$6W4<N,
M?I-VQ%W[Q,@J*&*F0!YC"``(UF53A?>#HZ9RK?JJP,--J6H^OH,DH25*,@],
MR`.@U,8G3Y=L755#=*S34I>=<2A(]16)J40E(F6I"9(U.@B7']P39#[)FWSU
M56?]%UJ#X@YS[WN/W[GI1M3]QL-]UT'W+?HQQ^X)LA]DS;YZJK0^BZ?$'.?>
M]Q^_<]*'[C8;[KH/N6_1A^X)LA]DS;YZJK0^BZ?$'.?>]Q^_<]*'[C8;[KH/
MN6_1A^X)LA]DS;YZJK0^BZ?$'.?>]Q^_<]*'[C8;[KH/N6_1C\[S8AL6CFCA
M_(;5]N;!BS1.X=O7N,K*:M&J"91,HNY<KQJ:*"*90U$QC`4`\1K](SW/'%AM
MNZW)3A,@`^Z23U`!4S'Y7A.%-I*W+9;TH`F266P`.LF41^Y,S!V%,2R3R%NU
MILS<3+`YDW499^-(&_7":A!,4Z8J69;4XS%0AR"42]7F`W#2MA6RS;_7=I+]
M(;T&5<%./+:'_F+2?Y(P2XW;9"UN%FJ%H+R>(0REP_\`EH4/Y8UV?[\OP^;(
M0*CB?&$H/4.F;Y/VE36A`)X*<[ZRF29TSC[T2"81]S2LD;P'O#+\ZKJD:=->
MG_F=,<`YF^Q".%+3*\5"K_G;$?.^\!_#]_T(6'_LF+_9NO9\/>\)_CG_`&\>
MG'K_`'[V)_P3'L7_`'(^A';\_P`/H^6!%;$N,8K4Q"E6DMIDL"`B<V@B*C*S
M7O3*GXF$X%``KUN8!WAFT\R:RJ7X$UZ9_P`K@C]MYQL0X9&EID^.B5_S-G^6
M-V<")]EW<X_3A<(V=LZO2Y%4^H2TRX^M*#NY0`*8YRH6S<,)%3+LR1"B8X(H
MJ<A>(Z!6#Y`=Z\7;+]\>O+%,/Z3M7%-_*M"E)'@F1.,RL8V@R-SL;,U:7JCZ
M'9(2OY$+2E1^0&-N_P!P39#[)FWSU56A]%UA_P`0<Y][W'[]STHRO]QL-]UT
M'W+?HP_<$V0^R9M\]55H?1=/B#G/O>X_?N>E#]QL-]UT'W+?HP_<$V0^R9M\
M]55H?1=/B#G/O>X_?N>E#]QL-]UT'W+?HP_<$V0^R9M\]55H?1=/B#G/O>X_
M?N>E#]QL-]UT'W+?HP_<$V0^R9M\]55H?1=/B#G/O>X_?N>E#]QL-]UT'W+?
MHQ@3<AB#M:[2L:NLM9ZP!MULJRF\G'PJ+O\`F:@IJ3DYB45%-G%PT%"0#^8E
MGIR$.J8B")^FBF=0VA"B(9!C5YW5RZYBT6"X7)^M*2HCUE24I2GBI2E+"4CH
MU.I(`U,<%D-IVTQ:W&Z7RAM[-&%!,_5TJ)4K@$I2DJ4>G0:`$G01'A^_9^'L
M_HVQ/_LB75_9Y6Q?W"[Q'^)J_P#U!O\`MHP+]]=A_P##TOL*_P"RCL=H;Q/P
M_E[77;EG1&/L(-9:Z9J.@(QQ/[79FWH5.0E7*;-G\ISLQ8C2*B&9W"I2G<.5
M4T4]=3F`.-?/689WA*&D<K7JBN+32"M017)6J21,\J4NE2C+H`)/0(^BDRS8
MJLJFZ1IBB#KJPD%5&I"9J,A-2F@E(GTD@#I,2SAL%V0"`"&TW;X("`"`ABNS
MQ`0$-0$!"+T$!"M1?$#.?>]Q^_<]*-I?N-AGNN@^Y;]&'[@FR'V3-OGJJM#Z
M+I\0<Y][W'[]STH?N-AONN@^Y;]&'[@FR'V3-OGJJM#Z+I\0<Y][W'[]STH?
MN-AONN@^Y;]&'[@FR'V3-OGJJM#Z+I\0<Y][W'[]STH?N-AONN@^Y;]&'[@F
MR'V3-OGJJM#Z+I\0<Y][W'[]STH?N-AONN@^Y;]&->MS.*>UQM!QN7+.>=N&
M"[5L<\_%VP63CL$1UT.!F9@K@S!O\F6Y;<E(`14&I]5.GTRZ<1#4*R+%[MNI
MF-S_`&18+E7NUW9J7RFJ*!RIE,\RUI'2-)SC@,CM>VN*6_\`:E[M]$U1=HE$
MQ3!9YE3D)(03T<92B/K]^S\/9_1MB?Q`/]42ZO$1T#_]O/=K8?[A=XC_`!-7
M_P"H-_VT8)^^NP_^'I?85_V42ZP6Q[8C<D)#7%$;4MO[B)GXJ.FHM<^);4;G
M7CI5FB_9+'07B"+(&5;+E,)#E`Q1'00`0K3]1G6>TSZZ9Z[7`/-K*5#UAPR*
M20=0J1U'1&U6,,PFH914-6N@+2TA0/8($PH3&A3U&/J_N";(?9,V^>JJT/HN
MO5\0<Y][W'[]STH]O[C8;[KH/N6_1A^X)LA]DS;YZJK0^BZ?$'.?>]Q^_<]*
M'[C8;[KH/N6_1C/&-,38PPS;RMI8EL"T<;6NO*.IM>W[*@8ZW8=68>HM6[R3
M481B#=L=\Y09(D.J)><Q4B@(Z`%<!<[O=+U4BLN]0]4U02$A;BU+5RB9"9J)
M,@29#PF.;MUKMMHIS2VMAJGIBHJY6TA">8R!,D@"9`$SX(R#7'1]\*0A2$*0
MA2$5T/Q*7^J/AG^OQC_D;<M2/[L__N^M_P`@?]HB-`=X?_VK2?YX?[-<4ZL5
MQ5O3^4,;V_=Q71K5N"_;1@+B]"6]'>%AIR?814@HT7Y3]%RDW>"<AA`0`Q0U
M#36IEW5ZHI[74U%'+UMNG<6B>HYDH*A,=(F(B9;&F'[E3L54_5G'VTKEH>52
M@DR/7(QGS?#M`OS9-N$O+"%[HN'T8U75E\?7:HV%%C?>/Y!=8(.?:B'.@#LJ
M1!;OT"F,+9ZDH0>'*(X_@N8T&;XZS?*$A+I'*\W.9:=`',@],NE)Z4D'KCG,
MSQ2MPZ_/6:M!4V#S-+EHXT3Y*AT3Z%#H4"(L4=C;NKJ3Z-M[)=QUR]2<9MR1
M>W[(<Z\U6FV3<G\FQ5<#]R;5>68(%$(1=0W,X0)Z((BH1$#QRWUVG%.7<XQM
MJ3!/-5LI'FD\7T`?-)_6`<#Y?`JEOW9?<XOAO#L@<^V`E2NJ/G`<&5$_.`_5
MD\1Y'$)G:@J*429C7#==NDQ;L[PE=N<,L20-H2W6HHP\(V61+-WG<[DAPA;2
MMUNL8/2966<EY=0`2H)`=931-,PADN)8K=<ROC-BM*9ON&:E$'E;0/.<61P2
MD?E,@-2(Q[*,EMN)V9V\W14F6QY*1YSBSYJ$#I4H_D$R=`8_G4;N]V&4MYF;
MKJS?E>2,9]++*M+8ME!PH>!L"SVZRAXBTK?24'1)FP2-S+K"'4=NC*+J")C\
M+'</Q*U878VK%:4^0@36LCRW7"/*<7X3T#@E,DC01`/*LGN677EV\W17EK,D
M(!\EIL>:A/@'2>*C,GC&8<K;*)[!NQG#6YW)*3R*O+<7E(S#'-J.-6ZD7B2(
MM*7EE+FE6AQ*M\IW=+"U5:D,71&.*0XZ&<!IP]IS>GON=UN+6TI716VEF\X-
M>:H4XE/(D\.5M/,%'I7,<$QRUSP]^RX71Y)<04U=PJ9-(.G*PE"E<ZAQFM7*
M1U(D?G1K=ML_UB\!_P!<V-/\L(BLDR;_`-N7#_)/?[-48_CO_'Z'_.,_[1,?
MU%S>(_KJK&+*#'%(\0I"%(\CC'\YKNY?[R#=?_6&C_D]#59#M#_\;6G_`"W_
M`&U17_NI_P#(-T_S'_83&QW9"V@8#WD9ZR_9&X.RW%[6W:F(V]TP;%"?G;?%
ME-J7?#Q)G9W,`_CW"X&8NSD`ASB34VNFH!6-;Y9CD&&6"CKL=?#%2]6%M1*$
M+FGLU*E)8(&H&HUCG]FL4L>6WRKH[\R7J=JE"T@*4F2NT2F<TD$Z$Z'2+,?W
M%O;/_H$D?67DC[35&/X[[G>\$_<L^A$B_@KMU_@3]Z[Z</N+>V?_`$"2/K+R
M1]IJ?'?<[W@G[EGT(?!7;K_`G[UWTX\5.Q5VS%2'3/@.1$BA#$.'\Y>2`U*<
M!*8-0N;4-0&@WXW/!F+@F?\`H6?0CP=E-N2)&A5+_3.^G$KEM6]$VC;EOVI`
M-A9P5L0D3;L*S%55P+6)A&#>,C6PKKG476%!FU(43G,8YM-1$1&M3552]65+
ME74'F?=6I:CPFI1*B9#03),;0IJ=JDIVZ5@28:0E"1QDE(``F>H"/M5Z(]T*
M0A2$?SVN]S_O,]Q?_-QQ_HWMBK$-C_\`XQMW^N_VRX@=O)_\C7#_`%/^Q1';
M.RSM"P5O-W&Y%QUGZVI.Y[6M[$+V[8EG%W',6TLA.HW5;T61RH[A7+5RND#&
M05+TS&Y.8P&TU`*^3>S,+]A>-TURQ]U+56Y6!M14A*YI+:U2DH$#4#7C'T[0
M8I9<NR&HM]\;4Y3-TA6D!:D25SI$YI()T)TBS1]PKVT_Z([N]:]_?351A^/V
MYO\`C&?N&O1B1OP/V[_PKOW[OI1P;L*=M,Q3%_FDO`O,40YBY8OX#%U`0YBC
M\LCH8OB'Z:\_'[<W_&,_<->C'CX'[=_X5W[]WTHU-W-?AU-LTKCNYI?;1<^1
M,=Y(AH60D[?A[GN4][V;<3]BV5<I0TF66;A/1ORF*71(Y1=F!`YP,*1P#2LM
MQ?O'9.U<FF<G:IJFVK6$K4A'9.(!,N9/*>17+QY2G7A,1B^1[`XZY0..XZ[4
M4]P0@E*5K[1M9`GRGF',)\)A6G&1BFY!3=Q67<+*X;9F9BT[L@'_`%XZ>MZ2
M>0T[$23-42]9C*QRK9ZV715((<Q#AKX#PX5,Y]BFK:=5/5(0]2.)D4+2%)4D
M]!29@B(DL/5%&^FHIEK:JFU3"DDI4DCJ4)$&+\_96WHY"WE;47K_`"](!/90
MQ'>2V.[ANH4D475WQ813"7MNX99)`J:(3:S%T=N[4*4H.%6PK"',H8`K_P![
ML*MV&98ENSI[.UUC(>0WQ#:N8I6A,]>4$32.@*Y>`B<6SV7U^78N5W57/<J5
MXM+7TN#E"D+5+YQ!DKK(GQ,3`5IR-L0I"%(16-_$W_YD=JG]<MY?Z/W%2A[K
M_P#QR[?Y)O\`VHB./>-_X-;/\VY_LHJG;?/]8#`O]=V(_P#2';E2QR'_`-OU
M_P#D:C_8KB,5B_X[0_YUC_:HC^I(/B/ZQ_XZJMBRN.*0A2$*0BD_^('W@Y5N
MS<_([58:[)J!PUC&U[6<SEJ1#UQ',+VO*Y&`SCR4NDC<R1YEM$,G*#9HV6,=
MJF)3J`3J'$U3>[O6'6FCQ9.5O,H<O54ZX$N*`46FT'E"43\TJ()41Y1T$Y"(
M=;ZY9<ZO)%8RRZM%HIFT%2$D@..+',2N7G!(("09@:F4S$77;MVC-=[6ZRP<
M`R5P/+2MF59S]SW?-Q"#967;6Q:T>+^0;PZ;HAVA).27.BV354(H1#K"H)#\
MG(;:>XV7KPC$ZC(&FTO52"A#:5$\I6LR!5+7E2)J($B92F)SC6V`XJG,<G8L
M3CA:IE!2W%)`Y@A`F0F>DSH`3.4YR,I1</MWL(]MB":)MGF++SNE<J1$U)"X
M\IWJJ[74*!>=<R<5)Q3)%100X@FD0@:Z`4`J&]3O_N74+*D5;+29\$,-2'@\
MI*C^4F)94^Q^WC".5=,\Z9<5O.3/A\DI'Y`([#]Q?VS?Z!9#UF9'^TU?-\=]
MSO>"?N6?0CW_``5VZ_P)^]=].-(-^787VW--OU_WMM"L/(43F^UF+67M.R(B
M[)>[(N^13D&B4A;@Q%SO':C=XXCE55$%T7*0D53#G`Q1$*SG`=_<E7D-/0YA
M44Z[&ZHI<=4VEM36ADOF0!,!4@04F8.DC&&9OLACR+$_6XHQ4)O+20I#:5J6
M'-1-'*LF1()(((U&LXKN1?;"[ED%*1T[!;3<ZPL[#/&\G#3,2T81\K$R3-4J
M[1_'/VLZDZ9NVRY`,11,Q3%,'C4C'=T=LGVE4[]WH%L+24J2HDI4DZ$$%$B"
M.(,:#:VXW$9<2^S:ZU#Z""E20`I)&H((5,$'I$7[MH\OEZ=VR8-E,_1$G!YI
M7QQ;J63(V:02:RZ5VLF@,91>3;H'412?OU6WI"H$$2<ZHZ<-*K^S!FST^45[
M6/K2Y9!4K[%23-/9DS2$DZR`,A/H$3EQ5VZOXW1.WQ"D7@TZ.V"A)7.!)1('
M293/CC8FL;CGX4A"D(^3/ST):L',7-<DHQ@[>MZ,?34Y,R3@C6/BHF,;*/)"
M0>N51*F@V:-43'.81T`H5[J>G?JWT4M,A3E0XH)2E(F5*49``=))T$>I]]FE
M874U"DHIVTE2E$R"4@3))Z@-3'\]ONK]PJ=WY9\=N(%Z]:8`QB^DX3#=O*@9
MN610,8K:5R'+-1T'Y:NPS<#)%/J9JP!)(/.%036(;3[=L8#CX34)2<@JDI54
M+XR/%+*3]%N>LO.7,\)1`[<[/'LWOA4PHBQ4RBFG1PF.!=4/I+EI]%,AUQG_
M`+0O:B2WRKWME7-!9Z`V_6[&S=IVX\B5SQTK>>273,S9)S#N1+H>%L(5P=.C
M<2.'O2;CJ4%P#'MX=V3@B6+39.S<R%Q27%A0FEMD&<E#Z3LN5/2$S5QY8YW:
MG;`9HIZYW?G;L3:5(04Z*<>(E-)^BU.9ZU23PG$8F[#;%D7:#G6^<"Y/::3-
MJOA/$3:"2B<7>-IOC'5MZ[H8YP#G8S#$`,8GOF[@JB)]#IF"MHXEE%MS&PL7
M^UG[!U/E)/G-N#SVU>%)_*)*&AC7&48W<,4O;UCN0^V:5Y*AYKB#YBT^!0_(
M9@ZB+9W8O[EY\_60WVF9NN4SO-F-X?7&T_++E%[DO&\0V(F$>LX4T.^NVR6R
M8$7$1,J[CP(L/,=)8PQ'WWVQ&/UQRZQM2LE2O[9"1HR\H\0.AMTZCH2N:>!2
M(E%LMN*;Y1C%KRY.\4Z/LE*XO-)'`GI6V./2I,CQ"HL45'&-_0I"%(0I"((O
MQ$O^[^;_`->&.?\`S,]6^^[E_P#(1_R+W_9C26_O_L4?YUK_`+447/<_YQ?_
M`"@J=QX1"R/ZFN%_\SN)OZLK"_R5B:JJO?\`QJL_S3O^T5%E]G_X12_Y9K_J
M)C)=<7'(PI"%(0I"%(0I"%(0I"*Z'XE+_5'PS_7XQ_R-N6I']V?_`-WUO^0/
M^T1&@.\/_P"U:3_/#_9KBF[CW_.'CW_\_65_E/%5,^X_\.J/\N[_`-141)H/
M^(4_^G;_`.NF/Z(_<-V`XYW]X*-94\5M`9/M5BXEL09%*B!G=L7&JS2$T9)"
M0.J]M.X3()HOV_$0*!5D_A$RZUS;=;@W+;^_>NT\W+6\H)J&9Z+1/SD]3B)D
MH/C!T)B?&>X+;\YLGJ;\D7)I)4P[TH7+@>M"M`H?*-1'\]K*V*\G[=<JW+C#
M)$+*V)DW',\1M(-`65;/&#]FHF[BIR$DFYB"NQ>)@D[8/4#<JJ1B*$-[EB%I
MNMKR.TM72VK146NI;F#*8(.BDJ2>!&J5I/`S!B!]TMERL%S<MMP0IFXTZY$<
M""-4J21Q!T4E0XB1$78^T+W283=#@2X[7W`7A$0V;=OEL+3%^7%,N4(]&]<8
MP[81+E!4QN1,'<4BET)OE#0KCD7\'``6$.\.U3^+9`U58\RM=CN+O*TA()[)
M]1_4>)1U:\$T_-UF)M3N6SDEC<IKZZE%YH&^9U:B`'&4C]=XT\'/#)7SHJ]]
MT3N"73OTSY(R[%\^88)QZ_DH/#%I&.HDW/&%5]'=WW*M!$"GN.[N@"PB<!,U
M9BD@4?-.)I2[6;>4F`X^EEQ*57ZH2E52YT\W$-)/T&YR_.5-75$;=R<[J<WO
MBG4*4FRL**:='1R\"ZH?37Q_-3)/7/;WLP]K)?=A>C+<3G.`<$VW6%+D5@(.
M01.DCF>[XQQK\F%*<"F<6+`.D@&24+YKQ<`:E$2@N)<.WJW53B5"K'+$X/WE
MJ$>6H<:9M0\[P.K'F#YH\L_-C*MH=LU916)O]Z0?W>87Y*2-*AP'S?"VD^>?
MG'R>N)%_Q,K9NSPGM,:,VZ#1HUR7?#9JU;))H-FS9"S8Y)!NW02*5)%!%(@%
M(0H`4I0``#0*UOW8E*7?+NM9)6:5HDG4DEQ4R3TF-@=XM*46>UH0`$"H<``T
M``;3(`15EVV?ZQ>`_P"N;&G^6$14J\F_]N7#_)/?[-41IQW_`(_0_P"<9_VB
M8_J+F\1_756,64&.*1XA2$*1Y'&/YS7=R_WD&Z_^L-'_`">AJLAVA_\`C:T_
MY;_MJBO_`'4_^0;I_F/^PF/H]L79GE3>ME;(=B8GSX]V_3-HX^2NR2N-@C<J
MRLY&J7#'Q`0I@MFX;<<E(1R[*OJHJ=/S.!>;00]>Z&:6G"+335]WMZ;BR]4%
MM*#R>2KD*N;RT+'`2T`.O&/WMQB-SS"Z5%%:ZY5"\TQSE8Y_*'.$\OD+0>)G
MJ9>")L/N#MYW_P`RRX__`&+*_P#:C6D/C_A/_P#3#7Y:?^PC<?P.R[_^HG/R
M/_VT/N#MYW_S++C_`/8LK_VHT^/^$_\`],-?EI_["'P.R[_^HG/R/_VT9$Q#
MV/\`=SCK+6+<A3O<.G[JA+#R-9%Z3-KJL\GE2N2*M:YHR<D8!0SS)+MH5.99
ML3MC"JDJF`*><0Q=2CQMXWRP^XVBKMU/CC;3]13.MI7-CR%.(4D+T9!\DD'0
M@Z:$1]]JV:RJWW2FKWK\XZRQ4-N*1)[RTH6%%.KQ'E`2U!&NH,681XB(_IJ,
M<2*CBD(4A"D(_GM=[G_>9[B_^;CC_1O;%6(;'_\`QC;O]=_MEQ`[>3_Y&N'^
MI_V*(W&_#9?ZXV7O_P#/DE_ES:-8;WE__9E'_P#R*?\`9.1EG=Z_]W57^0/^
MT1%U^H0Q,6%(1\Z8=MH^(E7[U=-LS91D@[=N5CE31;MFS199==50P@4B:21!
M,81'0`"O:PA3CR&T`E:E``=9)D!'K=6EMI3BS)"4DD]0`UC^5;=+U"2NBYY%
MJ(F:R%R3[YL80`!,W=RSQP@80`1`!%)0*M=I4*:I6FU^>EI`/C"0#%952M+E
M2XXGS5.*(\142(N'?AG8A5OMRW&3ABJ@C*YJAV"9S$`$#'AK*8**E2/XF4($
MH7G#^"`E]VH;]YUX*R2VL:<R*)1\/E.'T8ECW=6BG'[@]K)58D?5;'_UBRK4
M98D1"D(4A%8W\3?_`)D=JG]<MY?Z/W%2A[K_`/QR[?Y)O_:B(X]XW_@UL_S;
MG^RBJ=M\_P!8#`O]=V(_](=N5+'(?_;]?_D:C_8KB,5B_P".T/\`G6/]JB/Z
MD@^(_K'_`(ZJMBRN.*0A2$*0C^?GWSXUS&]R[-P.2@7Y0@,9RC?3F\YJ[LR/
M(D8>8I>(F0-X:AP\:L*V(<2YME0\OS7'TGQAP_\`UB">]#:F]Q*WF^<AE0\1
M;'_TCO/X?QVV:]R"SB.%B)'>XIRNS:E.(@*[H8F/<@@GH`ZGZ#90_P"H@U\/
M>#0I6VKQ2)A-6P3X!S$3_*1'V[%J2G<)D*,ITKX'CY0?^0&+Z=0#B;\*0CKU
MVW9;UAVM<=[7;*)0EK6E"2=QW',+IN%D(J$AV:K^3D%DFB+ATHDT9H'.8$R'
M.(%X`(U]-'25-PJVZ&C07*MY:4(2)`J4H@)&LAJ3+4Q\]754]#2N5E6H(IFD
M%:U&<DI2)DZ3.@$]!$>8=XWMF"`"&[S'H@(`(#\EWQQ`>(#_`-5:V)\&MS_<
M]1]9KTXP+XM;<^]:?\CGH1O)B+,&-<]8^M_*V(;NC[ZQY=2;M6W[IBTGR+&4
M38/G,:[,@G(M63PH(/FBB8\Z1>)!TU#C6"WBS7.P7%RTWAE3%Q:(YT*D2F8"
MA.1(U!!XQFEJNUNOE`W=+2ZEZ@=!Y%B8"I$@RF`>((X1DFN,CD84A"D(J0]_
M+N3FEWTCL6PE<0_)4>HD;<9<<2XT*_D$S).F&*&[I$P@=HR$".9H`'SE@3:F
MTY%BC+WN_P"V?8MISN^-_;*']S0H<!P+Y!Z3P:\$U]*8BQOCN&7EJPJS.?9)
M/][6D\3Q#`/4.+GADD\#%=W:]AB`SYF^Q\:7=DRR</63*R!7=[9&OVYH:UH2
MW+4CA(XF56CV<=LVCNX';4!08-0,)E7*A1$`(4Y@D9E-ZJ,?L3]SHZ5^LK4)
MDTRTA2U+<.B9A()"`=5JZ$@],HT'C=H8OEY9MU74LTE&I4W'75I0E"!JJ140
M"HC1(Z2>H&/Z`>'MS';BP-C&R\08NW.;9+:L2PH-K`V_$MLS8]U(W;E$RSQZ
ML$X4SR4DW1SN'3@WGKN%3G-Q,-5[WG&-R;_='[Q=+7<W:^H<*UJ-.]Q/`#R=
M$I$@D<``!$Z;3D>WUCMK-IMMRMK=$P@)2D5#7`=)\K4DZD])),1O]W"WMA^^
MO!:DI9FZW:ZSW$XI:/IG&$TIF3'B"MRQY4U',QC26>!.@<8^X0)SLC'YBM9$
MJ9@Y2*+".RMH*G/<#OO8UMINJL<JU!+Z?5WCR'@EY(Y.*/G2\Y$QJ0F->[J,
M81FME[6CN=M%_I05,J]8:\L<5,J/-P5\WJ7(Z`F*:&.\A7MB._+4R7CN??6I
M?EBSK.X+:GHU;E<QLM'*\R9@,F;IN6JP<R2Z0B9)P@<Q#:D,.LT;C;J&\4#M
MLN+:7J!]LH6@\%)/_(>D'B"`>(B(]!7UEJK6KC0.%JN86%(4.(4/^4=!'`B8
MX&/Z*/;DWT6=OTV\PF28TS.*R1;A6=MYCLI%0.I;-ZIM0,J[9HF,98;;N4B9
MG<<J;Q2,9(1%1$]5R;DX'6X#D2[:[S+MKLUT[I^>W/@3PYT>:L=<CP(B?6WV
M:TF;V%%P;DFX-R0^W]!R7$?F+\Y!ZICB#&_=:^C.H4A"D(@B_$2_[OYO_7AC
MG_S,]6^^[E_\A'_(O?\`9C26_O\`[%'^=:_[447/<_YQ?_*"IW'A$+(_J:X7
M_P`SN)OZLK"_R5B:JJO?_&JS_-._[1467V?_`(12_P"6:_ZB8R77%QR,*0A2
M$*0A2$*0A2$*0BO/^(ZMZX;CVG8=:6Y;T]<;M'.S)=9I;\+)SCI%`+/N0@KJ
MMHMJ[620`Y@#G,4"ZB`:ZC4BN[;44]-EM8NI<;;0:`B:U)2)]HC2:B!.-"]X
M%A^HQ>D33MK<4*T&24E1EV:]9)!BG_C_`!=E%/(%@**8PR4FFG?=F****6!=
MY$TTR7-%F.HH<T,!2$(4!$1$0``#4:F+<+K:C;Z@"JIB33N?TK?T%?G1%&@M
MMR%>P335$NW;_HG/II_-C^HDV`0;-@'@(-T`$!\0'I$JK)?GGQF+)D^:/%$0
MG=G[8EO;[,8'O&P&45!;G,>QJRMCW"J5)FA?4.W*HX7QQ=3P`*`MGIA$T:[5
MU]!=B`"((JJUN':/=&HP.Z>I7!2W,7J%?:HXEI1T#S8ZQ\](\Y/YP$:IW2VW
M8S6V^MT*4HR.G3]FKAVB1J6EGJ/S%'S5>`F*+#K$^>+.EI^#<8PS#;LRU&5M
M2Y6"%DWLS<<A%_19F!DC,HP$WC)1=MRK)"91!;D`1Y@T&IX)N]@K&6WTU5&X
MP>5Q!+K1'":5IFK0R.AT(B%2[7>J1U;*J:K;>',A8#;@/&2DF2=1,:C4&)#>
MV7VN\E[U\SI)9`MJ[\?X#L!XPD<HW',0LM;4C/)&/UVMAVB:69-CJS,ZFF(+
MN2%.1@TYE!U4,D4VNMS]T[9A%E*K>ZS49!4)(80E25I3T%USE)\E/0DZK5IP
MF1GVW.VMQS&[@5[;K%C8(+RU)4@JZ0TCF`\I72=0E,SQD#?SLFR;3QO:%MV#
M8EOQEJV;:$.Q@+:MV';$:1L1$QR)4&K1J@F```%(74QC:G4.(G.(F,(C7Y75
MU7<ZQVX5[BG:UY96M:C-2E$S))__`$`-!I$YJ*CI;=2-T-$VEJD:0$H0D2"4
MC0`#_P#4^)UBN9^)3MJY;EP_M:1MJVKBN19KDZ^U72-NP4M.JM4CVDQ(15RE
M%,W9VZ9SAH4QP*`CP#C4C^[/54M->;JJI=;:2:5J16I*9_:*X<Q$_DB/W>'I
MZBHM5L%.VXX14NSY$J5+R!QY0915[VY8RR:VW"X)<.<9Y';-T,PXW67<.+"N
MU!N@BG=T2=19=96'(DBBF0!$QC"!2@&HCI4ILDNEK5CM>E-53%1HWI`.MDG[
M-7`<T1NQ^W7%-^HE*IZ@)%6SJ6E@?K$_FQ_3@-XC^NJOXL<,<4CQ"D(4CR.,
M?SR>['CS(<MW%-U$C$X]OV6CG60$5&LC%V7<\C'ND_J_#EZC9ZRBEVKA/F`0
MYB',&H:58KM+<;<SMS:FWJBG0X*?4*<0"/+5Q!4"(@3NA05[N?7-QIA]39?T
M(;60?(3P(208^+V_MT^XWM\9'O;)-A[;K@R%(WQ92=DO(V[[.R1&LF+-.;8S
M@/6JL-#==1R*S$J8E/YG(81\:]VX6*8WN';6+;7W-NG;8?[4%MQE1)Y2F1YE
M2E(STCTX+D]_P.X/7"AM[C[CS/9D+;=``Y@J8Y4SG,2B6+\PGO?]A.W_`)FS
M5]#5J7^'?!??SGUJ;THVA\><R]RH^K4>C#\PGO?]A.W_`)FS5]#4_AWP7W\Y
M]:F]*'QYS+W*CZM1Z,>"GXA7?`1,YPV)6^(E(8P!\C9KXB4HB`<(;7CI7D=W
M?!29?MYSZU-Z4>#OSF0$_P!BM_5J/1BTQ@>_YK*N%<4Y,N2#3MFX+]L"UKMF
MK>2(]32A).=B&L@\BTTY$B;\A&2ZXI@"Q04#E\X-:BI?[>Q:;W5VRF67:>GJ
M'&TK,O*2E1`5IIJ!/33JB2]CKWKI9J6XU".S??80M2-?)*D@D:ZZ$RUUC+-<
M1'*PI"%(10'[T]@7_-=R?<+)0M@WU-1K@N.O1Y*'LZY)2.<=/'5M)J=!\PC'
M#5;IJ%$IN4X\I@$!XA5@NR=PM[&VEN;?J&$.CMIA3B$D?;+X@J!$07W@H:Y[
M<.O<98?6V>RD4MK4#]DC@0"(P=L1W*[E]@F4+FRIC?;].WG,7392]CO(Z\[!
MR.G'-X]>7C9DSMN,-'M'/I95XLA0YC"3D,/#72N=SW&<9W`M;5IN5Q;89:?#
MH+;K,R0E29'F)$I*,<-A.19%@UR<NENH%O/.,ELAQIV0!4%3'*`9S$2N?F!>
MX#[&=H_]A<U_\M:F_A[V]]]/?>TT;.^.V=^Z&ONZB.#?B!>X$)3`79K:!3"4
M0*8;$S68"FTX&$O,7F`!\FH:T'=[V]G_`,:>^]IH?';._=#7W=1&LF?NYCW:
MMW5HS.+66)[YL&SKK9GCYV'PU@G)$7+3\,^3,@O%.[JF6\U,DCI!$QTUBLU6
MI5TC"0VI1$!RC']L=H\/K$75=6Q45K*IH54U3*DH4-0H-I*4S2=1S!4CJ(QV
M^[B[I952+MJ*5YBC=$E)IZ9T*4DZ2*U!2I'@>4B8TX1KMM^[,O<!SU+QK8<*
M2V'+6<J)`]O3,X?4MC',S"4#N4;;7ZEWRIRICJ1-%D`'_CE#B&1Y#O3M[8&5
M*]>16U8!DW3?:%1ZBL?9I\)*M.J.`L6T6=7QU*?4U4E,3JY4?9@#KY/UBO$$
M_+%W/8SL]LG8WMXM;!%F2+BX%6+I]<5Y7<];D:.[OO::Z)IJ<.S3.J5BT$K=
M)NT;@<_0:()D$QC`)A@YG>95V=Y&[?JU(;2H!#;8,PVTF?*F?2=25'2:B3(<
M(F1A>)T>%V!JR4BBX4DJ<61(N.*ES*ET#0!(Z$@"9XQM_6'1ED*0A2$5I_Q*
MMM7+<N%=K:-M6U<5R+-<PW@LZ1MV"E9U9JB>PETR+.4HIH[4;I'4'E`QP`HF
MX`.M2:[LU534M[NJJEUMI)HVP"M24@GM1PYB)Q'?O#TU146>VBG;<<(JG">5
M)41]GT\H,5:\!8QR<WSW@IPXQED=NW0S5B===PO85VHH(((Y`MY159=96'*D
MBBDF43&.80*4H"(B`!4J<@NEK58*]*:JF*C1/@`.MDD]DO0#FXQ&BQVZXB^4
M1535`2*Q@DEI8'ZU'YL?T[1\1_6/_'57D6/QQ2$*0A2$5Z^\UVEK^WCSUO[B
M-NRL&OEZV[53M*[K"FGB4*GD&"C'+AY"/X:=<CZ`TN>'([5;@DZ%)!TW$A04
M3.F'/(G9;=VWX93N8YD8<%G<=[1MU(YNR6H`*"DC4H5(&:9E)GH0=-#;N[6U
MV6OHO]@*#=6VN1;2CR]JD$E)2HZ!:9D25($2U!&M72$PAO\`-D^7;7R;&X+S
MMC#)&.YKY2@+A2QI/ST65P1)9J[1%Y%QLQ;T]"23%95!P0%%6SANH8HB(#K4
MIW[YM_F]H=M;M?055MJ4<JT=LA"I<09*4E:%`R(T!!`B-;-FSG#[JU<FZ*MI
MKA3KFE78J4)\#J`I*DD3!U(()$2]6Y^(5WY0#)*/O3:I85RRJ""1%GXVAEFT
M%US@`?RI>-(I)))G7+Q$"<A-1U*`!PK3U3W=L!J%ERBNU0TT3P[2G<`\`/D\
M/#KUQM:GWYS=A`166QAQT#CR/MD^$C7C\D=B_,8[PO8PL7_ZF6OHZOG_`(<,
M-]]/_P#^O_\`6/?\?\L]T,?^?_\`2-;-R/>2[B&Z?&EVXAA<'M\<6=?\5(6Q
M<ZF.<89*N"Z9."DTCH2D&UGI1-\FP2?L%!17.W:D<BD8W*H0##62XULQMSBE
MS9O#]<:FLIUA:.V?90A*DZI44IE.1U$U$3X@QCV0[MY]DUN=M3-$*>D?24+[
M)EY:U).BDA1G*8T,DSETB-#<%]K_`'V[@Y>.CK*VYW_`1+U5%-6\LDPSO'=G
M1C=0`,9XYDKG18N7:2*8\PI,T'*YO`I!$:SZ_;I8%CS*G*ZY4[CR1^K94'G"
M>H)02!/K44CPQA%EVWS:_.I;H[>^AHG]8ZDM-@=9*Y$RZD@GP1?HV7;<4-I.
MUW#FWHDRE<;O'%K!'S5P-T%&S:9N&2?O)N??-$%C&628GEI)8K<I_/!`I.;0
M=:K_`,VR167Y56Y$4%M%2[-*"9E*$@)0">OE2)]$YQ./#\?3BV-4EA"^T53M
M24H"04HDJ40.KF)EX)1M!6*QDL*0B*SNQ;X[DV?8"<Q6(X"Y+GW`Y5;/H''2
M-O6S-7$C9K'0J$YD&8&+CWJ+?Y$06Y8])42^DOSI\#)IJZ;8VDP6FS'(`]>'
M&FL>I"%O%:TH[0\4LIYB">8CRR.")\"1&L=T<SJ,3L9:M2''+[5`I:Y4*7V8
M^<ZKE!`Y1YH/%1'0#%"E'$V=KVN=)$N,,MW'=MX3Y2=5W8]X+R<]<=P2'G+.
MWKN**"KR2D70F465.`<QQ,8P!J-3[5=[#0TI4:JC;HV6^AUL)0A`X`!7!(&@
M`\`B$";7>JRH"?5JIRJ=7TMN34M1Z24\23J3%N;`GX<[;&&'K"4W%3V5)#-#
MR":R&02V5>T;$6K&3KX/2EH*':*6[(G50@B*E:F<"L?TE1(RH<I3`4(@Y!WD
M,H_;-0,<;I$V1+A#7:-%3BDC3F4>=.JO.E+R00-93B5-CV`QS]DL&_KJ57<H
M!=[-P)0%'7E2.0Z)\V<]2">F,O?ES^WO_P"F9\]9,5]D*X?^)#</Z-O^Y5_:
M1RO\/^!]==]ZG^SA^7/[>_\`Z;GSUDQ7V0I_$AN']&W_`'*O[2'\/^!]==]Z
MG^SB(_NM=E./VKV+;N;-I[?(E\X[CU48/*%I3*Q[SO"WGC]UTX:[XL8:(:.7
MENKJJ%:.T00,=HJ9-7F%,Y^GM[:;>US+*]RR9::9BY*',PXD=FVL`>4VKF40
M%C523/RA,2F!/5FYVSR,9HF[QC`J'Z!)Y7D*/:.))/DN)Y4@E'S5"7DF1X$R
MCHV![@]QVQ+<);V7K8Q?EJ4M%Z9"`RO8R%C7BDVO:Q'#DBCYH"9X4S<D[$'#
MTJ-7,412<$Y1^#44`=D;@8]C>>XZY9ZJJI$U@FMATNMS:=`T/G3Y5>:L=(,^
M($:_P:_9!A-^;NM-352J4^2\WV;DG&R=1YLN9/G(/0=.!,?T.,<W_;.5;#M+
M)%FN73NU[U@F%PPBSYB[BWX,I!$JI4)"-?)(O(^0:G$4ET%2%.DJ0Q1#4*KJ
MN5OJK37O6VM`%4PX4*D0H3!XA0F"#Q!&A&L3VM]?372A:N%(2:9Y`4F8*3(]
M!!D01P(.H,=TKX8^R%(1!M^(.@YRX-A+=A;T'-7`_#-F/%O0(&)D)I]T4TIS
MJ+>AQC9TYZ*?,',?EY2ZAJ-;V[O#[%/GY<J'$-M^HO":U!(GY.DU$"<:7WX9
M>?P<(80MQ?KC1DE)49>5T`$Q2#_FKRIP_P#TMR;P$!_S>WAY!U_^"_HJ<G[5
MM/\`BZ7[YOTHAI^S+E_AJG[IST8L-VMWY=^]IVQ;=JLMG5L.6=LP$-;S1PYL
M7-'I+AM"QS:-07<`F!4P662;`8P%`"@81T#2HZU>P>`5=4[5N7ET+=<4L@.T
MT@5$J('@$XWU3;W9Q2TS=*BTM%#:$I!+=1,A(`!/ATC[OY@7N`^QG:/_`&%S
M7_RUZ/X>]O??3WWM-'N^.V=^Z&ONZB'Y@7N`^QG:/_87-?\`RT_A[V]]]/?>
MTT/CMG?NAK[NHB?CMA;N,M[TMN4QEW-&-X_%EW1^5+JL=O;<9%W-$-EH.#AK
M6D6,L+6Z_P#&9E7;B;7()R_`B"0`7B!JC]NEB%GPG)$6>R5*JNC52-NE:E(4
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M:!Z$/CW@G57_`'!]*./S#_;V^(W!^IY?Z>I_#GN)UV[V@>A#X]X)U5_W!]*.
M0_$0=O</!'<'ZGE_IVG\.>XG7;O:!Z$/CW@G57_<'THY_,0]O?XG<'ZGE_IV
MG\.>X?7;O:!Z$/CW@G57_<'TH\?S#_;V^(W!^IY?Z>I_#GN)UV[V@>A#X]X)
MU5_W!]*'YA_M[?$;@_4\O]/4_ASW$Z[=[0/0A\>\$ZJ_[@^E#\P_V]OB-P?J
M>7^GJ?PY[B==N]H'H0^/>"=5?]P?2A^8?[>WQ&X/U/+_`$]3^'/<3KMWM`]"
M'Q[P3JK_`+@^E'E^8A[>_P`3N#]3R_T[3^'/</KMWM`]"'Q[P3JK_N#Z4/S$
M/;X^)W!^IY?Z=I_#GN)UV[V@>A#X]X)U5_W!]*'YB'M\?$[@_4\O].T_ASW$
MZ[=[0/0A\>\$ZJ_[@^E#\Q#V^/B=P?J>7^G:?PY[B==N]H'H0^/>"=5?]P?2
MA^8A[?'Q.X/U/+_3M/X<]Q.NW>T#T(?'O!.JO^X/I1X_F'^WM\3N#]3R_P!/
M4_ASW$Z[=[0/0A\>\$ZJ_P"X/I0_,/\`;V^(W!^IY?Z>I_#GN)UV[V@>A#X]
MX)U5_P!P?2A^8?[>WQ&X/U/+_3U/X<]Q.NW>T#T(?'O!.JO^X/I0_,/]O;XC
M<'ZGE_IZG\.>XG7;O:!Z$/CW@G57_<'TH\@_$0]O<.`([@_4\O\`3M/X<]Q.
MNW>T#T(?'O!.JO\`N#Z4/S$/;X^)W!^IY?Z=I_#GN)UV[V@>A#X]X)U5_P!P
M?2A^8A[?'Q.X/U/+_3M/X<]Q.NW>T#T(?'O!.JO^X/I0_,0]OCXG<'ZGE_IV
MG\.>XG7;O:!Z$/CW@G57_<'THX_,0=O?XK<)ZGW'T]3^'/<3KMWM`]"'Q[P3
MJK_N#Z4/S#_;V'Q1W"#_`/P^X^GJ?PY[B==N]H'H0^/>"=5?]P?2CC\P_P!O
M;XC<'ZGE_IZG\.>XG7;O:!Z$/CW@G57_`'!]*'YA_M[?$;@_4\O]/4_ASW$Z
M[=[0/0A\>\$ZJ_[@^E#\P_V]OB-P?J>7^GJ?PY[B==N]H'H0^/>"=5?]P?2A
M^8?[>WQ&X/U/+_3U/X<]Q.NW>T#T(?'O!.JO^X/I1R'XB#M[AX([@_4\O].T
M_ASW$Z[=[0/0A\>\$ZJ_[@^E'/YB'M[_`!.X/U/+_3M/X<]Q.NW>T#T(?'O!
M.JO^X/I1X_F'^WM\1N#]3R_T]3^'/<3KMWM`]"'Q[P3JK_N#Z4/S#_;V^(W!
M^IY?Z>I_#GN)UV[V@>A#X]X)U5_W!]*'YA_M[?$;@_4\O]/4_ASW$Z[=[0/0
MA\>\$ZJ_[@^E#\P_V]OB-P?J>7^GJ?PY[B==N]H'H0^/>"=5?]P?2A^8?[>W
MQ&X/U/+_`$]3^'/<3KMWM`]"'Q[P3JK_`+@^E'/YB#M[_%;A/4^X^GJ?PY[B
M==N]H'H0^/>"=5?]P?2CT*?B%^W:J83JL,^*''0!.IA@QS"`<``3&FQ$=`K]
M#N[;C`2"K>!_F?\`NQX._&`DS*:Z?^7_`.]'A^82[=/_`,-SSZE1^FJ?P[[C
M_3H/:?\`NQX^.^`_1K?9_P#O1[T_Q#G;R1+R)-=P"1!'7E2PVJF74=-1T).`
M&HZ5X/=TW%.I-O)_S'_<C]#?G`QP%</_`/'_`.]'G^8@[>P^*.X3U/N/IZO'
M\.>XG7;O:!Z$/CW@G57_`'!]*./S#_;V^(W!^IY?Z>I_#GN)UV[V@>A#X]X)
MU5_W!]*'YA_M[?$;@_4\O]/4_ASW$Z[=[0/0A\>\$ZJ_[@^E#\P_V]OB-P?J
M>7^GJ?PY[B==N]H'H0^/>"=5?]P?2CD/Q$';V#P1W!^IY?Z=I_#GN)UV[V@>
MA#X]8)U5_P!P?2CG\Q#V]_B=P?J>7^G:?PY[B==N]H'H0^/>"=5?]P?2CQ_,
M/]O;XC<'ZGE_IZG\.>XG7;O:!Z$/CW@G57_<'TH?F'^WM\1N#]3R_P!/4_AS
MW$Z[=[0/0A\>\$ZJ_P"X/I0_,/\`;V^(W!^IY?Z>I_#GN)UV[V@>A#X]X)U5
M_P!P?2CD/Q#_`&]@\$=P?J>7^GJ?PY[B==N]H'H0^/>"=5?]P?2CG\Q#V^/B
M=P?J>7^G:?PY[B==N]H'H0^/>"=5?]P?2CQ_,/\`;V^(W!^[_F>7#B/C_P#C
MOE&G\.>XG7;O:!Z$/CU@?57?<'TH?F'^WM\1N#]3R_T]3^'/<3KMWM`]"'Q[
MP3JK_N#Z4/S#_;V^(W!^IY?Z>I_#GN)UV[V@>A#X]X)U5_W!]*.0_$0=O8/!
M'<'ZGE_IVG\.>XG7;O:!Z$/CW@G57_<'THY_,0]OCXG<'ZGE_IVG\.>XG7;O
M:!Z$/CW@G57_`'!]*'YB'M\?$[@_4\O].T_ASW$Z[=[0/0A\>\$ZJ_[@^E#\
MQ#V^/B=P?J>7^G:?PY[B==N]H'H0^/>"=5?]P?2A^8A[?'Q.X/U/+_3M/X<]
MQ.NW>T#T(?'O!.JO^X/I1)9M#W@XAWNXK?9BPH6[BVA'WE,V(X"];=-;$Q\N
M03"'DGPIQQW3P3L?1IU#D5Y_.-S!H'+6L<QPV\8-=DV:^=CZXIE+H[)?.GE4
M5`:R&LTF8\4;$Q3++5F5L5=K/VOJB7E-GM$\BN9(23I,Z24-?'&TE8I&30I"
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M3E/;(>RP]3E/;(>RP]3E/;(>RQWNV_\`W>;_`*N?X2K_`-5__=WO$O?_`/K7
G\;_Q>6O@JOUG])P^?Q__`&C[:;]7_1\?F</_`-X[!7S1]$*0C__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex10-14a1b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-14a1b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!?P)8`P$1``(1`0,1`?_$`(T``0`"`@,!`0$!````
M```````&"`4'`0,$`@H)"P$!`````````````````````!````8!`@($"@<&
M`P<#!0$```$"`P0%!A$'$@@A$Y@),2(45M;7&%AX&4$R%;:W.#GP46%Q(Q:!
MD22AL<'1X4(E\3-34D,T11<F$0$`````````````````````_]H`#`,!``(1
M`Q$`/P#]-G=_<AO(UFO)#RIY?F7)ARGY;EF3[$[<7N291DO+IM!?9#D-[:XY
M"G6MU>75IA\NQMK:SFOK>D27W7'GGG%+6HU&9F%P/ER=WI[A_)GV7]D?0<`^
M7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>
MGN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\
MF?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?
MV1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!
MP#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<
MG=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>
MX?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9
M]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9
M'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`
M/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=
MWI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A
M_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV
M7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?
M0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^
M7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>
MGN'\F?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\
MF?9?V1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?
MV1]!P#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!
MP#Y<G=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<
MG=Z>X?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>
MX?R9]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9
M]E_9'T'`/ER=WI[A_)GV7]D?0<`^7)W>GN'\F?9?V1]!P#Y<G=Z>X?R9]E_9
M'T'`/ER=WI[A_)GV7]D?0<!6[G(Y`.0_&>4/FIR3'.2;E&Q_(L>Y;]\+VAOJ
M3EMV;JKFDNZ?;+)[&IN*BT@X8Q-K;2LGQFWXTAE:'F7FTK0HE)(R"P/=K?I_
M<FWPY[4_=*M`7<``````````````````````````````````````````````
M```````````````````````````````````````````````````5;YX_R4\X
M/PM\P/X39:`@_=K?I_<FWPY[4_=*M`7<````````````````````````````
M````````````````````````````````````````````````````````````
M``'63S*G#92ZV;R4\:FB6DW$HXC3QF@CXB3Q$9:Z::@/O4@'(```*M\\?Y*>
M<'X6^8'\)LM`0?NUOT_N3;X<]J?NE6@+N```````````````````````````
M```````````````````````````````````````````````````````````!
MX`&'N[RKH(#EC:2.H80I+;:$H6]*DR73X&(D**V2GY4R0L^%MM"5+6H^@@%8
M<TW(R;R^P3?5<F%B;+D1E::1^79-T2I2#-$+.X-)PY'?9+,67]*FIG%QT-*_
MUCI%T@(\]6TF05J;"+(9:@,2E)+(JZZ76_9U@V:"X4W&*6=53U=I%4E/!7P2
MN)Y+,B>\=#B3#8-#F.Z6*.+^WJBVW*P]*3<;NZG'K&#FU:VM;*&6WZQ^NJ8&
M6PFV]5&_&;C3"(NEAT_&,+!4]S67T!FSJ9;<V&_Q<+K?$E2%H/A<8?:6E#L>
M0ROQ5MK2E:%$9&1&`[V;*OD2I,&/.AOS81-G,B-267)44GB-3)R6$+-UCK2+
M5/$1:_0`QF299C.'USMOE5]4X]6,_7FV\Z/!8-1_5;;5(6CKGEF6B4(XEJ/H
M(C,!2SG`W=PW*>4GFXQRK=MBE67*3S!W%#.F4UA#ILEK&MI<L.1,QZV>9*)9
M(B\7]1!*2XCPFG0!E^[6_3^Y-OASVI^Z5:`NX```````````````````````
M````````````````````````````````````````````````````````````
M```(MDF5UF.^1Q7%>6WMLIYJAQV*['^U[M^.A+D@H4=YQ'^FAH42Y#Y_TH[?
MC+/I21AH6TNYD^=]HR)OEMJXN9#8L:MQLX54VPG2UJ,"5-X8IOPVCTM<DE$4
M>&DS2@^-26C#&5\.5+E08==#<DN.,*.LKJIZ1!4=?+5_J9$6<^7EM!C<Y6OE
M=S(+[5N>DF$H:,M0\4C'TT*K'-L)F5["L<@7$G*+[R`RP&*Q&K)'#6X'BS2E
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MI^=:6E)7Q%LH><:BDI;[ZNK5JE1!83NUOT_N3;X<]J?NE6@+N```````````
M````````````````````````````````````````````````````````````
M`````````````>`!#LDRHJM:*JICM6N2R6%2&*];Y1HE=#1T.W.03=%)JZ>-
M]*E$;CZO$92M6N@5_EPO[PL6H<-#N2VLYYFR>R%3DJHE7+<<W64*@R8;I2L-
MVLB&XMHR9<\LNR-3+9N(6_(4$H=KJ5%=/K8+U3/.&J(C+]P;F+&:QJA;JW.O
MB45!5I4F%**K<+_35C.L**9FY+6X^X:9`2"AQE=ZPZPTQ84^&37#D3'9KSJ<
MNW$>6GA=GY!+4EN57TDA'0F-XCLAHR2:6(^C2PD>4,1I3F.X#61XS4>Q>;G6
ML5E!-1H.(T3T9Z:DV6NK03=G*-B`A!&G4I"UD2B:61!IW<3":+,<KFM0>HJI
M;LRGQQR5'9;.!.DM26\IR.1<0$.1F;'R.!`81UIN-2F'3+JG6U'J81/'3W$E
MY7MMC#TIB)47%]N9FRKN32P+B8S61X:XE2[26%GF-O91ITAV^)3)V5?+-MLG
M$...&39J"U%=C./XZ;MFY_7GJ0DIF17TLYMH\1'T=;935&<9A*C/@:;ZIAO7
M1"$EH0#^<&X^[&U^)W67P-VLSS//L@<R^Z<QOEHQ1^MQJO?J;6S<C4]A<5V.
MOHO-QY5\JN>7&*TF2D/.(ZF+6H<;XEAYMY*+.+KDJYF]S<OV^7M))D<DG,71
M2<-NYE;9YS+:7@.8RL?DY3+I%JK8ZZO'6F&T-.+=G(<=6A\FE-\)AOCNUOT_
MN3;X<]J?NE6@+N``````````````````````````````````````````````
M````````````````````````````````````#C7]O]_^0#6V4YHMH["KQ^5"
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MWWG$*,B,XQM_S`8/<['SM=H;R]R>?*OIUK3U)L1'.*+352KZ?5LI*'61UI;>
M7".67"MXW%*-!'T&>@"=[?X!@M(E[.V,7QZ/EUPY;RK;,GZV"K)'HC]G82"A
MOY$^RJQ35Q&7C2VP3J8[2->%):GJ&I^<^VJ;SD=YO;&ELZZX@.\KO,(AN=5S
M8MA"=4WM1EZ'$HDQ'7F5FA9&1D2CX3Z`$:[M;]/[DV^'/:G[I5H"[@``````
M````````````````````````````````````````````````````````````
M``````````````#@ST(_HZ-=3TT+]_\`E_D`U)D.8E:QYK539.5.,Q'_`"*X
MS&.A3TN?+-?4_P!MX)&;0ZY:74M_^BJ2VEQ+2OZ;"77S-3`=V,8:;[<&7=5J
M:JIKEE)QO"DK2^S7.Z\?VUDKR7'$W.4/K6:SXEN,Q5*/A4XZ9N@,KEN<Q:%3
MU9`<@2+WR=+[IV$LH=/1QG-2;L<AGEQ'&CGH?5,-DJ3*47"VCAXEH""1\A@T
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M5MNMQ>,^I"'#21-JC*6ADW'5+?`3K*UHAS[9,="6&*;;B>AEEI"4)838SD1V
MDQB;+1">"LX3(M-"2G^`")[MY!1UV*XM@:["*YDMWD.WL"%0Q%>4V+L>#D5+
M.FRG($9+S\>I8B0%F](<2EAIO4U*(B`4;R3>7!\>IZ.#G.:[B[_[Q2&F8U%L
MOMBS"QR+A.0-QTRJVEBX%C]A+F7605BW&>MDV<B[DI2LY1E'AK/@#9>_.*9'
M4\E7.[E-[C$+`3S+E.W;L'<&BR:^7*J;UK8[*$9#,N5TJW\=192[)2T\,!UY
M@VVTJ-9J49$&PN[6_3^Y-OASVI^Z5:`NX```````````````````````````
M````````````````````````````````````````````````````#$V]Y54,
M0YUM-8A1]22@W%&;K[JC)*(\6.@E/RY3BS(DMMI6M1GH1`-$9YG%@<['(%Y!
MF46'Y1/53PZMF63&<9;;/HXZRM5`21?8V/STI-+ZU/)?27BN]4DU$8;*QG$W
MFGXEWD34,K*''\GHJ2`E)4F'05M]4<6I;X4(=L5L'P2)AI):DZH;X&S-*@U_
ME>\$25*GT6)/2.IA2'8-OEA--LPFI31$4FKQN3.)$6TMFS7PN/MI?:C'T$AU
MPN`@U)5S*VD9)FCC+C+>F.ON6DB3*M<AL[%XR2[82\FNC5:/6S[G0:V$UCAE
MHA*#224@)=%QK(GT+L)$<ZN,^LREV-M+.B;7Q'P$B5.L-+B;Q*5_[;K*4J^A
M1@/8Q#QR)!>FHG662QJMF9)4WB%8TW51W(CA]<;606JD5<:2VMLTK3'6TZ:M
M/"8#Q.6><_V;=9Y08MC>V\%G%KNXBV]Y(+,,[DR&8#RZIA]3Z50HB)$U""=;
M=D2.%)Z$1&`F3%%2-9+A<_.)K]RJ?BS\R!*RJ4E^I5E#$BFLW#:@/$W30[.%
M'8-^#HUUK:4OJ;/Q#,@F)33SG(*S[-)3N(X[)^TI%OHI,2\NVT+:A0JPU)+R
MN%6FXIYU]/B&\2$I,]%`.ZSIXF47V84DI^8Q#G8;3TTJ1`D>2SF"FR[YUQR%
M)2E9L/$RZ@TN:&9*+^`#%+PK"]L\,RN925\>MD*Q^R79Y%/E*DWUFMN$Z:'+
M3([-UVQEN]:9\!..&A"CT0DN@@&2V^VEV\VW;D2\3PW'*2]N&FUY+D4&JB-Y
M%D<Q2&#D2KZ^-H[:W===82HSD.KTX4D1$22(@U+SQEIR4\X/PM\P/X39;_O`
M0CNUOT_N3;X<]J?NE6@+N```````````````````````````````````````
M``````````````````````````````````````.IYYJ.TMY]UMEEI)K<==6E
MIIM!>%;BUJ2A"2+PF9Z`-4W6Y;2E'$QSJ%$XKJD7<YB6]&4X9?4IJ>&A5KD4
MDM=4]6EN/J6AN]!D`\%1CN33IGVMU+D&P<(TJRO+FXMCD3;;B5(<1C^.15*J
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M1YSD:*VBL;:=DY_:#+E]&88E'+:JED51$7%FJ4IKJV"ZM1='@`23.4D]6U6/
MM((_[BOJRI6RVDDF5<EPYUJILB+A+J*V$ZO^1`(!F6-YRYBF6X+3UL:WK,@-
M]%);>6QX[E)76<LY%G#L(4A32I:ZY*U^2=4O1\E$A1M\/$8?=?F64_9WV3D^
MV$XR@/K@)XDG81;./7.);@7#,9J#/9CM6#;1.I:6ZMUA7BJ/4M0&:5NY306O
M]?17E8VPRXMPG8T9IMEJ.V;BN%"I#;G`A#9Z$2"Z="+IZ`$'J=P<NRV]R67M
MCA-A*AVB:%,/-,XC2\9Q:/%15-.+.'">:3D%\MF0^OC0RRA!+Z#<(ND!+X6T
M#%K+8N-S[^9N-:QWVY42NL&4U^%U,EM25MJK<2C.*@O+9<07"[-5*=Z-2,C`
M;E(O]G@_@7\SU\("KO/'^2GG!^%OF!_";+0$'[M;]/[DV^'/:G[I5H"[@```
M````````````````````````````````````````````````````````````
M```````````X_?\`P_;_```:KS;=FEQ)URKKZ^RRW(T-+==J:4HS-?3M)T+R
MK+LKLGH>+X="U/4CGRFY#Y$HHS+ZTF@!J53&XV:E+N<RL:BJQQESRN,RUY?0
MX;30TMD7%-LKHH5_F4II9J4<E,6GA+0HC;6XGPALC#J_$Z&'(S";:RF6&#*(
MF^R!O^VZ=UI\FFB>K8TY45:X3[SA-LO/DHWS,C:-9&E2@^Z?<:?N++GQ]NZ]
MUK'("EPY.X-_!DQ:Z19H6XS,K<:H)91+6SE5;C9D_)DHCQ&G2)*"D>/P!D["
M%08:3%U8IF99E\UXXE*=@ZS(N;2R<XW40:6,LFX-2RV2E*6IEMM##.IJ/0M`
M'JQ[`H3<F;D.3Q*^TRBZD(G6"C82Y6P%MM-L185=$<XF-8,=M+:I)IZ]Y2>)
M2NG0@V*22(B))$1)\"2(B+0OH(BT(@%2]ZS/(=V-N\(+1Q-C7MI<:2GK%LPI
M^2UDR^?ZO73B*GQOJU$?1U;QZ]!](6U_W?Q^C^&G1X-`$*E%]H9]6LF1+CXU
MC\JU<U,R-JSR"2JKJW$EIXVM?76*3_=QD`FOAU_AT?[>G_:0#D!\FE*O"E)_
M1TD1_P"\!SH7[?Q_]`'(``JWSQ_DIYP?A;Y@?PFRT!!^[6_3^Y-OASVI^Z5:
M`NX`````````````````````````````````````````````````````````
M``````````````#Y4I*$J6M24(01J4I1DE*4I+52E*/H21$72`U+=;PXU#M"
MH*EYJSN7FNMB=<]Y!52B)\HCB(%B\@T6\EF4HFULPR?=2M24F1&HM0@D^]RO
M)I*X/7S92UZ)52T[<ROAMI49))4IN'(BWDQO51&9RIE4P:=24A:>@!DCV]E0
M:K[1NK.KIT5K;CU9"<D,PHE:ZOQEN%+KXT:!CQDE:R<^R([,]S0M9Z]3,!Y%
M/LL1HUJ3;]_Y`IENMR3*X\EK'X4DEI*.SA>)<;\^VM>)LS9?7ULI1ZFJ7P*,
MR##5&$3]T+J)D&32IUA6U$KKH$VQ<0XS#EM*-M:L:K(__AX-N1$:%V#:9#L$
MC-N/)<=XG6PL!:VM1AE-&0U%4:$$U74E'6M=9.LI1]$:OKHVI*==5]9:S/A0
MDE..*))*,!X,;QV:W->R;)UM2,FFLFPB.PZMZMQZN-:UHK*CK"2HW'$FDY<C
M0E2'2Z-$$D@$X`<'X#`5$QQ+>6\XFY,Q*EKB;3[=X73D9*U::R'-&;.Q>29'
MT$942$ZI+Z3(S^C4+,V.5XY5&2)MO"0\HBX8S;J9$I9ZFDB1'C]:\M1GT::`
M,9AZ79KV1Y&]'=C_`&[=**O*2VZU(^PZ>(Q55QFTZ2%M,RGV)$MM)I(])6I^
M$!-@```````5;YX_R4\X/PM\P/X39:`@_=K?I_<FWPY[4_=*M`7<````````
M``````````````````````````````````````````````````````````'!
M_P"/^`"+7V9XWC<JO@6UEU=G:FLJ^IA0["XMY:&T+6Z^Q4T\2?8KBLI;/C>Z
MKJD:>,HN@!\XAG6&[@5K]OA&3TF4UT2PF5$Z326,:>FOMZ]SJIU38H96IZNM
M(3O0['?2V\WKXR2U(!(Y<N+!C/2YTJ-"BQVU.R),MYJ/&8:1TK<>>>4AMMM!
M>%2C(B`5[O,Y;S=#3E._'>Q.5Y>52U8%+K(&0_8[BRN<JR*2_P"12(NWN/FT
M?0DT_:3I%PKZHR401B7AS67O0*M^*<Z59QCE0EVC"Z^<Q1,/)_\`]59MQ?))
MF)4#\MI!5=)#.+(DK0DY*BZMTHX3#"6LBI').-8)*?RW&F(K32<PRIYLJ^NN
M8SZV+")`7#98FY2RM)&9]6I#$9:>#KEF2DD',K"LQHLILLZO+=S=&L32(0SC
M-FN!2,X],@RYLMR?C<'@:H3<DP76V7E2S)]1L)43R2XB4'3C-18[I/0\MO')
M+6/2(_65[)L3*Q4N(]TG754*6VQ-KJ;@+@D2W$-R[,R\7JXII)8;DN;JJQ&I
M;=6R:6R6Q6U%3`:(WY\QPNJA5==%:3H3CBBX2Z"0VDC4HR2DS`8C&\?L%SCR
MK*S:>R62TMJ)";6E^#BT!XF^LJZIS1/6//DVDY4C3B?66A:(2E(">:``#@_`
M?_+7Z`&HJK9/"J?)]P<KB?;:I^YN05N397'=NIRH,FVJ<?KL8A*C1T.(.+&:
MJJQM/4I5U7&:E</$HS`;&KL>HZ@M*VI@0SU(^-F,VEPS(M-3=-)N&?\`$S`9
M@````````!5OGC_)3S@_"WS`_A-EH"#]VM^G]R;?#GM3]TJT!=P`````````
M``````````````````````````````````````````````````````'!@,=:
M6U;31%3K2:S!BI42.L>5H;CBM2;88;+5U^0Z9:(;0E2U'T$1GT`--W^XUE8*
MD1:1#]/#9+_4S5E#^VB;62>%:_+S^Q<4:<2>J7;`W9!DHN"*LST(-<0(5SDK
M\JIQN*4E,E]"KF8^<U=,XZ?BE*R&?8D=SF4IM&I)*P-N&2"X45[J4I2`S]AR
MZMPER\[PO(%4.^A18R6<^4TM%=>M5_C1<3S.GAFVWD.'.(2<=*9!.RJY"C5!
M6QPI:`1RKR^QW&I(<B?4VLK-%Y">'Y55S"*%BNT.2PU&60Q(C#I$5];U$$RE
M1)ZTON/QW&)3!L(=-`#-.3:2/&L+V[)3.+U-2WDEJQHEU\\5H9"F<%Q**VM:
M$K>O[!DYSC!$E<U];*.GB42@D+5+DN1-IQIZP*AR'(F*W+MU;6M2U*>A5D];
M\:FP"DE+X$H;3$@.Q2?))DF/'>?4@GI6JPV,[C$>FKE.2<RR.OJ:R+JO_545
M;`AQ(R"2A*2B4<9$6.PTG1*4&DB(M.DP&I%OY3F$]W'(EE,MZ)Q,:5"A9!7,
M,26HCG6.(O,X?@)AHE4C^B5U=,<=B5/-)+EF<;H<#=EQ>U>`XM]I9#:/R(]7
M&:95+?::596LPR)MIF/$ALLMNS9CIZ(::;))?N)*3,@Q^.4<V98(S#*$-'>O
MQUMU%8A?6Q<5JY*4*7"94A:V)-M)22?*I22\;3JVS)LC-83\````````````
M````!5OGC_)3S@_"WS`_A-EH"#]VM^G]R;?#GM3]TJT!=P``````````````
M````````````````````````````````````````````````?#BT-H6XXM#;
M:$FI:UJ)"$)+I4I:E&24I27AU/P`-37>YS*WFZW$HQW$Z1J4>;U+S\1SIX>.
MLB,&F5<DD_\`[J39A%],CH,@&JITN1)F>6V\]ZYME*<AM-199NMQY2]/]`JV
MJFEI1)2I1$Y74+2I!$G5^41$HP$VHMM;&X1%D90HZNM95UL3'X*&8CB"<,U>
M.S$<<AU!.$?C$VI^:O4^.26IH`;NKZZ#51&H-=$8A1&2(FV([9-MIZ"(S,B(
MC4L].E1])_2`\%WD-1C\=N1:2R94^OJX<1I#DB?8/EIPQJ^`PE<J8^9J+H0D
M^$CU5HDC,!3S*,UN\1W+W/5%I$5\3-=JJG,7Z:;,>5819]#=M8<Y>368+,BL
MHY=M2W3"'3=>,^&O;ZU24MF9!+:V9CN=N8S113=<C6FX#%I8UKYG&6[4[:5\
M-V!$E$VER+.AL9`422T;+JV5J:2:5*Z2(-UXS9UL&COLTLYC<>+=WUQ:O3GM
M$MJJX,LZ+'R82236IMZCJ8RT(21FMUU1D1J69@-6Y5E%AD,LR=CR&&8;["JS
M'_)4SI,.6LDNU[]K6J5U-SF\]&BX%0L^HKVS\JFGXA)`;@@JIL%Q1,R6P_7\
M2&I=BAQX[:ZLKJ:E'6-NR&TF_=W<V29-EP$HW%Z)3HDBT",4%?/S*3D-QE<9
M$>TA/6E%1T1/')KZ"OE1N)B6YXI-/9'.B24E,=3JEDR-EM1I2:EA-<'DG+Q/
M'W%:\;-8Q!=,SUXGJWBKWE'_`!4[%4?^("5@````````````````*M\\?Y*>
M<'X6^8'\)LM`0?NUOT_N3;X<]J?NE6@+N```````````````````````````
M`````````````````````````````````'_M`:_RC<2DQPWHJ%G9VS:T,JKX
MBTJ*/(<22VVILA).)8>6A1&EA*7)*TF2DMFG50#4UW+N[YU"LQE/UT5YKRR#
MB-<PT_:RXB%J-4Q53(/R6'$9X5&J?;*..V;?0PE9)4`5%-<Y0VY&I(D:OH9*
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MMU3/Q62*WSAU11#BVM7Y9.143'29AO*=B17E-:EQ-):<2M*DNI,B-`"/L,WL
MW'\8JJZ]GU]S@QR:6K8BU\2;75DO&)$S'Y33N-]8PQ/MM8*U.6LY4&OK#,GH
MB5&EHUAL3#9T?"6:ZYW'K:^)-EM2&<=OJ":K(<4)V<I+JZVGFN-HMI&1Y$[X
MZWGVS>L7B4EM75H2D!MJCI;&ZL&,LRN.F/*8)2L:QQ:FWF<99<2ZT<Z0I)<#
M^1SXSNCKA:HC(,V6CZ7%N!D:!*49%G#:>@OM:I>X2+Q24]CU::S+3HXEK29G
M]/3_`!`>?!"TJK%+>I149'D)04'T=5$*R=439'TD:2?X_!T=("<`````````
M````````*M\\?Y*><'X6^8'\)LM`0?NUOT_N3;X<]J?NE6@+N```````````
M```````````````````````````````````````````````"/7^3TF,1BDW$
MUJ.:]28CH)3TV6X1:=7$B-\3\A9Z^`BZ/I,!INTS#)LKBNR(KK6#X>G4I%W8
M27694E/%P\"9<-YJ2\ZH]=(U:ZAQ1EPJG,+(VE!A*UIJ%):K<2J[!-JIC5-I
M*@P'LP=BO+XE/5-.^VW0X!4/+/7RRP0E;NO$F+(<7UIALBAVSCI)4C)E-3E2
M'BENTC+\J76.22X5)E7MA/XK3,;-M:2,GIIIC-J0DV(S!EJ8;4)*4)224DE*
M$I)*$DE)$E)%H24ET)2DOH^@!";'-F"?D5V.1D7]E%+2<\4I$.@I>C7K;V\4
MEYB(ELM%*::2_*4G4TM'H>@5OO\`=&-96+K..L,[LY-6.*6_:R#53[/X,ZV1
M\;Z7%N+1<SH2?K.FZ\\73J_%;4:2"*4V(95NE:HNILD\_L&EK0G*+]EV!MCC
MNI%QL8KC[/5KR1QOA(B-"4PU'PF\[-2?$06DQ/:JAQR0U;V+LC*,G0@D%?W+
M;1JB((N!,:DK6B.!10FD>*AMA.J4>+Q&1%H&T.GP_P`]-2^GZ/WF0#3%]LM2
MNVDK)\&EE@&7R9D"Q?L*^([,QZSGP'EFB9?8DU85=?837HC[T9<IER+-6P\:
M#>-*4D0</8U(E29<R?ME7R;NTEQY-O(C9''8Q2WL(C3,*-<6D5Q29LDVX<5D
MB4[7OR$);2@N+@29A+JW$Y#]A'O,JDQ+.?!T^Q:F%'4SCV-:(-!KKH[QJ=F6
M1I\4YKI)<X3X6D,H,TF$[_G_`+?V_>`@F(N)=3E5VXHU)GY):*)PB+A7"ITM
MUD52#\*DJ8A=!F>G3]`#UX$A:<2IEK3HJ0W*F>`RT3.G2IB#T41*Z4/D`F``
M```````````````"K?/'^2GG!^%OF!_";+0$'[M;]/[DV^'/:G[I5H"[@```
M````````````````````````````````````````````````````/'.GPJR,
M[-L);$**P1&Y(DNI::0:C)*4FI:B(UK49$E)=*C,B(M3(!IRQW)M\A?DU>WE
M=Y9U*EM3;^::6X%;P]#IO&LR1%>83XQMNGUZ2^LT7TA`":J8;J;.1*1FEY,<
M6W]N6O7NX^N6@S2]#HX+*7+#+GV3T_IQ4'$21EQK2G4R"=U.%9#D$EBVR&3+
MK4((C9>D=0J^2@RX>"KA,]958BP2?`;1/32(BU=29:@-NU%+5T,;R.JALPV3
M6;CIH)2WI+RCU7(F2'#5(ER7-?&<<6M1_O\```QUYEE72.H@GY197+Z..)15
M;)S+1])J)).J929(AQ2,S,WGU-MZ)/0S,M#"OV>[G1X,LJ3(9,RVOY1I;A;3
M;?/+G7#SBRZQMO*;R.:?(VU-J(UMHZKQ#XO&3J8#4,I.7[B2TXU;Q2E1(AI)
MG9_;J4F#C=,E3G'KN+F$?2*;A.*)3L5M2W%&9F:-3,P%A,4V-AM1H*LV<@V;
M$(VW*_"Z6,==A%2ILDFT2H!:/7\E@TD9.RS4GBZ4H2`W\RTVPVAEEMMEEI"6
MVFFD);:;;07"E#;:")*$)(M"(N@B(!V``````#!9+<HQ^CL[A9<9PHKBV&O#
MU\M1=7#C)(E$I2GY2THT+I/4!#IK4S%]NHU2A:57DV-%HX^II4E5]D+Y1UF2
MD^*;4>7,6LU=.C;?$?@,!L"L@MU==`K&5+6S70HL%E3A\3BFHC#<=M3AD1$:
MU(;(ST+34![@````````````````%6^>/\E/.#\+?,#^$V6@(/W:WZ?W)M\.
M>U/W2K0%W```````````````````````````````````````````````````
M`-2+PGH``-8Y%N;5USIUU$R>17"GE14M1#>77L2DD2EQWI,./-E3IK;9FHXD
M%B7)21<3B&FN)U`:PM&WYTU4S/["7:649M4IC#*:3"AG7QCXTF_?6;<Y='AU
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M77)(RE0V&)#ME7-S4+09O^4$:/"NPCJ)4<!L3`MB)Q1%(LF%X%CLLC5+H:>Q
M3,SK)4K,U*/-<Y92E45E]7C+@51--:GX[JU<2C"S5#CM)C%<S4X]5PJBN821
M-Q83"&4$?3Q*<-/C.N*,]34HS49])F9F`S1?M_P_V`.0```````0"\45[E='
MCC:E+BTAM9;?$E)FT1LK<9QJ"XLD&27I5HVN4E/$7$W"61]!D1AS.4F[SNL@
M)5UD7$(2[N:25)X4W-NAVNJ6G/%4761JPY3IH,R/1YI7[@$^````````````
M``````%6^>/\E/.#\+?,#^$V6@(/W:WZ?W)M\.>U/W2K0%W`````````````
M`````````````````````````````````````!QKT:@(G?YC34*U1G%N3K5+
M"I)54'JU2FXY%TRYSCKC46K@)/ZS\EQIHB^D_``TE>Y/<9*VERRL44V/O(4I
MF)!\I7Y>UX#5&:(XEI?I0I/";Z_(JLC_`.]TBU`?%%7V]FDXF(5;U?"6V4=^
M\-UMJ4[&4>JXZ[YEGJ(45*T\1PJAGJ]=>)[B4:@&U*+;:FKDL.6A-6\AITI;
M49QDFZ:+*X>B2S7+6Z4R8T>I)E2U2).A%XY:%H&Q''&VVUNNK0VTTE;CKCAI
M0AMMM/&IQ:EF24(0DM3,ST(NDP&M[3/>NC2G\<*"FLA$OR_,KY\X&*UR6]24
MMAY:FGKIQ)D:=&3)GB+0W",]`%:+?=)VP=FVF#.1[9VO6IBPWGW!3Y%B&/+6
M1ZL8?2+2VF5+5JI+*&D&\X9Z?U"/0!B*/9S)]PK*OR!+UD2OM6+96FZ&XL(Y
M.0V\6*2GX\/!L)?4F+C]4<LTK2Y,(DJ2DC\G5T`+A8CMYC>&'(E5S#\Z\L"(
M[?)[J0NTR.W67_=-M)&KW5%IXK+?5L-ET)01$`G'^7^'[?0`Y````````UT_
M;^&O_`!'\DOHV-T\NUD-JE*:ZIF%!9,BDV5C*6EB!71B,CU>F2'$H+H,DD9J
M/Q4F`B\4SP3%+"\N?_(9#9OE9VQ,=+MID5CU,2!3P$F9K-AA740HJ"U-+39'
MTF:C,,[B-%(I:Q2[%Q$B]MY#EOD$M)%H]:2B2:VFCU5_I(#24QV$D>B6FRT(
MO`02L``````````````````5;YX_R4\X/PM\P/X39:`@_=K?I_<FWPY[4_=*
MM`7<``````````````````````````````````````````````'R:B(E&9Z$
MDM3,^@B+PF9Z^`B+Z?``\#%O4RG4LQK2ND/++5#3$V,ZZHND]4MMNJ4HM$GX
M"^@!YKN_I<>BE+N[*'7,+433/E+R4.2WS^I&AL:]=,DK,]$M-I4M1GT$`TSN
M%N>UCE1'M,FM3V[QZTDG7TS4GJ2SW+IZV''D5M'7.=:U2..LLJ6I;I.RD-:J
M4B.:>(!!*&GS',D$NEQG[!I)+S4Q$W)FG6X2G#4EQNS7!L&W+G++H]344NP0
M;!'KU+;"M'##=E)M=40C.5?2)&4V3JDN2'K754-3J23HKR(U.>4&1IT)4A;R
M]/"?00#9:&T-I0VA*4(;2E*$((DH2E):))*"(DD1$707T`(C;9A$B2W*FFB/
MY'?(+5RLKEM$S!U-22=N;-TRA4[!&@]>L4;AZ&2&UJT(PT!F.X<)$XJN<X>Y
M&5J4LX6#8RIYO#:IU/C)=MY9).3?.15(U6MTC;+0_P"DSKJ`UBQ69AN[9H\M
M;C9R[7OFVU6Q)3U3LUASB#0GJ[*R@J<7EMC$+0C@UIOG]#DM*=4D%F\2V<IZ
MB1!NLHE_WCDD!)%7/RX3%?CN.%I_^/B6*QM:RD91X"=,GI:]-5O*,P&XR(B\
M!$7\OW`.0````````#70!XY\Z'60Y5A/D-184-AR1)DO*)#3+#:36XM:SZ-"
M27@^D^CPF`@%+%F978,9A?QUPJF$:W\0I)2.K<BM+;4A626R5:&FRF,J/J&E
M:>2L*Z?ZBE&0<UAN9O>1,A-!)Q&@<D*QI*R\;(+=1+BN9(;9D1)JH+)N-P-=
M>O6M4@B)*65*#90```````````````````*M\\?Y*><'X6^8'\)LM`0?NUOT
M_N3;X<]J?NE6@+N````````````````````````````````````````````X
MU_AT?O\`^@"$2LR\JEOU>)UR\EGQG5,3I;3Y1<?J7F]#=8L+GJWT.S6_IC14
M2'DJT)PFDF2@%+MI]TY>ZVYVY%;O-N?BE9`QJ?\`8^,[+5#+^)*K_L]Z2S.O
M,WFV%F[>V=I8<*#C0W5QXW4&3B&5DKB(-O[L6NT=7@EG75M?10/*8BZRLOZE
MEFC9J)I-J5%?J+R`46;97$1S^HS#KEOR77-.,FVE+=2$#V$B9/ENW^/[IY/#
M5N',=39PY=7EM:S.RF`W76,NM=L,-R!U7DDYR3!92IU#:$,O/I<2PZDM$F&^
M%PZZJ8I,UQN/'RC#8KCM@[62V%6UGC;;R'&9=[A[TQ#]C"E13-29L$C)2D$L
MFR2X1H6&YX\AB6PS+C/-R(LEEN1'D,K2XR^P\A+K+S+B3-*VG&E$I)D9D9'J
M`Q-YDE1CS32[*2:7Y2^J@5\9IR9:63^FI1ZZMC)=F3'?W\"#)!$:E&E)&9!J
M/+LR?:CNN9-/<Q2L)GKO[7IY<5W+IL9Q7"VN^MT/%6XO#?7HGA0[Q.*U;2^M
M:B;`5\N,PO<I<8Q#&X$REK);?E,/#,.BK>R:XCNF:?M*><OR14"!(X2)RWN5
MPXSFFJ&G72-"@VOA6P.L8CSA46'6/<"UX+CLN2Y$EDG0R+,\G6B-;9:Z1_6C
MI*+6I46B&#+I`6;A08=;$8@5T2+!@Q6B9BPX;#4:+'93]5IF.RE#33:?W)(B
M`>H``````````<&>@".91EN/8;6';Y'9QJV(;\>)'ZY9=?.FRG4LQ($&/KUL
MN9)>5HA"",_"H]$D9D$>8IK3*GX]IES2(--'=9G56((=1(03K)]9&GY/,;-3
M%A,:,B<1%:,XD=>FJGU()T!XY[Z]Q)+E-6.K+"HDA3>0V[*C2G(GF%Z+QVI>
M(RZRM2XG2=(3XKA%U*#/5P!LUMIMEMMEE"&FFD(;:;;22$-MMI)*$-I3H2$(
M06A$701`.P```````````````````%6^>/\`)3S@_"WS`_A-EH"#]VM^G]R;
M?#GM3]TJT!=P`````````````````````````````````````````\`"/W^3
MTF,L,/7,YN*<QU4>!&22GI]C)2CK#CU\%E*Y,QXD=)I0D]/IT+I`5-N\WSC-
MJ>7FV<XMNAMIM!5NS'%X?1U9_P#]%R6IAK<2]DF8OU$QVUQK&%,-J>16P/\`
MR3C)$M];9'U1AM2G=FWV$45]L]F4?(,%MHD23#;8CU[5BNBZI1N-XI:(CQ(4
M*R5HE"$S(ZDM^,9^/H`Q]GM]L!D=&F^OL5JR?1*7$EV,UB9#S55ZDDD[$LYT
M1QJ_LKS4B\5Q;RE)TX=6S(!K^3M3MHS8Q+"9B46%()AYFK1ES]KFN7NPW31Q
MH@XVB4M<&&^9)-;;[QH6@RXD=!D`VOQ6%55)=6O,Z>IB,--(<>FXAB]=%80D
MD,,0*HH;J8<=+:22AE/C$6B2(!'\4O<SJ;Z1:(Q/*+?`LI4\JS.545M7<4E^
MP\;"L@;J&9IE:T>3P>%;ZV6FW4R&NN-LR?/0/<G*;/$J>UB//P\)Q.%93Y%/
MD>3$VJ=]BR"*9Y#1XVE9S9CT"2\M"#?X4)0:2)"B(B`:#E;]5==4VV51Z?)L
M5I;>-3LX7F.7-DO<'>65>6+==%CXQ4I:F7&/XZEUQMY*TPDFXR9.-L)+5P!)
M\2VBSW.9*;?)G).%TCCJI">O8;<RF4XYXBI%7535SXM'(=:,R.PLCG6:D]"4
M-$:>$+:XIA>-85`77XW6-0&GW/*)\HUNRK2WF&6BI]S;2W'[&WG+(]#>D.N.
M:>*1DDB(@E&G[?XZ_P`@'(``````````\TF9&A1W9<V0Q%C,)-;TA]U#3+:"
M\*EN.&E)$`@BLDO,E4;.&PTQJXSX%Y9<L.I@F7%H:J:K4;,FW/A2?"XHVXYG
MIXRBU(!YWJ_$,/0Y9Y),7=W-FP["=G7*4VEQ9M2$FF16U56TTI#,%XCT5&BL
MI;4GZ_$9<1A@,8Q/(+BI15Y(4BAQ"#86[=/C#,QP[6SQ]=I+>HHN13VW>MB0
M8=6MIE,%I:EFV@DO.*T-*@W)'BQX;#,6(PQ%BQVTLQXT=EMEAAI"22VTPTTE
M+;3:$EH22(B(@'>`````````````````````JWSQ_DIYP?A;Y@?PFRT!!^[6
M_3^Y-OASVI^Z5:`NX```````````````````````````````````````#CIU
M_A]/\/\`F`A^29:W3NM5-7!7D&53FC=K<=B/(9=4REQ+2K.VEK2XW34<=U1$
MY*=2>I^(TEUTTMF%+=K<[R>RWMW2NLJC1,POJ";88G6382+;^W<.Q^L?C)=K
ML>8I*/(I]:[96RG3F/V++:I26&S1)5P*82&\L_W'M&L=L)=BAC$L=;865K;3
M47,!IZ.I*C7$:L<@J<=FK7*;2:#:KX,QQ:#/61%(C=2$0Y;G+7`MHH$>VB2I
MUKEV39+=8)C"(#%1<2Z"=,2NL?F0$$F/1UYL:2W''2;1!BOMMN%UI$E02>OQ
MF\R7-%9/4VL55LEMZIRG+&8ZW\=AQVE&2*+`H#RVV9MY5ND;;UPZA7#JIM6J
MBZIH)Y!EUE9Y7"P"M8O+%"EM7.8VTIQ5-&E(U2ZJSR-SK)%[/:<,R5$AJ432
MTFV\Y%,TF82"/B<&(XO(LNLROK&$V[+5/MC:BTM*TVA3KSE=6K7Y#6QX[:#,
MWG#6]PIU4X9ZF`UMF6^%=!@NO4$J+`J4L=>K,KE"&Z]V(ITF&YN-5DI^$NY@
MO.D;;=E*=AU+BS3Y,]-6?4&%1\NDYIN3=0<0QK'[>7E60)\L9R#(8DF3?8[7
M+9=ZC+\A1*CQ6=O\95J95Z)T>-,LG"_T=3P(5((+I;;[*TN&OQ,COY1YEGS5
M)4T)Y19L()%754\=+$*IQBMU7%HJUDR4LS:+KGW%J6ZM1GT!NO3_`-?IZ`'(
M``````````XU_P"G^>G_`!`0JPS!*YDBFQ>`K)KN*YU,WJ7?)Z*D>UT-%[=F
MV\Q&E((]3B,)D3M#29LI0KK"#P)Q9C55]GUPQ<.04*F=5()%=B5(AE/6./L5
M[SRFE$PE.IORUNK(BUU3H0#Z.\OLF23.'Q4UE.I.G]W7,1Q+;[1I3HO&:-WJ
M9%@GA,^KE228B*T2MI,EM6I!F:/$*JF?78*.1:W;Z=)-[;.^663NOUD-N*(F
MX4?7P-,I0VDNC0!*="_<`Y``````````````````````%6^>/\E/.#\+?,#^
M$V6@(/W:WZ?W)M\.>U/W2K0%W```````````````````````````````````
M```!QK_O_B`TU=9Q?Y39R,2VJ1%>D1'_`"7)=P;!A4K%L44G_P!^'7L(=9/*
M<H0D]2B-.(C,&9'(>1T(4$YQ+#:C$(LEJ"J;/LK-Y$N]R*XD)G9!D,Y*#24V
MWGDVRA:D$9DRPRVS$BH/JX[+31$@@@V3[#;>Y+DLC-4QK?&<QF-LM3LGP^ZL
M,<MK!J.DT,-SG(#J6I/`@].(T=8HB(C4?"G0-;W>UNV^-W#<N2S8[A9BPPF>
MR6?9!+NJ7'8K"N)%YD+LU3C;-?%66K:9!ON.N$1-)XB)20R++ASY+C<A5M9O
MW##)V*(#2HN8YM&0I9L14M(6C^PMO6-5=2RIQEY]LU+,R6MQQP(=S";T85RZ
M[?U^:[[6/]NX-)L(^.U6(8M#F*QZ*^<)^7'CY385D<IDRO;C1%$J,RTW$7IU
M9MODHB`?FX[U/OTJJ@VQL-H.5F@N[7-,QDHP9>Z65TBL2V\VLJERE55U.VYP
M9[CLLNS"-'0IJNL+)#<."\29+3;:D$TX'Z((]CEVXL>FK,>B'DL&GI<;TM;M
MUV)MEC+S5'6/)DI*P:D?W?;QG5=8F7/;FN-KT4U$CK3UQ!EJ#"4Y!<3HN&7$
MC*\V@24N76]-_5'8X=A5FXOAEHV]I;!^1#O<[CQ-$%-D.S'HQ&772NKX8IA:
MW",$QW`*=530,2#5*E.V-S<64IRQR#);J1IY;>Y%</F<JUMIJDEQ+69(;026
MVDMM(0VD)D```````````"-7F555$IJ,^MV7:2=/(Z6M:.9:RU&>A=7%;/5M
MHU:$;KAH;3KTJ(!'_LC)\I,W,EEJQ^D61FG&J.6XBQEMF1EU=[D$=33S3:B+
MQF81M:^!3RD\2#!_<==`).-8%2LV\F`DXQ1:I+$'':3I4>EA8H04..9*(S-E
MDG'E&1^+J8#U0\/=GR&+/-)R<AG1W428E6ALV,7J9+:B=:=AU:C45A-BN?4E
MR^L=2I/$TEDS,@$[_;_@`$1%X`````````````````````````%6^>/\E/.#
M\+?,#^$V6@(/W:WZ?W)M\.>U/W2K0%W`````````````````````````````
M````````'3(D,Q679$EYN/'8:6\_(><0TRRRTDUN.NNN&3;;3:",U*,R(B+I
M`:V>.SW$)34=R72X(ZDT.34&[#N<O97T*37F7!)JL=>071(/@D2T'JV2632X
MX$_JJFLHZ^+54\&+6UL)HF8L*&RAB.PVGIT0V@B+4U'J9GTJ49F9F9@,@`U?
MG>X,?'E+IJYY"KMR/ULF3Y.[.8H8[S;AQGG(,9*I=Q>3UMFFOJXY*E3%)-6B
M6D+60:WQ+!\NRM"+/(XTW":)^6FS9HY[T6PSJ\DGTIN\SF1S?JZ^T<(RZF$P
MI]NN;(D(/B+H"5[A[G[-<MN)OY'GF156(5;CNC1/G(L<ERBT<-MMJ#3U41N;
MD657LQYQ"&V([3[RUK21%T@/XU]Z;N#N3NGRN5>;S<;@X#M?)S6,UCN-WC=A
M_P#U.QFJI[9<:VRR`ZU$CX*3<;76G=0[/0I>KRD="`'Y#-Y-@]T>9W?G;S9G
M9[&G\JS/)MS)+1LI0Z=30U2<FEG8Y)EU@A#C5)BU3%0MV5)>T+1/`V3CJD-J
M#_1NK\'R#)X5776#CE-B=;!KJ]B(U%<J4/18$&/$6FGH%*4_7QY*V5&B18J5
M*0RHB2PP9`-ZU-57TE=$JJJ(S!KX31,QHK"";::06IGH1>%2U&:E*/4U*,S,
MS,P&1``````````&-M;>LHX:["VG1X$-M24&](62"4XX9(:893]=^0\LR2AM
M!*<<4>B2,S(@$-.9EV5&::ME[#Z%9Z?:MC'2K);!DS,N.OJ7B4W2M+3TI<ED
MJ1H>O4MF0`1XM@9E%AL2K+(K-!NE$C:VV5W1FHTG*DN/+)QN&3B>%3[[C$1I
M6B36DS21@.BR+)_ZF52_LBH41<.*TDMPUO)_^F\O&RCORS,R\9F.33/3H9KT
MU,)Q`KX-7%:A5T2/"B,%PM1HS2&6FR(M#T0@B+B/3I/I,_I`>P``````````
M`````````````````%6^>/\`)3S@_"WS`_A-EH"#]VM^G]R;?#GM3]TJT!=P
M```````````````````````````````````&*N+JMH(#UE:RFXL1DTI-2B4M
MQUUP^%F-&802GI,N0X9(;:;2I:U'H1&8"&QJBSS)UNQRV(J!0-.MR*G#G#2I
M<E;2R<CV66<*E(E/H425LP",X["B)3O6NDCJ@V/^W[?Y``#5NXF<V]&J!C&%
M4_\`<>?9"9M5<):C14T$+ZLG*<JEIU\AHZ[I-*2(WI;VC323,S-(>6EQS'=L
M:>=EV<9+#D6$1B38Y#F^2RH];`AF^23G.1?*G_):B&LTDG7B-Q:"2@U&E*$I
M#5BMV]R]Y5G`Y?Z%%#A[BNKD[Y;@U<QBF>8,S2MW;O"GCAW&7O&@]69DHX=;
MKH9*>+0C"!Q=F]ML)WVPRYRZ78[B9E0X9D.<'EV:.IR7-+7,9-U2XU22*>M;
M8ZBG@4]?8ST0H59&C1(JWR=476-DZ0?.X6T^-<UT7(L-W`P!%]@4+.HUVQ6V
M%K:4U<[:P*MF'Y9;7N-V,27/)!.+;>K8*UDH]4/R$=)`-W[+\LNRFPT>4>VV
MW.&XM8V*E.65G08[`JGY3CAJ4[HXVEZ:I#CBU&:WWY$ESB_JNN'H8#?V@```
M````````-9(W`1D\ZSI=O?(;R93RO(;JXDOFU1TLDR5JVO@_UEK((DGPICIZ
ME1D9&Z6BM`]OV31XR191E]N5I:Q]4-W5P3:&H3KZ>$X>-U+9+CURI))X$HCI
M<F/EHE;CID0#K*;E>5]%6V_A]"OPV\^.AS))[1]/%653R7(]2VM/U7I9..$6
MFC/3T!)J/'*G'FG45T8R?E*)R?8R75S+2S?(B+K[*QD&N7+=(BT3Q*-*$^*D
MDI(B(,]_```````````````````````````````5;YX_R4\X/PM\P/X39:`@
M_=K?I_<FWPY[4_=*M`7<`````````````````````````````````",C\`"-
MY%DL+'VF$K;?GVD]:V*>D@D3EE:R2(C4VPVI24MQVN(C=?<-#+"/&4HBTU#%
M5.-3)5BSDN6N,S;QHE'65L=2G*7&&G4FDVJY"TH.99K0>C\YQ).*UX6TMM^*
M83D``0O(,CDHF%C6.>3/Y*_&3+>>EI6JLQVM6YU9V]P;:FS6H]%>2Q"6AR6X
MG3B;:)QU`5RO=[Z'#5Y+CFTM#.W>SRKCR+7/LG=EMU^(XXN/7^7N6&X&>N,J
MKHBFH&BX]37H?DDP:$-,-H,C`:HQ+;K-[U&*[]\WN>8[D3=E8Q)=3M._"9H]
ME-IJ>6U,L*>W;CVZVYM]G3#++77V-JXZT@W#;89;X4N&%E8^[O\`?3*XVTL6
M5<5C:%-,Y%!KT*ARR;0HD-TCUB4:E8C+)O1N9)<4P7_8T]IP@,#@&QMZK+,F
MW%W1N(LV[R6KI\>AXM1.RGH5#C-3(F3UU=SE\LF;S,+"ZMIJI,U1-U]>24-1
M6HO4,\3H68B18T*.S%B1V8D:.VEIB,PVAIEEM!:)0VVV1(0DBZ-"`>D`````
M``````'!D1D9'X#(R/\`D?A`5(QO:G<+"MP*Z?00Z!^NA%E58C*'9ST)ZQQ:
M^E?;%9`RVGCM]=<VF,6IJ1&<0M'7(/I4R1J`6(J\0BQIC=Q=2Y&29`DCX+2R
M0V34#B+QVZ6L;UA4S"B(B,FB-UPDD;CCBBX@$P``````````````````````
M```````````5;YX_R4\X/PM\P/X39:`@_=K?I_<FWPY[4_=*M`7<````````
M````````````````````````U\/\/^6H#5.[&Y*-N:>I;KX#UYF&7W43%<(Q
MYB/+?^T[Z<2U%(L#ALO.P:&JC-KDSI:B)MAAL]3XC21A&L#OOL[)':C.JJ76
M;@7#9F5W/=3(@733*]3@8_)274PZV.K7JXZ-#5]9>JS(S#??A`<:E_EX?#IX
M-?#X/``@LW.8CW7Q,4B2,LM$H<2W]F$2J5B3PGU:9]ZHTU[;27?%<)I;KB-#
M(TD8#0<D['&VK,\UDUN4S),E-C9XMAQW5O8R[:6V@DQ;V!71G)ELN.YHU%;?
M>APR82DN#Q3,!JRGQKFAS_!LJQBGPS#-AZ[<?+\GN+ZXRY3>49#4XI=.PX$2
M#68G2.QJ\LI<QZ`@WE2I*XK#KO5EQ=5XP6-3R^8K=.4DG<VSM=U%XZ_!ETU5
ME/DZ</K9]8SU$&?&PV$VU329D,E+-IR8F6XV:S-)D?2`WK'C1XK+46*PQ&C,
MI)MF.PRAEEI"?`EMIHDMMH+Z-"(B`>@`````````````````````````````
M``````````````````````%6^>/\E/.#\+?,#^$V6@(/W:WZ?W)M\.>U/W2K
M0%W``````````````````````````````!Y9DV)7QW9<Z2Q$BLI-;LB2ZAEE
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M5PI]KDC!J:+QW$VR$N$1IZK4]`FK&'SIK26LBO'E0R(B3C^+M.8Q0MI)'#U3
MJXC[E[8DE)FE9.3$1GDEJ<9/@`2RLIZNECHB5%="K8K9<*6(4=J,WIKKTH9;
M02C_`(GTZ_S`9,``````````````````````````````````````````````
M`````````%6^>/\`)3S@_"WS`_A-EH"#]VM^G]R;?#GM3]TJT!=P````````
M```````````````````'!GT:ZEX#/_K_`"`0.7FA2Y;M7B$$\EL6EFW)EMN=
M5C]8LCT44ZV)*FG'D]/]%@G'->A7#TF`YBX9Y9):M,OG'D5@VKCCPUM]3C]:
MKH-/D54:EMO/-J,]'GS<</7HTT(!.B/_`)=/1TEJ?^/^`"$V&9(7,>J,7A+R
M2Y94IJ24=PFJBJ=(BZ+:W-*H[+B#UU9;ZQ[4C(TD8"*V&VM]D=E7WF09U=L3
MJ\E+ATU(4>-BT.4HU+9F*KGVW7+.=!4:39=D+425I)1(^@!)Z#;K&L?8AMI8
ME74J"TEMFSR*6Y<3^(G#>-[CE<3+<A;ZE+-Q"$KXE'TZ=`"=@```````````
M````````````````````````````````````````````````JWSQ_DIYP?A;
MY@?PFRT!!^[6_3^Y-OASVI^Z5:`NX`````````````````````````:_2`C-
MWE=92NM03*39W4E)G"H:EHIEM*T/3K.H):&XD1*C+CD2%M1VR/5:R(!@SH;W
M*$DYE\A-?5.:&C$*64YU3R#Z>'([M!,R+52B,R5%C$Q$Z32LY"=%D$WBQ(L&
M.S#@QF(<5A*&V8\5M##+2$]'"AMLDH21:?00##WF455";3$I;TNRE$KR"EK6
M5SK>>9>$HT%G5PVR\*G5\#3:2,U*(B,P$?*GR7*O'R9]6/4J]3+%::62I\MM
M1%JWD>01U>,E9="XD$T,Z&:5OOH/0@FL"M@U<5F#71(\*''02&8T9I+33:2U
M\"$D1&9F>IF?29])@/<`````````````````````````````````````````
M`````````````````````*M\\?Y*><'X6^8'\)LM`0?NUOT_N3;X<]J?NE6@
M+N```````````````````````?\`#P@,5;7=511%3K>?'@1B42$N/KT4ZXKH
M0S'93Q/RGUGT);;2I:C\!&`B!2\JRO4J]N1A]"H]%6,YA!Y/9-&1ZG!KGN-F
MC8<+ZKDCCD<*M2::46H"34F.5./-.HK8Q(=DJ)V;/D.N2K*Q>T/B?GSWU+DR
MG#4HS+B5PIU\4DET`/9:6M;2PW9]M.CU\-GI<D2WDM-Z^-HA!F>KCCFGBH3J
MI1]!$9]`"'?:.594?!21WL5HUF?%>VT8CO)S1]&M/2O=%>VO3H>F>.9'JEDN
MA0"14>,5./DZN$RX[.E&2I]M.=7,MK!?1JJ98/<3[B-2U)LC2TD]>%):@)`1
M:?M]'[@'(```````````````````````````````````````````````````
M````````````*M\\?Y*><'X6^8'\)LM`0?NUOT_N3;X<]J?NE6@+N```````
M`````````````:_\P'4Z\TPVX\^XVRTTDUN//*2VTVA):J6MQ9DA*2+PF9Z$
M`@1Y;8Y`X<;"(3<R.2C2_E-HAYK'X_"OA64!M/4RKYXB\'4FAC][Q&7"89*H
MP^%`F%;V<F3D.0:*([JVZM;D5*]24W50VTE#IXZNDN%A*5&1^,I0"6+6AE"E
MN*2VTT@U+<6I*$(0DM5+6M1I2E*2(S,_H(!`W<NFW+BXF$0&[8T+6U(R&<IU
MC&83B%&AQ+,A!$_=2&U='5Q2X.C1;J-2`>ZKPZ.S+;M[Z6]DM^V?$U86"&TQ
M:XSTU125:.*)5(+3ZZ24^KIXG#U`3(``````````````````````````````
M`````````````````````````````````````%6^>/\`)3S@_"WS`_A-EH"#
M]VM^G]R;?#GM3]TJT!=P``````````````````-0$0M,MC1ICE/217LDR%O@
M)VKKEH2Q6]:DU-/9!:*2N%21U_6)*^.4ZC4V67>$R(,<UB$JY>:GYQ.;N%MK
M2]'QZ&AR-C$!PNE)*BK4J1=R$=&KLLU(4>JD--D?"03UM"&T);;0E#:$DAM"
M")*$H21$E*$)(DI21%H1%T$`BMQET*OEG45T:3D.1&A+B:.JZM;T=#FI-2;B
M6ZI$*D@*470[(6A2]#)I#JRX##%MXK99`M$K.)C4IE+G6L8M5+>:Q^,?0:4S
MW5$U+R!]M22U4\3;!F1FEE)&9&$\:9:8:;98;;99:0EMIII"6VFFT%HA#;:"
M2E"$ET$1:$1`.W]OV_D`````````````````````````````````````````
M````````````````````````````JWSQ_DIYP?A;Y@?PFRT!!^[6_3^Y-OAS
MVI^Z5:`NX```````````````#C4OW@,!>9/3X^EHI\@U2Y71"K(K:Y=G.69D
MDD1(3!+>=U4>AJT)!?29`(T4/+,J,E6KS^(42SU35UCY'DE@R9$9%86K6J*9
MM2="4W&UD>,9=:VHM3"95536TD-%?4PH\"&TI:R9CH)*5..*XG7W5GJX]*?7
MJIQQ:E..*,S4HS/4!Y+O)*?'F4/6DI+2WCX(L1M*Y$^<X>I$S"A-$J1(69F1
M>*DR+7I,@$80WEN6:^4*DX70.:D3++C2LLL&C21HZU[A>BT+:M?&)).R--4Z
MMGHH@F%12U5%$*!40FH48W%/.$WQK=DOK2DG)4R2\IR3.F/$DN-YU;CJ]-5*
M,!E0````````````````````````````````````````````````````````
M```````````````5;YX_R4\X/PM\P/X39:`@_=K?I_<FWPY[4_=*M`7<````
M``````````'CGSX-9#?GV4R+`@QD<<F9,?:C16$&I*"4Z^\I#;9&M1$6I])F
M1>$P$(.UR;*?Z>.1W<<I%]!Y+<Q%(M)C9F9&=%CTE"78[?27#(GDV?0?#'4D
MTN`,[1XI4T*W)4=MZ9:2=/+;JR=5.MI9D6AD[,>,W$-']#;?"VGZ"`9R5+B0
M(S\R=*CPX<9M3TF5+?:CQH[*/&6Z^^ZI#3+2"\)J,DD0"#'>Y!E&C>(QOLRH
M<+QLNNXKB?*&E$>KF/43Z6Y$WI^K)E$S'/0E-H?;42@&9I,0JJ5YR?K(L[F0
M7^KO+5TYEF_X/$2\LN"(P6FA-LI0A)=!$`E0````````````````````````
M``````````````````````````````````````````````````JWSQ_DIYP?
MA;Y@?PFRT!!^[6_3^Y-OASVI^Z5:`NX```````````#C4M-3Z"(C,]="+0OI
MU\`""2LQ782':W#8*<@G-.&Q)LENJCXU5O$HT**9:(0YY6\T9'JS%2ZO4C29
MI,!W5V'DN8Q<Y1/5DMTPKK89OLDQ2TKI^!5'3<;K$>0A)\/E3QO2S(S(G$H,
MT`)H?1KX?W_RT_G]`"$3<S:D3':G%H2LEM65]7)<CNDU1U*]=-;6XX5LMK3X
M399)U\^$RX2/34/F%AZIDEBUS*<G([..XB1#@=2;&-4SZ=%)76TZEN)E2V5D
M7#+E=:^2D\31,\1I`3K0OI_?K^[^6O[S(!R`````````````````````````
M``````````````````````````````````````````````````"K?/'^2GG!
M^%OF!_";+0$'[M;]/[DV^'/:G[I5H"[@````````#@ST_P`R_P`?]P"*W>75
MU0^FL8:D75\\@UL4%0A,FP4CIT?E:J3'K89Z'J](6VCH,D\2N@!ARQR[R7A>
MS*:B/7&9+3B5(^ZF`:2,E);NK3A9E7"M.A;2$LQ3Z2-+A=("<Q8L>$PU$B1V
M(L9A!(:8CMH::;01$7"VTA))21?P`8.ZRRII76H2U/V%Q)(U0Z*J:.;;RD__
M`")C(-*8T8OI>?4TR6A^/KH1A@_L+(,I+CRV2=35+41IQ6DE+)3K?A)%[>-&
MAZ9J1F2V8W5,'H6JG"U(!-H-?"K(K,*NBQX,2.DD,QHK+;+#:2\!);;))%_Q
M,!Z]/^@#D```````````````````````````````````````````````````
M`````````````````````````!5OGC_)3S@_"WS`_A-EH"#]VM^G]R;?#GM3
M]TJT!=P``````<&>FG\3T`8FYOJF@BIEVTQN*TXX3,=&BWI,Q]1&I,:##82[
M+G2EI(S)MI"UF1&>FA&8")ZY;E9]!/X50.?2HF'<ML&CTUT3_7A4#:RZ-3Z]
M_3Z$'TD$JIJ"HQ^.J+4PFXJ'7#>DO<3CLN;(47C29TQY;DJ;)7J>KCJU*_B`
M[;6XK*.&J?:S6(,1*TMI<=,S4Z\LE&W&C,MDIZ7+>X3)MEI*W%F6B2,^@!#S
MD99EFA0$/X;C[FNL^8PTO*;!KP:PJ]PG8M*VLB,TN2"=?TX3ZI)F>@2BDQRH
MQ]IU%9%ZMZ2KK)LY]QR596#W@-^?/D*<E2G?W<2C2DNA)$6A`,WI^W\O!_N`
M<@``````````````````````````````````````````````````````````
M`````````````````````JWSQ_DIYP?A;Y@?PFRT!!^[6_3^Y-OASVI^Z5:`
MNX`````Z)$EB(RY)E/M1H[*%+>??6EIII"2U4M;CAI0A*2+74^@!`_[JMLC4
MJ/A,%M</4T.Y;=,O-T;1)4:5*J8*5QYN1/),N@T+8B]'2_KXJ@S-/B4"LE*M
M9;\J]R!ULVGKVW4AZ8AI2B<5%KV6T-PZ>!UA$HF(K;3?%XRB4LS4825UQMA"
MGG5H:;;2:W''%DAM*2Z34M:CX4I27[^@!`UY;.O5KB8-"9LD$I33^3V)/-8S
M#4DU)<*-U9MR[^4WPGHU&-+6O0M]O4C`9*IQ&'$F(M[62_D>0D@T_;%F39^2
M)7P&MBEKFR*%20S4GZK*>L61$;KCJ_',)=H6NO[?1_R`<@``````````````
M````````````````````````````````````````````````````````````
M```````"K?/'^2GG!^%OF!_";+0$'[M;]/[DV^'/:G[I5H"[@``&`@]CFC7E
MCU/C4)S)KIE9LRF8:R;JZITCX5?;%N9+B17&C^LPCK)!?2@M2,!T,8?(M'V[
M#-9R+R0VI+T>D92MG&X"R\!I@K4:K)U.A?U))J+74R2G4!.TI)"4I024)01)
M2DB)*4H+Q4I21:$DDEIX.CZ`$1M<QC1ICE-217<COFS)+M;7+03%?J>G%<62
MC.)6D@NDVU&I\R,C)O0]0&/;Q&?>.)EYO8(LDDLG&,<KR=CX]&-)D9%)0:BD
M7+A'IJ;Y]61^!`">M,M,MMLM-H:::0EMIIM"6VVVT))*$-MHT0A"4D1$1$1$
M0#M(M```````````````````````````````````````````````````````
M``````````````````````````````%6^>/\E/.#\+?,#^$V6@(/W:WZ?W)M
M\.>U/W2K0%W`$<O,HJ*#J6YK[CL^4?#!J(#+DZWL'-#T1$KHQ+D.IZ#U69);
M21&:E$1&9!@OLS(\K(U9`\YC=$OI3C53-,KB:T9H419%?PUD<5M:?KPZY22^
MA<MYM2FP$QKJZ!51&8%;"BP(4=)(8BPV&X[#:4EX$,M)0E)EIT]!:@/!>9)4
M8\AE5E*X7Y*^JA08[;DNRGOF2N!B!71D.2I;SAIT(D)/4^@!&_),IROQK5V1
MB&/K+HJ*^2DLILFM?_VMS%6IJACN)T,V()KDZ:&<IL^)H!,*NHJZ6(B!4P(M
M=#;^JQ%90T@S,BXEKX2XG'%_]RU&:E'TF9F`R0``````````````````````
M````````````````````````````````````````````````````````````
M`````*M\\?Y*><'X6^8'\)LM`:][N*7%@=WKR>3)LEB)%C\N&U3C\F2ZAAAE
M"<2K3-;CKAI0A/\`,R`6`R?/ITR.NMQ8Y-8[9-.QX%_(K5S;)UQY"DIE8QBS
MI%(LU,EXZ)$PH\`M",U.)U(PTG36.0;$[A8/"R^PM+C#]W77\7CVV3K3?YC1
M9XPV=G#=O,NB1V8Z:G*XC;C;=<2"CPY;*$1U*):B,+B3IT.LBOSK&4Q"AL(X
MWY4IY+#+9:Z$2G%Z$7$9D1%J9F9Z$1F`A'VYD>4EP8K$.EJ%=!Y3=Q5]?(;,
M_KT=&X3;KR5%TI?D]6WX#)"R`9ZCQ2KI'7)J?*;&XDH-$R]M'O++601FG5LG
MU%PQ8WB%HTR3;6B4ZD9EJ`DQ?X]'1^X!R```````````````````````````
M````````````````````````````````````````````````````````````
M``JWSQ_DIYP?A;Y@?PFRT!47D?PW.I?))R995"LYF5XM$Y;=GU%MXT[&I7X#
M[&&0TR["IM(S!/V$J4M27"2^HW&C0:$<2%\"0NC4N8Y9I.SPO%,\Q_,F3;@S
M)+=0Y!FJ-@E+*+D$_(EHH[NN:-U1I2XZLR,S-DT+Z2#6VZ^S&\>[F1[=7M]9
M8_6Q=N[AO(ZC&:2RF?V_;9$E266+/+Y,V*J>35=%4M3+$!A;I*6I!2"UZP@L
M_`PUM4EBTR:<O)K6-HJ)Y0SU%-5+2DB_\-2FZ^S'61EIU[RWY2B(N)T]"T";
M%_E_+P`.0```````````````````````````````````````````````````
M````````````````````````````````````````5;YX_P`E/.#\+?,#^$V6
M@(/W:WZ?W)M\.>U/W2K0%W``````````````````````````````````````
M```````````````````````````````````````````````````````````%
M6^>/\E/.#\+?,#^$V6@(/W:WZ?W)M\.>U/W2K0%W````````````````````
M````````````````````````````````````````````````````````````
M`````````````````%6^>/\`)3S@_"WS`_A-EH"HO=]<S.W&+\CG*;CMECO,
M%+L*383;2KF2<=Y2.:W+:)Z5`QB!&D+J,GQ;9:XQK(:\W6U=3-KY<J%*;T=8
M=<:4E:@N%[6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^
MU?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.
M=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]0@![6^U?FIS.=B?G,]
M0@"MG.9S1[:7G)_S64L+&>8MB9<<MF^=5$>N.3[FVQ^I9DV&V&41&';2_OMD
8:VBHZUMUXC?F39,>)%:)3CSK;:5*(/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex10-14a2a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-14a2a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!40(<`P$1``(1`0,1`?_$`/H``0`"`@(#`0$`````
M```````)"@<(`08"!`4#"P$!``("`@,!``````````````@)!@<$!0$"`PH0
M```%`P($`00,!PH'#`D%``$"`P0%``8'$0@A$A,),4$B%!51,B-4U1:6UI<9
M61IA<4(SU%8*D;%20R2V%W<86(%B<L8W.)CPLM)3-(0E)C:&5SG!8W.SE)5&
M)WCAT[5F21$``0(%`00$!PH)"`@%`P('`0(#`!$$!08'(3%!$E%A$PAQ(C)"
MDA07@=%2(U.3TQ56"9&A8G+29)06&+&",T-C)'15HK)S@[-4-3;!PX0E-S1$
M=?#$X<+BHV4F&?_:``P#`0`"$0,1`#\`OSU\X\PI"%(0I"%(0I"%(0I"%(0I
M"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I
M"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(1J'NOWE
MXQVI6\BK<)C7+?LP@=2U\?13I%.4?D#G($I++GZ@0L`DJ7E,X.4QU#>:D0X@
M/+M73'23(]3:\IH!ZO9&E2>JE@E"?R$#9VCI&T)!``VJ*1*<>]>N\=@^@UH2
M[>5&LRFH2334#2DAYP;1VCA,PRP#L+B@23XJ$K(,H&KV[I&[FZIXTK"7;"6%
M%IK&.SMRV[<C'+%)+7S$GKV;0D)"2-RZ<QC'(`CX%*'"IM6?NUZ66RA]5K*5
MZNJ2)*===6E1/2E+92E'4)'K)BJG)^_5W@+[=?7K574EIH$JFBGIZ=M:`.A:
MWPMQSK,TCH`W1-)V\]T]Y[I,67-*9!CHM"[;$N5M;DA+PR'H3&X6[V*1DVD@
M:-`QTV#X@',18B8](V@&*!=1`(A:\::6G37):>FL3CBK76TY=2AP\RFBE90I
M//YR=@*2?&W@D[XLH[H>N^1:Z8+6U^6,,-W^UUJ:=QUD<C=0%-)<2YV<SV:]
MI"TI/+L!2`#(;^UHV)90I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0
MI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(1R`"/@`C^(-:0CHE
MX91QICY)5>^\@V79Z:)0,I\8[EB(A0I1#F`>@\=I+CJ7B&A?"NZM.-Y#?E!%
MEH:NK43L[)EQ8_"E)'XXQ7(LYPO$6U.Y3=K;;D)$SZQ4M-&73):P?Q1J;>'<
MHV<6>*B?]*Q;J<I"8#-K+MZ>G]1+_P`6](Q;QBP&$.`D7,'^"MH6GN]:LW:2
MOJPTS9XU#K;7X4E16/=2(T#D??2[N>.\R?KX5[Z3(IHV'W_P+#8:5X0X1&OD
M[WC=O++G+;]A96N`Q1$"*+L+>@VR@`/`>=S-NG)-?8%&L[HNZ;GKP!KJVV,#
MB`MUPC\#8!]*-2W3[Q?1ZFF+5:[]5J&XJ:892?=4^I0]",7O^]1;11,6+V^W
M`KH8O*I(7Y%H@8O'FU2;0*HE-['G"%9(QW0;B=M3?:<=2:99_&7!_)&#U/WE
M=A!(H\2KE;=A76LC9X`R3^./4;=ZF(Z@^F[>I44M.'HF0&(*`;4.(]>W1()=
M-?8'6OJYW0*OE^*OS7-UTJI?B=CX-?>66KF^/Q&KY/R:YJ?XV(R;;G>2P2^,
M0ET8TR?;G,(`95@%O7&W3#7B8PDD8MR;0/(5(PUCEP[I6:L@FVW"VU$N"NU:
M)_T%C\*HS6S_`'C>E55(7RS7RB43M*$L5"1[H=;4?<08W*Q%OCVP9L>M8>S<
MHQ;6XW@@5M;-V(.;3FW"@@`@BT1F4V[1^X'73IMUE3Z^2M2Y5HSJ1AS*JN[6
MUU5O1O>8(>;`Z5%LE21UJ2D=<2-T][T&B&IM2W;L;OC"+R[Y--5)52OJ/0E+
MP2EQ7Y+:UGJC;00$.`AH/X:U=&_XXI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I
M"%(0I"%(0I"%(0I"%(1B3.N8;<P+BB\<J7.8#L+7C#K-&`'*1:9FG`@WA85M
MJ("*TE(*$3$0UY"<Q_`HUE.%8G<,WR>DQFVCX^I<`4K@VV-KCAZD)!/69#>8
MU_JCJ'9M*L#N6=WP_P!TH6"I*)R4\\KQ664_E..%*=DY`E1V`Q3FRGD^\<RW
M]<F2;\DU)2Y;G?'>.U#&'T=DW`1*RB8Y(?-;1D6V`J*"90``(74>(B(VRXUC
M=IQ&QT^/61L-6ZF1RI'%1\Y:SQ6LS4HGB>B4?G/SS.LCU)RRLS3*WB_>JUTJ
M4?-;2-B&6QN2TTF24)'`3.TF.K0$!-W5.1%LVW%O)NX)Z0:Q,-$1Z1EWDC(O
M52HMFK=(H"(G44,&HCP*74PB``(UV5=74=LHG;C<74,T+#96XM1DE*4B9)/4
M/P[AMCH;1:;I?[I3V2R,.55WJWDM,LMCF6XXLR2E('2>.X"9,@#%NK9;MM1V
MP80AK'>';.KRF')[HOZ0:B!T%KE?H(I&8-E?XUG",T4VJ9_!04S'#0#``58:
MO:A+U'S)Z\M!2;0TGL:9*MX922>8C@IQ1*R.$P.$?H0[MFC#6B&F--C#Y0YD
M50HU-<XG:%5+@`*$GBAE`2TD\>4J&Q4AMG6KHW]"D(4A"D(4A"D(4A"D(4A"
MD(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A#QX!QI
M".D7MDO'>-6!Y/(-\6I9C$B8J]:XYV.BA.0HZ"**+I=-=<0$/`A3#7<V?';]
MD+_JUBHJFK>G*33:U[>LI!`]TB,9R;-,1PRD-=EMSH;;2`3YJA]MJ8Z@M0*O
M<!C0G)7=:VKV.+AK;+^Z<I2*(F(4EHPIVD2<Y1$HAZ[N`\6W.GKX'2(J40X@
M(UN['N['J9>0ERXMTUMIS\NX%+E_LVN<^X2#TRB*.:=_/0C%RMBROUM]K$[`
M*-DI:)']L^6D$=:>8$;03&AF1^\GE.6%RVQ9BZT;+:GU*A)W6^>W?+IETTZ@
M-6GJ.*35\H`8%BE'@/,'CN['^Z5C5*$N9+<JJK<&]#"4L(/5S*[19'@Y2>J(
MI9E]XYG5P*V,%L5OMK!\ERJ6NK='7R([!H'C(\X!V'FXZ'Y#WK[J,H"X)=&:
M[Q18N=>I$6N[3LV*Y=!#D]%MA*,,<G*.@@<Y@,'CK6[+#H]IGC82;;9Z0O)W
M+>27U_A>*_Q`2X1%7+^\QKOG!6F^9-<44J][5*L4;7@Y:8-$B6R1)GQG&L#I
M==^X.[?N'#YVH83J.GJZKMR<QAU,8Z[@ZBIC&$=1$1XUL=I"&&PTPE*&AN2D
M!(_`)"-'ONO5;QJ*M:W:@F94M16HD]*E$G\<?E7O'SA2$*0A2$*0AY2B&H&*
M8IRF`1`Q3E'4IRF#B4Q1#4!#B`TZN!AQ!X@S'4>D=!ZXF*V%=QJX['FH+#F>
MIQS<&/Y1=K#VO?4NX,XF;&=*F*W8LII^L)EI2U5#F*GU%3&69<!`QD@$I8FZ
MWZ`6^\T;^6X0REB^M)4X]3($FZE(VJ4VD;$/#?)(Y7-NP*VFQGNH=\:\XU<Z
M33?5:J75XF^I+-+7/*YGJ)9DEMM]Q6UVE)DD+62MG9M4V))L4E,4Y2G(8IR'
M*4Y#D,!B'(8`,4Y#!J!B&*.H"'`0J`Y!!DH2(BX1*DK2%((*2)@C<1TB.:\1
M[0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(1#OWE274?#.+!C
M$I`]I)9!?+78=JFH=DB[+!J$MP\J8@"5)'K'<=(3Z$ZNGY7+4L.Z2JV#+KF*
MDMBZ&A2&.8CF([0=J$3WF03.6WEGPG%=7WCJ+^K3:QFA2\K'TW=:JLH!*$J#
M)%.79;D\Q<Y2=G/+C**]=M6]/WE-,;<M&%D[GGY-<C:/AH)DO)R+M=0="D2;
M-2**:>R8="E#B(@'&IX7&OH;11KN%U>;IJ%M)*G'%!"4@=)5+\&\\(J(LEFN
M^37-JRX[2OUUV?4$MLL(+CBB=TDI!V=),@!M)`BR?V_M@:6WUNEE?*[=G(9D
MDV9THF*343>,,<QCM,2.$$%R"9%W<[]$_(Y7((D03U22$=3F-7KKIKDO.EG&
M,84MO$FUS6L@I55+2=A(WI92=J$G:H^,H;$@70]TKNFM:1LISS/$M/:C/M$-
M-@A;=O;6/&2E6Y=0L&3K@\5"9MH)!4I4IM1IB=<*0A2$*0A2$*0A2$*0A2$*
M0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$``1X!Q'\%(1
MB7)V>,-X99'>Y/R1:MGE*03D924HB>8<@!1-HTA&HN)9T8VF@`1$=1X>-91C
MF$Y;ESP9QRWU-69R*D(/(/SG#)"?=4(P'-M4M.].:4U>;WB@MR`)A+KJ>U5L
MGXC*>9U<^'*@S.SC$9&6.\7BZ!%RPP]CZX;_`'A.8B,Y<RP6C;O.',`*I-`(
M^G'B.N@Z&3;"8->)1J1F+]T[):WE?RNNIZ%D[VVAV[LN@F:6TG?N4OP&(29_
M]XK@=I*Z33RU5EWJ1,!Y\^J4\]NT)(6^L;C(H;F-DP8C4RKW*]V&4`7:-[W;
MXWA5N<OJG'3$L,MTS\!36GG)WLZKYHB`\BZ11U]KK4AL9[O&F&-E+KE&JX5@
M\^J5V@GU-)Y6Q[J2>N(5YYWUM>\X"Z>GN3=EMJI_%6]`:5(\#4+*WSLV>*I`
MZHT9F)F9N)\I*7#+RL])K&$ZLC-R+R6?*'$1$3'=OUG"YAU'^%6Z*2DI+>P*
M:@::8I@-B&T)0D?S4@#\41;N=SN=ZJU5]YJ:BLKE&9<?<6ZLGK6XI2OQQ\VN
M3'!A2$*0A2$/#QX4A,#?'LL63Z45*A%L7LFN<W(1&.:.'RIS\?,*FU35,)N'
MAIK7R?>9IDE=2M#:`)S6H)'^D1'(I*2KN#@:H&77W29`-H4X2>B20=L99B=O
M&?)U(%XC"N4GR(EYRK)V-<2:1R#H`&34<,$2J%$1\2B-8O59]@U$KDJ[Q;$+
MZ#4-$^Z`HR]V-@V_1K5RZH[2WXQ?G&Y3GZD^D$=(*T)F/!./3N7!&;;-8'E+
MKQ'D>WXQ(.9:1D[/FT&*!>/G.'?H9D&Y>'B<Q0KZV[-L-N[PIK7=;>_4'<A#
M[94?`GFF?<!CCWO2;5'&Z4UU^QV]4E$D34XY2/!"1TJ6$%*1UJ(C%("`AJ'$
M!\!"LHC7P,]HA2$<"`&`0$-0$!`0'P$!X"'^&@,C,;X$`B1W&+5G;-S9(YBV
MRPK.?=JOKEQ?)K8^DGKA0ZSE]',&K=Y;CQPJH(G46]3.DT3&'Q%#41$=1JLO
MO%8?3XGJ*\[0I"+=<FQ5(2!()4HE+J0!N':)*@/RN`E%\_<JU+K-1M$:1F[.
M*=O5D>5;W5J)*EH:2E5.M1.TGL%H23Q*-I)F8D)K1$2XA2$*0A2$*0A2$*0A
M2$*0A2$*0A2$*0A2$*0A2$*0A2$*0CTI&-CIADYC)>/8RL:\3%%W'231N_8N
MDAXBDY:.DU6ZZ8B'@8HA7VIZBHI'DU%*XMJH09I4A12I)Z0H$$'P&.-5T=)<
M*9=%7M-OT;@DMMQ*5H4.A25`I4.H@QUFU\;X\LA99Q9EAV;:;AP!BKN;<MF&
MA7*Q#FYC$5<1[-NN=,3![43<OX*[&Y9!?KPD-W:MJZIM.X.O..`=8"E$`]<=
M+9</Q+&W%.X]:[?0NK$E*IZ=IE2AOD5-H22.HF4=SKJ(R.%(0I"%(0I"%(0I
M"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(1URZ[QM
M.Q8A>?O2YH*TX1L4QUI2X95G$LB@4HF$I5GJR)5%!`.!"\QC#P`!&NPMEINE
MZJDT-HIWJJL4=B&D*6K\"0=G6=@XQT]]R&PXQ;UW;(ZREH;8V)J=?=0T@?SE
MD"?0!M.X"(R\S=VS`5B^E1N+XR;S!.)<Z9'K,IK<LXBH:E`QIF10._?)E,&H
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MD9334C:&J=(D$(2$I`ZDI``]P1$^MK:VY52ZZY//5%<X9J<=6IQQ1/%2UDJ)
M\)CTZ^T<:%(0I"%(1V2U;-N^^9`D395JW'=TFH8"D8VU"R,TXU$>7SB1[=QT
MR@(\1-H`>40"NNN=WM5E8-5>*JGI*<><\XAL?Z1$_<W\([NP8UD>558H,8M]
M;<:TF7)3,N/*]WLTJD!Q)D!QC>K&W:]W:9`!!S*6I#8UC%C!S.K]FT&KXA-0
MYC!!1!923$P`.H%4*D!OX05I;(>\CI=8BINFJGKC4CS:9LE/SCG(B76"KP1*
M;"^XUK]EH0_<*&ELE"H[55SR0X!/:>P9[5R?$!7(#TB-],>]F2S6A$'&5,Q7
M!.KAQ<1=CP[.`8ZA^064EQEGRA!#R@BD;\-:1OW>YN[I4WC-IIV$<%U"U.J]
M!'(D'^<H1*S$/NW<9IDH>SO(:RK>\YJC:13M^#M'>V<(/4E!'3&Z]A=NO:#C
M\$E&N)8^Z7R.@A(WW(2%UKF$/:F,T?K!$@8H\0$K8H@/EK3U\U\U5OI*7;HY
M3,GS*9*61Z21S_A68DUBG<_[O6(A*J;'J>MJD_UE:M=4KT75%J8X$-@]<;:V
M[95FV@@#6U+2MFV6Y2%(",#`Q<23D(``4#`Q:HB?0`\NHUJZON]VNJ^TN=54
M5#G2XXM9_P!(F-_VC',?L#786*AHZ)F0$F&6VALZ0A*9^[':.<W\(W[HUULA
M'<QX*`"I#I*E*JDH4Q%$E2@HFH0P:&(<AP,0Y3`.@@("`A7LDE)"D[%`["-A
M$>JDI6DH6`4D2(.T$'@8JD]RK$=HXAW/S;"R63>)A+PM^)O<\&T(1)G$RLNL
M]0E462"8%3;,G3MF*Y$B@!4Q4,!0`N@!9QW>,INN5:;LO7A:G:RD?73AQ6U2
MT("2@J)VE24JY2H[3($[8H8[ZNG^/:?:X5#&,M(I[;<J-JM+*)!#3SJEI="$
MC8E"U([0(``25*`D)`:!5O*(DPI"+'/9RL^3B,&Y$O!X51-A>>0"(0Y#<"+-
MK9BDF3MX0H@`^>_='2U\!!*J_N]G=::JS2@M3)!?I*&;G47EE24^XD`_SHN5
M^[HQZNMVE=VR"I!32W*[D,@[BFG;2VI8'6X5)GQY(E[J*L6%0I"%(0I"%(0I
M"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(1U.];\LK&\"Z
MNB_KJ@K0M]F4QEY6?D6T<UU(43BD@*YRG=.#`'FI)%.H8?`HUVEGLEXR"N3;
M;'3/5=<L[$-(*SX3(;!TDR`XF.@R7*L;PZU.7S*JZEM]H:!*G7W$MHV"<@5$
M<RI;DIFH\`8BES'W@L46PLZBL-67-9+?)`8A+AFU%+4M7J@80YVZ*B*\]((Z
M<0$46P&\@Z:&J3>)=U')[DA-3EM8S;F3_5-CMGI=9!#23_.7+HX1`S4;[Q#3
M^Q..4&G5NJ;W5IV!]TFEI9]*>9)?<'^[;GTRD8T=E^[SNF?/3.(R)Q5!L^KS
MECT[7DY$H):\$1=/9[KCJ'B;QK<U+W5=-66>2I=N;SLO*+R$;>F26I>Y$7[C
M]X7KE551=H*:PTM-S3[,4[SNSHYUU`/NRC83"W>-D5)9E$Y\QW%HP[A5)!:\
M,>B^(XC2G,!3/)"VI)P\]-0)KS']%7(H4H>:F<:P3+^Z8PFE758/7N*JT@D,
M57+)?Y*'4!/*>`YTD$[U"-O::?>,U#EP;M^J]G9;MZU!)JZ`K);GO6Y3.*45
MIXGLE@@;D*,3@6A>%KW];4/>-F3D=<EL3[--_$346N5PS>-E/*4P:&352.`D
M43.!5$E"B4Y0,`A4-;K:KE8[@[:;NRY3W%A92MM8DI)'\H.\$3!!!!(,6=X_
MD-CRNS4^0XW5,UMDJVPXT\TH*0M)X@C<1N4DR4E0*5`$$1V2NOCN84A"D(4A
M"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A'.@C_N\`]D?P4A&IN;=[FV[`8.6EY9
M!82ERMRFTLRS1)<]S&5+J`(N6S!46<2<1#Q>+MP#6MH8=HYJ#F_*[:*!;=O5
M_P#</_$LRZ05#F7_`+M*HT#J=WF]&=*`NGR.[M/7I(_^CI)5-23T*0V>5K_?
M+;$0_P":N[_EBZ#.HO"5IQ.,X@QE$TKBGR-[IO!9(0$A54FRI`MZ).8!UY>D
M\,4=-#\.,K,/[J>,6T)J<QJG;C5;"6FILL`]!4/C5^&;8/1%>&I?WAV>WQ2Z
M'3*WT]EM^T"HJ`FJJU#=,((]7:\!2\0?.Z8M;_R=D3*LPI/Y(O6Y+UEE#"8'
M5PRCE^5#7\AFT.<&3%(`X`1%-,H!P`-*DI8L<L&,T@HL?HZ>CIAP:0$S_.5Y
M2CUJ),08R[.LRSZX&ZYI<ZVYUQ.]]U2PGJ0B?(@#@$)2`-D=&KNXQ2%(0I"%
M(1D/'>),H9;D2Q6,K!NJ]WHF`JGQ?B'3QFVU'E$SV3Y"1C!,H^)EEDRA[-=#
M?LIQO%J?UK(ZZEHF>':N!*C^:CRU'J2DQF&'Z?9SJ#5^HX1::^Z5$Y'U=E2T
M)ZUNR#2!TE:TB),,2]H#-MU`UD,KW?;&+HU02&6BH_\`ZY74"0@!A*9-FLT@
M6:N@Z<72P@.H"4-*CME/>LPZV<S&,4M3<JD;EJ^(9GX5!3JA_,3U&)K8!]WA
MJ;?@W5Y[<:&QT1D2TW_?*J7@24,(/^]61Q`B2[%W:[VH8[*U<S=L2V49EOR'
M/(7[++.(\ZY>/,2W(KU="]'7P3537X>V$WC4=\D[R6I]^*FZ.I:MM(KS:9`"
MI?[5?.Y/K24]4HFO@O<;T$PX-OW&A?OER1(ERO=*T%0XBG;[-B7Y*T+V;R8W
MSMJT[6LR.3B;0MJ!M:+1(0B<?;T2QAVA2D#0@=%@@@0>4!\1U&M(W&Z7*[U!
MJKK4/U-23M4ZM2U;>M1)B5EFL-CQVC%OL%'2T5"D`!MAI#2!+=XJ$I'XH[!7
M!CMH4A"D(4A"D(Z+DK)-FXBLBX,AW],-X.U[;9'>/W:Q@ZBQ].5M'L$=0.\D
MI!<0201)J910P!X:C7=8]CUVRJ\L6&QM*>N50L)2D;ATJ4=R4)&U2CL`$8MF
MF9XYI]C-7E^5U**6QT316XM6\_!0A.];BS)*$#:I1`BGKN-SA.[BLPW?E:=1
M%EZ\=D;0<1S\Y8.V(X#-X*)YP\U15NT\Y8X:`=<YS!H`@%6O8!AM%@.)TN,4
M1Y^Q3-Q?RCR]KB^H%6Q(X)`$?G9UEU0NNL6HMPSRZ)[(5*PAAJ<^QIFYI8:G
MQ4$[5G<7%*(D"!&#ZS.-7QVBR;-N#(EX6S8EJ,C2%R7=-,(&&:%`1!1[(+%1
M(=40]HW;E$553>!4R&'R5UMYN]!8+34WNZ+[.WTK*G7%?DI$Y#K.Y(XD@1WV
M+XU>,RR.AQ2P-EV]7&I0PRG\M9E,]"4B:EG@E)/"+G6$L60^$L3V'BN#$JC*
MS+?9Q:KLI>49*2Y17EY0X<I1YY&3656'4.`&`/`*J+S'):O,<GK<EK9AZK?4
ML)^`C<A`ZD("4^Y'Z1],\%MVFF!6K!;7(TUMHT-%6[M'`)NNG8-KCA4OJG*,
MI5C49U"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(QGD7,^)<1H(.,FY&M"R"N
M@U:(W!-LV3UV4!T$[6.%0S]RF4?$Q$C%#RC616#$<HRE:F\=H*JL*?*+3:E)
M3^<J7*#U$B,(S'4G`-/F4O9M>+?;$N>2'WD(6L=*&R>=0'$I20.,?*Q]N#P=
ME=R+''.5[%N^1`#&]51%P,5)<Q"\#*)Q2RB,BJF40XF*D)0]FN5?<$S/&&^W
MO]LK:6G^&MI01X.<`I!ZB9QP,0U=TOSU[U;#K]:[A6;^R:J&R[(;R&B0X0.D
M)EUQF&L3C8T*0C$>1L^84Q$L@UR7E&RK,?.0*9"-FIQHC*G3,&I5O5:1E9`J
M!@\%!3`GX:RK'\'S#*D*=QVVUE6RG>MMM10#T<YDF?5.?5&O,RU9TTT]<0SF
MM\MMMJ5^2V\^A+I'3V0)<Y?RN7EZX^ACK,V)LNMW#G&.1;1O@C,`,]1MZ::/
M7K(@FY"J/(\IROVJ1S<"G42*4WD$:X]_Q'*,5<2WD=!5497Y)=;4E*NI*I<J
MCT@$D1S,-U)P#4)E;^$WBWW-+>U8IWD+6@3E-;8/.@$[BI(!X1DRL=C-X4A"
MD("(``B(@!2@)C&,(`4I0#43&$=``H`&HB/`*;]@WQX)`$SL`B*'=MW0K#Q`
MK*6)A1*,R7D9L*S-_.F6,M85J.P`R9BJ.VIRFN>5;'XB@V.5N0P:*+:@)*D]
MI;W;KWE:6[WF!<MV/JDI+<I5+R=^Q*A\2@_"6.8CR42DJ($]X'OQXIIXM_%=
M-4LWK,D30MZ<Z&E5M!YEI,ZEU)_JVB$`R"W)@HBOUEC-.4LXW$K=.4[SE[ME
M#&,+9-ZMTHF+3$>#>&A6X)QD4W+Y"HIE$?RA$>-3HQ?#\:PRWBVXS2-4M,-Y
M2)K6>EQPS6L_G$]0$5)9_J;G>J-W-[SNY5%PK)^*E1Y66A\%EA,FFD_FI!/$
MDQBZLEC!(4A"D(F%[1>>+B@<K2F`Y!\LZLN]H>7N*"8+',=*$NV%31=.5F`#
MS`@E-QA5`7(70IU4B''CKK$_O483;Z[&6LX80$WBC=0TXH#:XPX2$A726URY
M2=H2HC=*5BWW>^JEXM><U&D]6ZI>-7&F=J6$*.QFJ9Y5+*-\@\WS<Z1(%2`K
M?.=B^H"1<3"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(^-<%Q6_:<2ZGKIG(B
MVX1DF95Y+SLBTBHYL0H"83+/'JJ*!.`#PUU&N70T%=<ZI-%;67:BL69)0VE2
MUGP)2"3'776[VFQ4+ETO=33T=M:$UNO.(:;2!MFI:R$CW3$7V<^[/@W'_IL/
MB>.?YAN1$5$22#8RD%8[=<`T`YYIT@9_*ID/X@U;B0VG!6I(X7W7LSOO)5Y0
MXBTV\R/*J3E01_LTGE0?SU`CX,0=U2[_`)I;B':6[`FG<CO29@+02S1)5TE]
M:2IP`[^R;4#P7$.>;=_>YO.0O&,S?CFS[5=@JD-GX_%>VHH[50PCZ/(/6ZQI
MN6+RCH/7<F(;^#X:2RP[0[3G"^1ZDHDU=S3(]O52=7,<4I([-'\U$QTQ7/J=
MWL];=4>UI+A=%VVPN`CU2@YJ=LI/FN.`E]T<"%N<I^#&F(\3&,.HF.83',(Z
MF.8PZF,<PZF,8PCJ(CQ&MN\)#<(C7Q*CY1,R>)/23Q,*0A2$*0CZ,1#R]PR+
M>'@(F3G9=XH5)K%P[!U)R#A0X@4I$6;))9PH(B(>!:X]75TE!3JJZYUMBE0)
MJ6XI*$@=:E$`?ACG6RV7*]5J+;9J=^KN+ADEIEM3KBCU(0"K\42/86[5^Y')
MH-9.]6\9ARVUN10RUV"9[="J!A`3>C6M'J"N@J)!X`[6;"`^(<!"H_9?WF-/
ML<YJ>SER[7`;),^*R#UO*$B/]FE?AB9>FO<0UDS7DK<H#&.6A4C.I^,JB./+
M3-GQ3+Y5QLCB.$2S8=[7&V+&16SVZ(>0R_<*/*<[Z^52^HRJE,!@,VM6/%&,
MY`T\'(N1'CJ.@Z5%[+.\GJ/D94S;746J@/FTP^,E^4\J:_0Y(G[IWW&M#L)2
MBHO5*[D%W3O<KB"S,&<TTJ.5H#J<[3PR,HD*A(*$MJ-;PUN0T5;\0U*!&T7"
M1[2*CFY`*!0*BS8HH-TP`I0#@7R5H>LK:RXU"JNX/.OU2CM6XI2U'PJ423^&
M)=6RU6RRT:+=9J9BDM[8DEIEM+3:1^2A`2D>X(^K7&CGPI"%(0I"%(0I"%(1
MTW(&0;.Q9:$U?=_3S&V[6@&IW4C)OU0(4-`'I-6J7%5X_='#D102`RBIQ`I0
M$:[>Q6*[9+=6;+8V%U%R?5RH0D?A).Y*1O4HR"1M)C'<LRS'<'Q^IRC*ZMJB
ML5(V5N.N&0`&Y*1O4M1V(0D%2E$!()BJSO4WF75NKO0R#0[^"Q';;U0;*M!0
M_3.Y5(4Z'QHN))(PIN)QZD<W3((F*S2/TR#S"<QK,=']([;IE:.=T(?RFH0/
M6'QM`!D>Q:)VAM)E,["XH<QV2`H@[S'>0O>O.2]C2EVET^HG#ZG2DR*U":?6
MJ@`R+RP3R),PR@E*3S%2CI'6XXC#`1``$1'0`XB(\```\1$:0)`$SNBP;VK=
MH"MJ11-RN18@4;BN)@=MBV*?I&*O#VX]()7EVJMU2`9!]/HCTV@CYQ68F.'Y
MX-()=YC59-TJ3IY8'9V^G6#6+2=CCJ3XK`(WI:.U?`N2'FQ;MW$>[NO'K>-:
M,QIRF]5K)3;6ECQF:98\:J*2)I<J!L;XADDR^,V33U$&+*84A"D(4A"D(4A"
MD(4A"D(4A"D(4A"D(4A$:V^[?O#;;(U;'^/SL+@S7,,1.1)04W498#)RG[A,
MSR("(.)18IN9FQ'3FTZBNB>@'D+HIHA5ZA5`OM]"V,/:7M(F%U*@=K;1X(&Y
M;G#R4^-M3"_O4=ZVVZ+4)Q3%"U6:E5+4TI)"FZ%"AXKU0!O6=[3)D5>6N2)!
M59B\+QNK(-R2EX7O/R=TW1-.3NI.;F71W;URJ<=0*!SCRH-T@\U-),"))%`"
ME*`!I5BMIM-LL5O:M-F8;IK:RGE0VV.5('_B3O*C,D[228I*R/([[EUZ?R/)
MZM^NOE2LJ<>>45+43P$]B4C<E"0$I$@D`1\5@_?1#YI+13YW%R<<NF\82<>Y
M69/V+I`P*(N6CMN=-=NLD<H"!BF`0KF/L,U3*J6I0EVF<24J0H!25`["%),P
M0>@B.LI:NJMU4W<*!UQBN96%MN-J*'$*3M"DK20I)!W$$1<OVMW1>MZ[=<-W
M9D4%?CG/6)#2$VNNGTG#Y15(P,Y1TGREY'4K'E1<JAH'NBH\`JI#4JVV>SY]
M=K78)?5#%:XEL`S"0#XR`>A"N9`Z@(_2#H9?,FR;1_'+_F(/[RU=J9<?*A)2
MR1XCBALDIUOD<4)#QE'8(P[OFW;Q6UG&)U8M9J\RK>:#N/Q_"J<BWHBA2=-Y
M=<FW'72*A.H`E`P:+N1(F&H<^F6:,:6U.I>1A-2%(QFD4E=4X-DQO2R@_#<E
MMEY*9JZ)Z[[T/>!M^A6#EVC4V[G5Q2MN@9.WE4!)=2XGY)B8.W8MSE0)S5*I
M]/STW=<Y*7-<TL_G[AFWBTA+S4JY5>R,B]<'%19=RY6,90YC&'@&O*0NA2@`
M``59]0T-';*-NW6UI#%`R@)0V@!*$I&P``;/_$G:=L4%W>[72_W1^]WRH=J[
MQ5.%QUYU16XXM1F5*49D]0W`2````C;CM[PMV3.[W#Q+07D&BK";6F+B=,#+
M)IDM.-9.%YM&3%(0*>/>I<K<2J:D,HL3AKH(:KUXK+72:578W4-K2XR&V@J1
M/;K4`V43\Y)FJ8VR2>$2%[H-MO\`<>\-CPQY3K:V:A;U0I$P/56VU%Y+DMA0
MX"&Y*V%2T\91;G'Q'3PUJK*/T%1Q2$?!NBZ;<LFWI>[+NFH^WK;@&2TC,3,H
MX(U8L&:!1,=594XAJ8?`A"ZG.<0*4!$0"N=;;;7WBO:M=K9<?N#ZPAMM`YE*
M4=P`'XSN`VG9'57R^6C&K147Z_U+5)9J1I3CSSJ@E#:$B9*B?Q`;29``D@16
M[WI]R6[<V+RN.L,O)2RL2:KL9"81.K'W5D!N8!25%ZH3D<0ENKE$0*T(8%ER
M#JL;0>D%@ND'=[M>'(:O^7(;K,IV*2V9*9I3O'*-H<='%9\5)\@3',:9^\MW
MS[_J4]48;IJZ];=/_&;<?$VZJO2=BN8[%,4ZAL#8DXX-KA`/9B*P```T````
M\`#@`5)C?OB!H``D-T<TA"D(4A"D(E2[1F.I"YMR4G?OHYQA,;65+*N'0E-T
M0FKG%.(BFH*!PZYFH.E0*/B1,1\E1F[T]_8MVGS5DYAZY<*Q`">/9LS6M4NC
MFY!/I,3R^[WPZJO6LE3E903;+-;'.91!EVU20VVF?PN0.JET`F+,8`(^`"/X
MN-5VQ=;`2B'B`A^,!"D(XI"%(0I"%(0I"%(0I"%(0I"%(1C+*&9\686A33^4
MKZM^S(_IG4;DEGR99&0Y-=4XJ(2ZLG)JZAIRH)''7QTK(\;Q')<OK/4<;HGZ
MM^<CR)/*GK6LR0@=:E",*S?4;!M-[8;OG%TH[;12)3VS@"URX--";CJNI"5&
M(<L]]X8=7D%MTLOP%1$M_7\AP$/:E<P]I(*@;QXD,]6#_&1\@RRPCNH>16Y_
M6=!]6IC^)Q\C\(;2>I<5SZK_`'B;:>TM6CMMYE;4^OUR2$]2F:5)YCT@O+3U
MM\##OE/-F5\V3)YW*=]W!>+P3F.@WDGABQ$>4QN8$HN$;]&*CD2>0$D2C[(B
M/&I8XSAV,8=2"BQJB8I&I;2A/QBNM;AFM9\*HKISS4_/]3KB;GG=UJ[B_,E*
M%KDRW/@TPGE:;`X<J)]))VQBVLEC`X4A"D(4ANC-&(MN^:L[/TV.+,>7!="1
ME027FDVAF-LL1UT,9_<;[H1#<">4O5,I[!1'A6(95GN'X4P7LEKV*9<IAOFY
MGE?FM)FL^&0'7&S-/-'-3-5:H4V"V>KK6>:2G^7LZ5'Y]0YRM"70%%70DG9$
MP6#>SK'-P936X2_%9%71-96Q\?G.T9E$0YA;R5UO$O2U^4W`X-$$@\>50>!J
MBCF?>QJ%E=)@E"&T;A457C*\*64GE'5SJ5UIX18EI?\`=TV]CLKEJY=55#L@
M314)+;8X\KE4L=HJ1V$-(;XR7N,2Z8MP;B+"D66)Q;C^V[.;\A2+NHU@F,N^
MY0TYY&:<=:5?',/$>HL8-1'0`J*^2YGE.85/K62UU15N3V!:CR)_-;$D)]Q(
MBP;!],=/]-J`6[![316YB0!4TV.T7+BXZJ;KA_/6>,96K&8SN%(0I"%(0I"%
M(0I"%(0I",'Y\W#8RVX60ZO7)$VDS()54H*WVITUKANF3*F8Z<;"1_,"BQC"
M`=18P`@@4>90P<`',L(P/(]0+PFSX\R5JF"XZ9AIE$]JW%;AU)'C*.Q(,:QU
M6U=PG1O&7,FS2J2TW(AEA)!?J793#3+<YJ)\Y6Q"!M6H"459=U&[G)>ZF[AE
M+H<'A;*BG*IK/Q\Q<J'AX)$0$A7CPVB82T^NE^>='*&FHE3`A.`V6:9Z68]I
MG:_5K:D/7AU([>J4!SN'?RI^`T#N0#MWJ),45:\=X7-=>+]ZW>E&EQ>G<)I*
M!"B6F1N#CAV=K4$>4X1(3*4!*=^JM;-C0<*0B5;MW;$G6;YR/S%E6)50P[`/
M07A(=ZDHB?)$PS4`R9"$,!1-:4>N35RK[5V<.B34O4$(R:]ZUM8=1.8EC+H.
M6/HDXXD@BD;4-O\`OU#R1Y@\8[>41/;N>]U>HU+N;&I.>4Y3IY2N<S#"P0;@
M\@[#(RG2-J'CG<\H=FGQ0LBRVDDD@DD@@DF@@@FFB@@BF5)%%%(H)I(HI$`I
M$TDR%`I2@```!H%5XJ4I:BM9*EJ))),R2=I)/$GB8NF;;;:;2TTD):2`$I`D
M`!L``&P`#8`-PCSKUCWA2$*0A2$*0A2$*0C`65]TFWW"#H([)^5+8MJ8,F54
M($7"\I/E34#5-1:&AT'\@U34#B4RQ$RF#P&LXQC3;.LQ:]8QRV5-12`R[200
MU,;P'%E*21Q"23&J,\UQTETR>%)F]^H*&O(![$K+C\CN)9:"W$@\"I(!Z8^)
MBS>-MIS1<"5IXZRO!35T."JG9P#E"3A9-^5`@JJ^KD9EDQ+(*$3*)A31,=0"
M@(\N@:US,ETFU#Q&A-TO]K?9MJ2`IT%#B$SV#G+:E<H)V35(3V3G'68+WB=%
M]2;L+#AU_HZJ]J!*6"'&G%@"9Y$O(1VA`VD(*E``DB4;,5KN-U0I"%(0I"(Z
M]^F^&'VRVP>S;,<,I;-MSL#C$,!%-RVLJ-<$,0MT3Z.I@!P.NK%H<-5SASF#
MI%'FWYHCHU5ZBW(7:[I6UAU,L=HK:#4+&WL6CT?*+'DC8/&.R'W>K[SUMT1L
M9Q_'EMU&I=<T>Q;V*32-D2]:J!_P6CM<5XQD@$FKG.3<Q<TS*W%<,F]FIZ<?
MN928EY%<[E])2+Q4RSEVZ<*"8ZBJJAA'B/`-`#0``*LFHZ.DMU(U04#:&:)E
M`0VA``2A"1()2!N`$4872Z7*^7.HO-X?=J;M5/*=>><45+<<69J6I1VDD_@&
MP;`(^77)C@1O]L&V=RNYG(K>>N5BY:X:LA^@\NN3.F=-*Y9%N=-=K9D6J(`5
M95V(`9Z<NH(-M0'SU"!6C-<-6*;3JP*H;<M*LNK$%+*)S+*""%5"QP"=S8/E
M+V[DF);]TWNZ5VM68HO-\:6C3>V/!=2X00*EU)"DT;9W*YMA?4)A#?BGQEIB
MS-EC*-D8&QG/Y#O!PC$VM:$63HLVX)I*O%R$*VB+?AVWFE4>OU@(@@F4-`#B
M.A2B(5UXOC=YS;(F+#:4EVY53FU1F0D;UNN'@E(FI1/\I$78Y[G&,Z6875Y?
MD;B:>QV]B82)`K('*TPTGBMQ4D(2.G@`2*?^>\WWCN&R?<63KT<&%Y+N#(Q$
M210QV5MV\@HIZI@(XH\"H,4#>>;35983J&U$U6M81AMIP+&V,<LZ?B6DS<7+
MQGG2!SNJZU'<-R4R2-@C\[^K.J&1ZP9Q5YODJ_CWU<K+0/B4U.DGLF&^I`/C
M*WK65+.TQAH1``$1$```$1$>```<1$?P!66[]@C6Y(`F=T6:NUMME'$6(U,M
M70Q.WO[,#-F\;H.D3).8&Q$5#.(1ARJ`51%>;.;TU<!`-2BB`^UJNCO*:B_O
M5E(Q>VK"K':5J22#,.5)V.*V;"&_Z-/7SGC%W'<8T2]GFGISV]M%&6Y$TA8"
MA)3%$"5,-R.T%Z?;N#C-L'R8E+J-<3GCI>0\AV9BFSIN_;_GF5N6K;[4SF1D
MGJ@%#7VJ#1HD'NKR0>*Z)H()@91500``KM[#8;ODUV9LEC8747-]4DH2/PJ4
M=R4I&U2C(`;3&-Y=EV.8)CU5E65U35'8J1LK<<69#J2D;U+49)0A(*E*(`!,
M58MYF]N]]U5QFC6WIEK8BA7BA[9LLBXE4DCIG$J-PW6*1NF^EU2!JDCQ1:%'
M0FIQ,<;+=(]'+-IG;Q4.\E3E3R/CJB6Q`(VM,3VI0#Y2O*6=ID)"**>\EWGL
MFUVO!M](7:'3NF<_N](#(O$'9454MBW#O0WM0T-TUS5&CE;GB+4?6@8&;NF9
MC+<MJ(D9Z?F7:3")AHEHL^DI%XN8"I-VC5`IU53F$>/#0H`(B(``C7%K:ZCM
MM&Y<+BZVQ0LH*EN+4$H0D;RI1V#_`,=PVQV-IM%TOUS8LMDIWJN[U+@;:9:0
M5N.+5N2E*02>L[@-I(`)B<W;#VCV)F4?=VYN2=J/7!$W*&+K9?\`HJ+(IM#E
M2NJY&IA77<<OYQLR,0A-=!6,("%0OU'[TSX><M>G3:0RDR-8\F95ULM*V`="
MW)D_`$6D:(?=]T0I6<@UM>6NK6`H6RF<Y4(X@5-0@\RU2ES-LE*4[BXJ(TM[
M:F$V^X"Y+<P!;$+;=@V8S96J<\"==5A/7)'&7&>ETU5W+H5B$=*@U*H4VBGH
MXFXZ@(R(T<3F#F"T]PSBI>J+W6+4\.UD%-M*EV2"`!*8'/*6SF`X1"KO/*TT
M9U<K;+I10TM%BUL;12J]7GV;]2V5%]T$J5S<JE!KF!\;LRK;,&-2:VE$>X^A
M$1,I/RL9!0;!U*S4R_:1<3&,4C+O)"1?+$;M&C9$@"919=90"@`>S[%<>JJJ
M:AI7*VM6EJC90I:UJ,DI0D34HG@`!',MUNK[O<&+3:F5U%SJGD---($UN..*
M"4(2!O*E$#_^$6O]L6(+4V-;7GSZ^GC1G)L(M[D/+4ZD!%!-*>BE,6&:'#07
M1(=L";%J0!]V7U$O%2JP]1LJNFL^I"&;*A:Z=;J:6B;.SQ)^6KH*S-Q9\U.P
M[$Q?EHAIY8.Z]H>X_D[K;=8TPNONKXD9N\D^R2?.#20EAH3\=>T;5Q'7D/<?
MFO+\7;^6<HY=OK:MMWR'.RD'B.U\46H_N?)%[$BA`%)"0=QQFSYLFZT\Q83@
MDHKJ5!$Q0`YM]V'3_#\4JG\7QJU4639[0,H<KGJUY+-)3\_FH2N:5%/%,I@;
M5K!V"(F6:Q:D:AT%)J!G&0W3`](+Q5N,6FEM=*Y4W*M#?]8ZML<Z`N4TJGRJ
M5L;;*9+5YV#<&3"R[XVTC>/E+)&1K?8.+A=[?=RMM3,;+WM#L4P6?DMSXS<'
M3@K8IC%2(9!73B10OC7B^4..&E0-4<3MMOQ]]8:3=+2ZVM%.XHR3VO8[A.0F
M>8=*3'OBMVS9-Q=]@6HU\O69T;2JA=@R2G>;=K64`%?JYJ0E1/+,@)*#Q"T[
MXW"^LHLG^S-_2[\6'7]+/QC_`*,OZ'^=7UA_2GT]/0N;D]+]0\O\IYN3K\GN
M&G5XUJG^'N\>T7]U?64?NOZOZYZ_LY/4I^5\'M/,E/EGX_DQ(/\`C,QGV)^T
M/U%W]^O7?JSZIF>U^M-W9;N;L9?&3ES\OQ?])$FE1TB:T*0A2$*0A2$*0A2$
M8;S%N"P[@.']<96ON%M8JJ1U&$4LMZ7<,N)>;1.)@&8+2CX3&+R\Q4P2*/MC
M%#40RW$\%RS-ZOU3&*)ZI(,E+`Y6D=:W520GID3,\`8UQJ)JWIUI3;Q<<\NM
M-0)4"6VU*YGW=^QIA',ZYM$IA/*#Y1`B$G<+W=[WN7TZW=O5NA8D,<%6_P`>
M+G1;25W.DAYB`O%1`"M$0(F*.I3*B[6#@/F&\)BX'W5K/;N2OSRH]=JQ(^KL
MDH82>A;FQ;G6$\B?"(K-U>^\*R.\=K9](*+ZLMYFGUVJ2ERJ4-HYFF9J:9GP
M+A=4-\DG=$1=EX79?DXZN6]KEF[LN!Z<RCJ8N"2=2C]03#J)06=**"BD'D3)
MRIE#@```5*FUVFUV.B3;K-3LTM`@2#;2`A(]P`3/69D\3%>F0Y)D.6W1=[RB
MMJKA=W#-3M0XIU9GP!43RCH2F21N``CKE=A'20I"%(1P(@`:B(`'LCPIOW1X
M)`$SNC<'!.Q;<?N`,S?VQ9#FV[1="0PWS>Y5[?M\S<Q@`R\<FNB,K-@!1U#T
M5!0AOX85JC-=:=/\&"V;C6)J+JG_`.WIY.NSZ%D'D;_GJ!ZHD5I7W6M9-6BW
M566V+H<><D?7:WF88*2?*;21VK_5V2"D_"$36X$[4^!\9`SF<G*N<S78D5-4
MR,ND:,LADY+H8?1;<05,I)%(?P,]65*8`UZ85#[-^\WFV1E=)C@3:+69B;9Y
MZA0_*=(DF?\`9I21\(Q9AI1W#=*L([.Y9J5Y)?T@&3X[.C0K\BF23SR.XOK<
M!W\@B3>)B8J!CFL/!1D="Q#%(J#*+B63:.CFB)`T*DV9,TT6Z)"AX`4H!4<Z
MJJJJZH55UKCCU4LS4M:BM2CTE2B23X3$VJ"WT%JHV[?;&&::@:2$H;:0EMM"
M1N"4)`2D=0`$>P[=M&#1T_?NF[)BQ;K/'KUVLFW:M&C9,RSARY<*F*D@W02(
M)CG,(%*4!$:]&FG7W4L,)4MY:@E*4@E2E$R``&TDG8`-YC[5%0Q24ZZNJ6AN
ME:05K6HA*4)2)J4I1D$I2`223(`3,0:YZ[O[Z"OB1MW`EEVS<MJ0KE1D>];L
M6DSEN1R@<2+.H.-8*L_18?G`0256.91<H`<"E*(!4S<([J;5;9FZ_-ZRHIKF
M\D*]79"/B@=P<6H*FY+RDI`"=TR1%7VJ_P!X<]:<H>LVE5MHZZQ4RR@UE4IR
M50I)DI3#;?*0S/8E:R5+ES!(!$;+;)^XQ';FKH=8SONUHZQ<B&9+R=NC#OW3
MRW[J:LB=20:-BOB>EQ\NR0**W2,=0BJ0&$H@)!`=>:PZ`U&G-M3D5EJ7*VP<
MX0[SI"765*V)4KE/*I"CXLP`4JE,;9QNKNS]\6AUNO;F%Y/0LVK,.R4ZQV3B
MEL52$";B4<X"D.H3XY02H*3,I,TD1)Y4<8F["D(4A"D(4A"D(4A&C6[[?3C7
M:U$N(=-1K>>7'K0%(6P6;H`]7@X*/H\O=SI$#^J(L@>>5(='+K3E3*!1%0NY
M]*M%LAU*JDU:@JDQ9"I.5*D^5+>AA)EVB^!/D(WJ)(Y3%[O"]Z/"M"[<J@"D
M7+/W439H$+VH"MSM4H3[%H;PD_&.;`@2)6FL'F',^1L\7J_O[)MPN)Z<>"=-
MJD(F1BH./%0RB,1`QP&,C&QK?F\TA=3''SCF,81&K'L3Q"P839T6/'&$L42-
MJCO6XJ4BXZO>M9Z3L&X`#9%'VH^I>9:KY,[E>;5:ZJY+F$)W,L-SF&6&YR;;
M3T#QE'QEE2ML8LK)HP*`B`!J/``XB(^`!2&[:=T2K[$>W?-9P<Q65\Q,'T#A
MY!5-Y"P:Q564SD@R1@.F*0&`BS"T1,'NCC@=X'F(Z$$5`C)K7KW1X:V[C&)K
M0_EA!2XX)*;I)[Y\%/\`0G<WO7MDF)[=U7N?7'4UVGS_`%':<I=/$J"V*=4T
M/7&1F#P+='/>O8I[R6Y()7%D^,C(V%CF,/#L&<5$Q;1!A&QL>W2:,6#)JF5)
MNT:-4"D10;H)%`I2E````JO6IJ:BLJ%U=6M;M4XHJ6M1*E*43,J43M))VDF+
MGZ*BH[;1M6^W--L4##:4-MMI"$(0D22E"4@!*4@`````1[U?&.5"D(4A"D(4
MA"D(4A&`=T.:66W[!>0,H+G1]8PT.HSMAJL(:2%VRVK"WVA2#^<`'RH*J`&H
M]%(X^2LYTVQ![.LTH<;0#ZN\Z%/*'F,(\9U75XHY1^41&I]<-2J;232Z[YP\
M4^MTM,4TR%?UE4[\6PCK^,4%*'P$J/"*;DW-S%RS,I<5PR3N9GIQ\XDY>6?K
M'</9!^[4,LX<.%U!,<YCJ&'0-="AH`:``!5M-'1TENI&K?0-H9H64!#:$B24
MI2)``#J_#O,?G'NETN5\N=1>KP\Y4W:J=4Z\ZX2I;BUF:E*)VG:=G`"0&P1G
M/:2RE'^Z';^VAE%4I$V6+.5162,<IT46\JDX>JB8@"8$DV"2HJ<!U3U`>&M8
M7JD]3,:;7URK`+'U6^"#Q)00D;>)41+KE&T.[[35M7KGB+-O)35_7]&01O"4
MNA2SLX!L**NE,P=D7+S>V'3PU']^JD1NC]($<4A"D(T>WM;R[:VK6.=O'J,9
MK+MSLU2V3:JAP4*S3.8R![JGTB#S(PL<H`B0AM#.UB@F3ASF+N71W2.XZF7D
M+?"V<5IECUAX;.;CV+1XN+&\[D)\8\`8P]YGO'V30?&"W3%NJS^M;(HJ4F?*
M-J34O@;4L-G<#(NK'(GSE)JFW;=EQWW<TW>-WS#R?N:XY!Q*3,N_5,JY>O')
MQ,<YA$=$TDPT(FF70B290*4`*`!5F]KM=OLEN9M-I:0Q;J=L(;;2)!*1_*3O
M).TDDG:8H7R'(+UE=\JLDR.I=J[Y6O*=>=<,U+6HS]Q(W)2))2D!*0`(Z]7/
MCIHVSVA[3;RW69#3@8LKB'L.`6:NK_O04A%O#QZAQ.6+CS'#INKCE4TS%;(A
MJ"8:JJ:$+QU=JKJA:-,K":VHY7;X^%"EIY[5J'GKXAI!(*CQ\E.T[)`]WC0#
M(]><O3;*0.4V)4BTJKZR7BM(.T--D[%5#H!"$[>03<7)(VVQ\=8[LK$%CP=@
MV)$-+=M*V&'H[-J02E\T@"H[D9%V?0SI^\4YEG#A0>8YQ$1'3PJ_O]_O&5WE
MZ^7MU51=:E<U*/X$I0GS4I$DI2-@$A%^N'8?C6GF,4N*8M3MT>/T+7*A`Z!M
M4MQ1VJ6LS6XM1FI1))BM+W&=WH[B,D_$BRI,ZN(,</G+6).@82M;ON=(RK62
MNLX!H*[)(O,WC^;@"/,H``*M6':`:5#`L>^N;PV!E=P0"N?E,,F2D,]2CY3L
MO.DF?BQ2QWR.\-[7\R&+8R^5:>V9U26RG8FKJ@2ARI/PFTB;;$]G+S.``KB-
M^I!Q#"-U=ANVMQN2SK#QDDT%3'UC'97=D%P<!Z"\<V=@,9;P&TT,XN)^CTA+
MX^C$6-^36G];=0T:>X4[44ZI7VM"F*4#>%%/CN^!I)G/X90.,29[J.B[NLVJ
ME/25S?-B-J**NO)\E2$K^*I^@JJ'!(CY-+AX1;<3321331133111(1)%%(A4
MTD4DR@1-)),@%(1-,A0`H````!56JE*6HK625DS).TDG>2>DQ^@-"$-(#;20
MEM(``````V``#8`!L`$==O&\;8Q_:\Y>EYS+*WK7MQ@M)S,Q(*@DV9M$"ZF$
M1'SE5E3:$33*`G54,!2@)A`*["TVFXWVY,VBT,K?N50X$-MI$RI1_D`WDG8`
M"20!'49%D5DQ*QU629'4M4EDHV5.O.N&24(2-I/23N2D34I1"4@D@15)WI[R
M;IW5WN)6QGT%B>VG2R=E6B=02&<"!C)C<]P))F%-><?I\2D'F*T2'ID\[G,:
MSC2#22VZ96:;G(_E%0D&H?`W<>Q:)VAM)WG85J\8[)`4+=Y?O'WO7G)N2F[6
MEP"B611TI,BL[O6:@`R+RQY*=H:1XH))4HZ35N*(QQV:S;-NC(5T0EE65"/;
MBNFXWZ,;#P\>F*CATZ6-IJ8?:(-D":G66.)4T4RF.80*`C777:[6VQ6UZ\7A
MY%/;:=!6XXHR``_&2=R4B942`!,QW>-XW?<OOM+C.,TSE9?:QT-LM($U*4>)
M.Y*4CQEK5)*$@J40!%I797LALS:K:Y;CN((NX<PRK$RMRW@L1,6=L-#H@HYM
M^V%G`?R*-;%*/I+OS%'1@$3"5,"D"M75_62[ZFW+ZOM_:4^)M+DRP">9Y0,@
MZ\!Y2SYB-H1N$U3)O5[M?=CQK0:Q_7%U[&LU#J&9U-8H#DIT$34Q3%7]&TG^
ML<V*=()5),DC2+?AW+&"[&>PMMRE_2C.TUHJ\<K1RP@V(W4`Z,A!V2L70ZRI
MPU27D@'D`!,5#F_.!N/1/N\/H?8R_/VN5*"%L42QXQ(VI<J!P`WI:WG85R\F
M(R=ZCOJ4:J2KTVT<J.T><!:J[HVKQ$I,PXS1J'E+/DJJ!XJ1,-<QDL00_P#Z
MB(B.HB(\1$1'B(B-38BJK^6.0`3"4I2F,8QBE*4I1,<YS"!2D(4H"8QS&$``
M``1$1T"O!(`F=@$>0"2``2HF0`VDD[``!M))V`#:3%B;MK[%5\:M6.?\P0P)
M7]*LP5L"U9%#W>RHIXD(#/2;=0/<;GE&ZFB28AS,VYN.BIQ`D".\+K2C(G%X
M-BCT[$TN52\@[*A:3_1H(WLH(VG<XK\D"=Q'<O[K3N$4[>J^HE-RY?4-SH:9
MP;:)E8_IG$D>+5.I,@#M9;,MBU*Y=K.X[;MP7-LWS"RMQ%PY=LF$--OFC4#F
M6<PT-.Q[Z6T33`153:M4A<'`>'(B(^2M8]W^OH+=JU:7K@4I:6XXVE2MP<<;
M4E&W@5*/*.M0C?'?(L]WO?=SR.ELR5N5#;+3RT)F5*99?;<=V#>$H27%#X*"
M>$1_[F+@A,GX8[;CK%5PH6^A(WK;-MPLU'((2*EG7#'Q<##N`58&,1-1_;TJ
MB(G04$H'$@?DF`1WCIY0UF-Y=J"WD].I];=$\ZXVLE'K#2EN."2MI"74'8H3
ME/I$HBGK3=[9G6G.C51@%:BC:?N]+3L/MI2Z:-]#++)FV2`5T[H/,VHB93T$
M&.Z;4X253WNY#'=ED*?F-P^)K<D6^.%Y4L5#6=<6-W#1P9[=469NT:&7,WBW
M)W`I&,!$DU5#&U.B<"]3J;64QT=H/9?0L-8'=*A)JPCG<?:JPH<K*YJ5*:P$
M@@344I`V*3/(-"+97#O,7<Z^7>JJ=7[!1N(MI<#3%'46U:%<]4SRI25$-E2U
M))Y4)4HF:FU\NA'K:'_M-?VCO0C?V>/[;7-ZZ]'/ZBY_2_6/K7H\GHW0]%_E
M'-X:>;6[_5JOV<^S[G__`-]_<[^CF.T\GEY)[Y\WBR]V(I^OV[VV^V;LS[(?
M:A_3R/83YN?M92Y>7E\?FW>;.+4E5H1>M"D(4A"D(4A&.,H9>QIA>VU[LR?>
M,-9\(D4_25DW(`[D%2!KZ+$QJ0*2$J\/J``F@F<W'CH'&L@QO%<AR^X)M>-T
MCU76'>$#Q4CX2UF24)ZU$",-SC4'"]-[*O(,WN--;K8F<E.JDI9'F--B;CJS
MP0VE2NJ(.=R/=TNFX!?6QMNA#VA$&ZC<^1+H:-W5T/4Q`2"M!6^IUXZ"(8!'
ME5<BY7TT$")F\)F:?=UBVT/)<M07A5U6P^JLJ(92>AQT24YUA'(G\I0BKW6;
M[P>^W8NV31FE-OMQFDW"J0E52L;IL4YFVS/@IWM%RD>1!B'2Y;GN.\IM[<EW
M3TQ<]P22AE7\U/2#J4DG1S#S#U';Q157D`?:D`0(4.```5+*W6VWVBC1;K4P
MU34#8DEMM"4('@2D`3Z3O/$Q73>KY>LDN;MZR&KJ:Z[O&:WGW%.N*)V[5+),
MN@"0&X`"/AUS8ZJ%(0I".2E,<Y$R%,=10Y4TTR%$ZBBAQT(FF0H"8YS".@``
M"(C7@D`%1V)`F2=P'23PCRD*6H(0"5J(``$R2=P`&TD\`-L;^X![;NXW.)6,
MR_A4\5V0[$#_`!FOI%PUD7+?0I@4B+3("<T^ZI!]S.L#9`W_`!FE:-SCO!Z?
MX:5TC#QN=Y3L[&F(*`>A;^UM,N(3SJ'P8EKI/W,-9-3@U<:VF38<9<V^L5H4
MEU2>EJD$GES'DE?9(/PHF_V_=N3;G@GU?,.8$<G7VSZ:WQNOI%!\BT>$X]:#
MMD`-"10%/Q(8Q%W!=/SM0VSK7_/\UYZ1M_ZNLJYCL*8E)4GH<>_I%]8!2@_!
MBSK23N<:.Z6=C<7J0WO*6Y'UNN"5A*QYS%-_0M?DDI6X/E(WW```"E``*4I0
M*4I0`I2E*&A2E*&@%*`>`!PK2&\S.^)7``#E&P"%(\P`-1T#Q'A2$5]NYQO?
M-=#Z5VVXFF-;8C5O1<IW-&N!Y;@DVZ@">RX]RB;12&C52!Z><IA*Y7#H^T(?
MGG5W<]&A;66M0LH9_P#<G!.C96/Z)!'_`-0H'<XH?T0.U*?'WD2J0[[O>=7>
M:JHT7P&I_P#96CRW2I:4?CW`=M$VH;VD$#U@@D.+^*\E*^:%2I@Q6?$Q?:*P
M!*W)DR8W`RS=5O:U@-']N6RJHF)23-WS33T>0,W.(EYT(*'6,"A@U#JN2E\0
M-I$WO49S36_'6<%I5!5RKEI=>`/]&PVJ:)];C@V#X*">(BQG[O?2:OO&9U.K
M=P0I%CM33E-3$@R>JGD\KA2=DTL,DA1$QSN!.\&5BFH#1<-"D(4A"D(4A'@J
MJD@DJNLHFB@BF=9998Y4DD4DRB=1554XE(FFF0!$QC"```:C7LE*EJ"$`E9,
M@!M))W`#B3'HM:&T*<<(2VD$DDR``VDDG8`!M),0L;S>Z/%VP66QGMI?-9NY
MBBM'3F4Q2(Z@H$VATG+>SDU-4IJ72-P]-.4S-$P")`6-Q++W2/NV5-R[+(M0
MT*9MQDMNCGRNN\07SO;0?DQ)Q0WE`WUK=Y+OS4-A]8PC19QNJOHFV_<Y!=.P
M=H4FD!V/O).SM2"R@^3VAW0"RTM*STI(3<Y)/YF9E72SZ3EI1TL^D9!XX.)U
MG3QXY.HNX74,.HF,81_P5.6EI::AID4=$VAFD:2$H0A(2A*1N"4B0`'0(J8N
M%PK[M7/7.Z/NU-RJ'"MUUU:EN.+49E2UJ)4HD\28^?7WCAQYIIJ+*)HHIJ++
M+*$11113.JLLLJ8"))(I)@91550Y@*4I0$3".@!K7JI24)*UD!`!)),@`-I)
M)V``;R=T>[;;CKB66DJ6\M02E*02I2B9!*0)DDG8`!,G8(G"V/=L5S(*0^6]
MR\09M&E]'D[5Q*[YB.GIRG*LVD[\3#\PRY2@9.,`>=74!<<I0Z1H:ZR]XYMA
M+N+:=N\U09H>K4[DB4BBF/%7`O;A_5S/C"S_`+L/<A?J7:;4#6JGY*0<KE+:
ME^4L@@I<KAN".*:;>HR+T@.S5/6BBBW11;MT4F[=NDF@W;H)D10001(":2**
M28%32223*!2E*``4`T"H1*4I:RXLE3BB223,DG:22=I).\Q:TVVVRVEEI(2T
MA("4@```"0``V``;`!L`C]*]8]X^?+2T5`QCZ:G))A#0\6V4>24K*.T&,>P:
M(E$RKAV\<G30;HIE#43&,`5]Z6EJ:ZI11T3:W:MQ02A"$E2E*.X)2)DD]`CB
M5]?0VNB=N-S>:I[>P@K<=<4E#:$)VE2UJ(2E(&\D@1$3GKN\8WLQ^\M[!]IJ
M93D6BBB"MVS#M>!LDJR8\HC&))(GFI]'4-.H`-$A#B0YPJ5.#]U;(+NPBOS.
MJ%LIU`$,(2'*B1^&20VT>KQU=(!BO;5C[PG#,9JW+/IA0&_5C9*35NK+%$%#
MY.22]4)_*`:0=Z5J$:+ON[ONM<.E5F4?B6.;'-JFS"SY5YT2_P`'TE:YR**?
MC$`K=+/=7TQ;:"'EW1QP;U=NA,_<#)`B+-5]X1KT\^IRF9L#+!.Q'JCRY?SC
M4@GW1&?<1=Y.<3D6D?G/&$6YB%3D2<W/CI=TUD6)!$`,Z6MJ7<.D)`A>(B1%
MVB<`\`,/`<&RKNE42J=;^&7)Q-4`2&:H)*5?DAYL`I/6I"ATR$;:T\^\<N:*
MQNCU1LC"K>H@*J;>I27$=*U4SRE!P=(0ZD@;@H[(FUQKDVQ,OV?%7[CFXV%T
M6O,)B9K(,3B!D5R:`X8/VJ@$<Q\BT./*J@L4BA!\0T$!&'60XY>L4NSMDR"G
M737)H^,E7$<%)(V*0K>E220>F+-L,S7%]0L=I\JP^L:KK'4IFAQ!W$>4A:3)
M3;B#L6A8"DG>([Y721E4*0B`+O%9M]8W'8.`8AV!FUO-@OZ\4TCCH,O)D696
MTP<%X!S-(T%G.G$/Y00>`EJ<O=.P[L+?79S5)^,?5ZLP3\!$E/*'YR^5'\T]
M,5,_>+ZF^MW>TZ2V]SXFE0*^L`/]8X%(IFU#\E'.[Q'QB#L*8A(J8T5C1)UV
MG,:FO/=`6\'#<%8W%EIR]P"H<!Y234T0;=B`(;B`JE2?.3<OCH&ODJ./>?R(
M6C3CZI;5*HN=4AJ7]FW\:OW)I0/Q<8G!W!,*_>76XY&^CFHK%0.OS/!Y_P#N
M[4CNF$K=,NC;PBSU5<47?PI"-7=U^Z:RMJV.5[LG^G+73+==A8MFIKE3>W%,
ME3U!1;351K!QW,"CMQIH4NA"ZJ'*`[)TPTTO&IF0)M=#-JVM254U!$TM-SX<
M%.*W(3Q.T^*"8T;KWKIC6A&&+R&[RJ+V_-NBHPH!=0]+CQ2RWY3KDO%3(":U
M)!J59.R;>N8KYG\BY!F5YRZ+C=F<O'2HB"#5$-2M(N-;Z]-C%1R&B3=`@`4A
M`]D1$;1L<QVSXG96+!8F4LVVG1)(&]1\Y:SO4M9VJ4=I/5*/S_9QF^2ZBY35
MYCEM2JJOE8X5*4?)0GS&FD[D--I\5M"9``=))/0J[R,3C/.W+;S?>Y?)49CN
MR&PI$-TWUSW(X24/%6E;Q52D=S$B<H:&4T$2-D`$#N%Q`A>&HAA&?YY9-.\>
M<OUY5-6U++((YWW9>*A(Z.*U;DIF3P!VOHUH_E6MF:,XCC*.5O8NJJ5`]E2T
M\Y*=6>*CM#3>]Q<DC9,BW!@_"EB[?L<P>-,?QY6D1$(@=Z_5(GZSN&85(7UA
M/S3@A0%S(R"I=1$?-3(!4R`!"E`*M,RS&]9U?WLBOKG/5.F24CR&FQY#38X(
M2/PF:C,DF/T#Z8:9XMI)AU+A>),]G;J=,UK,NT?=,NT?>4/*<<.TG<D20F24
M@".7ND[N?Z,[,'`5@RID<@7]'@>\WS)7E<6O8KHAR'9`HF8%&\M=6G3+X&39
M@H;\L@UO_NUZ6?O'=_WXOC058J%R3"5#8]4CSI'84,[SP+G*/-,0Y[]'>"5@
M^-C2G$ZCDRV[,SJUH/C4U"H$%,QM2[5>2GB&@M7G),5P``````-``-``/``#
MP"K`XIG``$ANC]44%W*Z+9J@JY=.5DF[9L@05%W#A=0J2""*9=3*++*G`I2A
MQ$P@%>JUH;07'"$MI!))V``"9)/``;28^C33U0ZBGIT*<J'%!*$I$U*4H@)2
MD#>5$@`<28MQ;%-MB&VK!4)!R31-/(%X`WNS(;G0#+$F7C<OHD""@``BUMQB
M8J!0XAUA5-^5566M6H2]0\U>K:=9-BI9LTHX=FD^,Y+X3JIJ/Y/*.$?H,[K>
MC#6BVEE+::QL#+:\)JK@KCVRTCE8G\&G1)L#=S<ZAY4;DK+(MT5G#A9)NW;I
M*+N'"ZA4D$$$2&46665.)2))))E$QC"(`4`U&M2H0MQ8;;!4XH@``3))V``#
M:23N$2,<<;9;4ZZI*&D))4I1```$R23L``VDG8!%8+N);UW&X:[E<:8^DE"X
M7LN3-TW#<QTB7]<;,3(J7`Y#4!5A6!^8D<F;@8!%<0U,0"V/Z!Z/HP.U#(KZ
MV/WOK&]H.WU9I6T-#H<4)%TC=L0-QG1]WP^\P[J[D*L)Q!\^S:VO>4G8*^I1
M,%]72PV9BG2?*VND3*0F,RI%1"2/=C8V1F9%A$1#%W*2TJ\;1\9&L4#N7K]^
M\5(@U9M&Z0&46<.%C@4I0#41&OC45%/24ZZNK6EJE:05+6H@)2E(FI2B=@`&
MTF.514-;<ZUJW6UIQ^X5#B6VFFTE2W'%D)2A"1M*E$@`"+-^S#:K8FRK%\AE
MW-$I;\+DB8A_2+LN2;>M4HRPH0Y/20M*'=JFY%'Q^0/3%$>95TN`))@8A2@:
MN;5W4R]ZP9(WBV(M/O8^T[)AIM*BNI<G+MW$CS?DPK8A/C*D297<]VW0?%N[
M3@[V?ZCOTE/F=13<]74O+2&J%F7-ZJRLF7-N[929J=<`0B:4I!CHWR]R&5S6
MC)8IPDM)6WBE0QVT_<Y^O'7%D%(`$JC,B.I%X6U%!UU1$0</"_G>0@],=_:,
M=WVFP];>3YBENHR<;6F=BFJ4\%$[G'_RO);/DS5XT0Y[T??+KM2VW\!TR6]1
MX&?%J*KQFWZ\<4)&Q3-*>*3)QX>7RH/(8F@````````#0`#@``'@`!Y`"I0[
M]IWQ`(``2&Z/(I3G.1-,AU%%#D3333(911110P$3333(`G444.8`*4`$1$=`
MXUX)"05*("0)DG8`!O)/`#B8]DI4M0;;!4XH@``$DDF0``VDD[`!M)V")^NW
MQVZQMP\)G?/T,F>?*#:6Q[CJ02$Y8(3%ZK6Y;M:JEZ:DP`&*=HR,!BM1T44U
M5Y2D@WKMK[]8)>PK!GCZB9HJJM)_I.!:8(W-[PMP;5^2GQ9E5L_='[G1LBZ;
M5+5JF2;P.5V@MZQ,4^R::BJ2=A>XM,F8:V+7-R01-:]D6$<F5>2?LH](YP(5
M5^[;LTSG-P`I3N%$RF,(^`!4/F6'ZA7)3H6M0&Y*2H_B!BRZHJZ6C0'*MUMI
MLF0*U!(GT341MC]%4FK]HJ@NFW?,'S=5!9)0J;EF\:.$S)+(J$'G1<-UTCB4
MP#J4Q1$!KU2IUAT+05(>0H$$3"DJ!F".((.T<1'LXVQ5L*:<"'*9Q!!!`4E2
M5"1!&T$$&1&XB(MIW87E/$MX2=X[-\MP=CPTO)GFW>(LFP*5U6,PEC&YS.K;
M6<LI0T4?FX)B5!-RB0`*#D2@4H24HM;<9RBTMVG5JU/5M8TWV::ZD=+-2I'P
M70%(YQTS44*.TMSF3!FZ=U7.\`R)_(N[ED--:[;4OE]=IN3`JJ%#N_GIBI#I
M:,]B2$)<0F20]R@`>A<6TG>CN"=HQFXS/>.K8L?E*WF(_#=HIM+HN".#458Q
M6?>1S-XV8N"',0Q#N5D``PB*!]1K[T&J.D."-&IP"QU]3>M[:J]_F9:5P6&D
MJ4DJ&P@A"5="Q'#N_=_[R>K=0BAUBRRT46+2Y7F[/2<E54-\6C4+;2M"%`E)
M!<6C:9M*G&[_`/9>PC_07_9R^);/^BSU;Z#ZJYA]8>F\_I'QD]:\OI7QG]._
ME'IFO/U?)R>96F_:3F7[Z?O_`.N+_>;M.;G\WEW=ER>3V/+XG9[N7KVQ)[V'
M:8^R[V._5C7[B=AV?8^?SSYO6.U\KUGM/C.V\KG_`"?%C8"L%C;4*0A2$>G(
MR,?#L'DK+/V47%QS=1V_DI%TBR8,FJ11,JX=NW)TT&Z*90U$QC``!7UIZ=^J
M?134J%N5+B@E*$@J4HG<$I$R2>@".-5UE);Z5RMKW6V*)I)4MQQ00A"1O4I2
MB$I`XDD`1#MN@[LMH6AZRL_;DQ;7U<J8JM%\@RR2@65%+%$2'4@V6J3NZ%TQ
M]HJ846?,&H"J'"I8Z;]U^[77L[MGZU45N,E"E01ZPL=#BMJ60>(\9<N"3MBN
MS7+O]XYCG;8[H\TW=;XDE"JYT'U)H[B64[%U2@=Q\1F8GS.#9$#V2<IY#S!<
MSJ\,EW=,WA<#HQQ!W+.C*HLDCB(@TBF)>1E%,4_`J+=-,@``<*FSCV-6'%+<
MFU8[2LTE"GS4"14?A+5Y2U'BI1)BJK-<\S'46]KR'-KA4W&ZK)DIU4TM@^8T
MV)-M(&X(;2D2CH-=Y&(PI"%(1YI)*KJI-T$E5W"ZA$4$$$SK+KK*#RD2113*
M9154X\`*4!$1KU4I*$%Q9"6TB9),@`.))V`=9CW;;<>=2PRE2WUJ`2E(*E*)
MW!*1,DG@`"8D;V^=L?<#F<K&=NQHEA^R7/17"3NYJL:YI!HIRFYXBTTQ3>%$
MZ0ZE.].U)X<#>%:`SOO&X+B)716M1NUX3,<C!'8I4/AO[4[]X;"SX(F5I'W(
M-6M1PU=,B0G'<97)7/5))JG$&1^*I00I,QM!?4T.HQ.9M]V(;>MNY&DC`6L2
M[;V0(7J7Y>J;:8FBK`(&,I%-#I!%0(<X>;Z,B54`X"H:H89WK7GF>E5/75)I
M;.H[*:GFVW+H69\[G7SJ(Z$B+1=(^ZSI%H^ANKLU`FNR5`VUU8$O/SZ6P1V;
M`GN[)"5<"HQN6(B/$1$1_#6I(D;'%(0I"%(1&;W(-X8;?\?ACFQ),J67\B1Z
MZ35PV.`N++M17G;/KD.("/H\H]'F0CP$->?G5_BPUD3W?M)SG5]^O[TV3BE`
MX"H'=4/"12UUH3Y3LN$D^<90I[Y7>)3I'B/[H8N^!J'>&5!!3M51TQFERI/P
M7%;4,#?S<R_,VU?C&,<QCG.=10YC'444,8ZBASB)CJ*',(F.<YA$1$1$1$=1
MJR$``2```W`;@.@=44;DJ42I1)62223,DG:22=I).TD[S'>L8XYN;+F0+3QK
M9S7TNXKPF6L.P`0$46H+&$SN1=F`!Z;&,9D476,/`J:8UTN1Y!;L5L55D-V5
MRT%(T5JZ3+R4)Z5+40E(Z3&58-AE\U#RZWX5CB.>\7&H2TB?DH!VK<6>"&D!
M2UG@E)BY/A7$UMX-Q=9V+;52(6+M2(09*.P2(FM+2APZTM-.^4/.=2L@<ZQA
M$1$.8"^`!52F7Y1<,SR2KR6YDFIJG2H)G,(1N0VG\E"9)'@GO,?H[TVP*S:8
MX/;L&L*0*"WTZ4<T@"ZYO=>7+>MUPJ6J<]\MP$92K&HSF%(0I"%(1C/+.8L<
M8.M![?.3[G86S`M"G*B9R?GD)9V4@F3C(2-3U=RLDN.@$22*(AKJ82EU$,BQ
M?$\@S*ZHLV.4SE37+(G(>*A/%;BSXJ$#BI1'0)G9&%9[J'AVF6/.Y/FU<S0V
MEH&16?'<5*8;9;'CNN*W)0@$[9F0F16WWA]Q7(>XP[^RK'"1QUAXQQ1/$(.>
ME<MXHD-P6NQ^T4Y4F*HAS%CT#=$`TZIE1\+!])]`K#@`;O%Z[.ORP"861-E@
M]#*5#:H?*J'-\$)BF/O%=\7+]85/8QBO;6?3LGE+85*IK$CC4K2?%;.\4Z#R
MR_I%+.Z-\```T`-`#@`!X!4@HAB`!L&Z%(1VZQ;#O')MU1-DV%;TE=%TS:X(
M1\1%H"LL?B'4<+J#RHLV3<OG*KJF(DD4-3&"NJO5[M..6QV\7Q]NFMK(FI:S
M(=0`WJ4=R4I!43L`C(<5Q/),XOS&,8G1O5U]J5<K;38F>M2CY*$)WJ6LA*1,
MDQ9'V5]N.TL`!'9$RH6*OC,()IN&*0)@[MBP%C%UY(,BY.63G4@'E-('(`)C
MJ"!2AYYJ^-7]?[IG)<L.-=K18G,A6WE>J1_:$'Q&SO#0.WSR=PN?[M/<XQ_2
M,,Y?F_8734;E"D;.:FH21NIPH>.\-QJ%)!!GV02/&,G]1PB;\*0C#^<,ZXXV
M\V(^R!DN9+&Q3<1;QT<V!-Q.7%)F*)D8B!CC*)G>OE?$>)4TB:G4,4H"-97A
MN%Y!GE[18L=9[2J5M4H[&VD<5NKD>5(]TD[$@G9&O-3M4<-TBQ9W+<UJ0Q0(
M\5M"9*>J'/-:8;F"XX>C8$B:EE*02*OF[+>[E+=-,KLGSA:T<7LW1SP./(QV
MIZ(J0AQ]'D;J<)B3U],"0`'SP]'0$1!(@<3#9#I?HWC6FE(EYE(JLD6GXRJ6
MD<PF-J&09]FCP>.KSCP%'.O_`'GLYUUN*J1]2[=@K:SV-`VL\J@#XKE4H2[=
MV4MA'9M[0A,YJ.EU;?B-,*0A2$2"]NK=`_V_YKB[;FI-9/%N4)!E;]U,55-6
M47-.C`TM^ZTB&'E069.U2HN3%XJ-5!UU$A--$Z^Z<,9SA[EPHVP<EMK:G65`
M>,ML>,ZR>D*2"I`X+'`$Q+ON<ZX5.DVIC%DNCZDX-?74,5*"?$:?5XE/5`'8
MDI40VZ1Y3:MLRA,6L!#01#V*K*B^2/2D9!E$1[^6DER-HZ+9.Y*0<J#H1NR8
MH*.G2YQ\A4D$C&'\5?6G8=JGT4M."I]U:4)`WE2B`D>Z2!'&K*RFM]([7UB@
MBD8;4XM1W)0A)4I1Z@D$F*6V?<IO<UYFR/E%XH8X7=<\@]C2&,)@;03<X,8%
MHGS<03;0[5$H?NCQ$:M[P;&FL/Q&WXVT)&EIDI7UN'QG5'K+BE&/S7:N9W4:
MF:EWK.7R2BOKEJ:'P6$?%L)'4EE")?A.V<8@K*XUU%C[L\XV/;N#KWR2[0!-
MWD>]/0F"AR"54T#9K8S%$Q1$.*2TL_=F`0'0P`'L57YWK\A%?F='C[2IM6^C
MYE">SM7SS'W0A*!%S'W=F&*LVEMSS&H1RU%YN7*@D;2Q2)[-)'475O$$;]G1
M$NU17BP>,-YXSI8>W?'$SDF_WW1CXX@H1<2@<GK6Y9M8IO0(&'0,.JKMXH'G
M&T$B*0&4/H4HUEN$X7>\]R!G'K$CFJ'#-:SY#38\IQ9X)2.&]1DD;3&N=4]4
M<5T@PVIS/+7N2B9'*VVG^EJ'E`]FPTGBM9XRDA,UJDE),5&]P.>KYW'9+F<D
MWTZ_E+TPM8.#;J'&*M:`1.86$'%)&'0J:)!YEE=.=PN8RA^(Z!:;@N$673_'
M6<>LJ?BT#F<<(\=YT^4XL])W)&Y*9)&Z/SZ:NZKY1K+FM3F>4+DXX>1AA)/9
M4K`/B,M`]`VK5O<65+5OD,)UF,:QC(N)\57MFN_K?QMCZ*4EKEN)V5!$NABL
MXYH00,]F)9R4IBLHJ-0U465-P``T#4P@`X_E&36?#[&_D-]=#5OITS/PEJ\U
MM`\Y:SL2!X3L!C,]/\!R;4W+:3"\28+]XJUR&_D:0-JWG5`>(TVGQE*/4!-1
M`-MK:QMDLO:WC-E9-ME2D9]\"+^][O.@";ZZ)[IZ*+"(ZJ(13'F%-FWUY4DN
M(ZG,<PU;ZEZC7?4K(EWBX3;H4333L3FEEJ>P=!6K>XK>I74`!^@30O1/&M#,
M):Q>R@/7-R3E95%(#E2_+:H\0VC:EIN<D(Z5%1/:=PV<K7V[8GNC*-TG343A
MVPMX.)%0"+W#<KPITX:#:AJ!C'=N0U4$/S:!#G'@6NMP/#+EGV44V-VP$*=5
M-Q?!II.UQQ7YHW=*B!QCO-7=3[%I!@5=G%^4"U3-R9:G)514*!#+".M:MY\U
M`4K<F*=61,@71E2^+GR'>D@>3N:[99S+RCDPF$A%%S^XLFI!$0181[<"(()A
MH5-),H`'"K8K!8K;C-FIK#:&PW;J5H(0.)EO4KI4LS4H\5$F/SI9EEU]SW**
M[,,E>+U[N%0IUQ1W"9\5M`\UMM,D-I&Q*$@1TRNXC&8E/[6>V0,M995R_=#+
MJV+B%XU<QZ*Z8&0G;^5)UXAKRJ%$BS6!0_EBP<=%11*/MJC1WE=1OW7Q<8I;
M5RO5U00H@[6Z8;%G9N+I\1/Y/.>$3P[B>B7[^Y\K4:]M!6+X\XDM!0V/5Y',
MT)'84TZ?C5;_`!RT#O,69?'B/EJNN+KXAE[J&[Y6RH(=M^/)44;INN/*YR7*
MLE>5>!M5V3^36TDLF8#H25R$'G<>`IL@Y?X[A+CNT:5)O%;[0+\U.V4KDJ1"
MAL=?3O=(.]#6Y/2YM\R*X._;WAG,7M7L<Q!_EO\`<6>:XNH/C4](L>*PD@S2
M[4B97Q2SL_K-E>4`````#0`X``>``'DJ>>^*?P`!(;H4A'>\8Y#GL39`M3)-
MKHQB]PV;+)S4.G,L_6$9Z<BFJFB=TT!1$RH)"KS%T.4Q3@!@$!`*Z3([!193
M8JK'KD7$T%6T6W"VKE7RD@F2I&4Y2,P01,'?&5X-F-UT^RZ@S6QI87=[<^'6
M@\CM&N<`@%29I)E.8DH$*`(,Q';LR[A\RY_E@E<K7W+W,5%8ZT?#"H#&VH@Q
M_$(JWV8)1K00#AS\AE1#Q.(ZC758E@6(X-2^JXQ1-4Y(`4Y+F>7+X;JIK/@F
M$]`$9%J1K%J3JW7>O9Y=7ZQ"5%3;`^+IFB?DJ=$FTGAS$*7TJ,86K,(UE'OQ
M<7)SDG'PL+'/9>8E7:#"+BHULJ\D)!\Y.";=HS:H%.LNNL<0`I2@(U\*FIIJ
M*F<K*QQ#5(T@J6M9"4H2!,J4H[``.)CET%!776N9M=K9=J;E4.);::;25N.+
M49)0A*9E2B=P'\D6+=AW;C8XE]59>SI'LI?)XE3>VS9RH)/8FP`.0IDGLB`@
M=O)7:7F'00YD60^T$RGGE@)K9K^]E/:XKA:UM8WM2\^)I74R.U*>*&.K8ISS
MI)V&X[NK=S>DT[[#4'4]IJISD@+IZ4R6U03$PI6]+E7^4)H9W()5XPW8W5[J
MK#VKV`K=%S')+75+$<MK'LINX*G(W)*ID_.*CYQV4&Q.<IG;H2B!"CRE`QS%
M*.GM,M,[WJ9?1;+<"U;6B#45!$T-(/1\)Q6T(1/:=ID`3$E=>-=L6T)Q%5^O
M9#][?"D45&E0#E2Z!^%#*)@NN2(2G8`5%(-47,F<,F9YO.4O?)%S2$Q(2#E1
M5I&E=.4X&`:"(@WBX&*ZHM8]DU2$"AREZBG$QS&,(C5G6)89CN$6AJS8]3-M
M,-I`4N0+CJN*W5RFI2CMWR&Y(`$4)ZD:I9MJODC^3YE6O/U3JR4-!:@Q3H\U
MIAJ?*A"1LF!S*,U+)428D6[5VX_)<3FN%P3(SDM<6.;RC)T64+(N%Y`EJ3$7
M'K2R$G#JN#J*QS%P1J=%P@4P(F%0I@*!@U'07>8T_P`=JL/>S6G9:I[_`$CK
M?,X@!/;MK4$%"P)!:@2%)4?&D")RB8O<1UGS6@U)I]*ZZJJ*W#K@P^6VG%*<
M]4>:070XTI1);;4$J0M`/)-22`%;[(E5]1<Q"D(4A"D(4A&IVYO>5AS:[$'&
M[Y7UY>SIL*L'CJ`707N.0$P#T7$@!C"E!11C>V<N>74->F500TK:&G6DF6ZD
MU8%J:[&SI5)RJ=!#2>D)XN+_`"$3_**1MC0>MG>-TZT-MQ5D51ZSDBT38M[!
M2JI<GN4L3DRU/>XY(2GR!9$HK<[FMZ^:=S[]5M=$K\6K"26$\9CJW%W"$"D0
MI^9%::5$Q7%QR)`TU5<>YE-^;3(%6"Z<Z/8AINP'+<WZS?"/'JG0"X>D-C<T
MCJ3M/G*,4RZW=YO4G7"J53WE_P!1Q$*FW;Z=2@S(&:5/JV*J'!TKD@'R$)C4
M*MK1':%(0I"/---195)!!-1===0J2""*9U5EE3CRD2123`RBJIS#H!2@(B/A
M7JI24)*UD)0D3))D`!O))V`=9CV0A;KB66DJ6\L@)2D$J43N"0)DD\`!,Q)'
MMU[8F><S@PG[V1##MB.>FN#^Y6AU;MDVAM#`>(M/G1<(`J0=2JOCMBZ#J!3U
M'S/N\=A.(\]#9C];7I.SE:5)A!_+?V@RZ&POK(B:.CW<>U4U(#5VRE/[N8LN
M1YZA!-8XG^RI9@HF-RGU-[-H2J)T]OFR#;]MR3:OK3M1.X+S23*"U_7@5O,W
M(94`#J*1PJ(E80)#F#VK-)(=.`F-4+<[UDSG/U*9NE46+03LIF)MM2X!4CS.
M>%Q2NH"+2M(^[)I+HVVBHQZ@359&E(YJ^JY7JDGB4$@(8!/!E*.@DQMX(B/$
M1U'V1K5<2"CBD(4A"D(4A&(,[YHM/;_BVZ,HWBN4(^`9F"/CBJ%(ZGYYR4Y(
M>`8`;43.I)V`%U`!Z:8&4'S2C65X3B%TSK):;&K2GX]]?C*EXK38VN.J_)0G
M;UF21M(C7NJ>I%@TFP:NSG(U@45(T>1$Y*?>4"&F&^E;JY)X\HFH[$F*>&6\
MIW=FO(MTY.OAYZ7<5U2)WBY"";T6.:$]RCH>.(<1%&.BF92(HE_@EU'SA$1M
M@Q;&;7A]@IL<LR.6@IF^4?"6H[5N*Z5K5-2CURW`1^=;4+/<AU.S&NS?*'.>
M[USO,0)\C2!L;9;!W-M(DE(ZIG:3&.:R",+BPIVE]K_Q7M9_N0O".$D_>3=:
M&QP@Z2,56,M$J@DE)\A%"@)5KD=)@FB<-!!JB(AP5J!_>BU(^LKDC3ZU.3H:
M10<JB#L6_+Q&]G!I)FH?#5^3%O7<!T.-AL+NLF1,RNUS;+5O2H2+5)/XQX3X
MU*@`DC^J1T+B:"HB19+"D(4A'(`(\`XC2$1R[MNXSB[;L60M"SQ99,RVF0R0
MP$>]`UN6NX$-`/=TPU,IR.$AX^@MQ,Y'30XI`.M;^TMT!R3/BBZW7GMV+DS[
M52?C7A_8-JE,'Y14D='-NB'?>`[XF"Z.I=Q^P]G>M0`)>KMK^(IR>-6\F?*1
M\BB;IW*Y!MBN#FC.F3]P%W.+SRC<SN>DC&5+',`,9O!6\S4.)@CK?B"&%M'-
M"<`$2@*J@AJH<YN-6!XAA6-X+:DVC&Z9+%/LYU;W'5#SW5[U*_T1N2`(IHU+
MU5SG5S(%9'G-:Y554SV38FEBG03/LV&I\K:1Q.U:MZU*.V,15E4:[A2$;<[7
M-F.7=TTR0UL,!MVP&CD49[)$TV5+!LNGH*S.(2U35N"8Y1T!%`>1,1`55$P\
M=6:DZNXKIK2$7%?K%]4F;=(V1VBI[E.':&F_RE;3YJ51(70ONUZ@ZZW`+LK1
MHL1;7)^XO)/8IEY2&$[#4.\.5!Y4F7:+2(LT;;MJF)MKUL#"8_B1<SC])$+E
MOB7(BO<]QKIAJ/I#HI`*QCB*:BDS0Y$4_*!C:F&NG4'4W*-2+EZY?7>6C;)[
M&G1,,M`]`\Y<MZU34>H;(NTT:T(P'0^Q&U8C3\UQ=`]8K'9*J:A0^&N7BH!\
MEI$D)Z"9J.R=:]C<T*0C"^?,\6%MSQQ+9(O]\*3%D'HL1#MC)C+W-.+$,+*#
MAT#F`57+@Q=3G'S$$@,H<0*6LOP?";YG^0-8_8D3>7M6L^0RV/*<</`#@-ZE
M22-IC6^JVJ>*:/8=49EESO)2-#E::3(NU#Q!Y&64G>I1WG<A(*U22#%3#<;N
M.R'N;R"[ON_78)(I=1I;%K,U51A+3AA4,=&.C43CH=P<!`7+DP=5RIYQN`%*
M%H>G^G]ATYL2;+9$S69*>>4!VC[DMJE'@!YB-R!L&V9-`>LVLV7ZW9<O*<I<
MY6$312TJ">QI69DA#8.]9V%QTCF<5M.P`#`59S&I([SCG&E^9;NMC9..+7E+
MMN>1`QT(R+1`XI-T].L]?.%#)M8]@WU#J+K'(F7V=1`*Z7(,BLF+6Q=YR"I;
MI;:WL*UG>3N2D":E*/!*028RK#,(RO4*_M8QA="_<+XZ"0VV/)2/*6XHD(;;
M3YRUJ"1NG.0CN^;=N&9MNTI&167+-<6V>:146AY%%XREX24Z`$%RBRF(Q9PS
M4=M04+U$1,50@"`Z:<:Z;#M0<1SZF<J<6JTU`9(#B"E2'$3W%3:P%<JI&2I$
M'=.<9/J=HQJ1H[7,4.H-N51FI22RXE:'F'.67,E#S94CG3,<R"0H`@REMC!]
M9G&KH<QT_=$CF353$%$E"")3IJD'G34(8.)3IG`!`?((4DE7BJ`*3L(Z0=X]
MV',M'CMDI<3M!&\$;01U@[1%U7;[>*F0<%XAO5=3JNKCQU:<B_4UU$9$\.U3
MD0$=1U,5\FH`CY1"J?LZM*;%F=UM"!)JGKWT)'Y`<5R?Z,H_2]I/D2LMTPQ_
M)7#S/UMGI'5G^T4RCM/P+YA&M7<DRZ.)]JM[),G(-Y_(YD,<0H%.)%@3GRJ#
M/.$M!`P]"`0<`(@("45`$/"MB=WS%?WGU,HE/)YJ&WSJG-DQ\5+LP?"Z4^&1
MC2O?-U!_<+0>ZIIU\EVO`3;V9&2O[Q,/*'YK`<G+:)@\(J?`````'``#0`_`
M%6>Q06!(2&Z!N;00(4QCB&A"E`3&,<>!2E*&HF,8W``\HT$I[=@CP>8B202K
M@!O)X`1=`VQ8_2Q;M[P]8B:0(JPEB01I`@%`NLO*-@F)@XAH`ZGDWZH\>/D&
MJB-1KZK)<[NUZ49I>K7.7\Q"N1O_`$$IC]*&BF)-X+I+CV*H`2NDM;`7_M5H
M#KQ]UU:S&1,@7_:6+;,N&_[YEV\%:ML1ZLE+2+@?:))Z%3;MT@\]R]>+&*D@
MB34ZJIRE`-1KH;%8[IDMW8L=E:4]<ZEP(0@=)WDG@E(FI2CL`!)C+LLRNP8/
MCE7E>45"*6Q4+)<=<5P`W`#>I:B0E"1M4HA(VF*EV[W===VZO(ZMPR77B+%@
M5'3+']G]411B(PY^4TE(%*/3<7#+$(4[E73S`T2)H0O&T32K3"U:98^*"GY7
M;V^`JJ?EM6OX">(:1,A`X[5':8H#[Q&ON0:\YDJZ57/3XG2*4B@I)[&FR9%U
MR6Q50Z`"M7FB3:?%3MU-K:,1^C[ELVS<%YW##6G:D2]GKDN&0;Q4+#QZ1EGD
M@_='`B*")"^'E,8PZ%(0!,80*`C7"N-QH;10/72YNH8M].V5N.*,DI2G>3_(
M!O)D!M,=K8['=\EO--CU@IW*J]5CR6F66Q-;CBC(`?RDG8E(*B0`8M;[(=G%
MO[5;#ZLB#28RS=C5LO?%R$(50K(N@+)6I!*B',E#QB@^Z'#07:X"H;@!"EK&
MUDU9KM3+WRL<S6+TJB*=K=S<"\X.+BQN'F)\4;9DWV]V3NZ6C0?$_P"]=G49
M[7H2JNJ0)\O$4S)X,M'>1(NKFM7FA.\.H``B(@```B(B(````:B(B/```/$?
M)6FM^P;XDX2`)G=%6GN2;JC9^RXI9-K/@6Q=BE\_B891NJ)FUR7.`^BSUS&Y
M1Y%4$U$S-&8^`(D,</SHU95W>],Q@V+"\W)$LDNB$K<F-K3/E-L]1((6Y^40
MGS8HN[Z&O*M6-0#BUB=G@]@><::*3--35>0]4=!2F1:9_)"E#RXCAJ0,0RCL
M5HVG/7W=-O67:S%23N.Z9AA!0K%(IC&</Y%<C=$#<H")4DQ/SJ&\"D*(CP"N
MONMTH;);*B\7)8;M],TIQQ1X)2)GW3N`XD@1W..8_=LLO]'C%A:+UYKZE##*
M!YRW%!(GT)'E*/!()BY'MTPA;^WC#]GXLM\I%!A&!5YZ3`NBL[=#XI5YZ86'
M0!'TIZ)@2`?:($(3\FJEL_S*NSW*ZO):XD=LN3:.#;*=C;8_-3OZ5%1XQ^CC
M1[3*T:0Z=V[!;0`12L@ON<7ZE?C/O'\]<^4'R4!*>$>.X[.-O[=L/7?E*>%)
M8\,R%M;T4<VAYZZ7X&0@H=,`$IC%</!`RP@.I$"'-Y*\Z?X979]EE)C5#,!Y
M<W5_)LIVN.'P)V)Z5%(XQXUBU.M.D&GEQSJ[<JO56B&&B9%^I7-+#(X^.N7,
M1N0%*X13BO2\;BR%=MQWS=T@K*W-=<N]G)I^J(B*[Y\J*IP('\6W0*()I$#@
M1(A2AP"K9K1:;?8;73V6U-AJW4K26VTC@E(EMZ2=ZCQ))C\Y>39)><PR&LRG
M(7E/WNOJ%O/+/%:S.0'!*1)*$C8E(`&Z.LUV4='"D(4A"D(R;B3#N1LYWDPL
M/&-M/+DGWIB&6!$.E'0[(RA4U96=DE`]%BHQOS:G54$-=-"`8P@4<<RG++!A
M=H7>\CJ$4]"B<I[5N*E,(;0-JUG@!X20-L9OI]ISF6J61MXM@]$Y6W5P@JEL
M:902`77W#XK3:9[5*,SN2%*D(LV;.=A&/=KS%&YI<[6^<PO&H)R%WN&W_1]O
ME5('7C+-9K@8[%$1U*H[/_*G!>&I"#R571JSK??M2'C;J4*HL40J:6`?&=EN
M6^H>4>(0/$3UGQHNY[NO=2Q#0VE3>:PHNFH3C<G*Q2?$9!'C-4B%3[-/!3A^
M-<&\I22B,Q;I-TE@;6<?KW9=:Q).XI$JS6R[*;.")RUT2I2#H4H:',SB&AA`
MSIV8O(D3@',H8I1Q/373:^:E7U-KM@+=`W)514$$H91__,M6Y"`9J/0D$C8N
MN6N6):%XDO(<@6'KJZ"FCHTJ`>JG9;`!MY6T[W72.5">E12DU/,UYJO[/V0)
M?(V198\C,R1S),V:9E"Q5OQ)#F,S@X1J8PE:1S,IO`/.5/JH<1.81JS[#\/L
M>#6)K'[`T&Z1L34HRYW5R\9QQ7G+5^`"21("*"M3=3,LU;RZHS++WR[7O&3;
M8)[*G:!\1AE)/BH3QXK5-:IJ),8GK*(U_$]_:0VQ2,0A*;FKN9JM#34<]MC&
M3-RD9-5:)673+/W4`'`IRH/5&WHC4?!1,JI_`2C4(.]+J/3U2VM.K4L+#+B7
MJQ0,P%@'LF?"D'G7T$I&\&+8/N^]$:RVL5&M>0-J;55LKIK<A0D2R5#MZK;M
MY7%)[)K@I*5JW*28G%J&<6?PI"%(1^+ERV9-G+UZX09LV:"SIX\=+)MVK1JW
M3,JX<N7"IB)(-T$B"8YS"!2E`1$=*]VVW'G$LLI4MY:@E*4@DJ),@`!M))V`
M#:3'R??8I65U-2M#=,VDJ6M1"4I2D34I2C()2D`DDD``3,0:;O\`NKBS<2F.
M]L"S=PHB99C+Y==MRN&H'Y1362L6.<%Z:YDC"(!(N"BGS!JBD8-%*F=I3W9>
MV;;O^HX4E)DINA29*Z0:E8VB?R2=LO+4-J8J\[P_?R]5>?P_0]3;CB9H=NRT
M\R`=RA1-JV+(W>L.`HG_`$:%`!<083<W,W++R$_<4M(SLY*N#NY.8EWB\A)/
MW*@ZG7=/')U%ECB(^4=`#@&@5-&CHZ.W4K=#;VFV*)I(2AM"0E"0."4B0$5;
MW6ZW.^7%Z\7JH>J[K4+*W7GEJ<<<4=Y4M1)/\@W"0CY=<F.!"D(X$0#Q\H@`
M?A$1T``]D1'P"D(D#VV]N//.?P87!*L!Q5CIR*:P75=[)PG*RK0P\5+:M<PH
M2$@"A?:+KBV;#X@<_@.B]0M?\(P;GH:9?UG?T[.Q84"A"NAY[:E,N*4\Z^!`
MWQ+;1CN;:K:LAJ[5[7U#AZY'UFK0H/.HZ::E/*XN8\E;A:;.\*5N,]^WG8QM
M^VXD;2%L6R%S7LD0O6OZ\BMY>?!7E`%#1*0HDCH!(QM="M4B*``Z&.;QJ$&>
MZT9SJ`I3%RJ?5[.3LIF)H:EPY]O,Z>M9(Z$B+8-(.Z]I+HVA%78J$5F2I&VO
MJ^5VHGQ[+Q0AA/0&DI,MBE*WQN((B/$1U'V1K4\2)CBD(4A"D(4A"D(\%%$D
M4U%EE$T444SJK++'*FDBDF43J*JJ'$")IID*(F,(@``&HUY2E2U!"`2LF0`V
MDD[@!Q)X1Z+6AM!<<(2VD$DDR``VDDG8`!M)BJYW$-VZNX_*1[8M1_SXBQJ^
M>Q]L=`YP0NB;#^2RUX+AP!9%8R8HL-0\QL`G#05359AH)I:C3_&A<KFB657%
M"5/3WLM[T,#H(GS.]*]FY(BB3OA=X%>LF<FPV!V>GUE=6W3\I/+5/^2[5JZ4
MF10Q,;&P5["X8CQK?40^C9S:)MXD=S.;K:QX0KA&V4#?&"_)1$IP"-M*-53,
M^3*L4HE2>RRABM&^O\8KS>!1$-<ZJ9[3Z=8=47XE)N2OBJ9!\]]8/*9<4H$U
MJZA+B(WAW>='ZO6S4ZBQ$!:;$C^\5SJ9_%TK9'.`=P6\2&FY\5$[DDBX/#Q$
M9;\1%P,*R1CH>$CF43%1[8O(W8QT<W3:,FB)?R4T&Z12A^`*JBJZJHKJIRMK
M%ERK><4M:CO4M1*E*/6228_1';Z"CM5`Q:[<VEFWTS2&FFTB24-MI"4)2.`2
MD`#J$?1KCQS(4A&.\H99QUABU7=Z9.NR*M&WF@&*5U)+:.'[D""<C")8)`=[
M*R*H!YB*!#J#XZ`'&N_QO%[_`)=<T6C'*5VJKU>:@;$CX2U&24)'%2B!&'YQ
MGV'Z;V%S),VKZ>WVAOSG%;5JE,(:0)K=</!#:5*/1*9BO?NM[I.1,L>M+*PB
M20QCCQP55FYN`5`1R#<K8PB4XB[;*F3M:/<I\!1;F.Y$HB!U@`1($[=,N[78
M,8[.[YD6[E?DR4&I3I6C^:1-Y0/G*`1/<@RG%1>O/?JS#.^WQO2\.V3$E30J
MI)E<*A/&2DDBE0H>:@J=(WN)F4Q%"<QU#G44.=110YE%5%#&.HHH<PF.HHH<
M1.HH<PZB81$1'B-2>`"0$I`"0)`#8`.@#@.J("J4I:BM9*EJ)))))).TDD[2
M2=I)VF/&O,>(^C$1$M<$HP@X&+D)J:E'*;.-B8IFN_D7[I4>5-NT9MB*+KJG
M'R%*.GB/"N/555+0TRZRM<;9HVDE2UK4$H2D;RI1(`'ACF6ZW7"[U[5KM+#U
M5<WUA#332%...*.Y*$)!4H^`=>Z)P=IG:>46"-OS=")D4QZ3R.Q'%O`!4?.!
M1(;XF6AS`4IB@`FCVA]>.BJP:&3J&NJ/>>2CM+)IOM.U*ZY:=G0?5VU?B=6.
MM*-RHL_[O_<'4OL,KUQV#8MNTMK]T>NO(/'9-AI74MSRD1.;!P4+;,1'P%N1
M,=!0<2V39QD1$LT&$<P:I!RIH-6C8B:**90#P`.(\1XU"^MK:RXU3E=7NN/5
MKJBI:UJ*EJ4=Y4HS),6BVRUVVRV]FU6AAFEME.@(;::0EMM"1N2E"0$I`Z`(
M^K7&CGPI".IWW?-K8TL^X;\O:6;P=K6O&KRDQ).3`!4FZ)?-21)J!EW;I42I
M(I%U.JJ<I2@(C7:62RW/(KJQ9+.TIZY5+@0V@<2>)Z$@3*B=@`).P1T&4Y18
ML+QZKRG):A%+8Z%E3KSBCL2E/`?"4HR2A(VJ40D`DB*C^[?=/=VZK);BZI?K
MQ5G0IW,?8%G@L<S>#A3*CH\>$`PI+W#*D*4[M<`\=$R:$(%6EZ6Z:6K3/'DV
MVEY7;N\`JJ?EM<<EY*3O#2-H0GPJ.TF/S\=X+7C(=>,S5>Z_GI\:I2I%!23/
M*RT3_2+&Y50Z`"ZN6S8VF24B-5ZV9&AHS-@?!&0=Q60XS'6.X[TF0=:.I>7=
M%5+"VO"D4*1U.3CI,A^@T1YN5,@>Z+JB5,@"8>&(YMFUBP"PN7^_N<K"?%;;
M3+M'G"/%;;!WJ/$[DIFI6P1LG2G2K+M8\P9P[$&>:J7X[SR@>QI600%//*`,
MDB<DI'C.+(0D3.RUWMEVMXTVN62G;%DL@>SL@DW4N^]I!%+U]=,@F74QUU2@
M/H44@H)O1F:8@DB4>/,<3'-6)J+J5D.I-X-RO"^2B03V%.DGLF4G@!YRR/+<
M/C*/0)`7W:):&87H9C";'C+0<NCJ4FKK5@=O5.#>5'S&TDGLV4GD0.E14I6F
M7>%6CB;:;42<H)*2*^5X,(M<Y2BJW%.&G%'W1,(<Q>LU*)3:"&H5MSNH(J#J
M)4J;413IMCG..!FXV$S\"MHB./WB#M$C1.C;?0DUB[[3]DH[TD-/%<NB:`0>
MJ*U=6&Q2M'!O:F_$/[U!OCP=T7%-E"*K?:;@)-9,R1QQS#*@0X:#TU^LLB?3
M^"HDH4P?@&JF]7UI7J??%(,T_6#@]T2!_`1*/T8]VMMQK03$T.`I7]2L&1Z%
M#F!]T$'W8A[[Q>5QG<IX]P^Q<`=C85N*W3,I$,/"X;L4%)HFJ`")3&:PC`AB
M^!B^D&\@U+#NFXP*+&J_*WDR>KJ@,MG^R8$U$>%Q1!X'E'1%=?WB^>JNF<6?
M3JF7.EM=&:IX?V]42E`/#Q66P1Q':*X&(<*EI%<<9=P!99LB9RQ%9`$,=.Y<
MBVE'.=/R&1IEJL]5/P'W-)JD<QO\4!K%<YNXL&%W6\DR-/;WU#\[LU!(\)40
M!UQL/2/&SF&J6.XR`2BLO-(A74CMD*63U!()/5%TB4DHJWXM_+RSUG#PD,Q<
M/I"0>*I-&$;&L$3*KN7"QQ(D@V:MTQ$1$0`"A50M-3U-=4HI:5"W:QY82E*0
M5*6M1D`!O)),?I0KJVAM-"[<+@ZW3VZG:4MQQ9"$-MH$U*43()2E(F29``15
MEW[;V)7<[>!K4M)=U&X5M"15"WV/,=):\91`QT1N^:2`0`4S!J$>W,'N")N<
M?=#CI97HCH]3:<VD7.ZI2YF%6V.U5O#"#M[!L]/RJAY2A(>*!.BOO7]YFNUN
MR$X]CRULZ9V]\]@C:%5CJ=GK3P^#O]7;(\1!YSXZC*/2M\Q$"/T225752002
M57775300003.JNNNL<J:***28&.JLJH8"E*4!$QA``XUZJ4E"2M9"4)!)),@
M`-I))V``;23N$>[;;CSB664J6\M02E*02I2E&02D#:220`!M)V"+,_;KV-HX
M%MYMEO)L8F?,USQYO0(YP!%0QW;S],HA&I!H)27+)(#J^5*(BB0P(%TT4$U=
M6OFLZ\WKU8OCCA&(TSGC+$QZTZD^6>EI!_HQYQ\<[TRNT[GO=?;THLZ,]S9A
M)U(KFO$;5)7U?3K']$G?*H<3_3J!\4'LA*2^:4FHUQ.B(V.Y?NA/@G#HV+:K
M\J&2<M-G\+'J(+<CRWK2Y!0N"XB`0P*(KKD4]#:'_P"-4,8.*8Z2%[N^FR<V
MROZZN:.;'K6I+BP1XKK\YM-=!`EVBQ\$`'RHA?WU-<UZ5:=_NU870G-+^E;+
M9!DNGI92J*D2,PJ1#31^&HJ'D&57(`TX?O\`$?QB(\1$:LFBC"%(1.?VC=LA
M7#B5W-W;'B*;0[ZU\6H.D@$IUS$]'N6ZT2G#CT2F%@V4#\H5Q#P`:A=WIM1B
MVAK3FUN>,KE>K"#PWLLGP_TBQ^9UQ:3]WUHB'%OZW9`SL27*:V)4./DU-4`?
M=8;5_M9<#$\M0EBU:*TG=:W%*9+S$VPW`/!/9V'55D90$CZHRF0'R!"RRR@E
MT!0L`S,5FF`Z\BIE]--1JP_NQX"G'<35EM<C_P!VNP!1/>BF2?$`Z.U5-9Z4
MA'1%*W?VUA7F>HC>F]I<)Q['20]([':]8^,)EO%.V0T`9R678BFJ3D0)A2$*
M0C@1`.(CIX!_A'@`?C$:;X$@;XD>VJ]MS+V?E(^Z;V1?8JQ6J*+@)J78F3NF
MY6AA`PDM6!=E(HFBN3@#YV4B``/,0JVFE1^U,[P>*X,ERVV<HN>2B8[-"ILL
MJ_MG$["0?ZM!*N"BB)E:#]S'4+5E;5\R=+MAP54E=JZB554H.W^[,+D0E0W/
M/!*.*$N2E%C;"F!<6;?+21LW%ML-H./\P\C(JZ.[@N!V4N@OY^94(#J1<CQT
M`>5)/71,A2\*@#F&;Y+G=T-VR6I4\_N0@>*TTGX+38V(3^,[U$G;%R.FNE6"
MZ28^G',%H6Z2CV%Q?E/OK`EVC[Q\=Q?A\5.Y"4C9&--UV[?'>U2RQF;C53F[
MUF$%R6583-RF65G79`$H/7O$QXRW6BNG7='+H/M$P.H.E9#ICI;?]3;QZI;P
M6;0T1ZQ4J!Y&T_!3\-U0\E`\*I)VQA6O7>`P_0?&3<[RH5.1U"2*.A0H!U]8
M\Y6_LV$'^D=(EYJ0I9`BJ9F;-&0<^7Y)Y$R3,GEIV0`&[9!,!1BH.+2.<[2%
M@V/,8C&-:=0="AJ90XB<XF.81JS?$<0L6#V1NP8\SV5$C:2=JW%D`%QQ7G+5
M+P`2```E%"VI.I>7:LY6_F.9U';W1T<J$CQ6F&@24LLHF>1M,SUJ42I1*B3&
M*JR>,"C?W85LTDMT%^^O+G;NF&&K*?-UKKD@(=(;GD4S%71LR(7$`*95R4`,
M^5*(^CMC:<%%"5HW6[5NGTWLGJ5M4E>75B"&4;#V*3L-0L=`W-I/E+$_)28E
MIW4>[?6:XY7]:WQ"VM.+8ZDU2Y$>M."2A1M*_*$B^H'XMLR\M:8M51D;'0L<
MPAXADVC8J*9MHZ-CF:1$&C%@S1(W:M&R*8`1)!NBF!2E`-``*K,J*A^KJ%U=
M4M3E2ZLJ6I1FI2E&:E$G>23,F+XJ.CI+?2-4%`VAFB8;2VVA`"4H0@!*4I`V
M!*4@``;`!'NU\8Y,*0A2$5\>ZAN]N.3O&2VRV)*.8FU;=1:?TFO&*YT7%SS3
MUNB^1ME95,2J%A(EHLF9=(!`'"ZFA]2D`!G9W9]*K?36EO46]MI=N=0I7J:5
M`$,MI)27@-W:+4"$GS$B8D514;W[N\->*S(7M$L5>73V.D0@W):%%*JEU:0X
MFE)$B&6T%*G$_P!8M4E32G;"S4OXK2W0I"%(1LUMWVC9KW-2A4,>VX9O;2#D
MB$O?L^"T=:,2`C[H4'PIF4E7J9=1]&:%55U]MRAQK7.>ZIX?IU3<]^J.:XJ2
M2BF:DI]?1XLY(2?AK*1T3W1O#1[N]:F:VUP1B=&6[$E82[7OS;I6MNV2I3>6
M!M[-H*5T\N^+">VKMQ8)P$6-N";CTLJ9):@DN-U74R24B8IZ4-1/;-L*"NPC
M^DIQ377](=`(`8#E'@$$-0^\!FN<%RAHW#;,?5,=BRHA:T_VSPDI<QO2GE1P
M*3%N^B_<VTJTG2Q=KBPF^9FW)7K54@%MM?334Q*FVI'R5J[1T':%C=$@_P#N
M_P!WX`K1,2XA2$*0A2$*0A2$*0A2$1!=TO=T?&UI!M_L"5Z-\WY&G5OF09*@
M#FV+)=E%((TJJ8\[>4NH.8G`2G39E,;^,+4J^[7I6,ANG[\WUJ=EH7`*=*AL
M>J$[>:1WH9V'B"L@>:8KS[]/>$7A6/\`LFQ-_ERF[,$UCB#)5-1*V<@(VI=J
MMJ1N*60I7GIBN.````````````'```.```>P%6`;]IWQ38``)#<(YX^``8PB
M(`4I0$QC&$=`*4H:B8QAX``<1&G\D-O"9/0-YZAUGA%KCMW;8B[=L(LY"X8]
M-#)N3",KEO!0Y`]*BF!D3*6]:PF'44PBF;@5%RAIJZ6.`Z\I=*Q=>]1SGV8K
M8H%E6.VXJ98'!:IR=>Z^=0DD_`2F6\Q?=W0-$$:/:9-55V:"<VO245-82/&;
M202Q2SX!E"B5C9\:I<YR$M_*T=$L8_-99%LBLY<+)-VS=)1=PX74(B@@BD43
MJK++*"5-)),A1$QC"```:C7LA"W%AML%3BB``!,DG8``-I)X`1Z..-LMJ>>4
ME#*$DJ4H@!(`F22=@`&TD[`(B@W3=T[&N+B2=GX/(QRE?R76:*W`!SCC^W70
M`)#*&?(F(K<[MN?P1:F!OJ'G+?DC)[37NTY#DA;NN9%=ML9DH-2'K3J>@).Q
ME)^$L<W0CC$"==>_7A6")?Q[3,-7W+DS07@3ZA3JW3+B2#4K2?,:/),;71N-
M?W+.9\G9RNA:\,IW?)W7,GYRM0=G*C&1+<QA,#*$AVX)QT2T+K[5%,HF\3"8
M=1J<^+XCCF%VT6G&J1NEI!OY=JUGX3CAFM:NM1,N``BI+4#4G-]4KZK(LZN#
MU?<3,("CRM,IG/D893)MI`GN2D$[U$G;&,*R2,&A2$;=[8ME>9-T,FDM;$8-
MMV$@X*G,9&N%NX1@D"%,'70A4M"+7%)E+P!)N/3*80ZBA`XUJK4?5_$M-J<H
MN3GK%\4F:*1H@N'H+AVAI'6K:1/E28D/H?W9]1M<:Q+UF9]1Q%*P';@^E09`
M\Y+"=AJ'`/-1X@)'.M(BR1MIV9X7VOQB9K.A@F[W7:]"9R-<"23FY9`3@'61
M8"`"W@(PQM=&[4":E_.'4'SJKXU$U<R_4BI(NSW8V=*IMTK1*64]!5Q<7^4L
MG;Y(2-D7.:+=W#370^A!QNE]8R1;?*]<*@!=2Y/>$&7*PV3.3;02)>65D3C;
M&M81OR%(0I"'LB(@```B(B.@``!J(B(\```\1I'C=M.Z*S7<NWC*9KO9;#E@
M2O5Q/8$J/K)ZR5'T>]KS9`HW<O3G(/(XA8!4RB+0`$2*J\ZW'W,0L4[N^DPP
MZSC+;XU+)ZYKQ$J&VGIU2(3U..B2E\0F2/A12AWU^\6=2\F5IQB51S8':7SV
MJT'Q:RL1-*E3&Q3-.>9#>\+7S.;0$2BPJ2\00CO6-,;W?EV^K<QS8<6I+W1=
M#\C&.:EU!%$N@J.I%^L`"#6,C6Q3+.%3>:FF41\=`'I,BR&U8K9:C(+VZ&K;
M3(YE'B>"4)'G+69)2D;R8RO!\*R+43*J/#<58-1?*YT(0G;RI&];CB@#R--I
M!6XH[`D=,A%N+:OM@LC:UC=G9UM)(R%QR!&SV^KP.EROKHG2I`513F-Y[>(9
M&,9-FW#0J:?G"`G,<PU::EZCWG4K(5W:X$MV]!*:9B?BLMSV#H*U;"M>\G9Y
M(`'Z"-"=$,8T,PQK'+*E+MX="5UM61X]2_+:J9VI:1M2TV-B$[9<Q43LQ6NH
MW9$#7>?R`FH]PIBQNL`G;(7#?TL@!M>07`HV_!G,`>U.)$WWCQY1#3@-3:[H
MEB4EJ\9,X#RJ+5,@^";KG\K?NSBJK[R7+DJ>QG`V5#F2*BO=3X94[!_X^_@1
M+?$&%31BK6/<CXU[,R$?#1R)G$C+OF<4P0(4QCK/9%PFS:IE*4!,/.NL4.`5
M\7ZAFC875U!":=I"EJ/0E`*E'\`CD4=%4W*L:MM$DKK*AU#3:1M)6XH(2/=4
M1%W''-L-L>XWL:SA$B#2RK*MV`4,<X`FBE`PK5FN<Y]=.1/T8PB.O@%4YW^X
MN7W(*V[;5.UE8ZZ-FTEQQ2AL]V/TX8A96,2PZV8\)(I[;;:=C:=@##*$$D[I
M#EVF*>>Y?)1\OY]RSD3J'4:7#>DN,3SF$W3@XU;U3"I%XB`%)&L4_#@(B(^6
MK7M.L=&*8-:[#(!UBD1S];BQSN'TU'^2/SMZWYH=0]6\@R\$FGJKDZ&I\&&C
MV+('5V;:=VPSGQC!U9I&JXV4V@9.LO#>X_&.2LA$?FM.V)217DE8UJ9\Z9G>
MP<E&LI`&1/=72;%Z\(J<I//Y2B)0,(<HZ\U6QR[Y;I_<<>L11]:5+:`@+/*%
M!+B%J3S;@5)20"=DS(RG,;K[NV<8UIOK+9<TR\._4%$ZZ7"VCM%(+C#C2'.0
M;5!"UA1"?&D)@$B1W#W[]PS^T$S#%6'5)J&Q,!BJW3*/T!C)3(#I)0BK9FHS
M`YG#&UV2B8'Z*HE4=*Z&4*!2%*.I]$-!_P!Q'OWGRP,O91N90D\Z*8$$%7-N
M4\H;.83"$S"2228D5WK^]Z-6Z7]PM.C4T^!3!JGEI+3M>H$%+?)/F13((YBE
M4E.J`*DA*0#%14FX@5`1``$1X`'$1'P`*0)D)G=$\/;)V-$32B-RN7X8#+J@
M5[B:TI1N.K<@&'I7Y*M%B@`+*@`^K$C@/*0?2!#44A"$W>,UG*E.Z>8H]\6/
M%K7T'RNFF01P']<1O/Q>X*BU?N2]UQ++=/K/J)3?WE4EVJD=3Y`X5SJ3YRO_
M`+9)'BI/:R!*")TZA;%I$?!NFYH.R[;GKNN5^C%V_;,2^FYF07.4B36.CFYW
M+E41,(`)NFF(%+XF,(`'$:YMMMU9=[@Q:K<@N5]0ZEMM(WJ6L@`?A.WH&V.J
MO=ZMF.6>JO\`>74L6FC86\\XHR"&VTE2B?<&P<3L$4X]R^=IW<;F2[LH3)ET
M6<F\,QM6(64$Y("TF!S(PD6D70"$4Z'NRX@`<[A4YA\E6SZ=X518!B5+C=)R
MEYM',\L"7:OJVN+/5/Q4]"4@1^<S6S52Z:R:CW#-[B5II7G"W2-$S["D;)#+
M8W2)'CN;-KBU&,"UF\:HC,NW_"]Q[@LMV?BNVB*%7N"0(>7D2$YDX*VF9B+3
MTVX'P*FQ8Z\FOMUC$(&HF`*Q'.LOH,$Q:KR:X$%#"/BT<7'E;&VQ^<K?T)!.
MX1LG2+36[ZN:A6[!+0"%5;H+S@&QBF1)3[ROS$3">E92D3)E%R6Q[+MS'-G6
MU8=HL$XRVK2AF4'#,DP#W)FQ1*D0ZIM`%5RX,`J*G'SE%3F,/$1JI6\W>X9!
M=JB]W5PN7&J>4XXH\5*,]G0!N2-P``&Z/T<XQC=GP[':+%L?92Q9:"G0RRV/
M-0@2$SQ4?*4H[5*)4=I,8\W'9<:8*PCD;*3@R8N;8MUTI"MU!+H]N-[HP@&@
M%,`\_5E'*8F#0=$RF'30!KOM/\6=S7,;?C3<^SJ:A(<(\UI/C.JZI(!EUR'&
M,1UBU`IM+M,[QG+Y3VE#1K4TDR\=]7B,(D=_,ZI,Q(^+,RD(IC2<G(3<E(S,
MNZ5?2LN_=RDF]6,)EG<@_<*.GCE0PB(B99=4QOP:U;I3T[%'3MT=*D(I6D)0
MA(W)2D!*0/``(_-K75U9=*UZYW%Q3MPJ75NNK49E;CBBI:B>DJ),>C7VCBQ]
M.&A)JXI%O#V]#RD]+NQY6L7#1[N4D'`AIKTF;))9P<I=>(@70/*-<:KK*.WT
MZJNO=:8I4[UN*2A(\*E$#\<<^V6JZ7NM1;;-35%7<7/):9;6ZXKP(0%*D.)E
M(<8D$PSVO]SN4U6KRY8-IB"VEN4ZLG?1A+-&1$-1%I:;(YY0RHAX`Y%J77Q'
M3C6BLN[R&G.-)4U;GEW6XC<BF_HY_E/J\27YG/$NM-^XWK;G+B*B^T[6.V96
MTN5AF_+\FE02Y/H[4M?@VQ-+MY[<VWG`IXZ=<PQ\FW^R$BQ;NO9%!VW8NR@.
MJT#;10-#Q?*(ZD4.5PX*(`(*AY(@YYK]GF;ARB0\+=8U[.PIR4E2>AUW^D7U
M@%*#\&+*-(>YUI!I2IFZ.4IO65M2/K=:`L(7TL4_]"UU$A;@.T.1OQXZ!^(`
M`/8\```#P"M(1*Z(Z=YO<&L/;:QD;,LU2/OG-*R(I(P**_6A;-,L0>21N]RW
M,(%<)`(&2CR&!=4=.?ID\X=^Z1Z$WO4)YN[W8.46(`S+I$G'Y>8P#P.XND<J
M>',=D0\[R/>WQ31>D>QS'E,W/4M29)IPJ;5),;'*M2=Q&]+`/:+\[D3XQK+Y
M$R->^6+NE;[R)<<A=-U3*A3O920.`B5),!*W9,FZ8$;Q\<T)YJ+=$I$TR^`:
MZB-BM@Q^S8O:FK)8*=%-;&1XJ$])WJ43M4M6]2E$DF*2LQS/)]0,B?RO,:QV
MNOM2?'<6=R1Y+:$B26VT#8A"`$I'"<R>DUW,8Q&W^S[:%>NZV^R1S(KJ"QQ`
M.6ZE]WN9`PH,&IAZGJ:&,H7H/KDD$RZ))ZB"!!%53S2@!M4:KZJV?3&RE][E
M?R!])%-3SVJ/RCDMJ6DG>?./BIVF8D5W=N[ODNO63BF8[2DPND<2:ZMY=B4[
M^P8)\5=0X-PW-@\Z]@`-K['&.;-Q+94#CZP(5M`6M;C,C..8-PU.<?;+O7JX
M^ZO9%\L(J+K'$3J*&$1]BJQ,@R"[91>'[[?'E/W.H7S+4?Q)2-R4I&Q*1L`$
MHONP[#L<P'&Z7$L4ID4EBHVPAMM/XUK5O6XLS4M:IE2B28[O731D\*0A2$*0
MBJEW-<53^/-U5ZW(^9KA;N4C,[QMN4%,_HCI08]I'S4<18=2"[C7[,14)KS`
M14@Z<H@-6:=W3)J&_:94=N86GU^V<S#J)^,D<ZE-KE\%:5;#NFDC>(H=[[N"
M7;$=>+C>ZIM?U/?0W54[LCR*4&D-O-@[N=M:)J&_E6DRD1$?%;WB(4=@M6U+
MFOF?C;5LV`E;GN277*WC82$9+/Y!VJ80`>F@@4QBI$UU.H;E3(7B80#C7`N=
MTMMEH7+G=WVJ:WM":W'%!*4CK)XG@!,D[`#'<6#'[[E5W9L&-4E177JH4$ML
MLH*W%$]0W`<5&24C:2!$[&U/M-Q<4$9?&YQ9&:D@Z3QGBF)=&-"LS"'.1.\)
M=N)#RJY!TYVC4Q6X"&AE%`U+4*]3>]!551<LVG(+--M2JM6GXQ76P@[$#H6L
M%?0E.PQ:AH-W!+=;@QD^MBD5=?XJT6QI7Q".(%4ZF1>4.+;9#0(D5."8B:F%
MA(:VXIC!6]$QT%"1B!&L=$1#)O'QK%NF&A$6K-JFD@BF7V"E#6H@5E95W"J7
M6U[KCU8XJ:UK45+43Q4I1))\)BRFW6VW6>A:MEI89IK<R@);::0EMM"1N2E"
M0$I'4!'TZXT<Z%(0I"%(0I"%(0I"%(1K_N;W`VSMJQ%<62[@,BY>MDACK3@3
MJ@FO<MU/$U`BXI$`\\42F**SDX?FVZ9S>.FN<Z=8+<=0\JI\=H)I94>9]V4P
MTRDCG6>$_-0.*R!&IM:M6;'HOI_69K>"E;[:>2E8)DJIJ5@]DTGC*?C+(\EM
M*E<!%/>^[XN?)=Y7)?UYR2LO=%URKF8F'ZHC[HY<FU*B@3P09M$0*DBF70J:
M1"E`-`JUZR6:W8[::>QVAL-6VE:#;:1T#B>E2C-2B=I)),?G:RO*;YF^25N6
MY*^JHOE>^IUU9^$K<E(\U"$R0A(V)2`!'4Z[2,>B2;MD;;&F<LW*7C=#,CNP
M\/A'7%(-%R`=M,W4Y74-:T0N0Y#)JM4E6:KM<H\#%0*4>!ZCUWC-0W<,PX6F
MVK*+W=N=I*AO;8`';+'$*(4E"3PYB1NB:7<BT7IM3]359)?6@YBV.AM]:%":
M7JI:CZLTH$$%*>1;JP=AY$I.Q46C^)A]D1&JV=T7FQI7N3WXX(VVHNHN7F@O
M3()$E/1L?VBX;O9-)<.!`N"1`QX^W$!/[;KB*^G$J1JV_I[HGFNH2TU-(SZG
M8B=M4^"E!']DGRG3T<OB]*A$;-9^]/I9HNVNBN=3]8Y8$GEH*525N@\.W7M1
M3IGO+AY^*6U17NW*;[<Z[E%W<9,S1K,QZHH<&V/K3<N&<8LWU\P+AD"F3?7&
MOR^VZPE;Z^U2+4[M/=%,*T]0BII&167X#;5/@*6#_9)VI:'1RS5TJ,5$ZT]Z
MK5+6=QR@KJDVS$%$A-!2J4EM2>'K#FQ=0>D*DWT-B-+@````````X``<``/8
M`*V]OVG?$:0`!(;HYI"/LV];L_=LW&VW:T+)W#<$PY(SBX:'9K/Y%^Y4'0J3
M9JW(=0X^41TY2E`1$0`!&N'7W"AM5&Y<;D\W3T#2>9;CB@E"0.))V?\`B3L&
MV.SLUFN^171BR6&F?K+Q4K"&F64%;BU'@E*9GK)W`;20!.)V]I7:BCXSU9?N
MYX$960`4'L;B>/<]2):#H"A/CK)("'K)<HZ<S%N8$`$-%%%`U+4*=4N\Z_4]
MI8]..9JGVI76J$G%</[N@^0.AQ0YO@A.PQ:CW?NX316_L<KUNY*FN'*MNUMJ
MFRCB/7'$_P!,H'>R@AL$26IP33$V,5%1<%&L8:$CF,/$1C9-G'1<8T08Q[!H
MB4")-FC-L1-!NBF4-`*4H`%0]J:JIK:A=76.+=JG%%2UK45*4H[RI1F23TDQ
M9A0T-%;*-NW6UEJGH&4!#;;:4H;0E(D$H0D!*4@;@``(]^OA'+A2$*0A2$1L
M=S;<LYP;A0MF6K(&9Y`RZ+Z`CW+9;IO(2U4$B!<TTD)#`JDLNBN5F@<`X'7,
M8!`2<)"=W33QO,\P^MKDCGL5JY75@B:7'B?B6SP(!!6H="0#L,0Q[[&M;^EF
MF8Q^Q.]GEV0<].TI)DMBG`'K+XD9@\J@T@_"<)!FF*N(!H``'D_P_NB/$1JR
M??%%PV1S^Z/L``"(B(^```<1$1\E(>#?%GCMJ[0D<&8Y2RE>\2F3+62(Y%R"
M;M(!>6;9SD$W$?`I@<O,UDI0H%<OM-#<4TATY#`-<7>&U57FE_.-69TG%K>X
M1-)\6H?$PIT_"0C:AOAY2O.$7A]R_N\M:68:G-\GIP-0;RR%$+'CT=(J2FZ<
M3$TN+V./RVSY4&7(9R>5'&)N1P8Q"%,=0Y4TR%$YU#B!2$(4!,<YS"(`4I"@
M(B(\`"O(!)DD34=PCPI24@J60$@3).X#IBGSO9S*EG7<KDB]8]P+FW&<D6T[
M3.!A,D>W[7*,8W=HAX%))NDU7/`/XT-==-:M<T=Q%6%:>6^SOIY;@MLOO](=
M>\<I/YB2E'\V/SO=YS4AK5+6J\Y'1+Y[,RZ*2E/`L4P[,+'4XOG<_G">Z<:I
M5LZ-!1('VS\/#E;=+:TD^8@[MO%S5QD"9%0@&;^FL!!K;+=0#`)#F4G5TU>4
M?$J`ZAI6BN\5E?[LZ:U-,ROEN%R4*5N6_E5XSQ^;!3/I4(EWW)=//W[UTHJ^
MJ;#EGL32J]V8F.T3XE,D\#\<H+ET-G9*+!>]C)QL2[7LP7<W=`TEU;7<6W`*
M<_(J,Y=1R0;,R`AH(K-B/3K@'E!(:@GH]CG[T:D6FU+3S4HJ0Z[T=FS\8J?4
M>4)]V+<.\MFW[@:'9%D#2PW7F@73L&<CVU3)A'+UIYRN70DQ3P*4"E*4/`H`
M`:\1X!IQ'RU;"3,SC\Z:1RI">@1S2/,*0A2$*0B4KMQ[)1SS<R>6LEQ:W]#]
MGR1/5T<Z2,1'(5RLE`4".#FT%:W(A4I3/3%`2KJ:(`.G4TC5W@-8AA-N.+8Z
MZ/WKJVSSK29FE94)<W4ZL3#8WI'C_!G.WN:]V7VI7I.H>;,*]GUN?'9-+$DW
M"H09\FWRJ9DR+I&QQ7Q4Y!<K,Z222"2:""2:""*9$4442%21112*!$DDDB`4
MB:29"@!2@```!H%5U*4I:BM9)63,D[22=Y)XDQ=>A"&D!ML!+:0``!(`#8``
M-@`&P`1YUXCWB$#NZ;E31D5"[:;4D>1W.)-;HR:=JJ('2ATU04MVVG'((<OK
M-RGZ8L0?%))+7@:ID]UC3P5-4]J'<VYM,$LT<QO<(DZ\/S$GLTGI4KHBL?[P
M?6E=OMM+HQ8'B*JL2FIN12=H8!FQ3JE\JL=JL'S$(X*B`JIQ14Q'`B``(B.@
M`&HB/@`!XB--\"0!,[HLR=K;;`&)<4FS!=<8+?(.66:#B/3=MQ3>6_8`'!>(
M9%Y_/15N$Y2OEPT`13Z)1]K5=?>4U'_>G)_W4M;G-8K6LA129I=J92<5UAK:
MVGKYSQB[/N,:')T_P#V@WYCDS"_MA:`M,ET]#/F9;V[4E^0?<&R8+8/DQ*C4
M:(G9$)/>6RBO'VKBC#C%P8A;DDY*^[@1*?3JL(``BX-%4@#YZ2DD]65#V#MP
MJ8O=(QI#]SNF6/)F:=M%,T>A3OCN$=80E(\"XK+^\>SEVCQ^PZ=4JR!7/N5M
M0D'>W3@-L@CH+JU*\+8B`&IS14I'`CH`CH(Z`(Z``B(Z>0`#41$?8H!,RCP3
M(3BV7L'VO6_MZPM;4D]AF(Y4OF(9W#>MP*-TU)1L642*]86NU=G**K6.AV:I
M"*)IB4JK@#G-J/+I5[K?J37YYE]0PR\O]VJ)U35.T"0@\AY5/%.XK<4"03,A
M,@);8O\`>ZEH=9](=-:*J?IFOWYN=.BHK:@I!=!=`6BF2L[4MLI*4E"9!3@4
MLS,I;U>-:6B4<?!N>Z+<LJ!DKHNZ<B[;MV';J.Y.:F7B+&/9H)E$QC*N%S%+
MS#IH4H:G.;0"@(B`5S;=;;A=ZUNVVMERHKW5!*&VTE2E$]`'XSN&\QU5ZO=G
MQRUO7N_U3%':*=!6Z\\M*&T)&TE2E$#P#>3L$R8@,W@=U&:NP)3'FVE9];5M
MGZS*5RBLF9K<<VB(<BB=I-5"@K;[!7CH[4#TPY>)`2\1G#I3W9Z.V=E?M0TH
MJ+AL4BC!FTV>!?(V.J'R8\0'RBK=%4/>([]UQOG;X?HHIRDM))0[=""E]X;B
M*1!VL(/RRAVI&U"6]YAA<.'#MPN[=KKNW;I91PZ=.EE'#ERX6,)UG#APL8ZR
MZZIQ$3',(F,(ZB-2Z;0VTVEII*4M)`"4I```&X`#8`.`&P16N\\]4O+J:E:W
M*AQ14M:U%2E*)F5*4HDJ43M))))WQ^5>\?.-YMFVQZ_-U$\C,.BO+4P]%/NC
M<5[G2*5:24;B0Z\#::2W!_**D,!5%]#-V@#J<3'Y4S:7U:UELFFE$JD:Y*K+
M'43:IY[$`[G7R/)0-X3Y2]PD)J$I>[CW7LJUVNJ;E4AR@TZ8=E45A$E.E,BI
MBD"O+<(,E.2+;0,SS*D@VD\:XTLC$%EPN/\`'D"TMVUH)`$6;%J4.HNL8`])
MD9!R(=9_)OE`YUUU!$ZAA]@``*U\AR*\Y7=WK[?GUU%R?5-2E;@."4C<E"1L
M2D;`(O1PO"\9T^QNFQ/$:1NCL=*CE0V@;SYRUJWK<6=JUJ)4H[S'>ZZ2,IA2
M$*0A2$*0C&N5</8TS;:ZMFY2M&+N^!.H*Z"#\AR.HYWR"0KZ)D6QT7\6](4=
M`414(80X#J'"LAQG*\BPZY"[8U5.TE<!(E)V*3OY5H,TK3U*!$87G>GF%ZF6
M-6.9S;V+A:5'F"7`>9M<I!;3B2'&EC@I"DGA.6R(]7W:!VON9(SMK.Y4CF!U
M2J#$H7+'+I$)KJ=%)XZAE792&#@`F,8Q0\HUOAGO6:D-L=DZS;''I2YRRH'P
ME(<"?Q`1$2I^[RT,>K.W8J+ZS2E4^R35((`X@*4R5@=$R2.F-V,&;8\*;<XM
M>/Q59C2'=O0*$I<;]0\M=4MRAH!7TZ\`SOT</$$$ND@`\0(`UI[--1LPS^I3
M49-5K=;1Y#21R,H_-;3XL_RC-72J),:7:)::Z.T"J+`[:W3/.@=K4+)=J7I?
M*/KFLCCR)*6P=H0(SY6#QM>%(0I"%(0I"%(0I"%(0I"/3D9%A#Q[Z6E7C>.B
MXMFYD)&0>*D0:,6+-(Z[IVY64$")(-T4Q,8PCH`!7VIZ=^J?12TR%.5+BPE"
M4B:E*49)2`-Y),@(XU964MOI':^N<0S1,MJ6XM9"4H0@%2E*)V!*4@DD[`!%
M2[?1NL?;HLMN'T6NX1QC92CV$Q[&',8A';4%A(]NMVAP*$A<!T@.34.9)J":
M>NO-K:)HMIDQIMBR6:E*3DE8$N52_@F7BL)/P6IR,MBE\RNB*!.]-KU4ZY:@
M*?MZUIP:V%;-`V=@6)R<JU)W<[\@4SVH:"$[^:-**W#$9(4A$BFR'?BCM'@K
MXMB5QTI>\3=LHSGVSF-F48:38R;1D#`S=P=RS=HNH]=`I1+IRG2/S"`&`V@:
M"UDT37JE6T5RI:\4=52M*:(6V7$*0I7-,24DA0,Y[PH2W2B8W=B[U;/=^M%S
ML-QLZKG;Z^H2^A33J674.I0&RE?,A04V0`1*10>8R5S;/;W!]SK<!FELZMZU
MED,.V:Z*9)>/M!XY5N610,(^YR5VJ$;O$TS$'E,1FFU*8->83!P#Y8)W<L%Q
M!Q-?<PJ[79.T*?2`RD]*&!-)/07"N7"4<C5SOP:LZD,N6C'RG',=<!"D4JRJ
MJ<2>#E40E21+80REN8WD[HCC4446446644666.95998YU5EE3CJ=59503**J
M''B)C"(B/C4@$I2A(0@`(`D`!(`=``V`=0B&:UK=<4ZZI2W5DE2E$E2B=Y43
M,DGB29F/"O:/6%(0I"-H=HFY$^UG+B.2QM!K>C1:$D+>D(M1V$=((LY$Z"BC
MR&D3-W2;1\F9``$#)B55,3$$2Z\P:VU4T^&I6+''A5JHW0\EU*PGF05)!`2X
MB:2I)GLD9I,CMW1O3N]:T'0G4`9FJW(N5,NE73N-\_9N)0LI)6RX4J"5@I`(
M*2%IFF8V$3"$[SN&1(05</94(H)2BH1-Y9ZB93B'G%(H:92,<@&\!$I1$/(%
M10/=%RZ9Y;M;"GA-+X/X.S,OPF+%$_>1:9E(*\?OP7+:`:0@'C(]N)CKD)]`
MCV$.\SA`ZG*OB;*[=/01%3J6@MH(>`<B<YS#K7HONCYD$S1=+6I71\>/Y6X^
MK?WC^ERE2<L5_2GIE2'\0J)QWJWN[QM<E54D9J,R;:PJ"4HKO;9:2;5'40U,
MLI$RCE4I"`/$2D,/#PKI*_NK:E4J2JC<MU2!P2\4*/@"T`3\)$939_O!]"J]
M:6[DW>:%2B!-RE#B4]:E-.+,AU`QN_BK<C@K-J938PR?:MTNA+S&AT7X,+@2
M#01'K6_*%93">@!X]'33CKI6F\FT^S3#E2R2VU-,W\,IYFCX'4<S9]*).X)K
M)I=J8T%X1>Z"O=XM)<Y'Q^<PYR/#W41F[PX#PK#HV9'I24E'PT<_EY9ZWCHN
M+9N9"2D'BI4&C%BS2.NZ=N5CB!$D4$2"8QAX``5]J>G?JWT4M*A3E2XL)0E(
MFI2E&02!Q))D(XU964MOI':^N<0S1,MJ6XM9"4H0@%2E*)V`)`)).X14!WF;
M@W&Y+/5UWTW76-:,<J-L6`U5$Q2M[3B55$VKOI"(@DO-N14>*!Y!6`O'EUJU
MC2/!$:>X12V5Q*1=7!VU41Q>6!-,^(;$FQ^:3QC\\?>2U>>UGU5KLG96HXZP
M32T"3.0I6E'E7+@I]7,\K\X#A&JU;-C0L2.]M3;&&>,U)WA<\:5WC3$ZK.=F
MB.DQ,TG+G.8REM6]H)1(L0BZ0O')1X=%$"C^<#6/_>'U&_<G#S:;<YRY%=`I
MMN1\9MG<\[U3![-!^$HD>3$S.Y3HC[4M2DY+>V0YA>/J2\Z%":'ZH[:9CH4$
MD=LX-W*A*3Y8G:7_`-WX/Q`'D`*K4B].%(1'UW(=QA,$8`E(:%?`WO\`RNF^
MLVV"I'Y73",6;`6Z+@+RB!T@CXUQT4C\-'#@FG$*WMW?<`.:YRU65:.:QVPI
M?>GN4L'XEKKYEB9'P4JB)'?*UD1I5I._;K<[R9;?DKHZ4`^,A"DRJ7QQ'9M*
MY4JX.+1+;%4\``H`4/````_$'`*LU)F9G?%"P`2)#<(YI'F+.G:GP<IC+;ZK
MD*89BWN7,TBE<).LF!7#>SXPBK.V$`$0ZA$WW47>:<`,"Y1XARU7)WF\S3D>
M="PTB^:WVALM;#L+ZY*>/02F26^KE(Z8N^[AVER\'TD.6W%ODO62.IJ-H\9-
M(V"BF3T@+!6]+CV@.T2C`W>8R:+*V,28>9KB!Y^3E+]G$2GT$6$&4L1!D53U
M\Y->0?.#E'R&;UFW='QP/7*Z98ZG8PTBF;,O.<\=R1Z0E*0>I<:I^\?S@TMB
ML&G-.J2ZQ]RN?`/]6Q)ID$="G'%J!Z6H@$J<L5+PI"%(0I"-O]F6U"XMU63V
M\(4KJ-QU;2K61R+<Z93$!G&&.)TH.-7$HD-/S@)BFB7CTD^94W`H`.J=7-3Z
M#3/'%5AY7+_4!2:5D^<OBXL?)-SFKX1DD;S*1/=NT"O&O&;)MTELX;0J0Y<*
MD"7*V3,,-G<7WP"E._D3S.'<)VU+3M2W;%MF"LZTHEI!6S;4:VB(6)8I@DV9
M,6B8)I)D`.)U#:"8YS:G4.83&$3"(U5S=+G7WJXO7:Z.K>N-0X5N+49E2E&9
M/_@!N`D!L$7_`-AL5HQBRTN/6%ANELU&REIEI`DE"$"0`'XR3M4222228[#7
M`CMXQGF3*EN83QA>>4KJ5`D/9\,O(F0`P%5D7YA*VBHEL`CYSF4DEDD"!Y!/
MJ/`!&LBQ+&;AF.1TF-6P3JZMX(GP2G>M9ZD(!4?!&%:BYU9M-,)N.<7]83;;
M?3*<(XN+\EII/2MUPI;3UJGNG%,S(]_W%E2_+MR+=CH[NX;QG'TY(G,<QR(F
M=JB*#%OS>T:1S4I$$2AH!4DR@%6XX_8Z#&;)2V"UI":"D92VCKY1M4?REJFI
M1XDF/S>9IEUXSW++AF5_65W:Y52WG-LPGF/BMIZ$-HY6T#<$I`CI5=Q&,1O-
ML!VQK;DLWQZ<TS.IC;'IV5TWXL<H]!^1)P)H:URG$.0ZLZ]0T5+KJ#1-4=/`
M:TOKGJ,G3[#7#2+ED->%,TPXIF/C'NF3:3XI^&4Q*7NE:(.:S:G,FY-E6%V=
M2*FM)'BN25-FFZ"7EI\<?))7TB+9:::2*::*"2:***9$D442%32122*!$DDD
MR`!$TTR%`"E````#2JO5*4M16LDK)F2=I).\D\28OX0A#:`VV`EM(```D`!L
M``&P`#<!'G7B/:*NW=?N=>=W;R<294QVMGV-:4*U3$=015=HN9E[RA^2"JKX
MHZ>R&OEJR3NPVY%%I:W5`2=JZU]Q1Z0DI;3^`),4;=_J^.W37YRWE1-/;K52
MM)'P2OG>7+HF5I_EXQ&I4AXA3'TH9^G%3,-*K-@>HQ4O%R:S(P@!7J,>_;O%
M69A-J4"NDT13'7AH:N-6,*JJ-ZE0KD6ZTM`5\$K24A7\TF?N1S[56-VZZTMQ
M=;[5JGJFG5(^&EMQ*RC;L\8)*=NS;%Q6Q=V.W:][$B+ZCLL6##Q#V.;+N(Z:
MN>&AI2"7Z!!<1,C%/7+9ZV=1Z@"F(`GRCRZE$2B`U4Y>M,,]LU[=LM1:ZYVJ
M0X0%-LN.(<$]BT+2"DI4-HVSVR,C'Z,,6UXTCRC%:?*J&_6IBVNLI4I#U2RR
MXR>4<S3C2U)6E;9FDCEELFF8D8U&SOW6<`XW;.XW%XN,S78"9R-S0_6C++:.
M-!`IWUQND2J/DR&T$2LD5@.'#J%\0VIA7=DSG('$5&2<MHM<YGM)+J%#\EI)
M\4GI<4F7P3$>]5._EI+A;+E%A*E9'D`20GL)HI$*X%RI4/&`WR92Y,;.8;Q`
MUN!W3YFW+3?K/)5S*JQ+94YX:S(?JQUHPA#&U(#:*(J8KQV0H``N7(K.#:>V
M`.%3:P733$=.Z/U?':8"J4).5#DEON>%<O%3^0CE3U'?%5&KFO&I.M=R]<S.
MM/U:A1+-$S-ND9Z)-`_&+'RKI6L\"!LC7:L^C3<<E*8QBD(4QSG,4A"$*)SG
M4.8"D(0A0$QSG,(````B(CH%>"0`2=@`F>H#>3U"/(!40E()42``-I).P`#>
M23L`&TF)A=EW;#N#(IXK)>X=C(6K81@0?PN/E.JPNB[TA$BJ*LZ'F.;=@%R>
M*?FO'!!X=(H\PQ0U>[QU#8`[CN!+;J;WM2Y5"2F6#N(:X.NCX6UM)^$1*+%>
M[9W'[KERJ?-=86GJ'%CRN,V\S14U0WI-1N53L*&WDV/.)/\`5@S-AB!@82UH
M:-MVVXF/@H&':),8N(BFJ+*/8-$2@5-!LV0*1-,H`''AJ8>(B(CK4#JVNK+E
M5N5]P=<?K75%2UK45*4H[R2=IBWJUVNVV2WLVFSL-4MLIVPAMII(0VA"1()2
ME(``'4(^M7%CGPI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"(&^Z
M?O)(Z%YMAQI+`=`ATC9?FV"XZ'52.59M82"R0\IBIG*5:2T$>/(@/\8%39[M
M&DI;Y-1\A:DO;ZBVH<#L-20?=2U[J_@F*JN_;WC@Z7-$,*J`6]ANSS:N((**
M%)'@"ZG:?-:/GB(+ZFE%6L*0A2$*0A2$*0A2$*0A2$<<Q0\H?NA21CQ,=(@`
M@/@(#^(:2,)B.:1YA2$?LU<N6+IN^8N7#)\T4(LT>LUU6KQJLF8#$6;.FYTU
MT%2&#4#$,`@/@->CC;;S2F'DI6RH24E0"DJ!W@I,P1U$1]6'GJ6H15TJUM53
M:@4K0HH6DC:"E22%)(X$$$1(5A3N<[F\1-F\/,3,?ENVVZ8)(1^0@=.9AHF4
M``A6EU,54)@Y4RAH4KH7)0#@&@<*T1F'=RTYRIQ572-.6NX*,RJED&U'\IE0
M+8GQ*.2)=Z:=]W6[3YE%NN52SD%F0)!%?S*>2/R:I!2Z9#8`[VH'"0CYVYGN
M+YMW(VVI8BS.%QS8;SIC-P%J+/UGER@F8%"-IV:?*>D+1A5``PM42(I*"`=3
MGT"OOIUH#AVGUP%Z2MZX7M$^S=>"0EF?G-MIV!<O/45$;>64XXFM??&U-UEL
MJL66W36;%G9=LQ2J<4NI`V\C[RSS%J>TM(2A*I#GYI1H!6\XB5'[-V[AVX;L
MVB*CEV[<(M&C9$HG5<.G*I$&Z"10XF466.4I0\HC7HXXVTVIUU02TA)4HG<$
M@3)/4`)Q]6&'ZI]%+3(4Y4NK2A"1M*EJ(2E('$J40!UF+A>SC`+7;A@2SK!4
M01+=#ML%S7X[3*'.ZNZ:126D$3*:<RB,2D5-FEY.1#4`#40JJ#5G.7-0,XJ[
MXDGZM2KL:9)\UALD(,N!69N*ZU2X1^B?NZ:3L:-Z46W$EI3]=J1ZQ7+'GU;P
M"G!/>0T.5E/Y+8,A.4;1UK:-YQZ$K*QL'%R,W,O6\;$1#%U)RDBZ.";9C'L4
M3N7;MPH/`B2""9C&'V`K[TM-45M2W1TB%.53JTH0E.TJ4HR2D#I),HXE=74=
MLHGKE<'$,T%.TIQQ:C)*$(25+4H\`E())Z!%/_>)N*?[F<X7)?8+."VC'G/;
MN/8U8Q@*QM./64!JY%`1$J3V;6$SM?3CS*`7\@*M9TGP%C3K#:>R$)^M7!VM
M4L><^H;1/BEL20GJ!/&/SP]XS6*JULU/K,I2I8QY@FGM[:I^)2MD\JRG<%OJ
MFZO\X)\T1JU6RXT3&=MM.%)/<)FNQ<61Y5"M)N4*ZN1ZF'",M.+T>7"_,;P*
M8K`@II\0YEE"%#B(5A6HF84V"8?6Y*_+M66^5E)\]]?BM)]+:?R03&U=%-,J
M[5[4RUX+2!0IJE[GJ5C^JI&I+?7X>3Q$]*U)`VF+E\1$Q\%%Q<%$-4V45#1[
M*)BV:0<J32/CVZ;-FW3*'@1%ND4H?BJI"JJGZVI<K:I174O.*6M1WJ4HE2B>
MLDDQ^CZWT%):Z!BV4"$M4-.TAIM`V!+;:0E"1U)2`!%4'N.90#*&[/(BC9QU
MX>Q#,\=1'*83)%^+1#DF#I@(B`=2><.0$0X&Y`$/&K.^[_C?[MZ7T`<3RU=;
MS52^GXT_%@^!L(\$Y10CWRLW&;Z_W<L+Y[?:N2WM2G*=.#VQ$^E]3@,MAY0>
M,:,5NF(M0I"%(1E'#.'[USOD:W<96"P,]G;@=`51R<AQ80D6D)324]+*D`>A
M&QC<1.<?$XZ$+J8P!6-Y;E=GPJP5&1WQ?)1,)V#9S.+/D-('%:SL'1M)V`QG
M6F^G63:JYC1X3BC)<N=4L340>S8:!':/ND>2VVG:>*C)"9J4!%OC;[@BRMN>
M,('&=DMB^CQR17,Y-*)$)(W1<3A,GK2?DSEU$RSM4NB9-1*@@4B9>!:JHSK-
MKQG^1OY%>%?&.&3;8/B,M`GD:0.A(WG>I1*CM,?H9TDTLQG1W"*7"L8;`893
MS//$`.5-0H#M7W2-ZED;!M"$!*!L2(S76'QLR%(17M[NFXXUQ7=![<[9D1/"
MV89M<V00;J:I/+L=H">#AG`D,(*!!1BWI!RCX+N2ZAJF%3N[J^GXH+6_G]Q;
ME5U<V:68VI82?C'!_M%CE!^"@\%143]X1K'];WZDT=LCT[?;BFIK^4[%5*D_
M$,JD=O8MJ[0@^>XF8F@1"[4O8K6CZ<+"RUR3,5;T"P<2LW.R+.)B(UH05'+^
M2D%R-F;5`@>)UEE`#V`\1X!7&K*REM]([7URTM43#:EN+5L"4)$U*/@`CGVN
MV7"]W.GLUI:6_=*MY#3+:1-2W'%!*$@=))'4-YV1;]V>[<HS;'A.WK#*1LM=
MK\A+@R#+H<IO6=VOT2"[236TYCQ\.D!6C8/#II<V@"<:JGU7S^HU&S&HO9*A
M:T'LJ5!\QA)/*2."EF:U]:I<!'Z'.[MHY1:):94>*`(7?G1V]>ZG^MJG`.<`
M[RVT)--_DHGL*C&TE:UC>D*0BK'W3[4>VYN]NF3714(SO.V+3N..7.!NFX*E
M&A"NRI"(!KZ,YB^4P!J`"-66=VBYM7#2JFID$%VDJ7VECB)J[1,_"%S$44=^
MZP5%F[P=97.I4*>Y4%+4-J.Y7*CL%@?FJ:D?#$<];_B&\*0CP%),QN8R9#&_
MA"0HF_=$-:\A2@)`F4>A;;)YBD%73(1YUXCWA2$9CPO@'+6X&Y"6SBJT']Q.
M2*(EDY00!G;L"@J<">ESDXX`K)BB0-1Y-3+'`-")F'A6)9?G.+8+;S<<FJT4
M[9!Y$>4ZZ1YK;8\91Z]B1YR@(V/IKI)J#JY=_J?`[<[6.)(#KI\2G8!,N9Y]
M4D(`W\H*EF7BH4=D6+=I';?QEMZ&.O2^3,LFY;0`BZ4L\::VK:3G0!`+4B'1
M3"J]0-KI(.@%?7BF1'PJ`NJ?>"R//`Y:++SV[%E;"A*OCGQ_;+3N2?DD>+\(
MKBXGN^]S3"=(2SDF3EN]Y^F2@ZM']VI52_\`M6E#:L&<JAP%SBA+6Z))!'7B
M/$:CW$SX4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A'`B!2F,80*
M4A1,<QA`I2%*&IC&,.A2E*`:B(\`H`29#>8\$@"9V`1%AOD[A]G8?MB5Q]AB
MY8FZLP2R:T<K*0SE"4A\>ME2'2=23Q\W,JS<W&F`\K5H0Q^FI[HKR@0"GDOH
MSH+=LLN+5]RZG=I<4:(4$.`H<JB#,(2DR4&CYZS*8\5,YS$%>]#WOL=TYLC^
M):<UE/7ZB5"2V7&E!QJ@200IUQ:24JJ!N:9!)"O&<D$\JJT3ERY>N7+UZX7>
M/'CA9V\=NE3KN73IRH99PY<+*"919==8XF.8PB)C"(C5B+;;;+:664I0RA(2
ME($@E($@`!L``V`<!%*#[[]4^NJJEK=JG5J6M:B5*6M1*E*4H[2I1)))VDF<
M?A7O'RA2$*0A2$<&,4H:F,4H>R80`/W1H`3NCP5)3Y1`C*5AX0S%E!=-#'N,
M+XNT5#%*#B(MV15CRB<-2&5E%448U!,P>!CJE+^&L:O>98EC:"N_7*BI9<%N
MH"]G0@$K)Z@DF,^Q32W4G.G`WB%BNEP!(',U3N=F)[B75!+20>DK`ZXWDQ_V
MG-U%W>CKW,C9>-6"P%,<UQSX2DJDF;Q'U1;R3\`5+Y2*+I?CK3%][T&FEJYF
M[::RXO#Y)OD03^>Z4[.L),2AQ+N!ZZ9`$/7WZLLM*J1/;O=LZ`?[*G"Q,?!4
MXGPQNY8G9EQTQ!!?)&7[NN-8`*9>/M.(C+:8\X#YQ`>R`S;Y5$P>P5$X>S6G
M;UWN+^\5(Q^U4M.C@IY:WE>'E3V:0?=4(DUBWW;^%T@0[F607&M=D.9NF;;I
MD3XCG7VZRD]7(KKC:^U>V?LWM<A.IBY:Z%B::.;LN>X9103!XF,D@_9-3<WL
M"F)0\@5J^Y]XC5JY$\MR%,@\&&6D#\)2H_CG&_+%W*^[E8TCFL/KK@\ZJJ*A
MT_@[1*?<Y9=49C9;.]JK!$$&^WO$YDP$!U=V=%2"NH`!>+A^BY7$-`_A>/'Q
MK$W=6-3'E\Z[[=.;\FH6D?@20/Q1LBF[O6A=(WV3.)6#D_*HF'#Z2T*5^./1
MF-E6TR=0%N_V^XR32$O*(Q5O(P2V@CKP<0AX]<#?AYM:^U)J_JA1+[1B^W$J
M_+=+@_`YS#\4<2Y=VW02[,]A68E9`W+^JID,'TF.S5^.(Z=X7;!Q!;^++VRA
MA`9FT)VR8>1NE[:KV6<3-MS,/%HB[DF;(9(RLA%/D&2:BB!@6434,7D,7S@,
M&_=*.\?E==DM'C>9=E5T58ZAE+R4!MUMQ9Y4*5R22M)40%#E!`,P=DC#SO$=
MQ_3JUX+<\VTR#]MN]MIW*I=,IU3M,\TTGG<0D.%2VEA"5%LA925`)4G;S"O^
M`Z@`AX"`"'^&ISG9LBI$&8G'-(0I"%(0I")%NV-@LN8-R,9<<NR!U:&(FA+V
ME.LGSM7,^5<K:THU3F`4SF-("=V)1\2-!X"&M:![QN:'%-/G+?2KY;K=5>KH
MD=H:E-]8_FR1/I7TQ,?N0:7#4'69F^7!KGQ_'F_7')B:55$^6E;/`GGYGI'>
M&N(G%I\1U'4?+QJM*+V(XI"(;^[)N?\`B;9;/;I:+_DN6_VB4G?J[=0O5BK(
M*J/HL.<Q#"=%U<SQ(!.40`?0TC>10-9:=U_3CZWNZ\^NB)VZA444P(V+J);5
M]892=GY9'%,5S]_K7']V<9;T@QYV5[O#?:5RDG:U13V-;#,*J5"1&P]BE7!8
MBNW4]XIXA2$61.T_MM/CO&4CG*Z(_H79E5%)"V2.$P!Q%X_:*BHW6(!P!1%2
MYGP>D&_A-TD1#@8=:^>\]J$+_D;>&6UR=KMA)>D=BZI0D1T$,I\4?E%<7.]P
MC1=6&X.[J=?&>7(+^A(IPH>,U0(,T';M!J%_&'I0EKKG)=EJ_P"/Q7C"_LCR
M9RD:67:DU/B!M!ZKABR549-B@80`QW3WIIE#\H3:5'?%[&_DV1T./TPF]653
M;7@"E`*/@2F9/@B:F?9728+A-US&N(%-;:!ZH/66T$I3PF5+Y4@<20!%)V6E
MGT]+2L[)J"K)3<D_F)!01$PG?2;I5ZZ-S&\X0ZZYM-?)5PU+2LT-*U14PE3L
MMI;2/R4)"1^(1^9JXW&JN]QJ+M7'FK:I]QYP[_'=65JW]:C+JCY]<B.'"D(]
MZ,C)&:DH^&AV+J3EI9ZUC8N-8HG</'\@]6(W:,VJ"8"=5=PNH!2@'E&OA4U-
M/1T[E75K2W2M(*UK49)2E(FI2B=P`$S'*H:&MN=:S;;:TM^XU#J6VFT#F6XX
MLA*$)`VE2E$`"+6VPW9_'[7<;^F3Z+5[ER^&S5[>TF0I%`A6P!UF5G1CC03>
MAQ@GU<G*(`X=:FXE(32L?6W59_4G(.RH2I&+42E)IT'9VAW*?6/A+\T'R42&
M\JB^WNK=WBCT+PSMKF$.Y_<T(76N@`]D)312-*^3:GXY$@XY-6T!$M\*TG$J
M(4A&%MPV9X+;]A^]<J3QB');L8<L.P$Q04F+D?#Z)`Q*)1,43F=R"A.?342(
ME.?P*-9?@>(UN=971XS0[%5#GCJX-M)\9U9_-0#+I40-YC6VKNI%ITET\N6=
MW<@MT;![)'%ZH7XC#2>DK<*09;D\RMR3%-"YKDFKQN.>NVXWJDC/W-+R$[,O
MEC&,HZDI-RH[=*B)A$0+U51`H?DE``\E6WVZWT=IM[%JMZ`W0TS26VTC<$(`
M2D?@&WKC\WU]O=SR6]5>17IPO7>NJ7'WEG:5..J*E'P3,@.``$?#KFQU43?]
MIO:H:2DEMSE[QG_1T4=W$XH:.T^#N5#J-9J[RI*$T.A'D$S5F</%8RIP'S`&
MH:]Z#4T4].-.;,Y_>'`E=:I)\E&Q3;$QN*MBUCX/*#O,6?\`<$T%-95*UOR=
MG^ZLE;5J0L>4YM0]5R(VA.UIE7PNT4/)!B?6H/1;!"D(4A$8O<XVK2F=\81N
M0;&8'D,BXH2D71(MLESO+ELYV4KB9B6@%`5%I&.60*[:IA^<T4('G'"I&]W/
M4RFPG)'+%>5\E@N92DK)\5E].QM9X!*@>19X>*3L3$).^UH/7:KX.SE6+M=K
MF-A#BTMI$UU-(L`O,IXEQ!2'6D^<0M(VK$5AA`Q3&*8IB'(8Q#D.42'(<HB4
MY#D,`&(<A@$!`0`0$-!JQW81,;0?_P!;.J*/"""4J!"@9$'801O!&\$<1PCB
MO,>(4A'><?8SR#E>?0M?&]GSUYSJY@*#*"8*N@;E'Q6?N]"LHYN4.)E%U$R`
M'EKI;]D=BQ>A-RR&K8I*)/G.*`GU)3Y2ST!()C*L/P?,-0+JFR85;:NY7-1\
MEE!4$CI<7L0VD<5.*2!TQ,UMR[0C@ZC&YMRUQ)II%%)P3&MF/A.=4/;"WN2Z
MB%("9==`.BP`1$-?=PJ(VH'>J0$KMVG;!YMH-74)W=;3/\BG?0BR31O[O-06
MW>M:JP%(DH6ZC69'\FHJI#JFA@;=OQL3:6/85E8TMQC:-@6O#6C;<<0"-8B#
M9),VQ1``**RXD#K/'2@!YZRQCJG'B8PC4.[S>[QD->NZ7RI>JK@X?&6XHJ/@
M'!('!*0`.`BS'&<5QO#+.U8,4HJ:WV9D20TR@(2.LRVJ4>*E$J4=I),=MKJX
MR"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"/2DI.-A6#F5F9!C$Q;
M)(RSR2DW;=@P:(E]LJY>.E$FZ*9?*)C`%?:GIJBL?334C:W:E9DE"$E2E'H"
M0"2?`(XM96T=NI5UMP>:8HFT\RW'%)0A(&\J4HA(`Z28C2SSW4<`8L,]A<>^
ME9FNQOU40"W%B,K-:.2`)0!Y=3A,Y'I"G\08I.0$`]N'`:D/A/=GSK)0BLOO
M+:+6J1^-',^H?DLC:G9\H4>"(7:J]^S2/`R[;<4+F1W]$Q*F(32(4/AU2@4J
M`/R*79CB-D0IY\W[;C=P`O(Z;NX]G68Y,H4MD6(=Q"12C8XB`(2K]-49><#E
M'0P+K=(P_P`6'``F!@^B&G^#!%11THJ[NF7]XJ9.+!Z4)EV;?5RIYORC%:&J
M_>QUDU9+M%7W`VS&W)CU.A*F6RD^:Z[/MGMF\+6$'X`V2TP``#@```>/`-.-
M;>WQ&H`#='-(0I".!$`TU\H@`!Y1$1T``#Q$1'P"D.KB8V^PQL5W-9R(V?VO
MCM]`VVYY#$NR^3&M6$.B<0#KLRODAE),@`.NK9LH`AY=:U5EVM6G.&%3%RKT
M/W%/]13?'.3Z%<IY$'\]8\$2(TW[J^MVJ"6ZNRV=RCLJY$55=.E9*3YR`L=L
MZ/\`9MJ'7.)/L6]FFV&?H[W,V5Y2=6#0RT!C]@G"QW-P$4SSLP1Y(K$\2B)&
MZ`B'$!*-1OR7O;W)[F9Q&V-,(X.U*BXOP]FCE0#X5*ZYQ.+!?NX+!2\E3J/?
MJBL=&U3%"@,-^#MG0MQ0W@R0V3O'+$B.-=DVUO%`(*VKAVU7$DWY1+-W0V-=
MLR*A?!4'EP'?`@KP\4BIUH3(M8=2<GYDW.[50IU?U;)[!N71RM<LQX28F#A7
M=JT.P$(7C^.V\UB)2>J$>M/3'G<]07"%=:>6-I&Z*+1!-LT11:MD2@1%NV23
M;H)$#P(FBB4B9"A[```5K9Q:W5EQTE3A.TDDD^$G;&\&FFF&TLL)2AI(D$I`
M``Z`!L`C]*]8^D*0A2$*0A2$:!]R3.$=A_;+=L.1RF%V98;.,?VRRY@ZQFTD
MF!;GE.3@;T>-@S*%$X"'*LLG[-;Q[OF&U&6:BTM44GZKMBA5/*X30?B4>%;@
M!EQ2E41.[YFI])IUHG<*)*T_7]]0J@ID<2ET2J7)?!:8*MO!:V^F*HP!H``'
MD#3]RK.M^V*$0)"4<TA"D(4A"D(M-]K_``M_17MEAKDD60M;GRZ\-?,F95/D
M<$@SE,TM)H?4O,"7J@GI)0U$-70CH`B-5I=Y#+_WFU&>M].OFMUJ1ZLB6[M!
MXSZO#VGB'\P#@(O9[CVFW[AZ(TMXK&^2]Y`X:YV8DH,J\6E0>,@R`X!.4W2=
MA)B1FM`Q,:,09XS3:>W[%MT92O!7_H^`::,(XBA".YZ==:I1$$P`X^<ZD78@
M41X@FF!CCYI1K*\)Q"Z9UDM-C5I']X?7XRSY+38VK<5^2A.WK,DC:1&O=4]2
M+!I-@U=G.1JE14C?B-@@+?>5L:8;GO6XN0_)$U'8DQ3GRADBZ,O9!NO)5YO#
M/;BNZ7<RKTW,846B:I^5E%LBF'W*/BF92-T"!P*FF'X:MDQO'[;BEBI<>M".
M2@I&@A/2HCREJZ5+5-2CTF/SG9UFE]U$RZOS7)'"Y=[A4*<7\%"29(:1T-M(
MY6T#@E(XSCH5=Y&)QMELQVUR&Y[-<-9JB;A&RH,$KDR)*)%,4K6VVCE,HQB2
MW*8I)"X'&C9`!X@`G/IH0:U?J[J&QIQA[UV24F\/39I4'BZH'QR/@M#QU>X.
M,2`[M>BU5KAJ93X\Z%IQBD`J;@X-G+3I4`&@9&3E0KXM'0.=6Y,6^&#%E%L6
M49&M46,=&M&S"/9-B`FW9LF:)&[5J@F70I$4$$RE*`>`!55+SSU2\NIJ%%=0
MXHJ4H[2I2C,DGB23,Q^A>EI::AI6Z*C0END9;2A"$B24(0`E*4C@$@``<`(C
M%[MF1#VCMB0L]JL9)YD^](>"4`AM!/#PG/<<F4Y0T,*:BK!`HCX`(@`ZZU(W
MNN6!-UU'-U<`+5MI''1/Y1SXI'N@*48A)W_LQ7CVA_[OL*(J+Y<6:<R.]IHF
MH<GU'LTCPD3WQ6/JQF*0X4A`1``$1X`'$1'R!2!,A,[HG[[7&S`8-FPW,Y.B
MA)-2*"@XG@'Z`@>+BW"?34O=T@J'F/I-(YB1X&#5)#5;Q.00@WWD]7A6NKTZ
MQQV=&VK^^NI/EK!V4Z2/-0=KLMZI)W),[:>XQW;%6BF:UJSBGE=7T?\`M;#@
MVM,J&VL6DC8XZ#)F>U#<U[UI(FYJ'$6;0I"%(1!3WGK_`)))/"^+FZJJ44\"
M>OJ52*)@3>.VJB<)#`IP`I_0BJ.C:"(^<H`Z!H`U-/NBV.G4J[Y(X`:E'94R
M#Q2%3<<E^=)`GU$15K]Y)EM8VQC>"LJ4FA=4_6NC;):D299GP/)S.F720>`B
M"&IL155&QVU;;O<.YO,-OXYB0<-84IBS%[SZ28F3M^TV2I/6#GGX$!\]$P-F
MA!'SUU`'P*80U_J9GM#IUB;]_JN559+LZ=HG:Z^H'E$M_*GRUG@D'B1&YM!M
M'KMK;J+28?1!;=I!#U<^!L8I4$<YGN#CG]$T#O6H'<DQ<%M*U("Q;8@+-M6-
M0B+;MB)90D+&MB%(DTCV")4$$PY0#F4,4O,<P\3G$3#Q$:JCNESKKU<7[M<W
M%.W"I=4XXL[U*49D^#H'`2`C]$5@L5IQBR4N.V)E%/9Z)A#++:1)*&VTA*1L
MZAM.\F9.TQV&N!';PI"%(0\.(4A$;^Y3MF83SU,R%Z6^]?XHOR444=2LE;K-
ML]MZ=>J!S&>2UN+F023?+'XJ+M5$#'$1,<IS<:D#I[WBLQPBD1:*Y"+G9&P`
MA#JBEUM(\U#HF>4#<E84!N!`B&VM'<HTRU8N3N26QQZPY4^2IUVF2E3#ZSY[
MU.J2><GRG&U(4K:5<QVQHT'9;OKTO0<]6CZ#S?G`LJ:],Y.<0Y>EZZZ'/T^/
M-S:<W#ETXUNC^+VR]E/ZDJNVZ/6&^7\/9SW\);N,1<__`.:V2]O+]ZZ'U6>_
MU)WGE/=+UCEG+CT\(V6Q9V@,&6JY;R.3+MNO*+E$4U!B"`E:5MG4*(&,1PA&
MJN)=XB.FF@NDP,`\0&M=Y+WK,TN;:J?':6EMK9F.?:^[+J*P$)/\P]1C=F"?
M=Y:5V!Y-9FE=7WUY,CV1E2T\^(4AHEU8X;70"-Z3$GUCX\L3&<(C;F/;1M^S
M8-`I"ECK>C&T<BH)"\H*.3($*L\7$/%14QSF'B(B-1PO-^O615AN%]JGZNM5
MY[JRL[>`F9)'4``.`B;V,XEB^%VQ-FQ.WTENM:``&Z=I+:=FR:N4`J5TJ42H
M[R28[C74QD4*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$=`R+E7&^(
MX12XLF7M;EDPZ93&*YGI)!HJZ$OBE'LA,9]).!\`3;IJ',/``UKO+!C.0Y36
M"@QVCJ*RK/!M!4!UJ5Y*!UJ(`Z8Q+,,\PS3^V*O&:7.CMEN2/*?<2@JEP0B?
M.XKH2VE2CP$1&9P[Q%K18NX;;_8CFZG12J)$O2^@7AH--7SB`M'VTW'UQ))!
MP,47"S,!_@B%2HPWNG7*IY*O.:U-,UL)IZ:3CA'0IT_%H/`\J7/#%?6IWWBU
M@H"Y;M)[4Y<'P"!65O,RP#M$VZ=/QSHX@K4SX#$.69=RV<,^OCNLI9!FY]EU
MCK-;<15"+M6/YAU`C*WH\$(X`('`#J%45T\3#4LL2T[PS!V0WC=`RP]*1=(Y
MWE?G.JFKW`0.J*Y]2-;=4=6:DNYS=ZFJI.8E-,D]E2HGP2PW)&SI6%*Z51@J
MLUC54*0A2$*0C.&W_;WD?<G?S2P,<QI%7'(5Y/3[\%4X"U(?J`FK+3;M,AS$
M3YAY442`99PIYI"CQ$,,SK.\?T]L:KYD#A")\K329%UYR4PAM)_"I1DE`VD[
M@=HZ1Z0YEK3EC>)X<R"Y(+?J')ABE9G(NO*`]Q"$S6XKQ4C>19/VU]O'`^WQ
M"/F7D2ADS(Z*:9W%YW:Q0<MV3P/.,:V;>5%Q'PJ1#^T4'K.N`"*ODJO74/7G
M-L[6Y2-.FW8^294["B"I/]LZ)*</2/%1^3%T>BW="TKTA:9N+U.F\YDE(*JV
MJ0%!"^/JS!YFV`#N5XSNS:Y&^OD`/(`:`'D`/8`/``K2,2K_`)(4A"D(4A"D
M(4A"D(4A&+\PYCQ_@FQ);(F29Q&$M^+3$$R:E4DIF0.4PM8:#8`8%I*5>G+R
MIIDX`&ISB4A3&#),3Q*^YK>VK!CS)>KG3MX(;3YSCBMR$)WDGP"9(!P;474;
M$M*\5J,PS.J336E@;!O<></D,LHWN.K.Q*1UJ44I2I0J8;JMR]V[I,I/[\GR
MJQD$R(I%6/:GI'7;VS;I%1.FB8Y2D3<2C\_NSQ<`#G5'E#S"%`+1-,].[7IK
MC2+)0D.5JR%U#\I%YV6T\2$)\E"9[!M.TF*!->=;,@UTSEW*+J%,6AH%JAI.
M;F33,3G(D`!3KA\=U<MJI)'BI3&M5;#C2D*0A2$*0C)6&K"4REEK&V.2:@6]
M+UMZWW)@U]S8OY)`DBJ(AH)2IL04$1_)`-:QW+KV,:Q:XW\[Z.C=='6I*#RC
MW52C-]-<3.=ZA63#1Y%RN=.PL]#:W$]H=FT21S;>&^+KL;&,86-CX:,0(UC8
MABTBX]LF`%3;LF#=-JU1(4```*F@D4`T`/"J?*BH>K*ARKJ%%50ZM2U$[RI1
M))/A)C]+U%1T]NHVK?1I"*1AI+:$C<E"$A*4CJ``$?E,S,3;L3)3T](LX>%A
MV3B2E9207(V91[!HD99RZ=+J"4B2**91$1$:]J2DJJ^J;HJ)M;M8ZL(0A()4
MI2C()`&TDF/2XW&@M%`]=+H\W3VVG;4XZXXH)0A"!-2E*.P``$DQ51WY;Q7V
MZ7(2;"VU'K##]D.7+>S8Q<3)*3ST1.@[O.4;<.1S()!RM4CZBV;<.!SGJS71
M+29G32Q%^X!"\KK$@OK&T-)WIIT'H2=JU#RE]21%#?>K[QE3KIEJ:*REQK3R
MV+4FD;5,&H<VI56.IX%8V-(.UMO?)2U1H76[HBC'T8>'E;AEXN`@F#F5FIN0
M:141&,TQ5=R$D_7(V9LVZ8<3*KKJ%*'D#74>%<>KJZ:@I7:ZM6EJC9;4MQ:C
M)*4)$U*)Z`!..;;;;<+S<6+1:F5U%TJGD-,M($UN..*"4(2.E2B!^,[(MR;*
M=KT=M<PZPMIR5H[O^Y3(3^1)I`H#UYE1'1"%;+^V4B[=04%!'R'/U%-`$XU5
MEK!J14:DY8Y<6^9-CIYM4K9X-@[7"."W2.970.5/FQ^@ONT:'T6ANG+-D=#:
M\LK.5^X/)\Y\C8TE7%JG2>S1P)YU[UF-OZU3$AX@8[U$BY&1V]Q`")68,LAR
M1@U'E5="O:S4@B73EYD$@-H.NNB@U-ON@4[?J]^JOZ[GI4>`2>)_"9?@BJ;[
MRNL?];Q&WS(INSN#A'`JG2I&SI2)R_.,095-"*N84A$BW;RV=*[D\A&NZ\V*
MY<.X^?-G$X8Y3II7?<"9DW+*SVJOF\[7DT6D3$'S$!*GJ!E0$-!:\ZL)T]L(
MM5H6/WLKT$-RVEAHS"GR."O-:!WJFK:$F)C=T#NZ*UGRXY#DK2AIW:'4J>F"
M!5U`(4BD2>*`)+J"-R)(F"X"+32**+=%%NW12;MVZ2:#=N@F5)!!!$A4T444
MB`4B:2290*4H````:!5::UK<67'"5.*))),R2=I))WDG>8O6;;;9;2RRE*&D
M)"4I``"0!(``;``-@`V`1^E>L>\*0A2$1^;_`#9F\W6V=;K^SY2.A\EV$I(&
M@1F#*(Q%P14F5(S^`?O$4UE6"PKMB*M5^0Y"*<Q3E`IQ,7>NAVKC6F-VJ&;L
MTX[CM<$AWLY%QI:)\KJ4D@*$B0M,P2)$&:0#$CO9=W"IU[QNCJ,=?9ILTM*G
M"QVTPR^TZ!VC#BD@E!)2E32Y*"5`A0DLJ3"Q#]KK>1)S9(AW8<!`M>L":]P2
MMYP!X5!/F`#."^K7+^3<D*`Z@4C?F-[%2_J^\EI-349JVJU]]R4PTBG=#A/1
MXX2@>$KD(K2MW<:[QE==!;JBU4E*QS254.UC!9`XJ'9*6ZH#H#<S$^&SO:3:
M^TS'SJWV,@2Y;TN9PWD;WN\6GH823MNF8C2,BVYSJK-8.**H<$2&,)U#F,H?
M0QN4L']6-4KEJA?4U[R#3VBG244['-S<B29J6L[`IQ<AS$"0`"1L$S;#W=M`
M+'H%B"[/2.BMR.M6ERMJ^7D[5:1)+;:9DI9:!(0DF9)4M7C*D-NJU7$@X4A"
MD(4A"D(4A"D(4A"D(4A"D(Y`IA\"B/X@&DQ".K7#?%E6BFHK==X6M;*:1>=0
MT_<$5$<A>7FU$K]V@;B7B'#B%=E06:\74A-LI*FI43(=DTM?^JDQT5WRC&L?
M05WZXT-$@"9+[[36S?\`UBD\(ULNS?KM!LT5B2F=K-?N$N8/1;8/(78L<Y=-
M4R'MYE(M@/\`Y2A0UX:ZUL*UZ(ZJW>1IK+5H0>+P2P/#\:I!_`#&EK_WKN[S
MCG,FNRFVNO)GXM,5U1)'"=.AQ(/A4(UJNCN];7H8%"6[$9.O-<G,!!86VSA6
MASAKR_RBX)1BJ"1OX0)&'3P`:V';>ZKJ15D&O=MU(@_">4XK\#2%"?5,1I>^
M_>%Z'6T%-H8O=R=$_P"CIDLI/1XU0ZV9=82?`8R_M;[@F)=TEU/+#@;?N^SK
MS:Q#F<0B[B18.V,G',CHD>G82T4Z<)@NT%<HF3731$Q1U+S:#6*:E:%91IK;
M$7NM?I:NT*=#96T5!2%J!*>9"T@R5(R*2K;OE&Q-"^]OI_KI?7<6M-)<+=D;
M=.I\-5"4*0XV@@++;K2U":.832L()!FF<;XUI.)50I"%(0I"%(0I"%(0I"->
M\Y;IL&[=6(N,H7S'QDJHW%PPM..`9>[I0H`'+Z)!,A.Y334UX++]%#V3UG>&
M::YGGS_9XW1..4P5)3ZO$81^<XJ0)'P4\RNJ-1ZH:Z:7Z/TG;YQ=&6*TIYFZ
M5OXVK=_,81-<C/8M?(CI4(A8SOW>LFW4+Z$P3;#+&T(IU$$[KN!-O/WJND.I
M.NT9&YX"#.H4=0U(\4(/@<!#4)?X3W5<=MG)69K4KN%8)$LM$M4X/0I7]*Y+
MJ+8/$$16GJM]X7FE^+MKTKH6[-;#-(JZ@)?K%#=S(;VL,D]8>4."@=T3]Y7Q
M>619US<]^W3/7C<+LPF7E[BDW,H\'7\A([E0Y&R!0X%32*1,H<`*`5)ZT6:T
M6"B3;;'3,4E`D;$-("$^$R&T])5,GB8@+DF49)F-U7?,KKZNXW=P^,[4.*=7
MX!S$A(Z$I"4@;``(ZM79QT4*0A2$*0A2$=NL*Q+IR;>5NV#946M,W1=,DA%1
M#!$!#G76$1.NX4T$K=DT1*95=4WFII$,8?"NJOE[MF.6BHOEX=#-MIFRM:CT
M#<`.*E&24@;2H@1D6)8I?LYR2CQ+&6%5%]KW@TT@;IG:5*/FH0D%:U'8E()B
MW;M2VRVCM;Q:PLB!!)_<<B#>4OVZ13`KJY+D%`"K'*80`Z<1&\QD62/@FD',
M/GG.(U7:G:BW74K)7+Q6S1;VYHIF9^*TU/8.M:_*<5Q5LW``?H1T%T3Q[0S!
M6<8M(2[=W>5VNJI274U'+)1GO#3>U#*-R$?E*43LS6NHW9"D(4A"D(4A"D(4
MA"D(U>W0;M,7;6+3]<7D]"5NJ205&T[`BW"(W!<*Y=2`L<AA,$7"HJ?GGBP`
MF``)2`<^A!V3IOI=DFI=T]4M*.RMC9';5*P>R:'1^6X1Y+:=O$R3MC1VM^OV
M#:%6#ZRR1WM[V\D^JT+2AZQ4*&R<C_1M`^6\N21(A/,N235LW%;E<G[F[V4O
M#(DH`-FO50MJTXTRR-MVK'',(@UC&9U#]1TH73KNU>9=<WB(%`I"V48#IYCF
MG-G%IL+?QBI%Y]<BZ\OI6H#8D>:@22D=)F319K%K5F^MV3JR++WI4S9(IJ1L
MD4]*V?-;23M61+M'536L\0F21K_6=1J2%(1(SM8[;F5-R=I&R"_N!CC"RGG7
M2MF0FH=W*2ETJ(\Q!>Q\2FYCQ1@O2"]/TI14.H("*1#E#6M`:E]X/&=/;I]1
M4["[E>$2+R6W$H0S/S5+*53<EMY`G9L"BD[(F5H3W,,YUFQXY?7UC=CQISF%
M,MUE3KU21_6(:YV^5CF\4.*5->TH2H"<:"W7;KZT+HN2TY,4S2-L3TM;[\R7
M-TCNXA\NP7.D!P*<$SJ("(:@`Z#QK>%KN#-VME/=*:?J]2PAU,]_*XD*$^N1
MB)N0V6JQN_UV/5TC6T%6[3N$3D5LK4VHB>V1*9B>V/@5SXZ>-AMIE]1&-=RF
M%KUGSHHPD/?<465=+@7HL6,IU8A=^IS"`%*Q*_ZO-^3R:^2L"U1LM5D.GEXL
M]"":UVB64)&]2D2<"1^=R\O7.4;C[OF4V["];,:R6[%*+93W1M+JU>2A#P4R
M7#T!':<T^$IQ<#O.^[-Q[:TC>]ZW+$6W:46V],>3TF\218%0,7G1%!341>*N
M2_FDT@.HJ(@!`$1JJ2T62[WVY-V:ST[M1='%<J6T))5/<9CS0/.*I!/$B/T/
M9%E..XE8WLER2MIZ*PL(YUONK"6PF4Q(^<5>:E,U*.Q()BM%OF[@,]N2<NL>
M8]!_;.%&3LIU$5]6LY?SEJH)D7\^5-0?185-0`.W8:CJ8`46YC`4I+$=&-"Z
M'3UM-^OW9U.8+3L(\9NF"AM2U,>,X1L4[T32B0F54J=Z/O;W769YS#\.[:AT
MS;7XP/B/UZDG8M\`^(P"`IMB>TR6[,A*41IU(>(4P$0`!$1T``U$1\``/$1I
MOV#?`D`3.Z+`':[V6FMUG'[F,H17+.RK0Q\46^_1#J0T4Z(8BMZ/6ZI>9*3E
M$1Y&`&`#(MC&5TYE"B6#'>2U?%P=<T[QMV="TO\`OKJ3L<6G=3I(WH0=KDMB
ME@)W),[;>XYW:562F9UJSAB5WJ&B;93N)VL-+$C6+2=SKJ=C((!0T2O>X.6;
M2H=Q9E"D(BI[L>"9W)^%K=R+:T>YEIG#\I)/Y./9I'<.U;.N!!HC.NV[=,IE
M%C13F.;.%`*`B"!#CIH`B$FN[!FU%C>7OV"YN):H[LVA*%*("0^T5%L$G8.<
M+6D?E%(B!_?XTIN>=::TF7V%E=1=,=><<<;0"I:J1]*4OJ2D;5%M3;3AE,A"
M5F45H`$!`!`0$!#4!#B`@/E"K$=VPQ2@"")C=&<]O&W^^MR62X?'5D-#AZ0L
MBYN6X%4CFB[3MXJQ2OYJ36`.0HII:@W1UYW*_*0H<1$,+SW.K+I[CKM_O*AX
MH(9:!\=]V7BMH'6?*5N0F9/">T]'M(\IUHS2GP_&6R$J4E534$'LJ6GF`MYP
M[IRF&T>4XN21Q(M\8@Q/9^$,=6SC&Q6(,K>MAB#9(YP)Z9)O51%:1F9-4H!Z
M1)2CLQE53CY3<H:%*4`JJRO*+MF5_J<CO2^>OJ5S/P4)&Q#:!P0A,DI'5,[2
M3'Z&-/<"QW3+#Z+"<6:[*T4+02)RYW%G:XZX1+F<=62M:NDR$@`!DJL=C-(4
MA"D(4A"D(4A"D(4A"D(4A"D(4A"D(_-=9%JB=PZ61:MTBB=5=RJF@BF0H:F.
M=54Q"$*`>(B.@5[(0MQ80V"I9W``DGW!'HXXVRV77E)0TD3))``'22=@C`EZ
M[JMMV.^H6\,V8[BET@$3LDKC92TCJ&NI21T,>0>G.&G$H$$0K-[/IGJ#?I&T
MV>O=0?.+2D(]-P)2!USC563:[:-X>#^\>2V>G<2/(%0VXYX`VT5N$]023&HM
MZ=VC:G;0KI6\K?F0'"8#TQM^V#1K%<0\.1]<CF)T`?PIAH%;4M'==U.N'*JO
M314+9W]J\%*'\UH+_EB/62=_W06R\[=I7=+L\G=ZO2E"%>!=0ID#W1&IUY=Z
M.54YT\>X*8-0`#`F\O2[5W@F$?:'-'P;!H!.4/$OI!]1\M;/M/=#IDR5?KTM
M72FG8"?])Q2I^'D'@C0>1_>45BB48ABR$#@NLJRJ?66V&Q+P=H?#&K=X]UO=
MS<P*IP\S9-B-U0$H$MBT&KAR0@^P^N1Q.+%4_P`9,$_Q5LNT]V/2RW255LUE
M:X.+SY`]%D-B749QHC(N_KW@KWS(MU3;+4PKA34B5J`_/J5/F?6D)\$:KW?N
MJW*7YU2W5G+)<D@OS]1FA=#^'CS%.&ADQ809XUH9+0=.42"%;+M6F>GEDD;9
M9;<VL2DHLI<5LX\SG.J?6#&B<AUXUIRH*3?LHO3S2IS0FI6RW([QV;!;1+J(
M(C`[QPYD%17D7+F07$PG%=^X6>K"8?$PJNCJGYA]G6LV:;;83R,)2VCH2`D?
M@`$:JJ'GJMSM:Q:WG9SYG%*69],U$F#-LY?KD:Q[5P^<J&!--LQ;JNW"AQ\"
M$0;$45,8?8`-:/.-L(+M0I*&P)DJ(2`.DDR$>:6G?K'13T3:WGU&02VE2U$]
M`2D$D]4HVFQ3LDW/9A>M4+9Q1<<3&.#$ZMRWHS7M&WVB1N(K*N9=)!TX`A!U
MZ;=%940$-"UK3)M8].,494NX72G=J4C8S3J#[JCT`()2)]*E)'7&^,#[L&N.
MH=2VU:+#64M"L[:FM2:1A`XDET!:I#;RH0I1X"+"VRG8U:VTZ*D)Q_+%O#*U
MSQZ+"X+D31,WB8J.(H5P:!MAHJ'739G<E`R[E4>LY$A>!"@!*@?K!K/<]4*E
MNC9:]4QFF65--3FM:R)=H\H;"J6Q*4^*@$[23.+>.[5W7K!H%0/7*H?^L<[K
MFDHJ*F7*TVV#S=A3(.U*.;:M:O'<($^4`)C?*M)1*J%(0I"%(0I"%(0I"-`^
MX?NDFML^'69[).1#(N1))Q;EKR2J*;A.WFS=J+F9N$$5BG16>,D#$3;%.4Q.
MNJ!A`0+H.\=!=-J/43+5"\`FP4#8=>0"0723)MJ8VA*C,K(,^4$#?$3N]]KG
M<M%-.$.8T0G,+N^::E<("@P`DJ>J.54P5(3(-A0(YU))F!(U7)V=F[HF)&X;
MDEY*?GI=RH\E)F7>+OY)^Y5,)CK.7;DZBJAA$>`:\I0X``!PJS"BHJ.VTC=!
M;FFV*%I(2AMM(2A('`)$@/Y3QBB&[7:Z7ZY/7F]U#U7=JA96Z\\M3CBU'>5*
M423U#<!L``CY5<J.OA2$*0A2$*0A2$!$``1'@`<1'\%($R$SNBR+VN-I">,+
M'3SU?429+(>08[2TVKU+E<6M8CPJ:J*Y4E`YVTK=!0!90=`.1ITR<.<X#7SW
MD]4CDEY.$V5V=AH'/CE).QZI3,$3&]#/D@;BOF/`1<_W&N[ZC!<63JGE-.4Y
ME>&?[LE8DJEH5R*=AVI=J9!:SO#?(GBH&6^HM18!"D(4A"D(4A"D(4A'(`(C
MH'C2$1>;SNY#9F!B2>/L4J1E]Y>`BC5XN50'=JV&N<@AU9E=`_)*S;?4!*P2
M-H0WY\Q=!(,D-(N[[=\W+=]R8.46*3"DB7*]4CH;!\AL\75#:/(!WB#_`'DN
M^5C6DZ'\2P8LW744`I5MYJ:A41O?4DR<>3O%.D[#_2J2`4FMW?=^WEDVZ92]
MK_N.3NJZ9E7JOYB6<"NX.4!'I-D">:BS8MBFY4D$BD22+P*4*L&LECM&.6QJ
MS6.G;IK8R));0)#K4>*E'>I2B5$[S%,65Y;DF<WY_)\MK'J^^U*IK==5,R'D
MH2/)0VD;$-H`2D;A'4:[6,=@(@`"(CH`<1$?``]D:0)`$SNB6W8'V\GV87$7
MF'-D4\C,4-U$WML6NY`[.0R(X15`4W+Q(P%<-+.(8G$_FG?:<I-$M3C%K7+7
MEG%&W<3PYU#F3J'*\\/&32@C:E)W*?ZMH;WGQI`6#=TWN?U6H3K&HVIU.XQ@
MJ%!=+2*FARX%)F%N`R4BCGX%/[DR;\8V/V+-G&M&<?'-&S!A'MT&C%BS13;-
M&;1JF5)NU:MTBE20;H)$`I"%`"E*&@57Z\Z[4.K??4I;ZU%2E*)*E*)F22=I
M).TD[XN3IJ>GHZ=NDI$(:I6D!"$(`2E*4B24I2)`)````$@-@BH1OLLU6QMV
M^<HDZ)DD)*\5[K9")>0JS2[6K:?ZR8?\6#M\J37PU(-6JZ*7=-ZTMLU2""MN
MD#"NI3"BU(]?*E)]V/ST=ZG'',8[P6442TE+51<35HF)<R*M"7RH=7.M:?"D
MQJ56THC["D-\=HF+XO6XHF*@+@O&ZIV"@R@2%A9BX9:3B8DI0Y2!'1SUVLT9
M\A!Y2\A"\I>`<.%=9266SV^J=KJ"DIF*U[^D<;:0A:_SUI2%*GO,SM.V.^N6
M4Y/>;>Q:+Q<J^KM-*),L/5#KK34M@[-M:RA$AL'*!(;!LCJ]=G'0PI")7^W1
ML56S3-,,T96B5$\1P#X%K=@WR)TPR-,LU-2F,0X%$]I1JY?=CAYKM8O2+J0%
M!J,&OVM2<0I',0QAT?O2^B3KB3_]*VH?B?6/)'F)/,=I3$_.YQW67-2+BSJ9
MGU.1@-*YS4S#B3_[@\@[%$'?2-J'C':'ECD'BA<64DTTT4TT44TT44B$2212
M(5-))),H$3223(`$333(4`*4````-`JO12E+45K)*R9DG:23O)/28N@0A#:`
MVV`EM(```D`!L``&P`#8!'G7B/>%(1P8I3E,0Y2G(<IB'(<H&(<A@$IB'*8!
M*8IBCH(#P$*\@D&8V$1X("@4J`*2)$'<1$>.3.V!M5R5<ZUUA!7'8SQ^Z,[E
MH^Q)HD3!R*RIS*.%0BG+-\WCEG!S:F%MTB:\0(`CK6^,=[Q^IN/6T6SMZ>L9
M0GE0JI;[1Q`&P#G"DE0'#GYCUQ$/-NY!H/FM\7?U4=7;:IU?.ZBA>[%EQ1)*
ME=D4K2A2B9DM\@XRF9QMCAG`^*MO]KC:6*K39VU&K*)KR;H#*/)F<>)DY"O9
MN7="H]D%RE$>4#&Z:8"($*4!TK6&79MDV<W+ZTR:J745`!"!L2VVD[>5M`DE
M(Z9"9XDF-]Z<:68)I-8_W?P2WM45$H@N*$U.O+`ESO.JFMQ71S&29D)`&R,O
M5BL;"A2$*0A2$*0A2$*0A2$*0CG00`3#P*`"(F'@4`#Q$3#H``%.,AOANWQB
M&^<_80QFFH>_<L6#;!D3"51M(W-%A(%,`:B3U:@X6?B<?('3U$>`<:RJRX/F
M.1*";):ZZI!W%#*^7TR`G\<:_P`HU6TTPI"EY7?K50%)D4NU+06#T=GS%<^K
MEC3"^^Z[M/M(5T("2O#(KQ+4"%M>VEVD>J<!T,4).X5(E/0-.!BD,4WD'2MN
MV3NQ:GW3E77-TE`T?EG@5#^8UVA]PD'JB-F5=_70+'RIJU5%PO%2G<*6F4$$
M\1VE061[LB#P,:9WUWG[E<=5'&F%(>+(/.5*0O:XG4JOH(CR*C&0K>/;IJ%+
M^2+A4HCY:VW9>Z);VY+R*\.N'BFG:"!X.=PJ)'7RI,1QRG[R6[.E3>%8RRTC
M:`Y6U"G#U'LF$H`(Z.T4.N-.KV[F6\.\^HFCDAI9C0_-HULBW(F($@&X!RR#
MQ&3E`,4/*"X:CQT\--LV?NZZ46B2E6]=8Z.-0ZM?^BDH1_HQ'+)^^UWB,D!;
M:N[-LISYM%3--D?[QP.NS\"QX(U)N_+.4\@+'7OG(]\78HH83&+/71,/VX&'
M41$C15V+-(!U\")E"MI6G%L9L2`BRV^BI4@?U;+:3[J@GF/NF(_9'J%GN7N%
MW*;U=;@HF<GZEY:9]2"KD3[B1&/"D(742E*41'41`H`(B/$1$0#B(C7?DD[R
M8PX)2-H`F8&,4NG,8I=1T#40#4?8#7Q&O`!.Z!4E.\@1DBRL097R.N1O8.-K
MXN]10P$*>"MJ5>M>8?`IWQ6P,4Q_RE`K'[QEF+X^@KOEQHJ4#@X\A)]&?,?<
M$9KC.F^H.:.!K$[)=+@29`LTSJD3Z"YRAL>ZH1NG8/:RW;7GZ.O+VW;>.V"P
MD$R]Y7$U]-33,/MAB(,)5X4Y0\2*=(U:@OG>6TMM',BDJ*BO?$]C#1Y2?SW.
M1/NCF$26Q/N(Z_Y'R.W*EH;/2*EXU74)4L`\>R8#JICBE108W3L/LP1"0(KY
M.S9(/5`$!6C+%MU!@@.@AJ4):>5>+F(<-0X-4S!Y!K4%[[W=4HE&.6=M">"Z
METJ/H-A(V?GD1)3%?NVK6VE+N;Y+4.N<6Z)A#2?G7BXH@C^S21P,;GV/VS-G
MME%3.OCAS>SQ,"_RN^K@E9H#&#Q$T<W681)@,;CH9`VG@`UJ*]=XG5>\$A%P
M31M'S:9I#?\`I$*7_I1)/%^Y3W=L9`4NR&Y5`\^N?=?_`/[?,AH^ZV8V_M'%
M^-;`0(VL>P+-M-(A`('J"VXF,5,4H:!U'#9J1PL.@>)S&&M4W7),AOBRY>:Z
MKJE$_P!:ZM8]P*40/<$2&Q_"<.Q1D,8S:K?0-@`?$4[31(&Z90D$^Z28[V(B
M/B(C^,=:Z6,HCBD(4A"D(4A"D(4A"D(4A&E.^G:D?=7B9O`P;]I%9`LZ24N&
MR'D@)DXUXZ5;"UD8&47(111LTEFH@!50*8$ER$,("7FK<&B^IHTRRE5=6MJ=
ML=6WV50E.U:4@\R'$`R!4A6],QS)*@#.41H[TF@RM>=/TVBUNMT^66Y_UBB6
MYL;4OE*'&72`2E#J#(*`/*L)400#%7;).#<OXAF','D?'5V6N\;*G2!=W#NU
MHIV!#"4%XZ9:)+Q<@V4`-2G25,`@(:Z59)CV:8IE=(FLQ^X4M2TH3DEQ(6GJ
M6VHA:2.(4D11MFFEFHNGEQ7;,QLUPHGT*(YE,K4RN7G-O("FG$G>"E1V;Y1T
MF(M2Z[@=$90%K7+-O%#`5-I$0,M).3F,(`4I46;190PB(Z``!7<U=TME`V7J
MZIIV61O4MU"!^%2@(QBW8]D-W?%+:;?7552=R&J=UQ1\"4()C;O&O;OW;Y-,
MBJTQ:\L^+5Y##,9">-[5;$2,.G5!@YZTVN`!^21J8W#P"M59%KWI;C@*7;DF
MKJ1_5TJ2\9]',)-CW5RB0N%=SSO`YLI*V;&NVT*I?&W!::8`'CV9YGU>`-$Q
MO_8'9?$4TU\IYM,140`58O']ND$H:AKH$U<*I_.(/`=&0@/CPK1M\[W<E%&-
M6<<O!=4Z?^&T!_Q(EGB7W;*2@.YWDRNTXM4%.`/GJ@JVC_8R/5$;^]7;?`[7
M,R_T<6U=;Z[(AU;,5<C9Q+I-$IN."14<HF82@,$D&:JFK;J)G(F3F3.&I0$.
M,@=']0:[4G$OW@N%*BEJDU*VB$%1;7R@'F1S$J`VR(),B-\0T[S&C%IT,U&&
M'V2O=K[>[0MU"2\$!YKG*DE#O9I2@D\O,E02F:3M&S;J-6U(CU"D(WN[?6V$
M=R&;F9K@9'6QGCKT2Y[W4.01;2BI'!1@K4$^I0$\V[2$RP`.H-$5/9"M)Z[:
MC^S[#EB@6$Y%<.9FGV[4"7QCW^[29)_+4GHB5?=$T0.LFIS;MW:*L)LW)4UA
M(\1U05-BEGL_IE`J6)_T2%](BV(FFFDF1)%--%%(A$DD4B%32223*!$TDTR`
M!2)ID*`%`````-*K!4I2B5*)*B9DG:23O)/3%^24(;2$(`2A(D`-@`&X`<`(
M\J\1[0I"%(0I"%(0I".L7E>EI8\MN3N^^+ABK6MF'0.XD9F8=IM&:!"%$W(4
MR@\R[A331-),#*J&T*4HB.E=E:;1=+]<&[59F':FXNJDAMM)4HGW-P'$F0`V
MD@1TF19)8<1LS^0Y-5L4-EID%3CSR@A"0.L[R=R4B:E'8D$F45[=XG=#NG)@
M2F/-ORLI9%@J@JQE+X,)V%Y78W,!DUDXP"CU;8A'!1TU*(/5B>V,D`B2IW:3
M]VZVXZ6K]G0;K+X)*13>4PP=X*^#S@Z/Z-)W!1$XJ+[Q??EO>9A_#](E/VW%
ME30[7;45=4G<H,C?3,JW<W],L<6P2F(A1$3&,<QC'.<QCG.<PF.<YS"8YSG,
M(F.<YA$1$1$1$=1J50```&P`2`X`=`ZHKP4I2E%:R2M1)))F23M)).TDG:2=
MI.^.*\QXCS33454311346664(BBBB0ZJRRRI@(DBBDF!E%553F`I2E`3&$=`
M#6O"E)2DK60$`$DDR``VDDG8`!M).P1[(0MUQ+325+=6H)2E()4I1,@E($R2
M3L``F3L$3F[&.V6=R,1E_<K"BFW`6LI9^*'H&*JL8I@7;RU^MS%#E1X%,E%B
M.IN`N.'N0POUH[Q:4!W%-/'IK\9#]:G<.!13'IWA3WN-_"BTGNN=R52U4^H>
MM--)`*':2UKZ?*2[7I_`44VT<7ODXG@222;I)-VZ22#=!)-%!!!,B2*"*10(
MDBBDF!2)))D*`%*4```#0*A.I2EJ*UDJ6HDDDS))VDD\2>)BU%"$-(2TT`EM
M(```D`!L``&P`#8`-T?I7K'O$!/>)P@^;W#8NX&(9'5B9&.1Q_>3A$AC%92C
M)5R[MAZ[,!1`B4@T75;`81``41*7Q.%3B[IV9,.4-;@M4L"J;<-4P"?*0H!+
MR4]:2$K\"B>$5/?>+:8535SM6KEO;*J%QH4%8H`GD<25+IEJ/`+2I;<]P4E(
MWJB$&IDQ6#"D(4A"D(D_V&]O^:W`24=D[*+!Y"X38..LT:J]1G)Y'=-C@(,X
MT!*"J-L%4#1R\#3K@`I(B(\QR1OUMUSH\&IW,<QM:7LQ6F2E"2D4@/G+X%Z6
MU"/-\I?`&<G=2[I=RU9K6,ZSIE=/IFTOF0A4T.7%23L2@2F*4'8X[L[210W/
MQE)LRQ,3%P,7'PD)'LXF'B6;>.BXR/03:L8]@T2*BU:-&Z)2I(H()$`I2E``
M``JNNJJJFMJ7*RL<6[5NK*EK42I2E*,RI1.TDG:28NPH*"BM=$S;;:TVQ;V&
MTMMMMI"4(0@!*4)2)!*4@```2`CZ%?".7"D(4A"D(4A"D(4A"D(4A"D(4A'J
M2$A'Q+51[*OV46R1*)U7<B[;L6J1"AJ8RCATHDD0I0\1$=`KZL,/U3@9ID+<
M=.Y*4E1/@`!,<>JJZ2A954UKK;-.D3*EJ2A(`WDJ40`/#&JF0=]>T_&OI"4_
MF>UI%^W'0T5:*J]X2!S\0Y"DMY%\W+J8-.8ZA2`/B(5LRQ:+:GY%RJH;14H8
M5Y[X#"1[KI2?<`)ZHT3EW>BT%PHK;O&24#E6C^JIE&K</N4X<`Z)D@3WD1I#
M?W>5Q3%]=#&V++TO!8H&!!_<CV.M&-,8-0`QD$1FY$2"/$`Y"B(>P-;DL?=)
MRBIY5Y#<J.D1Q2TE;Z_PGLT3]W\,1BRS[QS3Z@YFL-LESN3@\E;ZFZ1LGP?'
M.2Z/$$QT1I%?W=MW0W3UD;3;V+C9FH!B)FA8,\[*ID'VI@D+C7>MP5T\1!N`
M"/@`5N2Q]UO3>V\J[HJMN#HW]HX&T'^:T$F7\^?68C%EGW@>M]]YFL?:M5FI
MU3`+3)?=`X'GJ"I'-T_%RZ`(TNOG<UN%R2*H7MF;(DVW6$W/'FN60CXOE-[9
M,L7%*L6`)#K[3I\OX*V]9M.<"QZ1L]HH&7!YW8I6O9QYUA2I]<YQ&S*-<=8<
MSYADF2WBH95.;8J%M-2.\=DR6T<I^#*75&#3>>H*J@BHJ;7F54$3J&U'4>90
MPB<=1_#6:#Q4\J=B>@;!^"-5JFM?:+FIP\3M/X3MA2$<`("<J9?.4./*1,OG
M*'$?(0A=3F'\`!24@5'R1O/`>[`&:@A.U9W`;2?`!M,9YQ[M>W$94%$UB8<O
MR::+B3IRJL&YB(7E4'E*KZWF@CX\R.OB8JA@#RUA%]U)P'&9B]7:B9=3.:`X
M''-G#LV^94^H@1MC$-"M8L[Y5XMCEUJ*9<I.J94RS([CVK_9H*>D@F7&-Z,?
M]H+<5<70<7W<MA8X:'`IEFPOG-V3291'SB>C0Z:4654`XA_*SE]FM+WWO68#
M0<R+)35UP=&X\H8;/7-9*Y?[L&)1XE]WAJ_>.1W*ZZU6>G,B4A:JMX=(Y6@E
MH'P/*$;QV!V>,"P'17R!>U^Y"=$*456S95E9\,HH&@C_`":.(]DQ3'B`@+L=
M0]BM,WWO89O7`MV.CH:!LG82%/N`>%7*B?\`NXE!B?W=FD]IY7<LN5VO#X&U
M(4BD9)_,:"G)<)%XQN]86SS;#C,$C6CA*PV[I("\LE+1!+EE!,4.!_6-Q&E'
M0&UX\#``#Q``K3=\U7U'R(D76\5JFSYB%EI'H-<B?Q1)[%.[SHEA(2<=QFU-
MO)'](XR*AWYRH[5?X%>"4;'-D$&:";9F@@T;)%`B3=JBFW03(4`*4B:2)2)D
M*4`T``#0`K7[BUNK+CJBIP[R223X28W$TTTPV&F$I0TD2`2```-P`&P"/UKU
MCZ0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"/%0A%4S)+$(JD8-#)JD*HF8!\
M0$AP,40'\5>4DI5S))"AQ&R/524K24+`*#O!$Q'@@@W:E$K9NW;%$>82MT$D
M`$WAS""1"AKIY:\K6MPS<4I1ZR3_`"QZMM-,IY6DI2GH``_DC]A$1XB(B/X:
M]8^D=/O^^;<QE9-T9`NUZG'VY:$,]G)9R<P%'T=FD)RMT0$0ZCIXMRHHD#B=
M4Y2AQ&NUL=EK\BO%-8K6@N7"J>2V@#I4=YZ$I$U*/!()C'LKR>SX7C5=EE_=
M#-FM],MYU9X)0)R'2I1DE"=ZE$)&TQ3-S9EBX,XY4O;*=RJ*>L;NFG#Y!H=0
MQR140F(-X6&;\PB!&\7&))I``<!,!C>)A$;<</QBAPS&:/&;>!V%*R$E4I%:
MSM<</25K)/@D.$?F\U-S^[:H9Y<\ZO)5ZU<*E2TH))#+(\5EE,]R6FPE,ALG
M,[R3&+*R6,$CV6;-Y(O&D?'M5WK]^Z;L6+)LF95P[>.UB-VK5ND4!,HLX74*
M0I0XB8:^;KK5.TNH?4$,-I*E*)D$I2)J)/```DQ]Z:FJ:VI;HJ-M3M8\XEMM
M"1-2UK(2A*0-I*E$`#I,6^=E>W9MMJP/;-F.D$`O.8(6Z,A/4B@)W%T2B1#J
M,.KIS*-H%ITV:7'0>D8P:<PU51J_GSFH>;5-W:4KZH:/8TJ3P909!4N!<5-P
M_G`<(_0WW:]'V=%M*J'&7DH_>-\>LUZQYU4Z`5(GQ2PGE93P(05"7-&V5:OC
M?L*0A2$*0A2$``1X!Q'\%(1HENF[@&&=M39Y!)/$<AY2!$X-+$MU\BHG&+CJ
M5)6[IE(%VL"W*?B*/NCPX!YJ0`/,&Z]--#,NU#<16J0:#&ICFJ74D%8XAALR
M+I_*V-CBJ8E$5]=N]IIQHLRY:T.)N^=<AY*&G6#V:N!JWAS)83/:4'F>4!XK
M<CS"MUN"W.Y>W+W*,_DNXCKL&RJAH&SXL565I6VB<>"49%]0X+.>0``[IP*K
ME33B?30`L%P33G%=.[=ZCCK`#Z@.T?7)3[I'%:Y;$]"$R0.CC%,NKFN&H6M=
MZ-US2L*J-"B6*-J:*2G!X-M3/,N4@IUPJ<5+:H"0&OM9W&HH4A'>,=8UOO+5
MUQUD8XMB4NVYY,X%;QL6@)P12U`%'LB[/RM(R.;@.JCA<Z:1`\1UT"NFO^0V
M3%K8Y><@J6Z6W-C:M9WG@E"?*6L\$I!)Z(RC#L*RO4&_-8SAE"_<+V\=C;29
MA*>*W%GQ&FT^<XLI2.F+).S'MS65MZ+'7_DGU;?N8P33<-5Q1Z]LV(LHGYR%
MN-W!='TNESB4\BJ0#`/YDJ8<35[ZNZ_7C/"Y8\>[2AQ*9"A.3U2`=[I'DH.\
M-),OAE1W7/=VWN<XSI"&<MS+L;KJ-(*2J4Z:A)&U-,E0\=T3(-0L!7R:4"<Y
M,_'B-1UB;,*0A2$=0OZP[3R?9T_85\PS:>M6YF"D=+QCH/-51.('3614#11L
M\:+D*J@L00.DJ0IBB`A7:V.]W3'+LQ>[*\IBYTRPM"T\#Q!&XI4)A23L4DD'
M88Q[*\5L&;X]5XKE%,BKL5:T6W6E[B#M!!WI6E0"D*!"DJ`4D@@&*Y^X3M2Y
MOQ]+R,IA=$N7+&4657CV*#ME'WW$MC&$R;&0C'JK5I,G0`>0KAHIS*@&IDB"
M-3]P/O.8;?:5NFR\FU7H`!2BE2J99XJ2M(4IL'>4K$D[@HQ3EJ]W"]3<1N#U
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M8OZC=Z6HKF'+3IXRY3-K!2JK>`[61V'L6P2&Y\%K*E#@E)VB?NB/W?=#:*MG
M(M:*EFOJ&U!:;;3%1IYC:/67R$K>`.]IM*&SYRUIF#-<T:-&#5LP8-6S%BR;
MHM&3)F@DV:-&K=,J2#9JV1*1%!N@D4"D(4`*4H:`%0]===?=4^^I2WEJ*E*4
M25*43,DD[22=I)VF+,*>GIZ1A%+2H0U2MH"4(0D)2A*1)*4I``2E(``````D
M(]BOG'VA2$*0A2$*0A2$*0CD`$?`-?Q4A'P;@NFU[2:&?W7<MOVPQ(7G.\N&
M:C85J0@<.8R\DY;)@74/'6N;0VRY71WL+93OU+Q\UIM;BOP(!,=5=K[8[!3F
MLOM;245(!,K?>;90!TE3BD@#W8TXR#W'=H./.NBME)"\9%N)RFC,?1CZZ5CG
M(.@IED$$T(,AA\@G=E*(>6MM6+N_:JWX)6BVFDIU2\>J6ED2/'D)+GX$$]41
MRR[OE=WK$"MIV^HN-8B?Q5`VNJ)(X!Q(#`ZBIT#KC1;(/>?CD^NWQ5A5X[,'
M.5O+Y`GTF2/C[FJ:#M]-VLH40\2"]3'_`!JW38NZ(^KE<R>\(0.**5HJ/6.T
M=Y0/#V9\$1:R[[R6D1SLX%C3CAV\KM>^$)ZB6&`M1ZT]LGPQHSD'N<[O;\%P
MBSOJ-Q]'+"?E96#`,HQ=-,_#IA,R02TP'('M3D63.'LUN>Q=W+2JR\JW:)RO
MJ!+QJEU2P2./9HY&_<*2.J(N9=WW>\+E16W3W1BT4:B?$H6$-J`/`/.]L]LX
M$+2H=,:6W9D&_K\=J/[WO>[KO>*F$YU[DN.7F3"<?$P$?.UDR&'_`!2A6W[7
M8K'9&@Q9J.EI&@-S32&_]5(,1LOV7Y;E50:O)KI<;A4J,RJHJ'7OQ+61^`1T
M\I2E#0I0*'L%``#]P*[4DG?&.!(3L2`!'-(\P+YQR)E`3J*&`J:9`$ZBAC<"
ME(F74YS&'P``$1H=B2H[$C>>`\)@F:EAM$RX3(`;22=P`&TGJ$9[QYM:W%95
M.A\1,-WY+M5Q*!)5S!N8.$`IQT!0TS.A&QPI@/B)5#"`>2L'OVI>`XR#]=7>
MA:=3Y@<#CFSAV;?.J?A`C;.(Z$ZQYVM(Q?&[J^PHCXU;*F&1/B7G^S;ETR49
M=$;YXZ[/>>[BZ+G(MYV-CAF;E%5DS5<WI.D*/MBBE'@QADS@'@(/%0'\%:2O
M_>NPB@YF[!25MP=&Y2@*=O\`"KF<(_W8B56'?=VZK7?E>S&Y6NS4YES(055C
MXZ1)'9L@^!Y8C?''?:(VVVN"#B^)F^LG/DS`91-])I6O!J"&FI0C+?*F^Z9N
M.H'>J>/C6DK]WJ=0KES-V9JBMK)W%*"\X/Y[LTS\#8B56'_=[:,6+D>RBHNE
M[JDF9#CHIF#_`+I@!<CT*>5X8WMQ_MSP-BQ))/'^(["MI1+3E?-;>8N98PET
MY3*S,BF\EESAI[8ZQA_#6E;[G^;9,HJOMUK:A)\U3J@CW&TE*!X`D1*C$='-
M*L#;2C$<?M5"M,I+0PA3NS=-Y84ZH]:EDQFG4=-->`>`>`!I[`!P"L0C94<4
MA"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A$"G=SW,@\
M>16V2U'Q3-V!HZZLG.&RP&!1]H+BV[66$GAZ*F)7[@@C[8R("&H#4W>ZQIUV
M33NHUS1\8L*9HP1N3N=>'AVMI/1SRWQ5-]X-K6'WJ?1*PN@M-ENJN2DGSO*I
MJ4RZ-C[@GO[*8V1!M4SHJYA2$2H]JK;F&4LRN<MW&P,M9N'3MGD<"R8^C2E_
M/2&-"(`)@Y%BP+8IGBA0UY510UX#QC/WFL__`':Q).*T"Y7:[`I7([44R?Z0
M]7:F38ZN>43Q[ANCAS?45>HEW:YL=QTI4U,>*[7K!+0'3ZNF;JAP66I[]MF/
MQJNR+KH4A"D(4A"D(Q#F+/.)<"6^:X\JWI%6NU,FH9@P64])G9E0A3"#>%@V
MW4D9%8YB\NI"<A1'SC%#C658GA.49O7BWXS1NU+LQS*`DVV#Q<<,D('':9G@
M#&O=1-5,!TJM!O6=W*GH::1Y$*/,\\0#XK+*9N.*,I>*D@'RB!MB`;=%W3LF
MY5+(VCA5!]BFPU^JV7G`7)_2#/M3:D'G?MS&0MEJNGXI-3'<:#H*_DJ<FFW=
MIQS&2W=<P4BYWM,B&Y?W5H[_`"3M>4.E<D?D<8J;UR[]N:YVE['M,T.V'%E3
M2JHF/7WTG8?'22FF2H>:V5.?VHW1%*HHHLJJNLHHLNNH=9==8YE5EUE#"=19
M9503**JJ&$1,8PB(B.HC4FTI2A(0@`(2)`#8`!N``V`#@!$"%K6ZXIUU2E.K
M42I2B2I1.TE1,R23M))F8\*]H]8"(`&HCH`<1$?``I`D#:=T;U[4]@F7]S+I
ME.JME\?XJ%0IW5^SC%0#RR!3Z*H6?%*BBM-.#``@"X\C-,?$YA#D'2FINN.*
M:=M+HD*379-(@4S:A)!X%]8F&Q^2)N'H`VQ*K0;NEZAZU/M76H0NT8',%5:\
M@\SR9[11M&1=)W=H9-)/G*/BFRK@3;EBC;=:9;4QC;J4?URIGG+B>B1Y<URN
MR%`!=S4L8A55@U#5-`G(W1`="$+QUKSS?4#)]0;H;GD=07.6?9M)\5EI/P6T
M;AUJ,U*\Y1BZ32K1W`M&[`+!A%&ED*`+SZ_'J*A8'EO.D<RNI`DVC<A*8SI6
M%QM&%(0I"%(0I"%(1Y<YOX1OW1I(0C@3"/B(C^,1&D(XI"%(0I"%(0I"'CP#
MC2$=9NB];-L=D:1O2[+;M)@0@J"[N.;CH9#D`=!,4[]PAS!K[&M=C;;/=KR\
M*>T4M15/DRY6FUN'\"08Z2]Y)CV,TIK<BKZ.@I`)E=0\VRF73-Q21&EV0^Y?
MM#L`%4D<AKW[()<X>K\?0[R=YE"?Q?K1<K"%+S>0PN>4?9K;UA[N^JE\(4J@
M%$P9>-5.);V'CR#F<]SDG$;<O[Z?=[Q$*;3>3=*Q,_BZ!I=09CAVGB,"?`EV
M77&B>0^\\\-UFV)\+H(A[H5"7R#.G6$?'IK>H[?(D'L:D,]#3V1K=5A[HK0Y
M7,GNY.Z;=*W+PCM'9_A[/W(BQE_WDKIYV,!QH#>$O5[_`.!784XGX07QX8T4
MR'W'MWF1.LBIDY2RXY7F`(['T8SMH")FU]S]:$(YFQY=>!O20-[(C6ZK#W?M
M*[#):;<*RH'G52U.S/3R;&_<Y)1%G+^^9WA,OYFS>_JRC5/XN@:13D`\.UDM
M_P!T.`]<:9W!<EQW8\/(W5<$Y<S]0XJ'>7!+/YAR)S>V-U9!PX,41\NFE;<H
M;=;[6R*>V,,TS`$N5I"6Q+P)`B-UXOE[R&I-9?ZRKKJM1F5U#KCRIGC-Q2I>
MY'Q0``X`&@>P%<R.K``V#="D(X$P%XF$`#\(@'[]`"=T>"0-\94Q_@[,F552
M)8YQ?>]X`<2@#J'M]\I&E`P@`'4E5DD(Q)/4?;F6`H>S6,WW,\2QE)5?[E1T
MA'FK=3S^`(!*R>H)G&?XCI7J5GJPG#K%=+@@^>TPOLMO$O*"6@.LK`ZXWUQM
MVDMS%W@@ZO5[9F+8]3E,HG+R9KAGBI#Q$2Q,""K0JH>'*J[3$/PUI'(>])IW
M:N9JSHK+D^.*$!IN?Y[DE2ZP@Q*S"_N_-:,A"'\F?MMCI%;2''#4O@=3;'B3
MX$*>3+KC?_&_9]P+;@-W61KOO;)#Y,2'59H+M[0@3F``$R9FT:#F653`_#B[
M+S%\0K1F0]ZW-[AS-V"EH[>R=RB"^Z.OF7)`/\PRZ8EKAGW>&DUEY'\PK[G>
MJH2)3S)I6#U<C4W2)_VPF-XC?K'6V;;]B<B88_Q#8UON$P`"R181M(S(Z<=3
MS,J#Z3,(CQ_.@&O@`5HZ_P"HN<Y0HF^W6M?0?,[0I;^;1RH_T8ECA^BVE&`H
M"<2Q^V4;@_K`PE;ONO.!;I].49TU'0`UX!X%#@4`#P``#@`!6&1L^.*0A2$*
M0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$84W#YL
MMW;UB&[\IW$HD8L$P,C!QIS@56=N9\!D(*%;%U`QSNWH@)]/:($.<=`*(UF&
M!8=7YYE5)C-O!!>7-Q?!ME.UQP]`2G=TJ*1O(C6FKVIEFTBT^N&=7I0[.E:D
MRV3M?J%^*PRGI*URG+R4!2CL23%->[;JGKZNBX;SNA\K)W'=,P_G9I\J83'<
M2$BX.X7,`C[5),3\B9?`B92E#0`"K;+7;**RVVGM%M0&[?3,I;;2."4"0]T[
MR>)),?G$R+(+KE=^K,FOKI>O-?4N/O+/G..**C[@GRI'!(`&P1UZN?'31P8=
M`$?'0!']P*#:90.P3BX%L;QO:V,MK>(XNU5V4@G<%KQ]Z3<TQ.15.9N*Z&R4
ME*.3+$$04]#45!J0!T$B:`%$`$!"JI-9L@N>1:DW6IN:5MJ8J54[;:A(MM,D
MH0)<.8#G/25$S(C]$/=@PVQ83H;C]!8EM/(JJ!NL>>000]45*0ZZN8W\I5V8
MW22@`@$&-LZU?&_H4A"D(QWDO+>-,.0"MS9.O2!LR'3*8Q%IAX1-T],3Q1C(
MU/J2,HX'70$T$E#"/DKO\=Q;(<LKA;L<HWZNK)W-IF$]:U&24#K40(P_,\_P
MS3NTJO>:W*DMUM2">9Y8"E2X-H$UN*_);2I75$+&XSN]O797UM;:[</'(F!5
MN;)-Y,R'?&`0Y0<6[:QQ.DV'7B15\)S?^H`:E]@'=59:*+CJ'4!:]A]4IU>+
MX'7MYZTMR_/BM;6/[PQYY+MET6HRA!FGZQK$>-T<U/2G=U+?/^ZB%^\[XO'(
MUPO;LORYIJ[KDD#B=W,SSY9^\.`CJ"29E3"1LV)X$22*1(@<"E`*EW:+-:<?
MH$6NR4S-+;VQXK;:0E/A,MI)XJ))/$Q6QDV59)F=X<R#+*ZIN-Z=/C//K*U?
MFIGL0D<$("4C@!'5J[..@A2$=\QQB_(.7KG:6=C6TYB\+B=F)HQB6PJ$:)&,
M!1>2;PXD913!/74Z[A1-,H!XUTF09)8L5MJKMD54U24"/.69%1^"A/E+4>"4
M@F,LPO!<OU$OB,<PJWU%QNZY>(TF80DF7.ZLR0TV.*W%)2.F)\]J/:IL^P#1
ME[[AE8^_KQ1%%XSL1H)EK'@')1(JGZU5,!#W4^0.'$IBD9`8/:*AH:H/:G=Y
MJ[7P.6;`PY0VDS2JI5LJ'1N/(-S*2.@ESK3NBV+03N'8WB"F<GU<4S=\C3RK
M11)F:*G4-H[2<C5+2?A`,@C8A8DJ)@&[=!H@BU:H(M6K9)-!LV;))H-VZ"10
M(DB@@D4B2*29``"E*```!PJ*2UK=6775%3BB223,DG>23M)/$F+#6FFF&DL,
M)2AE"0E*4@!*0!(``;``-@`V`1^M>L?2%(0I"%(0I"%(0I"%(0I"%(0I"/%0
MY$4E%UCD102(91594Y4DDDR!J<ZBIQ*0A"@&HB(@`!7E(*U!"`2LF0`VDGH`
MCU6M#:"XX0EM()))D`!O))V`"-8,F;T=K^)171O#,5I^LT`,!H.W71[KFNH4
MO/T3,+>3D#-U#`/#K&3*(\-=:V/CND.I&4\J[3::KU=7]8ZGL6Y=/,Z43'YL
MS&DLU[R&B&GY4UD>16]-:D'XEA9J7I@3EV=.'"DGAS\H.Z<1\Y-[RMA1O7:8
MBQ7<-U+EU*C-7H_0MF+$0\%"Q;`).553'Q#G,@;R"`>-;VQSNDWRHY7<JN;%
M*CBW3I+R_!SJY$`^`*'7$1<W^\=Q&AYZ?3ZQUEP='DO5:TTK7A[-/:ND>'D/
M2(CQR=W,]VF1_2&S.]F6.(E;J%".Q[%(Q3@J1PY1(:=>FD)HP\OY1%DQ`>)>
M6M]8YW==+L?Y7'J-=PJA+QZI96)C^S3R-^X4GKG$0,W[[>OV8\[-)<6;-;U3
M'9T#0;6`=DNW<[1[W4J3MVB4:-7!<EQ7;(*2MU3\W<TFL8QU9"X)5],/#G/Q
M,87$@NX4`3#XZ#QK<]!;[?:F!2VQAFFI@-B6D);3^!(`B+EXO=ZR*K5<,@K*
MJNKE&9<J'5O+).\\SBE';QE'Q:YD=7"D(4A'U(6#F[E?I1=MPTM<,FN8"(QT
M'&O99ZH81T`"MF"+A;34?'30/+7&K*VCMS!J;@\TQ3#>IQ:4)'NJ($<^UVJZ
M7RJ30V2EJ*RM49!MAI;JS_-;2H^[*73&[6->VWNXR1Z,Y''(6'$N!((RF0Y-
MM;QDTC\>KZF*+R?,`!QT%L41\FM:<R'O":68_P`S?KYKJE,_$I4%V9'#M#RM
M?Z9B3F%]R[O!9CR.KM";30K(^,N#J6"`>/8)YW]G06P9;IQ(1C/LS6ZU%N[S
M!EV3F%`$IG$'8$6C$,QX`(I^O9H'SQ0`-PYBM4A$/(`UHC(N]Q<'>9K%+4TR
MG@Y4K+BO#V;?*D>`K,NN)=X5]V]8Z<HJ-0\@J*I0D5,T+:6$>#MG>T<.WB&T
M3'`&)"<9;%]JV)Q;KVWB&W9*5;@3EG+P(I=\J90F@E6!2=,[:H+`8-0%))/E
M$>&@5HC(]:-3,H"D7&ZU#=,K^K8(81+HDWRDC\XF?&)>81W7]"L`Y';'CU$[
M7(E)^J2:MV8W'F?*PD@[04I3([I1M@V;MV:";5F@@T:I%Y4FS5%-NW3+_!31
M1*1,@?@``K6+CCCJRXZHJ<.\DDD^$G;&^666J=L,L)2AI(D$I`2!X`)`1^M>
MD?2%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(
M0I"%(0I"`!J.@>(\*0BL]W4-R_\`2KEM+#ULO@6L;$+I=O)*MU@.UF[_`%D0
M2EW`B3S54K>1.+)/QT6ZXAXA5B7=HT[_`'9Q8Y9<42O-U2"@$;6Z4&:!U%T_
M&'\GDBE+OW:U_OWGR=.+(YS8SCSB@Z4F:7J\B3AV;Q3I)93ODOM2.$165)F(
M&PI"%(1-%V=\@Y#=9*OC&A[H?N<;Q]D.+E+:KY873*.FSS#)H@^A2+&,>-%8
MJZG7(CHFKJ!C%Y@UJ(7>PL5A;Q^BR$4R$Y"Y6!GMDB2EMAM2BER7ERD.4JVC
M<#+9%E?W=>79C49A=,+57.+PNGMIJ!2K/,EMY3R$!;$]K?--7:)3XJC(D3VQ
M83`!'@`"/XN-01BW2-8\T[Q-NN`TG">0,D0Y9U`!Y;/MTX7)=JR@"(=(8:+,
ML=B(B40YG9FZ8#XFUTK8V(:3Y]G"DJL5O=]2/]>[\4P!T]HN05X$!1ZHTCJ5
MWBM']*$+1EMYIA=4#92,'UBJ)Z.Q:YB@];I;3TJB'_./>"OZXB.X;`]EM;!C
MU2JHENV[?1IZZC%$QBE<,(E$30,4H9/00ZHO#%'\/A*S#.ZC8Z!2*O-JQ5<^
M"#V#$VV?`I9^,6)_!#<XKRU/^\2RF[H<MVE=L1:Z50(];J^5^I_.;922RV9?
M#+TCPB).][^O;)4^YNG(%USUXW"[$16EK@D7$@Y`HCKTFX+&%%FW+X%21*FF
M4.`%"I26:QV?':%-LL5*Q24"=R&DA(\)EM4>M1)/3%?N4Y=E&;W9=\R^X55R
MNR][K[BEJ'4D'Q4)'!*`E(X".I5VL8["D(_9NW</'#=FS;N';QVL1NT:-$57
M+MTX5,!4D&S9`BB[A=0P@!2$*)C#P`*]''&VFU.NJ2AI()4I1`2D#>23(`#B
M291]&67JAY%-3H6Y4.*"4H0DJ6I1V!*4I!4I1X``DQ+!MC[5&3LF!&W9G!RZ
MQ39*PH.D[;*F13(<XS.7J`!FJ@':6JBJ&@"9T"CH`'\P'C48-1N\UCF.]I:\
M-2FYW@3279D4K:MV\24\1T(DC\L[HGUHAW#<VS7L;_JBMRPXRJ2A3"1KWTG;
M(I,TTH/2X%.B?]$G?$_6(L)XOP3;"-HXMM",M:*(5,7:S9+K2TPX(707LW,+
M\\A*NSB(CS*G,!=="@4.%0<RK,<DS6Y&ZY+5.5-49\H)DA`^"V@22A/4D"?&
M9BV;3_33!]+K&G'\&M[%!;P!S%`FZZH"7.\Z9N.K/PEJ,IR$ALC*E8S&=PI"
M%(0I"%(0I"%(0I"%(1R`"/``$1_!2$8^OS*^,<7LC2&1<@6A934I.IK<<_'1
MBRA..@H-'"Y7;@1TX`F0PC7>V3&,CR1X,6"AJJQPF7Q32U@>%0'*/=(C$<JS
M[",'IC5YA=K?;6`)_P!X?;:)'Y*5*"E?S08C^R7W:-L5F&7:V8G=^5I!(3%(
M:WHD8.#.<O#C,W*+!4R?-^4DV5X<0U#2MYX[W7=1[N$NW<TEL8/RJ^T<^;9Y
MA/J*T]<HB5FO?^T0QM2V,<%POU6G<:=KL62?]M4]F93XI;7TB<1_Y,[P>=+C
M%PUQE9MFXV8G,8$)!^1:\[A(F/M1ZCXK.$35`/'^2*`/DTK>F.]U'"Z#E<R*
MKJ[@\-Z4RIVB?YO,X1_/3$3,U^\3U.NY6QA%LMUFIB3RN.SK'P.'E<C(/3-M
M8\$1ZY'W&YWRXHH;(N5[VN5NH8QO5:\TY90A.8QC@5.$C3,XLI2"80+JD(@'
M#72M[X_I_A.+)`L-KHZ=P>>&PIP^%Q?,OP[8B)F6M&J^H*E?O?D%SK&%&?9=
MLIM@;2=C+7(WLG(323+9.,*@4I0T*`%#QX``<1\1X>4:S`DG?&L`D)W"4<TC
MS"D(X,8I0U,(%#PU$0`-1\.(^S0`G='@D)$U&0C,F-=O6<<P+))XVQ7>MU(*
MF*4)1G"N&L$GSCR@=:?D09PR20#XF%?0/+6)9#GF&8H@JR&YT=*L#R%.!3A\
M#2.9PGJY8V1A>D.J&HCB4878;E7M*(':H94A@3XFH<Y&0.LKD(D3QGV>LXW%
MZ,[R;>UF8W9*"F9>-C1<7E<)$S><9,2LQ80B*P%X"/I2I2B/@8`K0F1=Z_#*
M#F:QRCJ[@\)R6N5.U/I\;F<(_F)F.B)A81]W9J=>.2HSBYVZS4QD5-M<U94`
M<1XO9L`\)AQ8!X$1(=C#M2;6[$!LZNME<N5Y9$0,HK=LJ9E"**!IQ+;T$#!N
M9/A[5=1<*T+DG><U*O?,U;%T]KI3N#".9P?[USF/NI"8F!@_<,T+Q7DJ+ZS6
M7ZX)WFK=Y62?\.P&T2ZEEP1O]9F.[!QU'IQ5A65:UG1Z90(#:VX..B0.!0Y>
M991FW26<*"7@)E#&,/E&M&7>_P!\O[YJ;W65-6^3O=<6O\',2`.H2$2SQS$,
M4Q"C%!BUMH;=1I$N6G9;:!X3/(D%1ZU3)XF.YB(CQ'C^.NIC(XXI"%(0I"%(
M0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(
M0I"%(1J!O?W'MMM."9^Z&:Z87Q<I5;4QZT$^BIK@D&ZA5)?E`0,+>W60G=''
MP%0B9!]OK6UM&]/W-0\U8MKJ3]34\GJI7#LDD21X7520.HD\(CSWG-9&=%=+
M*N_4ZA^\U9.EH$3VFH<2?C>GEIT3=5UI2G9S3BH@X<.';A=V[75=.W:ZSIVZ
M7.*B[ERX4,LX<+*&$3'566.)C"/$1&K4D-MM-I::2$M)2$I`V``"0`'0!L$?
MGJ>>>J7EU-2M3E2XM2UJ49J4I1*E*)XE1))/28_&O>/G"D(4A'>,=9+OW$MU
M,;VQO=,K:%SQP'(WE(I8"'4;K``+LWC=4JK208.```407(HD?3B7@%=+?\=L
MF4VQ=GR"F:JK:Y(E"QN(W*21)25#@I)!'3&48=FN5Z?WYK)L,KG[??&9A+K1
MWI5Y2%I(*'&U><A:5)/$;!&?LE;ZMUN5XT(:Z\PSS:(,D"+B.M-O'66B^+IH
M;U@K;+6-=O`4U\XIU!(/ARZ<*P?'M%M,<8J/6[9:6%54YA3Y74%/YH>4M*9<
M"!/KC;.9]Z77O/*(6V^Y%5HH.62D4J6Z,+''M#3(;6N?$%7+U2V1J481.<ZA
MS&.HJ83JJ',)U%#FXF.HH81.<XCXB(B(UM$``!(V)`V`;AX!PB/Y)4HK425J
M,R3M)/22=I/68XKS'B%(1P(@`:B(`'LCPIOW0)`WQO1MJ[?F=]QAF<VG%CCO
M'*QB'4OF[FCAN#]OKYPVS!#T9&=.8H#RJ^Y-=?%7R5I;4/77"<`"Z,N>OW\;
M!3L*!Y3_`&SFU+?6/&7^3$I]%NZ+JIK"6KF6#9L.7(FMJD*!<3^K,;''I\%G
MD:_+BP5MNV.8*VT(-I"V8,;HOPJ0%=Y%NQ)L^N`3F*`*EAD0)Z#;C0PZZ$:D
M*H(#H=0_C4%=0M9LUU$6IBXO>K62?BTK!*6NKM#/F=5UK)'0E,6W:,=U_2W1
M1I%79*7UW*N62[A5!+E1/CV(ER4Z#\%H`D;%K7OC<.M3Q(J%(0I"%(0I"%(0
MI"%(1X+*I-T5'#A5)NW2*)U5UU"(HID*&ICJ*J&*F0I0\1$0"O9"5.*"&P5+
M)D`!,GP`1Z..(:07'5!+:1,DD``=))V`1J5E'?5M7Q&+EM<N6H&5EVH>=;]F
M&/>$N8_D2$D(#EDW4'P]V72*`AH(@-;0QO1;4S*>5RW6M]NE5_6U$F$>&;DE
M$?FI48T#G/>CT*T^YVKUD%&]<$?U%(35O$]$F.=*3^>I`Z3$=62^\XP2,NTP
M_AUR]T$Y4)S(<P5BD;Q`BI("!!RN8O$!T4>)CPT$/+6_L=[HSZ@EW*[LE&Z;
M=*WS'K':N<H_`V?#$.\V^\BHFRJGT[QUQX@D!^X.AM)Z"&&.=>W?XSJ3P(XQ
M'GD_N([M<I`NV>9/=6;$+<Y1AL=,T;20!)3@*1Y)L9>?7+R_PW@\>(:5OC'-
M!-+L:DXU;4U=4)?&52B^9CCR&30]Q$1`S?O@:_YSS,U%\7;;>J8[&WH%*)'@
M74\U0KW7O!*-,)*1D9EZK)3,@_EY)<YE%Y"5>NI)\LH;VQU7CU5=PH<P^(B8
M1&MNT]/3TC(IZ1MMJG2)!*$A"0.@)2`!^"(VUM;67.J577)YZIK5F:G'5J<6
M2=Y*UE2B3TDQZ=?:.-"D(4A'Z()+.ETVK5%9RZ6,!$6S9)1PX5.80*4J2")3
MJJ&,8=```'C7JM:&T%UPA+8&TD@`>$G8(]V6G:AU-/3I4Y4*,@E(*E$]24@D
M^X(V_P`5;"MU67BMW4#BR5M^%<:&+/WX<MGQO2$=!531E"EEW1`_]2U4$?Q5
MJG)M;],\5*FJVYM/UB?ZJF';KGT$H^+'\Y8B16!]T[7C4$(?MEC>HK:O;V]>
M?5$2Z0EP=LH?FM$^YMB1_&79D:%!L\S'F%PN8#$.Y@,=1)&Z1BZ:F1-<<^"R
MNH:Z"*;(O$-0&H_9%WN725,XG:4I'!VJ62?#V34A^%P^")DX5]VY2I"*C43(
MG%JF"IB@:"$RZ/6'^9749,CI!X1(MBS8AM5Q$9NZMS$T',3+?02W!>_4O.6Y
MP``ZJ8S8N(]H?4-?<&Z0`;B``-:"R76S4S*@INONCS-(K^JIY,(\![.2E?SE
M*B86"]U70?3XH?L]@I:FXH_KZV=8[/I';\R$'C\6A`GM`G&W*223=%-NW230
M;I%*1)!!,B**1"AH4B:292ID*4/````K5BU*<45K)4LF9),R?"3$A&VVV6PT
MRE*&DB0````Z`!L`CSKUCWA2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$
M*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A_A``\HB.@`'E$1\@`
M%(15$[BNY`^X#/<HPA78+8]Q<H^LZT024$[>2>(..6Y+D#0>F<9220Z:)@#_
M`)*@G[-6=:!:?#!L':?JT2OMS"7WYB10DCXIKI'(@S4/AJ5%"G?'UF7JQJN_
M06USFQ&PJ724O*9I<<"I5-1T'M'$\B#\FA/3&@U;QB)<*0A2$*0A2$*0A2$<
M"(%#41``]D1T#]T:`$[H\$@"9V"-O-O^Q_<)N*5;/+4M%:W;.54*"U^WD1>%
MMTJ(F#G4C2*I>L9Y0I1U`K1(Y!'@)R^(:KSG67`\!2IFYU0J+L!LIJ<AQV?0
ML@\C7A6H'H!B1.DG==U=UA6BJLE`JAQM1$ZZL"F6)<2TDCM7SU-I*>E8WB=W
M;EVS<#804CKBNML;+M_M.BN67NEHC\6HMZF)3]6#M3W5F4R2@>8J[,Y5X`(<
M@U"?/^\3FV9)<H+:H6JQJF.S94>U6D\''MBC,;TH"$\#.+4='.Y3I3I>MF\7
MILW_`"QL`]M5)3V#2Q(S8I=J$D'<ITN+X@I,2-E*4A2D(4I"$*4A"$*!2$(4
M.4I"$*`%*0H!H``&@!6@2222=I,3%`"0$I`"0)`#A'->(\PI"%(0I"%(0I"/
MC3]Q6]:D<M+W1/0UMQ3<HG7DIZ391+%(I0U$3NGZR"(</PURZ&WU]SJ!2VUA
MZHJE'8AM"EJ/@2D$QUUTN]IL=&JX7JJIZ2@0)J<><0T@>%:RE(_#&@V5>Z#M
M4QOZ0TA;DE,I3:/4(#"P8\74<"Y.`)KW%)'8Q)2F,`AS(F7$!\0TXUO#&>[?
MJ;D/*[5T[=MHSYU2KE5+I#2.9?I!/AB*&>]^#0?"^>GM]<]?+FF8[.@;YT<P
MX*J%E#(Z)I4L@[Q$;>4N\-F:X3.&>*;&M3',>;G*C*30JWC<8%'4"J`"H,(-
MLJ`<=.@N!3>4P5(3&NZ?B-!RNY/6U5>_LFAN3#7@V<SA'\Y,QP$0QSK[Q346
M[E=/@-JH+12&8#KY-742V[9?%L)/&10X`>*A$<V2=P^<LOKK*Y(RI>=T(KF$
MQHQS,N&D&3SA,!$H*.%G$)IE,/FE!'0/)6_L>P+#,40$X_;*.F6D>6&PISW7
M%\RR>OFB&^::Q:I:B.*7F5^N5:RHS[(O*0P-LY!AKD9`!W#DV<(PR!2E#0H`
M4-1'0```U'Q'AY1K+B2=\:U``V`2CFD>84A"D(^K!P4Y<\BC$6U"R]PRK@X)
MH1D'&O)9^J<WM2D:,$5UQ$?\FN+6UM%;:<U5Q>:IZ5(F5N+2A(_G*($=A:K1
M=K]6)MUCI:FMKUF0;8:6ZLGH"6TJ/XHWSQ3VQMUN3`;O).U8[%\*MR&&1R"_
M*R?=,P:\R-NQQ7TP<W*("`*D0`?X0#PK2.3=X[3''>9JFJ7+E5CS:5/,F?6Z
MOE1Z)5X(E?@?<?UYS0(J+A1,6*VJ\^N<Y7)=(IVN=WW%]F.N>R))\7]G;#T"
M1J\RM?MV9!D"=-1Q%P0(6A;HJ!H)T3&3!_-ND1$!#7KH"8OD`>-1[R3O8Y97
M%3.,45+04YF`MR;[LNG;RMI/\U4CQ,30P;[NO3>TI;J<[NEPO%8)%334J2GG
MLF))YWE)WB?:(F#N!B2#&FWC!V'4$DL:XNLZU54BE*$DTB$',VIREY>9:=D`
M=RZQS!XB981'RU'W(L\S++%E60W*KJDGS%+(;'@;3RH'N)V1,K"M(M,M.V@W
MA=CMU`I(_I$-)+QV2\9Y?,ZH])*R3QC,PB(\1$1_'6)1L:.*0A2$*0A2$*0A
M2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A
M2$*0A2$*0A2$*0A2$:$]Q;<0.`]O<RWA'WHM_9,Z]E6@*1@!RQ1=H_\`6.>3
M+X@$7$'.5,_#E<+)CQTT'=^@6!?OQG;*ZQ'-8[=*H?GN44GXIO\`GN2)'%*5
M1%/OA:OJTGTBJ4VMWL\LO)-'22/C(YQ\>^!_9,SY3P<6C?NBJ#_A$?9$1$1$
M1XB(F'43"(^(CQ&K/(H,\.^%(1GS;9M\N_<QE2&QI:9BL2+D4D[EN)PB=9C;
M%N-#$!]*N2%$@++B)RI-D>8HKKG*74`YA#!]0L[M6G6,NY%=/'4D\C+0,E/.
MJ\E`WR'%:I'E2"93D#MG1;2'(=;,[I\*L)[)M0+E34J25(IJ=)'.ZH;.91F$
M-(F.=9`F!,B7[*_9PM7XH$6PMD:?+?$<S`5&-^BP7@+G=)DU.4CN+8MG-N++
MGUY!Y7*)>`&`.)ZBGC'>TN?UJ49?;V#9G%[%4W,'60?R5J(=`X[4*WD'A%A^
M>?=RX^<>#FFUXK$Y.RWM17%"V*E0&T<S3:%4Y4=Q`<0-@*=ZHA4RAA;*N%YQ
MU;V3K%N"TG[90Z95G[!4T2^(0V@.8N;0*K%2350.)3I*F#0>.@\*F!C>7XSE
M]$FOQRM8JF%#<E0"T]2VS):%#B"GP3BM'.M,\^TTN:[3G%JJ[?4H)`4M!+*P
M/.:?3-IQ)W@I6>L`[(Q@B/I)@(V`SDXB``1L4RYQ$>(`!$@.81$`K)%_%B;G
MBCKV?RQ@K/\`>%<E/-Q?0D<Q_`F9C+]C;?LY9+622L3$F0+E!8P%*Z9VS)(Q
MQ=3<NJLJ^1:1B(`/E.J'`-:Q2]9WA>.I*KW=:&G(\U3R"OW$)*EGW$QL;%M(
M-5,U6E&+8]=ZQ*CL6FF<2U[KK@0T/=6(D&Q+VA\]7:HU>Y2N&V,50YS%,NR1
M7+=UU"D.@Z$8QRJ,,V4,`_QCPQBCXEK1.4=ZG";6E3.-4]3<ZL#8HCL&9_G*
M!</N-@=!B7.`?=Z:J7];=3G5;0V*WDS4A)];JI=24%+"2>MXD<4Q+!A'MR;8
M\+'92@6D?(UV-.DH%RY#.E-=)TGH(KQUOE32M]AY_$H]!10H?EB.HC&#,M?]
M1LP"Z8U0H+6J8[&EFW,'@IV9=5U^,`>B)\Z8=SO1+3-3=<W;S=[^W(^LUY#Y
M"AYS;,@PWMW2;*A\([2=[4TTTDTT4DR)(I$*FDDD0J:229``I$TTR`4B9"%#
M0`````K2JE*4HK425$S).TD]),2E0E+:0A`"4)```$@`-@``W`1Y5XCVA2$*
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M`HLR<OD$1XU)#%^ZY@%G"7;\NINE6-I"U=BS/J;;/,1^<X?_``B#N??>!:P9
M*5T^'L4-@MY$@4)]9J9=)=>'9@]:&1+K.V(Z+YR3D+)LDI,9#O:Z+UD5#F.+
MBY)I]*`F)M-0;MW*QVK4N@`&B9"!H`!6_;+CUAQRG%+8:.FHZ<#<TVE$_"0.
M97NDQ#G*<VS'.*PW#,;I7W.K)G.H>6X!^:E1Y$CJ2D1TFNYC%X4A"D(4A'U(
M2#F[EDD(:W(:5N"7='*FVBX2.=RL@N<XZ%*FS8HKN#"8>'M:XU964=NIU5=P
M>:8I$B96XM*$CPJ40/QQS[7:KI?*U%MLE-45EQ69):8;6ZXHG=)#84K\42#X
M?[76Z#)P-9"XX>*Q);[CD4%[?+D1FS(FT$1;VM&"XD2J\HZ@5R9J''QUU"M$
M97WD]-\<YF+>Z[=*Y.SEIQ\7/K>7),NM`7$N].^XQKAFW9U=Z8I\>M"Y$KK5
M3?E^32M<RP9<'5-?B(B4C%':1VZ68FU=Y%D+GRU,I@4RZ4@\4MFV!4`0,)4H
M:#63?*I`(:>[O%.8..@:Z!&O)^])G]W4IJP(IK72'<4)#STNMQP%(/YK8EU[
MXG1@/W?VCF-);J,O<K<@N2=J@ZLT]-/J88(61^>\N>_9.42+V+C#'.,(\L5C
MNQK5LM@4@$%&W(1C&&5`O@+APW1*Y<F]DRAS"(\?&M!7K([_`)'4>M7ZMJ:Q
M^<YNN*7+P`F0\``B8N+X3A^$T8M^(6RAMM&!+EIV6VIC\HI2"KPJ),=ZKI8R
MB%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I
M"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I".0#40`/*.E(15`[CF>SYPW(7
M$TC'GI%EXOZ]A6N1,W,W7<L'`C<\N3E\Q09";(<A3Z:F103XB&E6>=W_``@8
M;I]3NU*.6\7*52]/>`H?$H/1RMR)'!2E<9Q0AWRM5W-3M9:RDHW>?&K$54-,
M`?%*T'^].B6P\[P*0KBAM&TB4:$UN^(GQ[#1H[D';2/8-5WS]^Y09,635(Z[
MIX\=*D0;-6R*8&.JNX6.4I"@`B)A`*^;KK3#2GWU)0PA)4I2C()2D3*B3L``
M$R8^U-35-94MT=&VMVL>6E#:$`J4M:B$I2E(VE2E$``;R8MC["MJ3?;#B)!*
M=;-E,IWT5K.7\^*0IE(XW3YHNT6R_$19P*"@]42\%79U#<0`NE7^MVISFH^5
M*51*4,:HIMTR9[%;?'?(^$Z1LGN0$C?.+^.ZGH,SH?IXEFZ(;5G%TY7ZYP"9
M09?%4J5?`829*EL4Z5JVCEEO+6F(E#'I2$;'2S86<K'L91H8>86LBS;OFPF#
MP$4'2:J6H:^.E?9BHJ*5SM:9Q;;OPD**3^$$&.-5T='7LFGKFFGJ<[TN)2M)
M]Q0(CXK2R+*CU`686=:C)4!`P*M+<AFR@&*`@!@.BR(8!`!'0=?+7,=O-X?3
MROU=2M/0IUPC\:HZRGQG&Z1?:4MOH6G`=Z&&DG\(0#':`$0*!0X%```"AP*`
M!P``*&@``!76]?&.\ZANCBD(4A"D(4A"D(\%5$T4E%UE$T4$2&4666.5)%),
M@<QCJ*G$I$R%*&HB(@`!7E*5+4$(!*R9`#:2>H1Z+6AI!==(2VD$DD@``;R2
M=@`XQI'FCN&[7<+"[CWE])WY<[7J)C:^.2(W*Z(X)J7HOI9)=*WXX2J!RG!5
MUU":#Y@CPK<>(:#:D9>$/LT1HK:J7QU5-E,CQ2@@NKV;1)$CTQ&/4KO?:'::
M%RDJKH+I?&YCU6W@5*PH;.5;H4&&]NPA;H4/@D[(B:S'W>LUW>#N-Q';$#BF
M(5ZB:4N]!.[;P,D8!+U"KO$$8&.5Y1U#D:KF*;B!ZE#B7=5P^U<M1E52_<ZH
M2);3-AB?@22ZH>%:01PB`>HWWA>I>0ARBT^H:2PV]4P'G)5=7(B4P5)##9Z)
M-N$'<J(R[^REDG*DF:8R1?=TWO(&-S%6N*8=R"2(^0&K)10&+,I0X`5%(@`'
M``TJ15CQK'L9I_5,>HJ:C8Z&FTI)\*I<ROYQ,0HRW/<VSVL-?FEVK[I5=-0\
MM:1^:W,-H`X!*0`-FZ.AUWD8E"D(4A"D(]EBR>R;M&/C&3R2?N#E3;L8YJN^
M>KJ&$`*1%JU3574,(CX`4:^3SS-,T7ZE:&V$B94M02D#K4H@#\,?>EI:JNJ$
MTE"TZ_5K,DH;0I:U$\`E`*B?`(WMQ#VV-U66/17B]EI8SM]P!3^N\DN#P:PH
MFT'G;VX@D[N-8PEU$H*-T2C_``@`=:TKE7>%TRQ?F:;K#<:Y/]72#M!/H+I*
M6AUR4H]1W1*C3SN7:\9\45#UM39+2N7QUQ4652/%-,D+J#LW<S:`>*@"#$I6
M(>T#A.U/19'+5U7'E243Z:BL0R$UH6D"H:"9,Z#!=>=?H@/#SW:13`/$E1JR
MKO69C<^:GQ:FI[93&8"U?'ORZ9J`;2?`V2.!B=.GGW>.F=AY*S4"NK+[7"1+
M2":2DGQ!2VHOK'A>2"-Z8DOQYB+%V)HXL5C2P+4LED!`(<+?AVC)RX#S0YGC
M\J9G[U0>4-3*JG,.G$:CO?LJR3**CUK(:ZIK'I_UKBE`?FIGRI'4D`1-?$-/
M\(P&B%OPNU4-LI0)$,,H0I7YZP.=9V;2M2B>)C(M=!&80I"%(0I"%(0I"%(0
MI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0
MI"%(0I"%(0I"%(0I"%(0I"%(0I",'[E\A.L4[?\`,&0F`",E;%ASKR+Y3&()
M)5=J+",4YR\2=)\[3-S>336LRT\L+63YS:K"_P#_`$]36MI7Q\0'F6)<9I21
M&L=:<O?P'2?(<PI1.LH+6^MO;+XTIY&S,;I+4DSX12^445644675.LNNHHLN
MLH.JBRZQS*++*#Y3JJ&$PCY1&K=TI2A(0V`EM(``&X`;`!X!LC\V"W''5J=>
M45/+45*4=ZE*,U*/6223UF/"O:/6)TNU?LW.JJSW/9*B=$$^L3$,)((<5%0,
M9!U?JZ"I>!4]#HQNH<1$ZX>"1AA;WE]6@E*].,==\8R]><2>&\4P(]Q3ON(/
MG"+3>XEW<B2WK?FM/L$Q:67$^%*JY25#9Q13=7,Z)?%F)XJA-%J4*0A2$*0A
M2$*0A2$*0C'&3<O8RPS`GN;*%ZP-F1`%.*"DN\(F[?G3`!%"*C4^I(RCGB'F
M()*&XUD&.8KD>75PMV-T;]75\0VF83/BM9DE`ZU$",-S74'"M.;2J]YO<Z2V
MVX`R4\L!2R/-;;$W'5?DMI4>J(@<U]XV*9J.XC`./#S)BBHDG>>0C+,(\P^U
M*O'VM'JED%R:\2BY<MQ'RD#RRLP_NF53J4U6<UX9!VFGI9*7X%/*'(#^8A?A
MBO+4S[QBVTRW+?I-:%52A,"LK^9MK\Y%,@AU0X@N.-3XIZ8F<Q;L-P>>%52Y
M(R7.R,2H81+:\2J%OVHD&NH%]11'HS1R)0#VSCK'_#Q&I0XGIA@F$I!Q^W,H
MJA_7+':O'_>+F4^!/*.J(!:C:_ZO:JK4G,KW5.V]7_VK)]7I1_N6N5*_"YSG
MKVF-=0`"@`%`"@'@````'X@#A6?$D[3OC38``D-@CFD>84A"D(_9LW</'"+-
MFW</'C@Y4V[1H@JZ=.%##H5-!L@11990P\`*4HB(UZ..-LMEYY24,I$RI1"4
M@=))D`/"8^K#+U4^FEI4+=JED!*$)*UJ)W!*4@J)/``&-T\1=O7=1F`6KMAC
MQS9-ON13'XQY%.>UVG04T'TAM&.$E)Y\F!1U`4VH@;R#6H,JUXTSQ3F:>KTU
ME<F?Q5*.V,QP*P0TD^%?N1)?3[N@:[ZA%M]BT*M5I61_>+@33)Y3YR6B"^L<
M=C<CP,2E8A[.^,(#T61S/?DYD!^3D45@+8(-J6SSAH)D5G@F<SS]'R:E4:B;
MQT#72HU95WL,DKN:GQ&B9H&#L#KWQSWA"=C:3X0N7XXG5IY]W7@MHY*S4>Z5
M5XJQ(EBG_NM-/H*@5/N)\"VB9;AM$2>8SP=B##C`D=C''5J6:D4O(=S%13<L
MJY#RB\F5RK2KPP^RHL;\%1QR+,\JRQ\OY'7U56J>Y:SR#\UL20GW$B)OX7IE
MI]IW2"BPFST%N:`VJ::2'%?GNF;B_P"<LQE81$>(\?QUC,9U'%(0I"%(0I"%
M(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%
M(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"/A71;$!>MN3EHW3%MIJV[
MDBWD--Q+PHF;/XU^B9!RW4T$#%YTS<#%$#%,`"`@(`-<VVW&NL]P9NEL<4S<
M*=Q+C:T[TK29@CW?<.XQU5\LEJR2SU-@OC#=39ZQA;+S2Q-+C:P4J2?"#O$B
M#M!!$0?91[,[E:3?OL-9;8-(I=599E;F0(QX=6/(<PF39DN*&ZYW:*0#RE,H
MT`^@!S&$=1J96-][AM%,AG+;6M=4D`*=I5I`5TJ+3D@DG>0%RZ`(K$SK[M]3
MM<[5:;Y`VS0K42BGKVEJ[,$S"!4,S4I(W`J:YNE1C7G&G:ZSTUS[9%JY0MB/
M<8M2D4)V[;S@YA%[;SRWXQ;KN8--0WHTDC+3)TBMRHF1`Q2*BIKRE&L\R+O)
MX0[@]9<L;J7$Y*6RVPPXV4NI=6)!P[T%#<RHJYMI`3*9C4.$=Q?52GU8M=DS
MFBIW,$0\E^KJV7@IA;#2IJ8$^5T.O$!L(*-B5%4Y`Q998,&,4Q91<8T;L(V-
M:-V$>Q:)$0:LF31(B#5JW13`I$D&Z*92E*````%5XOOO5+RZFH4I=0XHJ4I1
MF5*49E1)VDDF9,73TM+345,W14:$M4C*$H0A("4H0D!*4I`V!*0``!L`$>W7
MRC[PI"%(0I"%(0I"%(1'QODWTV_M:A4[5MA)C<V9[B8'<1$(N?J1UJ1ZH"FC
M<ESIIF*H8BA]?1&@"4[DQ1,82IAJ;>VC&BU?J76&YW$KIL1IU@..#RWEC:66
M9[)CSU[0@&0FH[(C=Z#O26C0FUILEE2W7:CUK14RP3-NF;.P5-3(SY29]DT)
M*<())2@3-8[)&3[_`,O72]O3)-TRMVW&^.8QWLHX,HFU2,83%9QC,O*SBV"6
MNA$$"$3*'D\M6-8]C=BQ2V(M&/4S5+;T#R4#:H_"6KREJ/%2B28I%S7.LNU%
MOKF29K7OW"\.$^.XKQ4#X#38\1IL<$-I2D>';'0Z[N,3A2$*0AKQ*7\HP@4I
M0XF,8?`I2AQ,8?8#C3KX"'$#B=PXGP1M7B+9-N:S6+5S:&+IMC!.A*);IN\G
MQ4M\$A$-5DW,N5%V](!1U#T=!81#P\:UCE6L6G6'\S=UN3*ZU/\`4L?'.SZ"
M$32G^>I,;\T^[L6MVI?9O6"QU+%K<VBIK!ZJQ+X22Z`M8_V;:Y^`SB5##_9N
MMMAZ+)9SR6^N!<.11:U\?H##Q8&`0,*+BXI--:2=$X:&Z+=L/$=#>!JC1E?>
MTN+X53X7;D4Z-H#U2>T7X0T@A">KF4OP<(G=IW]W)8J,HK=4+T]6N["::A'8
M-3Z%/N!3JQP/*AK9.1W&)2<4;:\$X1;IHXRQC:]MNB%*4TT#`DE<2X@&@G7N
M"4%W+'$_E`%0*(^2HV9/J%FN9.%>1W&IJ&S_`%?-RM#P-(Y4?Z,3GP+1K2_3
M)@-839*&B=`VNAL+J%?G/N<[QGQ\>1Z(SB(B/B(C^,=:PR-G1Q2$*0A2$*0A
M2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A
M2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A
M2$*0A2$*0A2$=1OZ\XG'-CW=?T\?DA[-MR7N21XZ"=M$LEGAD2CH;0ZXI`0O
M`>)J[2QVBJO]YI;'1"=75U"&D>%:@F?N3G&/Y7D=OP_&;AE5U,K=;J-VH<_-
M:0I9&X[3*0V;S%+?*62+CR_D.[\F78X,XGKQFG<P[`3"*;-)8_*QC&Q1$>FS
MC&14T$B!P*0@:5;WC6/6_%+#28[:T\M%2,I;3TJ(\I9Z5+5-1/28_-;G>:WG
M47,+AFU_6572XU*G5#@A)V-M)Z$-("4)`V`".@UWD8E`1``$1'0`XB(\``/P
MTWP)`$SNC,F*-O6:\X/"-,6XVN>[$Q4!-66;,3,[=:B(@`B\N.2,SA6_+J&H
M"OS?@K$LGSS#\-:+N2W"FI52F$%7,ZK\UI',X?1E&Q\"TAU,U/J`Q@MEKJ]N
M<BZE')3I_/J'.1E/ISZHE.PYV<+LD?19/.N1X^VFP\BBUJV"D6:ES%U`3-W5
MQR"246T./@(H-W/X#!XU&C+>]G;*?FI\*MZZAS<'JD]FCPAI!*U?SEH\$3NT
MY^[EOE9V==JG>6J1DR)I:`=J[^:JI<`;2?\`9MN=2A$K>'-EFVO!@-G%DXSA
MW,\W*7_K9=9`NFYCJ$$#`NF_E2K)1ZO,&O\`)4D"@/@`5&/+-7]0\SYF[Q<7
MDT2OZAGXEF704HD5#\\J/7$]=.>[9HQI<$.XO9*95T0!_>JD>LU)(\[M'>;D
M,]OQ26QT`1M/[`>0`T`/(`!X``>``%:TC>O5PA2$*0A2$*0A2$*0A2$*0A2$
M*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$
M*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$*0A2$
M*0A2$*0C"VXS&DEF/!>4<80KYO&S%YVE(1$4\=B<K-.1'IN&9'ATRG4(T<.$
M"IJF`!$I#B.@Z5E^`Y#3XGFEMR.L0IRDHZI#BTIES%&Y7+/9S`$D=8C6^L&%
MUNHFE]\PBVNH8N%RMSK+2USY`X1-'/*9Y"H!*B`2$DR!BMFR[8&]!V_,Q4QI
M$,2)G`BD@\OJTRQX%YN7JIJHR:RZZ>G'S$S&T\GDJPA[O(:1-,=NFXO+)&Q*
M:9_F\&U``/A('7%,%-W&N\B_5&E79Z1I(,BXJNINSET@I65*''8DGJC;'&O9
MGO-\=!UEW+D%;S80*=:'L&+<S\D(:^>B,S-DC(]N?3P.5LX`!\@UK#(N]Q:&
M06\5M3S[G!RI6&D>'LVRM1\!6GPQOK"_NWLCJ5I?U!R&EI&-A+5`TI]P]([9
M\-H2>L-.#JB0;%7;.VGXN>(2JMG/\C3#?I&1>9(D@GF*"Z8@;TA"`0;L8+G$
MQ=0ZJ"O+Y-*T5D_>)U/R5DTJ:M%OI%3FFD1V2B#P+I*G/P*3/C$N<"[E&@F#
M5*;@NVNWBXHE)=Q<]80E0\Y+`2AB9_*;5+A*-]&#%C%LF\;%LF<;'-$RHM&$
M>U09,FJ).!4F[1LFD@BF4/`I2@`5I%]]ZI>545*UN/K,U*42I1/25$DD]9,2
MLI:2EH*9%'0M-LT;:>5"&TA"$I&X)2D`)`X`"4>U7RCD0I"%(0I"%(0I"%(0
MI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0
MI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0
MI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0
MI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0
MI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(1J+O$WL88V.6/;.0
M<V)7FK`79<_Q2BBV3;A[E?A*^KG,IJZ:$=-10:>C-#^Z<P^=H&G&LQPS!KWG
M=<[;[&6!4,M=HKM5\@Y9A.PR,S,C9&*Y9F%HPVB;K[QVW8.N<@[-'.>:1.T3
M$A(;XCM^\*[`?>>?OHH6^&*V/_#IJ%TV_P#:!^C&!>W?!?UWY@^_#[PKL!]Y
MY^^BA;X8I_#IJ%TV_P#:!^C#V[X+^N_,'WX?>%=@/O//WT4+?#%/X=-0NFW_
M`+0/T8>W?!?UWY@^_#[PKL!]YY^^BA;X8I_#IJ%TV_\`:!^C#V[X+^N_,'WX
M?>%=@/O//WT4+?#%/X=-0NFW_M`_1A[=\%_7?F#[\/O"NP'WGG[Z*%OABG\.
MFH73;_V@?HP]N^"_KOS!]^'WA78#[SS]]%"WPQ3^'34+IM_[0/T8>W?!?UWY
M@^_#[PKL!]YY^^BA;X8I_#IJ%TV_]H'Z,/;O@OZ[\P??A]X5V`^\\_?10M\,
M4_ATU"Z;?^T#]&'MWP7]=^8/OP^\*[`?>>?OHH6^&*?PZ:A=-O\`V@?HP]N^
M"_KOS!]^'WA78#[SS]]%"WPQ3^'34+IM_P"T#]&'MWP7]=^8/OP^\*[`?>>?
MOHH6^&*?PZ:A=-O_`&@?HP]N^"_KOS!]^'WA78#[SS]]%"WPQ3^'34+IM_[0
M/T8>W?!?UWY@^_#[PKL!]YY^^BA;X8I_#IJ%TV_]H'Z,/;O@OZ[\P??A]X5V
M`^\\_?10M\,4_ATU"Z;?^T#]&'MWP7]=^8/OP^\*[`?>>?OHH6^&*?PZ:A=-
MO_:!^C#V[X+^N_,'WX?>%=@/O//WT4+?#%/X=-0NFW_M`_1A[=\%_7?F#[\/
MO"NP'WGG[Z*%OABG\.FH73;_`-H'Z,/;O@OZ[\P??A]X5V`^\\_?10M\,4_A
MTU"Z;?\`M`_1A[=\%_7?F#[\/O"NP'WGG[Z*%OABG\.FH73;_P!H'Z,/;O@O
MZ[\P??A]X5V`^\\_?10M\,4_ATU"Z;?^T#]&'MWP7]=^8/OP^\*[`?>>?OHH
M6^&*?PZ:A=-O_:!^C#V[X+^N_,'WX?>%=@/O//WT4+?#%/X=-0NFW_M`_1A[
M=\%_7?F#[\/O"NP'WGG[Z*%OABG\.FH73;_V@?HP]N^"_KOS!]^'WA78#[SS
M]]%"WPQ3^'34+IM_[0/T8>W?!?UWY@^_#[PKL!]YY^^BA;X8I_#IJ%TV_P#:
M!^C#V[X+^N_,'WX?>%=@/O//WT4+?#%/X=-0NFW_`+0/T8>W?!?UWY@^_#[P
MKL!]YY^^BA;X8I_#IJ%TV_\`:!^C#V[X+^N_,'WX?>%=@/O//WT4+?#%/X=-
M0NFW_M`_1A[=\%_7?F#[\/O"NP'WGG[Z*%OABG\.FH73;_V@?HP]N^"_KOS!
M]^'WA78#[SS]]%"WPQ3^'34+IM_[0/T8>W?!?UWY@^_#[PKL!]YY^^BA;X8I
M_#IJ%TV_]H'Z,/;O@OZ[\P??A]X5V`^\\_?10M\,4_ATU"Z;?^T#]&'MWP7]
M=^8/OP^\*[`?>>?OHH6^&*?PZ:A=-O\`V@?HP]N^"_KOS!]^'WA78#[SS]]%
M"WPQ3^'34+IM_P"T#]&'MWP7]=^8/OP^\*[`?>>?OHH6^&*?PZ:A=-O_`&@?
MHP]N^"_KOS!]^'WA78#[SS]]%"WPQ3^'34+IM_[0/T8>W?!?UWY@^_#[PKL!
M]YY^^BA;X8I_#IJ%TV_]H'Z,/;O@OZ[\P??A]X5V`^\\_?10M\,4_ATU"Z;?
M^T#]&'MWP7]=^8/OP^\*[`?>>?OHH6^&*?PZ:A=-O_:!^C#V[X+^N_,'WX?>
M%=@/O//WT4+?#%/X=-0NFW_M`_1A[=\%_7?F#[\/O"NP'WGG[Z*%OABG\.FH
M73;_`-H'Z,/;O@OZ[\P??A]X5V`^\\_?10M\,4_ATU"Z;?\`M`_1A[=\%_7?
MF#[\/O"NP'WGG[Z*%OABG\.FH73;_P!H'Z,/;O@OZ[\P??A]X5V`^\\_?10M
M\,4_ATU"Z;?^T#]&'MWP7]=^8/OP^\*[`?>>?OHH6^&*?PZ:A=-O_:!^C#V[
MX+^N_,'WX?>%=@/O//WT4+?#%/X=-0NFW_M`_1A[=\%_7?F#[\/O"NP'WGG[
MZ*%OABG\.FH73;_V@?HP]N^"_KOS!]^'WA78#[SS]]%"WPQ3^'34+IM_[0/T
M8>W?!?UWY@^_#[PKL!]YY^^BA;X8I_#IJ%TV_P#:!^C#V[X+^N_,'WX?>%=@
M/O//WT4+?#%/X=-0NFW_`+0/T8>W?!?UWY@^_#[PKL!]YY^^BA;X8I_#IJ%T
MV_\`:!^C#V[X+^N_,'WX?>%=@/O//WT4+?#%/X=-0NFW_M`_1A[=\%_7?F#[
M\/O"NP'WGG[Z*%OABG\.FH73;_V@?HP]N^"_KOS!]^'WA78#[SS]]%"WPQ3^
M'34+IM_[0/T8>W?!?UWY@^_#[PKL!]YY^^BA;X8I_#IJ%TV_]H'Z,/;O@OZ[
M\P??A]X5V`^\\_?10M\,4_ATU"Z;?^T#]&'MWP7]=^8/OP^\*[`?>>?OHH6^
M&*?PZ:A=-O\`V@?HP]N^"_KOS!]^'WA78#[SS]]%"WPQ3^'34+IM_P"T#]&'
MMWP7]=^8/OP^\*[`?>>?OHH6^&*?PZ:A=-O_`&@?HP]N^"_KOS!]^'WA78#[
MSS]]%"WPQ3^'34+IM_[0/T8>W?!?UWY@^_$L.W3/EB;H<+V-GG&1)Y.Q<A-)
M5Y`$N:*-"3H(P\_*VV\]819EEQ:'&1AUN0.<W,GRF\NE:CR3'KABM[?L%T[/
MU^F*0OD5S)FI"5B2MD]BA/KF(V?8+Y19):&;W;N?U)\**>=/*KQ5*09IX;4G
MW(S771QW$*0A2$*0A2$:);^M[&%=CF-[/R!F^P;KR#;]V7E\4HJ,M*#M6=>L
MI;U2\E/37+:[)J$9HMO1FAB<Z:AU.80#ETU$,_T]P>]YU<WK?8JAFGJ&F>T4
MIQ2T`IY@F0+:%F<SN(EUQA.<YC:,+MS5PO+#K[#CW(D-I0HA7*3,A:DB4AP,
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MZ^AY"BE22I0((,B""9@@["#N,;S;IZ!YM+K3;*FE`$$)2001,$&6T$;08]_X
MB6-^I5H?)F$_0:^?UC7_`"[WIJ]^/?U*C^2;]%/O0^(EC?J5:'R9A/T&GUC7
M_+O>FKWX>I4?R3?HI]Z(Y=]/<%V;;`G=FP>5;&&\+TO9-T_8V-C:SK&E+DBK
M?:ZI_&2>2G9&`9QD2[>>X-A,L*KA0I^F02IG,79>!:>9IJ$AY^U/]C1,2!=>
M<<2A2SYB2E*RI0&T[)`2F=HGK[-<\Q/!5,LW-DNU;TR&VD-J6$CSU<RD@))V
M#;,G<-AE'S]X5[?7]V7-7T=87^?];$_AUU#_`,TH?GJCZ&,#]O>"_P"75OS5
M/]+'=,;]]W8;D[(5C8WA-M^7&4S?UV0-GQ3R4Q[A].,:2-PR3>,:.)!1K>[I
MR1FBLX`R@II*'`H#H41X5P;GH)GUJMM1<W[E1J9IV5N*"7JCF(0DJ($V0)R&
MR9`ZXYEMUMPJYW!BW,6^K2\^ZEM)4VQ(%1D"9.DRZ9`^")[1L.Q@$0^)5H<!
M$/\`LS">3_F-1^^L*_Y=WTU>_&\?4Z/Y)OT4^]''Q$L;]2K0^3,)^@T^L:_Y
M=[TU>_#U*C^2;]%/O0^(EC?J5:'R9A/T&GUC7_+O>FKWX>I4?R3?HI]Z`6'8
MPB`?$JT.(@'_`&9A/+_S&GUC7_+O>FKWX>I4?R3?HI]Z(/,^=[#8YMXS/DG!
M]W;=\HR]SXPNA[:<Y)VYC_$B\$]?L"I&5<12TC>4<_49G!4.454$C^R4*WOC
MVB&=9'9*6^T=QI$4M4T'$I6Z^%`'@H):4)^`GPQIB_:QX=C]XJ++5T%4NIIG
M"A10VR4DCX)+B3+P@1B$?VA;M\!X[9\U!^/'>%P_?O\`KN?X==1/\SH?GJCZ
M&.H]O>"_Y?6_-4_TL<?>&.WO_=HS1]'F%OG_`$_ATU$_S.A^>J?H8>WO!?\`
M+ZSYJG^EA]X8[>_]VC-'T>86^?\`3^'343_,Z'YZI^AA[>\%_P`OK/FJ?Z6/
M`_[0WV]DR'..VC-(@0IC"`8[PMKH4!$=/_N!X\*\CNYZB$R^LZ'YZI^A@=?,
M$`G]7UGS5/\`3181@[:Q]/0D-.M+'M9)K-Q,;,-4G%L0)7";>39HOD$URIM%
M$P6(DN`&`IC%Y@'01#C4=*BJN5.^NG6^Z5H64F2U2F#(RVQOIJGHGFDNI9;"
M5)!'BIXB?1'U/B)8WZE6A\F83]!KX_6-?\N]Z:O?CZ>I4?R3?HI]Z'Q$L;]2
MK0^3,)^@T^L:_P"7>]-7OP]2H_DF_13[T/B'8P__`$5:'R9A/T&GUC7_`"[W
MIJ]^'J5'\DWZ*?>B$S<?WGMD>V/.62,!WMMZR9-77C&<2@)N5M>P,3N+?>NU
M8N/E2JQ:\I=\7(*-P0D2%$56Z1N<!X::".\\9T4SG*+#39!17&E1253?.E*W
M7PL`**?&"6E"<T\%&--9#K!AV.7JHL=90U*ZFF6$J4AMDI)*0K9S.),I'B!&
M$1_:%NWR'CMFS4'X\=87^?\`7>?PZZA_YI0_/5'T,=-[>\%_R^M^:I_I8?>%
M^WQ_=GS3]'>%_G_3^'74/_,Z'YZH^AA[>\%_R^L^:I_I8?>%^WQ_=GS3]'>%
MOG_7G^'74/\`S2A^>J/H8>WO!?\`+ZSYJG^ECNT'W].V=)+%3E\691ME,P$U
M<OL+6?)I)B8IA/SIP$Y)N!!(0`!Y2&UU\W6N`_W?M3VQ-FKI'3T"I<'^NA(_
M''-8UTT[<5)ZFJFQTEA!_P!52C^*)!=N^^SMV;I9)G;V(,CXDD;P?%U:V+<U
MLLK)O)RIP'H,(.ZH>+6EW`%'42,S.#`'CI6N\DP+4C%&E5-XIJM-$G>ZA9=;
M'65-J4$C\Z49W8,XP')G!3VFII55:MS:TAMP]02M*2H_FSC>;XAV,'_T5:/R
M9A/T&L"^L*_Y=[TU>_&;>I4?R3?HI]Z'Q$L;]2K0^3,)^@T^L:_Y=[TU>_#U
M*C^2;]%/O0^(EC?J5:'R9A/T&GUC7_+O>FKWX>I4?R3?HI]Z'Q$L;]2K0^3,
M)^@T^L:_Y=[TU>_#U*C^2;]%/O1'9OUWX;7^WH?%I,N87G[N'+);O-`#CJR<
M>O@8?$L;="2];_&.9MSI>D_&5'H='K:\A^;ET+S;)T^P'*M1A5FT5K;/J?9\
M_;..B?:<\N7D0O=R&<Y;Q*?#7^<9QCF!&F%UI''?6NTY>R;:,NSY)\W.I&_G
M$I3XSE&GN&.^'L6SCE[&&&;8VYY5C+CRK?5M6!!24[C[$2,*PEKHDT(IB[EE
M6-Z/GJ<>@NX`RID4%5`(`\I##PK,KWH7GEALU5>ZJY4BJ:DIUNJ2AVH*BE"2
MHA(+0$R!LF0.N,5LNLV&7R[TUFIJ"J3453R6DE3;'*%*,@52=)ETR!/5$ZHV
M'8P"(?$JT.`B'_9F$\G_`#&M"?6-?\N]Z:O?C=7J5'\DWZ*?>A\1+&_4JT/D
MS"?H-/K&O^7>]-7OP]2H_DF_13[T/B)8WZE6A\F83]!I]8U_R[WIJ]^'J5'\
MDWZ*?>A\1+&_4JT/DS"?H-/K&O\`EWO35[\/4J/Y)OT4^]&-\J7+MRP=:;N^
MLPO<18UM!D/(M/WBUM>$8'7$HF*T:&=MB*OWR@!YB"!5%CCP*41KL[339-?J
ML4%F35U-8K<EOG49=)EN'23(#B8ZZYU5@LM*:V[*I:>D3O4YR)'@$]YZ`)D]
M$1&W_P!\SM;V:^=QT#$W+DY1JH)`>V/A-BE$.=!TYFDC=P6P1P0?(8"Z5N&W
MZ$:JUK8<J%M4H(W.U)YAX0WVDHU57ZUZ;4;A;82[4D<6Z<<I\!7R3C!+[]H;
MV%HF($?M;RZ[*/-U#.[,PY'B40$.3IE)=S[J`8.(Z\HA[%=^WW=,_/\`276C
M'@<J#_Y0CI'-?,)2?B[;5D=:&!_YACT/O$.QO^Z?E'Y.8?\`A^OI_#EG7^;4
MOIU'Z$?/V_8;_EE5Z+'Z<?8B?VA78(Z5*27VR9<B4C*%+Z2A8F(I5(B8@(F4
M5(C=C=QYHAIRD(<1UKXO=W74%*9LW2C6KH+KZ?Y6R/PD1]FM>\(69.VZK0)[
MPVPK_P`P'\`,2%;7^Y)VYMVMPL+)QG<=HPF090W3BK`R18+&QKDF%P()S-8,
M9-@,-.O"@`Z(M':JQ]-2D$`'37.5:::DXA3*KKFV\Y;D>4ZRZ74)'2KE/,D=
M:D@=<9[C6HF`94^FCMSK:*]7DM.MAM:CT)YARJ/4E1/5$COQ$L;]2K1^3,)^
M@UK3ZQK_`)=WTU>_&PO4J/Y)OT4^]#XB6-^I5H?)F$_0:?6-?\N]Z:O?AZE1
M_)-^BGWH?$2QOU*M#Y,PGZ#3ZQK_`)=[TU>_#U*C^2;]%/O0^(EC?J5:'R9A
M/T&GUC7_`"[WIJ]^'J5'\DWZ*?>A\1+&_4JT/DS"?H-/K&O^7>]-7OP]2H_D
MF_13[T:$[Z=[NT?M_0%FR>8+(1N.?OV1<M;9L.P+/LN1NYW&QZ?-*W(X:S;R
M"8LK?CE3IHF647`RBZI2)E.('Y=@X%@V8:AU#S5G?[.GIT@K==<<2V"?)0"D
M+)6K:9`;`"21LG@^:YGB^"T[3MU:[1]]1"&VD(*R!Y2B%%("1L$R=I,A/A&K
M]X5[?/\`=FS5]'6%_G_6SOX==0_\TH?GJCZ&-=>WO!?\NK?FJ?Z6,G88[Y?;
MUS%E.R,6GP]?..%K[G6EMQ]XY`L+%C.SHN6DC="*3G7T-=<R]8-I!^9-N5?T
M<R2:BI14,0G,8.KO>A&HMFM+]U%93U(IVRLMM.OEQ24[5<H4VD$@3,IS(&R9
MV1V5FUIP6[W1FV>JOTZGUA`<=;9#84?)"BEQ1$S(`RE,B<AMB=,;#L<!$!LJ
MT0$/_P"LPGZ#6A/K&O\`EW?35[\;K]2H_DF_13[T<?$2QOU*M#Y,PGZ#3ZQK
M_EWO35[\/4J/Y)OT4^]#XB6-^I5H?)F$_0:?6-?\N]Z:O?AZE1_)-^BGWH?$
M2QOU*M#Y,PGZ#3ZQK_EWO35[\/4J/Y)OT4^]#XB6-^I5H?)F$_0:?6-?\N]Z
M:O?AZE1_)-^BGWHT*WX;T-M7;ZMO'MSY:P[+W8RR1.3$##(8[LNPGSIFZA6"
M,BY5DRW%*VZDFW517`""D=4PF`=0`.-;!P#"LGU$J:FEM%8AE=,VE:B\XZ`0
MHR'+R)7MV;9RC!\WS#'\$IF*JZ4JW45#A0D-(;)!`GMYU(V>"<1ZVCW\M@UX
MW9:]GQVVO,+>0NRXX2V6#A[CS#A&:#V=DFT6U6=G1OI=8C5)=T4R@D(<P$`=
M"B/"MC5G=_U`HJ-VL<N=$6V6E+(#U1,A"2H@39`G(;-HC`:37+"*NJ:I&[?6
M!QUQ*`2TQ(%1"1.3I,IG;(&+`!K#L8HB'Q*M#@.G_9F$_0:CQ]8U_P`N[Z:O
M?C>WJ5'\DWZ*?>CCXB6-^I5H?)F$_0:?6-?\N]Z:O?AZE1_)-^BGWH?$2QOU
M*M#Y,PGZ#3ZQK_EWO35[\/4J/Y)OT4^]'8&3%E&M4F4<S:1[)`#`@S8MD6C1
M$#G,H<$6S<B:*0&4.)AY2AJ81'Q&N,XXXZLN.J*EG>29D^Z8^Z$(;2$-@)0-
MP`D/P1[5>D>T*0A2$*0A2$5R/VE3_55P;_7J/\S)NI*]V3_NNN_P'_F(B/W>
M(_[7H_\`'#_AKBH/AM&WW67\5,KMC$YFU9'(]DQ5RQ*QSII2$#+7''1DJV,H
MF=-1+G9.SZ&*8#%$`$.(5,:]&H39JM=&HHJTTSJD*'!:4*4D_A`B*-F33KO%
M(W5I"Z552TE:3N*5+"5#\!C;/N.[&;NV(;AYW'3Y)[)XPN=1Y<N&;T7(8Z%Q
MV8NX$21CMT!01-<MKF5*U?IAH)A`BQ0Z:Q1K$--<\H\^QQNXH*4W1H!%2V-Z
M'`/*`W\B_*2?"D[08RK4/"JK";^NA4"JUNDKIW/A(GY)/PT3Y5=.Q6XQ+-V0
M.ZF;%\K`;--Q-S@3&<V["/P??4ZZ'I6#//G`BCCZ8?N#:-[/FW*H^KE5#=-@
M[/T1$J*I>GJ+772<75ES-,<:_P#<VTSJFDC^E0!_3)`WN)'E@;5I\;R@9[2T
M8U-^KW&\/O[G]Q6J5,XH_P!&HG^B43N0H^03L2KQ=Q$KBX@(#H/C4,(EG&B_
M<!WT8ZV%X+E<F749I-7S,$=0V)\>"ZZ+Z]KN%'F2(H5/F7;6Y#`<KB2=``%2
M1`"%'JJ)E'/=/,"N6?WY%LI)HH$24^]*8:;G^`K5N0GB=NX&6%YSFENPBRJN
M57)=6J:66IR+CDM@ZDC>M7`=9$?SPLU9GR1N(RG>.8LKW`\NJ_K\F%9.6?*=
M0R:0JF!*/@X5B43E80L2VY&K%HB`$22(4I0$1$1L;LEEMF.6IFS6EM+5OIT<
MJ1_K+4>*E&:E*.\S,0&O%WN.071V[7-9=KWUS)Z)[D)'!*1)*4C<(WUW5[$7
MFT'9%MHR)DQ@HQSQN.R'-W'*0CM-5)U8.-(>SDW-O6DX1.0`1G9%Y+)OY/40
M.DH*3?3W(^NO\3SY&8YS<[=:U!5@MM,E"5#<Z\IR2W!^2`DH1TB:N(C.\HP@
MXGA5NKKBGEOMPJ5*4#O:92W-+<N"B2%+ZY)X&-/=HW^M7ML_KRQC_.V+K,LQ
M_P"TKG_@'_\`AJC$L1_[JMW^-:_UQ']/,_MS?Y1OWQJK4[XL?CQI"%(1Y$]L
M7_*#]\*\'="/YNO<_P#_`#"=WG]=%Q?^Z959?I7_`/'-F_P2/Y3%>^IG_?UU
M_P`4K^01OWV%,7;;,HY<W`,-REI8GNV"BL;VP\MIOE=*WU8]G++7.=%TM$A<
M"J21'BC0.504_.Y.`\!K7^O]UR:U6>WN8R]5LU"ZE866"L$I"!(*Y.$]T^,9
MQH=;,>N=TKT9"S2O,(IT%`?""`2LS*>?C+?*+.O]D?M7?^#.S?\`^%QM^F5%
MS]\-6/\`G;SZ3T20_=33/_D[3Z+,/[(_:N_\&=F__P`+C;],I^^&K'_.WGTG
MH?NIIG_R=I]%F/:9;..UU*NVT9'8,V@R3^0739LH]C&8\>/'KE<P)HM6K1NY
M47<N%CF`I2$*8QA'0`$:]%YIJJR@NN5UX2VD3)*G@`!O))V`#ICV1B&FSJ@V
MW0VI2U&0`2T23T`#>8D':M6S%JV8LT$FK-DW0:-&R!`31;-6R1$&[=%,NA2)
M(HD`I0#P`*URM:G%EQ9)6HDDG>2=I,9XE*4)"$B20)`=0C]Z]8]H4A'(>(?C
M"O!W0C^<_P!W'_S)-W']9+/^9EK59-I!_P#&=G_PQ_XKD5_:J?\`R'=?\0/^
M&B-W^P)MUP9N+S+N!@\Z8LL[*D1;F,;<EH*.O&*3E6L5).;K39N'C)-0Q017
M6;#R&,'$2\*P7O!Y)?L;LEOJ+#5O4CSE4M*BVKE*@&Y@'I`.V,TT+Q^RY!=J
M]F]4K-4TW3H*0XD*"25R)$]Q(BTC]6!V]/[G^#OD@A_^[44_:IJ+_G%=\X8D
MM[-L"_RFB^;$>"G:\[>2J9TS[/L'B10IB&`MI)$'E,&@Z'(L4Y1T'Q`0$*\C
M5744&8O%=/\`VAA[-L"_RFB^;$:,;U.R#LJO7"V1;CPKC=+!V4K4LZX+FM63
MLB2EPMR2DH"+<RJ<-/VI(/7T:Y82P-!0,H@5!RB8X'*<0*)#9Y@^NF;T5[IJ
M:]U)KK4\\A#B70GG2E2@GF0X`%`IG.1)292(VS&&Y?HWAU?:'WK33)HKDVTI
M2%-$A)4D$A*D3*2#*1D`1O!BC$V6714;.T#N&3ULJBY;KH*J-GC%VB8JB:J"
MZ)B+MG394NI3D,4Y#!J`@-3Q4E*@4*DI!$B#M!!Z0=A!B%"2I)"TS2L&8(V$
M$=!W@B+_`-V2=S>0-SFR&$E<ISSJZKZQE>D_BZ0N>15,XEY^(A6L9(VX_FW1
MQYWDN2)E"(++FU.OT2G.)CF,8:]=<L6MV+YRXU:6PU053"'P@;$H4HJ"PD<$
M\R20-PG(;`(G7H[DE=DF&-O7)9<KJ=U;*EGRE!,B@J/%7*H`GC*9VQ+Q6G(V
MK"D(4A%3W]IW_P"4;+/_`&>>O]]BBI<]UKR;W_Z3_P#<1%WO(>59_P#U7_D1
M`7V]O]?+9K_^2V(/YY1E2!U&_P"P+U_^,J/^&J-(Z>_]]V?_`/(,_P"L(_I<
M']L;_*']\:K$&Z+$(\:\PA2$<@&H@'LB`?NTA'\^OO59WOG,F_S,MM7'-22]
MGX8F6V.<?VPJ[7&'@F<7%L5IB2:QW5,T3E)Z9=+*KN`*"JB8)D$="``6(Z(6
M"@LNGM%54R$BMK4%YU<AS**E'E252GRH2``-P,SQB".L=[K;MG572U"U&CHU
M!II$SRI`2"I0&[F4HDD[Y2'"/S[.&S;&.]/=@[LO,B#^4QS8%@2F0INV8^2<
MPY[I=-Y.-AXF(>2+$R;]")!W(=5R5!1)54A`(!R@(UYUGS2Z81B2:VRE*+E4
M5`92LI"N0<JE*4`=G-(2!(($YR,>=(L1MF89.NENX*Z"G8+JD`E/.>8)2"1M
MY9F9`()Z8N6PO;&[?-O-09QFT'!Q4``A=7UG-9=<P$YN43NI8[UR<X\PZF$^
MIA\:A6_JEJ)4*YW;Q7<W4X4C\"9")<-:<8(RGE1::*76TD_C,X^S]7+L+_NA
MX!^CF`_1J^'M*S__`#BX?/+]^/I[/L'_`,JH/F4>]$;G<=[+6$\M82=O=G&!
M["Q[N$B[AA7<2-O29+'MZXH)5R*%P1D\@Z<'@2E29*==NH5$BQ54P*4W*80K
M9FFNMU[M%\",TN%148ZMM05SI[5:%@30I!'C[]A$Y2.V-?Z@Z06:ZV4G$Z&G
MI[ZEQ)24GLDJ23XX5YN[:-DYC9LB"%KV%.YU&.VDG$V-CR.EHQTWD8J199EM
MML]CY-BJ1RP?,W*0%5;NFCI(JB9RB!BF*`A6_%]X#2UU!:>?J5,J!"@:99!2
M=A!'$$;"(TFC0[45I:76FZ9+J%!22'P"%`S!!EL(.T1>8Q>A>+7&>.VN1#$/
MD!K8UJ-;X43<D>D4NYM!L4;B5*\2$4G8*RQ%3=0H\I]>8/&H'W55$NZ5*[;L
MMQ?<+6R7Q94>39P\66R)HV\5::!A-?\`_6AE`<VS\?E'-MX^-/;'>JX$<R%(
M0I",+;A\^XYVP8;OG..594L59MBQ*C]T4ID_3YB15,#>(MV%0.8HO)J=D5$V
M[=(/$Y^8VA2F$.\QO'KEE5Z8L5I1SUKZY#H2-ZEJ/!*1,D]`Z=D=1?KW08Y:
M7KS<U\E(P@J/23P2D<5*,@!TF/YQ.[S=3D?>1G>\\Z9+>*%>3SM5M;%N%<**
MQ=BV6T65]06E$$.84TV\:T/S+J%`!<NCJ+'U,>K*L.Q.VX78&+#;!XC8FM<O
M&==(\=Q763N'FIDD;HKYRS*+AE][=O5Q,E+,D(\UML$\J$^`;SQ5,G?$^7:?
M[,EF9NVXWWFK=+"NT#9RLQ[;V"HL060E[%@W6JC?,::'.B`3T@_02&+26U)Z
MO3.<Q1!T42Q]U;UKK;%DM/9,4<!%"^%U2MA2ZH;Z<G;XB1/G(V\Y`'D;=Z:7
MZ0T=WQ]Z\9,@SKF2FG3N4T@[G_SU$`HGN3^=%?+<_MOR-M,S??.",HL3-[DL
MV2,FTE$4ED8VZK=="*UOW=!**`4RL7.,.54@@.J2G.D;0Z9@"1.+9-;<NL3%
M_M2ITSR=J=A4VL>6VK\I)V=8D1L,:%R;';ABMZ>LER$GVE;%"8"T'R5IZE#\
M!F-XBW5V-NY4;<98".UC-%PK/,[8OA#+69<$NY,L]R?C>-Z:*?6=KF%1Y=EF
MI'(BZ`1,JY9=-?SC$6$(>Z[Z8_NW<#E=D;";#5+^,0D;&'E;=W!MS:4\`J:>
M*8E9HQJ)^\-O&-799-[I6_$4H[7FAL!GQ6@2"N)$E=,6$*CI&]X4A"D(4A%8
MC]II_P!$FU3^LB_?YL1]2E[KW_6+M_AFO]<Q&_O&_P#2+;_B5_ZD54L%?Z<,
M,?ULXZ_G?$5+*_\`_0JW_"/?\-41BL?_`%NB_P`6S_Q$Q_4G4]N;\=54>_%E
ML>%(0I"%(0I"%(0I"%(0I"*Y'[2I_JJX-_KU'^9DW4E>[)_W77?X#_S$1'[O
M$?\`:]'_`(X?\-<4]<9?Z3<:?UC6'_.R(J9=S_Z95?X9W_AJB)ML_P"ITO\`
MB6O^(F/Z0^]#9QBO>_@J8P]DQBDB[,T&3L*]4&Z9YW'UXIL@)'7!$+"`*&0,
M<"IO6HF!)XU$R9M!Y#%K0PG-+M@M_1>;8HE'-RNMD^(ZW/:A0_&E6]*I$<0;
M"LNQ.V9E95VBY)VD3;6/*:<EL6D_B4-RA,&/YWNYK;7E/:9F2Z\(9@A315U6
MPY`[5^W!48:Z(%P85(>Z[:?&*4'L/*MP`Y#%'G14`R2@%53,4+',7R:U9=96
M;[9E\](Z-H,N9"QY3:QP4D^X1(B8(B`N28Y<\5N[MFNJ"FH;.Q0GRK3YJT'B
M#^$'8=HBU+VBN[W9DWMXO/&>[:_THJ]=M]D/;IB;VGG132&1<3P**:2;,IUU
M2JS-]VTJ=)D")1%Q((JH'`!.54U1/UAT<K6,C8NF(4Y70W)\-J:0-C+ZSOV#
MQ6E[53W((4-W*(D[I5JK25-@>M^4OA%=;V2L.*.UUA/A\IQ&Q)`VJ!2=\XK3
M;Z]Y=_[X]P-TYEO-PZ96^19Q"8SLU1<PL+&L)HX.,5%H(<PHEDWQ`!U(K@',
MN[4,(CRE(`2=P+"K?@F/-66B`54$!3[DMKKI'C*GOY1Y*!P2!Q)B.F;YA79I
M?7+K5DBF!*66^#;0.P2^$?*6>)/0!$X'8\[5)KN?6YO4W'6N!K3CED9;`-@3
MK8>6Y)-!0PH9.N&-<%#J0D<J36';JE$KI;^5&`4R)<^BM==611MN81C3O][4
M.6K=0?(!WL(4/./]81N'B#:52W/HQICZPIO,<@;^(!YJ9I0\H\'E`\!_5@[S
MX_1&8/VG`1&Q-HPCQ$;TR=__``$!72]US_J%X_V#'^NN.U[QW_3[5_MWO]1,
M5GMHW^M7ML_KRQC_`#MBZD_F/_:5S_P#_P#PU1'7$?\`NJW?XUK_`%Q']/,_
MMS?Y1OWQJK4[XL?CQI"%(1Y$]L7_`"@_?"O!W0C^;KW/_P#S"=WG]=%Q?^Z9
M59?I7_\`'-F_P2/Y3%>^IG_?UU_Q2OY!&;NU%V\K#[AN0<MV9?>0[SQXUQS9
MD)=$>]LQG!/',BXE)LT4JV?%G6CM(B"20<Q>F!3"8>(Z<*Z35O46X:<VVCKJ
M"G8J%5+ZD$.%0`"4\P(Y2-OACN=+<#M^>U]727!]YA-.RE8+?+,E2I$'F2K9
MX(F_^[,[>/[S6=/_`)'CWX'K17\4&1_Y90>D]^G&Z?X=,<_Y^N_`U]'#[LSM
MX_O-9T_^1X]^!Z?Q09'_`)90>D]^G#^'3'/^?KOP-?1QE;!/[/A@O`^:\39M
MA=PF9)Z8Q)D*ULAQ<)+P]CI14N_M65;RS:.D5646D\39.U6X$4%(Q5`*(\H@
M-=1?^\3?K_8ZRQOVZB;9K*9QE2DJ=YDAQ)22F:B)B>R>R.SLNA%ALEXI;RQ6
MUBWJ5]#J4J#7*2A04`9(!D9;9$&+`PCJ(C[(ZU'B-YQQ2$*0CD/$/QA7@[H1
M_.?[N/\`YDF[C^LEG_,RUJLFT@_^,[/_`(8_\5R*_M5/_D.Z_P"('_#1$H_[
M,Y_IZW-_U06M_/1*M5=Y_P#[>MG^,<_X<;,[N?\`UNY?X5O_`%XN,5"^):PI
M",29^NF$L?!>9+PN1^UBX*W,7WU*2;]XNFV;H(-[:DA`#+*B!"G64$I"!XF.
M8``!$0"NYQVD?K[]14=,DK?<JFDI`$R25CA'67JI9H[/5550H)8;IW%*)V``
M),?RX^H*PBN)!3%<QENF80$Q.L85.0PAP$2<V@_BJU27+XO1LBM*?,>;IV_A
MB\'^SFP"\;L2NB:50423N;/=\.6RB@CRN4HJ'MF(,JB00#1,BS8Q-0U`QBC^
M&H*]Y.H#N>M,`@EJWM`]14I:O_&)GZ`4Y:PA;Q$@[6ND=<@E/_A*)]*CY&\8
M4A"D(J>_M.__`"C99_[//7^^Q14N>ZUY-[_])_\`N(B[WD/*L_\`ZK_R(@+[
M>W^OELU__);$'\\HRI`ZC?\`8%Z__&5'_#5&D=/?^^[/_P#D&?\`6$?TN#^V
M-_E#^^-5B#=%B$>->80I".2CH8!]@0']P:0C^<MW9(5U`]QO=JR=E4*=?)OK
M=(5$C)=1I.6[!2[10@&$>=,4'H`!@'0VGD\`LGTC>2_IK:%HE(4O*?"E:DG\
M8BO[5-E3&H-T0K>:@*]Q2$*'XC&_?[.!,QL?O7R3%.W2:+^X<!3B$0W,8@'>
M*QEU6[(/2)%,8#',@S*)QY0$0`-1X<:U]WE6'7,'I7D";;=P25'HYFU@?A.R
M,Z[O;S;>7532S)QRB/*.GE6DG\`B[;4&8F/"D(Q%GO-MD[<,/7]G+(XRX6/C
M>&).W'Z@8$E)GT$[YG'%".CE'3(CQP+E\30G5*(AKIJ.@#W./V*NR:]4]AMO
M)Z]4KY4<QY4SD3M,C(2&^4=5>[Q1X_:G[S<.845.CF7RB:I3`V#9,S.Z(AA_
M:).WB`"/_P!_-`#7_1,3P\?UGK<7\.&HO_\`C_G_`/\`HC5?M[P#?S5GS!]^
M)C<.Y5M7.6*\?YBL;UF-GY*M:)O"V_73$(R6]43+<KIF$C'@LX!F[!,WGI]0
M_*/#4:TO>K35V&[5%FK^7URF=4VOE/,GF29&1V3'7*-LVNY4UXMS%TH^;U6H
M;2M',)'E4)B8X'JC)-=9'80I"/R770:H+NG2Z+5JV15<.7+E4B#=LW0(95=P
MX64,5-%%%(HF,8P@4I0$1KRE*EJ"$`E9,@!M))X`1X4H)!4H@)`F2>$4,.\M
MW'5]YV9AQEC*:7-MOP[*O&5N>BJJ)L\CWHV,LREL@NTP,`.HU(.=M#E.'F-N
M=<``RXZ3_P!%=-4X39?K2Z('[RUJ`5SWLMF12R.A1V*<EQDG<F(1:O:A'+KM
M]5VQ9_=^D40F6YYP;"X>E(W-]4U<8TDV)VYM8FMP=L2V\?)3+'V#K-.E=$Y&
MK6_=EQ/,BOX]RD:-L=!M:<-,.&<<_<:*/UUNF7T0ADR")U`TSG/:G*V,==9P
MRE54WU_Q$J"VT!D$>,Z2XI(*@-B`)^,03L$8;@U-C#U_;>RZI13V9GQU)*5J
M[90/BM^(E1"2=JB9>*)#?%TIGWL>US',VD?'[BV3"/8-6[%@Q9XJRPV9LF31
M(B#5HT;(V(1)NV;()E(0A0`I2@``&E0C<T/U5=6IURVJ4XHDDE^G)).TDDNS
M))WF)@HU?TU;0&T7)M*$@``-/``#<`.RV`1$GW<]SW:ZWVX8;S=@;AXIKN/Q
M4@[?XWD5\:91CRWC$KZ*2V-IJ3<6.BDDTE#%ZT>LNH"3-\741*FLJ-;?T>Q?
M53`;V6+A;5G&JL@/`/,'LU#R7D@.G:G<L`34GI($:NU4R'33-K/VM%<FAD%*
M"63V;PYQO4RHEL;%>:29)5MW$Q6/QKDB]\07[:.4<;S[VU;[L:;8W%;,ZQ/R
MKL)-BH"B8*$UY'+1P3F2<(GU371.8A@$IAJ4=SME#>;>]:KFVEV@?04+2=Q2
M?Y"-X(V@@$1&RVW*MM%>U<[<X6JYE84A0X$=/2#N(W$$B/Z*_;TWP63OQV^0
MF4X'T2(OF&%O;F6['2<%4<6C>R+8IW`HIF-US6]/)@+N-7,&AT3"F(BHDH`5
MNZC8+78!D3EJJ)KH%S73NRV.-$[.KG3Y*QP.W<1$_P#!,RHLVL+=TIY)K$R2
M^W/:VX!M'3RJWH/$=8,;U5@49I"D(4A%8C]II_T2;5/ZR+]_FQ'U*7NO?]8N
MW^&:_P!<Q&_O&_\`2+;_`(E?^I%5+!7^G##'];..OYWQ%2RO_P#T*M_PCW_#
M5$8K'_UNB_Q;/_$3']2=3VYOQU51[\66QX4A"D(4A"D(4A"D(4A"D(@E[^6`
MLV;A-N.'[9P;BZ\<JW!#9B&:EH>RXSUH_CXGXJ2[3UBZ1!5+IM?2EB)\VOMC
M`%;][ON0V/'<DK*J_5;-)3KH^5*G%<H*N=)D.N0)C2>N5BO-^QVEIK+3/550
MBK"E);',0GD4)GJF0(JZ8_[:O<!CL@6!(O\`9]G1HPC[ZLU^^=KVB)$&C)E<
ML8Z=NES^ECR(MFZ1CG'R%*(U*FX:G:>.6^H;;O-`7%4[@`#FTDH4`!LWD[(C
M5;].\[;N%.XY::U+:7VR24;``M)).W@(_HQI@())`/`012*(>P()E`0'\("%
M5M'RCX3%@`W1'%W+.WE8N_["ZMO+>K[:S/92+R3Q%D11N7J1TF9,QUK5N!9,
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M0LMF8@*2*_FF<Z`V3X&4,366J6M]FM=E]0PJK:JKS4I([5H\R:=&XJG*1<.Y
M`\WRCN`.QM-=';K<+L+AE],Y36JG4"&G!)3Z]X!$YAL><?.\D<2+JC-FSCF;
M2.CVC9A'Q[5NQ8,&2";5FR9-$B-VK-HV1*1%NV;()E(F0@`4A2@`!H%0@6M;
MJU.N$J<42229DD[223M))WF)@H0EM(0@`(2)`#8`!N`'`"*\7[03MNS[N*LW
M;(RP1B&^<LN[6NO(+RXVUDQ/K56$:R,+"H,%Y`H+)=%-VL@<I!XZB4:D;W=\
MFQ[&ZVZ.7^L8HT.LLA!=5R\Q"E$@=,AOC0FN^/7V_P!%;F[)2/52VGG2L-IY
MN4%*0"?"1$`6V7MS[\K6W'X$N:X]I6;82WK?R_CZ9G)F0M046$5$QUS1[I_(
M/5O2C=)JT;)F.<V@Z%`1J0N4ZDX!5XS<*6FO%"Y4N4;R4I#DRI2D$`#9O)V"
M-%XS@&;TN1T%34VJL13MU;2E**)!*0H$D[=P&^/Z$A^)C#_C#^^-5UF)XQXT
MA"D(\B\#%'_&#]^AW0BAGW"^W]O>R-O>W.WW86UG,EW69=65YV7MNYH.UQ=Q
M$W%N$V@(/X]SZ43K-E1(.AM`UTJ?NG.H>"VS!;507"[43-:U2)2M"G)*2H3F
M");#$(M0,%S*XYI<JZ@ME6]1NU)4A:432H2&T&>Z/2VB8J[Q6QZX[QNO`&TS
M*,3,7U",+?N!6Y\3MKH05C8U\,BU(T;NI-`K58'1A$QPU$Q>%?3,;MHSG5,S
M29#=Z1;+"RM')4%!YE"1F0DSV1Z8G;-6<+J'JJQVFI2Z^@)5SL\XDDS$AS"1
MG&^']LW]HN_NTS_^SE#_``W6`?N5W;O\T;_;%?H1G'[XZ_?Y8O\`91^G#^V;
M^T7?W:9__9RA_ANG[E=V[_-&_P!L5^A#]\=?O\L7^RC]./$^\[]HP`AQ+MHG
MQ,!3"4/[.4..I@`=.'KOCQKR,*[MT]MT;E_C#^A`YCK]+9;%S_PH_3BU?BZ0
MNR6QGCR5OUF:/OF3LBUW]YL#M"L#L;I=PK->>:'8D,<C(S>345(*0"()Z<NH
MZ5$NZMTC-TJ6;>>:@2^X&S.<VPHA!GQFF6WC$F[<Y5.V]AVM'+6*907!*4EE
M(*A+A(SV<([U7`CFPI".0\0_&%#NA%%;N:["-ZV4M^FYK(..-K^8;UL>Z;]:
MR%N75;]LB]AIIB2U+=:&=1[KTDG61*Z;*)B.@><00J>NE^H.#VK`+7;KE=:)
MBN:IR%MK7)23VBS(B6PR(/NQ"C4;!LQN6<7*OM]LJWJ)U\%"THFE0Y$"8,]T
MP1'0MJ.'N\9LIN*[;JV^[6\P6U-7O",[>N%Q,XIB[F3<1;!^62;)((2JZB;1
M0KLH")R:&$O#PKGY=>=&,XIF:3(KM1NL,.%:`FH4B2B.4S*1MV<(X6+6K5K#
M:AVIL5KJD.O("5<S`7L!F)3.S;&\/]K/]HV_\#,@_P"SQ:'_``JP3]T.[9_S
M]/\`MCD9K^]7>`_Y![]E1[\>"F[#]HV43.0,'Y%2$Y#%!1+;S9X*)B("'.F)
M^<O.7Q#4HAKY!KR,1[M@(/K],?\`UCD>#E7>`(EZ@^/_`$J/?C6C->'._7O&
MC_BGFG'N?IZTU'"#L]HR'Q"QS9+E<AQ5:J2$+#24#&R(LSAJ3TLJHI#H(^=Q
MK*;'>=`<,<]<LE1;VZL`CM!VSSH''E4I*RF?'EE/P1CMXM>N.7-^J7=BM52&
M4T'LF6ST<R4E(5+\J<=VVZ_L[&[*_P":C7FX6Y+-P/97525EF<;+LK_R$X:@
M8!5:QK"%.I:[!RJ34H++OU2ICQ%(^G*/`R3O'XC;V%HQQIZOKI225)+3(/2H
MJ^,(Z@@3W3$<S']`,GK7DKR!UFBH_."5!UTCH'+X@/65&708N$X$P7CC;5B*
MR,(XGAAA+%L*()%Q+=97TF0>JG4.YD9F8>B4AG\U,R"RCETL(%`RJ@\I2D`I
M0AID%^N63WA^^W=?:5]0OF4=P'`)2."4@`)'0.)VQ+&R66WX]:F;/:T<E$PC
ME2-Y/$J4>*E&9)XDQE^NFCM84A"D(K8_M"&V/</N,6VGFP-AJ_<MA:*>9@N@
M;(A_6P0(S8XV]4!):+)=#UEZL<=+QYNB?V*DWW=<IQS&TW<7^MIZ/MO5N3M5
M<O/R]MS<O3+F$_"(COKSC=_R`VOZCHWZKLO6.?LT\W+S=CRSV[)\IEX#$+FR
M'MZ;YK$WE;5KUO/:EFBV;1M+/N+[AN>XY>UA;14%!15U1[N2E9%QZ4;H,F+9
M,RBA]!Y2@(UNS.M1<#K\*NU#17:A=K'K>^A"$N34M2D$)2D2VDG8(U'A&!YI
M09C:ZVMM=8U2-5K2EK4B24I"IE1,]@$7\S<3&'_&']^J^!NB<D>-(0I"%(1`
MSW7.S>?>W=;?/>$KM@[*SFUM]C;UQP=U$<HV=D6-A@7]3.'$JP0=/;?N9@@L
M+<'`HKH.$"D*H4@I@<9`:2:T#!Z0X_?65OV$N%:%-R[1E2I<P"20%H,IRF"#
M,@F<HTCJ=I&,SJ1>[.ZAB]A`2H+GV;J4SY9D`E*Q.7-(@B0(V3BNFS[8G=CV
MOY$B+[QS@O)L9>UHOEG5OWUAVX[9N-1N8$SH++-5XF<,Y68OFRAB*-W#?19,
MPD42XB%217JCI'E5M707*OIE4+R0%M5"%HGQV\R9`@[00=AV@QH!&F^J.,7!
M%=;J.H36-&:7*=:%^'<J9!&\$;1O$;[Q.]3]H>MEOZI?81R)/N&Q4TE'MP;9
MXEZ^,)"`',=S"-XQDJ<X"`F,4@@(_P"&M?/81W<ZI7;-U],VD\$5J@/P*YC^
M.,Y9S/7JF3V3E`^XH<54<S^%'*(^K_;U_:$O[NES_P"RX;]*KX^S_N[?YFU^
MW#WH^O[]:[_Y:Y^QJ_2C6K<"IWX=YMIGL'*^'L_2>/9-RW<O;,@\:0&.[9E5
MH]R1PV&<(B$4\DV[1XF15-)XX41!1,IRDYB@-91CHT"PJL]?M%;;TW%`(#BG
MUO+2")'E\H))&PE(!D9$QCE^7K=E])ZA<Z.M-O402VEE+252,QS;B0#MDHRF
M`8^7MZ[`.^'*\[&#EZ*MS;U8BCE(9J7N6>B;DO#U?S%%R2"M.V7<F0\B=+4J
M8OG+5(A]!,!@U"OKD?>$P6T4Z_J=;MQN$O%2A"D-SX<SBPGQ9[^5*C'RL&A.
M971]/UN&Z"AGXQ4I*W)<>5""1/HYE`#KB[EBO'%N8>QEC[$]GI*HVMC:S;=L
MB`*X,4[DT7;44VBFBSHY"D(=VX3;`HJ8``#*&$=*@Q=KG4WJZ5%WK"#55+RW
M5RW<RU%1`Z@3(=43*MM!3VJWL6VE!%-3M);3/?RH2$B?7(;>N.^UU\<V%(1"
M%WG[]WDSV*4-M&T'`V8;X4R<P.IEK)]C6^LXC(:RCF41/84/*E<-U!FKG4+_
M`"\Z?!"/`4M1,N(%WKHG;\*I[L<GS&X43`I5?W=AU8"E.[^U4F1\5'F@[U[?
M-VZ;U>K\N=M8Q[$Z*K>74I/;O-H)"6]W9I5,>,OSI;D[/.BJSC[M.=P6^[WM
M2RU]K^4K%:7)-Q\0[O&\K?"*M2U6+E8I'<[./3.AZ,?&-0,J8I0$ZG*!"`)C
M!4L+CJ[IW04+U:FZTCZVFRH-MKYG'"!L2D2WJ.SH&\[(C%;]+<[KJYJB7;:E
MAMQ827'$20@'>I1GN`VRWG<(M_6'V2NW1:ME6K;=QX#BK\N"$@8R-G;UG+CO
M-"6NJ8;-4R24\^;QUQM&#562>`=4$D4B)I%,!"AH%0XN&N6I%77/5-+<%T],
MXXI26DH;*6TD^*D$H)(2)"9))WF)84.CF`4M&U3U%`A]]"`%.*4YS+4!M49+
M`!)VR`D-T=L^IJ[9_P#=7M7Y49`^==</VU:G_P";/>@U]''*]DFG7^5L^D[^
MG#ZFKMG_`-U>U?E1D#YUT]M6I_\`FSWH-?1P]DFG7^5L^D[^G$''==[)<K9L
MQ:N5]A.(Y^X+3F.A;E\85L\SV?E+7E4$3G8WC`%EY%Q).H.733,F_2,L<6KD
M"'+[FJ8";WTDUR9K67K3J!6-MUB)K:J7)(2M).UM?*`D*3O09#F3,':!/2^J
M.CCE*XU=,'I%KIE20Y3MS44G@XCF))2=RQ,R,B-A,M4>WQB;N@[#]PL#E>`V
M;;A9>R);H6YEJQD;743;W?9#AP!G`HI^G`B6X;?4,+N-6,`\BY13'W-4X#EN
MHEWTKS['7+347JW(KD373NEP3;=`V3V3Y%^2L=&W>!&,8#;-2<(OR+FS:*]=
M"N2'VPCRVY[QMESH\I!Z9C<3%YZ)D23$5&2R3208)RD>SD",9=FI'RK(KQNF
MX!G)L%O=64@VZG(LD;BFH42CX5`UYHLO+9)2HH41-)FDR,II(W@[P>(B:33@
M=:2Z`H!209$2(F)R(X$<1PCZ%?./I"D(KW_M`FW3/.XG&>W"+P3B2]\LR-LW
MY><A<+*RHGUJXAV+ZWF39FZ?DZJ711<N$S$(/'4P5(KN\9)8,;NER=O]8Q1M
M.T[8075<H40LD@=8$:'UVQ^^7^UT#5DI7JIQNH65!M/,4@HD">HF*RMN]N?N
M.VM<$#=$-L[SLA,6W,Q<_$KJV45=)&3AWJ$@P5404=BFLFFZ;E$2&X&`-!X5
M*&IU)TUJZ=RE?O-`674*0H=K*:5`@[9;-AB.%/I_J#2U#=2S:*T/-K2M/Q<Q
M-)!&R>W:(EW'=I^T;&$1_H+R`&HB.@;=[0``U]@`-H`5IW]T.[9_F%/^V.1M
MC]ZN\!_R#W[*CWXX_M9_M&W_`(&9!_V>+0_X5/W0[MG_`#]/^V.0_>KO`?\`
M(/?LJ/?A_:S_`&C;_P`#,@_[/%H?\*G[H=VS_GZ?]L<A^]7>`_Y![]E1[\64
M-BUU;A+VVH8@NG=7"/[<W`2T;<:F1H64@&EK/V+UO>=QLX4CB!8B+2.,K;+=
MDH!2<#E.!QXF&HRY[28[0Y;64F).)=QY"D=BI*RX""V@JDL[3XY4-N[=PB0V
M%55^K<7I*K)T%N^K2OM4E(000XL)\4;!X@2?QQMI6(1E,*0A2$*0A2$:=[SM
MU%W[3[$M>\K-VVY;W,OKBNGXN.K3P^Q=/YN!:A&NG_KZ23:1$P<D9U&X(:BF
M4.HH7SO)6:83B=%EU>[15USH[6VVUSARH("5GF`Y$S4GQML]^X1BF6Y)68S1
M-U=%;JJY.+=Y"VP)J2)$\Q\56S9+PF(W_KGLZ?9+[X?DY-?,:ME^Q3'_`+7V
M+TT_2Q@'M9OWV4O7HGZ./'ZYS.7V2N]_Y-S/S%I[%+!]K[%Z:?I8\>UF_?92
M]>B?HX?7.9R^R5WO_)N9^8M/8I8/M?8O33]+#VLW[[*7KT3]''E]<]G3[)??
M#\G)KYC4]BF/_:^Q>FGZ6//M9OWV4O7HGZ..![SN<Q\>TKO@'\=N3(_YC4]B
ME@^U]B]-/TL/:S?OLI>O1/T<<?7.9R^R5WO_`";F?F+3V*6#[7V+TT_2QX]K
M-^^REZ]$_1QR'>=SF'AVEM\`?BMR9#_,:GL4L'VOL7II^EA[6;]]E+UZ)^CC
MGZY[.GV2^^'Y.37S&I[%,?\`M?8O33]+'GVLW[[*7KT3]''C]<YG+[)7>_\`
M)N9^8M/8I8/M?8O33]+'CVLW[[*7KT3]'#ZYS.7V2N]_Y-S/S%I[%+!]K[%Z
M:?I8>UF_?92]>B?HX?7.9R^R5WO_`";F?F+3V*6#[7V+TT_2P]K-^^REZ]$_
M1P^N<SE]DKO?^3<S\Q:>Q2P?:^Q>FGZ6'M9OWV4O7HGZ./+ZY[.@<`[2V^`/
M^[DU\QJ>Q3'_`+7V+TT_2QY]K-^^REZ]$_1P^N?SI]DOOA^3DU\QJ>Q3'_M?
M8O33]+#VLW[[*7KT3]'#ZY_.GV2^^'Y.37S&I[%,?^U]B]-/TL/:S?OLI>O1
M/T</KG\Z?9+[X?DY-?,:GL4Q_P"U]B]-/TL/:S?OLI>O1/T</KG\Z?9+[X?D
MY-?,:GL4Q_[7V+TT_2P]K-^^REZ]$_1QX_7.9R^R5WO_`";F?F+3V*6#[7V+
MTT_2QX]K-^^REZ]$_1P^N<SE]DKO?^3<S\Q:>Q2P?:^Q>FGZ6'M9OWV4O7HG
MZ.'USF<OLE=[_P`FYGYBT]BE@^U]B]-/TL/:S?OLI>O1/T</KG,Y?9*[W_DW
M,_,6GL4L'VOL7II^EA[6;]]E+UZ)^CCGZY[.@<`[2V^`/^[DU\QJ>Q3'_M?8
MO33]+'GVLW[[*7KT3]''/US^=/LE]\/R<FOF-3V*8_\`:^Q>FGZ6'M9OWV4O
M7HGZ.'US^=/LE]\/R<FOF-3V*8_]K[%Z:?I8>UF_?92]>B?HX?7/YT^R7WP_
M)R:^8U/8IC_VOL7II^EA[6;]]E+UZ)^CCQ^N<SE]DKO?^3<S\Q:>Q2P?:^Q>
MFGZ6/'M9OWV4O7HGZ.'USF<OLE=[_P`FYGYBT]BE@^U]B]-/TL/:S?OLI>O1
M/T</KG,Y?9*[W_DW,_,6GL4L'VOL7II^EA[6;]]E+UZ)^CA]<YG+[)7>_P#)
MN9^8M/8I8/M?8O33]+#VLW[[*7KT3]'#ZYS.7V2N]_Y-S/S%I[%+!]K[%Z:?
MI8>UF_?92]>B?HX?7.9R^R5WO_)N9^8M/8I8/M?8O33]+#VLW[[*7KT3]''(
M=YW.8>':6WP!^*W)D/\`,:GL4Q_[7V+TT_2P]K-^^REZ]$_1QS]<]G3[)??#
M\G)KYC4]BF/_`&OL7II^ECS[6;]]E+UZ)^CCQ^N<SE]DKO?^3<S\Q:>Q2P?:
M^Q>FGZ6/'M9OWV4O7HGZ.'USF<OLE=[_`,FYGYBT]BE@^U]B]-/TL/:S?OLI
M>O1/T</KG,Y?9*[W_DW,_,6GL4L'VOL7II^EA[6;]]E+UZ)^CA]<YG+[)7>_
M\FYGYBT]BE@^U]B]-/TL/:S?OLI>O1/T</KG,Y?9*[W_`)-S/S%I[%+!]K[%
MZ:?I8>UF_?92]>B?HX?7.9R#_P#R5WO_`";F?F+3V*6#[7V+TT_2QY]K-^^R
MEZ]$_1QY?7/YU^R7WP_)V:^8U/8I8/M?8O33]+'CVLW[[*7KT3]'#ZY_.OV2
M^^'Y.S7S&I[%+!]K[%Z:?I8>UF_?92]>B?HXX'O/9T'@/:6WP#^.W)D?\QJ>
MQ2P?:^Q>FGZ6//M9OWV4O7HGZ../KG,Y?9*[W_DW,_,6GL4L'VOL7II^ECQ[
M6;]]E+UZ)^CA]<YG+[)7>_\`)N9^8M/8I8/M?8O33]+#VLW[[*7KT3]'#ZYS
M.7V2N]_Y-S/S%I[%+!]K[%Z:?I8>UF_?92]>B?HX?7.9R^R5WO\`R;F?F+3V
M*6#[7V+TT_2P]K-^^REZ]$_1QR'>>SH'`.TMO@#\5N3(?YC4]BF/_:^Q>FGZ
M6//M9OWV4O7HGZ.'USV=!X#VEM\`_P#=R:^8U/8IC_VOL7II^EA[6;]]E+UZ
M)^CCCZYS.7V2N]_Y-S/S%I[%+!]K[%Z:?I8\>UF_?92]>B?HX?7.9R^R5WO_
M`";F?F+3V*6#[7V+TT_2P]K-^^REZ]$_1P^N<SE]DKO?^3<S\Q:>Q2P?:^Q>
MFGZ6'M9OWV4O7HGZ..0[SN<PXAVE=\`?BMN9#_,:GL4L'VOL7II^EA[6;]]E
M+UZ)^CCGZY_.GV2^^'Y.37S&I[%,?^U]B]-/TL>?:S?OLI>O1/T<>/USF<OL
ME=[_`,FYGYBT]BE@^U]B]-/TL/:S?OLI>O1/T</KG,Y?9*[W_DW,_,6GL4L'
MVOL7II^ECQ[6;]]E+UZ)^CA]<YG+[)7>_P#)N9^8M/8I8/M?8O33]+#VLW[[
M*7KT3]''(=YW.8>':6WP!^*W)D/\QJ>Q2P?:^Q>FGZ6'M9OWV4O7HGZ..?KG
M\Z?9+[X?DY-?,:GL4Q_[7V+TT_2QY]K-^^REZ]$_1P^N?SI]DOOA^3DU\QJ>
MQ3'_`+7V+TT_2P]K-^^REZ]$_1P^N?SI]DOOA^3DU\QJ>Q3'_M?8O33]+#VL
MW[[*7KT3]'#ZY_.GV2^^'Y.37S&I[%,?^U]B]-/TL/:S?OLI>O1/T<2Y[;<P
MS>?<(V'EZX\5WKA*:O-I+.7V+<B-UFMYVF>,N"6@TF\XW<,HY9-61;QA'B7,
MBGJW<$'B`ZCI[)K,QCU]J+/2U;%<PPI(#[)FVYS(2J:2"K<5%)VG:#&T<?NK
M][L[%TJ:5ZB?="B67=CC<E*3)0D-X',-@V$1G&NACN84A"D(4A"D(_=#Q-^+
M_P!->4[X\1[5>\(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(
M4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(
M4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(])7\X;_``?[T*]#
+OA'YUXCS"D(__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex10-14a2b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-14a2b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!GP*R`P$1``(1`0,1`?_$`+D``0`!!`(#`0``````
M```````(!@<)"@0%`0,+`@$!``$$`P$!``````````````<%!@@)`@,$`0H0
M```&`@$#`P,"!`0#!P0#`0$"`P0%!@`'"!$2$R$4"3$B%2,605$7"F%Q,B2!
MD3.AL=%"0S08\,%2)>'Q8I(1``("`0,#`@0$`P8$!00#```!`@,$$04&(1('
M,1-!42((83(C%'&!%?"1H4)2";$S)!;!X6)R@M'Q0Q>2LM+_V@`,`P$``A$#
M$0`_`-_#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#HY"S
M5N)EX*ORMA@HR>M!WR=:A)"7CV4Q8E(MM[R33@HQRX2>RYXYG^JN#<B@HI_<
M?H7USVT;;N.5B79^-CWV8.-V^]9&$I5U=[[8>Y-)QAWRZ1[FNY]%JSIGD45V
MPHLG"-UFO;%R2E+1:OM3>KT75Z:Z+U.\SQ'<,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`,$GR.?.KI#A1;1U!JRN1_(S=D4^\%\@8NUA`TO6I4%5$G,/9[:RB
M;`#B[>1$Q#Q#5%1=CZ&>&0$4TU,]_M=^P?R%]P6$N6<@OLXYX[E%^SE6T.V_
M,?P>+CRG3WT_/(E.-<M.VOO>O;"7DGS;L'`[/Z;B1CG[ZG]549Z1K7Q]R:4M
M)?\`HTU^;71.-VZ_[D71/_Q986+0E7GEN5]Y@)6-C]<W2+*%,T[9V:2#5W:;
MY9RO6;&RU=!=P=Q"M8TQW\R"9$W*4>!E3HWGC_[9OF'`\G6['R/)P*/%V);&
MR>\]^L+\9O51KQNZ-RR=-(6UR<:ZIR<HW6PBG*BW?<5Q.SC,-QP:[[.16KM6
M(EK*-GIJYZ.#K3U<9+6322E"$GHL)W"KAK\D/R\<EZ=RKV)NJ8@:1JC8&OI.
MV\BM@P$C%35G4UQ8VYW-#TM4:G#U2J!+E_;AFTG[56-:QAE_*Z\KI0$%LA?N
M;\K^.?MD\0U>`_#U>`H[KBV^_2I>[ENK(4W++S&X2C&-[DU179-V]BBXU0I4
M9%F>->/[_P"0>5SYMRY7MXTUV2:4:E**7;77Z.;KZ.4E%1[M?K[GH_H/#ZB(
M_P".:4#+H\8`P!@#`&`,`8`P!@#`&`,`X,G*1L+'/9>8?LXN*CFZCM_(OW"3
M1DS;)!W*+N7"QB)))D#ZB(X!!2$YFR^Z-P0^N^+E`#9U,@+,$9N?<4TH]A==
M4=FT!NZE8:/F$DU592]J1K@IF48DBNX\ZB7O4V350'>`3YP!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8!Y$!#H'3Z_3`'0?ITP``"/T#`':/3KTP#Q@'D0$/J&```1^
M@?3`/&`>1*(?4,`\8!YZ#Z?X_3`*=F;=5*[*U:"L%F@(.;O,L[@*5#R\Q'QT
MG;YQA!REG?PU98NW"3F=E65;@WL@JW;%5539-%EC%!-(YB@5#@'D`$?I@'C`
M//0>G7^&`>,`8`P!@&JE\SWS`[(J2UGXT\,Y?\:U8$D:UN;D!`J@O*1LN!CL
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MDH-.::]7U^.9/`O&O%MNKCMF12K^Y:RE+UE+M>O5--+35=/_`#7TU=F<C.%_
M`RI4"B;)V5J;CI4U6:D7KRE+K-H5(8UB*BCE6(K40V</21J;@QA</!1!$SE0
M?(J*JGW8+</\6>8/->7N.\\0VG=M_P`O'[K\W)C&5NDG]4I77V-*5DEK+M<W
M9))R2:3:F3<^1<7XE71A[EDX^%7/2%5?2/1=$HPBM5%>FNBBGTU);-G+=XV;
MO&BR3EJ[01<MG"!RJHN&[A,JJ"Z*A!$BB2J1P,4P"("`]<BJ47%N,EI)/1ER
M)IK5>A[L^'T8`P!@#`&`,`8`P!@#`(J<F^8VE>*U9<SFP[(Q-*%%))I66CY`
M95=RX`WM$ET2>=RB9V<H$12326=N%#E*BBH(CT`@[4=1<EOD&.QV'R2=77CI
MQKD%3NZSH"*=R%6VSL"`4;(GC9"Y2+)PTDM5P<H=0QE61RGM*R8"4RT64Q4A
M`RRTJD4_7%7AZ30:S"4^HU]J5G#5VNQS:+B8]`#&.8$&C4B:?E75.9150W51
M94QCG,8YA,(%48`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`+-;[VA8M.:VD]@5O6LKM-6%
M?Q!9B`B+!"5I2)KCQ^DUG+E(2<\<&I(&H,E1?2'B*JX(R25433.)!*($3M^;
M)W1=^*G*1*Y:#1UK!K<;-H2$#9#[AIUUB[!(.JLZ280YDZ>W7?LXZ49NSJG?
M%(LF5$@]I#F,4H@6OD-&3^HXM\-HH>F=%Z?W%LWC?J^_:OT9;[)9-:(5M"[6
MQ:P6698SNO-61;-_N.6L<#29Q-G$&,K!@"[MXHDF";8"T^\(9U%)7#6NGY5W
M5Z%?=MV#@CJ]S26QWL#KR$Y+:?T9=U)Z`4BUO&2NZJOL-9#(MV@D&(&24216
M:(LB(8!2M86?\B)SC%>]NZTU=<XS:EPY*2UBH/)&<<0<;5V&JX+1.AIR99ME
MZ+;8J=O;.5H$L\C$?:L&SUG)G4,];F.<3`5[M/482V^KR:H:XTI3JFGNCC1K
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M4Z)`+_\`">X'_H[96MKO!I*V.=$<;U5',S/NEYZ6EG'&2K&?2;0L]-2D\^5D
M91-95-9=RY=.!^]59143GP"K>!=*U=K[3M,O4AK3BYJ.]S.M];QCZR:@M;&:
MD[+7IR$J(,7%YGI2@ZXD6<]8;@Z3*=B)7Z2CQ1'M=++*=,`R,_3_`/G`,8]C
MC34+7?)^%)9+0K2'?-#7+/:UHLMNFI>:B-4W6K\;W.S5#3LB^5=1-<)$S2[1
M<B(%;1T*LL)"(IIBJF!>C0M!UG^^=GP%1KU:=:TT9M>%?:991J392OZMN]FT
MS$!?XC7K)L)(Z$B4HBZBLF1LF*+9>?D$DCE[E$40+B\KGX1>CY]^9Z$<FUMV
MH5%WPNO9D;MOZQ4$KHZKH3I%10%N8P*")@+V"(#Z=<`M3N!/6&U=[4:A;9=4
M^U:76U)L*VP\//2<8K4W^TZW;:/%JRQ50=%0=VNFU:R"JQZG%:-,],Z0`BQ2
MJI@8XI;8]PJ6NN0^[YVYV:8J%CX@\?:+?W<O,2;D(Z/L]!V:XT_NT&YG1215
MFE)&>:-[.J@T3<O232*[CP%B"I`!-)23U\.Y[7==HQ4_)[AKW+RFZ@U_9:NZ
MK*%UUOKVQP-$>4N)<-Y>9C9-IIJ\N[&JC.I1;9ZO)#+F662-X1<M`,EF`,`8
M!BY^5+FQ_P#%'1BE5H,Z@TY`;C0D*WKQ)F_9IS=)@C-SH6;;PLG+1^15K4"+
MII,BJ)E*YEG+<@")2+"3+3[0_`K\R^0%N?(*9/QUL<H7YLG!NO)M[DZ-N4DX
MZ2R7&3M:;<,>%LM.YPUA[S/Y&AP'B\HX4U_W%FJ5>/'7K#5?7>UUZ5)K3736
M;BOGII:;7V'3>-&AK#O>^L&$ZF+I]3M/T.74*X':&U5F_NUEY9`Y_,]J-,*[
M"4GEC>KM8Z37N[W)C%VV^5/)%7%,:>'AVNG<8U1LLE5I"5-+UC533Z*-V0X^
MU0H]*:867::51C+!/A7%<KE^\QJGW/'[G*V;U?QUE*3^/5_'\TFE\6S5>N-N
ML5ZL4K:+3)+2LU,/%WSQRKVE+Y7"AE#$013`J3=NF)NTB9"E*0H``````9KX
MY;RG?.8;S9O._P!\[LN;Z)MN-<?\M<$_2,5T7Q?JVVVS,_:=JP-FPH8&W5QK
MQX+3IZO\6_BWZLF?\:_*FY<*>6FO>1FND*ZI=ZW%;)J$$]MK=R]KU?=[(UI:
M*<WM+V-:JH*2BE=&34>)-C'\*ZJ!"*@*9C`/LX=XSX[Y6W;!XCR;*OP]GS-Q
MA7?;5V.4:X53R8I=[BH^Z\>RMSU?8GW=K>B?#=^2;AQC"R-SVVF%^95CN=<)
M:_5+N5;]$_R^XI::==-#87X\?'3N?Y+[')<FN:O*:Q:<T=8[$W2O^]-SNVE3
MM-_7D7]E7=4/7;[8RU?K$0HHVBD1;H1;=2'A(U^D5!,5$O:DRB\R^;-M\,<!
MQ_`OVR[=;D<A]J7_`$^W1CFWPQ](NW.SWB5V-76S<JU5)POBXRLMC75*KOCG
MAW%<SE6_2YQY&NKKPHS3[[Y.JOW=7V4T^Y*/=&"TDY_5!ZJ$=6I*/T'Z!"5>
MM4.DURD*HN*77ZC6H2GN&TC^8;KU:)AF3"OK-Y;S./RB*L2W1,5SY#^<H@?N
M'NZYI"SYY=F??/<%*.>[INU27;)6.3[U*+2[9*6NL=%H^FB,PJ%4J8*AIT]J
M[6GJG'3IH_BM/1_$JW/(=HP!@#`&`,`]2JZ*``9=9%$IA[2BLJ1(##TZB!1.
M8H"(!_+`/;_W#]!_@/\`D/\`'`&`6ON>Y]84.%G)N?N=?!.OK+L7T:PEHZ0G
M%)E%N9R6O-8ANZ,[5GG"9?L;"!3]![C=I`$P`8L=R_(GL?;%W0X_<'=>SE[V
M7*MFHR\PZ;FCHVAL)`%2&L-\LZ:$O":ZKC84SE(NL#F2?*I'(R;F.!3"!>KB
MC\<E;U/8F.\.1%B;<@N2_E;RK"Q2K(5==:?DQ35%RVTK691([F.>B=P)%;#(
MBO.NRIE$#MB&.B(&33`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@'@0`P"4P`8I@$IB
MF`!*8HAT$I@'J`@(#ZA@$86S-KHJ6)3)=HW><>[Y)C%5HSQ!)Q&:FLL\L"2>
MOY=LJB=LGJZWOUQ)"J*_HQ,BL$8/1JX8$0`D7.0<+9HF1K]DAXJP04NU58RT
M).1S26B)1DL'19G(QL@BX9/6JH>ADU2&(;^(8!P(2G5"M0\17JY5:U7X"OKG
M=0,'!P47$P\(Y5.Z44<Q$8P:MV4:X4._7$QT2$,(K*"(_>;J!T]IU;K*\Q\?
M$7;7-#N,3$.'#N)B[53Z]88Z+=NP.5TZCF4O'/&S%PY*H8%#I%*8X&'N$>HX
M!W[:L5IG&?A6==@FD,*$>V&);1$>A&"VB6S1E%-_8)-R-?#&,V""+<O9VH)(
M)D(!2D*``=Y@%%PNM]=UMS*/*[0:3`.YN;3LLRZA*I`Q3F7L:0N!2L$FNP8(
M*OYM(7:HE=JB=<HJGZ'^X>H'"MVI=5;`.FI?=9:]NZB*ZCE(]OI=;LITG*K5
MLQ5<)FFHQZ8BZK%DBB8X=#&22(01[2%``/6]T_J23L,5;I'5FN)"UP2,:WA+
M.]H]8=6&';PP&"'0BII>+4DHY&)`P^V*BJ0J'7[`+@%&R/&#CV_A)FOM]-:U
M@(VQG@?W`6K4BKUI><:5VT0UP814NYAXEHK(0ZDY`ME%VRHF26*40,'KUP"^
MX^OK@'4/X"!E8^:B92$B)**LB3E"Q1C^-9/(^?0>,DHUVC-,G"*C:52=1R)&
MZA5RJ`=`A4S=2``8!QJO4JI2(9O7*76*]3Z\S.X5:0-6A8VOPS55VL=RZ4;Q
M<2V:,4%'+A0RB@E3`3G,)AZB/7`.5.P,':(>0KUFA8FQ0$NV.SE8.=C6<O#R
M;-3H*C61C)!%PR>MCB`=2*D,4>GTP"@3:*TB>LITH^F]4GIJ,P>PHU$VNZ@:
ML)3ZC86:DXE`##C%)S"C0PI&=`D"XICVB;M],`N`:#A#)ODC0\49*4:H,9-(
MT<S,G(L6R)V[9F^3%$2.VC=NH8B::@&(0AA```!$,`Z1[KZA25MC;](T>GO[
MW#-A90]U>UF%=6V*9B5T06D;9%V*DRQ;=CY</&DL0O18X=/O-U`J_`+/V[?V
MFJ'M?5NC;?L.NP6V]U(6ASJ^AO'1OSUM;4R-&7L3ADW234*W09,"F,0[@R1'
M!TSD2$ZA#%`"K-C["J.I:!<]GWZ8;P%*H%:F+;:)AT<I$6$+!L5G[Y;[C%\B
MHHHB5-,/N44,4A0$P@&5SC/'-YYAR'"XKQZB>3OFXY5>/15%-N=MLU""Z:Z+
M5]7Z):M]$SQ;EN&'M.WW;IN$U7@X]4K)R?I&,$VW_<NB^+Z&C?MS<,US(WCM
MKE%NN76U]K2`@E+9:'LLJQ<AI+CY6'*QJS1F2K5LR2E;0^7D#I((D()Y"QRB
M@_<F`F#??Q[CG'_MN\5;?P+CRJR=Y3E'N7=&.X;I.ONR<RSN<G7C50K[I2;_
M`$L.B*2[Y)/69RWDFZ>4>:6;K.,U79)5T5^KJH4M*ZUHDG.3;;Z=9R?P1J=\
MXN64CRZW4_N+")7IVJ:LV"I:6UJ#U5XTHU"8'$&J2BAP(5U8;`X[Y"5="4#N
M7K@XCT*!2AA7S'E&5R'.<)9,\G%KLE-W2C[<LFZ>BLR9P3?;W:*%,-7[./"N
MM=5+7*'AO%L?BNTQQ(17[R:3M:Z]?A!/XQCKZ_YI:R^)#%3_`%?\/_'+"O7U
M_P`B\8>A)[AS<]9Z_P"1.IKCN+4D7O?6]=O44_LVHYV=<5J#NY%XV<B8>.FI
MIJ@Z6:1#*QR3)ZZ+XSE<-VIT3%$J@@-S<;XWN?-8?]G;+F_T[=-PW+`JCDO7
M2F-T[<>4^G75*[X:=->NNAX,[<L;97+=\REWT48M\O;7K)P4;$OY]FG\S9%8
MZY^2/YP-^TFO2=NBTZ:49=5G.M*NJRT7Q=U.[56:(.ZM2HU1)5.)F%:ZJPKH
M2<FXG;(K'F_W7LT!72RXWCF'B7[$_%.?LWC>^K)YWF3A79?<DLS<<B,.U^TH
M]SACXB???9*7M0LN<(=]LW7&,,#;^4^9^38^7O\`7.G9J8N480;]NB#EJE9)
M^MEOI&$5JXP3EHEWGT#>.>F(GCEH'2V@8*:E+)#Z7U=1]81MAFDVJ,M.M*37
M8^OI2\BBR(FT0=R)6/E.FD'803]H=0#KFD'D>^YG)^09O(]Q[?W^?EVY%FGI
MWW3E9+37X:R9F#@8=6WX5.!1K[--<81U^44DO\$7FRBGK&`,`8`P"$_*CG+J
MSC$4L`Z(K=MFND4%VU#AG*:"T:S=HG5:RUFD3D52B(]4"@*:92JNEP$!(GV=
M3E`PY67=EHY,2Y[=>;C^;1C'3@T54F7D80]3(Z[1%LPA/04U#(@1-1VKY5E^
MP.Y0>@%`"Y-)Y4[5T#)&M5;1F=FP+1F"%@U1)61RG^X8I)PBNX=4YY**N&<1
M?6#1-0&/E\;20Z@T<&3**+AN!2.YODGM>[Z:TFX2QMJ+JRQL_P`G%Q--?/D)
MR:BUP[4FEGL9A:2AG#=0ATW31JFQ3(L!DE04[.H@8D8_?4]R(Y':KXC:0L:T
M%?\`==L1J1[)$Q*=H5HM;4*J_NE]EHL)".370K-:9.G9BJN4?*JF4G<)S`4P
M&W_PRX8:GX0ZJ5UMK->PV*5L$N>U[*V5=9'\I=]G79=J@R<62PKI$;QK$B+)
MJDV9L&*#9DS;)%*1,5!554`ES@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`.KG(
M.'LT-*UVP1K.9@IR/=Q4Q$R*!'+&2C7Z!VSQD[;J`)%4'""ABF`?X#@%D*+.
MS.MK/'Z7O<B^F(^01<FTUL*554<.K5$QJ!W+K7UMD5C&%?951CDC*)+J""E@
MATA=AY'3:1[`)!X`P!@#`&`,`8`P!@#`&`,`8`P!@&/KY'/D*U5\>&A9G9MP
M786#8LPBO$:@U45^1&9OEP7;KBQ\Z*0F>,*A%'2%>5D>SQH-TQ(03+J(IG`^
M>Y5N>F[Y;G?JKG'NF]3-UOU0W!4KG,.W3Q=%A&4EE9!7F:/6F)5@0@J:RK4D
M]:-6*?Z)$3CW@H)CB<#;&_N4N8_](^*>A=25]%Y(UOE9?PE;/-1CH6A7.K]6
M%JER=12`G*!S*62;L$.H`&+VBU;+%-T$P`.P7_;KXSMU_EO,\A;E!6OC^"UC
MQ?\`DR<Z-U$+]&OJ5-4;GVZQ;E*#3Z$$^?\`-R9</7'\279//D^YO71PJ<).
M'1IKNE*'7JNC374T[OE?YXZFO6J]3\5^+\$ZJM)9QD/L#D78TY%TZ7VYLA)F
MFWJS)ZH^\CLL14T3N%TVQ#D:`Z="<J0&ZFR:_-FX\QV#DF?A\IW*.;F71;JK
MK4(QP\"=CE7B1[-%WY4HPMO<M;'7"B$Y..L5$_B_B>T545;QCTRCDQ@J^Z6K
M[K=/U;5KZ**?MQ^&O>UH]#!VR@G2\*^FW!S))-BI"4@$_3[EE2(I)`?MZB8Y
MC_4<CO:^)YV5Q7*Y7FS==%,8M1T^G6<XPC%/35MN7J_B27D[I37N5>V4KNG-
MO5Z]=$FV]-?AIZ'1B!!43!0QB)B8H*'(0%#D)W!WF*F)B`<Q2CU`.H=1].H9
M:4HURO@KI.-#DE*27<U'7ZFHZKN:75+5:OIJO4J:<E!]B3GIT3>B;^";ZZ+7
MXZ/3Y%W-)P,)>]UZ8UW+FEX^J7;;FMJ;..(%\SC[*,;:KA#5Q](L95[&RS%I
M+-6LFHHU\C5PW04Z=4S^HCW[GR'(VS"G;QU/%ABIVPD^ML[:XMPMNDM-7&6K
MA7%J%7<U'N>LVP=MAF9"AG_J3L337^6,?5PBGKT:6CD^LM$WT^D^T+QTXWZ<
MXHZGJ>E-&U!M4*+3HAC#L$/.O)3,F#%'Q!)6.??G7E9^7<")C*+N5#F`3=I`
M(0"D#!/D'(M\Y5NMN]\ARKLS=+G]5ELG*6BZ**U?2,5TC%:**Z)$RX.!A[;C
M1Q,&N%6-'TC%)+\7T]6_B_5E\LHIZQ@#`&`,`H?8>R*9JJL/K?>9IM"PK$`*
M!E1%1W(.C^B$;%LD^KB0D71Q`J:28"/4>H]"@)@`UT;W&M=M;JV+NF51>D1N
M%D7D(5K+HM4W\=`MV[>-A(]1%H8[8KEK%LTB*&`Q^H_4QAZB8"C;M5(PJ))J
ML>TK=DBTU!:OFZ*2*$JB<!,K&3292]KILY/Z@<0,HF?U#ZX!'BR[7`61%0_V
MJID@\R('$3(N"AT62$>[J()J`(!_AT'`,7RNE.6/)7D,SXM<1:N1XUV2O*W]
MQ;GIY)E0].Q$B].;8$Y?9UFVD#P5?"R+B\:II)'<O7DH#5JD=0Q2X!N3_&?\
M6VCOC:UP_CZFL?8N\[VW;&W)OV?8BTLMY7:O'SYC#14:9Y(-ZC2X0[\Q&L<U
M4_6$A5G2BZ_0Y0,G.`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"C[W1H#8M
M8?U6Q)N@9NS-G3.1C7`L9NOS4<X3?0EEKDF0IU8FQ5^203=,G1`$R*Z91Z&#
MJ40*&UG>9Y26D]6;*5:EV;5F19!&6;-TXZ+V=317(T9;"KC$IS$;*@LHFVG8
M\G7\1*&[0ZM'+%9<"].`,`8`P!@#`&`,`8`P!@#`&`>0^H=?YX!\M;Y+MI;N
MVUSGY(2W(.;-,;`I^S[?K1NU192,7"5BITJP2,76:Y4X:5Z/8FN)QI".4BG#
MR.U')W2ACG6$X@04.0%"'3-U[3D,0W3Z]#`)1Z?X]!P#._\`*!R/U3RV^+_X
MLWY-@5E+=NF("^4G9%71E2J'J,)5JW`4!1[9XQN>2>1TG<)&B0JT01=0CAVB
M[64(F<H'%+9U_MX<<Y'35R?EN;3^UX%.C'J_>7)QKMRZ;+.VC';T=TE&R?NJ
MM25<G6I.,I1C+'/SSNVVQ>W[15)W;^Y3:HAHYQJEV:V6?Z(_3JG)KN2>FNFJ
MU#+ZT.>VS"2X^(%9!!?N,/=VMSE1.01Z=>G1/^'\/IGN\Q;=99Y)W3&S'V1L
MSH3U;UTKDH2B_CI]'P^'IH<.)Y$8\?Q[*EW.-,H__)-I_P"/Q*CM-EB0KS*J
M0'59$%D'LO(AU(1PJW3,1LQ1*)0%1)$YQ4.?Z&.!0`/M$<N_R%S7CRXGA\`X
M@_=Q(2A=EY"UC&R<$U71!-)RA!OW)S]'-145]+92=BVC/_J=N][JNVUIQJK]
M7%-_5-_)O\J7JEKKZE"0L#.VJ<AJQ5X66LEEL,DUAH"O0$<\F)R;EGZQ&[&,
MB8J/1</I!^[7.!4TDB&.81]`R`,ZZK'J=]\HPIBFW)O1)+XMLOK'JLNG[=2;
MF_[?V_N-_OX/O[9R(T\OK?F)\AD.G.;@CU8B\:OXQNNQ6NZHF6;MG*UVQ;;.
M@H=O:]@Q2[8%TX8IU8B-4.7W`.728`WQNYQY/MW#W-HX^W#`>L9V_P":Q>C4
M/],7\_62]-%ZR'M''Z\5*_*TE?\`+X+_`(?W?QU]=%NB9#!=`P!@#`&`1PW_
M`,EZ1HB,!N[$;)?9)`QJ_1HM8AI%P8>TI'\PH4%`A(4AC]165`#K`4Q42J&`
M0`##?L&\W3;=G-=]GRH2,@3RA!UUH8Z-=JK)4PF!C$L#&$A#=@%*JN?JX<B4
M!5.;H``!:NQV]E$HF.JJ0#%*/:F!@#Z!].OJ`8!#3:&\&[1-P)GA$TR`?H4%
M`#TZ=>@``_Q$,`QZ;6W>U_:/[J:KI%3_`'%)5UP<S@O<=RDP;2B!_$'H`BBL
M<!$1]>T/^`$Y?[=?;MEO'/O;$5%,F\A70XW6%>W2IVXK+Q`H;`I!JTB@\!\D
M#4LH_.X`Y?"MY?"'^CMZB!NR8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`MMLS7A+[%QZT;*'J]YJC\9_7]U;-S.758L)$#MS>Z9D<-/S-:FV:AV4O&
M**D2?L53D[DU0262`]6L-AJ7B/E(Z=C$ZSL.FO4X38-.]R=U^&E3I"JRE8AV
MJBV5F*7:6A!>0\CXB`Y;"9-0J3M!TW0`N=@#`&`,`8`P!@#`&`,`8`P!@'S8
MOG:U>EJOY3>2;9L<@LMD$H.XVA"*OES(J7:I,6DRFNJ](4H+GL%?=*@F@8Z"
M22I"E$!`2E`Q&>@%,8PB!2``F$J:JIQ$QBD3(FB@FJNNLLJ<I$TTR&.HH8"E
M`1$`RY.(\3WOF^_U<<X_7&>X6QE-N;[:ZJJUK;?=-*7MT4Q^NVSM:A'636B*
M?NFYXFT84L[-;5,6HI):RG*72,()M:SD^D8ZK5F:BP_%QJCCSP(N>Y?D7V#9
M-.<F=JQQ)GACQMK3F,E;E7%H]1LM^]MKU9"81:O37)!1%D^1>+()5"/5_P!9
MYA46J.P;[0I>5]WW[;O'?C3%IS_&^R;C=E;QG9%DH[?^YRH0J<\:UU_1.N%2
M_951C9;DV]]SC"%FL(,\I_\`:V#A9'(>0S=/(<W'A5BU0BGD.JIRFH3CW=5)
MR;MEK&,(Z0UDXZ/6IOFE+D[L$G))NH'L5]N8J`K2(*-T4FR:8K/E!8%2;>04
MQ$I1'O'^`#F6'E3[;/(F_<QSM_Q,C:HXMLH=L)3R.^,(5QAW7/V?;A*7:VJU
M)R7II\2,.,>1./8>TT8,X93G%2UDE7HVY-Z07?K)+7J]-/Q,^/PZ_"Y\?/R)
M=L7L[G!M2M[LK<B\>6_C'#46BZZMLQ3V4-"^>QT6USE@V*:RUI*Q38)?E46*
M2Q`3*DYCVRBI#&U[^:8^3O$6ZSV_<]NI_I[:5>7%63IFWJTGK&';)Q6O8W^*
M;1/G$7QWD^"LG&M;N?K!Z*<?35:*33Z]-6OY>C-T+X]/@KX`_&Q;GFS=+TNU
M7S<*S=W'QVW-VSD;>+I58M[YTW3"E$8P->K5/4=-')VSAY'Q[>0=M3"BNNHF
M(E'%WD7.N1<GK5&XVI8JZ^W!=L6_F^K<OPU;2^"1(F#M.%M_6B/U_-I:_P""
M7]M?FS,7EGE2&`,`8!X$0*`F,(%*4!,8QA`"E*`=1,81Z````>HX!C:Y#\VR
M-7,CKW0+ME,SR(@VGME`1%]6ZTH(J^9I7RK)JM;%,%(4@^<"GCR$5'L446(8
MA`,:QU/:KO)23E'\Y./A!63L$Z_=24J^5```574@_57=+#T#H`F.(],`LQ>M
MK1<$BL!720*%*(";N#J`A_\`B'7TP#&WN;DXT8$=]'R1A*!_7S@/K]WU_C@&
M(#='*Q[,/3QD.9>2?/%A:M&C'S.EW#A4W:DW;-FY5'#E=0P]"IIE,8P_0,`[
M25U'O%]H/76N8W7=[L_(?D7O+S4O4\5#H2-Q)%U^KR39,6D6T75DFR$JS>)+
M.S.`1(R`H>X%,O0<`W-?@(^*S;WQWZSVQL'D9*02>[.0O[*"1U[7UVLTTU;5
MZ2:S*QD)(6YJJLTGK+-N+*9Q(E9?[!J9%)%-5R)/.(&PA@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@%F]GT2:?O8K9.NO:--JTYHX;1R;M8S.)OU7
M74!U)ZVMKA,!Z1<FL3S1KTQ5%(64`CE,#HG=MW0%9:^O4+LFGPMS@"O$6$ND
MX*M'R:'M):%EHUXXBYVO3+0#J%:S->FF3AD[3*<Y"N$#]ASE[3"!66`,`8`P
M!@#`&`,`8`P!@#`-'?\`NE==(I<K.-^T&<S&B,CQ^GJM;(H\LR5DH5E7-@K/
MZW+?M]!'\N5"==6EVW;G,8P/EVQD6Y143.`SAXL^WOR+Y=V3<N4\=KQ<;B6T
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M7;DU'1IV^M]FZ:V#*-$W=3LZLA8X.\T2?%N,K";`@'HIC*1$XP$[9VQ7,GW)
M%.F?ITS`[G^\<S\D<=CN.T;9MM/&<_&]^&'DPE?D9-%T(3@[K9=(62A8G[7U
M./Y7)/HIYV'%VCCFXNC)R+[-PHL[';#2%=<X-Q:A!>L4X_FZ:^J^9])3^WK^
M3FQ?(_PN,3<,D#_DUQUF66M=S/5$$&;BY,'C-9]K[9IVS<XI@YM<(U6;2)@*
MF528C7BA4TTU$RYJ%\G<2GQ3D4H0HECX.2G976]?TWKI.M-]=(R_+KK]+BFV
MTS*G8-RCN6"I]ZLG'HY?/Y/I\7\?FUK\3/5D<E;&`,`8!!WY&K#::UQ%V8\J
MBZS-P]6K$++OVKT[%ZRKTQ8XYC*G9JIE%8ZKHBI6QBD,0WB7.8#!V^H&M53I
M2W:Q686,T8\;5V7$K%RV6`$6[]L7J<HIH`85&Z[<O4Z"@D*`^I0Z@(A@'YVS
MR-8QC9P"3Q-NW*4P@)A`HB`!U#N[C@/=T^H8!AYWWS-9LQ>H-7X+*_J!T*J4
M?IU]1Z"/3Z?SP#J>(OQW<\/E);V&Y:F@&]&TM#(S:2NX+^#IA6YR>CXI5\VK
M-#B`49R5\E7CKPMSK-U&\6U.KT7>IF*8F`;-/QD_#5\>UWX<\?N1E(:;0<;-
MV_K&K6VR[,L=JB)>XP-I=(`E>J9'QP1#FGUU&M6IL]B5"L6I5O\`:?J+**`)
MQ`SL<?>)VE^-D65"@UM)U9%47*$EL"PH,)&\R;=XHW5<,E)PC-NHRB3G:)#[
M)J5!J)DRF$@G#NP"2F`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8!'2ZQDCIZQRFWZ@R?2%-G%T76[:+%MEGBQB(-TVO]8*A%M$5G+BVP;!NDE.
M,4""I-Q*!5$RF?,D4G8%_HZ1CYB.82\2^:2<5*LFLE&24>X2=L)&/?($<LGS
M)V@=1!TT=ME2J)J$,)#D,`@(@.`<W`&`,`8`P!@#`&`,`8!C&^3+Y,]2_'GJ
MMZ\EI")G=XVBNR,AJ_7+I5Q[<Y$'"4<:YW9=D!EH6D1+U?ZB)7,LY2%DR`ZX
MG,EDY]MOVV;[YUWJS=-PL>V>*=JMB]UW.;C"-4.UV/'Q^]J-N59%:)+6-$9*
MZ[2':IQOY$\B87",*./1']URC*36+C1U<IR;T4YZ=8UQ?J^CEHXQZZN.J%.7
MIOQ#D(GG)S>=!R%^1/;+-]<M%\7MCH)2[7C8M.E3E*1OGD;7SR*BC'8IXMXW
M-3Z&D@T3K3!8#)BFY!1PRV);1Q'+^ZR=/`^!8MG%/L[X]?&A68T90NW^RN79
M*G$UBE>YRA)WY5GN)3_5O<['&M0)?N-/BZ-N^[_=#=/+FX0<VK'K#!BUJG/U
M]N,5)=L%VN2^F.BZO#-M#9VQM\;*M^X=NVB0MFQ;S,2$[89Q^Z\AD7#LX@9L
MQ$IA;,DHYMT;HE1*5M'-2$;MRAV@&;..&\*V'A/&L/C7'L6K!X_M^.J<>BK\
ME5>FCTFOJLOL:<K\EZV6V2DH/JY/&W>=[S=ZW&[<<^R5V=?9WSG+UG+U6L7T
MC!?_`(ZND8Q2<O@E?WAOPGWISGVZRTYHRL@Y,V*@[O=YFVDLAK;5U;6(=<)7
M8<U'LW8-',HDDI^'@RB$G.N2>OC;D671A3[C?N7X)]O_`!S]UOUD,CD-D/\`
MI=MKE'W;GIHIVQ;^FJ#:<D_ICI_GF^TN_P`>>-]\Y[N'9AJ56UQ?ZF3)/MC\
MXUOXS?IW?W:)&^KQ5X;\;OB-XM[#LD`@[M%@@:2\O>]=QOH\B%XVQ)TV%=.D
MDFT:#Q^SJ\&D)3-H:!9*E8LO*`F,JNHNY5T!<\\D>3?NF\IXBWR_W=WW'-KQ
ML/'3:Q\973C",8+X):J5EC7=))M]%&*SLV?8>->,>+W2PX*O`Q:96VS]9S[(
MN4FVV]6^NBU^/S;;^:OM_7[F=N=JL3F/%B>R6FVSY"(J`NV;DE;@HT*W2<DZ
M)+I&F&;]!N8.@KIMQ4```>@?H1QN$[%O.VXN#AV*61CXE=>OY>]0CBUQ:3]'
M9V63C'U2:U,$/^Y,J&19DV1TC9/73U:;4YM/_P!JE!2?IKT-H+^T/H<Q#V?G
MO;CL4$H1Y#\>*[[L'+8SDTNA([GF2MCMB#[@4BP\@@H"HAXQ,<2@/<4V:;?O
MSVR.Q\AX_MEU<:]QGAY-\TM&W"RY*EMI=6X1_P##^.7GA7)EF[=FY$9.6.K8
M0C\M8P^O1:]/JU7H;L>8!$VC`&`69WER`U1QSI+V^;8M+2`B6Q.C*.2$KVR6
M)V*B:1(VLU]$_P"1FWYCJ@)BHD$J*?<HJ8B1#G*!JU<SOFR=SMGD(YX:-IO'
M[W+5M^S'IFH6:8:)&2$)JXS"#E9JHL5\4%THU`3-4BE(!Q75*"@`02-?>1>Z
MM@,K%;J_8M)ZS@'#.2C:K<:^[B+SL%H\8I/(MTI`2J31W7:=)QS]-P@Z7)[E
MV0"BDF"1RJX!!W;]-Y+<FN5$WQOXH:WMVW+DDVKBDLTK)2G@ZBI+1;5=R[NM
MG<G;5NBQ#45BF.M)N6Y?7H3O.)2B!L5?'S_;0ZDU<Z@=N\^K!&<C=HI`VE&V
MFHGWJ>AZ?)@8%TTYL[D&<SME\R.!`-[U)G#B<IBBR7+T4$#:0B(F*K\9'0D#
M%QT)"0[-O'1,-$,FT9%1<>T2*@T81T>R21:,F39`@$322(4A"`````&`1<XA
M4VNZBJ&R-!5*M0E/JNE=SW^)J%=KK)M'0T;2]CO&^[:PU8Q[%$C-DE'LMF"R
M$@'564,T%982J+&(4"6>`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@$9NTO':Q]2]&^@+G,G%0H%*1CI.\3SWO%0O:4B4=J>ZRK@PG$1\<#
M-..OVL'8_CP),X`P!@#`&`,`8`P!@&.CY*?D0UK\>NBI6]SCF(F]IV!H_8:H
MUZ\>BE^8F$FXF7L=C*V,+YA1*L0Y7$@X(`'7'QM$!]RX2#,C/MO^WW=_/'+Y
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MFLDV])8K9^?N%_MDW>[_`&:<NU]L[]Q)6&U6&6D)^;D9!\L3W"[N8D%5W\F_
M=>,"*NSG,JL)0(GVIE^W9!Q_C>V\?P,?!V['QL3`Q:?:Q\?&KC5CXU,7JJ**
MHJ,80Z?5)).QZR;C%]<>]SW3(S[[+\FRRRVR7=.=DG*=DO\`79)ZMOKTBVU!
M?.1DM^-WXN-V?(I<%EJTX7UCQ^J<L@UV%O:2A5'S8ZJ:K\B]2U&P=E1B;S?6
MZS!1N[5!8\37#*%4<^=QV-5<)/NR^]?C/@_#LXKQ&5.Y>3+(-*N,E*G#U6GN
M7N+Z6+HXU^LM-$HQU9,7BSPON7-+([MO2GC<<33ZK2=R]=(I]5!_/U?J_AK]
M`3C+Q?TGQ`U%7=(:#IK:G46N@X6$HKK24_8IE^NH[E;-;[$],K*V:RR[Q4RB
M[MTH<_J5,G8D1-,F@'F/,^3<_P"0Y'*N7YEN;ON5/NG98]7^$8KTC"/I&,4D
MOXMMYV[5M6W[)@U[;M=4*<*M:1C%:+_S?]O0P??+I\F%)8S$UPMU),P$[<V#
MZ)/L^5>O5BU=E:6#MK-P^NWTO'+`BW;U`S5.?N*BAR),F35&.$P.7B@-\_?L
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MA()5M3:9_*ZZH]M.(&445>7^13EI@%>\R1XYVS[.H`)SZG?O5\H4>2/+L<3!
MC#^G[#MU&WQFNLK)U+NM<I=.[MG)UIZ)OLU?5O3.'PYQV_8>'PMRV_W>=;+(
ME'T458]8Q2^'3K_/H;"^8@DKC`,2/,[Y8=3<?$7U4U,M7]M;$22>HR,DWERG
MH%'=H^(J19J58]X6.4$QS_["/5ZI"F(.%D!$I3`:E-\Y`\I?D#Y"FUYI*#M'
M(GD)<3%:NGC9-"/K5-A4`5,#^R3::"%1UC1XI+N$#*F;D.;H1,JSA0I5`-BW
MXYO@5U7QWEJKR"Y@R<7R2Y3,"+2+*)=)!(Z%U/).15]O^R:G,1Z1[;9HM`Y1
M+.S*1U$'9?*Q;LS$*<P&8#=/$+0'(&<C+-L^D?EY^*C31#>6C9J:KSQ:-\HK
MHM7ZL(^8_D"-%#&%`5N\40.8"B`"(8!<G5>E]4Z0@5ZWJ>@UBB1;YR20F`K\
M2T8O;#*D;)-/S5FE$TPD;'-G:H$3,[>JKN!3(4O=VE```N=@#`(U-4@J/+.5
M`RJ*$?NS2D8^:-P.;O<6[25H=L)IPIYCB`+/*IM.,*D1``**<:J90.H$$0)*
MX`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`<20CV$LP?14J
MR:2<7*,W4=)1L@V1>,)"/>H';/&+YHX(H@Z:.VZIDU$SE,0Y#"`@(#@$?:9(
M/]-62+U':GKMY1)Y4[325TDEU7*K<Z29U_Z-VN26`1-/0[),QJX\6.968BT3
MMU3&>LS*O0)&X`P!@#`&`,`8!BT^3'Y5M#?'+KIRXL,I$W'>,_'K?L#4;.4;
M"_*JX;R*4=;KVD@X"0@J"VE67A443(=Z^6_09I*'!0Z63WVZ_;'R;SGN%N];
MC:MD\3[:U/<=WO793"$7%SQ\:4EV79DJY=T(-^W6OU+I1CVJ<=<]\AX'#L>.
M)C0>9R?(6F/BPZRE)I]L[-'K"I-:-^K](KHW'10WKRPV5L;<,SR<W@^>6?E%
M9;9"637=(<-Z[)TG6\7%-Y`T!*6FM.5YU2*GJ2Y5:*UBK.%")U55L,C-"ZES
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M2O,"?+Q]X3L5BN$E[9-#KNY;X:'46CRI0LS,.(1;76J9!^=N`3QSED)U(PI1
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MDY3D]?S?F;DWTU^,FW+X=#-[\8V@=U_(/N`:?2IV<@:[1HZ3C]C;C3-[YIHF
MJW^-5B[Q9ZRZ4!2(6Y2[-KG2OU0@E5"LPJ:KWL!-F";C`3[T_)?&?%&V]FV3
MQ;^8[JE"G'@X/]KC435D:[8+N?9.Y_N,IRT_<VZ5]8^ZYRSX=X)F\GS5/,KL
MJX_C25EDW%K]Q;U48Q;TUK@DU!+T:<GU[>WZ"U`HU6UA1*7K6CQ3>!I>O:G7
M:1481H4"-HBLU6(:0<'&H%*!0!)E&,4DP]`]"YI$RLK(S<JS-RI.>5=9*<Y/
MJY3FW*4F_BVVV_Q,XJZX55QJK25<4DDO1)=$E_!%,[BW7K#0=*?[`VQ;&%3K
M3#M(15P"SJ2E'BAR)H1L%#,4W$K-R2RBA>B+9%0Q2=5#]J93G+T',U3OD3^:
M&=M\?/5RDS;S3VH6AW13`UE!B[Y=XP[,J"H7*4:.E$H&(54$YR1[!4#F((`X
M75`3)%`AEPV^++F1\ECQ"\;!5LO$;B:59DNSMECK2[7:NVHMP)UE4]4TJ9(R
M_#0JC<A>MAF4`;'!<AF3=\`*&2`W,.)O#+C;P@UJ75?&K64/KVN.5V\A8Y%$
MR\G;KS.H-P;#9;Y;I)1S/6R>43Z@"SM8Y42#XT2I)`5,`)0X`P!@#`&`1JY"
M-U8*:T/M=K[=`VOMQ0<'87[E8&Z"5#V^T=ZNG6[U0HI**QR=AL,+(&(94C=-
MS'(.50.5L!<`DK@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P"F+E3X"_5F6J-F:&>0TP@1)<J*ZK1XU<-UTGD=*Q4@V,F[BYJ'D6Z3MD\
M0.1=H[1362,4Y"B`%MM<W&?BIQ;3^S77N;S$1YY&JVXS=-FPVW2VATF_[E:)
MI=K5K<H(ZJ2%CCD@*5!RHF\03(S>($3`OA@#`&`45?-DZ[U9`K6G9M\INNZT
MW!<5I^\6:%JL,G[9JN^<`,E./6+03HLFJBIB@<3`FF8W3H`CE5V;8=[Y%FQV
M[C^'E9VX2TTKQZIW6/5J*TA7&4NLFDNGJTOB>;+S</`I>1G6UTT+UE.481Z+
M5]9-+T6I@MY5?W)_QQ\=D7K"C6FQ<CK2BBZ*@VUHR1B:6G(-EE$0:25^N!HA
MAXE104$JL8VEOM`I^WQJ%/F5O$OLG\M[MCQW3F\]NXIL6JULW*^,;G%K76&-
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M2J:+,3*#&,2O!*\;[`/&_&^<^5]NVOEWG+&Q-MX3HI;-Q.$8T8TJW7K3D[O&
M.D:<>N.DJ\.<.ZSZ96KM[:YP5R7==HXS=D[7PN5EVZO7]WN;;LLU[OKJQ7ZR
MLDUH[8Z)?#K]:B&";>(;RD[/2Y3NUR@ZL,^_4<%23,8XG\+<3%.I[<RQQ[$2
M]RSE0>XW<8?3.Y/;.)[=?R+D&5",NR,K;WT@E%:1JJAI]%47TKIBFV]&]9Z:
M0#.>5NV37MVWTR:U:KK7677UE.3?63764WT2Z+IZV_:;0L!;+'3<1!P9H.$=
M@_BHB\P$79V,_()%4,SD;75YA"1AI:-8N%07;Q3Q%5D94A3.DU>GCS'_`)?E
M;UY8QKMIW*G(P.!VI*%"MLQ\C)6NKEDRHDKH537140E3/1R=DU+MBI#V3$PN
M)V0S*9PR-^CKK/MC.NKIII4IIPE)?&R2FO116FK+@[OY)\BN2\RO/[_W3L/:
MSI5T+M)C:+&^/5XI0"&122@J@W5;UF`9M6P^!%%FU1220*5,I2D*4H>+A?B[
MAW`\&.%Q7;<+;\6,.U^Q3&G6*]?<L6MUNK6KE==9W2^J75LJ&[<IWC>;O=W#
M(MMMUU3E)R:?SCKTC_"$8I+I%)$;I.S5J"()7\LQ1$O4?;)'(JJ/:`^A$$.O
MJ)0__P`C_P!^.2^0_'W"L>4^0[KA8\(]7'OBW_\`QB]$WZ=7%Z]'\SAM^P[[
MO%B6#C762?QT>G][_P#,J>@PT_LV69,H=F-:KSQ91%Y>[>PLPUR)3(@JH1Z[
MC:=!V.W/FGF2(F86C%R<HJ@82B0#&+B+S[[^?%7'N_%XW7D;KEZ-+L^B'PTU
M<6OXZ.Q_%,E+8_"7),[2S<90QJOQZR^/S3_PB;AO$'^UITK?*Y6=E;VYN2.Y
MJQ*G8RB=<XO1<+3:+,L#':2'XQ[?YA>U6QRB\CUS(KE;(Q3U$3@H51(W5,,,
M.;???Y5Y#"S%XW#'VG"FFOTE]>CUTZK1ZK7U;E_`E[:/#/%\"4;<SOR;HZ/Z
MWJM?CT?TZ?AVK^+-M#C[QNT3Q4UK$:AX[ZMJ.IM>0OWMJ]4HTC0'KTR::2\S
M/22IEY>S6%\5(ON9&1<.GSDP`*BIAS##>-ZW;D&X6;KO>1=E;C;)N5EDG*3;
MZ^K]%\DM$O@B5\;%Q\.E8^+"-=,5T45HB$?,GY2=.<;&SZKT-S#[8VB1!V1P
MTBYIH-+I+E(B8)'N4\T47%9[WJB8L:R!1P/B.5<[;J0QJ8>@U#]Q<KN2_.K?
MS?7NK(BU\C.1=Q3,TB("LH(-86LQ;5,P*.13]PVJ6M:9'-TC"X>NUFY%.W]5
M9=P8O>!DMXT_$U4N'?+/@#:_D"/5N1&P.4,[NJ@-:6Y<P[W0^C-Y5C7I=O:H
M0CX6P,4)#;<Y)52BV9F9^\3!FVF#-?;,A$J;HP&X64I2E*0I0*4A0*4I0`I2
ME*'0I2E#H!2E#Z`'H&`><`8`P!@#`&`6DWU1#[,TQLRCMBJ?E)VGS)*ZL@0B
MJ[&VQ[8TK3Y1N@JLW;.7$3:&#-R1%8P(+'2`BH"F8P"!4>L;FVV/K;7VPF0H
MBTO5)JUO;^W.=1`$K)!L9<I45%$D%#ID]WT`3)D,(!ZE`?3`*XP!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!;[9&O6.Q(-NQ/(.Z]88.
M2;V&E7*+304FJ;:F)%4V,W&@N`I.$E$%U6KYHI_MY&.<+M%P,BL<!`Z/6.RG
M-G-)4^[-(ZM;:IYD6EPK#5R(L9%-4B@QUWI8.E3OI*A6M%`Z[%4W<LU.19FY
M[7;5<H`7=Z>@C_``ZB(^@``?7J(^GI@$0-R?(#PBX^>1/<G*K1E$?)?CS'A9
M+85?>6,$97W/XYT%9B'<C8#,G7M%.U<&WAZD$!,'IUDSC'AGROS)*?&>/;ME
M4/N_46/9&K6.G='W;%"KN7<OI[^YZ]$4#.Y3QS;9=F;FX\+=$^WO4IZ/7KV1
MUEIT?730T:_E+^3_`(S\^>4%:->1WU?>)FN5+NTK]6UD^@-?3COVK$8VJR=4
MD;M#NRPCK8\^D23GIAY&K2<;$H-HUH@8P+JCMF\/^$O(WB/Q+/BO!+]HVOGN
M]1HMW'<[(3R+X=5)XM2AK!1Q>Z5,'"U5SM5U\GI97V8M<@Y?MW)N:SW??_W%
MO&\-2KQ,6$NR%G1]UUVJUUM:34)0DU'M3T<7K$:A?)5J7C;,(3?"OX[>*FFK
M7'HMP8[7W8ZN7+/=[!RI$MV<J]:W;8<C$0\*\7F&Q7S<8V)8(-.IT2I"DLL4
M_)_:%MO*LF67Y4Y9O_(,UO6<5;7BT_GU2=5:OFDH_3)>]UU<DXM+3U__`+6O
MVVA4\=VW$PJ4^GTRL?IZJ<NU-M]5^GTTTZHL'R,^8#G-O5C(16Z^8VP%*]((
M(MWU)ITJPUO57+9"'7@U6BE2UHRKC`S%Y'N%$W+8R8MG(J"91,QN@A=^W\"^
MUSPPXY*P=BQMPI3<97:YN2FG[C:]Z61;%PG&/;+HX+HFD4FW??(_+5[4+,RR
MF36O;^G!]--'V*$&FF]5V]?CJ01(A?9-P1M#:[FT#JI-7*;ZWD_;#4K=ZW3<
M-'@H/RC+*-U6BY%`$B`F,FH4Q0$!R8=AY+SCR+BU[EXQXSE9FTW]:\_/G#!Q
M))2E6[(=_?DVPBXM2]JF4FNL4TRS]QPMEX_;.CDFY559</S441=]J;2EVOMT
MKBVGJNZ:6OKH=\UK&Q7DC'P$G%S6PYYKUDH:JZ]AY>>902;A5!I^0?@"8@T<
MBZ7`@.W?B1(0WV"7[A"B>0^<8'A2.)G_`'%;O@V[P^ZW;\/"]R5%"BEW2TN<
M969,7)J-LXJ*@U[45+N9ZN/;-/F3NAP'$NAC/2&1==VJ=FK>BU@FE7HNL8MO
M5?6_1%7#JS=3J:KU7)5F<);+9)Q\+5J(FHK=]J625DS)IL8R%HE2+(*GDW*R
MOB\+A=`Z9PZG+XP$X8B\[_W&]JQ._&\?;4[K$FHVW^C]5KIT7]RDM/F2KLO@
M+(L:LWS*[8_&-?\`]?7^_1_P-E_AS_;"/9K5S_>_RE;WNVBZXQ20L">F=;SE
M1C)F.J3=FD\?+;.N8,+,Q@YN2#O32A87WKIL($[GAUSF:)X:<[^\/S?SISJO
MW)X6#+_\='TZ+Y:_P_#^&A+6R^*^';+I.O'5MR_S6=?\"-?(SBU\>NA*BXF-
M><;(6HZVAG3`*]9=M3$KL+<FP)&%5?H-K78;!,KD0ACV%NX*JM`0S1K%IJ$3
M!1)9<ICAC;N>\[OO5KOW?*OR;F_6R<I_+7HWHM=%KHNI?^/BXV)'LQ:X5P_]
M*2(]JU^_V>"8OX*K0.LZ6\:(K1+F=%"..HP.F4R0LZY'![IOVMQ`0*L5N(`(
M>G3Z4T[RI-`[\WWQ.O23KC5R`V%#W>0<++.ZW5/:/J//N5T_`JXLNO)=O,U&
M733`I1!R]0%5'LZ@L7UP#,-R'^:;DI8M&5RL;$FJ9IVQ(0[A'94OJ1])1CZ[
MNQ,J1$4'DDN[D:-''9`07+6/=J**.!4Z.00,5`H$0>''QS\Q_E$>QUN2&2XP
M<1/*Q=*;=M==D"6C9\*\5746+HNHO`8ISK=PDW$IY]^="+1%<BB`/Q`Z10-S
MGAMP3XR<"]=N-<\;M?(U9M,.&\C<[?+/5[#L/8LXW;%:A/7JX2`FD9E]XRCX
MT2^%BT`PD;-T4Q[,`[KEM%Q3/7$+MIS#,)*;X_[`I6W89\K'-74M$Q4+.LXS
M8GX!XH@=]'/Y;6,M,-!]NLV]V1;VZZ@-E5@$"4G^7J'\!_F'\!_XA@#`&`,`
M8`P!@`/3UP",_&(6U?@=EZE324;N-.[COU>33<+IK.%J]=9$NW::]-V''M2/
M6-AMVY>I4P$S4_0I2]`P"3&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`8C?E'A]0ZG?\>N?4Y>9>H;\XAV"XCI6M(6DL35]U0^RH-&
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M.]R%4K;83>ZG[7^V8Z1"NPB!B"*KIX=)ND)1ZGZ`(Y;WD[R5X_\`$V?7M7*,
M^%G(;K.RO%JE&=S<GVQ@WW)1<I:)1<^DEI%]-2O<<V#D7+<9Y>WTS6WQCJ[9
MZJ#T]6DUJ]%\5'T]49%N#WQ/[UYMZ&D>6C_=O&GBWQ0K]FFZQ:]K[FN3N2L,
M-)UJ3A6<Y'#185!FS2F5V,L5Q&MGTLU-("*:8=GN$3FQ+YG]W'+9<O7CO@'%
M,W,YE:TJ\>4)W7R<HZZ^S3TZ):S;[U%=W?\`E>DH[5XKVJO:_P"N;_N5=6W1
M7U235<(__.>K>NNB246WIVOJBPMFX2P>W^0*G'#@U8-L<P9>/9D,]V#)QC#3
M>N%&;&.0/:=F69B=1NVT_J&-=LG1V+NTS)'"S<Q"+"*YTD37WS+.L\;<!Q]U
M^XW=,FWR?N6CQ^.;??[=.,IR[:JKEA:7Y>5VI*4(35*;5?ZB3D43:\=<AWN=
M'`\:JOC./TLS[ZW*=CBM92A[[[*ZT_BUW?'Z6]"O1U1H'B&Y8P&J+%6]\;_C
MF+HMXWS%L$WVD=?6%R>2:GC>-S2;C4WUYFHV.52,6_2R:9VKTO?!-&@%*]4E
MCP+]K^X\JA#E?F?:8;-QE3A=B<?C%*=S_-&_?+7^I=;KW);=W/'KA)1N4F_;
M5K\Z\EXNTJ6T\0R7E[DTX6YK>O:NJ<,6*>D(^GZJ2G-KNBUHINV<-%SEZFWK
M")<I(`BO[^ZW:>66_%5IJZ636=OY%\N!PEK*X3<"JWCP4\[@XB=02)]Q\EG[
MJ/N\X/\`;7QW^D;>J,WR'=1V8FWUM)41[&JKLB*_Y=,-$HP6C?HDBS_&?BK>
M?(NX?OLMSJV",];+Y+5V/5=T*W\9/XR_^YDQX6\1>0_,697TUP;H2T)K=)VK
M_57EOLF.DV="1?-5B(/5GUIC8](+_>$DG8E90L8!O;I%[1]H@45,_.-Y$\C<
MQ\K<LR>:\ZS+,W?\N>LI2Z0@M$E75#\M=<4DE&/3XO5]38!L.P;3QG;*]GV6
MF-.#4M$EZO\`&3]92?Q;-T?@;\5O$[XWH">NE>]W?MN/XI5_L3DGN`\.]N18
MV/9JN)5O7W(MD(O6='23*HLLRCQ3*H4I3/%W)TRJ!9!6"#_.7EO0I?527)3D
M+8?VIQZK-@E%M&:8(51K:-H66/#V$?;[6`.13<@FX(J#0B!CMFZ3D2)BHOW*
M&`P,0VH[?OF9MO.OFJ[::MX_:P(9]KNB.E6B\$Q;"@@\KWLHYLLN2Q7=^18J
M;"*0`SCW*GWE\Y1*F!')SIGE+SKKL_N*NR+3CWJ![+(5;1%7E(QW*V+8<42>
MG(N75J\,T<I'LM@@W,,56TSRQVL!"@`1S51T^[T1`M1LVWZXX>QX:PUTN:[7
MXR1V]ELIUD9"9FYEN7I(.G4D!RHMHQD<#=Y@%-H@0H]O0I>H@8SMU/=O.KH[
M9[<8NVJD?.O827J:AO(A!2S5=5$S>5[141?D$R?0ARF%$PB`AW%,4P@;QO\`
M;=_)*ZW/K9_P7W!/JO-F:3K:4YI*9EWZ:SZY:4:*I1[BH($]HBJ=UIY55HW2
M%19916'?-BD`"M%.@&TQ@%/VVML+E5+/3Y4B:L7:Z[-UJ2363,LDHPG8QU%O
M"*HE50,JF=NZ,!B@<@F#T[@^N`6HXQVB2MVA-8R$ZHJK9HFO#1[BHNHDJL>\
MZVD'VN[R*JK=--JJ?]W59[U,CW(&'U3.=/M.8"^^`,`8`P!@#`&`1LC!4J/*
MVTQHMDVL/N;3T#;6*Y$U"D?7?45@<56V&64**34LBO3;Q6RD`P+.7+>/-]Q$
MFA2X!)/`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P"WNQ=I4K5+*KR%XE0B&EPO=5UQ!+&3$Y'%JN3X8^$:*F[BE0;G
M5*8RJIA[$4B&.;[0'`+>7#DQKVEW1Y2W\9?I(\0^B8&R6R"I$S)4&JW&SH13
MBF4:QW($T8>/L]O).,P;$`YVK0[QH5^NS,^9`Y`MW5N:E0L*]U0E]/\`(*@E
MH-A@*;/KW>@1#1/][VAI4I*"IL:E`6VQ.Y2?D(F\QCLA44C(>%QT\OE**8`7
M5GN1VIZY#QU@?3YUH63TW8]]HR<>V%ZS0UE6F=?>K3CQ9%02M33"=D;DC$S=
M!D%2+$1$PI'Z`41;N6=:J]DU+7H_5>[;VWW;'Q,AK^TT6HP,K5)`)2!DK6HT
M>2<E;X9Q'/(FK1*TB[!1`$R-R@"9U%1!/`.VG^5NJH&`K5E(E=+'&3\?)V)^
M%/ITM9Y*ET2%D7\1+;%NL-%D6EH:F,I2/40!8B#ARX,50R""I&[HZ`'+6Y5:
M2(\V['M[2K(O=(.M6H7U"-BWSLJ#?<T9`2^NI:$=$2!G8H6>9V)'HZ9J*II'
M35*<0%,>H%]+!-Q]9@INQRRATHJO1$G.2:J21UU$H^(9+OWJB:*8"HL<C9N8
M0*4.IA#H&`19J?,[7M@ABSMBHNX-6L7]18WJK!LNG1T0M>:LZ=P#1U(U$D)8
M[$5\I#&M4:H\;+F;.D47A%`3,4BHI@=WNWE?1]'%M_Y:F[2O"FOV=,E+LAK>
MJL9]>MP]^4L;:L2[U.2GH(7#)Z_J[EN;VON%$E13[R`4_<`'5H\MXP-D5'6$
MOHKD16IFW5Y>VIS-@IE29U2OUB+6K+6T3MHG4+\[2BX^G/K>P0DA*14Z9U1%
M(JQ"&.`'&D><&C8&D;#V+:2[&I]/UY09;;:DI:=97"(4NFI8)2-;RNR->QJL
M::4M-?8N9=N15N1%.63*X;*F9@@]8JN0)$P>P:M8[7.TZ%?C(2M>JE'NKU9N
MF*D4O7=B.;<UJSZ.DR"9L_!Z>DOC&!,1["`F;KT4+@%:X`P!@#`&`,`8`P!@
M#`&`,`8!I6_)7R:K/*[F-?J6NH]MNH]4.5**C5V+_HSM45KF<(Q-`LEVYU"M
M6N\N2+MM'R*[;HN]KE3(!C"B/V[IOM[\6;AXS\,[7*-<,?E&[5U[A=9.+^B_
M<%_TOO)Z>Y':]FJOS(U6/LKRLMZQU;UP/\O<M?(>:9,J+&]NP>[%JT>J7M]<
MFR'JE*RUQIC-==(K1]%I'/5_#4.;V_*QK[7\I(347,6Z>K#J^0*L=''KU)J+
MV!CN2G*9V1^F\9(I)RKQ.E:TC6C8$2"=`X]J(KF3KWD7SWG^%^"+?<J,?ZU=
MAPLQ,>:[E7.[WOV&.VFI3L=2>?N-LWKK+LAK*:*-X\X+9S3D:VAKLV^F2GE3
M7QBNU^U'Y)-J*7QE^;\IGRY'\L/C-^##C_*:1U5KNADN4K$*O"Z'J2K52S7E
MW()>T=V[?5\?H3+QLW?MWJAUGDXHZ?O$C"DS;J$]$]?/AW[>?+WW0<AR.>;_
M`)D]OX7'(E;G[]GMJFMMN<U0I2@\B[N6BA2U"MZ>Y.OIKEURGG'&?'V%#9L.
MI7[LX1A3ATK6;6B4>_1/LBE_J^II?2FDVM2/AM\0>PMDU^Y<N.4.X+;P+^,2
M9M,KL8T1/3[J*M&P#.W<@>JU_36M9U![^1.1L4L9#S\W'?DWS8J1XYI(`8#Y
MD3E\WEQ?RVN(?:?G;KS#R1D4?MEERQJ%&M**C=9[]>DG5'ZK++).JBN/6V;4
M=79,-KCG\7ENGDNG%VO883]QU*<FW_I6CU^N7HH)S<GZ)ZZ+@<B>8E/6U[*<
M3>#U)=<<N%+><,YD(E*1D7^V>24DQ=JF0V!R&NC]PXF+6_E3%2<-X4ZRL;%'
M3(5,IA3)XMBWVZ?:;MWC_)K\I^3LR7(O-^4E.W/NTNKPISBN^C;5-/ZEK*#S
M=%.:<HU1A!MO'CR'Y4OWV,N-\;J_9<1KZ*J'T.Q1?2=[B]-%HFJM>U=-=6D8
MXV;E:PSC&KPOY%PYD)9C`HHUYBZFK/.S4JX!G'5#7\.T:2*MCO$DZ,5,A"I*
MHM3&#N!13M3/9'WA_?!LO@S"LX/P&>/G^5+H2CTDK*-NBTM)WZ2^J_KK&KX/
MJ]>K=5\3>&,KF=L=[WY64\9BTTM.V>0T_2.JZ5_-^K_N1M=_')_;RW'9D+3]
MD<^&CW5&H$BJ2L!PQK4B]C[M8ECJ&2)-\@;W$/TW46]F2($<N(F-74?KIJE(
M\=MC@HS)^?3D?(]]Y=O>3R3DV5=F[YEVRLMNMDYSE*3;]7KI%:Z1BND5T2T,
MZ\#`PMKPZ]OV^N%.'5%1C&*2226GP^/S?JS<%UWKJAZCH]7UGJ^GUS7^O:5$
MMH*ITRI1+.#KE>B&@#X&,7%,$D6K5$#',<W:7N.H8QS")C"(T0]A`WFMLZ1N
M=LJG$2DR:4>:ZM$[7OBT)."D+1M1QK@'SADY>MI)%2(>V5*/4,N5PD*:D84Q
M!`2N2X!@*++*?(7S$?M(*!A%M'T>.E-6ZD/8&"$C!TJAU*0;!LS<WLY1J>+*
M[=M8YS!,'9!(HS7/(JE,0Y$%,`MS;=>U+Y*=F3^YYEY.A\;?#O9<'H[BUI6"
M1D89+F+O=-3I:K2$P@R9,FU7LJJ"[B9E455Y5M`)';,P;K.U%DP+\\F5[VXV
M=4^#G&2L0]VY?['K=6JEJD*C7D8#4G%/3R$:0C6LLF4$U-%:WH]/@3*G5(`E
M4,("V0*N_<#Y`,3WR"_'#'\([G-:O2L#K8UDGM'4*YW#9$B?P.K=:)A6UQEJ
M7CH/S+EIU1;ST89&,BRK+G(V3*=9594QE!`BWSI8I7XE/W:H4\E(;@XL\;MG
M3BKJ)C8F15M:6J(BAVYY)(QBRD<M(3=LUV\DA<)^/R)O""9,B@&+@%NZ4RLW
M";E#IK;U,NKY^\TUL73^PHZZ4UA+0@7?7-J:U2U/T8Z+L`PSIS#W77-H59+,
MWAB-7)7!TSG,D('P#ZEJ:A54TU2@(%53(J4#``&`JA0.`&`!$`$`-Z^N`?O`
M(W:2,M7=B<CM;.$'#9",V5'[0JR9R=C52H;?K;"4=KLA4,55<I]IP-I\IBI@
M@50?&4YSD4`@$D<`8`P!@#`&`,`C=OH'E?M?'K9,>D8P5K<472+&<5$TT/V?
MN:->Z\53<B<%#@0EZD*\X3%(@J"NV3(8Q$#+FP"2.`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"%EEV7RU+N>UZTK%1X
MX1<25N6?U?(7JZ;/0EM@4U!G%I3<F5.!HSR)93M8L+T[61C4UUU4&RC1UW&3
M=`"8%(\A-([\Y"RE6KK2=U[K52J:2N3>PV:7I5AV52Y?9.X8T]0<I4)%I?-8
MS\>^UM$U]ZN1[)%=-U$IYOWL55"B9$#WZDG=[TAQ)5R2T3-2MAW'L&"VH:Q2
MMB:!4*I'6*(H:.WX[8%C;Q:[F)L>OI=C)H56-08N2SD:E%)$6:@1^=@!W<UK
M6].9W;SE&MOE6]@YO\>]D1"@':]LA1*I0N-$78[(B!G`#["*?TZ425`W:J)F
M9^TA@$HF`L!7..O(=K7I2AM30M?6':^OM6T>UV.'5N]>@^-/'"VVK;M*L5LA
M&$[2Y69>[.F7Z,"O',WT?[,JGE1<IHI)M2@75U;J3;%/D^.--LT8G.--%[YW
M9[F[0<1^W*O)Z^N>H=AR]-F82`D;+:)F*@X61V(VJI474A(O?>1:AU%UBF\Y
M@.@UM6MOZ$BD9]KJ.Q;#G=F:MAM=1]:9NF"7[+V!3+9M65KS2[RZJBJ-2U3:
MX^]$<NY1%*0&.=-W!SH**.FR!P+$67B+N6FZ[N"-$K);->82V<2M9O#IKL62
M.TM)U77_`!8JVPIF.5=NVIA<:WLM#DIN+*Z.50@-)%LDD<\@'<!EEVG%R$YK
M+9$+$-A>RLQ0[C%Q;,OC[GDC(5Z1:,FI16,5+JX<K%('<(%]?4>F`8@=?Z"O
MMKIE>2USKSDC%3-3XPN=?V9CRPV3L08)U?22&G+##5K5[/8-OO3BNN9!W1'R
M$G*L(Y")]J*")U5>U,B($C;U3-I;AJG+*_QVK[35TMJTW1U*U]2[:#*-V+*.
M-66FW/K5*3%<3<.(^`CU75J%*/[GZZCU%F=R!2(JH&5`D#NC5EDV/M!)NP*_
MC*_/<4>3.JW=O9."-1K]EV18M)$KQ4ER^5TWD%&4$_=(*$14`GLS"/KV@8"+
M.UJEN_>>NBP:^C'E.?:KTM9J!.1#AVP-'7+9EG4UO&.Z_JQB*0-++J=A!0CU
MV2:<K,O-U;-09^4'8-0+^<=]9;#UKR`Y(L)N#<)ZE1I^B:_HFVK2#)U^5JD=
M,;QM$O2#M$G:[]B&J).\%B&7F31(,&$>1,#F24.($U,`8`P!@#`&`,`8`P!@
M#`&`6ZW!;`H6I-IWHR#ER%+UQ>+8+9DX!H\<!7*Q*3`H-'1O1LY5!GVIJ#Z$
M.(#_``RN<8VU[QR7;MHBX*65G44IR6L4[;80^I?&/U=5\CQ[CD+$V^_*>NE=
M,Y]/7Z8M]/QZ'R@FN[;&SA9.0BY==I.ST@S:MI)P\.=P24>BE68)XLZZBJ=:
M'--2,@GU`WD?F\IC"<,_3YOZVG<=KG"/MUW7Y4<2MO10B\B^&(W%)=/T:U"$
M5T[&XQ?U:&M.C!MKSD[DYPKKE;-=6Y*N,KY)Z^O=-KN;Z^FJ,L7!KFCR_AX^
MX<0/CIU')6WD9L)6K:^1VO&M4)9]K/3%3BGC(R2SB38'JNLVLCL*P2LD]M,P
M[\12`@F@@+@B:J>'?W$\0^WW:^50\G>=MS67LFW5V0P>/T3<;<S)A-1][*E&
M49>PHU0JA17&'?&,I3L4&X2F'QAD<U>T6[)P_&]K/S;O<R<Z:3C7"2U4*DUI
MW+N<G)MJ+>B2>DEDPA>"_#?X>Z?"<Q?DMNC?E_SNFG$E9]<:6;V`\]34;L\%
MS[6?CZ_:P+.7AU".S]).Z6-)TW;.3>6/CROBMRJ8SU<N\^???R7_`+%X+57Q
MKPCM\HPM]FN=.#B8ZT[:I^RNRW)G!?H85/:[9='VU]TXRC=@\)\+[=_6-XG+
M/Y=?%RBIRC.ZVSUE*+EHX5*7Y[9=(]/S3T4L$'./Y`.0O/O8PWS=DP+>N1B[
M]/7.HH)1RE2*#%NU"@*$='N%SE=3#MH@@5](.`]RY%$#*>-,"-T]MO@3[=_'
M?V^\2>R<0PG+,R8Q65E7Q@\W.G'71WS7TU4IMSKQ8_IX\7)VRLGW,Q4YSS_?
M.>;I^[W.U+'KD_;K@Y*JE/3I!?YI/31V?FL>BCI'1EM>&W!CEG\DM[>43BW4
MDG%0KK]K&;3WQ872\'JW7YG7<"L6UL1F3E>=F/`DH*C6*1>2!NWH!$4S>8F%
M'WE??G7P:-_C/Q!DT97.)0=>9N%;5E&!JG&=.++IWY'^JUZJ+^3T2F#Q)X0E
MO+AR+EE4ZMF4E*G'E],[M.JG:OA#Y1_^YOP_&]\,/%'XY6#>Q5MDKN'?"C,C
M5[O#8<+##,P2)T13>Q&JX)%%RUUC7'IC&,LDU7</G0F'W3QQ_#1MFYN9N69;
MN&XVV7Y]\W.RRR3E.<Y=7*<GJY2?Q;,S:JJJ*HT41C"F"TC&*T22]$E\$9>,
M\QV'634Q'UV&E[#+K@VB8&+D)J4<B43`WCHMHL^>KB4/402;(&-T_P`,`U(^
M?7+*;U)Q+D[)!.WKKD=\@6P9-@FL@NNYFJWKY\]8M"0\$G)&*Y:-6$2JSB6Z
M1BIIIH-E`$A`-@%JGVIMA<>^+FI.%6@6"3GF5\A\<TU<S=^8D<CK?2RC%V^V
M3=W7<Z>NHM%:+:O).17(=,#E14*D!EUR@<#(.D.B^'&H4YRKF9?_`!8^.O6[
MG5^DTS]IR;3WRN9PIL*^'$KQX6=EK;>DSG,*1U$NYNX,W`J:_:(&0#XKN,UN
MTMHV;V_NMJ@MR9Y76AQN_<<BYCV:4[`-K`F"]&U@ZDF[IZH\9T2!7ZF)WE23
MDGSP2IE[O4#%?\W8,[)NJ7,=&$=,];<=*ZE*"T`!F0?W.Y6EVBSGURJF`C=H
MSC$%F29BD,4KI4W4P*!T`P1;1TE6HKBYQB+"O';R=NO$.*V%:F+Q,J#B!<W'
M;&XI2NQ:D6H91>-;IUF0;J('5`/>(B5R4H$5*&`6CY,P<I>-+Z@N\@HT3F;+
MPMXVO%$HI-PU0B"U;7"^IX=)HJHZ=.#+G9ZO;NSK]Q1!TY4`A2D*7`/H<\/+
MJ?9'$GB]L%5.015N_'K35J62EGOY&4(M.Z[KLDL61D1,<7[WRN!\JPB(JGZF
M'U'`)&X!'"Q`O5N4FMIPJRR</MC5EUUO+D$W^W6MNO):/V%KQ`B*90.*YZU-
M710RJHF(0J)2$[3*#W@2/P!@#`&`,`8`P"S'(FCN]C:.VA48P52SC^HR3ZLF
M127<&);J\4ECJ!U&C;_<OFQ+/$M!5;IB!W"0&3*("8!`"NJ!;V&P:)2K[%BD
M,;=:G7;8P%!PDZ1!I88AG+(%3<HF.BN0B;L``Y1$ING4,`[\TI&$"2$\BP($
M,7OF!,\;E"))[0K_`+I,14`&!?8G*MU5[`\(@?\`TCUP"@6NZ=./;`[J3+;6
MLG=JCU'Z+^LMK[5%["R5BN_\HD[A4I8TDV4C?&;W!3I%%'M'OZ=!P#N+?LC7
M6OB-E+]?J51TWARILU+A:H*LD=J&!82D;&FG[(%SF!NH(`7J(]AO_P`1Z`4V
M.^M&%_`]VZ-3!^Z@[JOUV/3@_<A1DUH4#0'69_\`W!?S+=1IU;^3_=$,E_U"
MB4`*EA-D:[LMBFJ?7+[2K!;:W[D+%5H2U04K8X`63LD>\":@V#]Q)Q0M'ZA4
M%?.DGXUC`0W0P],`[V=GX*K0[^PV>;B*Y`12`NI2<GI)E#P\:V`Q2"XD).16
M;LF:`'.`=ZAREZB`=?7`*$-O'2A*TE=#[AU82G+2YZ^C;#;"J):RK/)-Q=J0
MB4\,N$4I,)M2BJ9L"HK`F'<)>GK@%91]KJTLQCY.*LM?DXV6;1+V*D(^9CGC
M&39SRJB$&[CW;9RHW>M9I=(Q&BB9C$<G*)4Q,("&`=-;-G:UH*:2UZV'1:4B
MN]/&HJVVW5^MIK2*;)O)*1Z1YF09%4>DCG:3@4@$5`05(H(=IBB("<V11Z]K
MZ4VJ^LL6OK^)K;FVK6>)<IS4:[@6S0SP'L0M%&=A->\2``:D:^4[I0Y")`<Q
MB@('M;[%H3BT(T4+E5D;\K&)3`T%Q889*\(1RK4CSW3FIB^&<103;'`YSBCV
M%+Z]>GK@%2I2D8N,>"$BP6&6;G=Q8)/&Z@R;1--%51U'@10WO6R:3A,QE$^X
MH%4*(CT,'4#\HRT4Y(R4;R<<NG)+N&L<HB];*D?N6A'*CINR.14Q72[9-DL9
M0B?<8@(G$P`!#=`*7M6S=;45L1[=]A4:FLU)%2'3=VNVP%=;'ED6I'RL61>7
MD&:1I%)DH58R`#Y2I&`XE[1`<`ZF<W;IBL'AD[+MW5]>4L42RGJ\2<O]3B3S
ML')&,6.F88K^6;C*1+\Q1!%RAY$51`0*8>F`=FTVGK%_;W&O6&QZ$]OS0[E-
MU1VEPKSFX-E&;8'CQ-Q649$\TB=HT$%50,@`IICW&Z%]<`KO`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P"W^R->L=BP3=@I(.Z_/PDDWL=*N$8F@I,4VV1Z:Z<=
M/1I')3-W)`2<JMGC18#-I"/<+M%RF16.40.HUCL*0M`3%4ND<SKFTZ29JVN=
M>9+J+1;QN\%P6%O%06<C[I]1K>FT559**=5FJR:[%ST=-5B@!=?`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`Z=?I@'GH(?4!#`,4ORM?(5Q?X<\<]
MK5#;-_:_U*V?JO8-1I.M*X9K+W)V\LU1E89E.34>#I!*JU-JXD"G5D9%1NDH
M0ARM@<+%!(<F_MM^W[R1Y:Y7B\AV#'AA\,VG-IR,S=,MNG"HC39&R4(VM?KW
MM0:C12ISU<79[<'WJ/>?<VV+C>V6X&9-V[ME4SA5C5+ONFYQ<4^U?DCJ_P`T
MM$]&H]TEH?+"@[4HBM!($<"/L)]BD])]Y#E%H,@)BF2.5-3H*R@CU,7^(#]<
MW";)S[&S\G`R-IR(VU+=81GV2U3C_P!0]4E^9-M/NTT::9BKNFQ3K_=0R:Y0
MG+'DXIK1K7LZ?@TNFGX&X1Q4^7[C+\>WQ<:)I/%V@T:X<TMO5V?M^WQCF!$X
M>M7UU9;)&K6O<4BW.WE[1;4(N-9`VA@7;IE9=JIW#=(")N,/>+_:#S'[C/-&
M\<_\F7Y.V^,_ZI=[%<)1EFY]:L>E6%">L,?'T4I6Y=J[*Y:J-=DVW&5MW\I[
M5X^XEB;'Q^,,G?EC04I2U5-/312L:^JR?HH50ZOXRBM%+7NW#N79^_MA6/<V
M\KU+7N^V)87\S9+"]!4C9)!!)))".)XV[.-B(YHB"2`))(I(I%`J)2%ZB.Y7
M@?`>)^/.,8VQ\=P\7:^,X%3]NFKZ::5IW66=\M)63D^Z5F7=K=-N7:X0>CQ#
MWS?=UY!N4\O.MLR-ROFDY/K.;](QT6J2711JC]$>B:;73/%\6OP&6SEY&P^]
M^9B-NU7QKDD2.JGJ)K^8IVV]W,`.[2]]97BZ+"9U;J]T=%)5M[<!F;`T6%1-
M2/0\*[G4E]Y_W^SW*67XL\%Y/;MKBZ<S=:W]5BTTG1AO_)!/53N767I'XLRG
M\1>#8X7M<FYG!2S->^K&DND'ZJ=G^J?R6FD?A\&;P6L]7ZYTQ1:WK+4U(K&N
M=>U"-;Q-:IU.AF,#7X=@V3*FFBTCH]%%`IS@7N44,`JK*")SF,<1,.GN4I3D
MYS;<Y-MM]6V^K;?Q;?J_B95I)+1>A7>?`,`@W\CM_)0N(.TR%=+M)"_(1.K8
ML[=04EC*7R3;P\KVG%H\2,1"M'?+*$4`B:J:9DQ43[@,`&HWMIPGR&YX:(I0
M-7#NF<;:E1X]%9)T<8N.O-K<RLT8AP3.JT;O2Q+5REX%40!4J(*^012`A@,D
M&I=F+W'9/R2<U:_)G9V*AH:N^/7C+-*G,U0KKFV.J]_4*?J;YDV5CW4TQ2?1
M+]N+4_N"&CCIJB`*EP"\##4<%REYJZ,X5Q[!20XO\*J35]^;S;`F@XC+OM)T
MX9*ZYI5K&19NV\NTF9Q%5VZ0.GW.V,8Y#O+Y!$0-DD1ZCUP#4O\`F)F7TI`\
MT;Q#MXV0=AM#6&D(%\T`$`6-5M6DD',*[6<*F!9ZSN,TNFL<#)$((`4?0!'`
M(P<[JHK1Z/N5HHDX;-]%ZUT!Q-IZDP^C7JR;V@:OJU,\+^9A$O$_40L*;Y4S
M@0$3$-T'T*``!W?RB:^;:^6B-4JLXP]9XO\`#/CGI<'4<Z)(2#F5CH&8EW(6
M!X1-JFK*E(X!0IP0;&4:KD4%,.\,`V2OB=H\AKKXV.%57DWI7[HF@*-/D7*5
M\3QL;DR-<HMDHG)='B:T;&3Z+=0IO0ITA`OV=N`9"<`C1RH$L%0JOM7SBW/H
MO:%(VHNIX07`:X@Z=TC89?$(G[CCK.[379VHN%@4`HH)BOXC%`DP/H(A_(<`
M\8`P!@#`&`,`\AZ"`_R'`(.4BI<PM.P*VN*%3N-EPH5;G[:77TQ<-Q[2J=D)
M296S2TY5X*8KL)H:V0L.I5HN23BTD63Y9H1JS2\14R=$B`4KNJM653>4'KIK
M!O"Q',"MTF)V@_KZK@8"$:Z(E',SLYO(2HHL5DC[,UG9$JXW<J-A<O&S,B1A
M;^)#M`A,O*:IL?'+E-JNP77BU9+U/2>_X6#U31JXP@.0D3$N]\WXMRBKRN-Z
MG9R?=+UYT10YF,1#&0;]ZIB&3$AB@74V[5)5Y8.6NK]DU=W=7.MOCSO"%(N%
MD@R65G<:I*36VDJ!(IS;I@=N\V7#QL6>/GDBE3>B\1(][`0D&YC@7/4D]/:U
MY=5Z&N]FXOZYJC_CGQ]:PE-V368.-OUBL2MWW\6+'4,T^M,'$0J;&R2+8TB@
M2&DEW+A=/L4;J'*80*=X_3NHY6TZ?IU'>T9YO2J<KN6T]MF)K`0ZNQ*S1RW3
MDVQD5]D_C"C.0D+)SUA@2IIR@IIOG*K44RJ&*02@3>Y2M]9JZ:FG6W+B?7=,
MB9VERZM^%M$/6%-FV5MAS5F?G6=EB9ZJ.*XUGSMROPEF:T:5L<YE_&4OF3`@
M`S"7W!)Z9B]6MN*<RI6][7ELVV[7=5N;MH/:[!#CW:A-8BT^MV^M?C+K!J.B
M1#WPV"59,7*1B)+J&4.T:`?BZ:?N^IVL9KJJR%7D;K%R?`UPSL"--E8/6\;/
M6#FEO6VS(0%*82\J]A:+2S6)4L3!EDU/9QK=JT4=D)U<`!3%YF:]3;9Q73O=
MDT'JRR5E/DW6MZV3E%5%[)5+5ME1;04M;Y6O24C<]?H.9[8;`P2U?D#N7"24
M`<K<K(I4!;M@)[RTG3MW6O6>J]=/:W-:>K413MWWEW5R1[VIRM<2D5GNB:A#
MNHX30RL=9;77E)U4B`*$_&P*:2A2HR"1C@65H5@X[-MKWC6EW9P[SDP;E?.V
M6/A(Q9DMMA=B_=-+KK_8#1LR=I66(U3$:K(Q9R;LPDBED6;ILL"QW0H+@1DA
MI;DIK2G\1+7,R^L[0_;\2MC5W1U9J&LKE59UELNWU31E6U5!WF>L&Q+S$29'
M=@E6;9\=**C2%$BK@">,HMP`H>TNMJZ4AM&5&;H5VJDSQ@Y1)\CX:HQ%R_J5
M+7/0DOQ_WY_4QD>Q0[.&:2\P_FD[BJ:-6,5ND]<1IQ$$C$;)@4NP:S]`M=0E
M]K7[1^M;59>2/*BWV^T\JX![=]:Q5MV+I'0EL=52%926P=;),EX-X]5CHE(D
MF5)&.C%FZ:1AZF(!<#CQ:=<T:WZW#<>SN)U6KC[0&L%)-ON:I1K&S;+-_6OE
MF8]QT._G-A1D72J!999ZWEHR/,PL:;.)D6K8CQ8`2=J@7TUUKNVDY#P5HN3;
M74;JUSRTY+3%4G:KKE]![<#9S*6M[&H5O86R'5F??D*);81W.K$58,(P%EV#
M"*<&<(/3E5`RTX`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`M-LV@25B-$7.D/
M6D'M6D$?*5"7?>4(B88O_;GFZ#<"-R'7=4VVE9I$7,4IUH]VD@_;E%=L0I@.
M\US?X[8M?&6;,GD)+QKY>"MU3E>PLW3;6P31/*5R8(F(IG7;`X350<)"9L^9
MK(NFYU&ZZ2A@*]P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@%I]L[MUQI.
M(;2M_G/8J21ETH.$8MEI*PV%TW(4ZK6&B6I3+N#$`Y>]0_C02[@%10H#UP#$
M/N#DCM/>*I49-R[UI0D5#G:TBL33DDC+_J$.@O<+"U!HX?*(BF`D;(`BV((B
M)BJ&`I@`LA>^0W)R@Z4V55>-^QXRK7^8@W!J=)W5@G9XZ'G2`!_*Q4F3O$89
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MS.Y*3C)QNDW!$C]HU:1;Y(0$4S=`<9%_C;S9R+@:C@RG99M<91E'M:[ZW%Q<
M>WTU2<?1RUTU2^1</(.)X.]Q]R44LC1K5ZZ-/75?%+777T]?EU-;?1]`Y.6"
M^_TVH.D]D;/EIVWC5X1CK:FS-Z3>7-RP=3)ZVSEZXU?PB[Y6-CEWP(*K)G1;
M)*K*`1,AS%S^\)?>/@\5NS/ZCETOB]EL\A:IJVFR6CL@XO\`-&4_J@I+13D]
M']1!W+_$=NZPJ>/6UN$8JM]5VRBND9=.NJ727;KJEZ=#=Z^(3X!;$T<U_DC\
MD5(8M)F(D&LUK'BJ\D(V>8Q[UDK'2D'>]WOHARYCY*?CI!(YV=90778-S%*H
M_,NI_MD8N^Z3[^^6^8-HEX_X,I[7PJ73(M3:R<O1ZJ,IK3VZ]>LHQ_/Z-Z+K
M<?C;PAM/$,I;YNC_`'.]:?0FOTZM5H^U?'5=-6D_P6NAN!YKE)Z&`,`8!@;^
M=JV/:QKGCF8KQ<(P-B7:7<19"MQ0?2433`;1KM0YT#N4W#!K,.R)BF<A1*Y.
M!P-Z=`-8CCKO2"@ZQL3?+Y8Y9]E:=HSD^\>LT4U_SJ+AE7Z_'LWRBAU7T7'5
MBNL#D()R(IKN5R^,.T#B!EBT1$1VKOCN^/&K6-J$5>>0>T=B\WMG1L@F4LJ[
M"PNI>-I$W))@G&+D;+TZT1)$$GR+E3JTZ)N.C8N`9.OA0@YBY5OESRSL(',X
MY&\C9B*J:CEBW3<FUWIAF:FPZB4@5JBNZCUK*[ERI$`ZB!?$)R#W**8!E_VM
ML6#U'K6[[,L:@$AZ37).><)]>BCU9HW,+"*;``"*CV8D3)-4"!ZG66*4/4<`
MU;>2T`GM6]\6>(^PRMAF]DWN>YL<SIMT554E5HT84NPKPT?+E!$T>V:T^,0@
MVR1#B/NGZ""?0XDP"B]_L6]WV[\;>AW\<JVM7,SG"GR-V-68@6S)Y#ZRC[1(
M[#4(X3DE7C<C5&)AUC"FH183I+"3[U#$[P*;^6I>=NB/*&<BF83SK:'*>)T9
M625E$?-*+4RGP%!;Q+0XN53.9Q27?IMA$`\9G1!``#Z8!N`T:KLJ/2:=2HT[
MM2.I]4KM68'?JIK/CLJ_#LXEJ9ZLBFBDJ[,@T**ABD*4Q^H@`!Z8!5.`4M>:
ME&7^DW"BS29EH>Z5>?JDHD595N<["P13J*=@1P@(+MU/"[$2J)B!TS=#%]0#
M`+?<<[>\O.CM93\J=8UA+5VE>MY'*::+EO>J8JO3;VS<HI'4*@X8W&!?(G3Z
M]Q#D$I@`0$``O5@#`&`,`8`P!@#`'_WP!Z=>O0O7^?:'7_GTZX!YZC_V]?\`
MC@'CH`_4`'_,`'I_D(AU#`'_``#J/U$``!'I_,>G4<`8`^GH'0`_D```?7KZ
M`'H'K@'GK_\`?_M]!P#Q]0Z"`"'\A`!_[P_QP"DZ[2H"L2URG8M!;\O?I]O8
M[*_=.#N5W;UC!1-:CFZ)C^C2,C(6%020;I@"9![S]!444,8"K/\`@'7ITZ]`
MZ]/Y=?KT]<`\]1]?\?K_`/7_`!P``B'_`-?Y?^&`>/J'00`0_D(`(?\`(?\`
M/``@`_4"C_+J4H]/\NH>F`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!8
MG8]3L%=G1W+K"/._N#%BUC[W26QT&Z.W*7''542C2F7,DW;[!JJ;A9>O/5#%
M(J)U8YR8K=T5=H!=2I6ROWFMQ%MJT@24@9ML+I@\*DNV4^Q51NZ:/&;M)!['
M24<\14;NFKA--PU<I'15(10AB@!46`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
MZ^@8!!C=W-&OU$[FM:G3B[S:DE7+*1G%UG!J=67*!O$<BCAJ"9K/(I+%,4S9
MFL5-,Y>BJQ!#MP#%A/3<E-STG;;9,/K-;9I45I&:DU"'=*@!2E(V:()@FSB8
MQNF4"IMFQ$D4RA]!,(B(%M[#;VK!)0RS@A>T!'MZ_3Z^@=1#_G@&,KEISXUS
MHB/=,W<B2>N:K58\73(IRC[WO\0BV=6%R!Q+7HA0XAU55`53EZ^)-0?3`(3U
M?Y2=Q[`XP1=4VKL59S1V=ZMK&A:IJ"#AC'O4GTP1^SC)6/:$/*7%RC.22J4:
MBX%P3L$OB1*H;U`R;\(?A,Y"\W31VX>=CNZ<=>/L@W(^J>CH!XM6M[;":'67
M`B]Y.[8JJZDK+M(I#D0`#3[M(P]2,`%-8X&X)IW2NI>/NOH#56D]>5/6.O:P
MB*4+5:?#,X>,:J'(5-P]5(U2(H]E7W;W.7:YE'+DXB94YS"(X!=#`&`,`8`P
M#6Z_N.)G\1JOC$/=V>ZOVR4P-U$.G93HP?H`AU`>[`-,!"?*?B_M6..N82JV
MJ\+`*0]!.*X=P@)1Z]>G3^6`;"O/W9\I0=1<-)%!0SM2$^+[C0:';`F@F+,\
MK37_`.05*LFD#A0'9VB0F!0QP#Q!V@7UZ@;0?QBZPAM0?'UQ#IT&X6=MG.C:
M3>GKQP54BSR?VG&DV;9G:A%7+L4S+V&VN3=I3]@`/0A2%Z$*!0?-'9%:M5KJ
M^F',JS4H^N%R;RY)*>4I&L=6J4W_`#FNJ#(O%%$V?Y.^6I%)<&7<+@6[,AS%
M!)4!,!@HXH`\Y.[7W;OF[/O:L-^VJ4_<LJZ;NDB5'B1HNQ'L$Q^-?',L@@CM
M3:<&=H("<Y3,JH5,"E!;N,!<O@];D-O<E.;OR\7V&3<T'CS7)7C/Q%@?&X,W
M=31F[1C/*5]-PH)4WSP%XJO`=$PB;\@[*(=2FZ@=Q,:D<;MY3<'>%TDHM8Y^
MH75]S=Y43SE65+^/DR3$-L)Y"NE6ZZ3A!28GD8J,)U!,Q7#XP]W0A@P#:='U
M$1_F.`>,`8!&W0QRUZX<B-7^,[9"I[<7NU;:>`R2!:CN>!C-@+.VQBII-127
MV>[M*8%1(4">'[Q.J)SF`DE@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`(X6QBZTG9I3:E<9N7
M&M;,]&0W558ULHY/`R!TDFYMT5N,:(J+JKMTD4RVEFB`B\8D"13*+MLN1\!(
M9F\9R+-I(1[MJ_CW[9!ZQ?,ETG3-ZS=)$7:NVCI`ZB#EJY04*=-0AA*<A@$!
M$!P#DX`P!@#`&`,`8`P!@#`&`,`8`P!@%"[!V53-70"]CNLTWBV293^U:@/G
ME9=P0`$&,+%IB+R4>GZA]B13=H?<82E`3`!B5W;RDO6W?=PL>=Q1M>BNKV0D
M>[.C/6!F43D1_=LLU6Z%073'O4CVI@0`1`JBJX%P")+R7;M4A2;>-))(.P#E
M*4J9"E#H!4DP[0]/^6`60NNSHN!9O'#E\W02;I*+.73E=))!!%,HF.LY<*G(
MDBDF4.HB(@4H8!@'YC_*,$>XDZ9HZ00?R*9Q;O;^*:#U@B<IE4UVM78N"*(2
M)RB4/_V"W5J7_P!(JO\`J`#!S(N;/L&5<34W*.)%W)JKR4N\?.G3IR9;R&[W
M<N^>B'N5CID`P*&4$A2"`!TZ=H`;XW]M#\?'&TO%>A\X;3K+]U;XEKYM&-UY
M>K>]<3$16*Q`3\E3DYS6M;66&#@G\J9N\;.)/VWY!04SE(HFF(E,!M@X`P!@
M#`&`,`8!@?\`[A7CM*[<X..-MULCYS8>,EB'8KJ-:]ZI']#G&R59OBQFI`$R
MJ\"Q7;R8'#KV-V2X=/OZ@!\_5M,^/4-X@4793J.I2:7$$^TQD_R28*$$">G4
M.GJ'KT$/XX!EUY5<HJ=R:T!P\M-2,FR-#\!-3ZDN<$+PCUS6+[J";O\`KNR0
M[XQ"(F_6/7TGZ/<0ACLWJ0]/7K@&?WC[\HD3K#XQ.%FMZ;<VMTY!S?&.D1=C
MN;M^QD8O3Z<;%-89!Y:!+W$>VYI%HB2/B@*(HG;%.[[4P*14#"]N+D'LCD'8
MH+B;QT6L*=1DI@\YLJXNE7BSR>D7KDIK+9[/9%%!-+66;,H)&;<ZIQ:E."IP
M(0!P"66U;+9$=?5/XQ."J86_EKR1CJW0[E88EP[?U?CIH&KE1-*JKRBJKI2)
MBH=B51,7S@55%UO*J`'4/^J!FDLM-U#QHUGHWB72U&!]&<':0AMO>KXK@#M[
M'L>"C3R--K$T]=J=CVTWFZ3#RR/VAC'4)WMU!(F4"!@%3_#[JE[8ZCM?GGL%
M@N.S^7MKDGE<<O\`K[B&T;5IE^SI3%DET(1LC:Y,KJ75.4A1<ME&7=U!%/H!
MF<P!@#`(USCI2I<KJ([.Y\<5N;3MJI+@BB:94QMNG["WN]/9(+B"JZKN2J^P
M;8OXR@BF5*-.8YE#>(I`)"2TM%P,8^FIN18Q$/%M5GLE*2;I%E'Q[-N05%W;
MQXX.F@V;(D`1,<Y@*4/41P"U$'R,T)9MAO\`4M>W'K>;V=%OYN*D:'&6Z&>6
MAG*5H5RV*-7B$71W9)"#,U5!VCV^1N*1P.`=AN@'6T?E+QMV8>33U[O;5-S-
M#,V4C*?MR\5^4*RCY&3:0L>_64:OE$P9/9A^W:I*@(D.NNF0!$RA`$"J";NT
M\ILP^F2;.HQ]LI("Y4UR6R18W`B(1Y983#!`X]^!@BS@Y$O9W>`>_IV^N`=9
M?^1&AM4P;2S;*W%K>BUU_/3-69SMIM\)#Q#BRUU^XB9^`3D7CQ)I^7AI5HJU
M=-Q."J+E,R1@`X"7`/47D=H$](>[)+N76HT&-:Q;V0MW[OA0@V+6<D7T/"KN
MGQG8)(IR\I&.6[43=/.J@H4G<)#=`*NJNT=;7E"L.:;?:A9T;K`R]IJ`PE@C
M)`]GK=?D8V(GYV"2;N3JR<3!RLRS;/%TBF3:N'22:@E.H0!`J>&FX:QQZ4M7
MY:.FXM==ZV1D8EZWD&*KF-?.8N103=-5%4#+,))FLW6*!NJ:R1R&Z&*(`!9!
MIRQXQO[C.:]:;^U(M>:R>33L=2+>J^$_`GAEG3:4"8C#/0<QI63ADLF<5BD`
M#HG+U$2FZ`5Y?]P:IU4R?2.R]CTJB,HUM$O'[BU6.+A2M&D]+C7X1RL#YRB<
MB,O.%%FV-TZ+.0%,G4P"&`=5%;^T=.4]#8,5M[6[VBN4YY9&WI7*!"NF1JQ!
M5LJII91\1FFG`(AWO!,8`;)_<IVE]<`JNS[#H5*1F7%ON=7K"-=KI[=.GG9R
M.C/Q%63='8FL,@#MPD9K#^^3%`'!@!,RP=@")O3`/7K_`&10-K5M"X:TN=;O
ME5<NG;%"P5679S44H]8*^%ZT!XQ562!RU5]%""(&+U#J'J&`5BLLBV15<.%4
MF[=NDHNNNNH1)%!%(@J*K+*J"5-))),HF,8P@!0#J/I@%J++OS2%.H$+M:T;
M<US!ZRLJ\<VK=_D+?!HU"PN)A-PM$HP4_P"]&-F%))!HJH@#=1054TCF+U*4
M1`#W0FY*79+_`!FOZ\J_FW$UJQGN"(M<4@@^HTE4)&>+7V'LK&W=*(N9-ZX,
M"Z21""4[7]0#_P`,`N$]FX>.?0\7(2L<QDK$Y=LH"/=O&[=[-/&$<ZEWK6*;
M*J%6?N&D4Q6<J$2`QB((G.(`4HB`%O[1O'3=(NU<UO<-H46L7^W^S_;%.G++
M%1MBG?R+Q2/C@C8MTY3=.1D'Z)D$.A?UE2B0G4WI@%6H76G.F:TBVM=<<Q[>
MSJ4EP];S4<LT0N2,\%66J:SA-P9)*R)680CS,C"#DKT?")/)]N`4E5-XZ;O5
MSLFNJ9M"BVF^4_W?[HJ$#9HJ3L,#^/>DC9#\E%M7*CIM["04*@MU+^DJ8"&Z
M&'I@%T\`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`C/%%#0%V
MA*>F!4M)[+FEXVE%$Q$6NJ-BR(N9!*DIG.!$6]!ORX*A!HB8/QDT(1R!3-WK
M%!H!)C`&`,`8`P!@#`&`,`8`P!@#`&`0JWES%K-$-(5;796ERNA$5T%)0BI%
MZA67P"='LD7+=8JDU)-5"]QF38Q2A_I562'TP#%A=KQ8+G/+VN[S3BPV1RD#
M?WCHJ*?@;%$QR,8QDV33:1K$AC"()(D*41'J;N-ZX!:.>LZ39,YW*Q$R%#J5
M`IN@]/KU4'ZB/^&`0@Y"\L:%IVNKS=QL+>':&\R$<T+W+RDT\31.H5A$L4@%
M9PL8I!ZFZ%22_P!2ARAZX!K*<K.>NQN0S]W7X-9Y6=?*&%)&LM')E%I8O4G:
MO9G2':286%0@F*@4"LT.O3HJ8`4P")T/6EXYHO9K9*+PT6[249J@4QQ?S"2H
M%.I&-T.J9GGF*B`B3T3*!0ZB`!@&1G@-\6/+SY0;,QCM*4U?5_&]I*.65JY"
M72/<$H48,:90KU%@)5F;[9UP272!$L7$F4;-'0E!VNU(!E0`^FKQ%XST;ASQ
MITSQEUR)EZKIZCQ541E56I&3NR2Z13O++;I%JFLX*C)VVQNW4BX+Y%.U9R8H
M',``.`2-P!@#`&`,`8`P#H+75X&\5:RTJU1R$Q5[A7YFK62(<@(MI2`L,<YB
M9B.<``@(H/8]VHD8.O\`I,.`?+FYQ_%-SK^/W8^SG%BT3?KOQAC['8F].WK1
MFB=^JSO7"+YZYJTY>"U@[^:HDFSA$BDD!F&;-%)PDH)5#I'144`@)J*[1T<V
MM=:15233G3&E6:Y#`)5%#(%;KI"(>A^A"D,4>OJ7J'\,`D!QSO4HTB)K6LW=
M74'#UE\N\BDVQ$Q?NXB;<KNW#=!PX$Z1$V;TR@`'882`J'H(%P"<VFKO=Y=]
M$\9^#M/E+_O'8<F\&/C&CYU*3"23]1(UIND[(F5*,?$1J0(B[=*JM63<@)^X
M52;D'H!GAX\:SU_\1FN942;/IVUOD1WHW'^L>W6\FTO,+Q_H:+Q![(UAH*XN
M&DI;'4BU!+VIP*#ARBFH9(C%HW(Y`C)6XODA\JVUE.+?&]Q,5'CQ4;@SD^36
MZW;WWB-;2LZCN2G9VP/GKML]OVZ;XT:JECXU(ZHL_,FNX%!HF*@@;LM0J=?H
M52J]&J<<A#U:F5V%JE;B6Q2D;QD#7HUM$Q+!`A0*4J31@T33*``'H7`*BP!@
M#`++[MU]<[U#U%]K>RUFI["U]>XF\525N=:D[9555$HN;K$_$SL)"62HS#AK
M+U2SOT4E&\@@9N\%%8Q5B)F04`L'M*N\H7ND-\1VSI_3EU826H[8QKT%I_6&
MQ:[:G%E7;I@U`ZMBV=?D))DHT\R?MD&:;@ZQDS`IVE,0P%L*GK_<<;:ZK)7V
M>D;7I&1Y0<CY:&UI%ZX_`3VO[FXW?L^?T_=+);$7[R5LFNW+HKA4ZGMF91>2
M<2L8RK$K@#@6!U[JW=<5I_3L=N!U:MA2\#QHX^AIYC#:T2IT928AQ>=`_P!8
MJ%>(YF:3G7VQ(<M=ACH+.5DD3Q;=X8K-%=JZ5.!>-U9KMK&0JE$7UN38UGU=
MLS=FZ=JI/-<;#?3]CCE(O9T[K7=E%V1`+A14)R?;N6<&K!.$)F3*L^.Q;(%+
M']Y@+6U+6/('6/'C;6F=EZSAF$U<B:5W)#$U58K;M2&>W9Y>]<Q^^6\G,RE*
MJ;N*L#NWL"V(8])LX9E0E7)FKE9)JL"`%_-H1DG6^4D]MZ>KD\XU?KRSZ*MM
MPDVE<EYU((AIISE#34)R,B8Y@]>68U,NMUAG+LC%)RZCB'*Z!,/'W`!;>"U%
M=+WOF'W!48I[`2QQY1[IT7:K/!6&,C&J%KL/$ZO1T);6*[5F^KT?N&N5F?(H
MQ=)`_)'._P`@#<';?M2`E[P@5FG/&37\C8:=:=>S$S+;.L#RDW:-/$6RL_N'
M;5ZG&\3/1Y^H(OVK60(!A()DU`Z'3,8ABB(%LMTZUN-^L?,Z&K\(^<.K1Q^X
M\M:J=9NHV8V2;JUEWO.O:[%2;D$8Y:5.4[9$2BJ!&ZCU`RPD(<#8!83D7:)>
M^61'?U&4OVN*?67_`!ZI2U]M&CKY+2T!8H7;]GL%M5+JI_$1MHGHFKLI-)A(
MO"(E9(/'!@365]NN*8%I[Y4[SLS7.QY5[%6C<K>]R>WSFV6IJ6QT)/;4+*:5
MI%9:(!JQ\S,_KD-7$F)ZTU.<@%G",S.2BJH=50X%UKOK_9E<WFZK<C4K58]:
MZ4I7'VUQ5T;14C,Q]MTS5N1\U;5:.8$FSA6R[%U##0"*KV._7>2,>SCWZ?F?
M.?"`$G-)[BC%[Q89VU,8:.9<DMQ+5S05IKNN=J5>2V=%4C43VS*.-@Q-I&8+
M6)&N0%)DV#>7>A!L9LL<F#=L4ZS8JX$SY.*C)R.?0TU',9>'E6JS"3BI1HW?
MQLBQ=$%)RR?L72:K9XT<I&$BB2A3$.01`P"`B&`8U=5L7^H]7\+;K<:G:V.O
M]7U/:E?LL%"4BS3,M1+1:BLX^A6AS1JS#2%E3BX^"83$(`MF*H-?SZ0F(5$3
M*I@2UXO524J6F:TSG*ZO59!Y)7N8CZY(HMTYJJTNS;(N-NH%,E_`HN*3ZIU&
MPM&:R!E#^W<)J$$1,!A$"WG*&X0NN=A\4]@VLDZC4*WM*_I3\S"U.U6XL-^;
MT1LV)BE9%E486=DFC5])N$VY%CH@EYU"$$P&.4!`L;M"?C+37>3]-@X*SR]L
MYCU2-_\`CO)I4>TE8V>+?:2J](C4Y>P.H9%'7R="NC.1E7J$Z:-5CVSL7:":
MBJQBX!3;O7=XU\M'V"JTFS2M;W)SN%]M.N1$&]<2%>GXCF(27J.^#MSE2%M2
MGFMZP2-G%RAXSHC%R!/L3=G5`N+HA_8E+-QPU(SI,0"N@*1+L=YC9-?W2&L=
M"V.M37T#^ZJ=L<\G'T&W--E2[]T<Z#5K++231ZK(J.&RB7C.!D7P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#HK/6("Z5Z8JEIBV\S7I]@M&
MRT8Z\A4W31<.A@*L@=)RU<)'`%$5T3IKH*E*HF<IRE,`%H=>VB=J%E)IC9,J
MXE9GV[MYJZ]R8IE6VA4X\GF<Q\HLFFDV'9M+:"4DJB4"C)LRDE$"@!WB#,"_
M>`,`8`P!@#`&`,`8`P!@%&WK8-/UK!*6.ZS;:#BRJ`W0.L"BKE^\.0ZB3"-9
M($4=/WJQ4S"5-(AC=`$1Z%`1`#%1O#EK<ME&>P%44=T>C`LNB8&3M5&R6-KU
M,D0\S(H"F>-9.$ON%DU$!^X2JJJ%ZEP"%;V92;@9)KVCV!T,<?1,@?Q'KTZ?
MQ^@>N`6?M5^:1!3F%P"KCH8.X!^[KZAT('J!2_P_F.`8>.7_`,BU:U<HYJ-.
M<-+MLY=<S!"!;K&5CX1T;LZ!.+-C)G4==JG4C5(X'ZA^J=(OW8!KWWZ];5Y"
MVIQ.7"9F)N=6?.&0M%T4PCXR-2.4R+./%%;P-T$W9E"^V22*D`%`XG4.81P#
M\O8%/7!HQE!5Q;:6T7CU+VVLX)F_FIQ^T2(HI(HIMX9-T_"8;-R^9!HFDHHM
MXS%,4@?>`&V!\/\`_;TQ7):GZQYK_(',/9FFW*-8V_67%R((M"M'=9<E*O$J
M;A?E%"2B&ZYNX5:RP!LNF<H>]=F,*C8`-VVDT>F:UJD%1->5.NT:E5A@E%UR
MIU*&CZ_78..0Z^)E%0\6W:L&3<HB(]J9"@)A$1ZB(C@%4X`P!@#`&`,`8`P!
M@'X433634163(JBLF=)5)4A5$E4E"B11-1,X"0Z9RB("`@("`X!KG\U?[9O@
M1R2-)W+0C&3X;[@=2"TP6>U:B>5UE+/UA>+KMYW4,K(HUY@Q>.G)>\8-6'.F
MF0`+U#[<`T5>7O!?F;P:M#TG)WC_`+#HM:BIN1CH?;*4,:9U;9&C5\#)E*,+
M]75YFM1Y9ANL@LFT>.D'9/<`D=,%`.4`.3H_F4MJ"J2<%4)XM().F.,RZIK5
MC6+-<"K.$7I(FP6N!096RT139VW*JVCW3U9FW,)Q21+WGZ@9<.&O"?Y(N<%X
MH<!":'V1H7CO;GK96X\AMG5=6I14)21/(!)2U,KME4AIRY6%R2*5;1R+=HH@
M5VJW4<J)-C`H8#?+XB\2-,<)='UK0FC(1W&U.!5=RDK-33E*3N%[MLJ8BD_>
MKU.I-F?YVUSZZ9177\222:1$T$$TFZ*21`),X`P!@#`&`,`8`ZX`Z_\`C@#`
M'7`&`,`8`ZX`Z_Q_C@#K_P".`<=5FT<.&KM=JV6=,3+'9.5D$E'#,[A(6[@S
M18Y3*-S+H&$AQ(("8@B4>H>F`<C`'7^/\<`8`Z]/I@#K_P!OUP!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`HC85"A]CUM:O2RSV/7
M1=M)BO6&(6!K/U*SQ9Q7A+17GHE/[66BG/J`&*=!PB91NX(JW662.!2NKK[,
M2Z\KK[8232-VS2VS92>09HG:0]QK[I==I"[+IR2JK@W[<L9VIRKM/*JO#2)%
M62QC@1%PX`O#@#`&`,`8`P!@#`&`0VWQS$IFKQ?UFG>UNU_22,F9%NJ"U8KC
MHP*$)^X9%LN07#M%0H"=@U,+@`_ZAD0,4P@8HKQM&U[$FG-HO<RO*R9R`DB8
M>C>.8MR]>QE%QJ8@UCVY`'U!,HG4'[E#'-]P@6@F;*5-,ZBRWMVQ0$2DZ@14
MX!_`1^J9!_\`^AP"+FT]ZU^G0LI+2LNRA(6*04</Y)\X2:LFB)1`/(LNH8"D
M[SF``#U,<P@``(B`8!KM<J_D?LNQQDZ=I9P]@:HY7/%26PG:+Q&4?K+,W:IX
M^-00*LYB&KM%(0(J4ONS#ZB9`H&`0,>L)5%Y6./)6`[>'B!,D\E)B75;K23Q
MR*21G)5915))<S$7A3JHM4P*!>\`4,L<H*"!DBX#?'CRO^16Q+UKB;34*5IR
M%E6<-LCD[?DUH>JUQ-4_60954G8:1M-E19$,*3&,365(H)`=*L4S^7`-^+XX
MOA^XD?&Q7C.M:U];8V[YA`X7/D3LAE&R>R9I9T@FE(,*\J1`S>AU5P<@B$;'
M"'D[A%TLZ5ZJB!,"T-U]$666V;$(+JZ@L[M:4W#7F22JYJ+,J$`5]S5]BF8Q
MBPZX)%+;&+=/[B=)=,H+)/P>@2-;.6[QNW>,W"#MH[02<M7395-=LY;+IE50
M<-UTC'26062.!B'*(E,40$!$!P#W8`P!@#`&`,`8`P!@#`&`=/8:[7K=!RE8
MMD#"VBM3;12/FJ[8HMC-P4NP6Z>9E*1,F@Y8/VBH!]R:J9R&_B&`0RTQ\9OQ
M_<>;Q/[)TQQ!T/0KU9)AO//;+%T&'<2,?)M?:&;+5@TFB^2IR*#AF5P5&)*R
M1!T91?M\JJAS`3E_@`?0`]``/0`#^0!]`#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@%K=GZ]<W)M$3M9D4*YLNDKO).@6I=`R[9FZ>(IHRM=L#=(05
MDZ3;6R!&THT`>X2D2<H"F\:M5D@.;K;8;;8$2]%S&+UBXUI^$!?J0_<).9*H
M69-J@[58'=(E(C*1#]HY3=QDBD4$)&/627(!>XQ"`7%P!@#`&`,`8!2%XOU-
MUK7W%IO5ACJU!-CD1%[(JB47#I4#"BQ8-DRJ.Y&07`AO&@@114X%'H40`>@&
M);>_,ZW[,"0J^OR2%$H:QG3)P_!4$;?;8\_D1-[E4I/)5XQXE]W@0/[PQ#=%
M5"=3)@!"`ZZ+9/QMR)$(F`@';T(@ET]1`>T/4PB/T#J(B/K@%N[/=8^'3444
M7(HN4!$IC"``3T_]-/KT*'7^/UP#&9RFYQT/3L;(#,2825A3:>[9U"+>M2S3
MA%4Y$47*Z:RQ09,CJJ%#R&`RARB)B)G`IA*!KE[KY+;8Y0610LPZ>-8!NZ[Z
M]2XCS!!I)G=$$0FCIK-W#YU[3J45Q`R@F'M*"91]`*4KE4C82:A*\Q@Y&_;,
ML\JQAJKK^J,'DY,RTW++E0C(2.C8XCJ1DI)VZ.1)%H@15=0P@``)OJ!MJ_&I
M_;673:RE8WO\G*KFN4]1JC*U?A]6I)[%3IC>9)9@MN*T0SQ`(-+VY#`K!QBJ
MKHY5@!P\;F(HV,!NC:]UY1=34BKZVUE4H"B4&EPS"O52HU>,;1$#`PL8W3:L
MF$>P:)IHHHHHI@'7H)CCU,81,(B(%98!Z7#=N\;KM';=!VT=(JMG35RD1=LY
M;KD,DNW<(*E,FL@LD<2G(8!*8HB`ATP".E0<*Z+L,/JF:74'5-@<(Q.D[&\5
M$Y:M("F84-*3[U4_<"2**0_M-TI_[EF08Q0WNF[4SX"2.`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`LGLNF6%O+L]
MM:Q;H+;&KL<6-E:XLY381VUJ0@NX>KT25>*@9NQFF3ARJZKTDH`?CY$YTE#@
MR>/2G`N#2;I`;!K4=:ZTX67C)`'"1D7C59A*1<BP<JL9:#FXQT4CN)G822;J
MM7K18I56[A(Y#!U#`*KP!@#`&`0XY"\Q:7IP[NJU=%M?]H%3*`UQHZ42AJZ"
MHF(5W;)MNDNBS,D("8&*8B\5```02*8JF`8B;[L2\;1L![1L2QN[!*^152/C
MR&50KM<15'U95F$\AV\<W(40**Q^]TJ`=553#UP"VLC+-V:9CN%"%*`"(IE/
MT#H`#_U#]`$?\@]/\\`CU?=N,8Q%4B3E-,H="%Z&Z!W'-V$(4"@'<8YQ```/
M4PCT#KG*$)V35=:<K)-)))MMOT22ZMOX)=6<92C"+G-J,$M6V]$DO5MOHDOB
MV8U>9.S]WT>*U)#U*K3+J\\@[).5/7E&:(*H[.E5(UNT-^6;1#U(4:K$*+/2
M@+Y^DJH5/H<J!`[E4[PWC@N_[!M&/NN[05-F5*790U+WHP@M96V+3MKBNBTD
M^Y:K5+5(M79>9[+R'=LG:]FE*^&)"+G?'3V7*3T5<):ZSET;;2[>CT;->G:$
M5<9_85F#9=KBG"-2FI"NOIQHL\&%_)1R_M9EK"JR'EE9A8DF@HDHZ5%9R]43
M%43'`P#EFEV$ON#7`KE7\@UT<ZYX:Z]%C4H1=-O?M]W=1U`Z^J39=1)%0\G8
MC-7"KF5*4_>G#1";V85*/>9--$#*$`^@/\9_PJ\3/C?@F-BA(5+<?(]XV*:S
M\@]A14:]LC1TL@W(]B=:QYD%&VO*N59$PD(V,I(K@<WN7:P"4A`,P^`,`8`P
M"GK958"\5R8J5ICDY6`G6AF<BR.HL@<Q.\BR#EJ[:J(O(^18.DB+M72"B;AJ
MY3(LD<BA"F`"U.NK;/UNP#IK9TBH_M35H[D->W9V1%NGMFEL!("KE3P]C=/8
ME01621GVA"IE<`9.2;D*@X40:`7WP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!3UNL
M\32*I9[I/J+I050KLW:)I5L@=TY3B:_&.9:24;M4_P!1RN1FT.)$R_<<W0`]
M1P"SU(Y$0EO;UAS)Z]VMKE*[6"#K5.'8=9BXL;)(3U5LMR:G8!"6*P^%HVA*
MLX,X4<^#QJG23Z"8_P!H'JLG(N+A-D3FKX75^X=@3E6:U%W:).BU>$D*[`%N
MI7ZT*D_DIFTP2RBP,HU1PN#=%8$4A+U'N,!<`])^3=*5GI.`AZSL*Q*)EL3>
MH2L-7F(P.U)ZGE6/;:KK*7DYJ-;6*>KI6C@5@5]JT6*S<F;+KE;+"0"W=?YN
MT^U0M'EZ_ISD))N=D.;>6EUY*C5Q&P3470R1Q+58RM'5W0:,8.+D)9!F)W*Z
M*ZKD_1-(Y`$X`5H/+;5#B$JMF@FM\M%>L-<1NDU*P-'F3EUK2EG\A$C:]G1T
MFG&3-5C492&?HG1%LN^`(YVJ#<4&JZJ8'<..2^OFFR'6NW,==$V[6?IU//L=
M*M*OM6C==@0\'.4VI'MD<Z>&9R5B866/*U<.6R,:L[>(-"NA=+HHJ`>W6W(.
M/VE.ECJ]J_<#.N+/+.R9['G:S"1M"?GJLI(PSM5J_+:7,YX)"1BU2,Q4CTS+
M!VF$"%,`X!WN[]SQ>B:>:\3M,V%;X-LX*C*?T]@X^??0J!^TB<A),WTW#'!B
MJY4(B44164\APZD`O4P`4+)\J*G'-$TD]?[;E+@-SKM`<ZUBJM%.;S'VFR:T
MD-N-6#UNK9&]>(FQHL6LZ=+$D3I)'*"0&,H/;@%W-8[,K.VJH2W58LRV:)S-
MBK,K%V.%?UZ?@+33YQ_6;579F*D4DU$9"#GXQPV.HD99HX\8*MEED#IJG`N#
M@#`&`,`8`P!@#`&`1YNL-+:JLLEN"CQ[R3KLTJ@ONN@Q;4[IS+-FK9!DGM6I
M1[9-1RXO58C&B:4BR0**D_$I`0I3OFC,BH%U=?[#H>UZ?"[!UC<:UL"C6--V
MK`VZGS+"P5V7(P?NXE_["6C%W#-R9A*L%VRY2G$R+A$Z9P`Y#``%7G.1,`,H
M<B91$``RABD*(C]``3"`"(]/I@%)7"_TG7\([L=SM,)7(9FDJJJ\DI!N@"GA
M)Y#(M$14%P^=F+_H11*=4XB`%*(B&`8B-W<Z+=ME)U`Z:7>436SI!VP?VI=-
M).[VI,3J-7)8HZ2RP5*.,!3)B)?_`-B!@'[T#=2`!"M!%I&("FD0&R7>954Y
MQ,HY<JG'N475.J)E5EU1]3'4$3"(]?7`*(LMVCXI)7HN5/H`FZ=_4YQ#H'W&
M_P!7I@&/[D'RPJ^MXMZ\FY9(BR;-Z[;1J2Z1%U4VK=5P*KI=4?;Q;$Q4Q`'#
M@2$.;[$P45$J9@,=FN.?5L<2[_85>K-5L+!69!A5[!<8&0%G5W2$>R:/G-);
MFDF!)-TW>/W!RR,BF95P+4Y$D&I!,0\V^*G_`$2N>^SQ*)YDY]M-ML9.5<=-
M)2J^I1U;;ZZ-_2XIZ-IQ#Y-IEN\J]E_<WUX:K[K:JY)*QN6L59]+DTNWTU2^
MI-K5(@;>.:W*/:>XM@Q=7<A=MV[=&M:N9R='IJSS:4!%QK.58O=1ZF0AO?R5
M88VAQ*>>3&&20=R2B0*BJ4AU@/:WD3D&Z;WNWNY]TIR<.UI:Q@NQZ=BCKI]+
MU;^;?=ZLN3@.QX&Q[.\?`J]NES[DWUE+7KW.7J]?1)^B6GHC/?\`&K_;#;<V
MO+U?='R3OW.NM=(F)*,.,\#+G_J3:D%$O,V:;!L<&[*RUM$+*+%.X8QR[B:6
M[#)+*,CB(C'9?1O"ZHU+K/16O:MJ?3M'KFN=<4J*:PM7I]5CD8R(BH]HD1%,
MI$D@\CEVL!.]=RN91RY5$RBJAU#&,(%P\`8`P!@#`&`6XVKKQ'9=27A$I5S6
MK''/&MAH]QCT4EI2F7.)\BD)86!%0[5B)&4.W>MA$I'\:X<-%!\2YP$#C:PV
M$M=6,I$V*-2K6R*8X;1.P:B1<[A.+DG")EF,U!NEDT%9>DVEND=S$2'84%T@
M.BJ5)VW=((@70P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`6-WSLBY:]@::RUO7ZS9]C;(
MV-7M=4V*N<W*UVJ@Z?,9JSV*4FYB&AIZ0;MX"C525?IIIMS&=KMDVY1*=4HX
M!9VY1W+NWZRW+5;[3M"_C+'I?:,'#M]77;84U;I"V2U1DH^O1C9G;:-5X4K5
M\Z<F3.H=X0Y#B3H`@)A`"TT'-O8?57'4D#IWE.]:Z/VA2I6W1M^KUVM>PW+&
M5U5LZNOW\.ZNMAF;);8V#L4VW07*BY5(Q063!,H(%`"@>R`FCQ/*.^[KF=1<
MM",K]5].)TI"OPNQ$*D5.,B+G6K"VV+KR)LK>J_G8=Y(%5$\O'K.$4#-UD#]
MI""4"\?'1+8VN65,T&_U9-'C]=JW,EMVU).8F-I+B,?2LW+4QSKP"/'\U:9:
MR$E$2O&HMVJ<.FDY*Z7!4&B3P",Q>*VR[S1>-%0?.-AZOF*=JWEA%O+;3;W.
M4J2I%SO4U63:^5F'E,GF+J;C'@(K.A8*>[9+`W#S)B8I.@%2P=!M>L:K9H*M
MZ(LD6RWIQMUIJ2K4BCL&SJ!U+?*G"[&AYR`NLE(3BQX.H^_OX/$)I19XDN@V
M<B<YG)D".@/Q_3/9C9+8O&V-H-D>A;K7QM>*[<=-`A]91M"USK;1<!<[)'S1
MS/%Y2V-)+7;UO'0)$DW*[HZ)U56[4%'*8%RN(O6C+2M"EM><D82V35FV/(ST
MK>QOTYJ&/,GL&Z3[`:4^G;)+TVL1LQ'S"9FR<,V:-W1!2(8G5,`*!(/DC69Z
MY:0V#6:Q&K2\]+1C!&.C6YD2+.U4IR+=*$3,X511`Q4$#F^XP>A<`C#?-#;(
MN^Z;*_CIG8>M862Y04:]M-B:]>4YO/MJK"\+;7KQ]),QML#<(L8Y:\/$8EP1
M6.46,9;J0"E_5`":^N]>UO5]6;5*KIR`L4GTO,/Y"9E'LW/3UAL4H[G+)9)^
M9D%5GDG-S\V_7=.53"!?(H)4RD3*0A0*WP!@#`&`,`8`P!@#`/PHDFLFHBLF
M19)8ATE4E2%43534*)%$U$S@)3IG*(@)1`0$!Z#@&+G0FKM8<193?>H>(MG=
M1^LI:\H6MGIIRV;26K.,]YL#1PXV'"Z93`B#QG!7F<$9QW7S+.8J'GEWIV_@
M(X.R)K8_W!?OHS/M1P-KX;P;!IW#RAOV-;?4[?JIPL6$_:5]E2:E9;;9WJB+
M:@O:G*:FM(RO#BO&8[Y*>1DR<,*II/3UE)]=$_@DO7X]>A9O>&L)1"M/)J>O
MUCM2"#UQ8Y).]RP2\(F\10<*.)-RUD@-',$VC9942J)%0!N01Z=I.H#J.X!_
MNA?=XN5XU6^;Q5G8WN1_Z6>!A=MW=]*K_2QH6=S;7;V2U[M--?1WYE<+V#V&
MZJW%Z?F[I=/QZMHQ`W>FZUO>L6/(C49)>E/7Q8U]VLW#EF!FLS$,5T?8*H>W
M[R*,Y1)4%R@9%?R&,0`+V=/U";%N4]YV/"WBVF6/;EX=-TJI/654K:XSE6WH
MM7!R<6]%U7HO0A:V"KME6GJHR:U^>CTU_F==I/?;V<:C5K-(%"VTXP*O7*Z3
M8?W=5W?<V0ENI2H&&7CG!`(Y5*'?Y.TQA,54`+5#@5W>=LL8ULX6]XB"2:"B
MYW!UBIH)HE()S+&4.($*F1,.X3"(``!U'`,/.^N=#N1M!-7Z9K]HV1L2=0$8
M./IL.K/R4FH<QRC^%C46SPQ44.SJL]>)%;IIF!1!-R`]2\H0=DXUQT[I226K
M26K>BU;T27S;:2]6]`^BU(3[7HVN./"2NPOD/N".QML/&K6Q53A;KJW.VQ&X
M2YW"K:=W_LMNFX_;_MU3&_V#91>54(F"*(II`5$EQ;+M.9N.Y1VK9J%F[W+O
M^GZ?:K4->ZSNE)5RC%)R=LY*J*ZON74Z;+(PAWV/MK_Q?X?/^2ZDHN'&LN1?
MR]2L!-<<Z%%(M]=>UB;A)1->'66D=)UAHZD%*SK:(G)5F9M/O?9$`6R#<)21
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M1^O0?7URF'N.UP!@#`&`,`8`P!@%FMI4.;DG,9L;7`L66V::U70B/?+'9P]Z
MK2JGN936=P<(E.<(284+Y6#P2*J0LH";M,IT_=-G0%84"^0FQJXA8H4KQH8C
MIW$SD%+(`SGZI98M7VTW5['']YQ8S4,\`2*%`QTE2"19`ZK=5)4X%:X`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@$;=H,G<[R#XP0Q!25CJ\?<NTY!HX[01\M:IL;KR,D6XB
MF8ZDHP>;<[$B=2E\#A<XCU(4!`DE@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@'&>O64:S=2$B\:Q\>Q;JNWK]\X2:,F;5`@J+N73I<Z:#=NBF43'.<P%*4.
MHC@&,+>_+"7NYGU0U8Z>U^F]R[.5N2?<UGK4F144E&]=`0*M!0"Y4Q`7@_[M
MXDH'B!`H=YP,?-8W\]XRS5\=GBTG,;9Y5E*DA9:)M3V"=JL(AO"M9.%GX<'A
M&KMU#-&I7;$4DS@Z8JJ"<Y5B'-KR^[K[*;_/_DC:?*NQ?TFW=]OV>>#?BYT\
MBI9,(V6VXWLW40E[4HSOM[G/2/Y?5-Z79L/(UM6'9@V^XJYV*2E'1Z/1)ZI^
MOHO0AQO3D+R'YG)6"B5U\=AJLS55"SPU9@9W6]&6\Y^@16Q]M686UK=0[9(R
M:CB+K:7OI),/&*J!#"<;`^WW_;1X3X]YCC>2/(<<3-Y+C2C;313.V=6/<FW'
M1M5P<J^G;;I9)OK%P:U/5NO,<G+QWAXG=&E]&WIJU_CZ_+H1<Y(\Q-6<6M1M
MM/04FE=9?VO65<JL63:1N5@$B(.I5:,9`1I"195&J*+5N3H1BQ00;D,)$@Z[
M2HQC"*A%:1222^271%DF"VJ<O]@--AQ-X6ZJN(IX[<N"+2C2-CS1+E%Q[J+?
M2#XI6$='NFQ>Q102B8`)W$`R@%`>0)#:]M^V^>;#9`CM2@<?],Z?0CI':^V;
M$M(J5F+;S#B5.PCJC&2!FR=JEWB48HJG^2<-P1*!"HMQ,<#CRAV.7ZC:CH_1
M)O73IZM=-=->O1:M:OH/X$9]J?(+J#CDFZTQ\;%.LCV^7U16O6ODC;8E:Q\C
M]I3]C=>R)'4@BJ2\A46$NZ>^-J!&I9-950OB0(J!%<O'CG&-QWO2=O=C;!W0
M=UFKBIJ#Z]BEJIV:.7:VNR,GKIIJGY[KH5^G6WKHOE_'\/\`$S$_%Q_:Q;8Y
M!RL7R/\`EFD+)4*3/)LK=7^,L';GS;:5J<2Z2<@#C=]F0(M)TLCE!P7W,>V>
M_N7R"=-RO'JIF3&ZMSYIM7'L2S8>$5]F$[G.4YZ6-R2[4W:XQE=VI?2FE5'6
M3A%JR6O1#'G;)6Y+^K3X=/\`#X?\?[C?.U5J76&C*#6]5Z;H%2UCKFH1Z496
MJ72(*/KM>B&:)0+VMHZ-000%=<P=ZRQ@,LX5,910QSF,88IR<G(S+I9&5.5E
M\GJY2;;?\W_A\CW)**TBM$7#SH/I&=82Z"OAG@F%AHC9,B<TAU`AXO5NW9^9
M3!.1$PF3-!T7:3R0,1R/11HRL8D4Z(ED5U``DQ@#`&`,`8`P!@#`&`1UV?&2
M>M;#_7.E1KE\@8\8QW?58U%9=2U45DG[4+W'1K-LY=O[_K5D`+(@@0SB6ADU
MF!BJJ$CQ;`7[BY2-G(R.FH9^SE8>78M)2*E(]PD[824:_03=,G[)T@8Z+EH[
M;*E434((E.0P"`]!P#JK?<:CKZMRUROEIKU*J,`W*[G+3:YF/K]>AVIUDFQ'
M$G,RKAK'L45'*Y$RF54*!E#E*'J8`$"W4MR0X]0%*KFR9S>FH8?7MP?*Q=2O
M$GL6I,:G9Y)NF^5<1]?GW,LG&3#YLE%N3*)-U5%"%;J"8``AN@%55O:^K;C4
MG=^J>R*)9J-'D.I(7&"MD%*U>/(DS;2*IW\ZR?+1C,J<>\17-Y%2]$52''[3
ME$0/,MM;5T`TJK^<V11(=A>9@E?I3Z3ML$Q9VZ>5!<R<-6G3E\FA.29P:J=$
M&QE%!\9O3T'`*85Y%\?D-A?TD6W?J5+:GY=O7QUN?854"\EG7;-"1:PIZM^5
M_-$EG$>Y37(W%$%C(J%.!>TP"(%U967B8)BK*3DI'0T8@=NFO(RKUM'L45'C
ME%DT35=NU$6Z9W3UPFBF`F`3JJ%*'4Q@`0.&^L]:C"3RLE8H*/3JL<28M"CZ
M68-25N(4;NG2<K/&77(6'CE&K%=0J[CQIBFBH8!Z$,(`?IS9*ZS?/(QY/PC2
M2CH3]RR$>YE6*#YC6P6<-QL#QHJN5PV@P7:*D]V<H(=Z1R]W4H@`%$-]XZ7>
M7N/U<SVWK5WLJ6B6L]%Z_:W>MN+G(PCZ-4FF4NQK24D>7=1KV'2,[16(B*:K
M8HJE$2!W8!WT_L?7M4I\EL*SWNG5Z@PW>$M=INRP\94XPR4J$$H5_87CQ&):
MG).#[(0.J`@[_1_ZGVX!P]=[6UAMV(>3^JMB4G9,%'R)XA_,T6SPUJBV<JDW
M;NU(UT^A'CUL@_3:NTE#)&,!P34*;IT,`X!7^`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!&B-24F.8EO=@L=)#7O&^A1O
MMS"95-ZXVSLJ_/SKM_O*1D>,1U`0JP=IS.0=I#U("(=X$E\`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`4E>+S5=;UF1M]SET(6`C`2!P[5(JLHHNY5*@T9LVK
M<BKIZ^>.#E(DDD0QS&'Z=`$0`Q&[FWU;]UNS-7I%:W0FZY58JEH+@=1Z*8!X
M9*W/4N@2C[NZF(T)T9M@,`""RA?,(%EL`Z&RVF$I\4XEY]^FR9MTCJCWG`#'
M`A1,(@7KZ!T#U$>@!@&OQSL^48J"LE0-4.DWLBGY6RCE$XGCHL?5,RBYRB)7
M3KT_T@(?\.G7`->N[6]])OY.T7J;7>6%X#)\DP?`\"6FT9`Q%DC,>C51JQC0
M9"*@+J"5,2B3L!0QPP"QMJO#F0;ORJKA`U4'1)'\&F^<J1C=5!!-NDZ=JN3F
M5?O>Q/J*BGH!S#XR)EZ$#NQ\>_+OCC8L)69$WI&,5JV_P1\;45W2Z)$JN`_`
MCG?\I$Y-Z=X@U]_&Z;CK'"S&T]OWN5DZOI2JS+=%>.CY1\H#=U^XK?'1DBN5
MLRC6DC,$;K'."2")C*A(>-QW9^-51W#ELU9F/K#%C]2^*^MIZ2T^,=8P36CD
M_1^1W67/LHZ1_P!1N9_%)\77##XO_DVMG$ZRUZN[TY%3G$76'*[1G(O9,81_
M=8]RQN=RU;O^!I\`X8#6:(5K8V45*12S,[N<".?N4W,@L0@$)0=\YANN]+]O
MW*C;DNV-4.B[5Z*36G<NBZ=(K3I$[:L>%?7UG\V;:V6H=XP!@'72\1%V")DX
M*<CVDM"S4>\BI>+?H$<L9*-D&ZC1\Q>-U0,FNU=ME3$.0P"!BF$!P"Q-)EY7
M5%EC=/7:0=R5;F5%T-)7R4=*NW,HT9M%7BNJK=).E57+F\UF.:J*QKU<PJ3T
M.D)CF4>LWBBP$A\`8`P!@#`&`,`8`P",#YI:^/\`+OW5$H-LV5J.T.G4A_3V
MAA7%++K&X/G*KZ3>59A9I^L1KO7=N775<.&17A5(:4[CMDE&KPY&(%G.1VX@
ML>@;I*7#6>Q],0%3OO'6:E+!N%&AP$`>+1Y#:V<2;PLE!7RT-VK6$9LC+O57
MGM4443`?O$`-V@1CVOL"$5WE2-K:_P!Z:IT]K&T;\L!*QN:_1<3.:EL4TQXP
M6F$OJU>_)W77L+,+S\@U:-RS+:1.U?K,%`2%UXE!(!?7:3AO9MO:W;:P4A[U
MK+E](:G-.W:G.VUDH4B[X[VY:ZW-T_F(5V^CD4+SJF,/#H+-U5"KKQ*#<W0A
M5E2`6?TM-:SJ.MT'/(Z.1EZ5L+CC&TW6->=Q#R8>7,A;AL-QM34=%@6W<^L&
MTKE+KP[MO$QR9I67;),Q;@I^.4]L!=;B]LFKUW?'(JDV#D+IN(3F=_6:.IG'
M>;_;\+NAM.R%)U<O&/5).3V&O8)[WL:U6%)B2`36-Y@-[E7Q=5`+_<YVLL^X
MN;)9P#]"+G'3W7*$/*.HLTXUC)13:=(*PDG4,5[&FEFS!T)55&P.6_F(02>5
M/KW@!"[8M7WM*7[<.CIR4U_O>Z;KLO'*/FF*D18-`TQWI"GL+S;]FPU@E(=7
M=\Q&Q\BPBR0R[]!%1592Q(-B)HF$%P`M=*C>F4%<-Q62!54W+QBX136I-RP$
M$O)V5W::76[1N&&V;"1+[\/`OK7*OHZKP5Q@5@8)J2!TTB)M2"_$A0*YKUOJ
MJU.MNI(6QP:V^+).<&YS5U):.VZ]Z3?P^J-!2+*^%KR0+3,=4*T6">N'\JY;
MEC4&[5PDL<>X43@5;-;IU2YXFS=(K._=-5+8E.Y`1LK-)3=FJ5A>:O:1'/*(
M]Y9[Y15+;`R36!KIG:)GH/',>DF!R@HLGW`.`9%=)WRM7VBL'D#N'66\7T.;
M\-:KWJAQ!#5WMC222=N$@BH"TW)M7W0,W:)Q9J2+A4A#E.)NAPP"[F`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!&_22Q)
MO9?*:UD,51N;<4%0HMRV$#L'T=K_`%'KM*0616^_S/HZ[3TU&/.TW8DO'BEV
M%535$P$D,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`.!*2D="1KZ8EWK>.BXQJN
M^D'SI0$F[1HV3,JNNL<?0I$R%$?YC]`]<`Q*[AV8^W1;B2KY)9K2J\X4+1*T
MZZAU$2F25MTVV#H4TY)I'$$$3]08-A[`_5.J80+/NJVHZ4*$0D=5=0>@,B]3
M'.8?7]`1]/\`@8?0/XX!:#>=UAN/]%>7F]R,5&LVZI6Q$EGR1E`<*-EG!>H%
M$4U.PJ(@8"F$2CT_GUP#4ZYG?(Y==[S+RGZ\E5(6IJ.3-59<[M)@+U,ZGB*"
M;ITJ@V8,NG^I8YB$`HB(CZ=V`8@IB],H\4#P*GY>771>A+/)B/;NXYHX74[$
MC195UW`R3Q-,#',Y<$!,#G`"IF$O?@$>K1=HV!^Y^Y6DI97L(C'I+"O(+F$.
MQ+RF-WB@G]``3>HAZ%*/TRYM@XING(9]V/'V\%/K=-/L7X1^,Y?A'X^K1TVW
MPJ77K+Y&U!\/7]L?N'E1*5_D=\FT!9-/Z!:J(RE*XS"M(5?:.U4E&X+-GUY]
MLHWF-:4A05DQ!,ZI+#(`10@)L$3)N%KKS-[V/B=$MOXJE;N,EI9D2TEZ?!/T
M?_MCI!=.[N>L5T1KMO???TA\$?0<U/J36.BM>574VFZ)6-:ZUI$2UA*K2ZA%
M-8:"AHYHD5)--!HU(0%7"O;WKN%1.X<K&,JJ<ZAC&&-<G)R,NZ63E3E.^;U<
MF]6_[?!>B]$>Q)16D>B+8;/,:K;[XY7A-LS]M:'&Q]$SCL4A!VFG;ZP39E9<
M+."%2(#1K.:@.S2%94Q2+RWC22,HX[R=!]))8`P!@#`*5NM,@-@5J0JMD;K+
M1LA[94JS-RLPE(N18.47\1.0DFV,1W%3L')MDG3)TB8JK=RD0Y1ZA@%OM672
M?4EK#J?8CINZV/0FD:]_.HH)1S;9-(E#+MX#8<;&E[2-'BSAFJRFVJ`"@QET
M3@GT;+M>X"]>`,`8`P!@#`&`,`8!8_D?NJL\>-,V[<%SA)*PU2IKU5*P1D2S
M&0?#%6:YUZHNY`C`K=T9ZC"ISWO5D@(8RB+<X!T$>H`6VMG*/5\38^05`"N+
M69?CAK#3VP))DQ8(/&=GF-UN-@Q^M]?4YL5DY1>V::<TIL@W*@"O<K--"`0.
M\.\#JGW(J_K3'']#4FEJ1;]>;T8-UH&T2FWUJ*_K+M&L3-QLT<_IS/5%J+Y8
M.'B%D@`CU-5:0[FZJ;<"F5P"A4^6NV'>HY+>CGCC10UTW0]U0C&WR#FTS$S)
MW]GKRG-YB#'398ZF%EG4D+AXZ3D)`8U$IRE*Z/Z8!655Y$2R^T7&NMI:7I]2
MV(WN&MH-%Y2]B,]H1Z<=L>L;)G(:7D;"OK^D/X:;8GU@\24BEFX.1:N6SM-0
M450``._KG+BI6QZ+&,K,N<A^1X<?&R[I4C=&126K<K9(K94:"[0A9"HS00CA
M)F9(3`OXA4(H)0Z8!+7M+W=_:7OZ=._M#OZ?R[NG7I@'D$R]3&!,O4_^HP$#
MJ?\`GW#TZF_XX!QRLV970OBM&I7HH@V%X5NB5T+8#`8&XN`("PH`8`$"=>WJ
M'TP"&5AY.U$%=_,*+K6.MUPU/>M8ZY*UFWK:G0&PI7:ETA-?&>(V]:LS@HP-
M8OSA_%RK@C20!-_#.$NT5``H`47+\P)VB&:4=YJ34=:VJZV;!4-[`.N0L-`Z
MD9KVBD66YU\KC;9M8I'_`*@2[2KF;H5A2OIRJX*D<)"HTZ+&`F[19RPV2IPT
MS;*@[H5E=HKDFZD\E&4X:'D6;QRP<D:34>5)O+Q+L[;W#%R*+95=FJD=5NW5
M,=!,"K<`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`\A]0_S#`(U<3_`&,AJ16ZQXG,WVELG;^T453=Y".(^Z;.M,C`.4FROZ[$
MCFM>R4,@H(JI*&,4_0P"``24P!@#`&`,`8`P!@#`&`,`8`P!@#`&`>ERY;,F
MSAX\<(-&;-!9T[=N52(-FK5NF95=PX75,5)%!!(@F.<P@4I0$1'I@&,W?^^$
M-G*(5JJ+K?L)L9N\<+J(K-CV>024*NW7715(FL2)8*$*9!,P`"ROZI@$"I]`
M(\(E*+=X_=.FD=$Q;91[+3$FX28Q44R1*)UGD@_<&30;()$*(B8PX!#[9W/F
ME5EG*PG'*GS.^K&U*NW?W:.51K6HHQ4C0K@%7FS98H14FQ(H=,#HPQ7ZH]>H
MF#J7J!J-_(-S,V9NN\N(B_[4;7!O`N7R9X.DM#1.O8IT=0O?!5A%41E)Y-BH
MGVN9-ZH(KK!T*'80,`Q5SEK?2#4[=PX390Z*JCL6XF232*<4R)G7=.C%(J<!
M21+]IC>(O3J!0$1$>4(66S5=493MD]%&*;;?R275O^`;2ZOT*^XH\5N4WR$[
M=:Z&X8:PE=@698!/9;VY36BM<:[BP2<*K35SN;IL>&K+'QMS`@=P87#Q;M09
MH.'!R)FEK&X5L/'=M_J?,<COW!NN==%4TZU%K5PN?;WSN;:UKJ^BN/6=DGWP
MK\#R;;9]F.OHZZM^O\5\-/Q?5_+Y_1#^)3^W"XH?'66`W%ML&'*/EX+1A(O-
MCW:$9.J)K*P"D"[I+3E0DT79F+U@Y4%(E@D3K2RX)`J@6/*H9L%K;_S+-W6/
M[+!BL7:8KMC7#HW'Y2TT23_TI:?"3EHF=]6/&'U2^JSYFQOEF'H&`1VY5M'_
M`/0VV6>'2(M-:P?53<D8F95-N9<VHK7"["DXY-TJ!R,S3D%7G;`RW8J*1'1C
M`FH(`0P$@FKIN^:MGS13RM7K=!VV5[#I^1NY2*L@IV*%(H3O2.`]#`!@_B`#
M@'OP!@#`&`6MVCKQS=&45,UF2;UK9=+<.)77]L604<-V+YP1(LC7K`W0.BXE
M:-;D&Y&LNQ`Y142*FNB9-XV:KH@<O6FQ&VP(E][J-6K-RK#_`/;^P*0^<).)
M*H69)NBY49G<(]$I*&DVBZ;V*D$P!&1CETER@43&3(!<?`&`,`8`P!@#`&`6
M<WWJT-T:PE-<J*QI&DS8M=R,FE,(+.8U_"U/8]2N$[#ND$/U#EFX:`79E_\`
M*!UP$WV]<`A13.`%DA++*#8]MRL]5;?8M?3=[E8Z7L-8VE,M])2VV5-+1K"Z
MUX\6_C/VS"3E-1=.D5DGKHU<5(98R3@X*`2#UWQME==26MXR.M8R-!U'M38]
MMHL?-O)F<L[.D;!U],18U:3L,LLZ?3$A#7VURBZ#ERNL?\0+=$3BHG@$7J9P
MDV)&Z:N_':9UCQ*@Z+>G3)S=+]3_`-PKW+:IX7:C2[M%=GT]WJJ%AY]6=@3O
M6C[W4R_%)9T;M,LD<X8!>QYQ#?TH;!&\>W&M]4U4^RFFYJ/76%1+'QM.V.[U
MI?*)9G*49%HFBW4,^E9>'F&S;Q$11<)O4A2%)1,N`6Z?\&[7JR6I<UQOLZ$R
MWJ:NF'JM1W[LW:,_'/)#2[2\5B#/"V-9&^OJ>R>4S8KQ%9JS8F:"O'L@(BF7
MRG$#(125KLO5HA;8\?58J['17&>CZ1,2\_56RX.W`-BP\Q/0=:EWJ)V`)&4%
M9BW$JPG*`&*!3&`M!<N*>B[_`'!]?;55IU_:9)RP=O'[79.T81JHXC&[5JR.
M2%@KI&0:!4D&28&*FV(100$3@8QC"(%_9`9`6#X8H682OLW/XPTB58T>$AX#
M^R%^5J8CDS('/;Y03$#BGU[1Z],`Q@V?X^)%M56P5::A-BVJPTRMQ.XJYO6U
MWNQZKV78*[O"C[\,#*K+H6B`HE:E[FRLX+-8^&%NFVG_`!%;&(BF5,"KZUQH
MVU1:I94Z3J'AC`)7NX1CJY<=V3.PLM`.Z_'U">@7EK92C/5J;I/9]CD'4<$B
MH:K^S<Q4>1J<QU0!T($L>/&M)G3^FZ5KN?E6\O+5]"9.Y48O9B2BHHDW8YBP
MM*K!2$^<TR^KE+92R<1&JN"HJ*,&*1A10Z@BF!>G`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`*,V/8R4_7=^MJBJR"=6I5JL9
MUVR9%G*!(."?R9EFZ2GV*KI`U[B%'T,8``<`H_CQ4W%$T+IBGO4&C>2KVKJ+
M&S)&)_*T/.HUN.&><(+=I/,5W,F75[^TO>)^O0.O3`+QX`P!@#`&`,`8`P!@
M#`&`,`8`P!@'J770:H+.G2Z+9LV247<.7"I$6[=!(HG56764,5-))(A1$QC"
M```=1P#$ER!Y%N]WNBUFB/I&.TVT.Z1E'@HJ,'.U7:3DR(="J%!RG06QD!%,
MOZ9I,YA$X>$H%.!8^2!PPB%WJKUE$KG2'VAWR1G!2=>T?.=H15N)B`01$A1.
M7J;IU^WK@$$MW[#I#A!1E<7A]B%;*F<MH>PJ)J4V.=`@*"B[&EH`2`3.8HCT
M4=)O'0!TZK&,`F$#6[Y__(S(6`\GI_4<H*+=OY(^PV"*421C&:7WD5AH0C02
MI`HE_I.9/M33ZB`=3>@`8%;-=8V&./O7*LE,.!`K>-;F,X?.5S_:BF?M!3P`
MJH(`'4.H]?M*(^F7+L/%-VW^:E1#V\%-*5L^D$OCV^CF_DH^OHVCIMOKJ]>L
MOD;*7Q2_VS');G":H;WYWFL/&OBK+-D+!7]7QRY(??.T&`N0-'BO"R4:^'7-
M9D44CF%Y+IEE543)G:LBI+$=%O&>]['PFJW"XTWD;M9#LMNEZ-)QEV]-$DI1
MC+LA\4NZ>L='Y_;MR6I7=*UU2/H1<6^)O'?A;J*!T7QCU96]3:TKX&40A8%%
M95Y*R*WJ[G;//R*SR>M-A?G^Y=](.7#E3T+W@4I2A&V?N.9NF3++SK'9?+XO
MHE^"2T27X)(]D(1@NV*T1(G/$<A@#`.'(QS&8CW\1)MR.XV59.HV0:J"<J;E
MB^04:NVYS)F(<"+-U3%$0$!Z#Z#@%@N*;UZ;1-*K,P_3D;%K`)G3EF<)F[@/
M.ZEG)"@.5@$>BHI/F\"DZ1,J`+*(+D.H`*&,&`2)P!@#`&`,`LILJE6%&88[
M8UD@@IL:NL21LI7EG)&$;M6DHKK/'%%EW2JB;-E-,UG"KFO2:WI&R"AR*&!F
M[>D.!7](NL#L*LQUKKBS@\=(>X14;/FRC"6B)./<JL)B`G8Q<`<Q,_`RC95H
M]:*@"C=RD<A@ZA@%68`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"-G+Q=Y_\>-@
M0L>X69/+XK3-3MY!$Q@-%J;BO]6U7^64(02'<M8HMQ%PL@4Q#.$4C)`8HG[@
M`D@FDDW330023000(1%%%$A4DD44B@FDDDF0"D333(4`*4````.@8!^\`8`P
M!@#`&`,`8`P!@#`&`,`8!Q7SYE%L7DG).VT?'1[9=Z_?O5TVS-DT;)F6<.G3
MA8Q$D$$$B"8YS"`%*`B.`8:N:_)&M[WKS;56N9&3&CMYUI+VN[(*KQC6T%C4
MWJ:5<@T#$1>O8<[A8BR[HPD17`@$*4Y.I\`@?`;D8ZVF(6LGE32M5;-'R4=!
M2KM>2/7W1_\`<NG42NL=5<B+HA3*BW4%1)%PF`H@F"RW<!$;D3S*0:K233\R
M#?PJ.$E"@L3N!1(YB'*4`-T^H?7`-<+F'SOL%K5EM?:ZE7#)NIW(62W-'ATW
M(!WB9Q#Q"Q/5/O+]KEP!@$H=4R>O<8`(U\9?CUYN\U73*/XN\>-A7YE+2S.!
M_J.O!NX/4U:=R2SA$TQ9MB3236MM8R((U77<BDJX7'P"D1)1<Z22GNVV&%9G
MU1W&7;@]^MCZMN*ZN*TZZRT[5^+]5ZG&?<HOL_-\#?"^(#^VSXS?'2I`[KWH
MM7N3_,%FZ-+L;])1#PFN-4/G#,J"K35]3F%E$Y&6:+*+&)8Y1L22$3`=L@P$
M!*-U<CYOG;PGB87=C[6HJ*@NC<5Z)Z>BT_RIOY.4EIIT4XT:_JEUF;*^6.>D
M8`P!@#`&`1MU0FC4MV<B=>)@#9G,2U+WI`LCCVD!OL>$<56V#%D*"2`-#7;6
MSQ^Z3(0RA'TJHNLH879"E`DE@#`&`,`8`P"-EJ9KZ-MD]MF%:*KZNN#I*3W=
M`Q[8R[FL32+-I&)[KA639$Z[INC%,6[:U-2=3&CVJ4BB7S-72;T"1K5PW?-F
M[UDX0>,WB"3IH[:JD<-739PF55!RV<)&.DNW72.!B'*(E,40$!$!P"!)=W;)
MM_+W8VAZ_O'5%$0H$G0#QVLI?2-HN5WN-9D:!7KW:Y4M]0VK6("%.Y&3=,VH
M?BUA:`W!4Q'`CV"!<(=W;%GM%<?;%4XVJI;8Y"GI,-$FDVT@XJ%7?SU/E[U;
M+*M"IRK&2FX^J56MR+M*."1:JO%$B)>X+W".`1UWSS4VOH2JS4:]K=0N.R:C
M)3&K7J[&,FHJKW#;DO!Z]N^G744V-,OGT%%7VCS<L=_$>61>QSUFJ#=P\1:=
MSP":VB=I/-PP-QNJ01*E,/LFU0.LY&+(OW3=)K!(V"_.OG(NWK"0/+VUC++L
MW#,X-U8L[01*5;RE`"$F[>7U]HW(':NN83:NK81W06VL":[T3):8O%SV+O6Q
M7:L.Y]&JPM[@=@QK"N2%KE6XQ;)0(1X6,!,[QP55$AP*!4]5W]O"_P"PM[QU
M&V=J6>GM-V/8[=/C*GJ"R-KM(1=1(2,@(Z0W*MM,U?1D9N8>-55'+>"5(!%O
M"1(!ZK`!2L]R`Y&+Z+W9?J/O#2$K;M11*=LFHNP\9]JTFR59<8R5<'UO<=0W
M3:]>ML4D^%%!TPL"[ULHNFBNC^.-Z+E`X6S.4^XM5;2LNLYC>6EI"[4:M:U&
M"UB''K8REFY"7"[MK"[2B*I(5O:EB4HR\\Z8I1K!N#*:,U604<KG41,8J0%Y
M8_>N[]H6^4U5KM?7U&N<9=-TNGMCM-5EKG#Q%#U38:96(6!D*]'76KK/;%<Y
MRVJHJ2C:0%%DE%KG!FIYDA`#IKGM+D_5MON0G+MK*J:U@M#3/(.V:[;Z>D+I
M>6#"ARE?C[?0(;91-TUF"EEYA-9Z=A+*0;;PB='R-1[#E,!2NW.3V]-+ZRG+
M?;Y[5*3V_P"JG.W];2K>C65S!Z<B8R[:DK=DK]\8!=T9#:Y(2%W"S=MI)DI7
M3O5X]P0[-`JB0@!?/BMNNS;:>["8.K[4=UU2J*0J,=N6A:UL6J:PO:7BTRA9
M]8_MZRVRYJS,Y26T<Q>.Y%F]%N49<K15))PV4[P)B8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!&_D`N#^P<<:
M6EVG=6KD#7)14J9RJ.V4/K6J7+9SV5*Q`0.X8?DZHPCEU1$J;8TFF<1$_C34
M`DA@#`&`,`8`P!@#`&`,`8`P!@#`**V+L>A:BH]GV7L^W0-#H%+AWD]:K;9I
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M0;_IVK;5J`/J]$VJ&5<FAY<R`2L%*1SQU#V"OG41`C5Z$-.Q[AN1RD4I'":9
M5.U,QC)DTX>;_$^\>#O*F\^+M\NJR<O:\GMA?7^2^BR*MQ[DO6#LIG!S@_R6
M=T$Y)*4I!VW.KW+!KS:DU&:]'\&NC7\G\?BC'35>4][W/O6$;TYG.R55JSU]
M+7:78,W;I!E$M8I\H,:15J@J+F=G5.QJP9)]5W3A8A4RCUZA%)[B_NH/A@^4
M[G?926"?I_\`\3=)S,HDJM;][+NXJ^/(%1=N1R_@M5,R*7!=^NW,HJ@25"&3
M5$O452E,0R@&QWP__MI/CDXTDCYW:%7F>6^QFO@74L6ZS)!2FT@DF4%'$+JF
M$51JZ2!EQ4.0DJ:853[B_JF.F0X`;`D1$1-?BV$)`Q<;!PL6U08QD1#L6L9%
MQS)JD1!LS8Q[))!HT:MD4RD333(4A"E`````,`['`&`,`8`P!@#`(U[!!*I<
MC="70C5,";%C-@Z%F77D4%4SM6!7W%2C>$`6_38AK6=2ZD*D41D.JIQ[$B8!
M)3`&`,`8`P!@'@0`P"4P`8I@$#%$`$!`0Z"`@/H("'U#`(VFXJ:S3,LG$6'>
M55C#*+'9URE\C-ZTZJ0B*IS'".K=6KFP(V!K<.V$PE;LV+=!JW)T(D0A0```
MNC3M<1-+L^Q[5'OY9X\V7-5F;ET))R1TDR<5>CUVB,TV2YD@>K%<QM;166.X
M565.X.<W=T$``",,'Q"N<53:_1G7)[9+Z)URO6I'33QO2]60TSK:9J/NF4,\
M,_C:JF6Y,7%<?+Q,BRDTU4)!BNJ!^TYQ.`%>?_%.E34#5VFQ9>1V5:X3<4'O
M6;N]BBZ\D_MFP("!<U)BN_A&<8G7HR&;TUP$0BR9MTDD61/M_5,HJ<"Z.D=1
M5G0NJ*/J"G+2;FMT2'"(CG<T[%]*O?([<OWCZ0<B!2'<O7[Q54Q2%(D03]J9
M"$`I0`I6S<>:K9U]OO7$S86,IMM]19L9:/68H2%&L^MXAA'4^STMS[(56,Q$
MO(Q!Z4ZHK=5R"7T3,)!`HYAQWV+"VBXO*[R8V!7*'=+=;K@^H452-5BM%2%U
M(NO+%@;I)5.0LC/VTVY,]:'6,Y,B?HF;R)!VX!U@<4Y2QQFUFFV=WW39LGM+
M6[75*TZ>K:_I;J!J#:0F)4J;9I4Z\RCYB3)(3:YT7#Y-?VX**%2*4%E>\"Z5
MJT/5[:;;"SV5GV3S:J=-65D8UTV:2--G:`T\=2M%/>$:^>/GH6221?(K*"J!
M7*!1`.WJ40+;S'%ATWF#V[66XKEJZ^.+9LZQ/+1'P%+M*;R,VT_K,S::JO`6
MF$?Q"L6WG*>P=,%CD.Z:&(J4IQ!=3J!7T/QXI$9(Q+UX[G[*UC]+R^CW\9:9
M,T\C9*O8)>/F9U_87K\BLG(2TJX8F(J/F*AXESE*F4H$`H%HVO#<)")3@]A[
MJV#L:.KM;C*7K4\K#T>'E*)4F-PH-O>1RDI!UYHXN,E-KZN@F[I_*@NX\310
MR?8JX6.8"3->H$75[C>[;#NGK9/82D%)3E=**18,EGAF:\4ZMC-`B93HS5AA
M2,6K\W42KEC&Y^@'`XF`KS`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`(WW!".GN4ND8TZWD>4;5VZK^=N@H":K
M1U,R.MZ%"+O0,40682#"6FBD(7H85VP'$0`G0P$D,`8`P!@#`&`,`8`P!@#`
M&`,`Q%_)C\T'$3XRH4D/L.:=;+WM-1KQY4]#:\<QSZUCXT4S,Y2_/U7(,-=5
MATNX3`CA]W/'9/(9DT=>%4"9@_:[]DOFC[J-U[N(XJV_A-,TLC=<N,XXL.ND
MH4)+NRKDM7[=>D(M)6VU=T=:!O7(]NV2'Z\N_):Z0C^;^?\`I7XO^29\Y[Y#
M_E8YA?)-=V\MR!L9HG7L6NY)0='TD[^KZIIJBRR8-I-:.=O#FM-D;>^2!27F
M5W#D"J>-([=N8J)?T1^&O`'VV?91Q.S+XM;C9/-E3&>;N=_9DYM\8QG*=5:@
MI/'IG[5G;5C5Z_0Y.-ML7)Q-N&Z[QR.]1O36-K],%K&*^3?S:U75OX_!&/74
M.B>1W*.Z2]$XN:6V=O&TP)6KR2B]<5:0L;N&CWT]'UV/DII6**Z8Q+-:6E&Z
M1EUEBH)]YCB<$B'.7&?[B/O[VO9Z%C;;D5/+G!-J,VH*7;W-+W%"3Z:Z*<83
M:]81>J58VGBT['K-/M_Q_P`-395T1\(?+[4NJ^,VQ><=*VE`<96^[:_5N1FK
MM9/6\YO:K5O;%@>-T;RU:LD9*,K6I*':$XMO<7IG9'3:-EY*48@)6Q%CZ%?/
M'E'(\Q>3,WG.3%1LOC77KIUFJTTI2?J_72+?5048]$DE*&UX2V_#CC+T6K_O
M_M_>;^FG.&G%'C[7J/5]-\>=24*,UJ>16I"T12H56<@'TPFW1FIAO:)!J\LK
MB>FTFB17K]=VJ]=@D3RJG[2](=*@26P!@#`&`,`8`P!@#`&`1PY7INF6E9R[
M1S<R\EJ.>I6Y6_B$@.@CM7VZ&MMN19@L<C4SN2HL=*,R`MU2ZN>IOIU`"0[1
MVUD&K5^R73<LGS=!XS<I&[DG#5RD5=NND;_S)JHG`Q1_B`X!R,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!&VH(%FN5.[;"H0BR=.U5I77<4JJ`
M$<1TC)RFR[[<46Q"`'>REX^7K9S*'$1,LS$A0*"8B<"26`,`8`P!@#`&`,`8
M`P!@%)7N^T?5U/L&P=DV^MT*BU.//*V:X6^:CZ]6X&.3.1(7DK,RB[9@R1,L
MJ1,HG.'>H<I"]3&`!JFR[)O')-VQ]AX_BY&=O>7:JZ:**Y6W6SEZ0KK@G*4G
M\DG\SA99736[;9*-<5JVWHDOQ9I*_*M_=)N98]HT%\:HOHI`'XP<MRUEV+8C
MJ3;"0J3XFFJ78(X5&""BJADDYZ7(DX'M,=JT3#PO#;T?M+_VGX86)3Y0^ZN5
M=>%75[]>Q0F^B2[HRW'(JD_@M98U'<O1663^JDC/?><]TGA;'JY-Z.W_`/PG
M_P#V?\E\32OV%>9$\]8)*^3BMOL]IEE9V7L\Q+#/S\A*K21_=NK'*$<R$B^7
M?H]RQO"\$3G.0WD.`"7-@W/ON'X'X]XA1_V`EM.T[;BNBO&A5+%I<72G%8==
ML:JU*NUJM3R,?HH61]JMN,BU,7:<K+R'^Z_4LG+5MON?K_F:U?5==$_EU9L#
M_%%_;5<H>?"U0WSR\=6;C=Q2EP_),6#TXLN0.UHA`QB,S56LS<8_3H]7DCI"
M!96:3(NHV$JS-DY1437#2G]QOWS[GR.^_8>$OV<;O>O9I&M-OZM>WMZOXJ/5
MO\THM:$C;1QF%*5N3U?X^I]$KBAP^XX<(=106D.,6JZUJV@PC=L19"&9D-.V
M>1;H^%2QW>S.`4G;E:'H=16?R"Z[@_7M`P$`I0UJ;OO.Y[]FSW#=KIW94VVW
M)MZ:O72*]$OP7_$O&NN%4>RM)1)"3,/%6*'E:_.L&TK"3D<]B)>,>I@JTD8R
M2;*,WS)TD/HH@Z;+&(</X@.4LYEB^/\`,3$1&S6D;G)OYB[Z6")A`GY3W"CR
M\Z[D47/].+ZJ\63$CV1DHF.5CY4WE65"9C71E!Z*)F.!(;`&`,`8`P!@#`&`
M,`8!U<W"QEEA9BN331&0AK!%R$)+L'*22[=[&2S19@_:+HK$4161<M'!R&*<
MIBF*80$!#TP"R?%N;EYC1-"964XFME):2FKK@!S.#*_NG54Y):[FUE3NSG=K
MA(/*T+I)=0""[073<`0A%2E`"0&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`C/QV<C/3O).[*E$%+!R+ME?:)K""KIA$:IK%.U.E'BZ_P#48N9R
MFR,JW2*!2H!*F(("IY#G`DQ@#`&`,`8`P!@#`&`,`Q8_)9\N_%'XR:69QM:P
M#<MSSD2\?:\T%4')%KK:542$*W>3CPJ#MA0JL9PNF!Y*1`HJ$[_:(.U$S)AE
M;]L7V<^8_NHWY8?!L/\`;\3IMC'+W3(3CB8Z;ZJ/I+(N23TIJUT?;[LZHR4B
MA[UR#;]DJ[LF6M[7TP7YG_\`1?B_Y:GSH?D8^73EU\D]V6>[IMZ.O-+(+,W=
M,XXUJ9L4)JF/:HJ$%A)RZ0*%=WZS`JD"ZLM)";Q+";V:3-`00+^BKPM]LWV]
M_97Q6S)XW5;O7DCMG#)W;VL;)SJ[%'6==4)OLQ*M-81H@G*2T]YVS7>XEW'>
M=VY%>E<U7A_Y:]91BU\&W_F?XO\`EHNA`?CAQ\Y-\R-JH<;>)^LY[;&PY,5'
M$S'0D7%.(>M1`/2PLE;K+<GJ8,:?3F/O&Q%7SER@B8ZI2D$RADB'QF^YS[W>
M*X%D=WQ[7+*C7%XZA?D5.,?HMKA?CQLC7.U6.QM3A*45%1[7]7;6=FXW?)>V
MU].O75)_@]'IJEIH?08^)'^V2XY\'U*_NWEJ:H<J^5$<]C9^`4<Q4@OIC3<R
MP.FZ:GHU;G12+=;%&/TBK(3\RP1506(11HS:*D!0VC[R[]PG-_*VYVWYN3?7
MMTV](=VC<7\'HWVIKHTFV]6G)Q>BDG`VK&P8)1BG/YFT9]?4<@(J@P!@$<-[
MLUJ8_J'(2&:`=UJP\@SV21JB8\A.:,G43#=&J14NTSM>DRK9A9VY#B8PDB7*
M"(=[L>H$AF3UG(LVDC'NF[Z/?MF[UB]:+)N&KQF[2(NU=-ETC'27;N$%"G(<
MHB4Q1`0'I@')P!@#`&`,`8`P!@#`&`1NU`5Y6MP<DM?K(F3BU;33=QU@5%$Q
M,$7M.M&B)YN@F0#G]I_4#74RZ`ZJ@JBL]4(!"()H=P%Q=J[-9ZMKT?+*P4M:
M9>P6.)J%4JT(XA8]_8K--`Y48QB<O9Y2#K$.4S9BNJ*[]ZV1-X@23,=PJBBH
M!;>8Y$N8N-IK5#3.TI/9EP"WKDU"DG48ZV1<5KQU$M+Q.*S4U:(ZBR\/$K6&
M-*U6CI5V$J,BA[,%0\PI`=*XY2?G;%%P6G-0WO=K>0UG5=J+SU7G]956)C(&
MYS]PKD''NT]CWBHRPSP2-%D2NVQ&PBS,D!%3%5$2%`J'3^][/M*Z;!ILQH?8
M6L1UI(M(&QSMLLVIIF+-9)"KU"ZQ\)'H478%JEG!W-8NK5Q[@S9-L0Y%$C'`
MY2@8"N=F[13U\-?B(FJSNP[[;UI(E2U[5GE<CYV;:P*#=W9)<9"VS=>KL5"5
MYJ[0]RZ=NTD_.Y;MR=Z[A%,X%D9[EZRCWK5&`TUM.UL&6IF>YKY)H'H=9'75
M17G;+`/D)R'NERKT[*ST.[IDH9=M%MGI3D:@*"BOE2[P.6\Y:Q<E+,J_K#5F
MP-L3LA:+37FK*!?Z_K*"S.ITJ@WI]922%\N59:_B'D7LJ+3;IB(/3+G4[T"$
M3$X@2!US?H':%*@;U6_>%BIU!T(-I%L+21C9&,D'</-PTBW[E$R2$)-Q[AFN
M*1U4#*H&,DHHF)3F`M9+\BX>)NTM61I%R>UB#M$5KB3V6U4JQ*FUVQ8&4(\K
M>NE6;RQM;0D^GU;-&,6\FHP)"_DY%!J=V50QNT"FKCRXIU;I6M;?"4V[WISM
M>!C)NK5BO?M1C,(*2UVUIKAO$S[BS6:#AH:2;WC:T7'.2G<F*W6*OWB`)".`
M?J;Y'7>OJ4>#?\9MI?O_`&%.6R.KU#1N6D%'_P"&IE>83TM:7\__`%."JM8U
M0T@1J@W!X=^=<IC&0*ET4$#U0?-'1\N%Y*ZE)FON];:*<<A;JRFHA<JT-0X6
MV;/HET3*JP,^:24S0;AJ.78RB+11<@']NHW.NBX24,!X5Y>TEQ"UVUURI76U
MTQQ0J/L[8EHB$Z\1IIZD;%A6UAK$I=6#^>:RTB[/!KG?.V4*A*/&3!(7"J8)
MJ("J!6<WR)J4-JS=&V`@[/(1&D978<)/0[1&'3FIV3UR<R,BA7?>3#:*.G*N
M``C11XY:$^X#*BD7J(`5-KC:G[W>3-;L5.L6L-@U]%G(RM`M[RM/Y?\`;TH=
M9*(M,5*5&<L5<G:_(.&JS<5FKM0S9V@H@X(DH!0,!=G`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!ZU5T
M6R2KERLDW;MTSKN'"ZA$4$$$2BHJLLJH)4TDDDRB8QC"```=1P".O$EHJCQ[
MU_)K>0#W(;;LP$U"F`6Z6UKS9ME(-$U##U=H,F]J*BDYZ%]TD0JH%*!^T`)'
M8`P!@#`&`,`8`P#HK/:*S2:],VZYV*"J-4KK!Q*V"SV>780->@XMJ3R.I&8F
M91PUCHUBW('4ZJRA$R!ZB(9[=MVW<=YSZ=JVC'ORMTR+%"JFF$K;;)RZ1A77
M!2G.3?11BFV_1'&<X5Q<[&HP2U;;T27XMFE=\IO]TRW:J3.COC-`KN6(^DH"
MQ<G[?7V;B)*)#"R(KI.M2RZR$D)G'<8DW-M/:F*4#-V:Q#$<YO"^TO\`VFLG
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M5JB`-Q3U=3W,>R)!U^5.B8B<Y,()LTT1*LT;20=<T7^>_O;W3,LR-EXQ95/-
MUG7[M,;J8JIR<HQFK+[W*:U^J7?WS>O_`"EH29M?&X12LN3[?71Z/K^&B73^
MW4^BCPUX,<7>`NIHS3G%W55>UW7&K2/3GYQNR9N+SL"38-O;A9-C7$&J,O;[
M`OU.85G)A(EWB1!-)+HF&M;>]_W?D>=+<-YOLOR9-O64F]-7JTM6]/Q^+]6V
M^I>%=5=,>RM)1)<91SL&`,`8!^3D(H0Z:A"*)J%,11-0H'34(<!*<AR&`2G(
M<HB`@/H(8!'#2@GUS8[;Q[D%%2,:H4MPTV=TY6='D=-S:Q$2023IVHJY</=6
MVPSF'52,=4Z$0I$*J'[G0%*!)'`&`,`8`P!@#`&`,`8!'+9NJ=H2>S*]MC3>
MP*'2[,THTQKNT,MD:YL>QX*=K[J=C++!N(QM6MGZQ=P<Q!RC9V4RJBSU)R@]
M$HIIF3*<0.HM='V]8M5SM:V[3>.G*)Z_L4,Y)0GM*D]84%]`L%FKU$\DSOD[
MOYH_L<)/-4W[58Z2*0>,H$*18A51`L]1M7<C]7N*7>X6G4JU2<;';7I!M52V
MV99`M'UQ:+95+5K>"AMER%,EE+`2E'@'S94%V!%#M9!L@FIXF)`$#OM$\1`U
MIL6I7^VJQ,_,4O1%)UY`2T9)6!D=A:D+WNBW7CMABKMXN0@CM=DM&S)=V59<
MXH*'\3<W3N`D7KRB3%4O6_++)+,%&&T-E5RWUY-HLLHZ;QD3IC5NO7*4JFJW
M13;O#3=*=G(5,ZI1;'2,)@,8Q"@4'OR@;#F)^@;'U8T;2]MIL+LRDKP[BUM:
M0Y"N;4B(-%]8ZY97M4N<>RMM6G:A&.&A7<>Y9JH&<%43,;Q]`(MS?"6^;++&
MV_<4W"7K:-=T!KFJP$W8)AXZ92NRZ+M*Y;)/$;)A*[!U.FW:AV-H_BHB;[XH
MB,BW]X9)FV[R8!7RG#P]TVDXM>T&,'+4]SM+;^Q4X:-M%ICI1H:_ZZTU4H-(
M74&$$JLX8NZ/*%<%\_A\2B!R@8QA!(";]5JU>H]9K]-J,0R@*M58:.K]>@XY
M/Q,8F&B6J3*.CVJ8B8P(M6J)2`)A,8>G41$1$<`AT^TWMXTQ8=9,(.IDU)/\
MCZSR$0V6M<70VF(1B]G5#=LU4%*(%:'\G(25[KKMFV>?EDD&L:^2-XSBU\2@
M%L-A\+K;(17(-"*2K-UB;;<M.R.I*#*6&5I"$90Z]OV+Y%;:ITE:X:->+PZU
MKO#^5)'+I-W!VC9!FF"B9!.!`*HLG%>0WM':;KVS->,=4TG5K;;U?3K]0W1:
MK-96,?=Z(RK=<LU:NS2%KLD2;C7KMZ/C>"L5`4TENY81`B8%`W;A'L6^1U=3
M6<:TJ#HFI-6Z#NL94VSV/K4UJ6,G-AGW!5X&+:1[,:Y%6]LO6)&/22/WMG#-
M5N)B"1-P(%5O>/&\:U4;EKNJPM%LT3O316K-5["L<E='L`KKJ>JVNEM4W"5A
M89*I/C7&!?5A5%RP3!5@Y(\16!0?&JD"0'YGM+\A1UKR>T7!Z]U^O6-JS.Y9
MVB7YUMAZU4(2XQQ'M3B)ZJ#KUV\CCFDD"L7;A-Z[!`@^X*57_I8!)+6]0V).
M;3FMU;4K<#19HE"8ZPJE+KEM4NZ36'"Q.K58['+V,T!64EW<[("P;MF:;3HR
M2CU%!64%UV(@2.P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`6=Y#V-Y4-";JL\;[896$U5?W\*F\(91JX
MG$JO*?@V:R1%$3K%>RQD4>PIR"<3]`$!'K@%6ZVJC2AZZH%'8%=$8TRDU2J,
MR/E4UWQ6M=@6$.W*\623226=E29@"ABE*4Q^H@`!Z8!6N`,`8`P!@#`&`8T?
MD3^5_B)\:E)<2V[KLWFMHR$4:0HN@J:[9R6T[J90YT&;D8KR"E4ZPJNDH!YB
M5,V9=$5"(BNX*5`^3?VW?:1YE^Z'D<-J\>;=.&P0L[<K<\B,H8&*DM9*5NGZ
MMJ36E%/?:^Z+DH5MS5&WC?MOV6GORY_JM?3!=92_E\%^+Z?Q?0^=G\F/R[\O
MODXL*;C9+N0U1QC3DG4M0=$4]P\<TUD:MHILUY:PS2<<QE-E6U):1`JCUVB#
M1FJY'V[5HD!P#]#W@?[;?MH^R/:KYXN1@[]YRQZJ:\K,R951R*YY:G*J%54Y
MNO!HG"JR<8*:NNKJ<79;9*M.)]SWC>>232DI5;8VW&,=='VZ:ZO363ZK\$WZ
M):F-'1.G-^<I-F0&D.(>O;GMO9-I4D6B\)3F,J<\1"R)@C1E[U,MVC"%K=68
MMG!3KOGSLK)`XJ%4-VF`IX.^YO[T=GV_]UA\BKK=N,\:>/#]"RGWJW[CG3W6
MW60FK(M2;JKG*M53K_5BW&I;-QVR?;*EO1ZIOJGH^G7HD^GXM:ZZ]#?>^)3^
MUWTCQ/>06^N=[JI\H.2L?*Q]DJU.:$E'FB=2R+!1N]9+HQLPDQ6VI;6;]'R^
M_E6:,:W/T*@Q,HD5XII"\P_<;S/REFS@[[:-FZJ-:>GTZ]$DFU!::+HW)_-)
MN))&W[1CX4==$[/F;8Z:::2::229$DDB$3223(5----,H$(FF0@`4A"%````
M````S'3UZOU*N?O`&`,`8`P!@%A=]U2>>0<-LJ@QH2.TM0/W%KJ+)(J8.;1"
M+I)-K]K@ZHE(LHTO5:1,1!'RI(A--(YRH(@U`,`NW5+3`7BKUVYU621F*S;(
M2+L=?E4"JD2D(:99HR$<[*FN1)='SM5RF$BA"*$$1*8H&`0`#O\``&`,`8`P
M!@#`&`,`8!'7D9OHO']GJ":>0*DU!;!WI1]265V@J0B]6B+M'V0J5L(B99([
MM"'FHYG[E,A55/:**G(F8Q0Z`1VN/.62B9+DXPJ>O36;^A6T-9ZTJW:L=)78
M+F1KRMNW+*L2'=("++6<%7K&D`E`IUGU>=$`JA0*)@.\O.\.0$'MV10K4SHV
M7TL7C]<^1$*1U1=A)W^1KU51@VK2O*V#^I#:`1=S;^;*Y!\,.`-VQ?"+0ZGZ
MH`6U1Y8[6:<<EM^*[WX47.O3-FT;2(ZZ4V*M*&M=:S^S=@T2LVI]LJ?5WI.L
MY!G582Z$5!HF]AEBK^,RZQ"'[,`N'K+F&\EUX$+G(:[L%*)#;^GIC=^N6MA:
M:VNM<TS"ZIL/[UUBSDY6RNGM5*78;Z*=KD?R:#B1@UE&;A5%0H%`K+6O)ZT7
M5OI)G8=?_LFWWK<5\U/LFHRRRIY"B.ZUJ&_;?@A:N&R[AD^?RU<A819<OD4(
MW"161-VN$3$(!,S`*+-LC719`8DU^I)94KW\<:,-:H$)$)'S^V]@+(7_`+D'
MON?T_%V^3O\`MZ=?3`.ZL:5C6@)A&H/(2/M*D<Z)7WUDC7\Q7VDN9(P,7$S%
M1<K!2,C&I+]!510>M55"`(%5((]P`8SZYR4Y4R<#I].P7'BC4;!MZZ;OB6U@
MF*%LAM4*_":5?S<`NS48/MW,'TS8;3*QI'22A7[5%FT*HD*+@_18H'<L>6.X
MKWL;6&K:U:>,>JK1<Z#;+*S3V*%IO".VY&J[0G*#[_1J,9?]7RDS4IB"KPSS
M94[9\X%B_0,)?"7W"P$N=L7&WH6K5NKM=24;&76\24O9IF4D8W\LR@];:\:-
M'MHD%HWSHJ*IV"T3$'7PZ*)*I(S"JZ2@*MR@($0'._>6U<I,Y9+;:.+2*QN0
MT-QW@GZ6N=G0T%#R3C:D?1Y&[6893=;H[^-4B17.WC4'#(Y'BB7<\.0IB*`4
MY9N<5RB'-$K3S<G#_7Z[R7Y`P-AW%?$[,KJB_P`OI-UIUG^*U1$%VK6Y1&7<
M2&T'L>]:*2\RLE)5]TD@"X"4P`9`]%;$F-MZ<UMLRP5)U0YN[U*)L4G4'OY@
M'$"[?H`HJQ,%A@:O/`F`_>F#V-8N@3,4%4$S]Q0`NO@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`C1RO6
M]SJ^&J!3]%=E;?T?KTZ!P$&TA#3NV*DXN44^6`IC-V<K0XZ5;F.7HH(J@4@E
M.8I@`DP/U'_,<`\8`P!@#`&`=3/3T'58.8LUFF(RO5RO1CZ:GIZ:?-HR'A8>
M,;*O)&4E)%XHBT8Q[%HB=5954Y2)D*)C"`!GIP\/+W#+JP,"JR_.NLC"NNN+
MG.<YM1C"$8IRE*4FE&*3;;22U/DI1A%RDTHI:MOT2-,SY5O[I2MU=.RZ-^-?
M\==)YQ'/8B=Y3SD<\-6JV\<`Z9.1U!59-LU-9Y6.+VJMYR2(,4"O046CU+M5
M'=E]HG^TUO/(Z\7R-]S\[-HXRI1MKV:$XQR<B"TE'][=%M8U4_25%;_<..JE
M.B6L2.-^YU72Y8FRZ67>CLT^E?\`M7Q:^;Z?@S2WVUL&R3=ND-N\@;W);SOM
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MVOC<>EMZ2K7HM%KHO371+K\]-%K_`''T:>"_Q\\5OCHU`TTYQ=UM'5"-60BS
M72Z/4VLALC:4Y%M3MD[/LBWE:MGEAEC"NL=-("HL&7G439MVZ1O'FL7D/)=Z
MY3N$]SWN^=V3*3?5MJ/<]6HIMZ?BVVWIU;9>=5-=$.RM)(FKE".T8`P!@#`&
M`,`8`P"-%#.&IMO6+4"W:WI.R!L&V-2*+N!(DPL+V2,_V]K9@5P8WE\$V_&T
ML$B'$X-I9\BDDFUC2]`)+X`P!@#`&`,`8`P!@#`+1[@T]`;GB:[`V9PNG#PL
M[+3#MDBDFI^61F->7K7KAB=4QRJ,C(M+RHZ273ZJ).&R8EZ?4`(QP7Q]ZL3D
MZPIL"14VO78)K!2LK5[M!L)!E<-H0U-FZBXVQ9G2[ARXDK3-FNMDD'8*@H56
M0G%5A,)TR&P"X\+Q0@H&+1A6-PF1BHS1.RN/==:+,FRWX&B7>T(3-=;-E5%S
MJ+!KV`8-(=D0_P!JS5J0QQ*;TP#A5[CWMES5J[3-K;NJUVK].LNE+36"5'2X
MZZD&\CIF[UFX-B2[QSLV[H2C>PIU=%HH5-!J9MWF5()N@)@!UMLX8U>T&:Q(
M6Z1CJ"W?;'9?T_2@XQ:$'7.WY[6%AV3JY%0%4#M:M8W%#D6X`F0!;L;"NW(7
MQ()%,!U,[PN;U^VPMNXY7.O:&/"VR(O*=4_IFC=J(XMK77FSM6S=B4KR-PIC
MA"7L5,V$V;+JHNTB]8)F)RJ@'0H$R*NSL4?785E;9R/LUG:Q[=&<L$5`GJ\;
M,21"`#E^RKQYB?/#-US^I6XO70IAZ>0WUP"WA^/.@%)XUI4T9IU2SGE_W`>Q
MGUC233QI\7OY(9PTP:$&1-,#(_[CW(J>?S??W=WK@%X@'UZ_X]<`B*EPYUH^
M;ZCCKLVA]CPFI9S=-@8P%WIU=L$-,2&Y)R4FG*[J/ET9!HS<5L)=5!LJF0RB
MB1C=PE[C`(';W_1>Q7VU8;:6G=K535SEEK1KJV3@+!J$NPXES!1EF4LD2M"`
MRV#0#5Y=F9RJW,3M=(F2%/M*04_N`J/5M=L$EL?;NVK=&KQKJ:DV.M-?,)!D
M5K(L-9:X5?(C*'3423<-BWR^R<O*I`/7S18QQC"/:4"`=#:N+E.NM0<4>T.D
M;!7'W(1MOZ3B9VOQ,S%2KMM?$[Z6HR,3(@X8.X@SY(J7E4(8X`4#@3N`,`JF
MV<?:!;Y:JGD(J-;4ZL:EVAIQ+7["&C6=;6JVSGFLW#E-JW;I)(Q)8%#6B*31
M)ND4A2N1$.T4R=0+H4Z%E*Y4ZU7INQOKA+04'&1$A:Y1!)M*V1S&LTF:DY*H
MMSG;EE9/P^9R*?:F=<YC%*0H@0H%28`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`(W;J<,I+:/%JE.4!<'
MD-L6.]J)N$R*1RC/7.J;TNB58!.)QD6EHL44]9AV"0JK,5.XATTP,!)'`&`,
M`8`P#'?\@_RA<3/C6U\G;^05S,YMLRB<:-IJF*1<QMB]*@5<`<1-:<R3#\=7
M4%D!(XEWRC:.0.()BJ98Z:1\B?MV^UOR_P#<[RC_`+<\9[?*>'6U^YS[U.O!
MQ(]/^=>H27N-/6%,%.V:ZJ':G)4G=M[V_9:/>S)_4_2*T<I?P7R_%]#YY?R1
M?,ER^^462F86SSO]$N)49873VOZ5I:CT[5^RCQ%=DOL"39%+,;4MS.,#W!DU
M@;0;=R7R(MFQ^U0?T(^&OM>^W3[#]NIW;<(0Y+YYOQ8?]3DNJ$:9V/LBZ/=?
ML[=BSNTK]W6W,G%Z+WDG&,4[AO6[\GFZX:T[6I>BUZZ=>NG6<M.NG2*_`Q?Z
MNJFP=R;1B^/O$"B[$VGMRW=L3#Q-*@$IJ0E5GS9JRF)"QK#&IN*Y6:VLNJ9=
MV=<D4T*0CQ54OC[AQ\^XK[L,_/PJ=R\A_P!+EA.[W(8"MR(2QZJ[ISHG3[-T
M\><\B"JE99DPAD*MVXFBC/157:=BC&3AB=_=IIW:+JVM'KJDUIUT2>FNDO@;
MF/P=_P!OSQ>/)6+DIS/V#KSEQR0U1LVSZ]MG'EBHTG=4<=MDU;N83-2V[3IV
M+;O;=LJ(>*F>-2O6J$`#95L^8HODU&S\VG+RE]P_).=16T;,Y[=Q>M:5TPE)
M-+\6YRE)]$G.<I3:2ZQZIR#A;33C?J6:3N?JW_;_`,C=,:M6S%JV9,FR#-DS
M;HM&;-JBFW:M&K=,J3=LV;HE(D@W02(!2$(`%*4`````S'9MMZOJV58]^?`,
M`8`P!@#`&`,`8`P"TNYM?R-^J)/VP]0A]B4^68WC6,^N*J:$7=X#R*,&DDLV
M[7G[8M3)5Q"SB*1BG=0LBZ0ZAY.N`=[J_8$;M/7]6O\`%,GT6WL<;[AS"RA"
MDE:],LW"\;8:S+%3$R(2U:GF3E@Z\9CI"NW/V&,7H80*]P!@#`&`,`8`P!@#
M`(^\CGLR[J%8US7I%Q"2VZM@0&KC6!JY79N8*O/6,U;;X^9.6O\`NT)=QKVG
MRS2.42$ADI%RW.)R%*8Y0(>[H+LS5FQ.5%PKF^]Y/(C67%^*W13-8&<Z[D:?
M&VBVRV^H9>+B8D]`9S+YA%,Z-'!$,W,H8B;I(!54.!S]0+H7CG)&ZTKSX^Q*
M3#4.^);C_H\RK-NV=#Q-34E%=31>]6SF2V.2!=QL6\-K:5(4[4&;A,)TIF:;
MA5J'Y'`."ZYU/'M;E+]2M"W*U:]@-;:LV-+RSBTUJ!LSL=M/I**@*35:<J$@
MXF[@UD628JJ.G4;!JM'!%F\BM_TQ`KF+Y4V4EK7K-RTO(55O5MDT346R[`UN
ML?8(NNWW;9*LYU<QJ12048ZO<3(,[S#?G'8DC!A7#\I$TWQ$EEDP*97YIRB%
M5B;4CI26ED]BLM9631L/#WJOC+;%I6T-J4#5<5*V$9UA7XK7<_'/-EQ,BXCE
MG3]$6*XE([,X350(!^+=RHFJG/P<E;J[*U@U#AMQ,]N:R@7\1:CR-NA(O4$G
M0FU6M+UG7DI>/G6>QVBK!VJ6)3`)`2OTVYT%2I`>FQ\TK%2H6\&O>H(6C6:A
M[-@==3?[FV_&M=:-$[%K2"V=%3TGLUG3'_X-.29SR<0U0=Q*95YT@HBL1L=)
MVH!U$=O'9\WL#=?[@7G:3JRN;@X=Q=&D*[*4F<N_FV[&:._*:RGJU(51]`QU
M7FK'>U$IJ6:SC]^FR7<#&G34!!0H$H-4;<FMI/)"21UW)PFN)!%\^USL!:99
M/$;I%Q4PI!N7TA`>U9R%7+-*I@_A!`[]&4ACE=&5;J"+8`+.\U+7;*Y#Z%B:
MM,[HAT;WOM*I6<./T?5Y':$G7T=+[FMY&$0G;HR5BT(Q*Q52/=2"I4RK@T;'
M`INAC%,!^5-EV73=RG=:#+VS<$JG2^/];U?$W*2B&EDMVQ=@6#D"XFI"T6>!
MJJ:;)HWK-$(]EGB48LG'Q,*JNDU.<IRJ@4]'\W5'1=1IR>J1J\ELBP7*L/H:
MS;%@8U\6>I6UK%J:7K.M7A(IQ7MHW!G)5M227CA?0IBQ;AL9%1PX6*VP#K=<
M<D=Q%1O4%8Z#$7#8LQRIWMK34M78[!;,(U_0=:I.)]5Q)VA?7T6W@G$?`,%D
M6319J[5=/#HD7=))&5<(`<Q;G4BX9/+57=)7J>UW!5_4$W9;$$Q7V4ZB^W<[
M&`I]1K-4%1T6S6J-MQT6<N4SYE'M&JQ'2#MT`@D('6W?Y`JSKFN0![K4X2M[
M!D;MM:FR5/G-G0\+7@<:76ABW4*ML&8@F$;8I=VE9HTL0S=M(@KU=PH"R[1!
MNHYP"^>I.0,WN2ZVIA7=7R$1K&IMZC[K9-HM$;%R4G)7?4VO=N0\9%Z\08/I
MQNI&0VP46TH>27C@;+IE]N#L#*@W`B9M*ZWF4I,;NZ#L.[8R&Y!;XU_6*7'Z
M+_#3>Q?Z`U^G71U6'%4B;?%2-?C5]ASS-S9'ZJ"8K*0KU`@J=Z(``%:ZNY4S
M52TW^X+S'6NYLTM$;>Y*4*8LCVNL]BSFF:#(U5*HQ>S4X-!.O,MHV!A:`4<`
MU1229I))INTBOO<D(!QS<F-J5^0Y'1=E@Q)5&.YMI:KU/LLD]#+2<-9XS2D9
ML&L0YZ(UKIC&J[5ZSD$@DW3Y5W^0`I5&@LS%<E`]\9SE+K32-0M7(VK):XNU
MAUQJVQTUE/76`=M-ANKT[J--*K-S]>C%X*E2L==+2U5G$$"R3:.BG17K=5V5
M-PBW`J#6O+]/D38:GK.LZ5DI:*O>OK1:[W9)"VMB:^A:1"[9N>C;&:$LT7"/
MQN:EGDJNK(UI,B<:::@U3.%3,%$5$L`O=QKFI%6K7FA2SU[*/-+[8NVJFTK(
M.EI!V_K$::-M.O\`W<FZ,+V5DH[7=NB63URN`*K/FRQC"K_UE`)%8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P".,B7\IRYJ
M77J4M(XZ7Q?IT\I7"VR]D:_;HJ&Z@`,58]'5ZQ4S?<9R5VH`=@(F[P)'8`P!
M@'!DY.,A(R1FIJ180\-#L'DI+R\H[;Q\9%QD>W4=OY&1?NU$6K%@Q:HG5665
M.5--,HF,(``CG=CX]^7?#%Q83MRK9J$(03E*<I-*,8Q6KE*3:223;;274^-J
M*<I/2*-0+Y5/[G2IT)6;X]?&?[#;^UW0?BY+D8G&A8==U%X"ZJ;YEK&N.6"Z
M>T+`FW2$4Y,P#`H&.4Z82(`<A-Q?VH?[6N\<CP*O+'W4WKB_C6A>Z]ONL6-E
MWUI+MEEW3G!8%$F]'&3_`',NL6J'VR<?[[S:NF3P=D7O9CZ=Z6L4_P#TK_._
M\/XFDAL_9,Q=[HZWQR+VM/['VW>7#BXSKV]5^:M2$\[(O(-CQTW+J2<4"LFU
M6;HF)'(IDC443`B=5(I12'9GS/S5QOQ9Q+<?$7@C9,+:^$;3_P!"\O"W7#PL
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M(0Z@J+K*J(Q[,C6*8^4Q6S9(HB`ZZ.3\LWWE^Y3W3?<B=V3.3?5MI:_+7U_B
M]9/3JR[::*L>"A4DD5Q(Z'JFA=H[0Y0Z1UXR2MVXI""F.4E?KK0QY_<C*HU]
MK6Z]<8A-5P"0[#U[!,O]JT1!-*:9J.FYB&>JMUR6X=Q*FNV&#ML%$6>M2C2:
MK\_'-):&EF"H+,Y".?(E7:ND#AT'L52.`]!`#%'J!@`0$,`[G`&`,`8`P!@#
M`&`,`8`P",Z()Z:WB5F4$FNN^1TL\7:!W"1*`WW%P:\B_1`!1\2++:=*@%G'
M452$)+PI@*0ZTD(X!)C`&`,`8`P!@#`&`,`M%O#7TCL>@.8NON6S&YUV<K&P
M*`^>J*),$+U0)YA:ZRA*'337$L++/XP&+\?$J)63I42D,<"A@'HM.EJG?SWR
M2M"$FUDMIZJKNJ;BVBY@#-6U=@7]SF&Z$0X4CTC$?HR%_D2F=&3#RI@E^D3M
M$!`Z2W<<J=:GUCG&MAO%-MU@V$RV8C=:=+QC.RUNRM];0.HGX5I:7A)J,9QL
M]KV`*P>(KM7(B*ZBZ)D7!4%40.0?CGK;\/9H%!.PH1=JB]9P\@B>POY%PDPU
M,]!_4B(2<R:3E5G'G_\`=KNEW"[H/4Q^[[L`[26T91YE[:W[S\UY[CMG6.YY
MCPR)4R?O+4B.O$*D#0HMC>"($FL8SW3<1,*X^;H<OD#M`CE>^#]2=TQ*K4J:
MNADPN^CBPS:Q[!L`MM6ZHUQNZA;3F*9J9PT3%Y6D6QJB#AAY#.'1EVK)F=R6
M/:-4&X%US\3M52L%^$NY[1LDTA'W=G<IJZ3"!YO8;G8#:JLIZ8MCBN1U<:IR
MC=E28M".&*1C$(I!DBFT21(DF!`.GC>)$'%QUJ3;;IY!C:+K<VERLNQ?WY"M
M[M(BUI4+KH];!9E46M=95IU3:^U:B5O')/6[D@R#9RA)B+S`*H+Q?UBU7;EA
MOW'7X5O&:2CAJT3+)!`N7''JX0=OU=..@?L7\LI8(@U>;QKER#LHR$44J+@J
MAT6RJ`%3Z\TG6]9V&Q3=?G;DO&S"DD,)2I2;17I&OT)Z94LEF:4B$9Q[%1JA
M8[(L9ZN9^M(+-AZ-V9VS,I6P`>S<&GVFWF5,3&\WW7$W0+H6]U:W:Y<U9O88
M^9-4K92':!R7.IW2ONXU_6[J_15358'.`G*<AR'(`X!2DAQMK4U$.T9^[;$G
M;BXAM>,$=J2#VHIWZ-F]5SURL=(NT:$=36-,;VJ+D;R\*IUASQSMN!$%VBB1
MEBK`4G'\-]=QM9JE/1N^XEZ]!.)L]GC9"^FDF>UVE@V!.;1DX_9C)]%N&,AY
M;Q87+L'T8E%2I43BT]W[,ZK=0#MY;BK4'\C8Y:*O6SZC(S>P7VS(9]5Y>KMG
MU`L]CBG,)L(U(D).GRK]JPV7&O5B2J+]60]NHH"L8:/63243`[5GQ:U#$U:4
MI,#$R-?JDE_2`B<)%2BI&L4VT?*0\O1FD8H[3>.B(D>0B(O3+*++/`$XG/WG
M$V`<2=XM:_F#.7+">O\`49A[=KW<GUBJ%B:Q5@=-=HK1*NQZ0636B7JL?3KA
M^!8@N#0&\HV.S169O6SA,BH`>N[:(4_9=YI>LG:T(AN:Z4@VRW\G-.U'$908
MNJ4;7-P:5=8[5Z]&5F-9:_0BT!64,H5X]4=F7`Q?0"\D_0:Y81HP.6RC)#75
MGC[95V<49%@R:R$7!35<8M5&J2`I#%H1<\N4J!`3`H@3H(`7H($?]@<,]5["
MJ3FEN9[9E5A'JNT6[O\`8MR-69%>I[BF/W+>M<C*MHY5^C09"T)H2"3%(Y#M
MS-R-2*A'F59J`<I;A_K)U=+M<G]@V9)(WJSV*]2%(D+HLYU]$WRS49#7#ZY5
MZM'9=L;,-ZBB9%ND*JC!%TNJ]]N+T_N,`]=8X>ZUJU,7IB5DV3.$9P-2JU"L
M]FLS&:N6I*Y0'D9+T6(US/+P95&B57L<,VDR+R9)1V_=-T2R"KQL@@@D!<.L
M:=BM=O7ERK[VT72^IZV1HX/[U:1<+VHT78K5=VSN=DTXHZ<?)3=LMKLSA9JU
M*R:(*$2:LTD$4T0`[G3FOG&M:.C"2CYM+6>8GK7>;M+LDE6[&2NU^L<G;K0M
M&MUS&6;Q#>5EU&[%,WW)LD4BF]0'`+I8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"-6KTW,KR(Y1V==+]&--I354<Z0Z>S7
M95"D2>Q%D%1[E!4F&<QN=V5<P"4@-S-B=@'(<Z@$E<`8!`OGI\D_$[XX]>MK
MQR3V`G$RT^VD34#6=>;C.;)V,]C2)^X;5FN('*9)B@LNDFXDGJC2,:F5("JY
M3&(4T[^`_MN\M_<GRM<4\6;9/*L@X_N,FQ^WB8D)?Y\B]KMCT3<:XJ=UFC]N
MN6CTIFZ;Q@;/1[^;/M3](KK*7\%_X^B^+/GT?(9\P_.7Y87DW7H`KC0/%.&>
MBR#4].M<DWC)Q-\N@DS-MVUIC&NMG3(>8@E8HLF\4V`Y#@S!0/<'WZ>,/MU^
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M3Y27T+N[;31Z>:J_&9M*(V_35-5<(E714VE(.6QVVSK*P?K*'&/;'-72*D`R
MAI$#_9J;\H_<-O?,(?T;CD*MMX]&,8J&/6J>[L2BI-1T;?;%*,I_5&*481@H
ME]86TUX_ZES<[?Q>O]O[>IN+Q$/$U^*CH.!BXZ#A(AFWCHF'AV+6,BHN/:)%
M1:L8Z.9)(,V3-LB0")I)$*0A0````S&^<Y62<YMN;>K;ZMOYME8].B.QSB!@
M$9E@#C_>)>87.=/26T[(V?2:IC%)':?V7,@@P7D3HE(1".UWLN3*FJ\6]`CK
M*Y4<+"9"2549@29P!@#`&`,`8`P!@#`&`,`M[M/7S/9](EZDN_<PK]?VDG6[
M+'F,24J=MA':,K5[1&*IJ(J%>0<TT16[0.4JZ93HGZIJ'*('5Z:V$[V-3`?3
MC!&&N]9EY*D[(KR"Q%TH"^5LZ;>::-U4U%B*QDDDJA(QY^\PJQKYN<1ZF$``
MNM@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#``>OI@
M$:N,+E>>KNTKZX.FL.P>0&XI5JNF44?-#4ZS'U#7!4:"4H-%TJ[K5HDH7ZJ*
M)BJ;[E#8!(UV[:L&KI\^<MV3%DW7>/7KM=)LT:-&R9EG#ITY6,1%NW;HD$YS
MG,!2E`1$0`,YUUV6V1JJBY6RDDDEJVV]$DEU;;Z)+JV&TEJ_0U1OE&_N3ZAI
M]C>-/?'?#,-[;8AIR%I,QO\`4;L;%H^DV2Q$<`A%TMJTD0=;5MQ!;*I(J)D"
M"1=D^Y1]V';CM@^U3_;1W?G5F'SG[D<U\4\?2Q+\Y8-KE1N65AXJB[K[79#L
MP,6*E&4YVR5\JVW&%::M5B[YS&O&4L;9X^_E]RCW+K",I>B6CUE+\%TU^?H:
M3NWK-L#9-ML?*+F_L&Z7[8MEGV+ITG/JQ\T]EU`<OECP\\W2F8U6J5Y@4B)$
MHJ-;)IM&;U'PI))F$";$^5?=!XT\7;4OMW^S3%V;%V^C;<CW=Q]R[&C1^G7V
MY&%;9BW4YN1+NN<<K*N]J>1BWUN4YPBK+3HV7,S9_P!6Y#*R4W-:0T3UZOI)
M*2<5Z?3%:I23^/297`+XKN;GRZ6X)'4]5-QDX@$?N74QR(M%4=5ZNRR*"Z;%
M[`ZT@8]P@OL"PK-U#%\+%4(9D9N)7+U`?`B?5EY0^XK"X[CJG-S[^2^0%5[5
MF1DY$\VF&DE*,JI7PC*R49)RCDVPC.7>W[<Y.=DKVPMHE<]8Q5.+KJE%=K_G
MIZ?P7R]5T1]#WX[?BKX<_&+0'%0XU4`Z=KGVK1+8&Y+HX0L6V=AKM2E$!G;*
M+5JE&Q`+AY$XJ,08Q:)_O!#R=5#8`\MYKR/FVY3W/D.39??.;EHVVDWZ^K;;
M^&K;>G3TZ%TT8U.-#LJ22,CF6H=XP!@#`.%)1L=,QTA#R[!G*1,JR=1LI&2#
M9%XPD8Y\@=L]8OFC@BB#IH[;JF343.4Q#D,("`@.`6"IDI(:?LD7J&X/W;^G
M3SA=KI*\2CI5VNH"""CP=0VR3>+K.7%LA&""JD(\6,)YF)0,FH8SUFLHZ`D5
M@#`&`,`8`P!@#`&`,`8!&:Y&/I[<$7LU']+7NX'5?H&U$R(F\$!?DBEB-8;*
M=*I-?$V9S"`IU:7<N%RAZ0@%`"HJC@$F<`BIL;E;&ZUV*^US):2W[/K,:W*7
M(UNJU4J$A2W-1KY:\%GL+23?7Z+DE&5:<6=JBZ3%F5T943@@DL4O<('7ON95
M$:R+P6FO-RS=*@Z_3[3<=JPU1AW&O:-`7*J1]Y;2=G<N;2SLZ;:$J,J@_DQ9
MQ;SVB!Q$>X2'`H$JY"48QL2]FW*Q1C6$<YEEW"'ZY18M6IWBJR/B[O,`MTQ,
M7MZ]WITP"($#S?H,M49>YR^L=XTF-:ZE>[LK+.WTV!;RFQ:%'FKB3UY1VL)<
M9U)S(H+W*&3%K(*1RHGE$>@="KBB!WJ?+RJ)05S>36K]U5FYT^:I4$EJ&;JM
M=#:=R=[$,Z)3W%$A8JXRD)8XZ6-$R@F<%D4DVI(214<"DFS6.4#J;!S1JT*&
MNPC=-[]N*VQYZ2I3)K4JE4'CJM;)@FUL?6/65R1E+_$#"W&O1]'DG#DI?.P%
M%`ID72H*I=X%25;E57[5+V$B>K=RP5"JTGLZ,G-S66O52+U4Q'4<E986Y/U9
M8+LXL9(QO-5)ZU16-%E!50A3="I&!3`*&?\`.BH1=&GKQ(Z1Y'L@KD+!W&3J
M;FAUA"X%US86<RYCMDMXU2^%8N:J#F"7:.$RNAEFCH4RKLDR*IG,!4LUR_KM
M:_%DL6G=]1#LU=>W2[QZM0J[U[J.B-;"^KK>[;+2B;Q($CX&85AY!TR".-*/
M%V48Z5!`/")1`[&P\LZ;7-BS%#<4+:[^&K-PHE%M6VXRO5];4M8L>QH>IS=:
M0F+"XMC69(R.SO40#AVC&K-FYWI`,?H502`2G_S].GUZ_0.GU$?\`P"+CGEK
MKQWKK6VR:'7-A;:C=LVN=IU*@M<0D._LKZ5K#2XO;"JZ:V"QUN+8,8E"BO\`
MRJ*O"F$Q4P*4PG#H!5Q>1VJR5?4UKDIES`M-SWF.UC3HV<9_CYLFQ'YYQJO3
M)F..L<8^<B)>N/6#Q,#*E2>H"F4QP$IA`H%#EW67,]/1B6I]XC7H6\VS63?8
MPU*N%H5@V!5+-(T8U6A)$;F$S[RPWR,/"1B[Q@S9.9)1(AEDR*IJ&`I6.YPP
M,G$LY!'CYR:2?R^R9?4]>K3BD4<EALESK,?L"3N+.(0)LM2/]G3F^LY0'[AP
MY;IB<J0-Q<>0.@'=.^8T2QE5(5UH/DB20B*I!W:]()4BH.CZUKEAF;?$Q;VX
MIM-A+K'56;4>0D!0BBRBX,2$'L\RA41`EG$2T9/Q,7.PKYM*0TU',I>(DV2I
M5V<C&239)ZP?M%R")%FSMHL11,P>AB&`<`[#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`4O=[
ME7]<TJX;#MKW\;5*'5K!=+/(^,ZWL*]5HEW.33WQ)@)U?:QK%0_:'J;MZ!@$
M0]![DH5"^/K6W(TBDI<J&?C\QW]Y*#"O;#:+ZUNT`KM`XU:O"1G(V"[7=[/B
M*#0036>2COLZ@)^[*QQ[9I\BW["V"K(P\2S-RJJ%?EW1Q\6EVSC#W<B^7TTT
M5]W?;8]5""<M'IH==MBIJE:U*2C%O2*UD]%KHE\6_@OF:+'RC?,/OGF]9;+J
M38MX<<2>/R5K&OK\5R/');BM#P)J_9D;=RFE(R*1E;,ZF4%TTF]#BW+=NSD2
MJI/7*"S`'3G]#WVU_:)XU^WG8:/)6WX,.<\O>WK)HWN,8?L96V^_CK&X_"VQ
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M@W$>ZUW!B5NB:.D-Q3-8.RA[/)MW1CJ&KD4`P@&(47CB0*LLU3UN>2_N'W+?
ML%\5X1[VW\0A)N,96VW6SU>NME^1*S(MDO13NLDXK2,(Q4(,O##VF%4O?R=)
MY'\$E_)+1+^"1ND5JM5RF5^&J=0@(6JU:N1K2'K];KD6RA(&"B6")6[&+AXB
M-0;1\;'LT"`1)%%,B9"@```!F,]EEELW;;)RLD]6V]6V_5MOJV5E)):+T.[S
M@!@#`&`,`8!2]TIM?O\`696I6=H=Y#RZ)"*^!=9D_9.FZR;N.EXB2:G3>1,Y
M#2""3IB\;G(X:.D4U4C%.0H@!;C4=QL`N)G56R7B2^S:)WG+*"B#,NR-?*O5
M6U4V9'H%21:'>/VA4VL^W:AXHV=36(!"-EV1E0+WX`P!@#`&`,`8`P!@#`*6
MO%,K^Q:=9Z):FJCRN6Z$D8"800<*LW7LI)L=LJLQ?-S$<Q\BV[P5;N$C%5;K
MD(H0P'*`@!'V'2YIP[6,AWB?&ZVI1:3.-<VR2L.RX.>LC=D";96PR,#'4M_$
M1,U+H)BX6:H.56R+A0Q"*"F`#@'?;7US:K7=W4W"-&Z\<IQNWIK<BJSULW.-
MKO4QK5Y768I*G`X-G*%:=B=?IXDA(`&$!,7J!8+4_#1FL]FI/<07OM<UO1D$
M2H0>Z]C1>MK&UH6E:/4;%'W+6E3N,=0+:R7LD2\:NB2L>Z)),DR$5\C;L)@$
MZ+9'.92I6:)CDDCO)&MS4:P1.*::)G+N+<M6J1A.'B(D*JA0'K]H!]?3`(`,
M.$C2O\475$BOZAR^XICCE7M0/%[AOG:%U&N*+Q52"X0U"FKC=YMIKYJ^F*Z@
MJ9>#,Q*=2/:'(8`;M^P#DI\=+QIVQ2E\H%3L>W):A;A3V75`LNR_W5LC;-)O
M=,F]?V'7LK>-NVI-VRL.D6<ZX7J[R7E3-5(@`CRK)K/G[@H%=5[3VR'T[K[8
MLW`HP,S/\N)OD%>*BM*P[A>@51QQJNVD*Y"K.XN1E(J:LB*+>#/*A'NGC7\D
M]=G;JJ-DRGP"S%"T=LI"M\C-+RVI]Z5_^ML_R?(&W)O?5>MNDXIAL#9&UKO0
M9:K:M'=LO8J0RF6-K8H/FL55HY554YR.R>,#*@!>:82Y";NTEM>H6?1R.HI&
M2TZA4:_"6&TT&5F[%?Y%D]+/J1CZA7&V5F#UXP!-JDQ%XNC(.%E%14;MDD4Q
M7`XN]J-MDESW2WU[J^8V-"<E-'1.L'MD;6RC0S'55IAPO-;)+61M;[1"SCBD
M.X&_D?\`MX%E*NB.HUV/@%1VGU`H9/AW-1^U)C9RI[):$8?=VFIJ,H$CLBQ)
MZRONOZCHG46K7UID-6+6+^GL?L"BVRO.Y^*=.&8/5EX=!$51(J@HF!,W>D/>
M+)IS9M9UHX!E?;12YZK566,Y1:_@9:RL58-"S%57513,I6"OS2!4^\IEC-@3
M*/<8,`@I6=#[WXWSE&1@8>S\H:;3MFLMA,G4(.EM;7=D$[H2_P"G+)"EA)BP
MZVI#J,BWL=7Y$JQ5T7*JLN\Z`J5(")`4K<>(/(+9U==K)6G^CDO7XK:6S:?&
M1[&A7*1D-K[QWY-\A9*G/IR4_)MZL77SNNUJ$-,Q1D%79G,@H@Y,B")R@2/T
M/Q7BX-Q);!V4VOY+O)[NW+MAI1I+=VQ;5JZ`<7+;-PN5/?,]8EM[C4R4S#1<
MNU<I+(1)#MI,#.B]KKJI@%L]OZ(V,^J6L2HT+9-U_:G,'?FVIR`TKN1GIW8?
M['V+&\C&56F(:^%V1JP[<GN-C1)G[`DTBL=%50ITE?&<F`=?<^,-WWE-[3V;
M-5S:FLIF6U%I*N4K6L]OB791%PD]66S;4S8:#NV'U1LJQ42Z5C8<9-,(U\^D
M#RSDL9++"0Q5TU$P`R2PR1$8>)13B$Z^FC%QZ1(%$&0(P9$VB)"PZ01ICQP)
M1@!X"^W$4>A/L$2],`[+`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`1@YHS6MXOBIR!8;8N+:@
MT2W:AV%1+!;7)D`3K\==ZO)5-S-']RX:MP2C`F05,*BB9.H`7KW&*`@:/G-7
MYO+=/4RH\>>'[R5I6L=3U6OZW@=C22;3WZU<I-=85*+<T>)5;@2.<N6D6"HS
M;T@NU`/U;-V1>T`^/1II^@,//!;X9>9GRM;QO%DHC0U4TDA9/-?>2^TU)U:K
M'>R@"Z?-:<H8?RNT;L02J&4;LCG:-%!)[YRV*JB*FT/C/W$[#XS\&\;KWR_)
MGR:.WQA7@U/ML[:9RA!V0;[:*9Q46IR496)N5<9-2TLN[:;<S<KG4HJGOZR?
MIUZ]/F_^'Q/HR?&Q\0_#SXOJ0O#Z*J*UDV=/I(C?-];!3CYC:-L7(W*@HS9R
M"+-NQI=5#H/CB(=)JT-Z'<>X7[ES:[^:\[Y!SO>+MXWRZ<[+;)2[7*4E%.3:
M3E)N4NW71.3>BZ1270NS&Q:L6M5U+HD91,LT]`P!@#`&`,`8`P!@%L=GZ\4O
M$?%R,%))UK8E-=K36OKA[<7'X>542!)Y%2[=,Z*TM2[2V(#29CO(0'382G3,
MDZ0;.$0/9K/8B5^C)%&0BU:Q>:F_"!V!27BQ5WM8L!4".">!R!$RR]:G&:A'
ML1))E*D_8*D/VIJ@LBD!<K`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@$=>57%C3O,K2=MT'O&$>S-&MR+?
MS*Q$HZ@[!"R3%RD]C)J!F61RKLI!@\;D/VF!1NX(`I+I*HG.F8#"A\?O]N=Q
MWXKW=+;?(2TI<H=AUZ>?O=?0<M76\3JFK,D';M.!F9:GNU)$;G<TX\45S*/C
M_C63WJ9NU$Z:2X/7H_0&Q5&1<9",&L5#1K"(BV28I,HV+9MH^/:)"<R@IM6;
M1-%L@05#B;H0H!U$1SMOR+\JUWY,YV7/364FY2>B26K>K>B22^221\245HEH
MCGYU'T8`P!@#`&`,`8`P!@#`++[,H\^I+Q6U-:I-?ZFU1D>.6B73E..B]G4H
MS@SQ_KNPOCIG(T5]P<[J"D3@;\1*F[AZM'+Y%P!7-`O,!LNF5R]UA1V>#LT:
ME(LTY%HI'RC(_<=![%2\<M^M'34._15:O&Q_O;ND3IF]2C@%7X!YZ#]>@],`
M=!_D.`.@_P`A_P"6`.@_R'_E@'C`//0?Y#@'C`//01^@".`.@_R'_E@'C`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8!'"VL7FE+/+[6KC-R[UO972;[=%2C6ZSA2`>@0B"VZJS&
MM$5EW#IJT3(2SL$""=^Q1*_1*+QJJD_`JJ&Y&\>;#*QD)`;YTO.3,T]:QT/$
M0^TJ-)R<M(/52HLV,9'LIU=V_>.U3@5))(ASJ&$`*`B.`8]M(Q^YK'-RE_C*
M_O6#6C]W<C5K+N.[<BY"Y:HLVNZKN+:L#^U*SH=SMB?1@'2\-&,H^).2LQ?X
M@60+E4*!/"[`LAINY;5;:A_<;8^\]522_'?0<;?WNW.0-IW!8K](<AK=J2%'
M?NLVDW>-BUVAPM"KRMH4_(-G+%4DL^\;R/21CD3'`O%OB/L.N]D0NC-=K\@+
M_17VQ./,RZHD%R2V)';%E7]TI?,5:VP+/=5YVK$6^+@`1U-6Y56)6LB+41:&
M%)/J[,14"G(E2]W#96F-03\%R1-"-;UR1B+;JF#Y06JOW?3<5%Q?&R2J#_8^
MY83<4)/;G91M;V(I9$DT)J;<,4[62.1(X-&]Y0,R4:P0B8^/BVIWBK6,9-(]
MNI(/WTM(*MV2";9$[Z4E'#N3DWATT@%5PX5576.(G4.8XB(@8F;M^^=)U;<D
M];+!L9]LFQZOY"S.IMM4[D5L6V:XV=-0]4M]V)7E-2VB;"G:3OL!!1(N(\(=
MJ,00(I0R,B@)SL3`=ENKDWNJ'V"]BYW6NT-$#8="V"M4Z.<2]:VH_E+S=]QZ
MFI*%YK-$T5/[%LE@L>JJO-2,S[9%F9XLS17!$IB%7,0"DX2]7#?5NXPUJ9A.
M0-V29:GW/6=GQ]#V]>^,L]7[IKS;&GJ(;9^SJTXOVGKBZ>258?GEDXI=%Z^0
M;2_<BV$%TU#@2@TGJ>"IO*O=K.-MVZI:+I.NM)/:Q!W;D)O78=<CGEY_JXUM
M+LU<O>Q+%!/W,FG760@HY;K';';@9N*0B?N`G9@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`?\`
M]?\`/`*<;TZH-7*+MK5*TV=MUB.&[IO`Q2+E%P0P'36163:%536(<.H&*(&`
M?7K@'6MFNOZ549(B!JQ6J.@YLTC+K*.V$;7&[JP3TI)VMV_>+K)L6ZDC8Y5V
MJ[,H<O5TLIW=#"(8!1<!`:"N,,RC:HEK:SP4;2)+33-O6Y*%F&"%#>QL6$GK
MT!BGCA,\0:*BVIC,S"/C13*<`*!A$0+22W&SAC5*!':WGZS0:_2Y6[-+##-)
MZ]2<;(/;W7F"M:9+P]ID[4E:%96%C%U&";=N]Z-T%5$`3*50Y3`==-Z-X-SK
M2JZIEFFKU'&O)2THUJN([-=1URA9FR^%2X-UWL?<&ES>R,M^-2%ZF\764.#5
M/O#]$G:!*XC^HTROM6ZDO#P-=KM?:J(K2<T@@TCJW&(-V3=ZYD91X)OQ[=($
MR&=+*F`1$!,<3&ZB!82G\<.*<M+6G95*I%%LB^P#WA&Q3D3..K1795S>G3LV
MP3-&)9J2J\:_LCIZY+(J,4$%E?<+D.;HJJ4P%\)77E'G+I5-BR]6AI&]49I.
M,*?:G30BDS7&=F;%9S[:*=C][9*6:D!-<`_UE#I@'ACKNC1ESE]B1]5AFEYG
MFJK*9M2#0A)F2:+-*TQ60=NP^]1-1G38I,P?Q*P1#_R!@'7I2FK(C8<FU3FJ
M1'[2ML?!,I2,&:AF]UGHROHS#NO(+1)WA9=XVC6\J^5;]$A`I%E3!Z=1P#O+
M'=J93A8!;[=5ZJ,JJHA%A9+!$P0R2R/B!9&/_*.VOO%4A7)W%3[A+WEZ_4,`
MM3'<G-+2F_Y;C`SMBI]V0D!(6B1J"D#/HE1@XR/I,H[?%FU8TD&J0&6PHPY`
M*X$5154`G<**@%`O?)R<;"QSV7F9!C$Q,8U6>R4I)NV[".CV3<@JN';YZ[42
M;-&J"91,=10Q2%*'41`,`Y*"Z+E%%RV62<-W"2:[=P@H19!=!8@*)+(JIB9-
M5)5,P&*8HB!@$!`>F`>%W#=JGYG*Z+9+R((^5=4B*?F<K)MFR7>H8I?(X<*E
M3(7KU.<P%#J(@&`=&^M]2BYZ,JTG::Y'6>:3\T/7'\Y&,YZ62`5B^6,AW#I.
M1?I]S90.Y),X=4S?_B/0#U6:[4REILUKC;JO4D9!51"/5LU@B8%-\LB4IUD6
M9Y5VT*Z52(<HF*03"4!`1^N`6>+RJT:;D.GQ6_>)R[Q6KSFTMZB,%/BDX@FD
M-'3ZS]*>+&F@?$,9)D.F)G)?*8BJ9.Y1)0I0)$8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@'D/J'^8?]^`87;IN
M+4#OACL_5[?;>D$]CU?D1<)>T4>XV>N2ZE4B8OY"SR,K-[(HB=@CIUM3HE@\
M2=28N!:)E8J=YE4R'*?`*XND?4=L2_$61T-=-#6S8&NMG[=N#.U<>3PJ&L$-
MMPVCK.@C$2[2"G[0C&M+C2YE:$?D?O'3A-A*'<)?J$;B0"S<;LW6R]<_J%M^
M`H47&W?6?+,VD:/R1F%-=0)]@/.7&SW6VZ(LI*0$]9D-@2T"\KR,<:"BG$DY
M0:+BFFN11`Q`+U7N@0)I^5LS_4\14KFY^,_94G+,W;%C8K/7[>Z&O@_C)"Z*
M1;:4L%DC5EEFRL@H!'+PQ3J&`!.(8!:RX5NT.DH-+DMM'5E,IJ/"K7+UEL"`
MUA,DK%(=Q&]-+RC%ULJ`OEUMD!:*D6;:,?R:#LS*/+&%=&>=J'51("?O#^QU
MZQU?9QJS_1^9C8C:9X?^I.B#-TM:;;7;ZZUZY/=HR+CW<M"P,RS([+"2C)C(
M239-_$*&\X'.=!$"ZVRY'D&RD8PFG*;IFRQ!V*IIESLW9EWHTDVD@<=$$(QC
M5=3[":OF)VOW'55<-U"J?:"8A]V`5Y3%[HYK,4OL.+JT+<U$EQG(RE3TM9ZN
MT6!TN5L6)G9RN5*5D$CL02.<RT<U$BICD`#%*!S`8X+M)ZGU]RRLUOI^\8"5
MWQ;]W<?ZK9N--@A-0'G1A+-#:WUK-6VJB^II=]KH0NLGZEB+(1<Y^"1_'N2K
MH&3(\Z`=GRMMFAK/-4;9!.150I%VJVO]XQFJ8:Q5[55II.W;+#W2HQ5GHI$M
MG5F6=SEDKU]H36+=0]7?Q-E\KSM*N7[`P">%"B6;Z(KE]F:-"U78EDK$?)VL
M$8ILC-1LS8X:L*V>%<21D0DE"D<UU@V7*H<14+%M@/U\"?:!%KY`YF0-I#^G
M+&WZPU23:\R%<=;NWBFR>Z<U*>#8NKE#3=TKLLYC*_L$9JRU]C&H5B5D(J*G
M$7+A)RZ,0OLG@%)_'GLPFP:I<HIOLAE*QVM(_6VN(S2Q3U=_.:B;U"OR-=>V
M:SS<,U3FG3[=D[$/)I@V?JF1;P2+!1HDBFY.!P+O\S*;!VG5M1DI:,6DW],Y
M`<9;+72E=21$&4N3D/J]@,DO',W*3*3.R8O%3I>[273;*@"Z8$53(H4"S.W9
M_C)9^4+'4CFYZFK&XRVS2UVO,]9KI5X_9C&2K,HQF]1ZWU1$34B6>3M-Z.R*
M,@$<D5)*#=JE.4[B20$H'2<GIC0-TO\`4-@3G*6F:UD*?2]RTRCQMNI^JK52
MK%>8._PD%>Z^V>;6KDJWDK1&6BDI1,O7H%PQLCE)-+P.6Q0[E@)S:UBVLO6Z
M7L6Q42#J^S+'3(*6M8IP:#.<B9VPUBJ$LT*J\<(C+)%0/7F+-5)103"G&-R'
MZ^`G:!=#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8!UPC$^=QW?C?<]BGNNX&GG\?0/+[CJ'D[.WIW=WIT^N`>
MYH+#L-[#V?C[_O\`9@AX_)VA_J\'V]_;T_QZ8!Y="R[4_>^T[?*'A]T"/;YO
MX>+S>GE_R]<`Y7IU'KTZ_P`>O3KT_P`>O\,`]:GB\9_+X_%V#Y/*!/'XNGW=
M_?\`;X^GUZ^F`?AM[7PE]G[?V_4W9[4$@0Z]P]_;X?T^O=]>G\<`]^`,`XIA
M8^[3[_:>_P"W]'O!#WG9VG_Z8F_7[>WN^GITZX!X6%A^C[CV?_7-[?S`A_[G
MN^[P]_\`Z_?]>W[NO^.`<O`/0Y]KX#^\]O[;[?)[H$A0Z]P=G?YOT^O=TZ=?
MXX!^DA0$5/#X>[J3S>($P'N\9?'Y.SUZ^+IV]?\`R].GI@'M]/X]/X?7^?\`
M#Z_QZX!P%!B_<D\WX_WG<3Q^4&WNN_J'C[!/^MW=>G3IZ_RP#]N!COT_=^Q_
MZQO#[D&__N.H=_C\H?\`6[NG7I]W7ZX!S,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&
,`,`8`P!@#`&`?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex10-14logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-14logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*@!Z`P$1``(1`0,1`?_$`)(```$$`@,!````````
M``````@&!PD*``0"`P4+`0$`````````````````````$```!@(!`0,&!P@+
M$0$````"`P0%!@<!"`D`$1,X$A05-SD*(3,T-64V9C$B,F-D519G4E,D5%87
MMWBX&CKP05%A@6(F5W<82%AHB)@967D1`0````````````````````#_V@`,
M`P$``A$#$0`_`+_'09T%%KWAC7FCX3RW<*39#ZMAD8;=H]J%!FQR!A94S4CN
M\;]L)KXC>16<F1A))F`G-'*G(H[SW!O>%K3@Y^]'G'0*+G6JF-\/6P.@>V'%
MN-TH&_[KO@543;5ZL7MY+K'96*$^A%9:9VIW*]5'3`X=5R9B4>8I">\,?$IQ
M7=+4Y)^`N\C5E)D8EK@,EO*)3^<+!J3R@$(P`+[P_)RD0@DA+(QC/E#SG`>S
M';]SH,0KD3FD3KVU8E<$*HO!R5:A4$JTBDH7X)J=20,PDXO/9\`@BSCH.L3H
MVA6B;!.*$+B%-E:)O$K3X6A1X%Y&58DF3._PFP+X.\\GR.W^_P!`+=X;BU31
MM\ZGZV/C@C<[=VZL"7Q*!0Y([)"'QOC<"JZ<V7+[&7M@@'*C8LS?H@G:Q&=A
M01KW8@(1YR$0>@*9P<6]I1GN+JN1MK>E!WBE<X*B$:-.#(L!\L]2I&622#RA
M8QVB%C';GH-@DXE044H3FEGD'E@.).)&$THXHP.!EFE&`R(!A9@,XR$6,YQG
M&>W'0:B]U:VI*J7.;D@;D*'`,K5B]8G1I4F#,@P7E4H4&%DI\#R8'&/+SCMR
M+'9]W'0;H!@-``TH8#"S`!&68`6!@&`>,"`,`PYR$0!!SVXSCX,XZ#ET&=!G
M09T""L*U:OJ1H(D%K61`JR85*H*%,]V%,(]"VA0M$'(PHR'*2.+:C-5"`'.<
M%A'D><8[>SH/?C,JC$U9$$FALC89;&W4KOVR01EX;WYD<B/*R'OD#LU*%:!8
M5Y6,X\HLP6.W'04OO>:6`F5\JON_<74.;\RD2/8H]B.>(L\KHY)FHIVO_6-`
M8Y1Z0-AA+BQO:(!^3$JQ.,)R8\(3`9P(.,]`L>:FE'SAQEM,\Q]`2-WV7F$6
MLN'TM9]>[RR)SV35MD.DR21.#2]Z^69/_2=BT/("U+<K0*LL;@%.9AS`?YOD
M!*DA6"[ENSR/E)YT=1=1[#:U[EHY"M%HIN]C7^2&9.A]O6C:4`8)["7.YXT2
M8%KF[77S1.6SS%G<RU+<2XH#S1%#"I&'(+6U+$#QK>\/Z8ZZ:S-!%>:R\A]'
MO"6Z]>(H64RU`V6TPK+'21>Z8%`$0"(W!IB/$6;$CP)I(1%NJ$!PE`3%`PG!
M"(=ZW.UEIZM9;I?S):#[,T%M0IN.9$SOE,BU=D2]X?YZZ66\2&.7@@M)S$P3
MYT@)K6-,C]`,JR0L*J.$91)D8D(@H"@)_=;6K5>:^]*\:;8PUQ#'NLMG]:YQ
M=UB"9U#AZ)M>32=@VJ?TT]7.*%Q+/6'.Q;.WGEFD&EE#*)+Q@/D?!D"[U.,@
M&^/.1NSK-<<#;99J1Q<4]"*CU;UAF:;,EIE@EZI6TL4MMI_@+X)='YE-S!$+
MT;2O=R%QJ%I/*P3D!I83,!KTZ=$*AYZMI.'TN+X>]`=DM<(ML>P:Y'K'4-=T
MO<#$ECTN>U-7MB161FOH3+UC4N6+69M&E;/21J81)18"\%B`1O=J]"->MXM1
M]QG7;]D?MAH@S;GV[6D)JBQI7)76LX.$NO*T,=IRSQD#L2D6V4YH')$B3OB_
MSI>RI6D@+68C$<L$I`WO=#YS.'O1/9JM)-,)%*XK16[5EUO5Z:2.1[LIBL**
MA->/`8ZW*E0AFD-(7AP5*P)PYP24>J.$`(?+SCH+$5W[K:A:TO;7&-@-F:.I
MZ4/28"YIBU@67$XW*%[:,WN,.R>..+H2]C9@G?>"6=QYJ`7P",QGH'WADUAM
MC15BG5>RR-3J$REN(=XS,(<^MDFB\A:E.,Y3N3&_LJI:U.J`_&,^0<0:86+L
M^#/0*;H,Z"L/PTDT1RHR3=S?O9^%P"^;K2[<VKKW6T*M9F:[!;-7]<8`WQ<%
M<UU!X)+"G1@A"Z7%+5;H]NZ)"F6/ZTXSOSC.Y$`(9R"\:K!KOMIQQ;.Z4ERJ
MA*KD'(MK+'-N]:*5>GJ#Z\6&!\EX2H1=CU2T5.;Z_3RV,R5,2W.*LM"`*TMR
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M2>I>O%/OLCG4,IQL?<R@R4V?.+6E<1@+I.[5D!<S<$1`$$>:FQH1&!\C*Q0`
MM06#.3W2GD^NSCZ7<:UYN&E4]89E6\>IV7[>KY3;3I*VVN$F&Y$I?$FO#K5X
MD,GO6*-:$L30^&SAM;E+LF)=#DZ8W`D?0-?MOQ#[0,W(9QO;Y:+NE&2YMT5U
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MTAM5K,$05.W1,\X]T3#4.`3C"P!1C#Y0P@-FE.I>XO`-HMR)V'8LEUDM&#@;
MMB=R$KW#'NT?TN:[-354W)(/!2XO(8&TL+O%E4@BZ8*M8-S3J0@/S@!`_NX!
MY/=HJL32SC40;K2UT%+]O]Y9M=MCW=L-+T*62V"^O+)9\TK>'M:AT<>U2.(1
M%LAQ!R)E+,);2#CCNZ*+"9V8`U>&CCYOKCHUVM2LMB]B&W8BP[6V0M&_5SU&
MF-1'(9&C;&&T'.K;&F10G1`:_P!(7Y`J?%Z9*F2-Z9P<S2DY60@$>>$NW09T
M%$+?[A&Y:=)MU;KWLX0+.>4<0O1]<+!GE)0J91N+RIBD;LY'OLE8%=?V$(NK
M;?@0Y"N5.#0G/P<O;_.AI2T8NZ`I/#GI/[R[O[KEM!6NI/-QK.JJE!93RT1I
MKN]RJZ0TA,HJH?'`AG;YK*XLL+_0:>USAU4%EKG"/IVW#<0(Q0'"ON^XR$W'
M)#R;V_&M_=0N(O2YYCT+V4V@_P!-+4OR311%/T.O=*(6^6OJYRB,&<U)$?E%
MH.S!`G94D+>.\:TA1*?!I!^5H1I@U+$V7W'T?Y.="]/L378K>*DMPH]/TMIR
MZTZAJ-J'2KNPFD"99S#K1H>K*K8QIFT9*DZ2,+\WJP)&<:8Y*J`<;@.0'2J-
M_-^HG[PHQ<7%NW]#;=HE!2LFME<ZM-%Q&L9(^KW6J%<Q8&9S4MSI)5!2&*N`
M@X+&D4)AJ\@QD_`L?>]`\3GR*3;>'E"V)T%H[9\.G5`:.Q!*;?MSQAOJ-PN6
MY[J=GDAD,K.NW>ZHY/('`H+7ZG*@IV7>@ESPK<T1B<O*=.,)N016I_)!L?,.
M03<OAFL39*&3"WX%`VNT=1=Z&BMH"].LDAZ]B@\R=XI;-7157'*LD]AQ5@F/
M=A5M!3*B5@;UAIJ4HS!8<@(_''OWS#;\[O\`(OI4#8.G8A#-4+(%63MLX11L
M2#*X-'X=:%JPL2^N:=.5KX_)+>NC$8)\A;(5Z^,15"TJ3/1R]2H3DF`^M#[P
M[JZK\\'_`*C+SV5?-OJ5O2D%=H5%:5F5Y6$4N&J).57TKFV$3LX53$X)%I<R
M''P)T3C).;0=@5*,9.2,%*"SP!VT'O>J2>]!:L:ER_>N0R@VIJ"LV<51.5M%
MU4@8X(MLJ@9XYSD".JV0ELC3RX/K>Q`0^DG%0K<"4^0A`9@)>`Y"2OGNVVY"
M^+_26"[-4KM1#9&_()'!*.F3)+=;H,<"7RV7AL1Y66TC<2G\::+K$;:TH49+
M*6A5-_E)\G#$+)H@8!S^7HB\;7X.;:M1'>/Z*(5F@BF8W%$_XM8F_?QMN$FK
MR*/:['I]28B503]T#5X[6PGR?W7VX"'!0,=`'7`-6>W0^$76JQ*NW.!6,0;(
MCL*_1^MS=<ZUG!+48PW=;YJA,;+'QT3O+D4ZNR`U2+)@`B*"HR4#/D@#GH%G
MQ'<VUHV/PZ;=<FV_S^U2I305UV0RIFB`1=AA*=6PL->TP;!Z[C2!,$!`G>5S
MZ<B2$*EYYYGG#B'O#.Y+"$`*_7J\.2?9;C+LOE?L+:FR:BDLDJBVK[UWT[UB
MH2CY[!(W`8&FE1T"B\O3676,XM^YI/814>*5*SD4BC^`IE@,)0IA8SD`0^_U
MI[E;_P#F*9X.OTW]7%Q>M?\`Y@_EOAV^SWSC]-]!.;[NWR!P39.A[EU4?)OA
M;L/J)L)L'&I!'9"]#5RR353(;NG$F@,];0N*Q0XN[$U%2`4?4F`R+"`]N)";
M@H"E+W@(3WI^G:YV"T-JFDBF-ODFVUI[2TW!-+V5&D`KFZ^PI+)V]LL,#/A,
M`;HGB":KSUZA\.^];R!$(C5(@C`F%@(]MCZS>M;?>Y^/RW+/<LH*XOZBBH=7
M\V<S,IF)RG3!KS95**H80N4C[O#ZKEV6H>$W;W@C)"DQV9R>'M"W)>>R$=I2
M8Z]5OEE6S*QMD;;25I!X6RKT2=Y*8VQF<I=9UG+B%/EF8A54PEH.7N9^`X#D
M\Y&CP,*A:GP,*JIO]M$3_P`SL7]'D_H&`XA-/Z78>??F=UQW)J&I+4EC^_2F
M[:=8+VK>'3D4AA,TN1TL`J9PE#.VAV)-,4Q&QF@:HY"'(LAR/`L]A(\!"U)7
M-?Z0T[N.T4KK[J!K["KA9J3DEISZSJBIJIX,Y5!$GJ1LD2A,9DC[%XPVOR5R
MNM3Z:-;40#@><(HPO.,#DL`,Y"NE[MK[6KWB/^=)C^D'M5T&I?.,_P!<_P!1
M?@_X3G#/^3^(;8[X>@[)_C)?OI=(9,QDO!NI3KDK(\9!@W'^[1;H.TK(NS!F
M/++%C[WM^$.<?=QGH']][]D<>E'#\F7QE^9I$A0[DUBP+5K$Z(7=(C?8XVVT
MQ2%E5*6\]02G=F%[0GHUJ88L')51(RC0A,`(.`._D5_LZ]]?_FLR_P`D4;Z!
MIO=W?[/-KA_LSVI_ERO3H*Q.@-$3C8;W13D<AE=-R]ZE,:VX?+9*9&Q">XN#
MLR5"V:JV'+4R1(F[5!QZ>)1]<I"$`1C$(C&,!SG/07$N`>R(/+.&/1*0L<G9
M5C-#J%1Q.5N.'%&!+''^O%[PPR]O?#A'8+:CF1:UFY.P?DO("?)-SV`$$60:
M/^L%ZU?ZI+>]:WE_)&_P.?\`TG_FK_E7RO\`Q=!5GM3XK4[P,>M^_?94>VF]
M<]E_)?QWYX_S>_Z"5;AT]JI)O6/ZGGWVOGM3/DX_"W^I?^%'XGH#8]Z6]G_'
M?!UZTF_Q*^MSYO.\''Z]/V7T;WO0`Y[O[Z[MF?6!X5D'M'/:5?+2O5S_`-%O
M[\^G_,.@AZB/BOB7LP_PXW\3XP_B4/Q7V2_8_1O03*^\T^)32;U<_*!^$_VS
M7RMZ\.WZI/VW\J\]Z!;:">QTY"?JEZSWOUW>-3XR$^T9_7?^:_LSZ/Z",/BR
M]H17'LT?$)"O"YZZ/K2]>N?[7_L/I'SSH!GLSQ4NWLO/CI3]9?&!^!)/JW]G
M/\/Y#YUT!H>\#^.KBF^/\.40\"7M/?F^6_47]5OYI_%>G^@8O<#P\ZB^RK\,
MU.^O?U%_/EH?*OUT_P`)/M9Z;Z`D+M]EUK=X)O6'L[ZQ?#)]7:/^4_83]M_(
M_-N@36I7L^]N?`=\EH#P\^''UQR[\#Z,_?GTAYUT!#>[R>*='[/7ZG6UX&OJ
M1\QQ3YT^T?YP_(_-N@AF>?$ANW]5_$.F\(OL!_G%+XWOH?\`/_XCR^@^B'_X
*3^"?^[_LGZ#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>15
<FILENAME>v167911_ex31-1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizer 4.0.6.4-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT
31.1</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certificate
Pursuant to Section&#160;302</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
Sarbanes &#8211; Oxley Act of 2002</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION
OF CEO</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Andrew
Makrides, the Registrant's Chief Executive Officer, certify that:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1. I have
reviewed this annual report on Form 10-K/A of Bovie Medical
Corporation;</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2. Based
on my knowledge, this annual report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this annual
report;</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3. Based
on my knowledge, the financial statements, and other financial information
included in this annual report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this annual report;</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
November 30, 2009</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="35%">
            <tr>
              <td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/Andrew Makrides</font></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Executive Officer</font></div>
              </td>
            </tr>
        </table>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>16
<FILENAME>v167911_ex31-2.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizer 4.0.6.4-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT
31.2</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certificate
Pursuant to Section&#160;302</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
Sarbanes &#8211; Oxley Act of 2002</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION
OF CFO</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Gary
D. Pickett, the Registrant's Chief Financial Officer, certify that:</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1. I have
reviewed this annual report on Form 10-K/A of Bovie Medical
Corporation;</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2. Based
on my knowledge, this annual report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this annual
report;</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3. Based
on my knowledge, the financial statements, and other financial information
included in this annual report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this annual report;</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
November 30, 2009</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="top" width="17%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/
      Gary D. Pickett</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
      Financial Officer</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>17
<FILENAME>v167911_ex32-1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizer 4.0.6.4-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT&#160;&#160;32.1</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certificate
Pursuant to Section&#160;906</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
Sarbanes &#8211; Oxley Act of 2002</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION
OF CEO</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">In connection with the annual report on
Form 10-K/A of Bovie Medical Corporation. (the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic">&#8220;Company&#8221;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">) for the period ended December 31,
2008, as filed with the Securities and Exchange Commission on the date hereof
(the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic">&#8220;Report&#8221;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">), the undersigned President and Chief
Executive Officer certifies, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that: </font>&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; (1) The Report
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended; and</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160; (2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Company.&#160;&#160;</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
November 30, 2009</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="35%">
            <tr>
              <td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ </font><font style="DISPLAY: inline; FONT-STYLE: italic">Andrew
      Makrides</font></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Andrew
      Makrides</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">President
      and</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Chief Executive
      Officer</font></font></div>
              </td>
            </tr>
        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>18
<FILENAME>v167911_ex32-2.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizer 4.0.6.4-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT&#160;&#160;32.2</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certificate
Pursuant to Section&#160;906</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
Sarbanes &#8211; Oxley Act of 2002</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION
OF CFO</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">In connection with the annual report on
Form 10-K/A of Bovie Medical Corporation. (the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic">&#8220;Company&#8221;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">) for the period ended December 31,
2008, as filed with the Securities and Exchange Commission on the date hereof
(the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic">&#8220;Report&#8221;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">), the undersigned President and Chief
Executive Officer certifies, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that: </font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">(1) The Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934,
as amended; and</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160; </font>&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt"> (2) The information contained in the
Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.&#160;</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
November 30, 2009</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="35%">
            <tr>
              <td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ Gary D. Pickett</font></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Gary D. Pickett</font></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="35%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Financial Officer</font></div>
              </td>
            </tr>
        </table>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
